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A toxicological profile for chlorinated dibenzo-p-dioxins was released in February 1998.  This edition 
supersedes any previously released draft or final profile. 
Toxicological profiles are revised and republished as necessary, but no less than once every three years. 
For information regarding the update status of previously released profiles, contact ATSDR at: 
Agency for Toxic Substances and Disease Registry
 
Division of Toxicology/Toxicology Information Branch
 









This toxicological profile is prepared in accordance with guidelines developed by ATSDR and EPA.  The 
original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised 
and republished as necessary. 
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects 
information for the hazardous substance being described.  Each profile identifies and reviews the key 
literature (that has been peer-reviewed) that describes a hazardous substance's toxicological properties. 
Other pertinent literature is also presented but described in less detail than the key studies.  The profile is 
not intended to be an exhaustive document; however, more comprehensive sources of specialty 
information are referenced. 
Each toxicological profile begins with a public health statement, which describes in nontechnical 
language a substance's relevant toxicological properties.  Following the public health statement is 
information concerning levels of significant human exposure and, where known, significant health 
effects. The adequacy of information to determine a substance's health effects is described in a health 
effects summary.  Data needs that are of significance to protect public health will be identified by ATSDR 
and EPA. The focus of the profiles is on health and toxicological information; therefore, we have 
included this information in the beginning of the document. 
Each profile must include the following: 
(A) An examination, summary, and interpretation of available toxicological information and 
epidemiological evaluations on the hazardous substance in order to ascertain the levels of 
significant human exposure for the substance and the associated acute, subacute, and chronic 
health effects. 
(B) A determination of whether adequate information on the health effects of each substance is 
available or in the process of development to determine levels of exposure that present a 
significant risk to human health of acute, subacute, and chronic health effects. 
(C) Where appropriate, identification of toxicological testing needed to identify the types or 
levels of exposure that may present significant risk of adverse health effects in humans. 
The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization 
Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive Environmental Response, 
Compensation, and Liability Act of 1980 (CERCLA or Superfund).  This public law directed the Agency 
for Toxic Substances and Disease Registry (ATSDR) to prepare toxicological profiles for hazardous 
substances which are most commonly found at facilities on the CERCLA National Priorities List and that 
pose the most significant potential threat to human health, as determined by ATSDR and the 
Environmental Protection Agency (EPA).  The availability of the revised priority list of the 275 
hazardous substances was announced in the Federal Register on February 28, 1994 (59 FR 9486).  For 
prior versions of the list of substances, see Federal Register notices dated April 17, 1987 (52 FR 12866); 
October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); 
October 17, 1991 (56 FR 52166); and October 28, 1992 (57 FR 48801). 
CDDs vi 
Section 104 (i) (3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a 
toxicological profile for each substance on the list. 
This profile reflects our assessment of all relevant toxicological testing and information that has been peer 
reviewed. It has been reviewed by scientists from ATSDR, the Centers for Disease Control and 
Prevention (CDC), and other federal agencies. It has also been reviewed by a panel of nongovernment 
peer reviewers and is being made available for public review.  Final responsibility for the contents and 
views expressed in this toxicological profile resides with ATSDR. 
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QUICK REFERENCE FOR HEALTH CARE PROVIDERS 
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous 
substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of 
available toxicologic and epidemiologic information on a substance.  Health care providers treating 
patients potentially exposed to hazardous substances will find the following information helpful for fast 
answers to often-asked questions. 
Primary Chapters/Sections of Interest 
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for 
educating patients about possible exposure to a hazardous substance.  It explains a substance’s 
relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a 
review of the general health effects observed following exposure. 
Chapter 2: Health Effects: Specific health effects of a given hazardous compound are reported by 
route of exposure, by type of health effect (death, systemic, immunologic, reproductive), and by 
length of exposure (acute, intermediate, and chronic). In addition, both human and animal studies 
are reported in this section. 
NOTE: Not all health effects reported in this section are necessarily observed in 
the clinical setting. Please refer to the Public Health Statement to identify 
general health effects observed following exposure. 
Pediatrics: Four new sections have been added to each Toxicological Profile to address child health 
issues: 
Section 1.6 How Can (Chemical X) Affect Children?
 




Section 2.6 Children’s Susceptibility
 
Section 5.6 Exposures of Children
 
Other Sections of Interest: 
Section 2.7 Biomarkers of Exposure and Effect 
Section 2.10 Methods for Reducing Toxic Effects 
ATSDR Information Center
Phone:  1-800-447-1544 (to be replaced by 1-888-42-ATSDR in 1999)
 or 404-639-6357 Fax: 404-639-6359 
E-mail: atsdric@cdc.gov Internet: http://atsdr1.atsdr.cdc.gov:8080 
The following additional material can be ordered through the ATSDR Information Center: 
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an 






history is provided. Other case studies of interest include Reproductive and Developmental 
Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide 
Toxicity; and numerous chemical-specific case studies. 
Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials incident. 
Volumes I and II are planning guides to assist first responders and hospital emergency department 
personnel in planning for incidents that involve hazardous materials.  Volume III—Medical Management 
Guidelines for Acute Chemical Exposures—is a guide for health care professionals treating patients 
exposed to hazardous materials. 
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances. 
Other Agencies and Organizations 
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the 
workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341­
3724 • Phone: 770-488-7000 • FAX: 770-488-7015. 
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational 
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains 
professionals in occupational safety and health.     Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or  NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 
• Phone: 800-35-NIOSH. 
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for 
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212. 
Referrals 
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact:
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 •  Phone: 202-347-4976 • 
FAX: 202-347-4950 • e-mail: aoec@dgs.dgsys.com  •  AOEC Clinic Director: http://occ-env­
med.mc.duke.edu/oem/aoec.htm. 
The American College of Occupational and Environmental Medicine (ACOEM) is an association of 
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact:  ACOEM, 55 West Seegers Road, Arlington Heights, IL 
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THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS: 
1.	 Minimal Risk Level Review.  The Minimal Risk Level Workgroup considers issues relevant to 
substance-specific minimal risk levels (MRLs), reviews the health effects database of each 
profile, and makes recommendations for derivation of MRLs. 
2.	 Data Needs Review. The Research Implementation Branch reviews data needs sections to assure 







A peer review panel was assembled for chlorinated dibenzo-p-dioxins. The panel consisted of the 
following members:
1.	 James Olson, Department of Pharmacology and Toxicology, State University of New York at 
Buffalo, Buffalo, NY; 
2.	 John Ryan, Bureau of Chemical Safety, Health and Welfare Canada, Ottawa, Ontario, Canada; and 
3.	 Arnold Schecter, College of Medicine, State University of New York, Health Science Center, 
Binghamton, NY. 
These experts collectively have knowledge of chlorinated dibenzo-p-dioxins' physical and chemical 
properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and 
quantification of risk to humans.  All reviewers were selected in conformity with the conditions for peer 
review specified in Section 104(i)(13) of the Comprehensive Environmental Response, Compensation, 
and Liability Act, as amended. 
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer 
reviewers' comments and determined which comments will be included in the profile.  A listing of the 
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their 
exclusion, exists as part of the administrative record for this compound.  A list of databases reviewed and 
a list of unpublished documents cited are also included in the administrative record. 
The citation of the peer review panel should not be understood to imply its approval of the profile's final 





Several drafts of the Toxicological Profile for Chlorinated Dibenzo-p-Dioxins were submitted for a peer-review in 
the past. 
Draft 1997 
Ross Norstrom, National Wildlife Research Center, Environment Canada, Hull, Quebec, Canada 
James Olson, Department of Pharmacology and Toxicology, State University of New York at Buffalo, 
Buffalo, NY 
Dennis Paustenbach, McLaren/Hart ChemRisk, Alameda, CA 
John Ryan, Bureau of Chemical Safety, Health and Welfare Canada, Ottawa, Ontario, Canada 
Arnold Schecter, College of Medicine, State University of New York, Health Science Center, Binghamton, 
NY 
Draft 1994 (scientific panel meeting) 
Anthony DeCaprio,	 Wadsworth Center for Laboratories and Research, New York State Department of 
Health, Albany, NY 
Thomas Gasiewicz,	 University of Rochester Medical Center, Rochester, NY 
Ross Norstrom,	 National Wildlife Research Center, Environment Canada, Hull, Quebec, Canada 
James Olson,	 Department of Pharmacology and Toxicology, State University of New York at Buffalo, 
Buffalo, NY 
Dennis Paustenbach,	 McLaren/Hart ChemRisk, Alameda, CA 
John Ryan,	 Bureau of Chemical Safety, Health and Welfare Canada, Ottawa, Ontario, Canada 
Arnold Schecter,	 College of Medicine, State University of New York, Health Science Center, Binghamton, 
NY 
Draft 1992 
Thomas Gasiewicz,	 University of Rochester Medical Center, Rochester, NY 
James Olson,	 Department of Pharmacology and Toxicology, State University of New York at Buffalo, 
Buffalo, NY 
Arnold Schecter,	 College of Medicine, State University of New York, Health Science Center, Binghamton, 
NY
 Draft 1991
Thomas Gasiewicz,	 University of Rochester Medical Center, Rochester, NY 
Arleen Rifkind,	 Cornell University of Medical College, New York, NY 
Arnold Schecter,	 College of Medicine, State University of New York, Health Science Center, Binghamton, 
NY 
Jay Silkworth,	 Wadsworth Center for Laboratories and Research, New York State Department of 
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1. PUBLIC HEALTH STATEMENT
 
This public health statement tells you about chlorinated dibenzo-p-dioxins (CDDs) and the effects 
of exposure. 
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in 
the nation. These sites make up the National Priorities List (NPL) and are the sites targeted for 
long-term federal clean-up.  CDDs (all types) have been found in at least 126 of the 1,467 current 
or former NPL sites.  However, it's unknown how many NPL sites have been evaluated for these 
substances. As more sites are evaluated, the number of sites with CDDs may increase.  This is 
important because exposure to these substances may harm you and because these sites may be 
sources of exposure. 
When a substance is released from a large area, such as an industrial plant, or from a container, 
such as a drum or bottle, it enters the environment.  This release does not always lead to exposure. 
You can be exposed to a substance only when you come in contact with it.  You may be exposed 
by breathing, eating, or drinking the substance or by skin contact. 
If you are exposed to CDDs, many factors determine whether you'll be harmed.  These factors 
include the dose (how much), the duration (how long), and how you come in contact with it.  You 
must also consider the other chemicals you're exposed to and your age, sex, diet, family traits, 
lifestyle, and state of health. 
1.1 WHAT ARE CDDs? 
CDDs are a family of 75 different compounds commonly referred to as polychlorinated dioxins. 
These compounds have varying harmful effects.  The CDD family is divided into eight groups of 
chemicals based on the number of chlorine atoms in the compound.  The group with one chlorine 
atom is called the mono-chlorinated dioxin(s). The groups with two through eight chlorine atoms 
are called di-chlorinated dioxin (DCDD), tri-chlorinated dioxin (TrCDD), tetra-chlorinated dioxin 
(TCDD), penta-chlorinated dioxin (PeCDD), hexa-chlorinated dioxin (HxCDD), hepta-chlorinated 
dioxin (HpCDD), and octa-chlorinated dioxin (OCDD).  The chlorine atoms can be attached to the 
dioxin molecule at any one of eight positions. The name of each CDD indicates both the number 
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and the positions of the chlorine atoms.  For example, the CDD with four chlorine atoms at 
positions 2, 3, 7, and 8 on the dioxin molecule is called 2,3,7,8-tetrachlorodibenzo-p-dioxin or 
2,3,7,8-TCDD. 2,3,7,8-TCDD is one of the most toxic of the CDDs to mammals and has received 
the most attention.  Thus, 2,3,7,8-TCDD serves as a prototype for the CDDs.  CDDs with toxic 
properties similar to 2,3,7,8-TCDD are called “dioxin-like” compounds. 
In the pure form, CDDs are colorless solids or crystals.  CDDs enter the environment as mixtures 
containing a variety of individual components and impurities.  In the environment they tend to be 
associated with ash, soil, or any surface with a high organic content, such as plant leaves. In air 
and water, a portion of the CDDs may be found in the vapor or dissolved state, depending on the 
amount of particulate matter, temperature, and other environmental factors.  2,3,7,8-TCDD is 
odorless. The odors of the other CDDs are not known. CDDs are known to occur naturally, and 
are also produced by human activities.  They are naturally produced from the incomplete 
combustion of organic material by forest fires or volcanic activity.  CDDs are not intentionally 
manufactured by industry, except in small amounts for research purposes.  They are 
unintentionally produced by industrial, municipal, and domestic incineration and combustion 
processes. Currently, it is believed that CDD emissions associated with human incineration and 
combustion activities are the predominant environmental source. 
CDDs (mainly 2,3,7,8-TCDD) may be formed during the chlorine bleaching process used by pulp 
and paper mills.  CDDs occur as a contaminant in the manufacturing process of certain chlorinated 
organic chemicals, such as chlorinated phenols. 2,3,7,8-TCDD is a by-product formed during the 
manufacture of 2,4,5-trichlorophenol (2,4,5-TCP).  2,4,5-TCP was used to produce 
hexachlorophene (used to kill bacteria) and the herbicide, 2,4,5-trichlorophenoxyacetic acid 
(2,4,5-T). Various formulations of 2,4,5-T have been used extensively for weed control on crops 
and range lands, and along roadways throughout the world. 2,4,5-T was a component of Agent 
Orange, which was used extensively by the U.S. military in the Vietnam War.  In most 
industrialized countries the use of products contaminated with CDDs has been greatly reduced. 
Use of hexachlorophene and the herbicide 2,4,5-T is currently restricted in the United States. 
Other chlorinated chemicals, like pentachlorophenol (PCP), used to preserve wood, do contain 
some of the more highly chlorinated CDDs (those with more chlorine atoms), but 2,3,7,8-TCDD is 
not usually found. The use of PCP has been restricted to certain manufacturing applications. 
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Currently, CDDs are primarily released to the environment during combustion of fossil fuels 
(coal, oil, and natural gas) and wood, and during incineration processes (municipal and medical 
solid waste and hazardous waste incineration). While incineration may be the primary current 
source of release of CDDs into the environment, the levels of CDDs produced by incineration are 
extremely low.  CDDs are associated with ash generated in combustion and incineration 
processes. Emissions from incinerator sources vary greatly and depend on management practices 
and applied technologies. CDDs also have been detected at low concentrations in cigarette smoke, 
home-heating systems, and exhaust from cars running on leaded gasoline or unleaded gasoline, 
and diesel fuel. Burning of many materials that may contain chlorine, such as plastics, wood 
treated with pentachlorophenol (PCP), pesticide-treated wastes, other polychlorinated chemicals 
(polychlorinated biphenyls or PCBs), and even bleached paper can produce CDDs. 
Although this public health statement will focus on CDDs, it is important to note that CDDs are 
found in the environment together with other structurally related chlorinated chemicals, such as 
chlorinated dibenzofurans (CDFs) and polychlorinated biphenyls (PCBs).  Therefore, people are 
generally exposed to mixtures of CDDs and other classes of toxicologically and structurally 
similar compounds.  2,3,7,8-TCDD is one of the most toxic and extensively studied of the CDDs 
and serves as a prototype for the toxicologically relevant or “dioxin-like CDDs.  Based on results 
from animal studies, scientists have learned that they can express the toxicity of dioxin-like CDDs 
as a fraction of the toxicity attributed to 2,3,7,8-TCDD.  For example, the toxicity of dioxin-like 
CDDs can be half or one tenth or any fraction of that of 2,3,7,8-TCDD.  Scientists call that 
fraction a Toxic Equivalent Factor (TEF). More information on TEFs can be found in Section 2.5. 
For more information on CDDs, please refer to Chapters 3, 4, and 5. 
1.2 WHAT HAPPENS TO CDDs WHEN THEY ENTER THE ENVIRONMENT? 
CDDs are released into the air in emissions from municipal solid waste and industrial incinerators. 
Exhaust from vehicles powered with leaded and unleaded gasoline and diesel fuel also release 
CDDs to the air. Other sources of CDDs in air include: emissions from oil- or coal-fired power 
plants, burning of chlorinated compounds such as PCBs, and cigarette smoke.  CDDs formed 
during combustion processes are associated with small particles in the air, such as ash.  The larger 
particles will be deposited close to the emission source, while very small particles may be 
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transported longer distances. Some of the lower chlorinated CDDs (DCDD, TrCDD, and some of 
the TCDDs) may vaporize from the particles (and soil or water surfaces) and be transported long 
distances in the atmosphere, even around the globe.  It has been estimated that 20 to 60% of 
2,3,7,8-TCDD in the air is in the vapor phase. Sunlight and atmospheric chemicals will break 
down a very small portion of the CDDs, but most CDDs will be deposited on land or water. 
CDDs occur as a contaminant in the manufacture of various chlorinated pesticides and herbicides, 
and releases to the environment have occurred during the use of these chemicals.  Because CDDs 
remain in the environment for a long time, contamination from past pesticide and herbicide use 
may still be of concern.  In addition, improper storage or disposal of these pesticides and waste 
generated during their production can lead to CDD contamination of soil and water.  
CDDs are released in waste waters from pulp and paper mills that use chlorine or chlorine-
containing chemicals in the bleaching process.  Some of the CDDs deposited on or near the water 
surface will be broken down by sunlight. A very small portion of the total CDDs in water will 
evaporate to air. Because CDDs do not dissolve easily in water, most of the CDDs in water will 
attach strongly to small particles of soil or organic matter and eventually settle to the bottom.
CDDs may also attach to microscopic plants and animals (plankton) which are eaten by larger 
animals, that are in turn eaten by even larger animals.  This is called a food chain. Concentrations 
of chemicals such as the most toxic, 2,3,7,8-chlorine substituted CDDs, which are difficult for the 
animals to break down, usually increase at each step in the food chain.  This process, called 
biomagnification, is the reason why undetectable levels of CDDs in water can result in measurable 
concentrations in aquatic animals.  The food chain is the main route by which CDD concentrations 
build up in larger fish, although some fish may accumulate CDDs by eating particles containing 
CDDs directly off the bottom. 
CDDs deposited on land from combustion sources or from herbicide or pesticide applications bind 
strongly to the soil, and therefore are not likely to contaminate groundwater by moving deeper into 
the soil. However, the presence of other chemical pollutants in contaminated soils, such as those 
found at hazardous waste sites or associated with chemical spills (for example, oil spills), may 
dissolve CDDs, making it easier for CDDs to move through the soil. The movement of chemical 
waste containing CDDs through soil has resulted in contamination of groundwater.  Soil erosion 
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and surface runoff can also transport CDDs into surface waters. A very small amount of CDDs at 
the soil surface will evaporate into air. Certain types of soil bacteria and fungus can break CDDs 
down, but the process is very slow. In fact, CDDs can exist in soil for many years.  Plants take up 
only very small amounts of CDDs by their roots. Most of the CDDs found on the parts of plants 
above the ground probably come from air and dust and/or previous use of CDD-containing 
pesticides or herbicides. Animals (such as cattle) feeding on the plants may accumulate CDDs in 
their body tissues (meat) and milk. 
For more information on what happens to CDDs in the environment, see Chapter 5. 
1.3 HOW MIGHT I BE EXPOSED TO CDDs? 
CDDs are found at very low levels in the environment.  These levels are measured in nanograms 
and picograms.  One nanogram (ng) is one billionth of a gram, and one picogram (pg) is one 
trillionth of a gram.  In some contaminated soils, concentrations of CDDs are reported as parts per 
billion. One part per billion (ppb) is one part CDD per billion parts of soil. The concentration of 
CDDs is often reported as parts per trillion, in samples of air, water, or soil.  One part per trillion 
(ppt) is one part CDD per trillion parts of air, water, or soil.  In some rural areas where CDD 
concentrations are very low in air or water, measurements are given in parts per quadrillion (ppq), 
which means one part CDD per quadrillion parts of air or water. 
CDDs are found everywhere in the environment, and most people are exposed to very small 
background levels of CDDs when they breath air, consume food or milk,  or have skin contact 
with materials contaminated with CDDs.  For the general population, more than 90% of the daily 
intake of CDDs, CDFs, and other dioxin-like compounds comes from food, primarily meat, dairy 
products, and fish. CDDs may be present at much lower levels in fruits and vegetables.  The 
actual intake of CDDs from food for any one person will depend on the amount and type of food 
consumed and the level of contamination.  Higher levels may be found in foods from areas 
contaminated with chemicals, such as pesticides or herbicides, containing CDDs as impurities. 
CDDs have been measured in human milk, cow's milk, and infant formula, so infants are known to 
be exposed to CDDs. 
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Most surface water in the United States typically does not contain 2,3,7,8-TCDD and other CDDs 
at levels that are high enough to be measured (1 ppq or more).  Municipal drinking water does not 
usually contain CDDs because the CDDs do not dissolve in water and primarily stick to particles, 
which are usually filtered out of treated drinking water.  This means that using tap water to wash 
clothes or to bathe or shower, or swimming in pools or in uncontaminated lakes, rivers, or at ocean 
beaches will not expose people to significant levels of CDDs. Although CDDs are not usually 
found in filtered, treated drinking water, they have, on occasion, been detected in unfiltered 
groundwater from areas with known CDD contamination. 
Exposure to CDDs can also occur through skin contact with chlorinated pesticides and herbicides, 
contaminated soils, or other materials such as PCP-treated wood and PCB transformer fluids. 
Background levels of CDDs in soil are higher than background levels in both air and water. 
Background levels of CDDs detected in uncontaminated soils in the United States are generally 
very low or not detectable. 2,3,7,8-TCDD is not usually found in rural soil, but is typically found 
in soil in industrialized areas at levels ranging from 0.001 to 0.01 ppb.  However, higher levels of 
2,3,7,8-TCDD may be found in areas where CDDs have contaminated the soil.  For example, 
contaminated soil at Times Beach, Missouri, had levels of 2,3,7,8-TCDD ranging from 
4.4–317 ppb. 
If CDDs are present at all in outdoor air in rural areas, they are generally present at very low 
levels or at concentrations near the detection limits for testing equipment.  In winter, because of 
the burning of wood and other fuels for home heating, CDD levels may be slightly higher than 
during other seasons. In general, the background air levels of CDDs in urban areas are higher than 
in rural areas. Typical levels of CDDs in outdoor air in urban areas and industrial areas averaged 
2.3 picograms per meter cubed (pg/m3). 2,3,7,8-TCDD is not usually found in rural or urban air, 
but it is found in air near urban waste incinerators and high-traffic areas.  The air around people 
who are smoking cigarettes may also have CDDs at levels above background levels.  Although 
breathing contaminated air is a minor route of exposure for most people, exposure may be greater 
in areas near these CDD sources. 
CDDs have been found in all samples of adipose tissue and blood (serum lipids) from individuals 
with no known previous exposure. This indicates that all people are exposed to small amounts of 
CDDs. Levels of 2,3,7,8-TCDD in serum from the general population typically range from 3 to 
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7 ppt (on a lipid basis), and rarely exceed 10 ppt. Typically, lower levels of CDDs are found in 
less industrialized countries and in younger people. 
The production, use, and disposal of pesticides and phenoxy herbicides, disposal of production 
waste containing 2,3,7,8-TCDD, industrial accidents involving 2,4,5-trichlorophenol (2,3,5-TCP), 
and the consumption of CDD-contaminated food, have all led to increased potential for excess 
exposure of some groups of people.  2,3,7,8-TCDD has been detected at 91 of the 126 hazardous 
waste sites on the NPL that have been reported to contain CDDs. People living around these sites 
may be exposed to above-background levels of 2,3,7,8-TCDD and other CDDs.  Elevated levels of 
CDDs have been reported in fish, shellfish, birds, and mammals collected in areas surrounding 
various chemical production facilities, various hazardous waste sites, and pulp and paper mills 
using the chlorine bleaching process. Sometimes these findings have resulted in closure of these 
areas for the purpose of fishing. People who eat contaminated food from these contaminated areas 
are at risk of increased exposure to CDDs. 
Occupational exposure to CDDs generally occurs through breathing contaminated air, or through 
skin contact with materials containing CDDs.  Workers with the potential to be exposed to above-
average levels of CDDs include those involved in the production or handling of certain 
chlorinated phenols (such as 2,4,5-TCP, PCP) or chlorinated pesticides or herbicides (such as 
2,4,5-T, 2,4-D, hexachlorophene, Silvex®), and those involved in application of chlorinated 
pesticides containing CDDs as impurities.  Workers whose jobs involve pressure treatment of 
wood with PCP and the handling of PCP-treated wood products, chlorination processes at pulp 
and paper mills, or operation of municipal solid waste or hazardous waste incinerators may have 
increased exposure to CDDs. Finally, workers involved in hazardous waste clean-up or clean-up 
of PCB transformer and/or capacitor fires including emergency service personnel like fire fighters 
and police who respond to such fires are also at additional risk of exposure to CDDs. Most of 
these occupational exposures have been significantly reduced in recent years. 
In general, workers involved in the manufacture of 2,4,5-TCP and subsequent products were 
exposed to far greater levels of 2,3,7,8-TCDD than those involved in the handling and application 
of chlorinated pesticides containing CDDs. Current serum lipid levels of 2,3,7,8-TCDD in a small 
number of U.S. Air Force veterans who were directly involved in the aerial spraying of herbicides 
(Agent Orange contaminated with 2,3,7,8-TCDD) in Vietnam as part of Operation Ranch Hand, 
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are up to 3 times higher than the general population.  However, while studies on blood or fatty 
tissue 2,3,7,8-TCDD levels in U.S. Army ground combat Vietnam veterans also found some 
individuals with 2,3,7,8-TCDD levels higher than those of the general population, overall, most 
Vietnam veterans and Vietnamese living in Vietnam studied to dated have blood and fatty tissue 
2,3,7,8-TCDD levels comparable to members of the general U.S. population. 
For more information on exposure to CDDs, see Chapter 5. 
1.4 HOW CAN CDDs ENTER AND LEAVE MY BODY? 
CDDs can enter your body when you breathe contaminated air, eat contaminated food, or have 
skin contact with contaminated soil or other materials.  The most common way CDDs can enter 
your body is by eating food contaminated with CDDs. 
If you breathe air that contains CDDs, the CDDs can enter your body through your lungs and pass 
into the blood stream, but we do not know how fast or how much of the CDDs will enter the blood 
stream.  If you swallow food or water containing CDDs, most of the CDDs will enter your body 
and pass from the intestines to the blood stream.  Smaller amounts of highly chlorinated CDDs 
will enter your body compared to the less chlorinated 2,3,7,8-TCDD.  If you swallow soil 
containing CDDs, a small amount of the CDDs will pass through the intestines into the blood 
stream.  If soil contaminated with CDDs comes into contact with your skin, some of the CDDs 
will enter the body but we do not know how fast they will enter the blood stream.  
Once in your body, CDDs can be found in most tissues with the highest amounts found in the liver 
and body fat (adipose tissue). Body fat and possibly the liver can store CDDs for many years 
before eliminating them from the body. CDDs with chlorine atoms in the 2, 3, 7, and 8 positions 
and highly chlorinated dioxins, such as OCDD, are generally found in higher concentrations in the 
fat than other CDDs. 
Little is known about CDDs breakdown in the human body.  Studies in animals show that some of 
the 2,3,7,8-TCDD from food is slowly broken down.  There is evidence from animals suggesting 
that the break-down products are less harmful than the unchanged 2,3,7,8-TCDD. 
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For people, the average time it takes to remove one-half of the 2,3,7,8-TCDD from the body is
 
highly variable and may take from 7 to 12 years.  There is less information on the other CDDs, but
 
what information exists suggests 5 to 15 years.  CDDs are eliminated from the body primarily in
 
the stool, and only a small amount leaves the body in the urine.  Some CDDs will leave the body
 
in the breast milk of nursing mothers. 

Much less is known about how much other CDD compounds will enter the body, how much will
 
be stored in the body and for how long, and how they are removed from the body.
 
For more information about how CDDs can enter and leave your body, see Chapter 2.
 
1.5 HOW CAN CDDs AFFECT MY HEALTH? 
Many studies have looked at how CDDs can affect human health.  Most of these studies examined 
workers exposed during the manufacture of chemicals and pesticides contaminated with 
2,3,7,8-TCDD. Other studies have looked at American Vietnam veterans and Vietnamese 
populations exposed to Agent Orange and populations exposed to 2,3,7,8-TCDD as a result of an 
accident. The workers and Vietnam veterans were most likely exposed to 2,3,7,8-TCDD mainly 
through breathing and skin contact. People who were accidentally exposed to 2,3,7,8-TCDD in 
Seveso, Italy, or Times Beach, Missouri, were probably exposed through eating and drinking 
contaminated food and milk, breathing contaminated particles and dust, through skin contact with 
contaminated soil and through unintentional hand-to mouth activity.  Epidemiology is an inexact 
science and many of the human studies have many shortcomings which make it difficult for 
scientists to establish an association between 2,3,7,8-TCDD exposure levels and health effects. A 
common problem with most of the human studies is that the people are exposed to a number of 
chemicals at the same time.  In most human health studies, we do not know how much 
2,3,7,8-TCDD people were exposed to or how long the exposure lasted.  In other studies, the 
people were examined many years after they were exposed and some of the effects may have not 
have been present at the time of examination or the effects observed may not have been caused by 
2,3,7,8-TCDD. Some of the more recent studies have measured 2,3,7,8-TCDD levels in the blood 
or fat tissue of exposed populations. The levels of 2,3,7,8-TCDD in the blood or fat tissue can be 
used to estimate the extent of past exposures.  
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A number of effects have been observed in people exposed to 2,3,7,8-TCDD levels which are at 
least 10 times higher than background levels.  The most obvious health effect in people exposed to 
relatively large amounts of 2,3,7,8-TCDD is chloracne.  Chloracne is a severe skin disease 
characterized by acne-like lesions. Chloracne generally occurs on the face and upper body, but 
may occur elsewhere on the body.  Unlike common acne, severe chloracne is harder to cure and 
can be more disfiguring.  In milder cases, the lesions heal several months after exposure ends. In 
more severe cases, the lesions may last for many years after exposure.  Most of the chloracne 
cases have been attributed to accidental exposure to high doses of 2,3,7,8-TCDD.  Other effects to 
the skin, such as erythematous or red skin rashes, discoloration, and excessive body hair, have 
been reported to occur in people following exposure to high concentrations of 2,3,7,8-TCDD. 
Changes in blood and urine that may indicate liver damage have been observed in people. 
Alterations in the ability of the liver to metabolize (or breakdown) hemoglobin, lipids, sugar, and 
protein have been reported in people exposed to relatively high concentrations of 2,3,7,8-TCDD. 
Most of the effects are considered mild and were reversible.  However, in some people these 
effects may last for many years.  Slight increases in the risk of diabetes and abnormal glucose 
tolerance have been observed in some studies of people exposed to 2,3,7,8-TCDD.  We do not 
have enough information to know if exposure to 2,3,7,8-TCDD will result in reproductive or 
developmental effects in people, but animal studies suggest that this is a potential health concern. 
Several studies of workers exposed to high levels (with body burdens more than 50 times higher 
than background body burden levels) of 2,3,7,8-TCDD suggest that exposure to 2,3,7,8-TCDD 
may increase the risk of cancer in people. 
The Department of Health and Human Services (DHHS) has determined that it is reasonable to 
expect that 2,3,7,8-TCDD may cause cancer.  The International Agency for Research on Cancer 
(IARC) has determined that 2,3,7,8-TCDD can cause cancer in people, but that it is not possible to 
classify other CDDs as to their carcinogenicity to humans.  The EPA has determined that 
2,3,7,8-TCDD is a probable human carcinogen when considered alone and when considered in 
association with phenoxy herbicides and/or chlorophenols. The EPA has determined also that a 
mixture of CDDs with six chlorine atoms (4 of the 6 chlorine atoms at the 2, 3, 7, and 8 positions) 
is a probable human carcinogen. 
To protect the public from the harmful effects of toxic chemicals and to find ways to treat people 
who have been harmed, scientists use many tests. 
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One way to see if a chemical will hurt people is to learn how the chemical is absorbed, used, and 
released by the body; for some chemicals, animal testing may be necessary.  Animal testing may 
also be used to identify health effects such as cancer or birth defects.  Without laboratory animals, 
scientists would lose a basic method to get information needed to make wise decisions to protect 
public health. Scientists have the responsibility to treat research animals with care and 
compassion.  Laws today protect the welfare of research animals, and scientists must comply with 
strict animal care guidelines. 
The health effects of some CDDs have been extensively studied in animals.  Some CDDs are 
much more toxic than others.  2,3,7,8-TCDD and, to a lesser extent, CDDs with five (penta) or six 
(hexa) chlorine atoms substituted in the 2, 3, 7, and 8 positions, are extremely toxic to animals. 
Other CDDs, which do not have chlorine atoms substituted in the 2, 3, 7, and 8 positions, are 
considered relatively less toxic compared to 2,3,7,8-TCDD.  
2,3,7,8-TCDD has been the most extensively studied CDD and it has been shown to cause a large 
number of adverse health effects in animals. There are always going to be some difficulties in 
using animal data to quantify health risks in people.  In general, the doses used in the animal 
studies result in body burdens that are at least 10 times higher than human background body 
burdens, often the animal studies use doses that are over 1,000 times higher than human 
background levels. Some animal species are much more acutely sensitive to 2,3,7,8-TCDD than 
others. For example, it takes several thousand times more 2,3,7,8-TCDD to kill a hamster than a 
guinea pig. The reason for the difference in sensitivity among species is currently being 
investigated. For other effects, such as reproductive toxicity, there is very little difference in 
sensitivity between hamsters and guinea pigs.  Another consideration in using animal data to 
predict health effects in people exposed to CDDs in the environment is the design of the animal 
studies. In most of the animal studies, the animals were exposed to only 2,3,7,8-TCDD, the most 
toxic CDD. 2,3,7,8-TCDD is rarely the main CDD found in the environment and people are 
typically exposed to a number of CDDs and compounds with similar toxic actions.  Until scientists 
learn more about possible differences between people and animals, levels recommended to be of 
little or no risk to human health are based on the more sensitive species and the assumption that 
effects in animals could occur in people.  This approach is further justified on the basis that 
humans are likely to exhibit a wide range of sensitivities to various health effects and the need to 
protect the most susceptible individuals. 
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In certain animal species, 2,3,7,8-TCDD is especially harmful and can cause death after a single 
exposure to small amounts.  Before death, animals may lose as much as 40% or more of their body 
weight following a single dose of 2,3,7,8-TCDD. Exposure to non-lethal levels added in their 
food can cause a variety of adverse effects in animals, such as weight loss, biochemical and 
degenerative changes in the liver. Some animals that were exposed to CDDs in their food had 
effects to the skin such as hair loss, swelling of the face, and moderate to severe chloracne.  In 
many species of animals, the immune system appears to be extremely sensitive to 2,3,7,8-TCDD. 
At relatively low levels (approximately 10 times higher than human background body burdens), 
2,3,7,8-TCDD weakens the immune system and causes a decrease in the system's ability to fight 
foreign substances such as bacteria and viruses. 
Exposure to 2,3,7,8-TCDD can cause reproductive damage and birth defects in animals. 
Decreases in fertility, altered levels of sex hormones, reduced production of sperm, and increased 
rates of miscarriages were found in animals exposed to 2,3,7,8-TCDD in food.  Rats and mice that 
were exposed to small amounts of 2,3,7,8-TCDD in food for a long time developed cancer of the 
liver and thyroid, and other types of cancer. 
The results of the oral animal studies suggest that the most sensitive effects (effects that will occur 
at the lowest doses) are immune, endocrine, and developmental effects.  It is reasonable to assume 
that these will also be the most sensitive effects in humans. 
We know less about the ability of other CDDs to cause adverse health effects.  However, it 
appears that all CDDs with chlorine in the 2, 3, 7, and 8 positions have similar effects to 
2,3,7,8-TCDD but the effects occur at higher doses. 
Relatively large amounts of 2,3,7,8-TCDD applied to the skin of some animal species have 
resulted in deaths. Smaller amounts have resulted in weight loss, acne-like sores on the skin, and 
biochemical and degenerative changes in the liver.  In addition, mice that had 2,3,7,8-TCDD 
repeatedly applied to their skin developed skin cancer. Although effects in animals following 
exposure through the skin have not been as extensively studied as effects following exposure in 
food, they appear to be quite similar.  The ability of other CDDs to cause adverse health effects in 
animals following exposure to the skin has not been well studied. 
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You can find out more information on the health effects of CDDs in Chapter 2. 
1.6 HOW CAN CDDs AFFECT CHILDREN? 
This section discusses potential health effects from exposures during the period from conception 
to maturity at 18 years of age in humans.  Potential effects on children resulting from exposures of 
the parents are also considered. 
Very few studies have looked at how CDDs can affect children’s health.  Chloracne has been 
observed in children exposed to much higher than current background levels of 2,3,7,8-TCDD. 
The children appeared to be more sensitive (effects occurred at a lower body burden) than adults. 
We do not know why children are more sensitive than adults to this effect.  It is likely that 
children exposed to higher than background levels will have similar effects as adults.  
We do not know if exposure to CDDs will result in birth defects or other developmental effects in 
people. Birth defects have been observed in animals exposed to higher than background levels of 
2,3,7,8-TCDD. The developing animal is very sensitive to 2,3,7,8-TCDD.  In some studies, 
effects were observed at body burdens 10 times higher than human background body burden 
levels. Offspring of animals exposed to 2,3,7,8-TCDD in food during pregnancy often had severe 
birth defects including bleeding, skeletal deformities, kidney defects, weakened immune 
responses, impaired development of the reproductive system, and learning and behavioral 
impairments.  Exposure to other CDDs, such as 2,7-DCDD, 1,2,3,7,8-PeCDD, OCDD, and 
HxCDD, can also result in developmental effects in animals. 
We have no information to suggest that there are any differences between children and adults in 
terms of how much CDDs will enter the body, where CDDs can be found in the body, and how 
fast CDDs will leave the body. CDDs from the mother can enter her unborn baby through the 
placenta. It can also be transferred from the mother to infant through breast milk.  Because CDDs 
have been measured in human milk, cows milk, and infant formula, nursing infants are also 
exposed to CDDs. In most cases the beneficial aspects (biological and psychological) of breast-
feeding outweigh any risks from exposure to CDDs from mother’s milk. 
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1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO CDDs? 
If your doctor finds that you have been exposed to significant amounts of CDDs, ask your doctor 
if children may also be exposed.  When necessary your doctor may need to ask your state 
Department of Public Health to investigate. 
Structural material used in building homes such as chemically treated lumber for decking and 
plastic PVC pipes used in water pipes and other conduits can release CDDS if they are burned as 
refuse during construction or if there is a structural fire in your home.  To avoid exposures from 
some of these sources, construction refuse should not be burned near your home especially when 
children are out playing. 
Children may be exposed to CDDs from ingestion of contaminated soil or by contact of 
contaminated soil with their skin.  However, skin contact with contaminated soil will result in 
much less CDDs entering the blood stream than if they ingest contaminated soil.  Also, the amount 
of CDDs that will pass to the blood stream after eating contaminated soil will depend on the type 
of soil and on how tight the CDDs are bound to the soil. Children should be restricted from 
playing near any known hazardous waste sites. Some children eat a lot of dirt.  Discourage your 
children from eating dirt or from putting their toys or other foreign objects in their mouths that 
may be contaminated with soil.  Make sure that your children wash their hands frequently, 
especially before eating. Discourage your children from putting their hands in their mouths or 
other hand-to-mouth activities. 
Older children may be exposed to CDDs if they smoke cigarettes.  Younger children and infants 
may be exposed by inhaling the second-hand smoke from their parents or other adult smokers. 
Parents should talk to their children about the dangers of smoking cigarettes. 
You and your children are likely to be exposed to very low amounts of CDDs in the diet 
particularly when you consume meat, milk, other dairy products, and fish. This represents the 
major source of background exposure to CDDs in most people.  Children and adults should eat a 
balanced diet preferably containing low to moderate amounts of animal fats including meat and 
dairy products, and fish that contain higher amounts of CDDs and eat larger amounts of fruits, 
vegetables and grains. 
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You or your children may be exposed to CDDs by eating certain types of fish or wildlife caught in 
certain locations. A number of states have advisories for CDDs in fish and shellfish species; and 
one state has a wildlife advisory in effect for wood ducks. Each state, Native American tribe, or 
U.S. Territory sets its own criteria for issuing fish and wildlife advisories. A fish advisory will 
specify which waterbodies have restrictions, and a wildlife advisory will specify which hunting 
areas have restrictions. The advisory will tell you what types and sizes of fish or game are of 
concern. The advisory may completely ban eating fish or game or recommend that you limit the 
number of meals you eat of a certain species.  For example, an advisory may tell you to eat a 
certain type of fish no more than once a month.  The advisory may also tell you only to eat certain 
parts of the fish or game animal and how to prepare or cook the fish or game to decrease your 
exposure to CDDs. Fish and wildlife advisories are often stricter for pregnant women, nursing 
mothers, and young children.  To reduce your children’s exposure to CDDs, obey all fish and 
wildlife advisories. Information on Fish and Wildlife Advisories in your state is available from 
your state Public Health Department, or state Natural Resources Department and signs may be 
posted in certain fishing and hunting areas. 
1.8	 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN 
EXPOSED TO CDDs? 
Specific tests exist to measure CDD levels in samples of body fat, blood, and breast milk, but 
these tests are not routinely available. All people now have some levels of CDDs in their body fat 
and blood. Levels of 2,3,7,8-TCDD on a lipid basis are generally below 10 pg/g of lipid (ppt) in 
the blood and fatty tissue of the general population of the United States, and usually range from 3 
to 7 ppt. Levels higher than these indicate past exposure to above-normal levels of 2,3,7,8-TCDD. 
Although CDDs stay in the body fat for a long time (see Section 1.4), tests are not used to 
determine when exposure occurred, but can be used to estimate dose of the exposure if the time of 
exposure is known. 
Although exposure to 2,3,7,8-TCDD has been associated with adverse health effects in people, no 
one effect is specifically related to exposure to CDDs. There are laboratory tests which can 
indicate whether you have been exposed to CDDs, but these are costly and take weeks to perform 
and they cannot be used to predict whether you will develop harmful health effects. 
CDDs	 16 
1. PUBLIC HEALTH STATEMENT 
1.9	 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO 
PROTECT HUMAN HEALTH? 
The federal government develops regulations and recommendations to protect public health. 
Regulations can be enforced by law. Federal agencies that develop regulations for toxic 
substances include the Environmental Protection Agency (EPA), the Occupational Safety and 
Health Administration (OSHA), and the Food and Drug Administration (FDA). 
Recommendations provide valuable guidelines to protect public health but cannot be enforced by 
law. Federal organizations that develop recommendations for toxic substances include the 
Agency for Toxic Substances and Disease Registry (ATSDR) and the National Institute for 
Occupational Safety and Health (NIOSH). 
Regulations and recommendations can be expressed in not-to-exceed levels in air, water, soil, or 
food that are usually based on levels that affect animals, then they are adjusted to help protect 
people. Sometimes these not-to-exceed levels differ among federal organizations because of 
different exposure times (an 8-hour workday or a 24-hour day), the use of different animal studies, 
or other factors. 
Recommendations and regulations are also periodically updated as more information becomes 
available. For the most current information, check with the federal agency or organization that 
provides it. Some regulations and recommendations for CDDs include the following: 
The government has developed regulations and guidelines for 2,3,7,8-TCDD.  These are designed 
to protect the public from the potential adverse health effects of the chemical.  The Food and Drug 
Administration (FDA) recommends against consuming fish and shellfish with 2,3,7,8-TCDD 
levels greater than 50 ppt. Such levels have resulted in the closing of several commercial fishing 
areas. In addition, EPA has issued guidance to states on how to evaluate health risks to 
recreational and subsistence fishers, and how to issue fish consumption advisories when 
concentrations of CDDs in fish and shellfish pose a risk to these populations. Currently, 66 health 
advisories have been issued by 21 states restricting consumption of fish and wildlife contaminated 
with CDDs. EPA also has recommended limits on how much 2,3,7,8-TCDD can be present in 
drinking water. EPA advises that children should not have more than 1 nanogram 2,3,7,8-TCDD 
per liter of water (ng/L) (ppt) in 1 day, or more than 0.01 ng/L per day for long-term exposure. 
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For long-term exposure in adults, EPA recommends that there should not be more than 0.04 ng/L 
(ppt) in drinking water. 
Human milk can contain higher levels of CDDs than cow’s milk.  Therefore, breast-fed infants can 
be exposed to higher levels of CDDs on a body weight basis than adults. The World Health 
Organization (WHO) has concluded that this risk to infants does not outweigh the positive 
biological and psychological benefits of breast-feeding at general population levels of dioxins. 
However, the specific concentration at which CDD levels in human milk would lead to harmful 
health effects in infants has not yet been determined. 
Regulation of many of the sources of CDDs appears to have been successful in reducing the 
amount of CDDs entering the ecosystem and in decreasing the potential for human exposure. 
EPA and ATSDR listed 2,3,7,8-TCDD as hazardous substance. Many regulations govern its 
destruction and disposal. See Chapter 7 for more information on regulations and guidelines. 
1.10 WHERE CAN I GET MORE INFORMATION? 
If you have any more questions or concerns, please contact your community or state health or 
environmental quality department or 













ATSDR can also tell you the location of occupational and environmental health clinics.  These 
clinics specialize in recognizing, evaluating, and treating illnesses resulting from exposure to 
hazardous substances. 
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* To order toxicological profiles, contact: 
National Technical Information Service
 




Phone: (800) 553-6847 or (703) 487-4650
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INTRODUCTION
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and other 
interested individuals and groups with an overall perspective of the toxicology of chlorinated dibenzo-p ­
dioxins (CDDs). 
CDDs are a class of related chlorinated hydrocarbons that are structurally similar.  The basic structure is a 
dibenzo-p-dioxin (DD) molecule comprised of two benzene rings joined via two oxygen bridges at adjacent 
carbons on each of the benzene rings. There are eight homologues of CDDs, monochlorinated through 
octachlorinated. Each homologous class contains one or more isomers or congeners.  The family of CDDs 
contains 75 congeners—2 monochlorodibenzo-p-dioxins (MCDD), 10 dichlorodibenzo-p-dioxins (DCDD), 
14 trichlorodibenzo-p-dioxins (TrCDD), 22 tetrachlorodibenzo-p-dioxins (TCDD), 14 pentachlorodibenzo­
p-dioxins (PeCDD), 10 hexachlorodibenzo-p-dioxins (HxCDD), 2 heptachlorodibenzo-p-dioxins 
(HpCDD), and a single octachlorodibenzo-p-dioxin (OCDD). The seven 2,3,7,8-chlorine substituted 
congeners are the most toxic CDD congeners, with 2,3,7,8-tetrachlorodibenzo-p-dioxin (2,3,7,8-TCDD) 
being one of the most toxic and most extensively studied.  This compound is often called "TCDD" or 
merely "dioxin" in the popular literature.  Chlorinated dibenzofurans (CDFs) are structurally and 
toxicologically related chemicals as are certain “dioxin-like” PCBs; the reader is encouraged to 
consult the toxicological profile for CDFs (ATSDR 1994) and the toxicological profile for PCBs 
(ATSDR 1996) for information on the health effects associated with exposure to these groups of 
chemicals.
2.1 HUMAN STUDIES 
This section presents information on human health effects, including those known to be associated and 
those possibly associated with exposure to CDDs (primarily 2,3,7,8-TCDD).  Since limited data exist to 
assign a specific route of exposure (inhalation, oral, dermal) to human studies, the information in this 
section is organized by health effects—death, systemic, immunological, neurological, developmental, 
reproductive, genotoxic, and carcinogenic effects. These data are discussed in terms of three exposure 
periods—acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more). 
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The human studies discussed in this section are of populations known to reside or work in environments 
with above-background levels of CDDs and related compounds.  Data on health effects in humans 
following exposure to CDDs have come from studies on accidental, occupational, and residential exposure 
and from studies on the use of 2,3,7,8-TCDD-contaminated pesticides.  Because a number of these studies 
examined several end points, brief descriptions of these CDD-exposed populations are included in this 
section. Several factors complicate the interpretation of data regarding health effects in humans following 
exposure to CDDs; these include incomplete exposure data, concomitant exposure to other compounds, and 
a small number of participants, which limits the statistical power of the study to detect adverse health 
effects. Many of the studies on health outcomes following exposure to 2,3,7,8-TCDD and related 
compounds did not monitor exposure levels or internal dose.  Surrogates of exposure were often used to 
identify potentially exposed populations and the level of exposure; some of the more commonly used 
surrogates include chloracne (a dermal condition generally indicative of appreciable exposure), potential 
exposure to phenoxy herbicides known to be contaminated with 2,3,7,8-TCDD, living in the vicinity of an 
accidental release of substances containing CDDs and related compounds, or an area with CDD-
contaminated soil.  Some of the more recent studies have used blood lipid CDD levels as a measure of 
internal dose in order to quantify exposure in individuals.  In many of these studies, serum 2,3,7,8-TCDD 
levels were measured a number of years after exposure termination.  CDDs are highly persistent lipophilic 
compounds which are resistant to biodegradation and have a great potential to bioaccumulate.  Thus, a 
single chemical analysis of blood or adipose tissue represents a measure of past cumulative exposure to 
CDDs. With the assumptions of first-order kinetics for the elimination of 2,3,7,8-TCDD and an elimination 
half-life of 7–12 years, it is possible to extrapolate or adjust the serum or adipose tissue lipid concentration 
of 2,3,7,8-TCDD back to the time of the original excess exposure which may have occurred many years 
earlier, if the time of original exposure is known.  Body burden or total dioxin amount can then be 
calculated from the serum 2,3,7,8-TCDD levels using the assumption that the concentration of 
2,3,7,8-TCDD in serum lipid is in equilibrium with total body lipid 2,3,7,8-TCDD concentrations and that 
in an average adult 22% of the body weight is lipid.  Body burdens were calculated (see Table 2-1) for the 
human studies reporting serum (or tissue) lipid 2,3,7,8-TCDD concentrations.  If only current serum 
2,3,7,8-TCDD levels were reported, then half-life-adjusted serum levels and body burdens were calculated 
using a half-life of 8.5 years (Michalek et al. 1996) and 22% body fat for a 70 kg adult (DeVito et al. 
1995). A number of studies have calculated half-life-adjusted serum 2,3,7,8-TCDD levels; in these cases, 
the reported half-life adjusted serum 2,3,7,8-TCDD levels were used to estimate body burdens.  Egeland et 
al. (1994), Jansing and Korff (1994), and Wolfe et al. (1995) calculated half-life adjusted serum 
2,3,7,8-TCDD levels using a half-life of approximately 7 years.  The 7.1-year half-life was derived from a 
study of 36 veterans involved in Operation Ranch Hand (Pirkle 
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et al. 1989). In a later study of Ranch Hand personnel, Michalek et al. (1996) calculated a mean serum 
2,3,7,8-TCDD half-life of 8.5 years using blood samples collected in 1982, 1987, and 1992 from more than 
300 veterans. In the studies of populations exposed several decades prior to measuring 2,3,7,8-TCDD 
levels in the blood, a difference of 1.4 years in the half-life can yield a large difference in estimated body 
burdens. For example, in the Manz et al. (1991) study, in which the workers were exposed for 33 years 
prior to 2,3,7,8-TCDD analysis, a body burden of 945 ng/kg at the time of exposure was calculated using a 
half-life of 8.5 years; using the 7.1-year half-life, the body burden would be 1606 ng/kg.  See Section 2.3.4 
for a more complete discussion on estimating human body burdens and the overview to Section 2.5 for 
information on background exposure. 
Occupational exposure to CDDs most likely occurs mainly through inhalation of CDD-contaminated 
particles or dust and through dermal contact with solutions containing CDDs.  However, data indicate that 
oral exposure to low levels of CDDs from contaminated food (including milk) represents the major route of 
environmental exposure for the general population and for people living in areas with known dioxin 
contamination (Connett and Webster 1987; Schecter et al. 1994a; Travis and Hattemer-Frey 1987). 
Occupational Exposure.  Exposures to 2,3,7,8-TCDD, one of the most potent of the CDD congeners, 
have occurred occupationally in workers involved in the manufacture and application of trichlorophenols 
and the chlorophenoxy acid herbicides 2,4-dichlorophenoxyacetic acid (2,4-D) and 2,4,5-trichloro­
phenoxyacetic acid (2,4,5-T).  Holmstedt (1980) has reviewed the history of industrial exposures that have 
occurred between 1949 and 1976, and Kogevinas et al. (1997) summarized recent data on these cohorts. 
The first reported cases of industrial poisoning were in 1949 at a 2,4,5-T producing factory in Nitro, West 
Virginia. 2,3,7,8-TCDD formation resulted from uncontrolled conditions in the reactor producing 
2,4,5-trichlorophenol (2,4,5-TCP) from tetrachlorobenzene in methanol and sodium hydroxide. 
Approximately 228 workers (including production workers, laboratory personnel, and medical 
personnel) were affected. Between 1949 and 1968, 3 other explosive releases were reported:  1 
involved 254 workers at the BASF AG facility in Ludwigshafen, Germany, in 1953 (Goldman 1972; 
Thiess et al. 1982; Zober et al. 1990, 1993); a second similar accident in 1963 involving 106 workers 
at Philips-Duphar facility in Amsterdam, Netherlands was a problem since the seriousness of the 
2,3,7,8-TCDD exposure was not anticipated and cleanup workers were exposed (Holmstedt 1980); 
and the third was an explosion in a 2,4,5-TCP manufacturing facility in Coalite, England, involving 
90 workers (May 1973).  Holmstedt (1980) cited papers describing occupational exposure in 24 
additional factories producing TCPs or 2,4,5-T during the same period of time.  Exposure data on 
most of these incidents were limited; various numbers of workers were affected, and many of the 
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published reports are anecdotal. Ott et al. (1994) measured serum 2,3,7,8-TCDD levels in 138 of the 254 
exposed workers several decades after the explosion at the BASF facility.  More than 35 years after the 
explosion, serum 2,3,7,8-TCDD levels of <1–553 pg/g lipid were found; these correspond to serum levels 
of 3.3–12,000 pg/g lipid (calculated using a 7-year half-life) at the time of the accident. 
Some of the most comprehensive studies on occupational exposure were conducted by the National 
Institute for Occupational Safety and Health (NIOSH).  They are cross-sectional studies of workers at U.S. 
chemical facilities involved in the manufacture of 2,3,7,8-TCDD-contaminated products between 1942 and 
1984 (Calvert et al. 1991, 1992; Egeland et al. 1994; Fingerhut et al. 1991; Sweeney et al. 1993).  Serum 
2,3,7,8-TCDD levels were measured in the workers at two of the plants.  The mean 2,3,7,8-TCDD serum 
lipid level in 281 production workers in the Newark, New Jersey, and Verona, Missouri, plants was 220 ppt 
(range, 2–3,390 ppt) 18–33 years after exposure termination; the referent group of 260 people who had no 
self-reported occupational exposure and were matched by neighborhood, age, race, and sex had a mean 
serum 2,3,7,8-TCDD level of 7 ppt (Calvert et al. 1992; Sweeney et al. 1993).  Sweeney et al. (1990) 
estimated current mean lipid-adjusted 2,3,7,8-TCDD levels of 293.4 ppt (range, 2–3,390 ppt) in 103 
production workers at the New Jersey facility and 177.3 ppt (range, 3–1,290 ppt) in 32 workers at the 
Missouri facility; the mean half-life extrapolated levels (using a half-life of 7 years) were 2,664.7 ppt 
(range, 2–30,900 ppt) and 872.3 ppt (range, 3–6,100 ppt) in the two facilities, respectively.  It should be 
noted that serum 2,3,7,8-TCDD levels were only measured in workers at these two facilities, and it is not 
known if the levels in these workers are reflective of serum 2,3,7,8-TCDD levels in workers at the other ten 
facilities. 
There are also a number of studies of chlorophenol and phenoxy herbicide applicators.  Some of these 
studies used job histories, questionnaires, and interviews to determine which phenoxy herbicides the 
workers had used. Many of the studies did not measure exposure levels or internal doses; rather, 
2,3,7,8-TCDD exposure was assumed if the worker was exposed to a phenoxy herbicide known to be 
contaminated with 2,3,7,8-TCDD, such as 2,4,5-T.  However, the level of exposure to these 2,3,7,8-TCDD­
contaminated products was generally not determined. 
Residential/Environmental Exposures. Several incidents in which populations were exposed to 
potentially high levels of 2,3,7,8-TCDD include:  an industrial accident that occurred during the production 
of 2,4,5-TCP at the ICMESA plant in Seveso, Italy and the spraying of roads and other places with a 
mixture of waste oil, including chemical waste generated during the manufacture of 2,4,5-TCP, in 
Missouri. 
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The most widely studied release of 2,3,7,8-TCDD primarily involving residential exposures occurred in 
Seveso, Italy in 1976.  The ICMESA factory produced trichlorophenol by hydrolysis of 1,2,4,5-tetrachloro­
benzene with alkali in ethylene glycol.  The reactor overheated and the safety valve ruptured releasing a 
cloud containing primarily sodium trichlorophenate but also 2,3,7,8-TCDD.  It was estimated that more 
than 1.3 kg of 2,3,7,8-TCDD was released into the atmosphere and that more than 17,000 people in a 
2.8-km2 area adjacent to the facility were exposed.  To investigate this accident, the contaminated area was 
separated into regions A, B, and R based on soil levels of 2,3,7,8-TCDD.  The population sizes were 736, 
4,737, and 31,800 in areas A, B, and R, respectively.  The respective mean (and maximum) surface soil 
levels of 2,3,7,8-TCDD were 230 (447) µg/m2, 3 (43.8) µg/m2, and 0.9 (9.7) µg/m2  for areas A, B, and R, 
respectively.  Dividing the populations into different zones based on soil levels has been criticized because 
it does not take into consideration actual-exposure levels and differences in within-zone 2,3,7,8-TCDD 
exposure (Mastroiacovo et al. 1988). Blood and tissue samples from exposed individuals have been saved 
and 2,3,7,8-TCDD levels in some of the original samples and in follow-up blood samples have been 
analyzed.  Serum 2,3,7,8-TCDD levels ranged from 828 to 56,000 ppt (lipid adjusted) in 19 residents of 
zone A (Mocarelli et al. 1991). 
Various populations in Missouri were exposed to 2,3,7,8-TCDD in 1971 and 1972 as a result of spraying 
approximately 29 kg  of 2,3,7,8-TCDD-contaminated waste oil on horse arenas, parking lots, and 
residential roads for dust control (Andrews et al. 1989).  The oils originated from an industrial waste 
residue contaminated with 2,3,7,8-TCDD at levels of 305 ppm (Needham et al. 1991).  An exposed group 
of 51 adults have been the subject of several studies.  Adipose tissue levels, as well as paired human serum 
levels, were measured for 36 of these persons.  Sixteen of the individuals were residents of areas where 
roadways had been sprayed and had mean 2,3,7,8-TCDD adipose tissue levels of 21.1 ppt (range, 
1.28–59.1 ppt) in 1985 (Andrews et al. 1989). Eight persons exposed to 2,3,7,8-TCDD at the horse arenas 
had a mean adipose 2,3,7,8-TCDD concentration of 90.8 ppt (5.0–577 ppt).  In a comparison population of 
57 people with no known 2,3,7,8-TCDD exposure, 2,3,7,8-TCDD levels in the adipose tissue ranged from 
1.4 to 20.2 ppt, with a mean of 7.4 ppt.  Although the population of study was not large, they were 
evaluated in depth for medical effects (Hoffman et al. 1986; Stehr et al. 1986; Webb et al. 1984). 
Exposures in Vietnam. During the Vietnam war, a program of aerial spraying of herbicides, code 
name Ranch Hand, was conducted in 10–20% of the Republic of Vietnam.  During the 9 years of the 
program (1962–70), 19 million gallons of herbicides were dispersed.  Six herbicides were used, with Agent 
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was a 1:1 mixture of 2,4-D and 2,4,5-T in diesel oil and contained <1–20 ppm 2,3,7,8-TCDD as a 
contaminant.  A number of studies have examined the possible association between Agent Orange exposure 
and adverse health effects in Vietnam veterans and Vietnamese residents living in the area of spraying.  The 
results of a study comparing blood 2,3,7,8-TCDD levels in Vietnam veterans and the general U.S. 
population found that on average there was no significant difference between blood 2,3,7,8-TCDD levels 
between Vietnam veterans and comparison populations (CDC 1987).  Thus, “service in Vietnam” or self-
reported exposure to Agent Orange is not a reliable index of 2,4,5-T or 2,3,7,8-TCDD exposure.  Studies of 
Air Force personnel participating in Operation Ranch Hand have found increased serum 2,3,7,8-TCDD 
levels in some of the persons (CDC 1987; USAF 1991).  The median level in serum lipids for 888 Ranch 
Hand personnel was 12.4 ppt (range, 0 to 617.7 ppt) in contrast to 4.2 ppt (0-54.8 ppt) in a comparison 
group of 856 matched Air Force personnel (Wolfe et al. 1995).  The median and high serum 2,3,7,8-TCDD 
levels would extrapolate to original serum levels of 43 and 3135 ppt, respectively, based on 20 years of 
elapsed time, and a half-life of 8.5 years.  Since the tour of duty in Vietnam for the majority of U.S. 
veterans was generally less than 1 year, the military exposure was considered to be of intermediate duration 
if not stated otherwise in the original study.  
No studies were located, however, regarding health effects in humans exposed to CDDs by specific routes of 
exposure (e.g., inhalation, oral, dermal).  In this profile, human health effects caused by combined exposure 
through various exposure routes are discussed separately from effects found in animals that were maintained 
under controlled experimental conditions (i.e., route, duration, and levels). 
2.1.1 Death 
None of the studies examining humans acutely exposed to high concentrations of 2,3,7,8-TCDD or other 
CDD congeners (as contrasted with long-term studies) reported acute instances of death.  A number of 
epidemiology studies have investigated mortality in populations occupationally or environmentally exposed 
to 2,3,7,8-TCDD or chemicals contaminated with 2,3,7,8-TCDD or other CDD congeners.  No significant 
increases in the number of deaths were observed in workers at phenoxy herbicide or chlorophenol 
manufacturing facilities (Cook et al. 1986, 1987b; Fingerhut et al. 1991; Ott et al. 1980, 1987; Zack and 
Suskind 1980) or in workers exposed to 2,3,7,8-TCDD as a result of the accident at the BASF AG facility in 
Germany (Ott and Zober 1996; Thiess et al. 1982; Zober et al. 1990).  Additionally no increases in mortality 
were observed in the 10-year period after the Seveso accident (Bertazzi et al. 1989b) or in Vietnam veterans 
involved in Operation Ranch Hand (Wolfe et al. 1985).  Although none of these studies found significant 
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increases in the overall mortality rate, several studies found statistically significant increases in cause-
specific mortality.  For example, Flesch-Janys et al. (1995) found a significant risk of cardiovascular disease 
and ischemic heart disease mortality in workers exposed to 2,3,7,8-TCDD and other congeners during the 
BASF AG accident, and Fingerhut et al. (1991) found a significantly increased risk of cancer mortality in 
phenoxy herbicide and chlorophenol production workers.  More complete descriptions of significant findings 
in the mortality studies are presented in  the appropriate effect portions of Section 2.1. 
2.1.2 Systemic Effects 
The effects of 2,3,7,8-TCDD exposure in humans exposed in occupational or environmental settings have 
been described in several studies. Few studies provided precise exposure levels.  However, for some 
cohorts, blood lipid 2,3,7,8-TCDD levels in samples collected shortly after exposure and stored frozen for 
several years have been analyzed.  In other studies, the original blood levels of 2,3,7,8-TCDD were 
estimated using 2,3,7,8-TCDD levels measured in recent blood samples, the amount of time between 
exposure and blood sample collection, and a mean serum half-life of 5–12 years.  2,3,7,8-TCDD body 
burdens calculated from available serum lipid 2,3,7,8-TCDD levels are presented in Table 2-1. 
Respiratory Effects. Information regarding respiratory effects of CDDs in humans is limited.  Effects of 
acute massive exposure in workers exposed to 2,3,7,8-TCDD in an industrial accident in Germany included 
bronchitis and laryngitis a few days after exposure, and hemorrhagic pleuritis 11 months after exposure 
(Goldman 1973).  In an occupationally exposed group, decreased pulmonary function was found in smokers 
10 years after the cessation of manufacture of herbicides contaminated with 2,3,7,8-TCDD as compared with 
nonexposed smokers (Suskind and Hertzberg 1984).  In contrast with the results of Suskind and Hertzberg 
(1984), Calvert et al. (1991) found no significant differences in ventilatory function between a group of 281 
workers employed 15 years earlier in the production of NaTCP, 2,4,5-T ester, or hexachlorophene and 260 
referents. At the time of the examination, the lipid-adjusted mean serum 2,3,7,8-TCDD concentration was 
220 ppt in the exposed workers compared to 7 ppt for the referents.  In addition, there was no association 
between previous occupational exposure to 2,3,7,8-TCDD contamination and elevation in the incidence of 
chronic bronchitis or in the prevalence of chronic obstructive respiratory disease.  Calvert et al. (1991) 
suggested that the disparity between their results and those of Suskind and Hertzberg (1984) may have been 
due to the fact that exposed workers in the Suskind and Hertzberg (1984) study were, on average, 10 years 
older than controls and to the potential exposure to 2,4,5-T acid dust in that study.  The 2,4,5-T 
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acid was finished as a liquid as opposed to a powder in the plant studied by Suskind and Hertzberg (1984), 
thus limiting inhalation exposure. 
No respiratory effects were associated with exposure to 2,3,7,8-TCDD-contaminated herbicides in a group of 
Vietnam Air Force veterans involved in Operation Ranch Hand examined more than 10 years after the war 
(Wolfe et al. 1985). In the 1987 follow-up (USAF 1991), no association was found between the initial or 
current serum level of 2,3,7,8-TCDD and incidences of asthma, bronchitis, pleurisy, pneumonia, or 
tuberculosis; abnormal spirometric measurements were often associated with CDD blood levels, but 
according to the authors (USAF 1991), the differences in the mean level between high- and low-exposure 
subjects were not clinically important.  The authors suggested that these findings may have been related to 
the association between 2,3,7,8-TCDD and body fat because obesity is known to cause a reduction in vital 
capacity.  
A recent follow-up of the cohort involved in the Seveso accident reported a significant increase in deaths 
(4 deaths) from chronic obstructive pulmonary disease in males from zone A (relative risk [RR]=3.7; 95% 
confidence internal [CI]=1.4–9.9) and in females from zone B (7 deaths; RR=2.4; 95% CI=1.1–5.1) (Pesatori 
et al. 1998). The excess found among zone A males was mainly detected in the first 5 years after the 
accident and mainly affected elderly men.  As mentioned below under Cardiovascular Effects among this 
cohort, Pesatori et al. (1998) stated that stress related to the disaster experience could have precipitated early 
deaths among people with pre-existing chronic respiratory disease.  The investigators also speculated that 
2,3,7,8-TCDD, through immunotoxic action, may have impaired protection and defense against episodes of 
respiratory infection, which play a major role in the natural history of chronic obstructive respiratory disease. 
The existing information suggests that acute exposure to high levels of CDDs may cause respiratory effects 
mainly as a response to upper respiratory tract irritation, but evidence from the numerous cohorts exposed to 
2,3,7,8-TCDD that have been studied suggests that the respiratory system is not a target for 2,3,7,8-TCDD 
toxicity. 
Cardiovascular Effects. Most earlier data indicated that exposure to CDDs does not induce 
cardiovascular effects (Bond et al. 1983; Moses et al. 1984; Suskind and Hertzberg 1984). In a cross-
sectional health survey in 1979 of 226 workers who had potential exposure to 2,3,7,8-TCDD from 1948 to 
1969 in 2,4,5-T production, 52% had chloracne (present for a mean of 26 years) which was used as a 
surrogate for heavy exposure.  When the chloracne group was compared to workers without chloracne (low 
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exposure rather than unexposed workers), there was an increased reported incidence of angina and 
myocardial infarction; when these data were age-adjusted, the prevalence was not statistically increased 
(Moses et al. 1984). Examination of West Virginia TCP production workers revealed no increases in the 
prevalence of hypertension or coronary artery disease, abnormal ECG findings, atherosclerotic changes on 
chest X-ray, or blood pressure elevation (Suskind and Hertzberg 1984). 
Cardiovascular examination did not reveal any changes in 17 individuals who were treated for dermal lesions 
following acute exposure to 2,3,7,8-TCDD in the Seveso industrial accident (Reggiani 1980) or in a group of 
Missouri residents living in 2,3,7,8-TCDD-contaminated areas for a chronic period of time (mean 2.8 years 
in one area, 4.9 years in others) (Hoffman et al. 1986).  In the 10-year period following the Seveso accident, 
there was a significant increase in the relative risk (RR) of death from chronic ischemic heart disease in men 
(RR=1.56; 95% CI=1.2–2.1), which was predominantly due to the increased risk during the first 5-year 
period (RR=1.76; 95% CI=1.2–2.5) (Bertazzi et al. 1989a).  When the residents were divided into 
contamination zones, the relative risks of death from chronic heart disease in zones A, B, and R were 5.16 
(95% CI=1.3–20.9), 1.57 (95% CI=0.6–4.2), and 1.72 (95% CI=1.2–2.5), respectively, for the first 5-year 
period and 3.28 (95% CI=0.8–13.2), 0.96 (95% CI=0.4–2.6), and 1.61 (95% CI=1.2–2.2), respectively, for 
the 10-year period (Bertazzi et al. 1989b).  In females, there was an increased risk of death from chronic 
rheumatic heart disease (RR=1.54; 95% CI=0.7–3.2) during the 10-year period (Bertazzi et al. 1989a), which 
was predominately due to the high relative risk in women living in zone A (RR=27.58; 95% CI=8.5–89.9) 
(Bertazzi et al. 1989b). Bertazzi et al. (1989b) noted that increased risk of cardiovascular disease deaths may 
have been due to post-accident stress rather than to 2,3,7,8-TCDD exposure.  The results of a 5-year follow-
up were recently published (Pesatori et al. 1998).  The recent analysis reported five deaths in males from 
chronic ischemic heart disease (RR=3.0; 95% CI=1.2–7.3); three deaths in females from chronic rheumatic 
heart disease (RR=15.8; 95% CI=4.9–50.4); and three deaths, also in females, from hypertensive vascular 
disease (RR=3.6; 95% CI=1.2–11.4), all from zone A, the most severely affected area.  Although these 
observations suggest an association between exposure to 2,3,7,8-TCDD and incidence of cardiovascular 
effects, they do not necessarily show that the effects were caused by 2,3,7,8-TCDD.  As previously 
suggested by Bertazzi et al. (1989a), Pesatori et al. (1998) also indicates that the disaster experience with its 
burden of psychosocial stressors may have played a major role in the increased deaths found. 
No cardiovascular effects were observed in a group of Air Force veterans exposed to 2,3,7,8-TCDD­
contaminated herbicides during the Vietnam war and examined several years post-exposure (Wolfe et al. 
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1985). However, a follow-up study of the Ranch Hand cohort reported increased mean diastolic blood 
pressure in those with current serum lipid 2,3,7,8-TCDD levels from 15 to 33.3 ppt, but not in subjects with 
higher 2,3,7,8-TCDD serum levels (USAF 1991).  In addition, the proportion of abnormally low peripheral 
pulses in all Ranch Hand veterans, regardless of serum levels, was elevated relative to a comparison group. 
Also, arrhythmias detected on the electrocardiogram were significantly associated with 2,3,7,8-TCDD 
exposure, but there was no consistent dose-response relationship. 
Flesch-Janys et al. (1995) found significant increases in mortality from heart and circulatory diseases in 
workers exposed to 2,3,7,8-TCDD and other CDD congeners during the accident at BASF AG.  Relative 
risks for cardiovascular disease and ischemic heart disease mortality were 1.96 (95% CI=1.15–3.34) and 2.48 
(95% CI=1.32-4.66), respectively, for workers with extrapolated serum lipid 2,3,7,8-TCDD levels of 
$348 pg/g (ppt) (current 2,3,7,8-TCDD levels were used to estimate 2,3,7,8-TCDD levels at the end of 
exposure). Additionally, statistically significant dose-response trends for increasing cardiovascular and 
ischemic heart disease deaths were found.  The risk for cardiovascular and ischemic heart disease deaths also 
increased as the serum lipid CDD and CDF levels increased.  However, the results from the Flesch-Janys et 
al. (1995) study are difficult to interpret since the percentage of chemical workers who died from cardio­
vascular disease was 38% compared to 49% for a referent group from a gas supply company with no known 
special exposure to CDDs/CDFs. An international study comprising 36 cohorts from 12 countries and a total 
of 21,863 workers exposed to phenoxyacid herbicides and chlorophenols followed from 1939 to 1992 
detected an increased risk for death from cardiovascular disease, especially ischemic heart disease (RR=1.67; 
95% CI=1.23–2.26) among the exposed workers (Vena et al. 1998).  Risks did not differ across latency 
categories or by year of first exposure, but increased slightly by duration of exposure except for those with 
20 or more years of exposure.  Vena et al. (1998) indicate, however, that the study was hampered by the 
reliance on mortality and the crudeness and inaccuracies of death certificate diagnoses.  Furthermore, they 
noted that possible confounding effects from important risk factors for ischemic heart disease such as 
cigarette smoking, high fat diet, blood pressure, obesity, physical inactivity, and serum lipids cannot be ruled 
out. 
In contrast with the positive findings described in the studies summarized above, a recent study of 281 
workers employed 15 years earlier in the manufacturing of 2,4,5-trichlorophenol at two U.S. chemical plants 
and 260 unexposed referents found no significant association between 2,3,7,8-TCDD exposure and adverse 
cardiovascular effects (Calvert et al. 1998). The mean serum 2,3,7,8-TCDD concentrations (on a lipid basis) 
were 220 ppt in the workers and 7 ppt in the referents.  Among the workers, the mean 2,3,7,8-TCDD 
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concentration when occupational exposure ceased was estimated to have been 1,900 ppt using a 7-year 
estimated half-life for serum 2,3,7,8-TCDD.  Cardiovascular outcomes examined included myocardial 
infarction, angina, cardiac arrhythmias, hypertension, and abnormal, peripheral arterial flow.  Calvert et al. 
(1998) indicated that although the study had sufficient statistical power to detect an elevated risk for cardiac 
arrhythmias, hypertension, and abnormal peripheral arterial flow, it had low power (approximately 50%) to 
detect an elevated risk for myocardial infarction and angina and concluded that further examination of the 
association between exposure to 2,3,7,8-TCDD and cardiovascular diseases is necessary. 
In summary, there is suggestive but inconclusive evidence of adverse cardiovascular effects in humans 
exposed to relatively high concentrations of CDDs.  Increased deaths from chronic heart disease were 
observed among the Seveso cohort, but psychosocial factors could not be ruled out; no clear dose-response 
relationships were seen among the Ranch Hand cohort; increased deaths from heart and circulatory disease 
were reported among German workers exposed to CDDs; and no evidence of adverse cardiovascular effects 
was detected among U.S. workers exposed to CDDs. 
Gastrointestinal Effects. Earlier studies of individuals with exposure to substances contaminated with 
2,3,7,8-TCDD found significant elevations in self-reported ulcers (Bond et al. 1983; Suskind and Hertzberg 
1984), but a study of Vietnam veterans (USAF 1991) failed to find such effects.  A more recent study 
evaluated the gastrointestinal effects of exposure to substances contaminated with 2,3,7,8-TCDD in an 
occupational cohort (Calvert et al. 1992). More than 15 years earlier, the workers were employed in the 
manufacture of trichlorophenol and its derivatives at 2 chemical plants.  A total of 281 workers participated 
in the medical study; the control group consisted of 260 unexposed subjects who lived in the same 
communities as the workers.  The participants underwent a comprehensive physical examination of the 
abdomen and rectum.  The mean serum 2,3,7,8-TCDD level (on a lipid basis) for the workers was 220 ppt 
and was found to be highly correlated with years of exposure to 2,3,7,8-TCDD-contaminated substances; 
controls had a mean serum 2,3,7,8-TCDD concentration of 7 ppt.  At the time of examination, the workers 
were not found to be at increased risk for any gastrointestinal diseases.  Moreover, neither gastrointestinal 
ulcer disease nor gastritis was found to be significantly associated with any measure of 2,3,7,8-TCDD 
exposure, as determined by logistic regression analysis.  The only significant finding from the physical 
examination was a statistically significant association between decreased anal sphincter tone and 
2,3,7,8-TCDD exposure. This, however, was attributed to examiner bias since all those that exhibited 
reduced sphincter tone were examined by the same physician (two physicians conducted the blind 
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examinations).  The results of these studies suggest that there is no association between occupational 
exposure to 2,3,7,8-TCDD and gastrointestinal disease. 
Hematological Effects. Human studies regarding exposure to 2,3,7,8-TCDD or 2,3,7,8-TCDD­
contaminated chemicals did not find any overt hematological effects after intermediate- (Wolfe et al. 1985) 
and chronic-duration exposures (Stehr et al. 1986). 
Contact with 2,3,7,8-TCDD-contaminated soil in Missouri by physical or recreational activities for 6 months 
at 100 ppb or for 2 years at 20–100 ppb resulted in a slight but statistically significant increase in total white 
blood cell (WBC) counts using a prevalence test (5.3% were increased above 10,000 WBC/mm3 compared to 
0.7% for controls, but the increase was slight) (Hoffman et al. 1986).  A follow-up study of the same 
population found no differences in the number of red blood cells, white blood cells, or platelets between 
exposed and nonexposed individuals (Evans et al. 1988).  In a similar cohort, Stehr et al. (1986) found no 
consistent differences in hematology parameters in a high-risk group (68 persons) compared to a low-risk 
group (36 persons) except a slightly elevated platelet count.  No significant differences in total leukocyte, 
granulocyte, or lymphocyte levels were observed between workers with high serum lipid CDD and CDF 
levels and workers with lower serum CDD and CDF levels (Neubert et al. 1993). 
A health study of Vietnam veterans involved in Operation Ranch Hand indicated an association between 
high initial and current serum 2,3,7,8-TCDD levels and increased erythrocyte sedimentation (Wolfe et al. 
1995), and an earlier study by Wolfe et al. (1985) indicated an increase in mean corpuscular volume; 
however, these changes were minor and were not observed in the 1991 follow-up (USAF 1991).  Higher 
serum 2,3,7,8-TCDD levels were also associated with positive dose-response trends for increases in white 
blood cell and platelet levels. 
The existing information suggests that CDDs, at the body burdens seen in the studied populations, do not 
cause adverse hematological effects. 
Musculoskeletal Effects. The only information available comes from two anecdotal reports.  In one of 
them, two individuals exposed to 2,3,7,8-TCDD in a horse arena that was sprayed with waste oil for dust 
control complained of painful joints (arthralgia) (Kimbrough et al. 1977).  In the second case, a chemist 
exposed to 2,3,7,8-TCDD and 2,3,7,8-tetrabromo-p-dibenzo dioxin (2,3,7,8-TBDD) complained of muscle 
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pain in the lower extremities and back (Schecter and Ryan 1991). The role that  2,3,7,8-TCDD played in 
these cases, if any, is unknown.  No further information was located. 
Hepatic Effects. Two of three laboratory workers synthesizing or working with 2,3,7,8-TCDD in the 
laboratory developed chloracne 8 weeks after potential acute exposures (Oliver 1975).  Blood cholesterol 
levels (the only biochemical change) were elevated in all three workers and remained elevated for two years. 
Biochemical examinations were conducted on 55 male workers in Prague who were admitted into a hospital 
in 1968 and 1969 suffering from chronic 2,3,7,8-TCDD intoxication from exposure in a plant producing 
2,4,5-T (Pazderova-Vejlupkova et al. 1981). The first symptoms of intoxication included chloracne (present 
in the majority of the workers) and neurological symptoms; levels of exposure were never measured. 
Hypercholesterolemia was seen in 56% of the patients, hyperlipemia in 67%, hyperphospholipidemia in 
42%, diabetes mellitus in 8%, a low glucose tolerance level in 19%, increased α and γ globulins in 42% and 
uroporphyria in 21% (the study did not include a referent group) (Jirasek et al. 1976; Pazderova-Vejlupkova 
et al. 1981). Liver biopsies revealed mild steatosis, periportal fibrosis, and activated Kupffer cells in those 
examined.  At 10 years postexposure, most of the biochemical changes were not detected; only cholesterol 
levels remained high (Pazderova-Vejlupkova et al. 1981). Transient alterations of liver function tests were 
reported in workers exposed to 2,3,7,8-TCDD following an industrial accident in Great Britain (May 1973). 
Jennings et al. (1988) found nonsignificant increases in serum cholesterol and triglycerides but no effect on 
gamma-glutamyltransferase (GGT), alanine aminotransferase (ALT), or creatinine in a group of 18 workers 
in England who had been exposed 17 years previously, when comparisons were made with a group of 15 
carefully matched controls. 
Mocarelli et al. (1986) conducted a 6-year study on clinical laboratory parameters of children exposed to 
2,3,7,8-TCDD following the Seveso accident. ALT, aspartate aminotransferase (AST), GGT, alkaline 
phosphatase, cholesterol, and triglycerides in plasma and delta amino levulinic acid in urine were monitored 
yearly in exposed and control groups beginning in June, 1977, approximately 1 year after the incident.  The 
children were 6–10 years old at the time of the accident; 69, 528, and 874 resided in the A, B, and R zones, 
respectively.  Chloracne was seen in 19, 0.7, and 4.6%, of the children in areas A, B, and R, respectively. 
Blood samples were drawn from 69, 83, and 221 children in areas A, B, and R, respectively.  A slight 
increase in GGT and ALT occurred in the highest exposure group (based on zone of residences) compared to 
controls, but the values were not considered abnormal and returned to baseline levels within 3 years of the 
initial exposure. 2,3,7,8-TCDD blood levels have been more recently analyzed in about 30 of the subjects 
(Mocarelli et al. 1991). Similarly altered biochemical values (mainly increased serum transaminases and 
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GGT) were reported much earlier in individuals residing in an area of Seveso with average soil 
2,3,7,8-TCDD concentrations of 580.4 µg/m2 (Pocchiari et al. 1979). A study of clinical chemistry 
parameters and urinary porphyrins in Missouri residents living in a 2,3,7,8-TCDD-contaminated area did not 
indicate any definitive changes that were of clinical importance in 154 persons (high-risk, based on soil 
levels of dioxins) exposed for up to 11 years (Webb et al. 1989).  Multivariate regression analysis with 
number of years of residence as a surrogate of dose gave a positive trend for GGT and alkaline phosphatase.  
A medical survey of workers employed more than 15 years earlier in the manufacture of sodium trichloro­
phenol and its derivatives at two chemical plants found no evidence of an elevated risk for clinical hepatic 
disease at the time of examination (Calvert et al. 1992).  The cohort consisted of 282 workers and 260 
unexposed matched controls.  Exposure was assessed by measuring lipid-adjusted serum 2,3,7,8-TCDD 
levels. The mean serum 2,3,7,8-TCDD level in the workers was 220 ppt, compared with 7 ppt in the control 
group. The results from abdominal and rectal examination were unremarkable.  Similarly, the results from 
blood and urine tests measuring liver function showed no statistically significant differences between 
exposed workers and controls, with the exception of a statistically significantly higher mean GGT level in 
workers. Also, workers were found to have a statistically significant elevated risk for an out-of-range GGT 
level compared with referents.  However, multivariate analysis with logistic regression showed a statistically 
significant interaction between 2,3,7,8-TCDD exposure and lifetime alcohol consumption, indicating that the 
elevated risk for an out-of-range GGT was confined to those workers with a history of alcohol consumption 
and that the risk among the alcohol-consuming workers for an out-of-range GGT increased with increasing 
2,3,7,8-TCDD level. 
In a follow-up study, Calvert et al. (1996) examined the association between exposure to 2,3,7,8-TCDD and 
serum lipids.  In the follow-up the authors chose not to adjust the 2,3,7,8-TCDD serum concentrations for 
total lipids to avoid the problems of interpretation that would arise when adjusting a covariate by the 
dependent variable. Consequently, the results obtained in this study cannot be compared directly with those 
from the Operation Ranch Hand study (see below).  The median serum 2,3,7,8-TCDD concentration among 
the workers was 406.6 femtograms/g serum (fg/g) compared with 36.9 fg/g among the referents.  The results 
of logistic regression analyses revealed an association between serum 2,3,7,8-TCDD and risk for an 
abnormally decreased HDL cholesterol concentration that approached statistical significance (p=0.09) after 
controlling for body weight index, use of beta-blocker medication, age, diabetes, and employment at the two 
plants. The concentration of 2,3,7,8-TCDD was not associated with having either an abnormal total 
cholesterol concentration or an abnormal total cholesterol/HDL cholesterol ratio.  When the workers were 
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stratified into quartiles according to their serum 2,3,7,8-TCDD concentration, and after controlling for 
important confounders, those with the highest 2,3,7,8-TCDD concentrations (1,516–19,717 fg/g) had an 
elevated risk for an abnormal HDL cholesterol concentration (odds ratio [OR]=2.2; 95% CI=1.1–4.7).  A 
small but statistically significant association between triglyceride concentration and serum 2,3,7,8-TCDD 
was also found (p=0.05) after controlling for gender, plant location, body weight index, cumulative cigarette 
consumption, use of beta-blocker medication, race, and diabetes.  However, in the logistic analyses, 
abnormal triglyceride concentration was not associated with serum 2,3,7,8-TCDD concentration (p=0.21). 
Analysis by quartiles showed that workers with the highest 2,3,7,8-TCDD serum concentration had a 
statistically significant elevation in mean triglyceride concentration compared with the referent group. 
However, no significant trend was observed in the quartile analyses that evaluated risk for an abnormal 
triglyceride level.  Calvert et al. (1996) concluded that the associations of serum 2,3,7,8-TCDD 
concentration with triglycerides and HDL (high density lipoprotein) cholesterol were small when compared 
with the influence of many other factors. 
A health study in Vietnam veterans involved in Operation Ranch Hand found no liver diseases linked to 
2,3,7,8-TCDD exposure, but biochemical examinations revealed a pattern suggestive of a subclinical effect 
on lipid metabolism (USAF 1991).  Blood triglycerides showed a strong positive association with both the 
initial levels of 2,3,7,8-TCDD and the current serum levels; the authors indicated that this variable is highly 
sensitive to body fat, which was increased in the more highly exposed individuals.  Cholesterol, HDL, and 
the cholesterol-HDL ratio also showed significant associations with 2,3,7,8-TCDD. 
In conclusion, hepatotoxic effects, such as elevated GGT levels and small alterations in lipid profile, have 
sometimes been observed in humans following exposure to high 2,3,7,8-TCDD levels.  In general, the effects 
are mild and in some cases appear to have been transient. 
Information regarding hepatic effects observed in infants exposed perinatally to CDDs and structurally 
related compounds is presented in Section 2.5 under Developmental Effects. 
Renal Effects. A child who played in a sand box contaminated with waste oils containing 2,3,7,8-TCDD 
developed hemorrhagic cystitis and focal pyelonephritis (Kimbrough et al. 1977).  Since chloracne was not 
seen and levels of 2,3,7,8-TCDD in the sand were not provided, the effects cannot be definitely attributed to 
2,3,7,8-TCDD exposure. No renal effects were reported in other individuals exposed at the same location. 
An early study in Missouri residents chronically exposed to a 2,3,7,8-TCDD-contaminated environment 
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found increased incidence of self-reported urinary problems, leukocyturia, and microscopical hematuria 
(Webb et al. 1984). However, the results of urinalysis on this group did not indicate any kidney effects 
(Hoffman et al. 1986; Stehr et al. 1986).  No renal effects were found in a group of Vietnam veterans 
exposed to 2,3,7,8-TCDD in Agent Orange based on case histories and evaluation of five laboratory 
variables comparing Ranch Hand veterans and the various comparison groups (USAF 1991; Wolfe et al. 
1985, 1990). Kidney lesions have not been reported in any of the several studies on occupational exposure 
or for exposed cohorts in Seveso, Italy.  These studies suggest that the kidney is not a target organ of 
2,3,7,8-TCDD toxicity in humans. 
Endocrine Effects. Jennings et al. (1988) examined thyroid function in a group of 18 workers exposed 
to 2,3,7,8-TCDD as a result of an industrial accident during the manufacture of 2,4,5-T.  At the time of the 
study, 17 years after the accident, all the workers appeared healthy.  No measure of exposure was provided. 
An unexposed group of 15 subjects served as controls.  The end points monitored were serum thyroxine 
(T4), triiodothyronine (T3), and thyroid stimulating hormone (TSH).  Without providing further details, the 
authors indicated that none of the subjects studied had biochemical evidence of thyroid dysfunction.  A 
35-year follow-up study of workers exposed to 2,3,7,8-TCDD during the BASF accident found a significant 
increase in the incidence of thyroid disease, as compared to an age-matched referent group (Zober et al. 
1994). The workers were divided into two groups based on back-calculated (using a 7-year half-life) serum 
lipid 2,3,7,8-TCDD levels of $1,000 ppt and <1,000 ppt. For both groups of 2,3,7,8-TCDD-exposed 
workers, the incidence of thyroid disease was significantly higher than for the referent group, but did not 
differ between the two groups of workers. 
Endocrine function was assessed in Vietnam veterans involved in Operation Ranch Hand.  A strong positive 
association was found between glucose intolerance or increased risk of diabetes and 2,3,7,8-TCDD serum 
levels (USAF 1991). The diabetes finding remained significant even after adjusting for body fat.  Further­
more, subclinical effects in thyroid function (significant decrease in mean T3 uptake and increases in mean 
TSH) were reported for Operation Ranch Hand veterans with high current 2,3,7,8-TCDD serum levels of 
$33.3 ppt (USAF 1991). However, the magnitude of the differences was not considered physiologically 
significant. A follow-up study of Operation Ranch Hand veterans provides further information on the 
association between serum 2,3,7,8-TCDD levels and the incidence of diabetes mellitus and glucose and 
insulin levels (Henriksen et al. 1997). The cohort consisted of 989 exposed subjects and 1,276 comparison 
individuals who served in Southeast Asia (54) during the same period but who were not involved with 
spraying herbicides.  Initial dioxin levels were computed using a first-order pharmacokinetic model with a 
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constant half-life of 8.7 years.  Four exposure categories were defined: 1) comparisons, with current dioxin 
levels of #10 ppt; 2) background Operation Ranch Hand veterans, with current dioxin levels of #10 ppt; 
3) low category, with initial dioxin levels exceeding 10 ppt but #94.2 ppt; and 4) high category, with initial 
dioxin levels >92.4 ppt. Adjustments were made for age, race, and military occupation.  The current median 
dioxin levels in the low and high categories were 15.0 and 46.2 ppt, respectively.  The results of the analysis 
showed an increase in glucose abnormalities (RR=1.4; 95% CI 1.1, 1.8), diabetes prevalence (RR=1.5; 
CI 1.2, 2.0), and use of oral medications to control diabetes (RR=2.3; CI 1.3, 3.9) and a decrease in the time­
to-diabetes onset with dioxin exposure. Serum insulin abnormalities increased in nondiabetics.  Henriksen et 
al. (1997) pointed out that although some unknown confounder may not have been adjusted for, the strengths 
of the study included high participation and low attrition rates and accurate serum dioxin measurement and 
that, taken together, the results indicated a possible relation between dioxin exposure and diabetes mellitus, 
glucose metabolism, and insulin production.  A follow-up evaluation of a cohort from the Seveso accident 
population found a significant increase in deaths from diabetes among women from zone B (RR=1.9; 95% 
CI=1.1–3.2) (Pesatori et al. 1998). Thirteen deaths were reported and 9 out of the 13 occurred in the second 
decade after the accident (RR=3.1; 95% CI=1.6–6.1). Pesatori et al. (1998) indicated that the fact that only 
women were affected might be explained by the systematically higher 2,3,7,8-TCDD concentrations in 
females than in males. 
In summary, the evidence available from epidemiological studies suggests that exposure to high 
concentrations of CDDs may induce long-term alterations in glucose metabolism and subtle alterations in 
thyroid function. 
Information regarding endocrine effects observed in infants exposed perinatally to CDDs and structurally 
related compounds is presented in Section 2.5 under Developmental Effects. 
Dermal Effects. The most commonly observed effect of 2,3,7,8-TCDD exposure in humans is chloracne 
(Jirasek et al. 1976; Kimbrough et al. 1977; May 1973; Oliver 1975; Reggiani 1980).  Chloracne is 
characterized by follicular hyperkeratosis (comedones) occurring with or without cysts and pustules (Crow 
1978). Unlike adolescent acne, chloracne may involve almost every follicle in an involved area and may be 
more disfiguring than adolescent acne (Worobec and DiBeneditto 1984).  Chloracne usually occurs on the 
face and neck, but may extend to the upper arms, back, chest, abdomen, outer thighs, and genitalia.  In mild 
cases, the lesions may clear several months after exposure ceases, but in severe cases they may still be 
present 30 years after initial onset (Crow 1978; Moses and Prioleau 1985).  In some cases lesions may 
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resolve temporarily and reappear later.  Scarring may result from the healing process.  Other chlorinated 
organic chemicals can also cause chloracne. 
Acute exposure to 2,3,7,8-TCDD in a chemical laboratory induced the development of chloracne in two of 
three individuals within 8 weeks of the exposure (Oliver 1975).  Chloracne occurred in workers 
occupationally exposed to 2,3,7,8-TCDD during the manufacture of herbicides (Bond et al. 1989b; Moses 
and Prioleau 1985; Poland et al. 1971) and after industrial accidents in several locations throughout the 
world (Goldman 1973; May 1973; Moses et al. 1984; Pocchiari et al. 1979; Suskind and Hertzberg 1984).  
Accidental exposure to 2,3,7,8-TCDD in a 1949 explosion in a trichlorophenol plant in Nitro, West Virginia, 
resulted in an outbreak of severe chloracne. Moses et al. (1984) conducted a cross-sectional survey of 
workers in this plant in 1979. In reviewing the impact of the accident, the authors indicated that 117 workers 
had severe chloracne as a result of the explosion; however, 111 additional workers were found to have had 
chloracne prior to the explosion. A cross-sectional study of 226 workers in 1979 indicated that 52% had 
chloracne which persisted for 26 years, and in 29 subjects it was still present after 30 years.  Blood levels 
were not measured, but the air dust in the plant was suspected to have contained 2,4,5-T contaminated with 
6 ppm 2,3,7,8-TCDD compared to 0.1 ppm in later years.  Similarly, high incidences of chloracne were also 
found in other facilities (Jirasek et al. 1976; May 1973; Poland et al. 1971; Vos et al. 1978). Appearance of 
chloracne after accidental occupational exposure may be immediate or delayed; since workers may not 
always be removed from the work environment, the duration of exposure and total exposure is difficult to 
assess. 
Skin lesions from environmental exposures to 2,3,7,8-TCDD have been most thoroughly studied in the 
population exposed in Seveso, Italy.  Reggiani (1980) described dermal lesions for 17 persons (primarily 
children) hospitalized shortly after the accidental release in Seveso.  Acute lesions probably due to alkali and 
burns were observed immediately and had a duration of up to 2 months; chloracne in children occurred 
within 2 weeks (earliest occurrence was 3 days) and usually persisted for 8–26 months.  Irritative lesions 
(characterized by erythema and edema of exposed areas, vesiculobollus and necrotic lesions, and 
papulonodular lesions) were observed in 447 people in Seveso 20–40 days after the accident, and 34 of these 
individuals later developed chloracne (Caputo et al. 1988).  In 1976 and 1978, there were 193 childhood 
cases of chloracne and 17 of the most severe were in zone A where soil levels were the highest.  Bisanti et al. 
(1980) reported that in zone A, 46 early cases (3–6 months) and 15 late cases (7–10 months) of chloracne 
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cases of chloracne were reported (Caputo et al. 1988). In the 193 people with chloracne, the comedones and 
cysts progressively decreased in the 2 years following the accident (Caputo et al. 1988).  In the most severe 
cases, regression of the lesions began at the end of 1978. All affected children were clear of lesions by 1982. 
Histological examination of the lesions from the limbs of severe chloracne patients revealed orthokeratotic 
hyperkeratosis with loss of adhesiveness, particularly near the follicular ostia; dilated follicular ostia filled 
with cornified lamellae; acanthosis; horny metaplasia with possible acrosyringeal cyst formation in the 
dermal and intradermal eccrine duct; and foreign body granulomas around the detached wall of the excretory 
ducts of some eccrine sweat glands (Caputo et al. 1988).  Thirty of the 30,000 samples of serum collected 
and frozen in 1976 (10 zone A residents with the most severe cases of chloracne types 3 and 4 [chloracne 
was rated as type 1 for the mildest form to type 4 for the most severe cases], 10 former zone A residents who 
did not develop chloracne, and 10 controls from non-contaminated zones) were analyzed by Mocarelli et al. 
(1991). 2,3,7,8-TCDD blood levels (lipid adjusted) of 12,100–56,000 ppt were observed in 6 children with 
type 4 chloracne and levels of 828, 1,690, 7,420 ppt were found in 3 children with type 3 chloracne.  In 
adults, levels of 1,770–10,400 ppt were associated with no chloracne.  No chloracne was observed in 
Missouri residents who had adipose 2,3,7,8-TCDD levels of 5.2–59.1 ppt 16 years after exposure (using a 
half-life of 8.5 years, peak tissue levels of 6–204 ppt can be estimated) or in Operation Ranch Hand veterans. 
While there is a higher incidence of this disorder in those with higher serum 2,3,7,8-TCDD levels, 
interindividual variability makes it difficult to specify a dose that will result in chloracne (Needham et al. 
1991). 
The results of a further examination of Operation Ranch Hand veterans was recently published (Burton et al. 
1998). The cohort consisted of 930 exposed subjects and 1,200 comparison individuals who served in SEA 
during the same period but who were not involved with spraying herbicides.  The authors examined the 
associations between serum dioxin levels and a) chloracne, b) occurrence of acne relative to the tour of duty 
in SEA, and c) anatomical location of acne after service in SEA.  Initial dioxin levels were computed using a 
first-order pharmacokinetic model with a constant half-life of 8.7 years.  Four exposure categories were 
defined: 1) comparisons, with current dioxin levels of #10 ppt; 2) background Operation Ranch Hand 
veterans, with current dioxin levels of #10 ppt; 3) low category, with current dioxin levels exceeding 10 ppt 
but #94.2 ppt; and 4) high category, with dioxin levels >92.4 ppt.  Adjustments were made for age, race, and 
military occupation.  The range of initial dioxin levels in the low and high categories was 27.7–94.1 ppt and 
94.2–3,290 ppt, respectively.  Because physicians did not find any cases of chloracne among Operation 
Ranch Hand veterans at any physical examination and no cases were found via medical record review, the 
analysis was restricted to cases of acne.  The results showed that among Operation Ranch Hand veterans 
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who had acne only after their service in SEA, the prevalence of acne at any location was increased in the 
high-exposure category, but the adjusted odds ratio relating acne in the eye-ear-temple location and dioxin 
category was increased for all three Operation Ranch Hand exposure categories.  The increase was greatest 
in the background exposure category (OR=1.3; 95% CI=0.8–2.2).  According to Burton et al. (1998), the 
results suggest that the Operation Ranch Hand exposure to dioxin, which was much lower than the Seveso 
exposure, was insufficient for the production of chloracne or that the exposure may have caused chloracne 
that resolved and was currently undetectable. 
The incidence of chloracne was examined in a group of 3 men and 4 women who were among 231 workers 
exposed to dioxins at a chemical factory in Ufa, Russia, approximately 25 years prior to blood collection in 
1991 and 1992 (Schecter et al. 1993). Five of the seven (three males and two females) were diagnosed with 
chloracne after working in the manufacture of 2,4,5-T contaminated with 2,3,7,8-TCDD between 1965 and 
1967. Blood analysis showed 2,3,7,8-TCDD levels (on a lipid basis) ranging from 36 to 291 ppt (mean 
185 ppt) in 1991 and 1992 compared with a mean of 4.4 ppt from a sample of 68 subjects from the general 
Russian population. Polychlorinated dibenzofurans and “dioxin-like” polychlorinated biphenyls (PCBs) 
were also detected, but it was estimated that in the workers, 2,3,7,8-TCDD contributed over 60% of the total 
dioxin equivalents (2,3,7,8-TCDD plus “dioxin-like” CDDs and PCBs).  One of the workers diagnosed with 
chloracne had the lowest 2,3,7,8-TCDD blood concentration of the group, whereas two workers with higher 
levels did not display chloracne.  This suggested that the presence of chloracne indicates exposure to dioxin 
(or similar chlorinated chemical), but its absence does not preclude such exposure, as noted by others 
(Mocarelli et al. 1991). Schecter et al. (1993) estimated that in the workers, the dioxin toxic equivalents 
(TEQ) in 1967 ranged from 226 to 1,707 ppt, assuming a 10-year half-life, and from 1,173 to 9,366 ppt 
assuming a 5-year half-life (see Section 2.5 for a detailed explanation on TEQs and toxicity equivalent 
factors [TEFs]).  They also estimated the total 2,3,7,8-TCDD body burden for the workers to have been 
between 22 and 172 µg using a 5-year half-life and 4–30 µg using a 10-year half-life (mean present body 
burden was 3.2 µg versus 0.072 µg for general population).  According to Schecter et al. (1993), this is the 
first reported incidence of chloracne in females with elevated dioxin blood levels from occupational 
exposure. 
A group of 8 individuals who had contracted chloracne between 1973 and 1976 while working in the 
manufacture of TCP or in the maintenance of a TCP plant were examined 15 years after the exposure 
(Jansing and Korff 1994). Slight residual chloracne was diagnosed in two subjects, but otherwise the 
workers were healthy.  2,3,7,8-TCDD levels in blood ranged from 163 to 1,935 ppt (lipid basis), and by 
assuming a half-life of 7 years, the authors estimated that the blood concentration during the exposure had 
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ranged from 545 to 9,894 ppt.  It was found that the concentration of 2,3,7,8-TCDD in blood correlated well 
(r=0.93) with duration of chloracne if 2 subjects with a disposition to hypersensitive skin reactions were not 
included in the analysis. 
Other effects manifested as dermal changes have also been noted to accompany chloracne.  In addition to 
chloracne, hyperpigmentation and hirsutism (also known as hypertrichosis or abnormal distribution of hair) 
were also reported in 2,3,7,8-TCDD-exposed workers (Jirasek et al. 1976; Oliver 1975; Poland and Smith 
1971; Suskind and Hetzberg 1984). In the cohort examined by Suskind and Hetzberg (1984), hypertrichosis 
was observed 25 years after exposure, particularly among workers with persistent chloracne upon clinical 
examination.  In contrast, Moses et al. (1984) found no evidence of hypertrichosis, even though 31% of the 
exposed workers had evidence of residual chloracne.  Webb et al. (1989) observed three cases of 
hypertrichosis, but not hyperpigmentation, among Missouri residents, one with serum levels of <20 pg/g and 
two with levels between 20 and 60 pg/g.  However, neither condition was noted on examination among 
residents of the Quail Run Mobile Home Park (Hoffman et al. 1986).  Actinic or solar elastosis was also 
observed among a group of workers diagnosed with active chloracne at the time of their examinations in 
1979 (Suskind and Hertzberg 1984). 
In conclusion, dermal effects, particularly chloracne, are the most commonly reported effects of 
2,3,7,8-TCDD exposure in humans because they are easy to identify.  Additional information is needed to 
determine the level and frequency of 2,3,7,8-TCDD exposure needed to cause chloracne and whether 
individual susceptibility plays a role in the etiology.  Also, chloracne in humans indicates CDD exposure, 
but lack of chloracne does not indicate that exposure has not occurred.  Other dermal conditions reported 
include hypertrichosis, hyperpigmentation, and solar elastosis. 
Ocular Effects. Eye irritation, which correlated with severity of chloracne, was reported by Poland et al. 
(1971) among workers employed in a 2,4,5-T factory; however, the role of 2,3,7,8-TCDD, if any, cannot be 
determined. 
Body Weight Effects. Limited information was located regarding body weight effects in humans 
following exposure to CDDs. A transient weight loss was reported in a laboratory worker following an acute 
exposure to 2,3,7,8-TCDD (Oliver 1975). Weight loss associated with severe cases of chloracne was 
mentioned in a study among herbicide-manufacturing workers (Jirasek et al. 1976), but further information 
regarding weight loss was not provided. 
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2.1.3 Immunological Effects 
A limited number of studies have examined the immunotoxicity of 2,3,7,8-TCDD in humans.  Most of these 
studies have found potential alterations in lymphocyte populations (e.g., T cells, B cells), cell surface 
markers (e.g., CD4RO+, CD8+), or lymphoproliferative responses.  The interpretation of these studies is 
limited by the lack of data correlating changes in immune function measurements and changes in host 
resistance to disease challenges (Kerkvliet 1995). Based on medical insurance records, Zober et al. (1994) 
found a significant increase in the incidence of infectious and parasitic disease in 2,3,7,8-TCDD-exposed 
workers in the 35-year period after the BASF accident. When the workers were divided into groups based 
on the severity of chloracne or back-calculated serum lipid 2,3,7,8-TCDD levels (assuming a half-life of 
7 years), the increase in infectious disease was significant only in the group with severe chloracne and the 
group with 2,3,7,8-TCDD levels of $1,000 ppt. Among the workers with severe chloracne, one disease 
subcategory, intestinal infections, accounted for the increased incidence of infectious diseases.  A two-fold 
increase in the incidence of upper respiratory tract infections was also observed in the cohort.  Dividing the 
workers into various groups did not result in evidence of increased respiratory infections in a particular 
group. Zober et al. (1994) also found a significantly higher incidence of appendicitis in 2,3,7,8-TCDD 
workers; it is not known if this effect was the result of immunotoxicity or a direct effect on the appendix. 
Although the results of this study suggest a relationship between 2,3,7,8-TCDD exposure and an increased 
risk of infection, the authors note that the difference may reflect differences in medical care use between the 
workers and the referent group. Jennings et al. (1988) examined immunological parameters in a group of 18 
workers 17 years after an industrial accident during the manufacture of 2,4,5-T in Coalite, England.  At the 
time of the study all members of the cohort were apparently healthy.  An unexposed group of 15 subjects 
served as controls. No measure of exposure was provided.  The exposed group had a significantly increased 
number of natural killer (NK) cells, and concentration of antinuclear antibodies and immune complexes. 
Total lymphocytes, B cells, T cells, T-helper cells, T-suppressor cells, the lymphoproliferative response to 
phytohemagglutinin, and serum levels of  immunoglobulins were similar between exposed and control 
groups. An immunological assessment of 41 subjects exposed to 2,3,7,8-TCDD-contaminated soil in Times 
Beach, Missouri was conducted by Webb et al. (1989). Sixteen participants had 2,3,7,8-TCDD adipose 
tissue levels <20 ppt, 13 had levels between 20 and 60 ppt, and 12 had levels >60 ppt.  The highest level was 
750 ppt. Results from multiple regression analysis showed that increased 2,3,7,8-TCDD levels correlated 
with an increased percentage and total number of T lymphocytes.  The increase was due to CD8+ and T11+ T 
cells; CD4+ T cells were not altered in percentage or number.  The lymphoproliferative responses to T cell 
mitogens or tetanus toxoid were not altered, and neither was the cytotoxic T cell response.  Serum
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immunoglobulin A (IgA) was increased, but IgG was not.  The study subjects did not exhibit any clinical 
disease associated with the 2,3,7,8-TCDD levels. In contrast with Webb’s findings, depressed cell-mediated 
immunity was found in residents from the Quail Run Mobile Home Park in Missouri (Hoffman et al. 1986); 
however, repeated examination of the group failed to confirm the observation (Evans et al. 1988).  The levels 
of 2,3,7,8-TCDD in adipose tissue from this group were unknown.  
No indications of immune disease were found in a group of 8 subjects who had worked in a TCP 
manufacturing plant 15 years earlier and had elevated blood levels of 2,3,7,8-TCDD (163–1,935 ppt) at the 
time of the examination (Jansing and Korff 1994).  The only significant observation was that individuals 
with the greater exposure (judged by 2,3,7,8-TCDD blood levels and duration of chloracne) showed a 
tendency of lower gamma-globulin levels.  Neubert et al. (1993) examined surface receptors on lymphocyte 
subpopulations of workers with moderately increased body burden of 2,3,7,8-TCDD and of other CDDs and 
CDFs. The group consisted of 89 volunteers involved in decontamination work at a chemical plant in 
Hamburg, Germany.  The volunteers were grouped according to their body burden, as defined by the CDD 
concentration in blood (on a lipid basis). Four groups were formed: a low-, medium-, and higher-level 
reference group, and the exposed group. Their respective median 2,3,7,8-TCDD blood concentrations were 
2, 5, 11, and 41.5 ppt. 2,3,7,8-TCDD was a minor contributor to the total dioxin equivalents.  Regression 
analysis of the data showed some slight trends for some of the biomarkers, such as CD45R0+. Except for 
one, all the trends were increases. The slight increase in the percentage of CD4+CD45R0+ cells remained 
significant even after accounting for age-related changes. The authors concluded that altogether, the data did 
not provide any evidence for a decrease in cellular components of the human immune system in subjects 
with moderately increased CDD/CDF body burden.  They also pointed out that adult humans appear to be 
less susceptible to this action of CDDs than adolescent marmoset monkeys.  In a follow-up study, Neubert et 
al. (1995) examined lymphocyte proliferation responses (measured as 3H-thymidine incorporation) in the 
same volunteers.  They found no decrease in the capacity of 3H-thymidine incorporation with any of the 
proliferation stimulators in the group with the increased 2,3,7,8-TCDD body burden, compared with the 
other groups. A recent study examined the long-term effects of 2,3,7,8-TCDD on immune function in 11 
industrial workers in Germany who had been exposed for several years to high doses of 2,3,7,8-TCDD 
20 years earlier (Tonn et al. 1996).  Current 2,3,7,8-TCDD blood concentrations (lipid basis) ranged from 43 
to 874 ppt, compared with about 4 ppt as the average for the German population.  Ten matched unexposed 
subjects served as controls. End points monitored included determination of lymphocyte subsets, and 
immunocompetence of T- and B-lymphocytes by mitogen-induced lymphoproliferation assays and by assays 
using sensitive mixed-lymphocyte cultures.  At the time of the study, the workers were generally
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healthy, although five persons still exhibited chloracne. Analysis of lymphocyte subsets showed no 
differences between the control and the 2,3,7,8-TCDD-exposed group.  Moreover, there was no statistically 
significant difference in the response to mitogen stimulation between the two groups, and no correlation was 
found between individual 2,3,7,8-TCDD levels in the blood or the age of the person and the respective 
proliferative capacity of their lymphocytes.  However, exposed subjects showed a reduced response to 
human lymphocyte antigen-allogeneic lymphocytes and interleukin-2-boosted proliferation.  According to 
Tonn et al. (1996), this suppression is indicative of a reduced T-helper cell response, although the actual 
number of T-helper cells was not altered by 2,3,7,8-TCDD.  The authors concluded that 2,3,7,8-TCDD 
immunosuppression is more likely mediated by a reduced functionality of individual cells rather than by a 
reduction in numbers of cells circulating in the blood.  Tonn et al. (1996) further noted that the changes in 
immunocompetence observed did not correlate with obvious diseases related to severe immunodeficiency 
such as certain cancers and infections. 
In a study of 192 persons exposed to 2,3,7,8-TCDD (and CDFs) in a pesticide-producing factory in 
Germany, there was also no correlation between the levels of 2,3,7,8-TCDD in blood from exposed workers 
and the frequency of infectious diseases (Jung et al. 1998).  The investigators also conducted a number of 
assays such as immunoglobulins, serum electrophoresis, monoclonal bands, surface markers, autoantibodies, 
lymphocyte proliferation, the rise of tetanus antibody concentrations after vaccination, and the in vitro 
resistance of lymphocytes to chromate to evaluate the morphologic and functional state of the immune 
system.  A subgroup of 29 most highly exposed workers was compared to a control group of 28 subjects not 
exposed to above background levels of 2,3,7,8-TCDD.  The median concentration of 2,3,7,8-TCDD in the 
workers was 217 pg/g blood lipid (range, 33.6–2,252) compared to 3.9 pg/g in the controls (range, 2.9–6.0). 
There was no significant correlation between the current 2,3,7,8-TCDD concentrations and alterations in any 
of the immune parameters among the entire exposed group. In addition, the results of the tetanus vaccination 
and the chromate resistance test were not correlated with exposure to 2,3,7,8-TCDD.  The only significant 
finding was that the chromate resistance of lymphocytes stimulated with phytohemagglutinin of highly 
exposed persons was significantly lower than that for the control group.  This, according to Jung et al. 
(1998), suggested that the function of lymphocytes can be stressed and possibly impaired by high exposure 
to 2,3,7,8-TCDD. A separate report on the same group of workers  found no significant exposure-related 
alterations in the phenotype and function of peripheral blood mononuclear cells (PBMC) as judged by the 
proportions of CD3, CD4, or CD8+ T-lymphocytes; of CD16+ natural killer cells; and of CD19+ B-
lymphocytes (Ernst et al. 1998).  However, in the 2,3,7,8-TCDD exposed workers, the proportion of CD8+ 
memory T-cells (CD45RO+) was significantly higher, and that of lymphocytes with naive phenotype 
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(CD45RA+) was significantly lower than in PBMC of the control group.  Also, in vitro tests of T-cell 
activation showed a significantly reduced interferon γ release in diluted whole blood cultures but not in 
isolated PBMC cultures of the TCDD-exposed cohort when T-cells were stimulated with tetanus toxoid. 
Based on these results, Ernst et al. (1998) suggested that exposure to high concentrations of 2,3,7,8-TCDD 
can partially impair in the blood milieu those T-cell/monocyte interactions that are essential for antigen-
specific T-cell responses, whereas isolated PBMC in the same donor appeared functionally less affected. 
The immune status of children exposed to 2,3,7,8-TCDD in the Seveso incident was also examined 
(Mocarelli et al. 1986). The group consisted of 44 children, 20 of whom had chloracne.  The results of the 
testing showed no abnormalities in serum immunoglobulin concentrations, levels of circulating complement, 
or lymphoproliferative responses to T- and B-cell mitogens.  However, a different cohort of 2,3,7,8-TCDD­
exposed children examined 6 years after the explosion showed a significant increase in complement protein 
levels, which correlated with the incidence of chloracne (Tognoni and Bonaccorsi 1982).  The children also 
had increased numbers of peripheral blood lymphocytes and increased lymphoproliferative responses.  No 
specific health problems were correlated with exposure to 2,3,7,8-TCDD in these children.  The findings 
from the Tognoni and Bonaccorsi (1982) study suggest that chloracne is a more sensitive toxicological 
endpoint than immunological effects because alteration in complement levels is a subclinical effect and 
correlated with the incidence of chloracne. 
A health study of Vietnam veterans involved in operation Ranch Hand did not find any correlations between 
clinically significant immunological alterations and serum 2,3,7,8-TCDD levels (USAF 1991).  The only 
significant positive association with exposure to 2,3,7,8-TCDD was an increase in serum IgA levels.  The 
authors suggested that this alteration was indicative of a subtle inflammatory process, but there was no other 
evidence for an inflammatory response. 
Parameters of immunocompetence were assessed in a group of 23 men with high fish consumption from the 
Baltic Sea (Svensson et al. 1994). Twenty men with almost no fish consumption served as controls.  The 
parameters examined included WBC, lymphocyte levels, serum immunoglobulin levels, and lymphocyte 
subsets. The mean dioxin equivalent concentration (TEQ, includes CDDS, CDFs, and dioxin-like PCBs) in 
blood (lipid basis) from fish eaters (n=7) was 64 pg TEQ/g (range, 18–88 pg/g) compared to 21 pg TEQ/g 
(18–33 pg/g) for controls (n=4). CDDs and CDFs were the major contributors to the total dioxin equivalents 
in blood. Of all the parameters examined, only the level of NK cells was reduced in fish eaters, but the 
difference between groups was not statistically significant.  No correlation was found between blood levels of 
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2,3,7,8-TCDD and the reduction in NK levels, but weak correlations existed between the latter and some non­
ortho-PCB congeners and p,pN-DDT. 
In conclusion, while some studies are suggestive, no consistent exposure-related immunological effects have 
been observed in human populations exposed to levels of CDDs several orders of magnitude higher than 
background exposure. This may in part be due to the lack of functional assays of immune competence in 
humans. 
Information regarding immunological effects observed in infants exposed perinatally to CDDs and 
structurally related compounds is presented in Section 2.5 under Developmental Effects. 
2,3,7,8-TCDD human body burdens calculated from available serum lipid 2,3,7,8-TCDD levels are presented 
in Table 2-1. 
2.1.4 Neurological Effects 
Symptoms of intoxication including lassitude, weakness of the lower limbs, muscular pains, sleepiness or 
sleeplessness, increased perspiration, loss of appetite, headaches, and mental and sexual disorders were 
reported in several of the 117 workers with severe chloracne who had been exposed to 2,3,7,8-TCDD in an 
occupational setting (Moses et al. 1984; Suskind 1985). Neurological symptoms persisted in these individuals 
for up to 10 years based on an increased incidence of sensory findings.  Similar symptoms of intoxication 
were observed in a trichlorophenol factory in Czechoslovakia (Jirasek et al. 1976) for which a 10-year follow-
up of 55 of the 80 affected workers was conducted (Pazderova-Vejlupkova et al. 1981).  At autopsy, damage 
to peripheral neuron Schwann cells was confirmed in a worker who died (Jirasek et al. 1976). 
Polyneuropathy and encephalopathy were found in 23 and 7% of the surviving workers, respectively (study 
did not include a referent group). Most patients suffered from peripheral neuronal lesions of the lower 
extremities (confirmed by electromyography).  Encephalopathy developed in older individuals (aged 50 and 
above) and was accompanied by an organic psychosyndrome due to atherosclerosis of cerebral arteries.  The 
most-affected patient developed paroxysms of temporal epilepsies and external and internal hydrocephalus. 
Patients with polyneuropathy did not improve during 10 years postexposure (Pazderova-Vejlupkova et al. 
1981). Similarly, neurological effects that included peripheral neuropathy, sensory impairment, tendency to 
orthostatic collapse, and reading difficulties were reported in workers exposed to 2,3,7,8-TCDD in an 
industrial accident in Germany (Goldman 1973).  
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Several studies have investigated the neurological effects of 2,3,7,8-TCDD in Seveso residents.  Residents in 
zone A and zones B and R participated in a neurological screening test in 1977 (Pocchiari et al. 1979).  Of the 
446 residents in zone A, 6.7% and 3.1% had evidence of “idiopathic clinical neurologic damage” or 
“idiopathic subclinical neurologic damage” respectively, as compared to 1.2% and 1.2%, respectively, in the 
255 residents in zones B or R. No definitions of clinical or subclinical damage were provided.  The authors 
did note that the most frequently observed effects occurred in the peripheral nervous system (particularly 
reduced nerve conduction velocity, which was considered a subclinical effect).  In 1978, 205 residents in zone 
A were re-tested. At this time, 11.7% had clinical damage and 4.9% had subclinical damage.  No relationship 
between chloracne and neurological symptoms was found (Pocchiari et al. 1979).  In another study of zone A 
residents, 22 cases of peripheral neuropathy were observed in the 470 residents examined in 1977 (prevalence 
rate of 8.9%, 95% confidence interval [CI] of 6.2 to 11.6) (Filippini et al. 1981).  Peripheral neuropathy was 
diagnosed based on the occurrence of neurological symptoms (paresthesia, hypesthesia, pain, and 
hyposthenia), clinical signs (superficial and deep sensory impairment, muscular weakness, and tendon hypo-
or areflexia), and/or electrophysiological alterations. During a re-evaluation in 1978, 26 of the 308 subjects 
had neurological symptoms, clinical signs, and/or altered electrophysiological readings and 16/308 had two or 
more electrophysiological abnormalities (at least one being altered nerve conduction velocity).  The 42 
subjects with evidence of peripheral neuropathy were divided into three groups:  1) residents with existing 
predisposing factors (e.g., excess alcohol consumption, diabetes, nutritional diseases), 2) residents with 
potential high exposure to 2,3,7,8-TCDD (assessed via increased serum levels of several hepatic enzymes 
[GGT, AST, ALT] and/or chloracne), and 3) remaining residents.  The prevalence rate ratio was significantly 
higher in the first two groups (2.6, 95% CI=1.2–5.6 for predisposing factors group and 2.8, 95% CI=1.2–6.5 
for high 2,3,7,8-TCDD exposure group) as compared to the third group.  In a 6-year follow-up of 152 subjects 
with chloracne in Seveso, Barbieri et al. (1988) found no clear-cut peripheral neuropathy but an increase in 
clinical and electrophysiological signs of peripheral nervous system involvement when compared to 123 age-
and sex-matched controls.  In 1985, 141 of these subjects were re-examined (Assennato et al. 1989).  No 
statistically significant alterations in motor nerve conduction velocity of the median or peroneal nerves or 
sensory nerve conduction velocity of the sural nerve, as compared to 167 matched controls, were observed. 
No significant increases in neurological effects (based on self-reported neurological effects and neurological 
examination) were observed in 68 Missouri residents with potential high risk exposure to 2,3,7,8-TCDD as 
compared to 36 residents with low-risk exposure (Stehr et al. 1986).  Abnormal neurological symptoms were 
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1989). The symptoms included abnormal pain sensation in lower extremities, abnormal vibratory sensation, 
and abnormal reflexes.  However, the distribution of these effects among residents with serum lipid 
2,3,7,8-TCDD levels of <20 ppt, 2–60 ppt, or >60 ppt was not dose-related. 
Nerve conduction velocities were measured in 55 employees of a 2,4,5-T and 2,4-D manufacturing facility in 
Jacksonville, Arkansas (Singer et al. 1982). Statistically significant decreases in median motor nerve and 
sural nerve conduction velocities were observed, as compared to a control group of workers not exposed to 
phenoxy herbicides.  No effect on median sensory nerve conduction velocity was found.  Sural nerve 
conduction velocity was significantly inversely correlated with duration of employment.  
Psychological effects have been associated with 2,3,7,8-TCDD exposure in some human studies.  Personality 
changes were reported following acute exposure (Oliver 1975).  Depression (Levy 1988; Wolfe et al. 1985), 
hypochondria, hysteria, and schizophrenia (Wolfe et al. 1985) were found more often in Vietnam veterans 
exposed to 2,3,7,8-TCDD-contaminated herbicides than in the control group of veterans.  A battery of tests 
used for the psychological evaluation included Minnesota Multiphasic Personality Inventory, Cornell, 
Wechsler Memory Scale I, Wechsler Adult Intelligence Scale, Wide Range Achievement Test, and Halstead-
Reitan Neuropsychological Battery.  Peper et al. (1993) reported that the results of neuropsychological testing 
of 19 persons living in an area with high concentration of dioxins in soil in Germany were within the range of 
values expected from standardized age samples.  However, increased levels of dioxins in blood (but not 
substantially different from a national sample) were associated with a reduction of cognitive performance in 
verbal conceptualization, mnemonic organization of verbal and visual stimuli, psychomotor slowing, and a 
variety of subjective complaints.  The concentration of CDDs (including CDFs) in blood (lipid basis) ranged 
from 16.1 to 80.4 ppt (TEQ), with a mean of 31 ppt.  The authors recognized, however, that given the small 
number of subjects and the relatively low amount of exposure (monitored by blood levels) the results must be 
interpreted with caution. 
A health study in Vietnam veterans involved in Operation Ranch Hand reported that elevated serum 
2,3,7,8-TCDD levels were not associated with any neurological disease and were not related to verified 
psychological or sleep disorders (USAF 1991).  In a more recent study, Sweeney et al. (1993) compared the 
prevalence of chronic peripheral neuropathy in a group of workers employed 15 years earlier in the 
manufacture of sodium trichlorophenol and its derivatives at two chemical plants.  The cohort consisted of 
265 exposed workers and an unexposed matched comparison group of 244 subjects.  Exposure was assessed 
by measuring lipid-adjusted serum 2,3,7,8-TCDD levels.  The neurologic status was evaluated through a 
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standardized neurological examination and electrophysiologic measurements and quantitative sensory tests of 
thermal and vibratory sensitivity.  The results showed that the workers had a significantly higher mean serum 
2,3,7,8-TCDD level (220 ppt) compared to controls (7 ppt).  In both worker and referent groups, 32% met the 
case definition for peripheral neuropathy; however, logistic regression analyses revealed that serum 
2,3,7,8-TCDD level was not related to peripheral neuropathy.  The results suggested that despite continued 
elevated serum 2,3,7,8-TCDD levels, peripheral neuropathy is not a long-term sequela of exposure to TCDD-
contaminated chemicals.  Nevertheless, the authors (Sweeney et al. 1993) indicated that the study could not 
preclude the occurrence and subsequent resolution of acute effects caused by high exposure, as observed in 
Seveso (Fillippini et al. 1981; Pocchiari et al. 1979) and possibly in early case reports (Goldman 1973; Jirasek 
et al. 1976; Oliver 1975). 
The overall evidence from case reports and epidemiological studies showed that exposure to CDDs is 
associated with signs and symptoms of both central and peripheral nervous system shortly after exposure.  In 
some cases, the effects lasted several years.  However, evaluation of individuals 5 to 37 years after the last 
exposure has not revealed any long-lasting abnormalities. 
Information regarding neurological effects observed in infants exposed perinatally to CDDs and structurally 
related compounds is presented in Section 2.5 under Developmental Effects. 
2.1.5 Reproductive Effects 
A number of studies have investigated the possible association between 2,3,7,8-TCDD exposure and 
reproductive toxicity in humans.  A common limitation of many of these studies, particularly those conducted 
prior to the development of assays to quantify serum and adipose levels of 2,3,7,8-TCDD, is the lack of 
adequate exposure data (Sweeney 1994). 
The effects of 2,3,7,8-TCDD exposure on gonadal function (production of germ cells and secretion of sex 
hormones) has not been extensively investigated.  A health study in Vietnam veterans involved in Operation 
Ranch Hand found a significant association between decreased testicular size and serum 2,3,7,8-TCDD 
levels, but no association was found for low serum testosterone levels (USAF 1991).  When the Operation 
Ranch Hand cohort was re-examined in 1992 using ultrasound methodology, no significant alterations in 
testes size were found (Henriksen et al. 1996). No alterations in sperm count or the percentage of abnormal 
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consistent alterations in testosterone levels, follicle-stimulating hormone (FSH) levels, luteinizing hormone 
(LH) levels, testicular abnormalities, sperm abnormalities, and sperm counts were found in a follow-up study 
of the Operation Ranch Hand cohort; reproductive parameters were assessed in 1982, 1987, and 1992 
(Henriksen et al. 1996). In workers at two 2,4,5-trichlorophenol manufacturing facilities, serum 
2,3,7,8-TCDD levels were positively correlated with follicle stimulating hormone and luteinizing hormone 
levels and inversely correlated with total testosterone levels (Egeland et al. 1994).  However, the magnitude 
of the change in hormone levels per unit of increase in serum 2,3,7,8-TCDD levels was small.  The 
prevalence of high luteinizing hormone levels, high follicle stimulating hormone levels, and low testosterone 
levels was significantly increased in workers with half-life extrapolated serum lipid 2,3,7,8-TCDD levels of 
$140 pg/g, $1,860 pg/g, and $140 pg/g, respectively (based on 2,3,7,8-TCDD levels extrapolated at the time 
occupational exposure ceased and assuming a 7.1-year half-life).  The study authors note that both low 
testosterone and high LH levels were not observed in the same individuals.  Although the number of workers 
with elevated or depressed hormone levels was significantly higher than in the referent group, the adjusted 
mean hormone levels (adjusted for age, body mass index, alcohol consumption, smoking, and diabetes 
mellitus) were within 20% of referent values. 
A number of studies have examined pregnancy outcomes following paternal exposure or paternal and 
maternal exposure to 2,3,7,8-TCDD.  No significant alterations in the incidence of spontaneous abortions 
were found in several studies of Vietnam veterans.  In a case-control study conducted by Aschengrau and 
Monson (1989), no association was observed between paternal military service in Vietnam and the risk of 
spontaneous abortion (odds ratio [OR] of 0.88, 95% confidence interval [CI] of 0.42–1.86).  A limitation 
of this study is that service in Vietnam is not an adequate exposure surrogate for 2,3,7,8-TCDD exposure; 
CDC (1988) found that 2,3,7,8-TCDD body burdens in Vietnam veterans were not significantly different 
than background levels. In a study of Air Force personnel involved in Operation Ranch Hand, no 
relationship between paternal 2,3,7,8-TCDD exposure (as measured by serum 2,3,7,8-TCDD levels) and 
the occurrence of spontaneous abortions (relative risk [RR] of 1, 95% CI=0.7–1.3 for veterans with half-
life adjusted serum lipid 2,3,7,8-TCDD levels of >110 ppt) or stillbirths (RR of 1.8, 95% CI=0.7–4.7 for 
veterans with half-life adjusted serum 2,3,7,8-TCDD levels of <110 ppt, current levels >10 ppt; and RR of 
0.3, 95% CI=0–2.3 for veterans with half-life adjusted serum 2,3,7,8-TCDD levels of >110 ppt) were 
observed (Wolfe et al. 1995). No significant alterations in the relative risk of stillbirths (3 stillbirths 
observed in 2,3,7,8-TCDD-exposed group compared to 0 in control group) or miscarriages (RR of 1.19, 
90% CI=0.58–2.45) were observed in the wives of New Zealand 2,4,5-T applicators (Smith et al. 1982).  It 
should be noted that many of the wives were occasionally exposed while helping with spray activities and 
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while washing contaminated clothing.  An increased incidence of spontaneous abortions was reported in 
women living close to a herbicide manufacturing factory in Sweden (Forsberg and Nordstrom 1985).  The 
residents were exposed to phenoxy acids, chlorophenols, 2,3,7,8-TCDD, and dibenzofurans which were 
released into the soil and groundwater. The small number of cases in the exposed cohort and concomitant 
exposure to several other chemicals limits the conclusions which can be drawn from this study.  
Several studies have reported alterations in the sex ratio of children of men and women exposed to high 
levels of CDDs. Mocarelli et al. (1996) observed decreases in the sex ratio of children born to parents 
living in area A at the time of the accident in Seveso, Italy.  More females than males (48 females versus 
26 males; normal ratio is 100 females to 106 males) were born between April 1977 (9 months after the 
accident) and December 1984.  Between 1985 and 1994, there was no significant alteration in sex ratio (64 
females, 60 males).  In nine families in which both parents lived in area A at the time of the accident, 
serum lipid 2,3,7,8-TCDD levels (blood samples collected at the time of the accident) ranged from 126 to 
1,650 ppt and 104 to 2,340 ppt for the mothers and fathers, respectively.  Basharova (1996) reported an 
alteration in sex ratio (more females than males) in children of workers exposed to 2,3,7,8-TCDD­
contaminated 2,4,5-T at a production facility in Ufa, Russia.  No additional information on the percentage 
of male and female children or statistical analysis of data was provided.  Similarly, more females than 
males (51.4% versus 48.6%; 19,675 births) were born to 9,512 male workers exposed to chlorophenate 
wood preservatives contaminated with CDDs (Dimich-Ward et al. 1996).  James (1997) statistically 
analyzed the results of this study and found that the sex ratio was statistically significant, as compared to 
the expected Caucasian live birth sex ratio of 0.514. Stockbauer et al. (1988) did not find an alteration in 
the sex ratio (53.% of children were males versus 51.2% in nonexposed controls) among the children of 
mothers potentially exposed  to CDDs in the Times Beach incident.  This retrospective cohort study did 
not monitor where the mothers or fathers lived at the time of conception.  Although three studies have 
found alterations in the sex ratio among the offspring of exposed individuals, a causal relationship between 
CDD exposure and alterations in the sex ratio cannot be inferred at this time.  Further investigation of this 
positive association is clearly warranted. 
In an inadequately reported study, Phuong et al. (1989a) reported a statistically significant increase in the 
incidence of hydatidiform mole in families living in southern Vietnam potentially exposed to 2,3,7,8-TCDD 
contaminated herbicides as compared to a group of Ho Chi Minh City residents presumably never exposed to 
2,3,7,8-TCDD-contaminated herbicides.  In contrast, a case-control study by Ha et al. (1996) did not find a 
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significant association between exposure to 2,3,7,8-TCDD-contaminated herbicides and the occurrence of 
complete hydatidiform mole or choriocarcinoma among women living in southern Vietnam. 
The results of the human reproductive toxicity studies are inconclusive.  In studies which measured 
2,3,7,8-TCDD levels (Egeland et al. 1994; Henriksen et al. 1996), mixed results were found for alterations in 
hormone levels.  The Egeland et al. (1994) study of the NIOSH cohort found significant alterations in 
testosterone and gonadotropins, but the alterations were small, frequently not found in the same individuals, 
and it is not known if they would adversely affect reproductive performance.  In contrast, the Henriksen et al. 
(1996) study of the Operation Ranch Hand cohort did not find any alterations, but the members of this cohort 
were exposed to lower concentrations of 2,3,7,8-TCDD and for shorter durations than the NIOSH cohort. 
Studies which examined pregnancy outcomes following paternal exposure (Aschengrau and Monson 1989; 
Smith et al. 1982) did not find increases in the incidence of spontaneous abortions and/or stillbirths.  Forsberg 
and Nordstrom (1985) found an increased incidence of spontaneous abortions in residents likely exposed to 
2,3,7,8-TCDD. However, the Aschengrau and Monson (1989), Smith et al. (1982), and Forsberg and 
Nordstrom (1985) studies did not measure 2,3,7,8-TCDD levels, and it is difficult to determine the level of 
2,3,7,8-TCDD exposure from the data reported.  Three studies found altered sex ratios among offspring of 
exposed individuals (Basharova 1996; Dimich-Ward et al. 1996; Mocarelli et al. 1996), but the role of CDDs 
could not be determined with any certainty.  Without exposure information, relationships between 
2,3,7,8-TCDD exposure and the risk of adverse pregnancy outcomes cannot be established. 
2,3,7,8-TCDD body burdens calculated from available serum lipid 2,3,7,8-TCDD levels are presented in Table 
2-1. 
2.1.6 Developmental Effects 
The potential for 2,3,7,8-TCDD to induce developmental effects has been examined in several populations: 
residents exposed to 2,3,7,8-TCDD during aerial spraying of 2,4,5-T or from accidental releases of 
2,3,7,8-TCDD or 2,3,7,8-TCDD-contaminated chemicals, workers involved in manufacturing or application of 
phenoxy herbicides and/or chlorophenols, and Vietnam veterans.  In most of the human studies, exposure was 
poorly characterized. 
In residents of Seveso, Italy, a significant rise in the incidence of birth defects, as compared to pre-accident 
levels, was observed the year after the accident (Bisanti et al. 1980).  A variety of birth defects were 
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observed, but the incidence for any particular defect was not elevated.  The authors suggest that the rise in 
birth defects may not be related to 2,3,7,8-TCDD exposure.  Prior to 1976, birth defects in Italy were usually 
under reported; the authors note that the reported incidences of birth defects after the accident (23 per 1,000 
births) were similar to incidences reported in other western countries.  Thus, the increased incidence may be 
reflective of the increased reporting rather than an increased number of birth defects.  In a study which 
assessed the risk of birth defects for the 6-year period after the Seveso accident, no increases were observed 
for the risk of total defects (RR of 1.2, 90% CI of 0.88–1.64 for zones A and B and RR of 0.97, 90% 
CI=0.83–1.13 for zones A, B, and R), major defects RR of 1.02, 90% CI=0.64–1.61 for zones A and B and 
RR of 0.83, 90% CI=0.67–1.04 for zones A, B and R), and minor defects RR of 1.44 90% CI=0.92–2.24 for 
zones A and B and RR of 1.14, 90% CI=0.92–1.42 for zones A, B and R) (Mastroiacovo et al. 1988).  The 
small number of observed birth defects limits the statistical power of this study to detect significant increases 
in a specific defect. 
In a study of residents of Northland, New Zealand exposed to 2,4,5-T during aerial spraying, no significant 
alterations in the total number of birth defects were observed in children born between 1973 and 1976, as 
compared to the incidence in children born between 1959 and 1960 (before the aerial 2,4,5-T spraying began) 
(Hanify et al. 1981).  Stockbauer et al. (1988) studied the Missouri cohort and found no statistically 
significant excess risk of birth defects among infants from exposed mothers (n=410) compared to an 
unexposed referent group (n=820). However, a significant increase in the incidence of talipes (incidence ratio 
of 1.66, 90% CI=1.2–2.29) was observed in children born after the spraying program began.  The relationship 
between 2,4,5-T usage and the incidence of facial clefts was investigated in residents of Arkansas exposed 
during the spraying of rice acreage (Nelson et al. 1979).  The population was divided into areas of high, 
medium, and low potential exposure based on herbicide application rates.  Increasing trends over time in 
facial clefts for both the high- and low-exposure groups were observed.  The authors attributed this to better 
case-ascertainment rather than 2,4,5-T exposure. 
In the offspring of male workers at a chlorophenol manufacturing facility, no significant increases in the 
incidence of infant deaths, health defects, or congenital malformations were observed (Townsend et al. 1982). 
The adjusted odds ratio (95% CI) for infant deaths, health defects, and congenital malformations were 0.63 
(0.27–1.39), 0.85 (0.6–1.21), and 0.85 (0.53–1.35), respectively, for workers exposed to any dioxin and 0.82 
(0.3–2.09), 0.93 (0.6–1.43), and 1.08 (0.63–7.83) for workers exposed to 2,3,7,8-TCDD only.  
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Several studies investigated the outcome of pregnancies fathered by Vietnam veterans potentially exposed to 
2,3,7,8-TCDD-contaminated herbicides.  Two case-control studies (Aschengrau and Monson 1990; Erickson 
et al. 1984) have examined the risk of Vietnam veterans having a child with birth defects.  The Erickson et al. 
(1984) study used a cohort of 7,133 infants with birth defects registered by the Metropolitan Atlanta 
Congenital Defects Program and 4,246 control infants; information on military service and possible exposure 
to Agent Orange was obtained during interviews with the mother and father.  The overall risk of having a 
child with birth defects was not significantly increased in the Vietnam veterans (OR of 0.97, 95% 
CI=0.83–1.14). However, Vietnam veterans fathered a higher proportion of the children with some birth 
defects (spina bifida, cleft lips, and congenital tumors including dermoid cysts, teratomas, hepatoblastomas, 
central nervous system tumors, and Wilm's tumors) (Erickson 1984).  The case group (857 infants with 
congenital anomalies, 61 stillbirths, and 48 neonatal deaths) and control group (998 infants) for the 
Aschengrau and Monson (1990) study consisted of infants delivered between August 1977 and March 1980. 
No significant increase in the risk of fathering a child with birth defects was observed for the Vietnam 
veterans (OR of 1.3, 95% CI=0.7–2.4). Among the children with birth defects, an increased risk of having 
one or more major systemic malformation (OR of 1.8; 95% CI=1–3.1) was reported in infants fathered by 
Vietnam veterans.  The largest increases were reported for malformations of the nervous system, 
cardiovascular system, genital organs, and urinary tract.  No pattern of multiple malformations was found; the 
only pattern of multiple malformations observed in more than one infant was ventricular septal defect and 
talipes. The results of these two case-control studies (Aschengrau and Monson 1990; Erickson et al. 1984) 
should be interpreted cautiously because there is no documentation of 2,3,7,8-TCDD exposure.  CDC (1988) 
found that in Vietnam veterans self-reporting exposure to Agent Orange, the levels of serum 2,3,7,8-TCDD 
were not significantly different than levels found in a control population.  
In a study of Vietnam veterans participating in Operation Ranch Hand (Wolfe et al. 1995), an increase in 
nervous system defects with increasing paternal serum lipid 2,3,7,8-TCDD levels was observed (statistical 
analysis was not performed due to the small number of defects:  3/981 in comparison group, 0/283 in Ranch 
Hand veterans with current 2,3,7,8-TCDD levels of #10 ppt, 2/241 in veterans with current 2,3,7,8-TCDD 
levels of >10 ppt and initial levels of #110 ppt, and 3/268 in veterans with current 2,3,7,8-TCDD levels of 
>10 ppt and initial levels of >110 ppt).  However, the authors caution that this relationship is based on a 
limited amount of data.  No relationships between paternal 2,3,7,8-TCDD exposure (based on serum 
2,3,7,8-TCDD levels) and the prevalence of other birth defects were observed.  In an earlier study by Wolfe et 
al. (1985) of Air Force personnel involved in Operation Ranch Hand, a significant increase in the number of 
reported neonatal deaths (no additional details provided), as compared to a comparison group of Air Force 
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military employees not stationed in Vietnam, was observed.  The incidence of major defects, prematurity, 
learning disabilities, or infant deaths was not increased in the Ranch Hand personnel.  A significant increase 
in the incidence of minor health effects such as birth marks, rashes, and neonatal jaundice was reported by the 
Ranch Hand veterans. It should be noted that the pregnancy outcomes were self-reported, and this finding 
was not corroborated by the follow-up study (Wolfe et al. 1995) which used birth certificates, medical 
records, and death certificates to assess possible relationships between paternal exposure to 2,3,7,8-TCDD 
and developmental effects in offspring.  Michalek et al. (1998) examined birth records of children born 
between 1959 and 1992 to Operation Ranch Hand veterans.  A slight increase in the incidence of preterm 
births (not statistically significant) was observed in the low (current CDD level of #10 ppt) and high 
(extrapolated initial CDD level of >79 ppt) exposure groups but not in the medium (extrapolated initial CDD 
level of #79 ppt) exposure group. An increase in the relative risk of infant deaths was observed in all three 
groups, as compared to the referent group of veterans in SEA not exposed to Agent Orange); the relative risks 
in the low, medium, and high groups were 3.2 (95% CI=1.0–10.3), 1.5 (95% CI=0.3–7.5), and 4.5 (95% 
CI=1.5–14.0). Short gestation and low birth weight were the most common causes of infant deaths.  No 
adverse effect on intrauterine growth was observed. Michalek et al. (1998) concluded that the increased 
infant mortality may not be due to paternal 2,3,7,8-TCDD exposure because the risk was increased in 
Operation Ranch Hand cohort members with essentially background current 2,3,7,8-TCDD levels (low 
exposure group) and in the highest exposure group.  In Vietnamese families potentially exposed to 
2,3,7,8-TCDD-contaminated herbicides during the Vietnam War, a statistically significant increase in the 
incidence of unspecified congenital anomalies was observed as compared with a nonexposed population 
(Phuong et al. 1989a). Serum lipid 2,3,7,8-TCDD levels were not measured and the extent of exposure was 
based on subject recall of how many times they were exposed to herbicides during the Vietnam war. 
The results of the available developmental studies in humans were inconclusive.  The lack of exposure data, 
small sample sizes, and the lack of reliable data for birth defect rates prior to 2,3,7,8-TCDD exposure limit the 
power of the human studies to determine if an association between 2,3,7,8-TCDD exposure and 
developmental toxicity exists. 
2.1.7 Genotoxic Effects 
Data regarding genotoxic effects in humans exposed to CDDs are inconclusive.  A statistically significant 
increase in the incidence of cells with chromosomal aberrations and a greater number of aberrations were 
found in fetal tissues from induced abortions in women possibly exposed to 2,3,7,8-TCDD after the Seveso 
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accident (Tenchini et al. 1983). The results from cytogenetic analysis of maternal tissues were comparable to 
those of the control group. Furthermore, no increase in the frequency of chromosomal aberrations was found 
in 17 individuals who were treated for chloracne following the Seveso accident (Reggiani 1980).  An 
increased incidence of chromosomal aberrations was found in a group of 10 Vietnam veterans (Kaye et al. 
1985); however, in another study, no increases in chromosomal aberrations or sister chromatid exchanges 
were reported in 15 Vietnam veterans (Mulcahy et al. 1980).  None of these studies included 2,3,7,8-TCDD 
dosimetry and all were limited by using exposed groups that were relatively small (less than 20 individuals) to 
have the statistical power to reliably assess the cytogenetic damage.  A more recent study examined the 
incidence of chromosomal aberrations and of sister chromatid exchanges in human lymphocytes in 27 
workers whose current 2,3,7,8-TCDD concentrations in blood were above 40 ppt, and in 28 age-comparable 
referents (Zober et al. 1993). The results showed no statistically significant differences between the two 
groups in the percentages of gaps, chromatid or chromosome exchanges, chromatid or chromosome 
breaks/fragments/deletions, multiple aberrations, or the overall percentage of aberrations including or 
excluding gaps. In the exposed group there was an increased rate of sister chromatid exchanges per cell and a 
higher percentage of cells with more than 10 sister chromatid exchanges.  However, these associations were 
no longer significant when smoking status was included as covariate.  Moreover, neither current nor back-
calculated 2,3,7,8-TCDD concentration was a significant predictor of these parameters.  Zober et al. (1993) 
indicated that some limitations such as the small number of individuals studied, a possible selection effect, 
and the possibility that some effects were transient should be considered in the interpretation of the results. 
The human data on the genotoxicity of 2,3,7,8-TCDD is inconsistent and inconclusive.  The lack of exposure 
data, small sample sizes, and the inconsistent results precludes drawing conclusions from these studies. 
2.1.8 Cancer 
The carcinogenicity of 2,3,7,8-TCDD in humans has been assessed in numerous case-control and mortality 
cohort studies of chemical manufacturing and processing workers and phenoxy herbicide and chlorophenols 
applicators, Vietnam veterans exposed to Agent Orange, and residents of Seveso, Italy.  A major weakness in 
many of these studies is the lack of adequate exposure data.  Exposure levels or 2,3,7,8-TCDD body burdens 
were not measured, rather surrogates of exposure such as exposure to chemicals contaminated with 
2,3,7,8-TCDD or chloracne were used to identify subjects likely exposed to 2,3,7,8-TCDD.  Another major 
weakness of most of the human cancer data is concomitant exposure to other compounds.  The focus of this 
discussion on the carcinogenic potential of 2,3,7,8-TCDD and other CDDs will be on studies that have 
documented exposure by measuring blood levels or in which exposure can be reasonably presumed.  The 
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section is divided into four parts: 1) the effect of CDD exposure on overall cancer risk in workers involved in 
the manufacture or application of phenoxy herbicides or chlorophenols followed by a discussion of specific 
types of cancer in this group, 2) cancer risks in Vietnam veterans, 3) cancer risks in Seveso residents, and 4) 
conclusive statement. 
Increases in the overall cancer risk were observed in a number of large cohort mortality studies of chemical 
manufacturing workers and phenoxy herbicide applicators (Becher et al. 1996; Fingerhut et al. 1991; 
Hooiveld et al. 1998; Kogevinas et al. 1993, 1997; Manz et al. 1991; Ott and Zober 1996; Zober et al. 1990). 
Most of the subjects in these studies were males working in chlorophenoxy herbicide or trichlorophenol 
manufacturing facilities.  In one of the few studies assessing the carcinogenicity of 2,3,7,8-TCDD in women, 
Kogevinas et al. (1993) found a significantly elevated risk for cancer in women probably exposed to 
2,3,7,8-TCDD during the production or application of chlorophenoxy herbicides and/or chlorophenols.  The 
Zober et al. (1990), Fingerhut et al. (1991), Manz et al. (1991), Ott and Zober (1996) and Hooiveld et al. 
(1998) studies used current serum 2,3,7,8-TCDD levels in surviving workers to estimate exposure.  The 
results of these studies, as well as two large multinational cohort mortality studies (Kogevinas et al. 1997; 
Saracci et al. 1991), are described below. 
Saracci et al. (1991) examined cancer mortality in workers on the International Register of Workers Exposed 
to Phenoxy Herbicides and Their Contaminants.  The registry consists of 18,390 workers (16,863 males and 
1,527 females) distributed among 20 cohorts from 10 countries.  Based on information obtained from 
questionnaires, factory or spraying records, and job histories, the workers were classified as exposed (13,482 
workers), probably exposed (416), exposure unknown (541), or non-exposed (3,951).  The exposed workers 
were workers who sprayed chlorophenoxy herbicides or worked in factories producing chlorophenoxy 
herbicides or chlorinated phenols. The probably exposed workers worked at facilities producing 
pentachlorophenol (145 workers) or 2,4-D, 2,4-(dichlorophenoxy)butanoic acid, (4-chloro-2-methyl­
phenoxy)acetic acid, and (4-chloro-2-methyl)propanoic acid (275 workers).  For 4 of the 20 cohorts, a 
minimum employment duration of 1 to 12 months was required for inclusion in the registry,  for the 
remaining cohorts, the criterion for inclusion was “ever employed in production or spraying of phenoxy 
herbicides.” The average follow-up period for the entire cohort was 17 years.  Cancer mortalities were not 
significantly increased in exposed and probably exposed workers (SMR=101; 95% CI=93–110).  Duration of 
exposure or time since first exposure did not appear to influence the number of cancer deaths.  The lack of 
both a clear definition of exposure and uniformity of exposure classification between and within cohorts 
makes the results difficult to interpret and lessens the confidence in the results. 
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After publication of the Saracci et al. (1991) study, the IARC cohort was expanded to include 12 
manufacturing facilities in the United States (also examined by Fingerhut et al. 1991) and 4 plants in 
Germany (also examined by Becher et al. 1996).  This expanded cohort, studied by Kogevinas et al. (1997), 
which included almost all workers world-wide who ever produced phenoxy herbicides, comprised  21,863 
workers (20,851 males and 1,012 females) in 12 countries.  2,3,7,8-TCDD levels were measured in 573 
workers at 10 facilities (approximately 50% of these workers were part of the NIOSH cohort examined by 
Fingerhut et al. 1991). The levels were 2-34 pg/g blood lipid (measured in 1990, mean not reported), 98–659 
(1990, mean of 389 pg/g), 1.9–194 (1993, 53 pg/g), 3.0–131 (1988, 53.3 pg/g), 9–37 (1992, 17 pg/g), 
1.3–6.49 (1996, estimated mean of 3.2 pg/g), 3–2,252 (1985–1994, estimated mean of 141 pg/g), 23–1,935 
(1989–1992, estimated mean of 401.7 pg/g), and 2–3,400 (1987–1988, mean of 233 pg/g).  Mortality rates for 
the cohort were compared to national mortality rates calculated using data from the WHO mortality data bank. 
There was a significant increase in the SMRs for all cancers for male workers (1,083 deaths; SMR=1.07; 95% 
CI=1.01–1.13) but not among female workers (44 deaths; SMR=0.93; 95% CI=0.68–1.25). When mortality 
rates were calculated for the 13,831 workers (males and females) exposed to phenoxy herbicides 
contaminated with 2,3,7,8-TCDD or higher chlorinated dioxins, the all-cancer SMR increased to 1.12 (710 
deaths; 95% CI=1.04–1.21).  The SMR for all cancer deaths was not elevated in workers not exposed to 
2,3,7,8-TCDD or higher chlorinated dioxins. 2,3,7,8-TCDD-exposed workers were divided into groups based 
on years since first exposure, duration of exposure, and year of first exposure.  The mortality rate appeared to 
be related to years since exposure and the related variable of year of first exposure.  Significantly increased 
SMRs were observed in workers with a $20 year latency period (394 deaths; SMR=1.20; 95% CI=1.09–1.33), 
workers employed before 1955 (335 deaths; SMR=1.12; 95% CI=1.00–1.25), or workers employed between 
1955 and 1964 (242 deaths; SMR=1.17; 95% CI=1.03–1.25), but these differences were overall small. 
The cancer mortality experience of 247 male workers who were exposed to 2,3,7,8-TCDD during an 
accidental uncontrolled decomposition reaction and subsequent clean-up activities in a German 2,4,5-TCP 
production plant (BASF AG facility) in 1953 and followed for 34 years was studied by Zober et al. (1990). 
Three subcohorts were defined based on qualitative exposure information: Subcohorts 1 (n=69) included 
workers known to be exposed to 2,3,7,8-TCDD during the accident, and Subcohort 2 (n=84) and 3 (n=94) 
included workers considered exposed to amounts of 2,3,7,8-TCDD less than in Subcohort 1.  Chloracne (114 
cases) or erythema (13 cases) developed in 127 (51%) of the main cohort.  Subcohorts 1, 2 and 3 contained 69 
cases (21 severe, 27 extensive, 21 moderate), 17 cases (1 severe, 3 extensive, 13 moderate) and 28 cases (0 
severe, 3 extensive, 25 moderate) of chloracne, respectively, and erythema affected 4 subjects in 
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Subcohort 2 and 9 subjects in Subcohort 3. Blood 2,3,7,8-TCDD levels were measured in 28 subjects in 
Subcohorts 1 (median 24.5 ppt, n=11), 2 (median 9.5 ppt, n=7), and 3 (median 8.4 ppt, n=10).  Subjects with 
chloracne/erythema had higher average serum 2,3,7,8-TCDD levels (15 ppt, n=16) than those without 
(5.8 ppt, n=12). There was no clear increase in all malignant neoplasms or site-specific cancer in the entire 
cohort or either subcohort based on comparison with national mortality rates in the Federal Republic of 
Germany.  When the 127 workers with chloracne/erythema were examined separately, the standardized 
mortality ratio (SMR) for all malignant neoplasms was not significantly elevated overall (SMR=139; 95% 
CI=87–211), although the SMR for all malignancies was significantly increased when analysis was restricted 
to workers whose first exposure was $20 years earlier (SMR=201; 95% CI=122–315, p<0.05). 
In a follow-up to the Zober et al. (1990) study, the cohort of workers exposed at the BASF AG facility in 
Germany, was followed through 1992 (Ott and Zober 1996).  The workers were divided into 3 subcohorts 
based on half-life extrapolated 2,3,7,8-TCDD body burdens of <0.01 µg/kg body weight, 0.1–0.99 µg/kg, and 
$1 µg/kg. 2,3,7,8-TCDD half-lives were estimated from repeated blood samples from 29 people with initial 
serum lipid 2,3,7,8-TCDD levels of 29–553 pg/g.  The mean half-life was 5.8 years, but the half-life increased 
with higher percentages of body fat.  Half-life estimates of 5.1 and 8.9 years were used for workers with 20 
and 30% body fat, respectively.  There was suggestive evidence that 2,3,7,8-TCDD exposure affected the 
occurrence of deaths from cancer (all sites combined) and deaths from respiratory or digestive cancer.  The 
number of cancer deaths increased with increasing body burdens, SMRs of 0.8 (8 deaths; 95% CI=0.4–1.6), 
1.2 (8 deaths; 95% CI=0.5–2.3), and 1.6 (15 deaths; 95% CI=0.9–2.6) in the cohorts with body burdens of 
<0.1, 0.1–0.99, and $1 µg/kg, respectively.  No increases in cancer deaths were observed among nonsmokers; 
among current smokers, there were increases in cancer risks for workers with 2,3,7,8-TCDD body burdens of 
1.0–1.99 µg/kg (6 deaths; SMR=3.0; 95% CI=1.1–6.5) and $2.00 µg/kg (6 deaths; SMR=4.0; 95% 
CI=1.5–8.6) but not for workers with lower 2,3,7,8-TCDD levels.  Ott and Zober (1996) concluded that past 
body burdens of $1.0 µg/kg 2,3,7,8-TCDD were consistent with a 2,3,7,8-TCDD-induced carcinogenic effect. 
At the same time, they stated that with such a small cohort, the risk estimates are not very stable and could be 
affected by selection and confounding. 
Becher et al. (1996) examined a cohort of 2,479 men employed at 4 German facilities involved in the 
production of phenoxy acid herbicides and chlorophenols.  The workers were divided into 4 subcohorts: 
1,144 male workers at facility 1 with a mean duration of employment of 7.7 years, 135 male workers at 
facility 2 with a mean duration of employment of 21.5 years, 520 male workers at facility 3 with a mean 
duration of employment of 9.1 years, and 680 workers at facility 4 with a mean duration of employment of 
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18.5 years.  2,3,7,8-TCDD blood levels in groups of workers in subcohorts 1 (112 males and 18 females) and 
2 (8 workers, all with a history of chloracne) were 3–2,252 and 163–1,935 pg/g blood lipid, respectively.  The 
study authors noted that 2,3,7,8-TCDD exposure was probably lower in subcohorts 3 and 4 because 
2,3,7,8-TCDD-contaminated products only made up a small percentage of the total products manufactured at 
these facilities. Messerer et al. (1998) measured serum CDD and CDF levels in 19 of the current employees 
at facility 4.  The mean CDD and CDF levels were slightly higher than background levels, even in the most 
exposed workers (involved in synthesis); the mean 2,3,7,8-TCDD and TEQ levels in the 7 synthesis workers 
were 3.8 and 35.4 ppt, respectively, as compared to 3.2 and 25.0 ppt in controls.  The SMR for all cancer 
mortalities was significantly increased in the entire cohort (138 deaths; SMR=119; 95% CI=100–141); 
subcohort 1 was the only subcohort with a significant increase in all cancer mortalities (97 deaths; SMR=134; 
95% CI=109–164). When the entire cohort was divided into groups based on time since first exposure, there 
were no increases in SMRs for all cancer deaths during the three time periods (0 to <10 years, 10 to <20 
years, and $20 years). 
In the Fingerhut et al. (1991) study, cancer mortality was evaluated in 5,172 male workers involved in the 
production of 2,3,7,8-TCDD-contaminated chemicals in 12 U.S. plants, as well as in subcohorts with low 
(<1 year, n=1,516) or high ($1 year, n=1,520) exposures and $20 years latency.  Exposure was documented 
by reviewing job descriptions and records of 2,3,7,8-TCDD levels in industrial hygiene samples, and 
measuring lipid-adjusted serum 2,3,7,8-TCDD levels in 253 of the workers from two of the facilities; it was 
assumed that a similar relationship would exist at the other 10 facilities. Duration of exposure was used as a 
surrogate for cumulative 2,3,7,8-TCDD exposure on the basis of a high correlation (r=0.72, p<0.001) between 
log serum 2,3,7,8-TCDD level and log number of years of exposure.  Mean lipid-adjusted serum 
2,3,7,8-TCDD levels were 233 ppt (range 2–3,400) for all 253 workers, 418 ppt for 119 workers with $1 year 
exposure and 7 ppt in a comparison group of 79 unexposed persons.  When compared to the U.S. population, 
mortality from all cancers was significantly increased (p<0.05) in the overall cohort (SMR=115; 95% 
CI=102–130) and the high exposure subcohort (SMR=146; 95% CI=121–176).  Cancer mortality increased 
with increasing latency.  The number of deaths were too small to allow meaningful analysis according to 
duration of exposure. 
A cancer mortality follow-up study of 1,583 workers (1,184 men, 399 women) who were employed in a 
German chemical plant that produced trichlorophenol, 2,4,5-T, and other herbicides known to be 
contaminated with 2,3,7,8-TCDD and other polychlorinated dioxins and furans (this appears to be the same 
facility as subcohort 1 in the Becher et al. [1996] study) was reported by Manz et al. (1991).  Production of 
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these chemicals was discontinued during 1954–57 after an outbreak of chloracne.  Cohort members worked 
for at least 3 months during 1952–1984 and were followed through 1989.  SMRs were calculated using 
national mortality rates for West Germany and deaths in a cohort of male gas supply company workers. 
Exposures of cohort members were classified as high (n=496), medium (n=901), or low (n=186) based on an 
analysis of production processes in the plants where they had worked.  Some validation for these categories 
was provided by measurement of adipose 2,3,7,8-TCDD levels in 48 males in 1985 (mean concentrations 
were 296 ng/kg lipid in 37 subjects in the high-exposure group compared with 83 ng/kg for 11 subjects in the 
medium- and low-exposure groups combined).  When compared with national rates, mortality from all 
cancers combined was increased in the entire cohort (93 deaths, SMR=1.24; 95% CI=1.00–1.52), especially 
among men in the high exposure subgroup with $20 years employment (8 deaths, SMR=2.54; 95% 
CI=1.00–5.00) or who began employment before 1955 (18 deaths, SMR=2.11; 95% CI=1.25–3.34).  The 
greatest increase in risk was found in high exposure men with time of entry before 1955 and $20 years 
employment (8 deaths, SMR=3.5; 95% CI=1.51–6.9).  The aforementioned findings were corroborated when 
the gas workers were used as the comparison group.  In a follow-up study (Flesch-Janys et al. 1998) in which 
the cohort was followed through 1992, the SMR for all cancers was 1.4 (124 deaths; 95% CI=1.17–1.68). 
When the workers were divided into four exposure groups, a significant increase in SMR (36 deaths; 
SMR=1.73; 95% CI=1.21–2.40) was only found in the highest exposure group (2,3,7,8-TCDD levels of 
$2,503 ng/kg blood lipid × years, a measure of cumulative lifetime exposure); the trend toward increasing 
SMR with increasing dose was also statistically significant.  
The cohort in the Manz et al. (1991) study served as the basis for additional analysis by Flesch-Janys et al. 
(1995, 1998), who investigated the relation between mortality and quantitative measure of PCDD/F exposure. 
The male chemical workers (n=1,177) were followed for an additional 3 years.  Blood levels of each PCDD/F 
congener at the end of exposure were estimated for all members of the cohort based on work histories 
(durations of exposure in particular departments) and tissue levels from a subgroup of male workers, and 
assuming one-compartment first-order elimination kinetics.  A total TEQ level was also estimated for all 
measured CDDs and CDFs combined as the weighted sum of PCDD/F congeners using toxicity equivalent 
factor (TEF) values (see Section 2.5 for a detailed explanation on TEFs and dioxin equivalents).  In the 
Flesch-Janys et al. (1995) study, risk ratios for the cohort were estimated with year-of-birth stratified Cox 
regression using seven exposure levels (the reference cohort, the first four quintiles and the ninth and tenth 
deciles of the estimated 2,3,7,8-TCDD levels and total TEQ); an external cohort of gas supply workers 
(n=2,158) served as an unexposed control group. The estimated mean 2,3,7,8-TCDD level for the entire 
cohort at the end of employment in the plant was 141.4 ng/kg blood fat (median of 38.2 ng/kg).  
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The estimated mean total dioxin equivalents, calculated as the weighted sum of combined PCDD/F congeners, 
was 296.5 ng/kg (median of 118.3 ng/kg).  There was a dose-dependent increase in cancer mortality with 
increasing levels of 2,3,7,8-TCDD (p=0.01 for trend), predominantly due to increased risk ratio (3.30; 95% 
CI=2.05–5.31) in the highest-dose group (344.7–3,890.2 ng/kg).  Similar findings were obtained when total 
TEQs were used as the exposure parameter, or when the two lowest-dose groups in the chemical-worker 
cohort were combined and used for reference.  In the Flesch-Janys et al. (1998) study, the mean blood 
2,3,7,8-TCDD level in the subgroup (blood or adipose tissue samples collected from 236 males) was 108.3 
ng/kg blood lipid (range, 2.0–2252 ng/kg), the mean TEQ for CDD/F congeners was 247.5 ng/kg 
(11.7–2,985.8), and the mean TEQ without 2,3,7,8-TCDD was 184.0 ng/kg (9.7–1,263.4 ng/kg).  When the 
workers were divided into groups based on cumulative TEQ exposure, statistically significant SMRs were 
found in the second (TEQ between 360.9 and 1,614.4 ng/kg × years) and fourth (TEQ greater than 
5,217.7 ng/kg × years) quartiles; SMRs of 1.64 (34 deaths; 95% CI=1.13–2.29) and 1.64 (34 deaths; 95% 
CI=1.13–2.29), respectively.  A significant relationship between cumulative TEQ level and SMR for all 
cancer was not found. Potential sources of error and bias in this study include lack of random sampling in the 
subgroup with PCDD/F assays and the assumption of first-order elimination kinetics.  Flesch-Janys et al. 
(1998) compared age of employment and years spent in each product department for workers with measured 
2,3,7,8-TCDD blood levels and workers without blood level data and found no major differences between the 
two groups. 
Workers at two Dutch phenoxy herbicide and chlorophenols production facilities comprised the cohort for the 
Bueno de Mesquita et al. (1993) study of cancer mortality.  The cohorts consisted of any worker employed 
between 1955 and 1985 (facility A) or between 1965 and 1986 (facility B).  An industrial accident at facility 
A resulted in a release of CDDs, including 2,3,7,8-TCDD.  Mortality rates in the workers were compared to 
national rates. In workers at facility A, there was a slight increase in deaths from all cancers; however, the 
increase was not statistically significant (26 deaths; SMR=118; 95% CI=77–173); the SMR for all cancers 
was not increased at facility B or in the combined entire cohort.  Likewise, dividing the workers at each 
facility into groups based on time since first exposure or duration of exposure did not result in any significant 
increases in SMRs. Hooiveld et al. (1998) followed the workers at facility A for another 6 years. 
Additionally, serum levels of CDDs, CDFs, and PCBs were measured in a sample of 47 surviving workers 
who were employed for at least 1 year and whose date of first employment was prior to 1975; 14 of these 
workers were exposed during the accident, 17 were workers not involved in the accident, and 16 were not 
exposed to phenoxy herbicides or chlorophenols.  The average 2,3,7,8-TCDD serum levels were 105.2, 42.9, 
16.6, and 7.6 ppt (lipid adjusted) in the accident-exposed workers with a history of chloracne (12 workers), 
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accident-exposed workers without chloracne (2 workers), nonaccident-exposed workers, and nonexposed 
workers, respectively; the mean serum 2,3,7,8-TCDD levels at the time of maximum exposure (extrapolated 
levels) were estimated at 2,014.4, 806.6, and 244.1 ppt in the accident-exposed workers with a history of 
chloracne, accident-exposed workers without chloracne, and nonaccident-exposed workers, respectively.
There was an increase in deaths from all cancers among all exposed workers (51 deaths; SMR=1.5; 95% 
CI=1.1–1.9), as compared to national rates; a slightly higher mortality rate (20 deaths; SMR=1.7; 95% 
CI=1.1–2.7) was observed in the subcohort of accident-exposed workers.  When nonexposed workers were 
used as a comparison group, the relative risk of all cancer deaths was 4.1 (51 deaths; 95% CI=1.8–9.0), the 
relative risk was adjusted for age, calendar year at end of follow-up, and time since first exposure/ 
employment.  When the workers were divided into three groups based on model-predicted 2,3,7,8-TCDD 
levels, the relative risk of all cancer deaths was elevated in workers with medium or high exposure, as 
compared to workers with low exposure (adjusted RR=4.8; 95% CI=2.0–11.3 for the medium exposure group 
and adjusted RR=4.4; 95% CI=1.9–10.4 for the high exposure group).  
Case-control studies have been designed to determine if 2,3,7,8-TCDD exposure results in increased risks for 
site-specific cancers. Case-control studies have found significant increases in the risk of soft-tissue sarcomas 
in Swedish agricultural, forestry, and horticultural workers (Eriksson et al. 1981, 1990; Hardell and Eriksson 
1988; Hardell and Sandstrom 1979), workers involved in manufacturing and application of phenoxy 
herbicides (Kogevinas et al. 1995), and New Zealand farmers (Smith et al. 1984a).  In the Eriksson et al. 
(1990) study, the risk ratio of soft-tissue sarcoma was 1.80 (95% CI=1.02–3.18) in subjects exposed to 
phenoxyacetic acid herbicides and/or chlorophenols.  In subjects exposed to phenoxyacetic acid herbicides 
only or chlorophenols only, the risk ratios were 1.34 (95% CI=0.7–2.56) and 5.25 (95% CI=1.69–16.34), 
respectively.  When the phenoxyacetic acid herbicide-only subjects were divided into two groups of subjects 
predominantly exposed to 2,4,5-T and those exposed to phenoxyacetic acid herbicides other than 2,4,5-T, risk 
ratios of 1.81 (95% CI=0.85–3.87) and 0.60 (95% CI=0.18–2.06), respectively, were calculated.  Hardell et al. 
(1995) conducted a meta-analysis of their four Swedish case-control studies (Eriksson et al. 1981, 1990; 
Hardell and Eriksson 1988; Hardell and Sandstrom 1979).  The odds ratios for workers exposed to 
phenoxyacetic acid herbicides or chlorophenols, phenoxy herbicides only, or chlorophenols only were 2.8 (90 
cases; 95% CI=2.1–4.4), 2.7 (59 cases; 95% CI=1.9–4.7), and 3.3 (34 cases; 95% CI=1.8–6.1), respectively. 
The data from this study suggest that the increased possible risks of soft-tissue sarcomas observed in phenoxy 
herbicide and chlorophenols applicators may be due to exposure to the 2,3,7,8-TCDD (or other CDDs) 
contamination of the mixture.  However, the results of the Kogevinas et al. (1995) study suggest that the 
possible risk of soft-tissue sarcoma may not be specific to 2,3,7,8-TCDD-contaminated 
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phenoxy herbicides.  An increase in the possible risk of soft-tissue sarcoma (OR of 10.3; 95% CI=1.2–90.6) 
was found in multinational workers involved in the production and spraying of phenoxy herbicides 
(Kogevinas et al. 1995). Exposure to chlorophenols was not associated with an increase in the possible risk of 
soft-tissue sarcomas (OR=1.29; 95% CI=0.24–6.91).  Using job histories, the workers were divided into 
groups based on the type of phenoxy herbicide used.  Excess possible risks of soft-tissue sarcoma were 
observed in workers predominantly exposed to 2,4-dichlorophenoxyacetic acid (2,4-D, OR=5.7; 95% 
CI=1.1–29), 2,4,5-T (OR=4.3, 90% CI=0.7–26), 4-chloro-2-methylphenoxyacetic acid (MCPA, OR=11.3; 
95% CI=1.3–98), exposure to any CDDs or CDFs (OR=5.6; 95% CI=1.1–28), and exposure to 2,3,7,8-TCDD 
(OR=5.2, CI=0.9–32). Although this study suggests that exposure to 2,3,7,8-TCDD increases the possible 
risk of soft-tissue sarcoma, it also suggests that exposure to phenoxy herbicides on their own may also 
increase the possible risk of soft-tissue sarcoma.  
Cohort mortality studies have also found increases in the incidences of soft-tissue sarcomas.  Fingerhut et al. 
(1991) found significant increase in deaths from soft-tissue sarcomas (SMR=922; 95% CI=190–2,695) in the 
high-exposure cohort, although this was only based on 3 deaths.  In the Saracci et al. (1991) multinational 
cohort, an increase in deaths from soft-tissue sarcoma was observed in phenoxy herbicide sprayers (3 deaths, 
SMR=297; 95% CI=61–868) and in workers dying 10–19 years after first exposure (4 deaths, SMR=606; 
95% CI=165–1,552). Similarly, the Kogevinas et al. (1997) study of the IARC cohort found 3 cases of soft-
tissue sarcoma in workers exposed for 10–19 years (SMR=6.52; 95% CI=1.35–19.06); shorter exposure 
durations did not result in significantly elevated SMRs.  Additionally, when workers were divided into 
latency groups, the SMRs were not elevated.  Duration of probable exposure to 2,3,7,8-TCDD did not appear 
to influence soft tissue sarcoma cancer risks.  
Case-control studies and/or cohort mortality studies have also found significant increase in the possible risk of 
malignant lymphoma (RR=4.8; 95% CI=2.9–8.1) in Swedish agricultural, forestry, and horticultural workers 
Hardell et al. 1981) and German phenoxy herbicide and chlorophenols manufacturer workers (SMR=239; 
95% CI=119–427) (Becher et al. 1996); non-Hodgkin’s lymphoma in Wisconsin farmers (OR=1.22; 95% 
CI=0.98–1.51) (Cantor 1982), multinational phenoxy herbicide manufacturers and applicators (OR of 1.25; 
CI=0.54–2.90) (Kogevinas et al. 1995), and German workers at a phenoxy herbicide and chlorophenols 
facility (SMR=375; 95% CI=101–957) (Becher et al. 1996); and stomach cancer in railroad workers (rate 
ratio of 6.1) (Axelson et al. 1980) and workers at a German trichlorophenol facility (observed/expected ratio 
of 3/0.52) (Thiess et al. 1982). 
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Cohort mortality studies by Fingerhut et al. (1991), Zober et al. (1990), Manz et al. (1991) (including the 
Flesch-Janys et al. [1998] follow-up data), and Kogevinas et al. (1997) found significant increases in risk of 
respiratory tract cancer.  In the Manz et al. (1991) study, a slightly increased risk of lung cancer was observed 
in the entire cohort compared to the risk in the West German population (30 deaths, SMR=1.41; 
95% CI=0.95–2.01) or the reference gas workers (26 deaths, SMR=1.67; 95% CI=1.09–2.44); the increase in 
lung cancer risk was statistically significant when the gas workers were used as the referent group (Manz et 
al. 1991). Smoking does not appear to be a major confounder because available data (partial cohort) suggest 
that the percentage of smokers in the study cohort and gas-worker control group were similar.  In the Flesch-
Janys et al. (1998) follow-up of this cohort, the SMRs for lung (38 deaths) and respiratory (44 deaths) cancer 
were 1.51 (95% CI=1.07–2.08) and 1.71 (95% CI=1.24–2.29), respectively.  When the cohort was divided 
into four cumulative exposure categories, the SMRs were not significantly elevated for any exposure group. 
In this cohort, blood 2,3,7,8-TCDD levels were not correlated with smoking status (Flesch-Janys et al. 1995). 
The study authors additionally noted that when lung cancer deaths were removed from total cancer deaths, 
there was a stronger relationship between 2,3,7,8-TCDD levels and cancer rates, suggesting that smoking was 
not a strong confounder. Death from cancers of the respiratory tract (SMR=142; 95% CI=103–192) were 
significantly increased in the high-exposure subcohort of the Fingerhut et al. (1991) study.  The expected 
number of lung cancers was adjusted for smoking using smoking-prevalence data for a small subset of 
workers; the adjusted SMR for the high-exposure subcohort was 137 (95% CI=98–187).  The authors 
concluded that the increased lung cancer risk was probably not due to smoking because the incidences of 
smoking-related diseases were not higher than expected in the subcohort and mortality from non-malignant 
respiratory disease was lower than expected.  However, when smoking was included as a confounding factor, 
the increased risk for lung cancer was no longer statistically significant.  Zober et al. (1990) found a 
borderline increase in mortality from cancer of the trachea bronchus/ lung (SMR=252; 95% CI=99–530) in 
workers with chloracne/erythema and $20 years latency.  In the follow-up to the Zober et al. (1990) study, Ott 
and Zober (1996) found an increased number of deaths from respiratory cancer in the subcohort with 
2,3,7,8-TCDD body burdens of $1 µg/kg (SMR=2.4; 95% CI=1.0–5.0). However, in 10 of the 11 cases, the 
worker smoked, which makes it difficult to determine if the cancer deaths were due to 2,3,7,8-TCDD 
exposure. The Kogevinas et al. (1997) examination of the expanded IARC cohort did not find a significant 
elevation in deaths from lung cancer (225 deaths; SMR=1.12; 95% CI=0.98–1.28) among workers exposed to 
phenoxy herbicides contaminated with 2,3,7,8-TCDD or higher chlorinated dioxins, but it did find a rise in 
deaths from other respiratory organ cancers (9 deaths; SMR=3.20; 95% CI=1.46–6.08).  
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Using regression analysis based on Cox’s proportional hazards model, Ott and Zober (1996) found evidence 
of association between 2,3,7,8-TCDD exposure and digestive cancer (conditional risk ratio of 1.46; 
95% CI=1.13–1.89); the primary tumor sites were the liver, stomach, and pancreas. 
A number of studies have looked at cancer incidences among Vietnam veterans to determine if exposure to 
Agent Orange with its 2,3,7,8-TCDD contamination resulted in a higher cancer risk.  Many of these studies 
compared cancer incidences in Vietnam veterans to Vietnam-era veterans stationed outside of Vietnam.  A 
limitation of this study design is that not all veterans in Vietnam were exposed to Agent Orange and exposure 
was lower than that of occupational workers. CDC (1988) found that the levels of 2,3,7,8-TCDD in Vietnam 
veterans were usually similar to a comparison group.  Thus, studies which examined cancer incidences in 
“Vietnam veterans” may not be adequate to assess the carcinogenicity of 2,3,7,8-TCDD.  Wolfe et al. (1985) 
focused on Air Force personnel involved in Operation Ranch Hand.  2,3,7,8-TCDD levels in 888 Ranch Hand 
personnel was 12.4 ppt as compared to 4.2 ppt in a referent group of Air Force personnel (CDC 1987; USAF 
1991). No significant alterations in the incidence of systemic malignancies were observed in the Ranch Hand 
personnel, as compared to a group of veterans flying cargo in Southeast Asia during the Vietnam war. A 
significant increase in non-melanomic skin cancer (predominantly basal cell carcinoma) was found in the 
Ranch Hand personnel; however, cancer incidences were not adjusted for sun exposure.  No significant 
alterations in systemic malignancy indices were found.  In a similar study of Air Force veterans involved in 
Operation Ranch Hand, a significant increase in benign systemic neoplasms was observed (USAF 1991).  No 
alterations in the risk of malignant neoplasm were observed.  No increases in the risk of Hodgkin’s disease, 
non-Hodgkin’s lymphoma or soft-tissue sarcoma were observed; however, the statistical power of the study to 
detect significant risk ratios for site-specific cancers was limited by the small number of cancers and the small 
sample size.  The incidence of benign neoplasms (primarily lipomas) was highest in veterans with the highest 
blood dioxin levels. The incidence of basal cell skin neoplasms was not positively associated with serum 
dioxin levels except among enlisted flyers with basal cell carcinomas at sites other than the ear, face, head, or 
neck. 
Increases in the risk of several types of cancer have been observed in residents of Seveso, Italy.  In the 
residents with the highest exposure (zone A), no increases in the risk ratio of all malignancies were observed 
(Bertazzi et al. 1993). However, the small number of zone A residents (724) limits the statistical power of the 
analysis.  Among residents living in zone B (4,824 people), significant increases were observed for the risk of 
hepatobiliary cancer (risk ratio of 3.3; 95% CI=1.3–8.1) and multiple myeloma (risk ratio of 5.3; 95% 
CI=1.2–22.6) in women and lymphoreticulosarcoma in men (RR of 5.7; 95% CI=1.7–19).  In zone R 
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(31,647 residents), the risk ratio of soft-tissue sarcomas in men (2.8; 95% CI=1–7.3) was significantly 
increased. In both zone B and R, the risk ratios of all malignancies was not significantly altered.  Estrogen-
dependent cancers (breast cancer and corpus uteri cancer) were consistently decreased in the women living in 
zone A, B, and R. It should also be noted that the latency period of 10 years may be too short to find 
increases in other types of cancer.  A study of children (aged 0–19 years at the time of the accident) exposed 
to 2,3,7,8-TCDD during the accident in Seveso found increased risks of Hodgkin’s lymphoma [RR =2; 95% 
CI=0.5–7.6), myeloid leukemia (RR=2.7; 95% CI=0.7–11.4), and thyroid cancer (RR=4.6; 95% CI=0.6–32.7) 
(Pesatori et al. 1993). However, the differences in RRs for these cancer types between the Seveso residents 
and the control population did not reach statistical significance. The small number of detected cancers and 
the relatively short latency period (10 years) limits the interpretation of the results of this study.  Similar 
results were found in the 15-year follow-up study (Bertazzi et al. 1997).  No significant increases in cancer 
mortality were found in zone A residents (805 residents, 70 deaths).  In zone B, death from all cancers was 
not significantly elevated in males (104 deaths; RR=1.1; 95% CI=0.9–1.3) or females (48 deaths; RR=0.9; 
95% CI=0.7–1.2). However, significant increases in site-specific cancers were observed, including rectal 
cancer in males (7 deaths; RR=2.9; 95% CI=1.2–5.9), pleural cancer in males (31 deaths; RR=5.3; 95% 
CI=1.1–5.5), lymphohemopoietic cancer in males (12 deaths; RR=2.4; 95% CI=1.2–4.1), leukemia in males 
(7 deaths; RR=3.1; 95% CI=1.3–6.4), and myeloma in females (4 deaths; RR=6.6; 95% CI=1.8–16.8).  The 
cancer with an elevated incidence among zone R residents was bone cancer in females (7 deaths; RR=2.4; 
95% CI=1.0–4.9). 
The available epidemiology data suggest that 2,3,7,8-TCDD may be a human carcinogen.  Statistically 
significant increases in risks for all cancers were found in highly exposed workers with longer latency 
periods. Although the estimated SMRs are low, they are consistent across studies with the highest exposures. 
The evidence for site-specific cancers is weaker, with some data suggesting a possible relationship between 
soft-tissue sarcoma, non-Hodgkin’s lymphoma, or respiratory cancer with 
2,3,7,8-TCDD exposure. It should be emphasized that some of the human studies do not provide adequate 
exposure data and were confounded by concomitant exposure to other chemicals. 
2,3,7,8-TCDD body burdens calculated from available serum lipid 2,3,7,8-TCDD levels are presented in 
Table 2-1. 
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2.2. ANIMAL STUDIES 
This section contains descriptions and evaluations of studies and presents levels of significant exposure for 
CDDs based on toxicological studies. 
The information in this section is organized first by route of exposure—inhalation, oral, and dermal—and 
then by health effect—death, systemic, immunological, neurological, developmental, reproductive, genotoxic, 
and carcinogenic effects. These data are discussed in terms of three exposure periods—acute (14 days or 
less), intermediate (15–364 days), and chronic (365 days or more). 
Levels of significant exposure for each route and duration are presented in tables and illustrated in figures. 
The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-observed-adverse­
effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies.  LOAELs have been 
classified into "less serious" or "serious" effects. These distinctions are intended to help the users of the 
document identify the levels of exposure at which adverse health effects start to appear.  They should also 
help to determine whether or not the effects vary with dose and/or duration, and place into perspective the 
possible significance of these effects to human health. 
The significance of the exposure levels shown in the tables and figures may differ depending on the user's 
perspective. For example, physicians concerned with the interpretation of clinical findings in exposed 
persons may be interested in levels of exposure associated with "serious" effects.  Public health officials and 
project managers concerned with appropriate actions to take at hazardous waste sites may want information 
on levels of exposure associated with more subtle effects in humans or animals (LOAEL) or exposure levels 
below which no adverse effects (NOAEL) have been observed.  Estimates of levels posing minimal risk to 
humans (Minimal Risk Levels, MRLs) may be of interest to health professionals and citizens alike. 
Levels of exposure associated with carcinogenic effects (Cancer Effect Levels, CELs) of CDDs  are indicated 
in Tables 2-2, 2-3, and 2-4 and Figures 2-1 and 2-2. 
Estimates of exposure levels posing minimal risk to humans (MRLs) have been made (see Section 2.5), where 
data were believed reliable, for the most sensitive noncancer effect for each exposure duration.  MRLs include 
adjustments to reflect human variability and extrapolation of data from laboratory animals to humans. 
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Although methods have been established to derive these levels (Barnes et al. 1988; EPA 1989c), uncertainties 
are associated with these techniques. Furthermore, ATSDR acknowledges additional uncertainties inherent in 
the application of the procedures to derive less than lifetime MRLs.  As an example, acute inhalation MRLs 
may not be protective for health effects that are delayed in development or are acquired following repeated 
acute insults, such as hypersensitivity reactions, asthma, or chronic bronchitis.  As these kinds of health 
effects data become available and methods to assess levels of significant human exposure improve, these 
MRLs will be revised. 
2.2.1 Inhalation Exposure 
No studies were located regarding the following health effects in animals after inhalation exposure to CDDs: 
2.2.1.1 Death 
2.2.1.2 Systemic Effects 
2.2.1.3 Immunological Effects 
2.2.1.4 Neurological Effects 
2.2.1.5 Reproductive Effects 
2.2.1.6 Developmental Effects 
2.2.1.7 Genotoxic Effects 
Genotoxicity studies are discussed in Section 2.5. 
2.2.1.8 Cancer 
No studies were located regarding cancer in animals after inhalation exposure to CDDs. 
2.2.2 Oral Exposure 
Information regarding adverse health effects in animals exposed to CDDs via the oral route was located 
for the following congeners: 2-monochlorodibenzo-p-dioxin (2-MCDD), 2,3-dichlorodibenzo-p-dioxin 
(2,3-DCDD), 2,7-dichlorodibenzo-p-dioxin (2,7-DCDD), 1,2,3-trichlorodibenzo-p-dioxin (1,2,3-TrCDD), 
1,2,3,4-tetrachlorodibenzo-p-dioxin (1,2,3,4-TCDD), 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(2,3,7,8-TCDD), 1,2,3,7,8-pentachlorodibenzo-p-dioxin (1,2,3,7,8-PeCDD), 1,2,3,4,7,8-hexachloro-
dibenzo-p-dioxin (1,2,3,4,7,8-HxCDD), 1,2,4,7,8-pentachlorodibenzo-p-dioxin (1,2,4,7,8-PeCDD), 
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1,2,3,6,7,8-hexachlorodibenzo-p-dioxin (1,2,3,6,7,8-HxCDD), 1,2,3,7,8,9-hexachlorodibenzo-p-dioxin 
(1,2,3,7,8,9-HxCDD), 1,2,3,4,6,7,8,-heptachlorodibenzo-p-dioxin (1,2,3,4,6,7,8,-HpCDD), and 
1,2,3,4,6,7,8,9-octachlorodibenzo-p-dioxin (OCDD). Some of the animal studies used a mixture of 
1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD. Of all the CDD congeners, 2,3,7,8-TCDD has been the one 
most extensively studied. 
2.2.2.1 Death 
Numerous studies provided doses associated with death following exposure to CDDs in animals.  LD50 (lethal 
dose, kill for 50% of dosed animals during a certain time interval) values for each congener varied not only 
among species, but also among different strains.  
LD50 values following a single oral dose of 2,3,7,8-TCDD were calculated as 22 µg/kg (males) and 45 µg/kg 
(females) in Sherman rats (Schwetz et al. 1973); and 164 µg/kg, 297 µg/kg, 303 µg/kg, and  340 µg/kg in 
Fischer 344 rats from Charles River Breeding Laboratories, Charles River CD, Frederick Cancer Research 
Center, and Harlan Industries, respectively (Walden and Schiller 1985); 165 µg/kg (males) and 125 µg/kg 
(females) in Osborne Mendel rats (NTP 1982b); 43 µg/kg in male Sprague-Dawley rats (Stahl et al. 1992), 
and 60 and 100 µg/kg in female and male Long Evans rats, respectively (Fan and Rozman 1995).  A single 
gavage dose of 100 µg/kg caused death in 95% of exposed male Fischer 344 rats (Kelling et al. 1985), and a 
dose of 25 µg/kg led to the death of 25% of exposed male Sprague-Dawley rats (Seefeld et al. 1984a). 
Furthermore, the reported LD50 values were 4.2 µg/kg in minks (Hochstein et al. 1988), 115 µg/kg in New 
Zealand albino rabbits (Schwetz et al. 1973b), 1.75 µg/kg in male Hartley guinea pigs (McConnell et al. 
1984), 0.6 µg/kg (males) and 2.1 µg/kg (females) in Hartley guinea pigs (Schwetz et al. 1973b), and 
1,157 µg/kg (Olson et al. 1980a) or 5,051 µg/kg (Henck et al. 1981) in Syrian hamsters.  A 42-day LD50 of 
2.5 µg/kg was calculated for female Hartley guinea pigs when 2,3,7,8-TCDD was administered in corn oil and 
19 µg/kg when administered in methyl cellulose (Silkworth et al. 1982).  No effect on survival was observed 
after a single oral dose of 200 µg/kg in B6C3F1 mice (NTP 1982b), but 69% of C57BL/6 mice died following 
exposure to 360 µg/kg (Kelling et al. 1985), and an LD50 was calculated as 146 µg/kg 2,3,7,8-TCDD in male 
C57BL mice (Smith et al. 1981).  An acute LD50 in excess of 3,000 µg/kg was reported for male DBA/2J mice 
(Weber et al. 1995). Increased lethality was observed in Hartley guinea pigs exposed to 0.03 µg/kg/day 
2,3,7,8-TCDD in the feed for 11 days (DeCaprio et al. 1986) and in pregnant rabbits following 10 daily
doses of 1 µg/kg during gestation (Giavini et al. 1982). Beagle dogs survived a single dose of 
300 µg/kg but not 3,000 µg/kg (Schwetz et al. 1973).  In addition, 3 of 12 pregnant rhesus 
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monkeys died following a single dose of 1 µg/kg (McNulty 1984).  It is evident from the above results that 
guinea pigs were the most sensitive species, while hamsters were the most resistant (up to 5,000 times greater 
lethal doses). In all studies cited above, the animals died following a latency period of several days (mean 
values varied from 9 to 43).  In almost all laboratory animals, a pronounced wasting syndrome appears to be a 
major contributor to lethality. 
In the intermediate-duration experiments, increased lethality was observed in Osborne Mendel rats exposed to 
2,3,7,8-TCDD by gavage in oil vehicle at 0.56 µg/kg/day for up to 13 weeks (NTP 1982b).  Mortality of 5% 
(no deaths in controls) was observed in Sprague-Dawley rats administered 2,3,7,8-TCDD by gavage at a rate 
of approximately 0.8 µg 2,3,7,8-TCDD/kg/day for 13 weeks (Viluksela et al. 1994); the first death occurred 
on day 57.  Four of 7 male Sprague-Dawley rats dosed by gavage with approximately 1.6 µg 
2,3,7,8-TCDD/kg/day died in a 10-week study (Li and Rozman 1995); the mean time to death was 53.5 days. 
Increased mortality was reported in Hartley guinea pigs exposed daily for up to 60 days to diets that provided 
0.03 µg/kg/day (DeCaprio et al. 1986); 4 of 10 males died by day 42 and 4 of 10 females by day 59.  In a 
dietary study, all male Sprague-Dawley rats that received the diet that provided the highest doses 
(3.4 µg/kg/day or more) died within 4 weeks (Van Miller et al. 1977).  C57BL/6 mice had decreased survival 
following exposure by gavage to 3 µg/kg/day of 2,3,7,8-TCDD 3 days a week for 25 weeks (Umbreit et al. 
1987). Two monkeys were exposed intermittently by gavage to 0.6 µg/kg/day of 2,3,7,8-TCDD for 3 weeks 
and both died (McNulty 1984); 5 of 8 monkeys died within 2 months following exposure to diets that 
provided 0.02 µg/kg/day (Hong et al. 1989); also, 5 of 8 monkeys died within 9 months of dietary exposure to 
0.011 µg/kg/day (Allen et al. 1977).  In all species, severe weight loss and body fat depletion were 
experienced prior to death, but usually no other overt toxic signs were observed.  Pancytopenia, a secondary 
effect, was the cause of death in monkeys. 
Decreased survival was reported after chronic exposure to CDDs.  Chronic dietary exposure to 2,3,7,8-TCDD 
increased the mortality over controls in Sprague-Dawley rats at 0.1 µg/kg/day (Kociba et al. 1978a). 
Increased mortality also occurred in Swiss mice given 2,3,7,8-TCDD by gavage at 1.0 µg/kg/day (Toth et al. 
1979) and in B6C3F1 mice at 0.36 µg/kg/day (Della Porta et al. 1987).  In both studies, the mice were dosed 
once a week for 1 year and followed for the rest of their lives or until 110 weeks of age.  No treatment-related 
effects on survival were observed in Osborne-Mendel rats or in B6C3F1 mice administered up to 0.25 µg 
2,3,7,8-TCDD/kg/day, 2 days a week by gavage for 104 weeks(0.071 µg/kg/day for rats and male mice; 
0.3 µg/kg/day for female mice) (NTP 1982b). 
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Increased mortality occurred after acute exposure to other congeners.  After a single oral dose of a mixture of 
1,2,3,7,8,9-HxCDD and 1,2,3,6,7,8-HxCDD, LD50 values were calculated as 1,800 µg/kg and 800 µg/kg in 
male and female Osborne-Mendel rats, respectively, and 750 µg/kg and 500 µg/kg in male and female 
B6C3F1 mice, respectively (NCI/NTP 1980).  In addition, LD50 values were calculated for several congeners 
in guinea pigs (29,444 µg/kg for 1,2,3-TrCDD, 1,125 µg/kg for 1,2,4,7,8-PeCDD, 3.1 µg/kg for 
1,2,3,7,8-PCDD, 70–100 µg/kg for 1,2,3,6,7,8-HxCDD, 60–100 µg/kg for 1,2,3,7,8,9-HxCDD, and 
72.5 µg/kg for 1,2,3,4,7,8-HxCDD) and in mice (825 µg/kg for 1,2,3,4,7,8-HxCDD and 337.5 µg/kg for 
1,2,3,7,8-PCDD) following a single oral exposure by gavage in oil vehicle (McConnell et al. 1978b).  In male 
Sprague-Dawley rats, the oral LD50 for 1,2,3,7,8-PCDD, 1,2,3,4,7,8-HxCDD, and 1,2,3,4,6,7,8-HpCDD 
administered in corn oil/acetone (95/5) was 206, 887, and 6,325 µg/kg, respectively (Stahl et al. 1992).  Other 
CDD congeners have a much lower order of toxicity, as evidenced by data showing no effects on mortality at 
much higher doses than those of 2,3,7,8-TCDD, TrCDD, HxCDD, or PCDD that cause death. No deaths were 
observed after a single oral dose of 1×106 and 2×106 µg/kg 2,7-DCDD in Sprague-Dawley rats and Swiss 
Webster mice, respectively (Schwetz et al. 1973).  In addition, rats and mice survived acute oral doses of 
1×106 and 4×106 µg/kg OCDD, respectively (Schwetz et al. 1973).  The relative species differences in 
sensitivity for 2,3,7,8-TCDD also applied for other congeners.  
Mortality rates of 15 and 50% were reported in groups of male Sprague-Dawley rats administered 73 and 
110 µg 1,2,3,4,6,7,8-HpCDD/kg/day by gavage for 13 weeks, respectively (Viluksela et al. 1994).  At the 
highest dose, the first death occurred on day 31; at the 73 µg/kg/day dose, on day 41.  Fifteen out of 20 
female Sprague-Dawley rats died during a 13-week treatment period with daily doses of approximately 2.6 µg 
1,2,3,7,8-PeCDD/kg (total dose was 233 µg/kg) (Viluksela et al. 1998a).  The first death occurred on day 16. 
The same mortality rate was observed in males treated with approximately 3.8 µg/kg/day (total dose was 
350 µg/kg).  In the same study, administration of approximately 10.3 µg 1,2,3,4,7,8-HxCDD resulted in a 
25% death rate (5/20, first death on day 61) in female rats; the same death rate was seen among male rats 
treated with approximately 15.4 µg/kg/day (first death on day 24).  The main causes of death were wasting 
syndrome, hemorrhage, and anemia (Viluksela et al. 1998a).  No effects on survival were observed following 
chronic dietary exposure of Osborne-Mendel rats and B6C3F1 mice to 5×105 µg/kg/day of 2,7-DCDD and to 
1.3×106 µg/kg/day of 2,7-DCDD, respectively (NCI/NTP 1979a), or following chronic gavage dosing with a 
mixture of 1,2,3,7,8,9-HxCDD and 1,2,3,6,7,8-HxCDD at 0.34 µg/kg/day and 0.7 µg/kg/day, respectively 
(NCI/NTP 1980). 
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In conclusion, 2,3,7,8-TCDD was the most toxic of all congeners tested, and doses on the order of 
several µg/kg body weight have led to death in all species tested, except hamsters and dogs, in acute-exposure 
experiments.  In contrast, of the congeners tested, 2,7-DCDD and OCDD were the least toxic as tested 
animals survived very high doses (g/kg body weight).  The wasting syndrome was the major toxic effect of 
acute- and intermediate-duration exposure to CDDs in most species.  It was characterized by body weight 
loss, adipose tissue depletion, and eventual death.  In most of the chronic duration studies the cause 
of death was not determined. 
The LD50 values and all reliable representative LOAEL values for death in each species and duration category 
for each congener tested are recorded in Tables 2-2 and 2-3 and plotted in Figures 2-1 and 2-2. 
2.2.2.2 Systemic Effects 
The highest NOAEL values and all reliable representative LOAEL values for each systemic effect in each 
species and duration category for each congener tested are recorded in Tables 2-2 and 2-3 and plotted in 
Figures 2-1 and 2-2. 
Respiratory Effects. Few studies have examined the respiratory system in animals following oral 
exposure to CDDs. However, serious respiratory effects have been observed in monkeys that died from 
2,3,7,8-TCDD exposure. 
Bleeding from the nose was reported in rhesus monkeys exposed via gavage to 0.1 µg/kg/day, 3 days a week 
for 3 weeks (McNulty 1984).  Hemorrhage, hyperplasia, and metaplasia of the bronchial epithelium (as well 
as at other organ sites that had mucous-secreting cells) developed in monkeys exposed to diets providing 
0.011 µg/kg/day for 9 months (Allen et al. 1977); 5 of 8 monkeys died with this dose level.  Focal alveolar 
hyperplasia and squamous metaplasia and carcinoma were reported in Sprague-Dawley rats chronically 
exposed to 0.1 µg/kg/day 2,3,7,8-TCDD in the feed (Kociba et al. 1978a).  Since powdered feed containing 
2,3,7,8-TCDD was given to the rats, there is a distinct possibility that the respiratory effects were attributable 
to inhalation exposure rather than oral systemic absorption.  In contrast, no respiratory effects were observed 
in rats or mice chronically exposed by gavage to 2,3,7,8-TCDD at approximately 0.071 µg/kg/day or 
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Similarly, no respiratory effects were found in rats and mice chronically exposed by diet to 5×105 and 
1.3×106 µg/kg/day of 2,7-DCDD, respectively (NCI/NTP 1979a).  In contrast, rats exposed chronically by 
gavage to a mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD at 0.18, 0.34, and 0.7 µg/kg/day had a 
dose-related increased incidence of adenomatous hyperplastic lesions in terminal bronchioles and adjacent 
alveoli of both males and females; no such effects were found in mice exposed chronically to 0.7 µg/kg/day 
of that same mixture (NCI/NTP 1980).  The existing information suggests that in animals, the respiratory 
system is not a sensitive target for CDDs toxicity via oral exposure. 
Cardiovascular Effects. Cardiovascular effects have been detected in animals following acute-, 
intermediate-, and chronic-duration oral exposure to 2,3,7,8-TCDD.  These included changes in heart weight, 
pathophysiological effects, and degenerative changes. However, exposures at or near a lethal dose were 
required to elicit these effects. 
Decreased absolute heart weight was reported in minks 28 days after a single oral dose of 5 µg/kg, but not at 
2.5 µg/kg (Hochstein et al. 1988).  A reduction of absolute heart weight which is attributed to weight loss was 
also found in monkeys at 70 µg/kg (relative heart weight was increased) (McConnell et al. 1978a). 
Histological examinations of the heart were normal in the monkeys.  This examination was not performed in 
minks.  Doses in both species were near the lethal dose. 
Kelling et al. (1987) assessed the effects of 2,3,7,8-TCDD on cardiac function tests in male Sprague-Dawley 
rats 7 days after single oral doses of 6.25, 25, or 100 µg/kg.  At 100 µg/kg (near-lethal dose), an increased 
sensitivity to the inotropic (left atrium) and chronotropic (right atrium) effects of isoproterenol were observed. 
Three daily oral doses of 40 µg/kg caused decreased heart rate, depressed blood pressure, and increased 
myocardial peroxidase activity in rats (Hermansky et al. 1988).  All of these effects may have been secondary 
to the modulation of adenylate cyclase activity at β-adrenergenic receptors as a result of hypothyroidism 
(Hermansky et al. 1987). 
In intermediate-duration experiments, monkeys that died after exposure to diets providing 0.011 µg/kg/day of 
2,3,7,8-TCDD (lethal dose) had hemorrhages in the epicardium, myocardium, and endocardium (Allen et al. 
1977). Myocardial degenerative changes and periarteritis were reported in Sprague-Dawley rats chronically 
exposed to a diet providing a lethal dose of 0.1 µg/kg/day of 2,3,7,8-TCDD, but not in those receiving 
0.01 µg/kg/day (Kociba et al. 1978a).  In contrast, no histopathological lesions were observed in 
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the hearts of rats and mice chronically exposed by gavage to approximately 0.071 and 0.3 µg/kg/day of 
2,3,7,8-TCDD, respectively (NTP 1982b). 
No histopathological lesions were observed in the hearts of rats and mice chronically exposed in the diet to 
5×105 and 1.3×106 µg/kg/day of 2,7-DCDD, respectively (NCI/NTP 1979a); or exposed for 104 weeks by 
gavage to approximately 0.34 and 0.7 µg/kg/day of a mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD, 
respectively (NCI/NTP 1980).  
Gastrointestinal Effects. One of the major 2,3,7,8-TCDD-induced effects in various animal species is 
the wasting syndrome and hypophagia which occur after a single near-lethal dose or after repeated dosing 
(discussed under Body Weight Effects).  Studies of effects on the gastrointestinal system have been carried 
out to investigate the mechanism of this starvation-like syndrome.  Ulceration of the gastrointestinal tract and 
bloody stools were observed in minks after a single oral exposure to 5 µg 2,3,7,8-TCDD/kg (3 of 4 mink 
died) but not at a dose of 2.5 µg/kg/day.  The response of the antral mucosa of the rat stomach to 
2,3,7,8-TCDD has been studied by Theobald et al. (1991).  In Sprague-Dawley rats, a single oral dose of 
100 µg 2,3,7,8-TCDD/kg caused a 7–10-fold increase in serum gastrin (secreted by G-cells in the antrum) that 
was not detected until 14 days after dosing, whereas control rats fed a restricted diet had atrophic changes in 
the antral mucosa and no increase in gastrin (Theobald et al. 1991).  The number of G-cells in the antral 
mucosa was not affected by treatment with  2,3,7,8-TCDD or paired-feed restriction, indicating that 
hypergastrinemia in treated rats is not due to reduced feed intake or antral G-cell hyperplasia.  In 
2,3,7,8-TCDD-treated rats, both gastrin and somatostatin (which inhibits gastrin release) levels in the antral 
mucosa were significantly decreased, and these changes were observed a week earlier than the 
hypergastrinemia.  Moreover, the ED50 values (half maximum effect level of 2,3,7,8-TCDD) for the decrease 
in antral mucose content and concentration of gastrin (29 and 22 µg/kg, respectively) and somatostatin (24 
and 19 µg/kg, respectively) was less than that for hypergastrinemia (46 µg/kg).  This suggested that 
hypergastrinemia in 2,3,7,8-TCDD-treated rats is not a consequence of reduced antral levels of gastrin or 
somatostatin.  Epithelial hyperplasia of the stomach occurred in rhesus monkeys following a single oral dose 
of 70 µg/kg; this response is unique to monkeys and cows and is not seen in rats, mice, or guinea pigs 
(McConnell et al. 1978b). Monkeys undergo a similar wasting syndrome as rodents after a single oral lethal 
dose. Moderate to severe ileitis, characterized by hyperplasia of the mucosal epithelium with hemorrhaging 
and necrosis, and peritonitis were observed in hamsters that died after oral administration of $1000 µg/kg 
2,3,7,8-TCDD (Olson et al. 1980a). 
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Repeated dosing of rats at 3.4 µg/kg/day or higher caused gastrointestinal hemorrhaging in rats that died in a 
chronic oral-dosing study (Van Miller et al. 1977).  Metaplasia of the gastric mucosa was found in rhesus 
monkeys exposed to 0.1 µg/kg/day of 2,3,7,8-TCDD for 3 weeks (McNulty 1984), and gastric ulcers 
developed after exposure to 0.011 µg/kg/day for 9 months in the feed (Allen et al. 1977).  No gastrointestinal 
effects were observed in rats and mice chronically exposed by gavage to approximately 0.071and 
0.3 µg/kg/day of 2,3,7,8-TCDD, respectively (NTP 1982b) or in rats on diets that provided 0.1 µg/kg/day 
(Kociba et al. 1978a). 
Gastrointestinal lesions were not observed following exposure of rats and mice to 5×105 and 
1.3×106 µg/kg/day of 2,7-DCDD, respectively, in the diet (NCI/NTP 1979a) or to 0.34 and 0.7 µg/kg/day of a 
mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD, respectively, by gavage for 104 weeks (NCI/NTP 
1980). 
The above studies demonstrated that monkeys are more sensitive to gastrointestinal effects of 2,3,7,8-TCDD 
than rodents. 
Hematological Effects. Hematological effects were reported in some animals following exposure to 
lethal or near-lethal doses of 2,3,7,8-TCDD. Increases in erythrocyte counts, hemoglobin, and hematocrit 
were observed 10–14 days after CD rats received a single oral dose of 10 µg/kg 2,3,7,8-TCDD.  Increases in 
total leukocyte count and neutrophil counts, and a decrease in platelet counts were also observed, but bleeding 
time and megakaryocytes were not altered (Weissberg and Zinkl 1973).  Reduction of germinal centers and 
increased hemosiderin deposits were seen histologically in the spleen of Sprague-Dawley rats after a single 
oral dose of 25 µg/kg (Christian et al. 1986a).  Mild anemia developed in rhesus monkeys after a single oral 
dose of 70 µg/kg (McConnell et al. 1978a).  No effects were found in minks exposed acutely to a lethal dose 
of 2,3,7,8-TCDD (7.5 µg/kg) (Hochstein et al. 1988) or in B6C3F1 mice exposed to 1 µg/kg/day for 14 days 
(Holsapple et al. 1986a). Reversible changes (suppression of progenitor cells, decreases in leukocyte and 
lymphocyte counts) were reported in CD-1 mice at doses between 1 and 10 µg/kg 2,3,7,8-TCDD (Zinkl et al. 
1973). 
Hematological effects have also been reported following intermediate-duration exposures to 2,3,7,8-TCDD. 
Decreased white blood cell counts were reported in guinea pigs exposed by gavage to 0.008 µg/kg/day 
2,3,7,8-TCDD for 8 weeks (Vos et al. 1973), but no hematological changes were observed following dietary 
exposure to 0.005 µg/kg/day 13 weeks (DeCaprio et al. 1986).  Exposure to higher doses 
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(3.4 µg/kg/day or more) caused splenic atrophy in Sprague-Dawley rats that died during the first 4 weeks of 
exposure in a chronic-duration dietary study (Van Miller et al. 1977).  In contrast, no hematological changes 
were found in rats exposed to 0.71 µg/kg/day of 2,3,7,8-TCDD for 6 weeks (Vos et al. 1973).  One month of 
intermittent exposure to 0.1 µg/kg/day 2,3,7,8-TCDD induced thrombocytopenia in CD rats (Zinkl et al. 
1973); exposure to 1 µg/kg/day caused increased erythrocyte counts and hemoglobin levels.  Administration 
of 2,3,7,8-TCDD by gavage for 13 weeks to male Sprague-Dawley rats at doses equivalent to 0.8 µg/kg/day 
(only dose level tested) produced a significant decrease in platelet counts, and in some animals, increased 
prothrombin times (Viluksela et al. 1994).  Anemia and bone marrow hypoplasia were observed in rhesus 
monkeys exposed to 0.1 µg/kg/day of 2,3,7,8-TCDD by gavage 3 days a week for 3 weeks (McNulty 1984). 
The changes were more severe with longer exposure; pancytopenia and bone marrow atrophy developed in 
monkeys exposed to 0.011 µg/kg/day (a lethal dose) in the feed for 9 months (Allen et al. 1977). 
In chronic-duration studies, reduced erythrocyte counts were found in Sprague-Dawley rats at dietary doses of 
0.1 µg/kg/day of 2,3,7,8-TCDD but not at 0.01 µg/kg/day (Kociba et al. 1978a).  No hematological effects 
were observed in Osborne-Mendel rats or B6C3F1 mice chronically exposed by gavage to approximately 
0.071or 0.3 µg/kg/day of 2,3,7,8-TCDD, respectively (NTP 1982b).  Results from a more recent study 
showed that 2,3,7,8-TCDD administered by gavage to female C57BL/6 mice in gavage doses equivalent to 
approximately 0.03 µg/kg/day (0.2 µg/kg once/week) for 14–15 months produced no significant effects on the 
total number of circulating red or white blood cells or in white blood cell differentials (Oughton et al. 1995). 
Hematological effects have been reported in some animals following exposure to other CDDs.  No hematological 
effects were observed in rats after 2 weeks of intermittent exposure to 50 µg/kg/day OCDD (Couture et al. 1988), 
but increased neutrophils, decreased mean cell volume, and hemoglobin (Couture et al. 1988), and mild anemia 
was observed at the same exposure level after 13 weeks of intermittent exposure (Birnbaum et al. 1989a).  A 
dose-dependent decrease in platelet counts was observed in male Sprague-Dawley rats following administration 
by gavage of doses equivalent to 73 or 110 µg 1,2,3,4,6,7,8-HpCDD/kg/day for 13 weeks (Viluksela et al. 1994); 
no such effect was observed with doses #24 µg/kg/day.  Some rats administered the highest dose also showed 
increased prothrombin times.  Administration of doses equivalent to 2.6 µg 1,2,3,7,8-PCDD/kg/day or 10.3 µg 
1,2,3,47,8-HxCDD/kg/day for 13 weeks resulted in decreased hematocrit and reduced platelet count in female 
Sprague-Dawley rats (Viluksela et al. 1998a); these doses also caused mortality.  
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Splenic hyperplasia was observed in rats exposed by gavage to a mixture of 1,2,3,6,7,8-HxCDD and 
1,2,3,7,8,9-HxCDD at 7.1 µg/kg/day, but not at 1.4 µg/kg/day for 13 weeks (NCI/NTP 1980).  No 
hematological effects were observed in Osborne-Mendel rats or B6C3F1 mice chronically exposed to 5×105 and 
1.3×106 µg/kg/day of 2,7-DCDD, respectively, in feed (NCI/NTP 1979a) or exposed to 0.34 and  0.7 µg/kg/day 
of a mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD, respectively, 2 days a week for 104 weeks by 
gavage (NCI/NTP 1980). 
The above results demonstrated hematological effects in animals following CDD exposure; however, the 
observed changes in the red and white blood cell counts were nonspecific and were probably due to the broad 
systemic toxicity of 2,3,7,8-TCDD rather than to a direct effect on the hematological system.  
Musculoskeletal Effects. The musculoskeletal system does not appear to be a major target of toxicity in 
animals exposed to CDDs.  Only one study reported hemorrhages in the musculoskeletal system of severely 
debilitated monkeys following dietary exposure to 0.011 µg/kg/day of 2,3,7,8-TCDD for an intermediate 
duration (Allen et al. 1977). 
No musculoskeletal effects were observed in Sprague-Dawley rats exposed to 0.1 µg/kg/day in the diet for 
2 years (Kociba et al. 1978a) or in Osborne-Mendel rats and B6C3F1 mice chronically exposed 2 days a week 
by gavage to 0.071and 0.3 µg/kg/day of 2,3,7,8-TCDD, respectively (NTP 1982b). 
Chronic experiments with other congeners showed no musculoskeletal effects in Osborne-Mendel rats and 
B6C3F1 mice exposed in the diet to 5×105 and 1.3×106 µg/kg/day of 2,7-DCDD, respectively (NCI/NTP 1979a) 
or by gavage to approximately 0.34 and 0.7 µg/kg/day of a mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9­
HxCDD, respectively (NCI/NTP 1980). 
Hepatic Effects. Effects on the liver are seen after acute oral exposure or after intermediate and chronic 
exposure to CDDs. Alterations in metabolism, biochemical changes, and increases in liver weights (without 
histologic changes) are sensitive markers of effects, but they are not clearly overt toxic effects; they may 
predict a toxic or histopathologic effect that will occur at higher doses or after longer exposure.  Likewise 
induction of mixed-function oxidases (MFO) and cytochrome P-450s are generally considered adaptive 
effects; they may be associated with increased liver weight, but are not necessarily associated with 
histopathologic changes. However, alterations in cytochrome P-450 (e.g., CYP1A1) may lead to altered 
metabolism and/or toxicity of other xenobiotics and endogenous compounds.  Increases in liver enzymes 
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such as AST and ALT in serum are an indication of cell death or necrosis.  Effects on the liver that occur at 
near-lethal doses or when animals are debilitated and approaching moribundity are secondary effects and are 
not specific to the action of CDDs on the liver. The liver should not be implicated as a target organ in these 
cases. The types of histological changes caused by CDDs and their severity vary widely between species and 
strains of laboratory animals and the doses administered.  
Histological changes in the liver were observed after acute-, intermediate-, and chronic-duration exposures. 
Enlarged hepatocytes with finely vacuolated cytoplasm in the centrilobular region were observed 20 days 
after administration of a single oral lethal dose of 75 µg/kg 2,3,7,8-TCDD to adult Sprague-Dawley rats 
(Christian et al. 1986a); cellular degeneration in the centrilobular region was observed in Fischer 344 rats 
20 days after a single oral dose of 1000 µg/kg (Kelling et al. 1985).  Three daily doses of 40 µg/kg caused 
centriacinar necrosis and enlarged hepatocytes in Sprague-Dawley rats (Hermansky et al. 1988).  In all the 
above citations, the changes were secondary to the wasting syndrome and occurred after severe weight loss. 
Focal areas of mild hydropic degeneration of the liver associated with increased liver weight was seen in 
B6C3F1 mice receiving 1 µg/kg/day 2,3,7,8-TCDD for 14 days (non-lethal) (Holsapple et al. 1986a). 
Swelling of hepatocytes, disruption of cell membranes, and dilation of sinusoids in the central vein area of the 
liver accompanied by cellular necrosis were observed after a single lethal dose of 360 µg/kg in C57B46 mice 
(Kelling et al. 1985); central necrosis in the livers of hairless A2G hr/+ mice dosed once at 75 µg/kg was 
reported (Greig 1984; Greig et al. 1987). Guinea pigs only showed minimal focal necrosis at 42 days after a 
single oral dose of 0.1 µg/kg 2,3,7,8-TCDD (Turner and Collins 1983). Hypertrophy, steatosis, cytoplasmic 
degeneration, and hyaline-like cytoplasmic inclusion bodies were observed at non-lethal and lethal doses (0.5 
to 20 µg/kg); no between group qualitative differences in this histological alteration were found (Turner and 
Collins 1983). No degenerative changes were observed by Kelling et al. (1985) prior to death in guinea pigs 
given a single oral lethal dose of 2 µg/kg. In minks, a sensitive species, pale and mottled livers were observed 
at gross necropsy 28 days after a single lethal oral dose of 5 µg/kg (Hochstein et al. 1988). 
Mild-to-moderate hepatic effects were also seen after intermediate-duration exposure to 2,3,7,8-TCDD. 
Unspecified histopathological hepatic lesions were reported following intermittent exposure to 
2,3,7,8-TCDD in female Osborne-Mendel rats at 0.07 µg/kg/day and in female B6C3F1 mice at 
0.7 µg/kg/day for 13 weeks (NTP 1982b).  Cytomegaly with focal necrosis was observed in C57BL/6J mice 
exposed to 10 µg/kg/day by gavage 1 day/week for 4 weeks (Thigpen et al. 1975). Increase relative liver 
weight and hepatocellular inclusions were found in guinea pigs exposed to 0.005 µg/kg/day in the feed 
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for 90 days (DeCaprio et al. 1986); this dose level also significantly reduced serum ALT activity in females 
and increased triglycerides in males.  Biliary epithelial hyperplasia has been reported in monkeys following 
exposure to lethal levels (0.011 µg/kg/day) in feed for 9 months (Allen et al. 1977) and after intermittent 
exposure at 0.1 µg/kg/day by oral gavage for 3 weeks (McNulty 1984). 
Liver necrosis occurred in Sprague-Dawley rats that died during the first 4 weeks of dietary exposure to 
2,3,7,8-TCDD at 3.4 µg/kg/day in a chronic-exposure experiment, while no non-cancerous liver effects 
were found in rats chronically exposed to 0.286 µg/kg/day (Van Miller et al. 1977).  Toxic hepatitis 
characterized by lipidosis and hydropic degeneration of hepatocytes with proliferation of bile ductules and 
by mild fibrosis was observed in 14/50 male and 32/49 female Osborne-Mendel rats following exposure by 
gavage to approximately 0.071 µg/kg/day of 2,3,7,8-TCDD administered for 104 weeks and in 44/50 male 
B6C3F1 mice receiving 0.071µg/kg/day or 34/47 female mice receiving 0.3 µg/kg/day (NTP 1982b).  In 
addition, cytoplasmic vacuolation, hyperplasia, hepatocellular degeneration, and liver necrosis occurred in 
Sprague-Dawley rats chronically exposed to diets providing doses of 0.001 (females) and 0.01 (both 
sexes) µg/kg/day 2,3,7,8-TCDD, respectively (Kociba et al. 1978a). 
Biochemical changes indicating liver effects following acute oral exposure to 2,3,7,8-TCDD included 
hypoglycemia and increased serum triglycerides and cholesterol 10 days after a single sublethal oral dose of 
45 µg/kg in Fischer 344 rats (Walden and Schiller 1985); earlier, Albro (1978) found increased triglycerides 
and decreased sterol esters after a non-lethal dose of 2,3,7,8-TCDD and increased cholesterol and free fatty 
acids after a lethal dose. Reduced retinol storage in the liver was found in Sprague-Dawley rats exposed to 
a single dose of 1 µg/kg 2,3,7,8-TCDD (Thunberg 1984).  Reduction of hepatic retinol by 2,3,7,8-TCDD 
was greater (87%) in younger rats with lower initial weights (Thunberg et al. 1984) than in more mature rats 
(60%) (Thunberg et al. 1979, 1980).  Significant and maximum induction of hepatic ethoxyresorufin-O­
deethylase (EROD, marker for CYP1A1 activity) activity and dose-related decrease in liver 
phosphoenolpyruvate carboxykinase (PEPCK, a key enzyme of gluconeogenesis) was observed in female 
Long Evans rats 4 days after a single gavage dose of 5.3–60 µg 2,3,7,8-TCDD/kg (Fan and Rozman 1995). 
Hepatic activity of tryptophan 2,3-dioxygenase (TdO, a key enzyme of tryptophan metabolism) was 
elevated by 2,3,7,8-TCDD-treatment (significantly at 5.3, 12, and 18 µg/kg but not 60 µg/kg), whereas 
serum tryptophan levels were not altered.  EROD activity had diminished considerably 90 days after 
dosing, although it was still 10 times the control values, and PEPCK and TdO activities had returned to 
control values. The authors concluded that gluconeogenesis is inhibited by 2,3,7,8-TCDD in Long Evans 
rats by reducing liver PEPCK activity (Fan and Rozman 1995). 
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Hepatic porphyria has been found after acute oral dosage of mice with 2,3,7,8-TCDD.  A single oral dose of 
150 µg/kg or 4 weekly doses of 25 µg/kg caused an accumulation of porphyrins and induction of delta 
aminolevulinic acid synthetase in B6C3F1 mice (Goldstein et al. 1973).  These were lethal doses and caused 
severe histologic liver damage.  Single oral doses as high as 30 µg/kg did not produce porphyria acutely or 
within 16 weeks (Goldstein 1982). Elevation of serum levels of ALT and sorbitol dehydrogenase, which 
are indicative of subclinical toxic effects on the liver, have been found in mice after a single oral non-lethal 
dose (Greig 1984; Rosenthal et al. 1989; Smith et al. 1981).  Smith et al. (1981) compared the sensitivity of 
C57BL/10 mice and DBA/2 mice, and found that the DBA/2 mouse was 20 times less sensitive than the 
C57 strain to 2,3,7,8-TCDD-induced porphyria.  Recent results from Weber et al. (1995) suggested that 
acute toxicity of 2,3,7,8-TCDD occurs between 37.5 and 235 µg/kg in male C57BL/6J mice and between 
375 and 3,295 µg/kg in male DBA/2J mice, as judged by decreases in liver PEPCK and glucose-
6-phosphatase (G-6-Pase, also a key enzyme of gluconeogenesis) activities, reduction in blood glucose, and 
changes in relative liver weight 8 days after a single gavage dose of 2,3,7,8-TCDD.  The ED50 for induction 
of hepatic EROD activity in male C57BL/6J mice was estimated at 1.1 µg/kg compared with 16 µg/kg in 
DBA/2J mice.  Also there was no evidence of a reduction of liver TdO activity or of elevation of serum 
tryptophan levels over the dose range tested (0.03–235 µg/kg in C57BL/6J mice and 1–3,295 µg/kg in 
DBA/2J mice).  Dose-dependent induction of EROD has also been observed in the liver from female 
B6C3F1 mice after single (Diliberto et al. 1995) and repeated (DeVito et al. 1994) oral 2,3,7,8-TCDD doses. 
In the repeated-dosing study (DeVito et al. 1994), both EROD and acetanilide-4-hydroxylase (marker for 
CYP1A2) activities were induced with doses as low as 1.5 ng 2,3,7,8-TCDD/kg/day.  Pegram et al. (1995) 
found no differences in the dose-response curves for hepatic EROD induction between young and old male 
C57BL/6N mice 8 days after a single dose of 0.015–15 µg 2,3,7,8-TCDD/kg.  However, induction of 
acetanilide-4-hydroxylase was significantly greater in old than in young mice.  Also a trend of greater 
relative liver weight with increasing dioxin dose was observed in young mice, whereas liver weight was not 
altered in old mice (Pegram et al. 1995). 
Increased liver weights were reported in pregnant mice that received 25 µg/kg/day (Courtney 1976), 
3 µg/kg/day (Smith et al. 1976), or 0.5 µg/kg/day (Silkworth et al. 1989b) for 10 days during gestation, and 
in monkeys receiving a single oral dose of 70 µg/kg (McConnell et al. 1978a).  The ED50 values for liver 
enlargement following a single oral dose of 2,3,7,8-TCDD were calculated as 100 µg/kg 2,3,7,8-TCDD in 
Sprague-Dawley rats, 1,000 µg/kg in C57BL/6 mice, and 14 µg/kg in Syrian hamsters (Hanberg et al. 
1989). These ED50 values approach and exceed the LD50 values for rats and mice (see Section 2.2.2.1).  
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In a 1-week dietary study in female Sprague-Dawley rats, a dose of 1 µg 2,3,7,8-TCDD/kg/day induced a 
significant increase in absolute liver weight and a lower dose of 0.32 µg/kg/day significantly increased 
relative liver weight (Van Birgelen et al. 1995). Other hepatic effects observed in this study included 
significantly dose-related increased hepatic microsomal activities of EROD and acetanilide-4-hydroxylase, 
beginning at the lowest dose tested (0.014 µg/kg/day), and dose-related decrease in hepatic retinol at 
$0.014 µg/kg/day.  In agreement with the results of Van Birgelen et al. (1995), Viluksela et al. (1994) also 
reported increases in absolute and relative liver weights in male Sprague-Dawley rats administered 
2,3,7,8-TCDD by gavage for 13 weeks at doses that supplied approximately 0.8 µg 2,3,7,8-TCDD/kg/day 
(the only dose level tested).  An increase in liver EROD activity and decrease in liver PEPCK activity were 
also reported in the study.  Liver TdO activity and total serum tryptophan were not significantly altered in 
surviving rats, but TdO activity was significantly decreased in moribund animals with signs of wasting 
syndrome, whereas serum tryptophan levels were doubled in these animals.  Li and Rozman (1995) 
examined the reversibility of 2,3,7,8-TCDD-induced changes in some liver enzymes in male Sprague-
Dawley rats treated by gavage with doses equivalent to 0.003–1.6 µg/kg/day for 10 weeks and allowed to 
recover for an additional 6-week period. As reported by others, there was a dose-dependent decrease in 
TdO activity with a concurrent increase in serum tryptophan levels (both significant at the highest-dose 
level) and a decrease in PEPCK activity (significant at $1 µg/kg/day).  These dose responses were very 
similar to the dose response for body weight reduction.  EROD was induced even at the lowest dose and 
maximum induction was attained at $35 µg/kg/day.  After the 6-week recovery period, PEPCK and TdO 
activities, as well as serum tryptophan levels, returned to near-control levels; however, EROD still remained 
induced. The authors (Li and Rozman 1995) indicated that the results supported the hypothesis that 
subchronic toxicity of 2,3,7,8-TCDD is similar to its acute toxicity when the dose is corrected for 
pharmacokinetics.  In other words, toxicity is determined by the body burden represented by the cumulative 
dose minus the portion of the dose already eliminated. 
Hepatic effects have also been reported in animals following exposure to other CDDs.  Pale, friable livers 
were observed in 3/20 Sprague-Dawley rat dams exposed to 100 µg/kg/day of mixed HxCDD during 
gestation (incidence in control group was not reported), but not in those exposed to 10 µg/kg/day (Schwetz 
et al. 1973). No effects on the liver were observed at 10 µg/kg/day of 2,7-DCDD in B6C3F1 mice 
(Holsapple et al. 1986b), at 20 µg/kg/day of OCDD in pregnant CD-1 mice (Courtney 1976), or at 
1,000 µg/kg/day of 1,2,3,4-TCDD in pregnant CD-1 mice (Courtney 1976). 
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Data for hepatic effects after intermediate-duration exposure to the other congeners were available for 
1,2,3,7,8-PCDD, 1,2,3,4,7,8-HxCDD, a mixture of 1,2,3,7,8,9-HxCDDs and 1,2,3,6,7,8-HxCDD, 
1,2,3,4,6,7,8-HpCDD, and OCDD. Mild hepatotoxicity (not otherwise specified) was recorded in rats 
exposed to 0.71 µg/kg/day of a mixture of 1,2,3,7,8,9-HxCDD and 1,2,3,6,7,8-HxCDD, and in mice 
exposed to the same mixture by gavage for 13 weeks to 1.4 µg/kg/day (NCI/NTP 1980).  No effects were 
seen at 0.36 µg/kg/day and at 0.71 µg/kg/day in rats and mice, respectively.  Absolute liver weight was 
significantly increased in male Sprague-Dawley rats administered $24 µg 1,2,3,4,6,7,8-HpCDD/kg/day by 
gavage for 13 weeks (Viluksela et al. 1994). Relative liver weight was increased at $4 µg/kg/day.  Liver 
activity of PEPCK was significantly decreased with the 2 highest-dose levels tested, 73 and 110 µg/kg/day, 
whereas hepatic EROD activity was dose-dependently induced over the dose range tested, 0.3 to 
110 µg/kg/day.  Liver TdO activity and serum total tryptophan were not significantly altered at 
#24 µg/kg/day; however, TdO was decreased and serum tryptophan was increased in rats that died at the 
two highest dose levels. Similar results were reported in rats treated with 1,2,3,7,8-PCDD 
(2–4 µg/kg/day) or 1,2,3,4,6,7-HxCDD (10–15 µg/kg/day) (Viluksela et al. 1998b).  Cytoplasmic 
vacuolization of hepatocytes (Couture et al. 1988) and liver hypertrophy with induced hepatic enzymes 
(Birnbaum et al. 1989a) were reported in rats gavaged with 50 µg/kg/day OCDD 5 days a week for up to 
13 weeks. 
Toxic hepatitis was reported in Osborne-Mendel rats and in B6C3F1 mice following gavage exposure to 
0.18 µg/kg/day and to 0.34 µg/kg/day of a mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD, 
respectively, for 104 weeks (NCI/NTP 1980).  The corresponding NOAEL values are recorded in 
Table 2-3. Furthermore, fatty changes in the liver were found in rats chronically exposed to 2,7-DCDD at a 
dose of 2.5×105 µg/kg/day in the feed (NCI/NTP 1979a).  In contrast, no liver effects were observed in mice 
following chronic exposure to 1.3×106 µg/kg/day of 2,7-DCDD in the feed (NCI/NTP 1979a). 
In conclusion, the above studies demonstrated that the liver is a primary target of CDD toxicity. 
2,3,7,8-TCDD was the most toxic congener, but other congeners were also capable of inducing hepatic 
effects. The induced effects were dose-related and species- and strain-related.  It also appeared that for 
some hepatic end points, and after repeated dosing, toxicity is determined by the body burden represented 
by the cumulative dose minus the portion of the dose eliminated. 
Renal Effects. Mild-to-moderate renal effects have been reported in some mature animals exposed to 
lethal or near-lethal levels of 2,3,7,8-TCDD. Acute exposure to 2,3,7,8-TCDD caused dilation of 
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convoluted tubules and Bowman's spaces at 25 µg/kg in Sprague-Dawley rats (Christian et al. 1986) and 
epithelial hyperplasia in the renal pelvis at 70 µg/kg in rhesus monkeys (McConnell et al. 1978a).  Similar 
findings were reported in monkeys exposed to 0.011 µg/kg/day of 2,3,7,8-TCDD for 9 months (Allen et al. 
1977). Kidney weights were not affected in male C57BL/6J and DBA/2J mice treated with a single 
0.03–235 µg/kg or 1–3,295 µg/kg 2,3,7,8-TCDD dose, respectively (Weber et al. 1995).  Rats administered 
doses of $0.047 µg/kg/day for 13 weeks exhibited an increase in relative kidney weight; a dose of 
0.026 µg/kg/day was without effect (Van Birgelen et al. 1995).  Chronic exposure of B6C3F1 mice by 
gavage to approximately 0.071 µg/kg/day of 2,3,7,8-TCDD induced renal inflammatory changes; no effects 
were found at 0.0071 µg/kg/day (NTP 1982b).  In contrast, no renal effects were found in Osborne-Mendel 
rats exposed to 0.071 µg/kg/day of 2,3,7,8-TCDD for 104 weeks (NTP 1982b) or in Sprague-Dawley rats 
exposed to 0.1 µg/kg/day of 2,3,7,8-TCDD in the feed for 2 years (Kociba et al. 1978a).  
Studies with other congeners reported no renal effects following chronic exposure to 0.34 µg/kg/day and 
0.7 µg/kg/day of a mixture of 1,2,3,7,8,9-HxCDD and 1,2,3,6,7,8-HxCDD by gavage in rats and mice, 
respectively (NCI/NTP 1980) or 5×105 and 1.3×106 µg/kg/day of 2,7-DCDD in the feed in rats and mice, 
respectively (NCI/NTP 1979a). 
The above data suggest that the observed renal effects in mature animals may be secondary to the general 
response to 2,3,7,8-TCDD toxicity with the exception of the epithelial hyperplasia reported in monkeys. 
However, developmental studies clearly show that the ureteral epithelium is altered by in utero exposure to 
CDDs as manifested by hyperplasia of ureteral lining epithelial cells leading to hydronephrosis (see 
Section 2.2.2.6). 
Endocrine Effects. Blood corticosterone levels were decreased to 29 and 26% of control values in 
male Sprague-Dawley rats at 14 and 21 days after a single oral dose of 25 µg/kg 2,3,7,8-TCDD, 
respectively (Balk and Piper 1984).  Since 11-β-hydroxyprogesterone levels were elevated, the authors 
suggested that 2,3,7,8-TCDD produced a block at the 21-hydroxylase step in the synthesis of 
corticosterone. This was directly demonstrated in a follow-up study in which the authors observed a 35% 
decrease in 21-hydroxylase activity 7 days after a single oral dose of 50 µg/kg 2,3,7,8-TCDD (Mebus and 
Piper 1986). Corticosterone serum levels from samples taken late in the light phase decreased up to 40% in 
male Sprague-Dawley rats administered a single 50 µg 2,3,7,8-TCDD/kg dose (DiBartolomeis et al. 1987). 
The effect was attributed to 2,3,7,8-TCDD-induced inhibition of cholesterol side-chain cleavage.  In 
samples taken early in the light cycle, corticosterone levels increased 4-fold relative to controls; however, 
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this increase was shown to result from nutritional deprivation rather than from a direct effect of 
2,3,7,8-TCDD. The possibility that altered levels of corticosterone result from a 2,3,7,8-TCDD-induced 
effect on adrenocorticotropin (ACTH) was examined by Bestervelt et al. (1993).  ACTH serum levels were 
significantly increased in male Sprague-Dawley rats over a 14-day period following administration of a 
single dose of 50 µg 2,3,7,8-TCDD/kg; maximum increases were observed on days 3 and 14.  Plasma 
corticosterone levels were significantly increased on days 1 and 5, but were reduced below control levels 
on days 10 and 14.  Treatment with 2,3,7,8-TCDD did not affect the activity of the rate-limiting enzyme for 
adrenal steroidogenesis, mitochondrial cytochrome P-450 cholesterol side chain cleavage.  Basal 
corticosterone concentration in adrenal glands from 2,3,7,8-TCDD-treated rats was significantly lower than 
in controls on days 5, 7, and 14 after dosing; however, secretion of corticosterone induced by stimulation 
with exogenous ACTH was not altered by treatment with 2,3,7,8-TCDD.  Based on these results, the 
authors concluded that 2,3,7,8-TCDD may interfere with secretion or synthesis of appropriate, bioactive 
ACTH from the anterior pituitary gland, which could compromise adrenal steroidogenesis. 
The effects of 2,3,7,8-TCDD on thyroid function has been extensively studied.  For example, a single 
gavage dose of 25 µg 2,3,7,8-TCDD/kg significantly decreased serum levels of T4 and increased serum 
levels of triiodothyronine (T3) in male hooded rats 9 days after dosing (Bastomsky 1977).  The decrease in 
T4 appeared to be the result of an increased biliary excretion of T4-glucuronide, and this was attributed to 
induction of UDP-glucuronyltransferase (UDPGT) by 2,3,7,8-TCDD.  UDPGT catalyzes glucuronidation of 
T4 and clearance. The increase in T3 was consistent with increased thyroid secretion from thyrotropin 
(TSH) stimulation.  Administration of a single dose of 6.25–100 µg 2,3,7,8-TCDD/kg by gavage to adult 
male Sprague-Dawley rats produced a significant dose-related decrease in serum T4 levels (50% of control 
with the lowest dose) 7 days after dosing (Potter et al. 1986).  Serum levels of T3 were elevated in a dose-
related manner, whereas levels of TSH achieved a maximum increase with the lowest dose.  Potter et al. 
(1986) also observed a small 2,3,7,8-TCDD-related increase in thyroid weight, but no consistent pattern of 
histological alterations. Hermansky et al. (1988) reported a 65% decrease in serum T4 levels in female 
Sprague-Dawley rats 6 days after administration of 3 doses of 40 µg 2,3,7,8-TCDD/kg; however, in this 
study the authors observed a 9% increase in serum T3.  A dose-related decrease in serum total T4 was 
observed in female Long Evans rats 4 days after a single dose of 5.3–60 µg 2,3,7,8-TCDD/kg; statistical 
significance was achieved with a 12 µg/kg dose (Fan and Rozman 1995).  Total serum T3 was not 
significantly altered.  However, 90 days after single doses of 27–60 µg 2,3,7,8-TCDD/kg total serum T4 
and T3 were elevated, which led the authors to suggest that 2,3,7,8-TCDD triggers adaptive responses 
which persist after most of the chemical has cleared the organism (Fan and Rozman 1995).  In male mink, 
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relative thyroid gland weight was increased over a 4-week period after administration of a single dose of 
7.5 µg 2,3,7,8-TCDD/kg, but a dose of 5 µg/kg was without effect (Hochstein et al. 1988).  Hochstein et al. 
(1988) also reported a significant dose-related increase in relative adrenal gland weight over a 2.5–7.5 µg 
2,3,7,8-TCDD/kg dose range. However, when the weights were expressed as a percentage of brain weight, 
only the increase in the adrenal gland at 7.5 µg/kg was significant.  The concentrations of plasma cortisol 
and free and bound T3 and T4 were slightly reduced as a result of 2,3,7,8-TCDD treatment (2.5 µg/kg, 
only dose level tested), but the differences relative to controls were not significant.  
Acute effects of 2,3,7,8-TCDD on thyroid function have been also reported in mice.  In contrast with 
observations in rats, in which 2,3,7,8-TCDD appears to have independent effects on T4 and T3 levels, 
serum T4 and T3 levels were decreased in a dose-dependent fashion in male C57BL/6J mice 8 days after a 
single gavage dose of 0.03–235 µg 2,3,7,8-TCDD/kg (Weber et al. 1995).  A similar effect was observed in 
male DBA/2J mice treated with a single dose of 1–3,295 µg/kg.  In C57BL/6J mice, maximum depression 
of thyroid hormones (35% of controls) was achieved with a dose of 133 µg/kg.  In male DBA/2J mice, 
maximum reductions in T3 and T4 levels (40 and 20% of controls, respectively) were attained with the 
highest dose level (Weber et al. 1995). It should be noted that the Weber et al. (1995) study did not include 
statistical analysis of the results. 
A significant decrease in serum total T4 was observed in male Sprague-Dawley rats administered 
2,3,7,8-TCDD by gavage for 13 weeks at doses equivalent to 0.8 µg/kg/day, the only dose level tested 
(Viluksela et al. 1994). Serum total T3 was not significantly altered and neither was the relative or 
absolute weight of the pituitary.  Similar results on thyroid function were reported in female Sprague-
Dawley rats administered 2,3,7,8-TCDD by gavage for 30 weeks at doses equivalent to 
0.0001–0.125 µg/kg/day (Sewall et al. 1995).  The dose-related decrease in serum T4 was statistically 
significant beginning at the 0.035 µg/kg/day dose level.  Serum levels of T3 were not significantly altered 
by treatment.  Sewall et al. (1995) also reported that serum levels of TSH were increased about 3-fold in 
the highest-dose group. Treatment with 2,3,7,8-TCDD also induced UDP-glucuronosyltransferase-1. 
Administration of 2,3,7,8-TCDD in the diet also affected thyroid function as demonstrated by Van 
Birgelen et al. (1995) who found a significant dose-related decrease in plasma total T4 in female Sprague-
Dawley rats at dietary doses of $0.047 µg/kg/day for 13 weeks; plasma total T3 was not altered with 
2,3,7,8-TCDD doses of up to 1 µg/kg/day.  Li and Rozman (1995) examined the reversibility of the 
2,3,7,8-TCDD-induced decrease in serum T4 in male Sprague-Dawley rats.  The rats were gavaged once a 
week for 10 weeks with doses equivalent to approximately 0.003–1.6 µg 2,3,7,8-TCDD/kg and this was 
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followed by a 6-week recovery period.  Serum T4 levels were significantly depressed with 2,3,7,8-TCDD 
doses of $0.03 µg/kg in a dose-dependent fashion and remained low during the recovery period.  Based 
on these results, the authors suggested that the ED50 for this dose-response is close to a total cumulative 
dose of 1 µg/kg.  
No significant non-neoplastic lesions were observed in the thyroid, parathyroid, adrenal, and pituitary 
gland from male and female Sprague-Dawley rats maintained for 2 years on a diet that supplied 0.001, 
0.01, or 0.1 µg 2,3,7,8-TCDD/kg/day (Kociba et al. 1978a).  Similar results were obtained in male and 
female Osborne-Mendel rats and in male B6C3F1 mice administered up to approximately 0.071 µg 
2,3,7,8-TCDD/kg/day by gavage for 104 weeks, and in female B6C3F1 mice given up to 0.3 µg 
2,3,7,8-TCDD/kg/day (NTP 1982b). 
Information regarding other CDD congeners is limited.  Administration of 1,2,3,4,6,7,8-HpCDD by 
gavage for 13 weeks to male Sprague-Dawley rats in doses equivalent to 24–110 µg/kg/day produced a 
dose-related decrease in serum total T4 (Viluksela et al. 1994).  Doses of #4 µg/kg/day were without 
significant effect. Serum levels of total T3 were not significantly affected by treatment.  A more recent 
study reported a 69% decrease in serum T4 levels in male Sprague-Dawley rats administered doses 
equivalent to 3.8 µg 1,2,3,7,8-PeCDD/kg/day or 15.4 µg 1,2,3,4,7,8-HxCDD/kg/day for 13 weeks 
(Viluksela et al. 1998b). After an additional 13-week CDD-free period, T4 levels returned to near control 
levels. In females administered doses of 2.6 µg/kg/day of the penta-CDD or 10.3 µg/kg/day of the hexa-
CDD, T4 serum levels were 40% below control levels at the end of the dosing period and 62% below 
controls at the end of the additional 13-week period.  Serum T3 levels were not significantly affected by 
treatment with either congener (Viluksela et al. 1998b). 
In summary, CDDs were shown to alter endocrine parameters mostly in rodent studies.  One of the better 
characterized effects was a decrease in serum T4, caused apparently by CDD-induced T4 metabolism and 
excretion. Alterations in T3 levels were less consistent.  Results from additional studies suggested that 
2,3,7,8-TCDD may interfere with secretion and synthesis of ACTH in the pituitary. 
Dermal Effects. A number of changes in the skin have been observed in rodents and monkeys.  In 
monkeys, skin lesions seen after a single oral dose or repeated dosing resemble the chloracne observed in 
humans.  Distinctive changes in rhesus monkeys included swelling and inflamed eyelids, nail loss, and 
facial hair loss with acneform lesions following acute exposure to a single dose of 70 µg/kg (McConnell et 
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al. 1978a). Monkeys had hair loss due to squamous metaplasia and keratinization of the sebaceous glands 
and hair follicles, and periorbital edema following intermediate-duration exposure to 0.011 µg/kg/day of 
2,3,7,8-TCDD in the diet or exposure to 0.1 µg/day, 3 days a week for 3 weeks, but not in those exposed to 
0.02 µg/kg/day (Allen et al. 1977; McNulty 1984).  Rough hair coats were described in Syrian hamsters 
exposed to a single dose of 1,000 µg/kg 2,3,7,8-TCDD, but not in those exposed to 600 µg/kg (Henck et 
al. 1981). Skin thickening was observed in A2G-hr/+ mice exposed to 75 µg/kg 2,3,7,8-TCDD (Greig 
1984). Chronic exposure by gavage to 2,3,7,8-TCDD induced dermatitis in B6C3F1 mice at 
0.36 µg/kg/day (Della Porta et al. 1987) and amyloidosis in Swiss mice at 0.001 µg/kg/day (Toth et al. 
1979). In the B6C3F1 mice, dermatitis regressed after discontinuation of treatment (Della Porta et al. 
1987). In contrast, no dermal effects were observed in Osborne-Mendel rats and in B6C3F1 mice 
following chronic exposure to 0.71 µg/kg/day and 0.3 µg/kg/day of 2,3,7,8-TCDD, respectively, by 
gavage for 104 weeks (NTP 1982b). 
No dermal effects were found in Osborne-Mendel rats and B6C3F1 mice gavaged with approximately 
0.34 µg/kg/day and 0.7 µg/kg/day of a mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD, 
respectively, for 104 weeks (NCI/NTP 1980).  However, male and female Sprague-Dawley rats treated 
with doses equivalent to 2.6–3.8 µg 1,2,3,7,8-PeCDD/kg/day or 10.3–15.4 µg 1,2,3,4,7,8-HxCDD/kg/day 
for 13 weeks exhibited occasional hair loss and sores in the ears, nose, neck, tail, and feet (Viluksela et al. 
1998a). No effects were observed following chronic exposure of Osborne-Mendel rats and B6C3F1 mice 
to 5×105 µg/kg/day and 1.3×106 µg/kg/day of 2,7-DCDD, respectively, in the feed (NCI/NTP 1979a). 
Ocular Effects. No ocular effects were observed in Osborne-Mendel rats and in B6C3F1 mice 
following chronic exposure to 0.071 µg/kg/day and 0.3 µg/kg/day of 2,3,7,8-TCDD, respectively, by 
gavage for 104 weeks (NTP 1982b). Also no ocular effects were found in Osborne-Mendel rats and 
B6C3F1 mice gavaged with approximately 0.34 µg/kg/day and 0.7 µg/kg/day of a mixture of 1,2,3,6,7,8­
HxCDD and 1,2,3,7,8,9-HxCDD, respectively, for 104 weeks (NCI/NTP 1980).  Similarly, no effects were 
observed following chronic exposure of Osborne-Mendel rats and B6C3F1 mice to 5×105 µg/kg/day and 
1.3×106 µg/kg/day of 2,7-DCDD, respectively, in the feed (NCI/NTP 1979a). 
Body Weight Effects. A characteristic effect of exposure to 2,3,7,8-TCDD in animals is the wasting 
syndrome.  This is observed following exposure in all duration categories.  
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Weight loss or decreased weight gain were recorded in Sprague-Dawley rats following a single dose of 
6.25 µg/kg (Moore et al. 1985), 10.6 µg/kg (Roth et al. 1988), 15 µg/kg (Seefeld and Peterson 1984), and 
25 µg/kg 2,3,7,8-TCDD (Christian et al. 1986a), and in Fischer 344 rats following a single oral dose of 
100 µg/kg (Kelling et al. 1985). Furthermore, about 40% weight loss was recorded in the range of LD50 
values (164–340 µg/kg) for Fischer 344 rats from different breeding stations (Walden and Schiller 1985). 
None of the studies provided a NOAEL value.  Acute exposure (10–14 days) to lower doses of 
2,3,7,8-TCDD caused reduced weight gain in rats at 0.5 µg/kg/day, but not at 0.125 µg/kg/day (Giavini et 
al. 1983; Sparschu et al. 1971b). 
Decreased body weight gain was observed in guinea pigs after a single dose of 6 µg/kg 2,3,7,8-TCDD in 
oil vehicle but not after 12 µg/kg in soil (Umbreit et al. 1985).  A decreased weight gain was recorded in 
pregnant rabbits exposed during gestation to 0.25 µg/kg/day (Giavini et al. 1982) and in hamsters exposed 
to 1,000 µg/kg (Henck et al. 1981).  ED50 values (doses causing a 50% decrease in a measurable parameter 
relative to the control value) for reduced body weight gain were calculated for 2,3,7,8-TCDD as 1.8 µg/kg 
for Hartley guinea pigs, 89 µg/kg for Sprague-Dawley rats, 890 µg/kg for C57BL/6 mice, and 1,000 µg/kg 
for Syrian hamsters (Hanberg et al. 1989).  Single doses of $75 µg 2,3,7,8-TCDD/kg produced a slight 
reduction in body weight in male C57BL/6J mice 8 days after dosing (Weber et al. 1995); feed intake was 
not affected during this period. In the same study, it was found that body weights of male DBA/2J mice 
dosed with 1–3,295 µg 2,3,7,8-TCDD/kg were significantly reduced at $1,500 µg 2,3,7,8-TCDD/kg.  It 
should be noted, however, that in mice, decreases in body weight resulting from 2,3,7,8-TCDD exposure 
do not become evident until 5–7 days after dosing (Shen et al. 1991), and that in C57BL/6J mice reduction 
of feed intake is insignificant during the first week after dosing (Kelling et al. 1985).  Weight loss (28%) 
was also found in monkeys after a single dose of 70 µg/kg 2,3,7,8-TCDD (McConnell et al. 1978a). 
Decreases in body weight gain or body weight loss have been consistently reported in animals following 
intermediate-duration exposures to 2,3,7,8-TCDD.  A decreased weight gain was observed in Osborne-
Mendel rats exposed intermittently for 13 weeks by gavage to 0.07 µg/kg/day (NTP 1982b) or in Sprague-
Dawley rats treated with $0.2 µg/kg/day for 10–13 weeks (Li and Rozman 1995; Viluksela et al. 1994), in 
guinea pigs exposed to 0.005 µg/kg/day in the feed (DeCaprio et al. 1986), and in mice intermittently 
exposed to 20 µg/kg/day by gavage (Thigpen et al. 1975).  A weight loss was recorded in rhesus monkeys 
after 0.1 µg/kg/day of 2,3,7,8-TCDD for 3 weeks of intermittent exposure (McNulty 1984).  However, 
weight loss occurred with longer exposure of 9 months at 0.011 µg/kg/day (Allen et al. 1977).  A recent 
study reported a 10% decrease in body weight gain in female Sprague-Dawley rats fed a diet that supplied 
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a daily dose of 0.047 µg 2,3,7,8-TCDD/kg for 13 weeks (Van Birgelen et al. 1995).  At the highest 
exposure level (1 µg/kg/day) terminal body weights were reduced to 72% of controls; this group consumed 
32% less food than controls. 
In chronic-duration experiments with 2,3,7,8-TCDD, decreased body weight gain was reported in Sprague-
Dawley rats exposed to 0.1 µg/kg/day (Kociba et al. 1978a) and 0.286 µg/kg/day (Van Miller et al. 1977) 
in the feed; Osborne Mendel rats exposed to approximately 0.0014 µg/kg/day by gavage for 104 weeks 
(NTP 1982b); and in B6C3F1 mice exposed to 0.36 µg/kg/day by gavage for 52 weeks (Della Porta et al. 
1987), but not in C57BL/6 mice gavaged once per week for 14–15 months with 0.03 µg 2,3,7,8-TCDD 
(Oughton et al. 1995). 
Experiments with other congeners showed milder effects.  Acute exposure during gestation caused a 
decreased maternal weight gain in Sprague-Dawley rats exposed to 10 µg/kg/day mixed HxCDD (Schwetz 
et al. 1973). Decreased weight gains were observed in rats and mice gavaged for intermediate-duration 
with 0.71 µg/kg/day and 0.18 µg/kg/day of a mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD, 
respectively (NCI/NTP 1980).  Chronic-duration exposure induced decreased weight gain in Osborne 
Mendel rats exposed to 0.18 µg/kg/day of a mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD by 
gavage for 104 weeks (NCI/NTP 1980). In contrast, no effects on body weight were observed in mice 
exposed to 0.7 µg/kg/day of a mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD for 104 weeks 
(NCI/NTP 1980). Male Sprague-Dawley rats administered 1,2,3,4,6,7,8-HpCDD by gavage at dose levels 
equivalent to 73 and 110 µg/kg/day for 13 weeks exhibited a 5.1% and 19.3% reduction in body weight 
gain, respectively, at the end of the study period (Viluksela et al. 1994).  No significant effect was 
observed with doses #24 µg/kg/day.  Relative to controls, the body weight of male Sprague-Dawley rats 
administered doses equivalent to 3.8 µg 1,2,3,7,8-PeCDD/kg/day or 15.4 µg 1,2,3,4,7,8-HxCDD/kg/day 
for 13 weeks was reduced by 27% and 24%, respectively, at the end of the dosing period (Viluksela et al. 
1998a). In females, doses equivalent to 2.6 µg 1,2,3,7,8-PeCDD/kg/day for 13 weeks resulted in an 18% 
reduction in body weight relative to controls, whereas doses of approximately 10.3 µg 1,2,3,4,7,8­
HxCDD/kg/day for 13 weeks were without significant effect (Viluksela et al. 1998a). 
No effect on the body weight of CD-1 mice was observed after 14 daily doses of OCDD at 1 µg/kg/day or 
2,7-DCDD at 1,000 µg/kg/day (Courtney 1976).  Chronic-duration exposure induced decreased weight 
gain in Osborne Mendel rats and in B6C3F1 mice exposed to 2.5×105 µg/kg/day and 6.5×105 µg/kg/day of 
2,7-DCDD, respectively, in the feed (NCI/NTP 1979a).  
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As summarized above, body weight effects were consistently observed in all species exposed to CDDs. 
Effects occurred after intermittent exposure by gavage and after exposure in a diet.  In acute- and 
intermediate-duration exposure experiments, the wasting syndrome seemed to be the primary cause of 
death. 
2.2.2.3 Immunological Effects 
An effect of sublethal exposures (acute, intermediate-term, or chronic) to 2,3,7,8-TCDD common to all 
species studied is thymic atrophy.  Depletion of lymphocytes results in suppression of T-cell immunity. 
The T-cell responses studied have included delayed hypersensitivity responses, rejection of skin allografts, 
and in vitro mutagen responses of lymphoid cells.  T-cell immunotoxicity is probably the most sensitive 
end point. Effects on T-cells can occur at levels of exposure three orders of magnitude lower than the 
effects on thymus cellularity.  B-lymphocytes are also affected by 2,3,7,8-TCDD, but higher exposure 
levels are necessary for suppression of humoral immunity.  CDDs suppress resistance to different 
infectious agents by various mechanisms (see Section 2.4 for more detailed information). 
Acute ED50 values for thymic atrophy following a single dose of 2,3,7,8-TCDD were calculated as 
26 µg/kg in Sprague-Dawley rats, 0.8 µg/kg in Hartley guinea pigs, 280 µg/kg in C57BL/6 mice, and 
48 µg/kg in Syrian hamsters (Hanberg et al. 1989).  A significant dose-related reduction in absolute 
thymus weight was reported in young male Wistar rats administered single doses of $1 µg/kg 
2,3,7,8-TCDD; this effect was paralleled by a significant decrease in thymic cellularity (De Heer et al. 
1994b). Thymic atrophy was shown to be initiated in the thymus cortex on day 4 after a single dose of 
25 µg/kg 2,3,7,8-TCDD (De Heer et al. 1994a). The initial lymphodepletion in the cortex was followed by 
a secondary depletion of medullary thymocytes on day 6, and on day 10, a preferential depletion of cortical 
thymocytes was no longer observed.  Decreased thymus weight was reported in pregnant C57BL/6J mice 
exposed to 0.5 µg/kg/day 2,3,7,8-TCDD for 10 days (Silkworth et al. 1989b).  Offspring of C57BL/6J 
mice similarly exposed to 1.5 µg/kg/day had severe thymic atrophy, cellular depletion and altered 
thymocyte antigen expression, and immune function (Holladay et al. 1991).  In contrast, similar changes 
were observed in DBA/2J mice only after exposure to higher doses of 8 µg/kg/day.  Furthermore, thymic 
atrophy was observed in rhesus monkeys after a single dose of 70 µg/kg (McConnell et al. 1978a) and in 
guinea pigs after a dose of 6 µg/kg (Umbreit et al. 1985). 
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Treatment of rats with daily doses of 0.72 µg 2,3,7,8-TCDD/kg/day by gavage for 14 days did not alter 
spontaneous NK-cell activity in the lung, but significantly suppressed influenza virus-augmented NK 
activity (Yang et al. 1994).  A significantly higher virus titer was observed on days 2, 3, and 4 in whole 
lung homogenate from rats treated with a single dose of 10 µg/kg (Yang et al. 1994).  Decreased resistance 
to infection, as evidenced by increased mortality, was observed in B6C3F1 mice infected with 
Streptococcus pneumoniae and administered 1 µg/kg/day 2,3,7,8-TCDD for 14 days (White et al. 1986), 
and in B6C3F1 mice infected with influenza A virus and administered a single gavage dose of 0.01, 0.05, 
or 0.1 µg/kg 2,3,7,8-TCDD (Burleson et al. 1996). The Burleson et al. (1996) study identified a NOAEL 
of 0.005 µg/kg for this effect.  Acute exposure to 2,3,7,8-TCDD reduced polymorphonuclear activity in 
B6C3F1 mice at 5 µg/kg (no effect was seen in DBA/2N mice) (Ackermann et al. 1989).  Suppressed 
antibody response to sheep erythrocytes (SRBC) was reported in B6C3F1 mice that were given a single 
gavage dose of 1 µg/kg; no such effect was found after a single dose of 0.5 µg/kg (Holsapple et al. 1986a). 
However, suppression of the antibody response occurred after 14 daily doses of 0.1 µg/kg/day.  In rats, a 
single dose of 20 µg 2,3,7,8-TCDD/kg administered 5 days before immunization significantly enhanced 
the primary antibody response to SRBC as judged by a significant increase in serum IgG levels 7 days 
after immunization (Fan et al. 1996).  However, serum IgM levels were not significantly affected by doses 
of 2,3,7,8-TCDD of up to 40 µg/kg.  Fan et al. (1996) also observed that cell-mediated immunity, tested 
with a delayed-type hypersensitivity (DTH) assay, exhibited a U-shaped response to treatment with 
2,3,7,8-TCDD, as doses of 1–20 µg/kg increased the DTH response, whereas doses of 30–90 µg/kg 
decreased it, even below control levels. 
Suppressed total serum complement activity was observed in female B6C3F1 mice exposed to a single 
gavage dose of 14 µg/kg or 14 daily doses of 0.01 µg/kg/day (White et al. 1986).  Serum levels of 
complement component C3 were also suppressed at doses of $0.5 µg/kg 2,3,7,8-TCDD (White et al. 1986). 
Subsequent studies by the same group showed that the 2,3,7,8-TCDD-induced reduction in serum C3 is not 
the result of a decrease in C3 production by hepatocytes but, at least in part, may be due to increased 
catabolism (Lin and White 1993).  Single gavage doses of $2.5 µg 2,3,7,8-TCDD/kg suppressed cytotoxic 
T-lymphocyte (CTL) activity in mice challenged with a tumor allograft by a mechanism that did not involve 
elevation in plasma glucocorticoid levels (De Krey and Kerkvliet 1995).  This was directly correlated with 
reduced numbers of splenic CTL effector cells (Kerkvliet et al. 1996).  In these same animals, a suppression 
of the alloantibody response was correlated with a decreased expansion of the B-cell splenocyte population. 
This dose of 2,3,7,8-TCDD also initially induced interferon-γ, interleukin-2, and tumor necrosis factor 
production, but the normal increase of these in response to the tumor allograft was 
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not observed. Based on these and additional studies, the authors concluded that these effects are due to 
TCDD initially interfering with the activation of CD4+ T cells and possibly T helper-B cell interactions.  A 
recent study from the same group of investigators presented evidence that immune 2,3,7,8-TCDD-induced 
suppression in C57BL/6 mice is not caused by direct alterations in the production of immunomodulatory 
metabolites of arachidonic acid (Lawrence and Kerkvliet 1997).  The above results indicate that 
immunological effects occur after moderate-to-low single doses or after repeated low doses that accumulate 
in the body, suggesting that the total dose of 2,3,7,8-TCDD is important.  As shown in Figure 2-1, 
immunotoxicity was a very sensitive end point; the lowest LOAEL for immune effects is 0.01 µg/kg/day 
(Burleson et al. 1996; White et al. 1986). In the Burleson et al. (1996) study, decreased resistance to 
infection was observed in mice receiving a single gavage dose of 0.01 µg/kg, and no effects were observed 
at 0.005 µg/kg.  Reduced serum complement levels were observed in mice exposed to 0.01 µg/kg/day for 
14 days (White et al. 1986); no NOAEL was identified in this study.  The NOAEL of 0.005 µg/kg/day 
identified in the Burleson et al. (1996) study was used to derive an acute oral MRL for 2,3,7,8-TCDD of 
2×10-4 µg/kg/day as described in the footnote to Table 2-2, Section 2-5, and in Appendix A. 
Several immunological effects were observed following intermediate-duration exposure to 2,3,7,8-TCDD. 
Decreased thymus weight after 2,3,7,8-TCDD exposure was observed in rats dosed by gavage with 
0.71 µg/kg/day for 6 weeks (Vos et al. 1973), in the F3 generation of rats receiving 0.01 µg/kg/day 
(Murray et al. 1979), and in guinea pigs receiving 0.005 µg/kg/day or 0.03 µg/kg/day (thymic atrophy) in 
the feed for 90 days (DeCaprio et al. 1986).  A significant reduction in absolute and relative thymus weight 
was observed in male Sprague-Dawley rats administered 2,3,7,8-TCDD by gavage at doses equivalent to 
0.8 µg/kg/day (only dose level tested) for 13 weeks (Viluksela et al. 1994).  Spleen weight was not 
significantly altered.  Similar results were reported in female Sprague-Dawley rats fed for 13 weeks a diet 
that supplied doses of $0.014 µg 2,3,7,8-TCDD/kg/day (Van Birgelen et al. 1995).  Relative spleen weight 
was increased at $0.047 µg 2,3,7,8-TCDD/kg/day.  Decreased cell-mediated immunity was found in mice 
and guinea pigs exposed by gavage to 0.71 µg/kg/day for 4 weeks and 0.03 µg/kg/day for 8 weeks, 
respectively (Vos et al. 1973).  Guinea pigs seem to be especially sensitive to 2,3,7,8-TCDD toxicity; an 
intermediate-duration exposure to 0.001 µg/kg/day reduced the lymphocyte counts, and exposure to 
0.03 µg/kg/day caused decreased humoral immunity and thymic atrophy (Vos et al. 1973).  A recent study 
examined the effect of low-level dietary exposure to 2,3,7,8-TCDD to young adult male Leeds strain rats 
(Badesha et al. 1995). A 30-day exposure to approximately 0.1 µg/kg/day (or a total dose of 
approximately 3 µg/kg) resulted in an exposure duration-dependent reduction of in vitro lipopoly­
saccharide-induced production of interleukin-1 in cultures of their splenic macrophages.  A 180-day
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exposure to approximately 0.017 µg/kg/day suppressed the production of interleukin-2 by either concan­
avalin A or phorbol ester/calcium ionophore stimulation, and reduced the lectin-induced proliferation of 
splenic T cells. The authors concluded that exposure to a low dietary dose of 2,3,7,8-TCDD suppresses 
the functions of several T-cell subsets. The highest NOAEL value for immunological effects (decreased 
thymus weight) was 0.0007 µg/kg/day 2,3,7,8-TCDD given to the most sensitive species, guinea pigs, in 
the diet (DeCaprio et al. 1986). The NOAEL value of 0.0007 µg/kg/day was used to derive an 
intermediate-duration oral MRL for 2,3,7,8-TCDD of 2×10-5 µg/kg/day as described in the footnote to 
Table 2-2, Section 2.5, and in Appendix A. 
Increased mortality that was indicative of altered immunity was also observed in C57BL/6Jfh mice 
challenged with Salmonella bern following exposure to $1 µg/kg/day of 2,3,7,8-TCDD by gavage once a 
week for 4 weeks (Thigpen et al. 1975); no significant effects were observed at 0.5 µg/kg/day.  In the same 
study, using the same experimental design, doses of up to 20 µg/kg/day of 2,3,7,8-TCDD had no 
significant effect on mortality in mice infected with Herpesvirus suis (Thigpen et al. 1975). Exposure to 
0.5 µg/kg/day 2,3,7,8-TCDD once a week for 5–8 weeks caused suppression of humoral activity in 
C57BL/6 mice (Vecchi et al. 1983a).  In addition, lymph node atrophy was reported in monkeys exposed 
to a lethal dose of 0.011 µg/kg/day in the feed for 9 months (Allen et al. 1971).  
Administration of 2,3,7,8-TCDD at approximately 0.071 µg/kg/day to Osborne-Mendel rats or at about 
0.3 µg/kg/day to B6C3F1 mice by gavage for 104 weeks produced no histological alterations in the spleen 
or thymus (NTP 1982b).  Chronic exposure to 2,3,7,8-TCDD in food induced thymic atrophy in Sprague-
Dawley rats at 0.1 µg/kg/day in a 2-year study (Kociba et al. 1978a) with the highest NOAEL of 
0.01 µg/kg/day.  Furthermore, rhesus monkeys exposed chronically to 0.002 µg/kg/day 2,3,7,8-TCDD in 
the feed exhibited degeneration of the bone marrow and lymphoid tissues (Hong et al. 1989).  A recent 
study examined the effect of long-term exposure to 2,3,7,8-TCDD on various immune cell phenotypes of 
female C57 BL/6 mice (Oughton et al. 1995).  The mice were administered 0.2 µg 2,3,7,8-TCDD/kg once 
per week for 14–15 months; this resulted in a cumulative dose of 12–13 µg/kg (approximately 
0.03 µg/kg/day) and a concentration of 2,3,7,8-TCDD in adipose tissue of 1.27 ng/g abdominal fat.  There 
were no significant 2,3,7,8-TCDD-related effects on thymus and spleen weight or in the cellularity of these 
tissues. Exposure to 2,3,7,8-TCDD induced subtle changes in thymic phenotypes which, according to the 
authors, were of questionable biological relevance given the age-related decrease in thymic cellularity 
observed. 2,3,7,8-TCDD did not alter the frequencies of the major leukocyte subpopulations, but 
significantly altered functionally discrete subpopulations within the T-cell compartment.  The most notable 
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change was a decrease in the frequency of memory T helper cells, with a concomitant increase in the 
proportion of naive T helper cells. Oughton et al. (1995) also presented preliminary data suggesting that 
phenotypic changes in spleen cells correlated with similar changes in blood cells. 
Other CDD congeners also appear to affect the immune system.  Significant dose-related decreases in 
absolute and relative thymus weight were observed in male Sprague-Dawley rats administered doses 
equivalent to 4–110 µg/kg/day 1,2,3,4,6,7,8-HpCDD for 13 weeks by gavage (Viluksela et al. 1994).  A 
dose level of 0.3 µg/kg/day was without significant effect.  Treatment with 1,2,3,4,6,7,8-HpCDD had no 
significant effect on spleen weight. Suppressed antibody response was reported in B6C3F1 mice after 
2 weeks of exposure to 0.1 µg/kg/day of 2,7-DCDD, but not after exposure to 10 µg/kg/day of OCDD 
(Holsapple et al. 1986b). Depressed antibody response was found in C57BL/6 mice exposed to a single 
dose of 33 µg/kg/day 1,2,3,4,6,7,8-HpCDD (Kerkvliet and Brauner 1987).  Suppressed serum complement 
activity was found in B6C3F1 mice following 2 weeks of exposure to 1 µg/kg/day 1,2,3,6,7,8-HxCDD 
(White et al. 1986). Splenic hyperplasia was observed in Osborne-Mendel rats after exposure to a mixture 
of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD at 7.1 µg/kg/day, 1 day/week for 13 weeks (NCI/NTP 
1980). 
In conclusion, the immunological system was a sensitive target of CDD toxicity under experimental 
conditions in animals.  Effects on all types of mediated immunity were seen at doses of 2,3,7,8-TCDD as 
low as 0.01 µg/kg. Doses of 2,3,7,8-TCDD that were well below the lethal dose affect humoral immunity. 
Thymic atrophy occurs as single or multiple doses approach those that may increase lethality.  Neonates 
and young animals are much more sensitive than adults to most of the immunological responses. 
The highest NOAEL values and all reliable LOAEL values for immunological effects in each species and 
duration category for each congener are recorded in Table 2-2 and 2-3 and plotted in Figures 2-1 and 2-2. 
2.2.2.4 Neurological Effects 
Limited information was obtained regarding neurological effects in animals.  Decreased motor activity was 
observed in Sprague-Dawley rats after a single dose of 5 µg/kg of 2,3,7,8-TCDD that was not associated 
with mortality (Seefeld et al. 1984a) and after 14 daily doses of 2 µg/kg/day to pregnant females that were 
sacrificed on day 21 of gestation for developmental effects evaluation (Giavini et al. 1983).  The NOAEL 




2. HEALTH EFFECTS 
Mendel rats and male B6C3F1 mice at doses of up to 0.071 µg/kg/day for 104 weeks did not result in 
significant histological alterations in the brain, spinal cord, or sciatic nerve (NTP 1982b). The same was 
found for female B6C3F1 dosed with up to 0.3 µg/kg/day for the same time period (NTP 1982b). 
Although motor effects have been described in rats dosed with 2,3,7,8-TCDD, in most studies, the 
neurological system was not specifically examined; therefore the issue of whether CDDs have a direct 
effect on the nervous system of animals has not been conclusively resolved. 
The highest NOAEL values and all reliable LOAEL values for neurological effects in each species and 
duration category are recorded in Tables 2-2 and 2-3 and plotted in Figures 2-1 and 2-2. 
2.2.2.5 Reproductive Effects 
A number of reproductive effects have been observed in animals orally exposed to 2,3,7,8-TCDD, 
including reduced fertility, pre- and post-implantation losses, decreases in gonad weights, decreased 
androgen levels, and altered estrus cycle and ovulation.  Increased pre- and postimplantation losses were 
observed in CRCD rats exposed to 0.5 µg/kg/day for 2 weeks before mating (Giavini et al. 1983). 
Increased resorptions were found in Sprague-Dawley rats exposed to 0.125 µg/kg/day (Sparschu et al. 
1971a), in CF-1 mice exposed to 1.0 µg/kg/day (Smith et al. 1976), and in NMRI mice exposed to 
9 µg/kg/day (Neubert and Dillmann 1972) on gestation days (Gd) 6–15.  In rabbits, increased 
postimplantation losses were recorded in a group exposed to 0.25 µg/kg/day, but not in those exposed to 
0.1 µg/kg/day on Gd 6–15 (Giavini et al. 1982).  Furthermore, increased abortions (10 of 12) were 
observed in monkeys after a single gavage dose of 1 µg/kg (McNulty 1984). 
Reproductive toxicity has also been observed in non-pregnant female rats.  Significant decreases in ovarian 
weight, ovulation rate, and the number of ova released have been observed in female Sprague-Dawley rats 
receiving a single gavage dose of $10 µg/kg (Li et al. 1995a, 1995b).  Effects on hormone levels were also 
observed in the rats. Within 24 hours after dosing, significant increases in LH and follicle stimulating 
hormone levels were observed; prolactin levels were not altered (Li et al. 1995a).  Following the 
administration of 17β-estradiol, LH and follicle stimulating hormone levels dropped below control levels. 
2,3,7,8-TCDD is also a reproductive toxicant in males.  Decreased seminal vesicle weight was reported in 
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6 postexposure (Moore et al. 1985). Inflammation of the epididymis with sperm granuloma formation was 
reported in Wistar rats exposed to 4 µg/kg/day for 7 days, and decreases in the weight of male reproductive 
organs together with reduced levels of serum testosterone and dihydrotestosterone (compared with the 
pair-fed controls) were seen in Sprague-Dawley rats after a single gavage dose of 12.5 µg/kg 
2,3,7,8-TCDD (Khera and Ruddick 1973). An ED50 for altered regulation of LH levels was calculated as 
10 µg/kg 2,3,7,8-TCDD in Sprague-Dawley male rats (Bookstaff et al. 1990a).  No dominant lethality was 
reported when male Wistar rats were given 12 µg/kg/day 2,3,7,8-TCDD for 7 days before mating (Khera 
and Ruddick 1973). 
In intermediate-duration studies with 2,3,7,8-TCDD, increased mortality was found in the offspring of 
Swiss Webster mice that were kept on a diet providing 0.35 µg/kg/day 2,3,7,8-TCDD for 4 weeks before 
mating, during gestation, and for 3 weeks of lactation (Thomas and Hinsdill 1979).  Blocked estrous cycle 
was observed in female C57BL/6 mice exposed by gavage to 3 µg/kg/day, 3 days a week for 25 weeks 
(Umbreit et al. 1987), but no reproductive effects were seen in male mice exposed 1 day/week for 
30 weeks to the same dose (Umbreit et al. 1988).  However, reduced spermatogenesis was found in 
Sprague-Dawley rats exposed for 4 weeks to 3.4 µg/kg/day in the feed, but not in those similarly exposed 
to 0.286 µg/kg/day (Van Miller et al. 1977).  Exposure of female rhesus monkeys to 0.1 µg/kg/day 3 days 
a week by gavage for 3 weeks caused abortions in 3 of the 4 monkeys; 1 of the 4 monkeys administered 
0.02 µg/kg/day aborted (McNulty 1984).  In a 3-generation study with 2,3,7,8-TCDD, significantly 
reduced fertility was observed among F1- and F2-generation rats exposed before mating to 0.01 µg/kg/day 
in the feed for 90 days, but not in those exposed to 0.001 µg/kg/day (Murray et al. 1979). 
In chronic-duration studies, increased abortions and reduced reproduction rates were reported in monkeys 
exposed to 0.00064 µg/kg/day of 2,3,7,8-TCDD in the feed (Bowman et al. 1989b; Hong et al. 1989; 
Schantz et al. 1992). No reproductive effects were found at 0.00012 µg/kg/day.  No changes were 
observed in the reproductive organs of Sprague-Dawley rats chronically exposed to 0.1 µg/kg/day in the 
feed (Kociba et al. 1978a), or Osborne-Mendel rats and B6C3F1 mice exposed by gavage to approximately 
0.0.71µg/kg/day and 0.3 µg/kg/day of 2,3,7,8-TCDD, respectively (NTP 1982b). 
Rier et al. (1993) found a dose-related increase in the incidence and severity of endometriosis in monkeys 
chronically exposed to 0.00012 or 0.00064 µg/kg/day of 2,3,7,8-TCDD in the diet.  Surgical-induced 
endometriosis was enhanced by 2,3,7,8-TCDD exposure in rats and mice.  In a surgically induced 
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growth were observed in rats (Cummings et al. 1996) and mice (Cummings et al. 1996; Johnson et al. 
1997), respectively.  In this model, the animals received a gavage dose of 2,3,7,8-TCDD every 3 weeks 
(first dose was administered 3 weeks prior to surgical induction of endometriosis) for a total of five doses. 
Mice appear to be more sensitive than rats in terms of the magnitude of the effect on endometrial site 
diameter and adverse effect levels (endometriosis promotion was observed at 1, 3, and 10 µg/kg in mice 
[Cummings et al. 1996; Johnson et al. 1997] and at 10 µg/kg [Cummings et al. 1996]; no effects were 
observed in rats at 3 µg/kg). In contrast to these results, Foster et al. (1997) found that 2,3,7,8-TCDD 
exposure suppressed endometrial growth in mice.  In their model, the mice were not pre-exposed to 
2,3,7,8-TCDD prior to the induction of endometriosis.  Foster et al. (1997) notes that pre-exposure to 
2,3,7,8-TCDD results in endometriosis development due to immune suppression rather than an estrogen-
responsive disease. 
Acute-duration studies examining reproductive effects have been conducted with other congeners. 
Increased resorptions were found in Sprague-Dawley rats exposed to 10 µg/kg/day mixed HxCDD during 
gestation but not in those exposed to 1 µg/kg/day (Schwetz et al. 1973).  No reproductive effects were 
found in rats exposed to 1×105 µg/kg/day 2,7-DCDD or 5×105 µg/kg/day OCDD during gestation. 
Similarly, no reproductive effects were found in rats exposed to 800 µg/kg/day 1,2,3,4-TCDD or 
2,000 µg/kg/day 2-MCDD, 2,3-DCDD, or 2,7-DCDD on Gd 6–15 (Khera and Ruddick 1973). 
The above data demonstrate that exposure to CDDs caused reproductive effects in animals.  2,3,7,8-TCDD 
was the most potent congener.  The effects included increased pre- and postimplantation losses in females, 
morphological and functional changes in male and female reproductive organs, and hormonal imbalance in 
both sexes. 
The highest NOAEL values and all reliable representative LOAEL values for reproductive effects in each 
species and duration category for each congener are recorded in Tables 2-2 and 2-3 and plotted in 
Figures 2-1 and 2-2. 
2.2.2.6 Developmental Effects 
A number of developmental effects have been observed in animals acutely exposed to 2,3,7,8-TCDD by 
the oral route. The types of effects observed in the offspring of animals exposed to 2,3,7,8-TCDD include 
structural malformations-cleft palate and kidney anomalies, functional alterations-damage to the immune 
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system and impaired development of the reproductive system, decreased growth, and fetal/newborn 
mortality. 
Cleft palate and other skeletal anomalies have been observed in the offspring of CRCD rats exposed to 
2 µg/kg/day for 2 weeks prior to conception (Giavini et al. 1983), in Long Evans rats exposed to 5 µg/kg 
on Gd 8 (Huuskonen et al. 1994), in rabbits exposed to 0.1 µg/kg/day during Gd 6–15 (Giavini et al. 
1982), in C57BL/6N mice exposed to 12 µg/kg once on Gd 10 (Weber et al. 1985), in C57BL/6 mice 
exposed to 6 µg/kg once on Gd 10 or 12 (Abbott and Birnbaum 1989a), in C57BL/6J mice exposed once 
to 15 µg/kg on Gd 9 (Dasenbrock et al. 1992), in CD-1 mice exposed to 25 µg/kg/day during Gd 7–16 
(Courtney 1976), in CF-1 mice exposed to 1 µg/kg/day on Gd 6–15 (Smith et al. 1976), in DBA2J mice 
exposed to 150 µg/kg on Gd 9 (Dasenbrock et al. 1992), and in NMRI mice exposed to 3 µg/kg/day during 
Gd 6–15 (Neubert and Dillmann 1972).  The incidence of cleft palate was not significantly altered in 
Han/Wistar rats exposed to 1 or 10 µg/kg on Gd 8 (Huuskonen et al. 1994), in Long Evans rats exposed to 
1 µg/kg on Gd 8 (Huuskonen et al. 1994), or in C57BL/6N mice exposed to 3 µg/kg/day on Gd 10–13 
(Abbott et al. 1992). 
Kidney anomalies, mainly hydronephrosis, were found in the offspring of CRCD rats exposed to 
2 µg/kg/day for 2 weeks prior to conception (Giavini et al. 1983), in Han/Wistar rats exposed to 10 µg/kg 
on Gd 8 (Huuskonen et al. 1994), in C57BL/6N mice exposed to 12 µg/kg on Gd 10 (Abbott et al. 1987a, 
1987b), in C57BL/6N mice exposed to 1 µg/kg on Gd 10 (Moore et al. 1973), in CD-1 mice exposed 
during Gd 7–16 to 25 µg/kg/day (Courtney 1976), in C57BL/6J and DBA/2J mice exposed to 
0.5 µg/kg/day 2,3,7,8-TCDD on Gd 6–15 (Silkworth et al. 1989b), in C57BL/6N mice exposed postnatally 
through contaminated mothers' milk (Couture-Haws et al. 1991b), and in Golden Syrian hamsters exposed 
to 1.5 µg/g on Gd 7 or 9 (Olson and McGarrigle 1992).  An increase in the severity of nephrosis was 
observed in 4–5-month-old Syrian hamsters receiving a single dose of 2 µg/kg in utero on Gd 11(Gray et 
al. 1995). No significant increases in the incidence of hydronephrosis or dilatation of renal pelvis were 
observed in Long Evans rats exposed to 1 or 5 µg/kg on Gd 8 (Huuskonen et al. 1994) or Han/Wistar rats 
exposed to 1 µg/kg on Gd 8 (Huuskonen et al. 1994).  
The immune system effects include thymic atrophy and immunosuppression.  Thymic atrophy was found 
in pups of Sprague-Dawley rats exposed to a single dose of 10 µg/kg 2,3,7,8-TCDD on lactation day 1 
(Håkansson et al. 1987) and in Long Evans and Han/Wistar rats exposed to 5 or 10 µg/kg, respectively, on 
Gd 8 (Huuskonen et al. 1994). At lower doses, the thymic atrophy may be transitory; thymic atrophy was 
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observed on Gd 19 in the offspring of F344 rats exposed to 3.0 µg/kg on Gd 14 but not on Gd 22 (Gehrs et 
al. 1997a). Similarly, transient thymus atrophy was observed in offspring of BALB/cGa mice exposed to 
10 µg/kg on Gd 14 (Fine et al. 1989). A dose-related decrease in relative thymus weights was seen in 
offspring of rats dosed at levels of 0.005–0.35 µg/kg 2,3,7,8-TCDD on Gd 16 (Madsen and Larsen 1989). 
Severe thymic atrophy and cellular depletion occurred in offspring of C57BL/6N mice exposed to 1.5 or 
3 µg/kg/day on Gd 6–14 (Blaylock et al. 1992; Holladay et al. 1991).  Thymus size was not affected in the 
offspring of Long Evans or Han/Wistar rats exposed to 1 µg/kg on Gd 8 (Huuskonen et al. 1994). 
Reversible suppression of cell-mediated immunity was reported in pups of Fischer 344 rats exposed to 
2,3,7,8-TCDD through the dosing of dams on lactation day 0, 7, and 14 with 5 µg/kg/day (Faith and 
Moore 1977). Increased neutrophils were found in pups of B6C3F1 mice exposed to 1 µg/kg/day 
2,3,7,8-TCDD on Gd 14 and lactation days 1, 7, and 14 (Luster et al. 1980).  Furthermore, increased 
lymphocytes and decreased erythrocytes and hematocrit were recorded in groups exposed to 5 µg/kg/day. 
Alterations in thymocyte phenotypes have also been observed following in utero and/or lactational 
exposure. A decrease in the percentage of CD3-/CD4-CD8-, CD3+/CD4-CD8-, and CD3+/CD4+CD8+ 
thymocytes and an increase in CD3+/CD4-CD8+ thymocytes were observed in the offspring of F344 rats 
exposed to 1.0 or 3.0 µg/kg on Gd 14 (Gehrs et al. 1997a). A decrease in CD4-/CD8- thymocytes was 
observed following in utero, lactation only, or in utero and lactational exposure to 1.0 µg/kg (administered 
on Gd 14) (Gehrs et al. 1997b). In utero and lactational exposure also resulted in an increase in the 
percentage of CD4-/CD8+ lymphocytes; this was not observed in the in utero only or lactation only groups. 
Gehrs et al. (1997b) also found a suppression of the delayed hypersensitivity response to BSA in 5-month­
old male offsprings receiving in utero and lactational exposure. 
A number of studies have found impaired development of the reproductive system in male and female 
animals exposed to 2,3,7,8-TCDD during gestation.  2,3,7,8-TCDD affects androgen levels, secondary sex 
organs, spermatogenesis, fertility, and sexual behaviors.  Effects have been observed in male and female 
offspring, although most of the studies have focused on males.  Malformations of external genitalia 
(clefting, hypospadias, and vaginal thread), delayed vaginal opening (only significant in rats exposed on 
Gd 15; Gray and Ostby 1995), decreased number of ovarian follicles (only tested in Gd 15-exposed rats), 
and decreased fertility have been observed in female offspring of Holtzman and Long Evans rats exposed 
to a single dose of 1 µg/kg on Gd 8 or 15 (Gray and Ostby 1995; Flaws et al. 1997; Heimler et al. 1998). 
Gd 8 exposure also resulted in accelerated onset of constant estrus, shortened reproductive lifespan, and 
increased incidences of cystic hyperplasia of the endometrium.  Malformations of the external genitalia 
were also observed in the offspring of Long Evans rats exposed to 0.20 or 0.80 µg/kg on Gd 15 but not at 
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0.05 µg/kg (Gray et al. 1997a).  The fertility rate was not adversely affected in the offspring, but there was 
an increase in time to pregnancy in the 0.80 µg/kg group.  In a cross-fostering experiment (Gray et al. 
1997a), similar morphological reproductive alterations were observed following in utero exposure to 
1.0 µg/kg (Gd 15) but not after lactation-only exposure.  Chaffin et al. (1996) found significant decreases 
in serum estrogen levels in the female offspring of Holtzman rats receiving a single dose of 1 µg/kg on Gd 
15. This study also found an increase in estrogen receptor mRNA in the hypothalamus, uterus, and ovary 
and a decrease in the pituitary; an increase and a decrease in estrogen receptor binding DNA were found in 
the uterus and hypothalamus, respectively.  2,3,7,8-TCDD exposure did not alter gonadotropin secretion; 
no alterations in serum FSH, LH, or androstenedione levels were observed on postnatal day 21 (Chaffin et 
al. 1997). 
In male Holtzman rats exposed to 1 µg/kg on Gd 15, significant decreases in plasma testosterone were 
observed on Gd 18–21 (Mably et al. 1992a).  Additionally, the normal surge in testosterone levels that 
occurs 2 hours after birth was delayed until 4 hours after birth and the amplitude of the surge was lower in 
2,3,7,8-TCDD-exposed male offspring.  Bjerke and Peterson (1994) observed significant decreases in 
plasma testosterone levels in Holtzman rats at age 63 days following exposure to 1 µg/kg on Gd 15.  But 
studies by Mably et al. (1992a) and Gray et al. (1995) did not find significant alterations in plasma 
testosterone levels in pre- and post-pubescent rats; although Mably et al. (1992a) did report a tendency 
toward dose-related decreases in plasma testosterone and 5α-dihydrotestosterone levels in Holtzman rats at 
age 32, 49, 63, and 120 days following perinatal exposure to 0.064–1 µg/kg on Gd 15.  Roman et al. 
(1995) found similar decreases at age 32 and 49 days, but at day 63 the testosterone levels were similar to 
controls. Most studies found large inter-animal variations in plasma testosterone levels; this coupled with 
small sample sizes may have been a contributing factor in the conflicting results that were found. 
Luteinizing hormone levels (primary hormone stimulating testosterone production) were decreased in the 
32-day-old male offspring of dams receiving a dose of 1 µg/kg on Gd 15; no significant alterations in LH 
levels were observed in 49-, 63-, or 120-day-old rats (Mably et al. 1992a).  Additional effects on 
androgenic status (androgen concentrations and androgen-dependent structures and functions) have been 
observed. Significant decreases in anogenital distance (corrected for differences in body size by dividing 
by crown-rump length) were observed in male Holtzman rats exposed to $0.16 µg/kg on Gd 15 (Mably et 
al. 1992a); however, Bjerke and Peterson (1994), Bjerke et al. (1994a), and Gray et al. (1995) did not find 
significant alterations in anogenital distance (also corrected for body size) in Holtzman and Long Evans 
rats exposed to 0.7 or 1 µg/kg on Gd 15. More consistent results were found for other measures of 
androgenic status. Significant alterations included a delay in testis descent (Bjerke et al. 1994a), delay in 
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preputial separation (external indicator of delayed puberty) (Bjerke et al. 1994a; Gray et al. 1995, 1997b), 
decreased ventral prostate weight (Bjerke and Peterson 1994; Mably et al. 1992a), and decreased seminal 
vesicle weight (Bjerke and Peterson 1994; Bjerke et al. 1994a; Mably et al. 1992a).  The results of the 
Mably et al. (1992a) study suggest that the decrease in ventral prostate weight may be the most sensitive 
indicator of 2,3,7,8-TCDD-induced toxicity on androgen status.  Decreases were observed in the rats 
exposed to $0.064 µg/kg on Gd 15; the other effects were observed in rats exposed to $0.16 µg/kg. 
Decreases in absolute testis weight and cauda epididymis weight were observed in juvenile (Mably et al. 
1992c), pubertal (Mably et al. 1992c), postpubertal (Bjerke and Peterson 1994; Mably et al. 1992c), and 
sexually mature (Gray et al. 1995; Mably et al. 1992c) rats prenatally exposed to 2,3,7,8-TCDD on Gd 15. 
The lowest LOAEL for these effects was 0.064 µg/day (decreased testes weight), identified in the Mably et 
al. (1992c) study.  Recent studies from the same group of investigators have focused on evaluating the 
potential role of the Ah receptor (see section 2.4.2 for a detailed discussion on the Ah receptor-mediated 
mechanism of action of CDDs) on the developmental alterations of the male reproductive tract (Roman 
and Peterson 1998; Roman et al. 1998a, 1998b).  These studies are summarized in Section 2.5. 
Significant decreases in daily sperm production (Bjerke and Peterson 1994; Mably et al. 1992c; Sommer et 
al. 1996), the amount of mature sperm stored in the cauda epididymis (Bjerke and Peterson 1994; Gray et 
al. 1995; Mably et al. 1992c), and the amount of sperm ejaculated (Gray et al. 1995, 1997b) were observed 
in gestationally exposed rats.  These adverse effects on spermatogenesis occurred at doses of $0.05 µg/kg 
(Gray et al. 1997b).  Sommer et al. (1996) suggest that observed decreases in cauda epididymal sperm 
number is likely due to a decrease in daily sperm production and an increase in sperm phagocytosis in the 
excurrent duct system.  Sommer et al. (1996) and Wilker et al. (1996) did not find alterations in sperm 
epididymal transit time.  Significant decreases in follicle stimulating hormone levels (necessary for the 
initiation of spermatogenesis) have been observed in 32-day-old male rats receiving a perinatal dose of 
0.064, 0.40, or 1 µg/kg on Gd 15, but not in 49-, 63-, or 120-day-old rats (Mably et al. 1992c).  In 70- and 
120-day-old males exposed to #1 µg/kg and mated with unexposed females, no significant alterations in 
reproductive outcomes (fertility index, gestational index, survival index) were observed (Mably et al. 
1992c); however, a non-significant decrease in fertility index was observed in the 0.4 and 1 µg/kg males. 
Gray et al. (1995) found a significantly decreased number of implants when males exposed to 1 µg/kg on 
Gd 15 were mated with unexposed females.  Altered fertility was not observed in the male offspring of rats 
exposed to 2,3,7,8-TCDD on Gd 8 (Gray et al. 1995).  Several studies have found a demasculinization of 
sexual behavior (prolonged intromission latency, increased number of intromissions prior to ejaculation) 
(Bjerke et al. 1994b; Mably et al. 1992b) and partial feminization of sexual behavior (increased intensity of 
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lordosis and lordosis quotient) in male offspring of rats dosed with 2,3,7,8-TCDD on Gd 15 (Bjerke and 
Peterson 1994; Bjerke et al. 1994b; Mably et al. 1992b).  Mably et al. (1992b) identified 0.16 µg/kg on 
Gd 15 as the lowest LOAEL for demasculinized and feminized behaviors with a NOAEL of 0.064 µg/kg. 
A demasculinization and feminization of male rats has also been observed in 2,3,7,8-TCDD-exposed males. 
In perinatally exposed castrated rats, no significant alteration in plasma LH levels were observed following 
injection of estradiol benzoate. However, the response to progesterone administration in the rats receiving 
0.40 or 1 µg/kg on Gd 15 was similar to that seen in unexposed ovariectomized females, and the plasma LH 
levels were significantly higher than in control males (Mably et al. 1992b).  Impaired development of the 
reproductive system has also been observed in male Syrian hamsters exposed to 2 µg/kg on Gd 11 (Gray et 
al. 1995). Decreased epididymal sperm reserves, decreased testis and cauda epididymides weight, and 
delayed puberty were observed.  
Alterations in mammary gland differentiation (less differentiation) were observed in 50-day-old offspring 
from rats treated by gavage with 1 µg 2,3,7,8-TCDD/kg on gestation day 15 (Brown et al. 1998). 
Specifically, treatment with 2,3,7,8-TCDD resulted in significantly more terminal end buds and fewer 
lobules II. However, no such effect was seen in 21-day-old rats.  Prenatal treatment with 2,3,7,8-TCDD 
also resulted in an increased number of mammary adenocarcinomas in the offspring in response to 
dimethylbenz[a]anthracene (DMBA) relative to rats treated with DMBA alone.  The authors speculated that 
the decreased differentiation may have rendered the gland more susceptible to mammary cancer. 
Intestinal hemorrhage (Khera and Ruddick 1973; Sparschu et al. 1971a), subcutaneous edema, and 
hemorrhages in brain (Khera and Ruddick 1973) were observed in the offspring of Wistar rats treated with 
0.125 or 0.25 µg/kg/day 2,3,7,8-TCDD during Gd 6–15, and gastrointestinal hemorrhage was observed in 
Han/Wistar rats exposed to 10 µg/kg on Gd 8 or 12 (Huuskonen et al. 1994).  Decreases in mammary gland 
size due to inhibition of cell proliferation and gland development were observed in female Sprague-Dawley 
rats dosed with 2.5 µg/kg/day at ages 25, 27, 29, and 31 days (Brown and Lamartiniere 1995).  Exposure to 
0.10 µg/kg/day 2,3,7,8-TCDD during gestational days 10–16 resulted in significant decreases in T4 levels 
in female Sprague-Dawley rat pups.  Thyroxine levels were not significantly altered in male rats or in 
females exposed to 0.025 µg/kg/day, and no alterations were observed in triiodothyronine or TSH values in 
males and females exposed to either dose (Seo et al. 1995).  A decrease in core body temperature was 
observed in the offspring of Long Evans rats exposed to 1 µg/kg on Gd 15; no effect on metabolic rate or 
evaporative heat loss was observed (Gordon et al. 1995). 
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Decreases in fetal and newborn body weight were observed in Holtzman rats exposed to 0.7 or 1 µg/kg on 
Gd 15 (Bjerke and Peterson 1994; Bjerke et al. 1994a). No body weight effects were observed in 
C57BL/6N mouse fetuses exposed to maternal doses of 3 µg/kg on Gd 10–13 (Abbott et al. 1992).  Crown-
rump length was also decreased in Holtzman rats exposed to 1 µg/kg on Gd 15 (Bjerke and Peterson 1994). 
Several studies have reported increased mortality in the offspring of rats and monkeys exposed to 
2,3,7,8-TCDD during gestation. Fetal/newborn deaths have occurred at doses which were either non-toxic 
or minimally toxic to the mothers.  Increased newborn mortality was observed in  Holtzman rat pups 
exposed to 0.7 or 1 µg/kg on Gd 15 (Bjerke and Peterson 1994; Bjerke et al. 1994a); and decreased 
numbers of live fetuses, caused by increased resorption and fetal deaths, were observed in monkeys after a 
single exposure to 1 µg/kg on Gd 25, 30, 35, or 40 (McNulty 1984) and in Long Evans or Han/Wistar rats 
exposed to 5 or 10 µg/kg, respectively, on Gd 8 (Huuskonen et al. 1994).  After exposure of mouse dams to 
12.5 µg/kg/day 2,3,7,8-TCDD on Gd 14–17, 75% lethality was observed in the pups (Nau et al. 1986). 
In intermediate-duration exposure experiments, decreased neonatal survival was found in the F1 and F2 
generations of Sprague-Dawley rats exposed via the feed to 0.01 µg/kg/day, but not to 0.001 µg/kg/day, of 
2,3,7,8-TCDD in a 3-generation study (Murray et al. 1979).  Thymic atrophy was found in offspring of 
Swiss Webster mice that were kept on a diet providing 0.35 µg/kg/day 2,3,7,8-TCDD for 4 weeks before 
mating, during gestation, and for 3 weeks of lactation (Thomas and Hinsdill 1979).  No developmental 
effects were found in the offspring of C57BL/6 male mice treated with 3 µg/kg/day of 2,3,7,8-TCDD by 
gavage (in oil or soil vehicle) for 30 weeks (Umbreit et al. 1988).  No fetal abnormalities were found in the 
3 fetuses of rhesus monkeys administered 0.02 µg/kg/day 2,3,7,8-TCDD 3 days a week for 3 weeks 
(McNulty 1984).  At the higher dosages (0.1 and 0.6 µg/kg/day) only 1 fetus (from the 0.1 µg/kg/day 
group) was not aborted. 
Developmental effects of 2,3,7,8-TCDD after chronic exposure were studied in rhesus monkeys.  Decreased 
offspring survival was found when mothers were exposed continuously during pregnancy to 
6.4×10-4 µg/kg/day in the feed (Bowman et al. 1989b).  In addition, alterations in peer-group behavior 
(Bowman et al. 1989b; Schantz et al. 1992) and cognitive deficits were observed in the offspring of rhesus 
monkeys exposed to 1.2×10-4 µg/kg/day in the diet for 7 months prior to mating and during mating and 
lactation (16 months total duration).  Significant alterations were observed in play behavior, displacement, 
and self directed behavior. Exposed monkeys tended to initiate more rough-tumble play bouts and retreated 
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less from play bouts than controls, were less often displaced from preferred positions in the playroom than 
the controls, and engaged in more self-directed behavior than controls.  Cognitive function was altered as 
evidenced by impaired-reversal-learning performance in the absence of impaired delayed-spatial-alterations 
performance (Bowman et al. 1989b; Schantz and Bowman 1989); no NOAEL was identified for these 
effects. Schantz et al. (1986) also found increased and prolonged maternal care of these infants.  The 
LOAEL of 1.2×10-4 µg/kg/day identified for neurobehavioral effects identified in the Schantz et al. (1992) 
study was used to derive a chronic oral MRL of 1×10-6 µg/kg/day, as described in the footnote to Table 2-2, 
Section 2.5, and in Appendix A. 
Other CDD congeners have also been found to induce developmental toxicity.  Rat pups exposed in utero to 
2,000 µg/kg/day 2,7-DCDD had edematous separation of the cardiac myofibrils (Khera and Ruddick 1973). 
Schwetz et al. (1973) found no developmental effects in fetuses of rats exposed to 100,000 µg/kg/day 
2,7-DCDD during gestation, but histological examinations of soft tissues were not performed.  Decreased 
thymic weight was found in the offspring of rats exposed once on Gd 16 to 0.125 µg/kg 1,2,3,7,8-PCDD 
(Madsen and Larsen 1989). Subcutaneous edema was found in the offspring of Sprague-Dawley rats 
exposed to 1 µg/kg/day of mixed HxCDD during Gd 6–15 (Schwetz et al. 1973).  Furthermore, decreased 
fetal body weight, reduced crown-rump length, delayed ossification, and dilated renal pelvis were observed 
at 10 µg/kg/day, and an increased incidence of cleft palate was found at 100 µg/kg/day.  The NOAEL for 
the mixture of HxCDD isomers was 0.1 µg/kg/day.  Subcutaneous edema was also reported in fetuses of 
rats exposed to 5×105 µg/kg/day of OCDD during Gd 6–15; no effects were found in the 1×105 µg/kg/day 
OCDD-exposure group (Schwetz et al. 1973) or in mice exposed to 20 µg/kg/day of OCDD during Gd 7–16 
(Courtney 1976).  In contrast to most experiments with 2,3,7,8-TCDD, the 1,2,3,4-TCDD isomer did not 
induce developmental effects in the offspring of Wistar rats treated on Gd 6–15 with 800 µg/kg/day (Khera 
and Ruddick 1973) or CD-1 mice exposed to 1,000 µg/kg/day during gestation (Courtney 1976).  No 
developmental effects were seen in the offspring of Wistar rats exposed to 2,000 µg/kg/day 2,3-DCDD or 
2-MCDD on Gd 6–15 (Khera and Ruddick 1973). 
In conclusion, studies in rodents and monkeys demonstrated that oral exposure to CDDs induced 
developmental effects with congeners primarily having chlorine atoms at the 2, 3, 7, and 8 positions. 
Following CDD exposure of dams, the primary effects observed in the offspring included cleft palates, 
hydronephrosis, impaired development of the reproductive system, immunotoxicity, and death.  Effects 
were observed in offspring from dams exposed before mating and/or during gestation; transfer of CDDs via 
maternal milk also resulted in adverse developmental effects.  Mice appear to be particularly sensitive to 
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the induction of cleft palate; this alteration also occurred in rats, but at dose levels that were maternally 
toxic. Alterations to the immune system from offspring (mostly rats and mice)  included thymic atrophy, 
alterations in cell-mediated immunity, and changes in lymphocyte surface cell markers.  The development 
of the reproductive systems of male and female rats was also affected by parental exposure to CDDs. 
Chronic exposure of monkeys starting before mating and continuing throughout gestation and lactation 
resulted in neurobehavioral alterations in the infants; this effect was used to derive a chronic oral MRL.  
The highest NOAEL values and all reliable representative LOAEL values for developmental effects in each 
species and duration category for each congener are recorded in Tables 2-2 and 2-3 and plotted in 
Figures 2-1 and 2-2. 
2.2.2.7 Genotoxic Effects 
Mostly negative results were obtained in animal studies following oral exposure to 2,3,7,8-TCDD. 
Cytogenetic analysis of the bone marrow did not reveal any increase in chromosomal aberrations in 
CD-COBS rats exposed to 1 µg/kg 2,3,7,8-TCDD by gavage once a week for 45 weeks (Loprieno et al. 
1982), but an increased incidence was reported in Osborne-Mendel rats exposed to 4 µg/kg twice a week for 
13 weeks (Green et al. 1977). However, chromosomal aberrations were not increased in peripheral 
lymphocytes of monkeys exposed to 0.001 µg/kg/day in the feed for 4 years (Lim et al. 1987). 
Furthermore, 7 daily doses of 12 µg/kg did not induce dominant lethality in Wistar rats (Khera and Ruddick 
1973). In addition, an intermediate-duration exposure to 1 µg/kg/week of 2,3,7,8-TCDD or 1,2,3,7,8­
PCDD for up to 6 months did not enhance the formation of deoxyribonucleic acid (DNA) adducts in rat 
hepatocytes (Randerath et al. 1989).  In conclusion, CDDs were not genotoxic in most animal studies. 
Other genotoxicity studies are discussed in Section 2.5. 
2.2.2.8 Cancer 
The carcinogenicity of CDDs has been demonstrated in several experiments in animals.  Chronic exposure 
of male Osborne-Mendel rats to approximately 0.0071 µg 2,3,7,8-TCDD/kg/day by gavage significantly 
increased the incidence of thyroid follicular cell adenoma; in females, doses of approximately 
0.071 µg/kg/day increased the incidence of neoplastic nodules in the liver and of hepatocellular carcinoma 
(NTP 1982b). Exposure to 0.00014 µg/kg/day 2,3,7,8-TCDD in the feed resulted in an increase in the 
number of tumor bearing male Sprague Dawley rats (5/6 versus 0/4 in control) (Van Miller et al. 1977).  
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The types of neoplasms found were ear duct carcinoma, lymphocytic leukemia, kidney adenocarcinoma, 
peritoneal malignant histiocytoma, skin angiosarcoma, and Leydig cell adenoma.  Each tumor-bearing rat 
had different tumor types, and one rat had 2 types of tumors.  The high mortality in the control group, 
inadequately reported results, and small group sizes (10/group) limit the interpretation of these results. 
Exposure to 0.1 µg/kg/day in the feed induced hepatocellular carcinoma, squamous cell carcinoma of lungs, 
and hard palate and tongue in Sprague-Dawley rats (Kociba et al. 1978a).  A significant increase in 
hepatocellular hyperplastic nodules was observed in the female rats exposed to 0.01 or 0.1 µg/kg/day. 
Females were more affected by 2,3,7,8-TCDD exposure than males.  2,3,7,8-TCDD was also carcinogenic 
in mice exposed chronically by gavage.  Hepatomas and hepatocellular carcinomas were induced in Swiss 
mice exposed to 0.1 µg/kg/day for 1 year (Toth et al. 1979).  Increased incidence of hepatocellular 
carcinomas was observed in male B6C3F1 mice administered 2,3,7,8-TCDD at approximately 
0.071 µg/kg/day by gavage for 104 weeks (NTP 1982b); females exhibited an increase in thyroid  follicular 
cell adenomas and in histiocytic lymphoma at a dose of approximately 0.3 µg/kg/day (NTP 1982b). 
Hepatocellular carcinomas (males and females) and adenomas (females) were found in B6C3F1 mice 
exposed to 0.36 µg/kg/day given by gavage for 1 year (Della Porta et al. 1987). 
Experiments with other congeners showed that chronic exposure to a mixture of 1,2,3,6,7,8-HxCDD and 
1,2,3,7,8,9-HxCDD by gavage induced hepatocellular carcinoma, adenoma, and neoplastic nodules at 
approximately 0.34 µg/kg/day in female Osborne-Mendel rats and at 0.71 µg/kg/week in B6C3F1 male mice 
(NCI/NTP 1980). Therefore, HxCDD is approximately 1/20 as potent a liver carcinogen as 2,3,7,8-TCDD. 
Furthermore, chronic exposure to 6.5×105 µg/kg/day of 2,7-DCDD in the feed caused leukemias, 
lymphomas, hemangiosarcomas, hemangiomas, and dose-related increased incidences of hepatocellular 
adenomas and carcinomas in male B6C3F1 mice (NCI/NTP 1979a).  In contrast, no cancer effects were 
observed following chronic exposure of Osborne-Mendel rats to 5×105 µg/kg/day of 2,7-DCDD (NCI/NTP 
1979a) in the feed. 
In conclusion, the tested congeners (2,3,7,8-TCDD, mixed HxCDDs) were carcinogenic in rodents. 
2,7-DCDD was carcinogenic in mice, but not in rats that received a lower dose. 
The cancer effect levels (CELs) for each species and duration category for each congener are recorded in 
Tables 2-2 and 2-3 and plotted in Figures 2-1 and 2-2. 
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2.2.3 Dermal Exposure 
2.2.3.1 Death 
Information regarding mortality following dermal exposure to CDDs in animals is limited.  For 
2,3,7,8-TCDD, a dermal LD50 value in rabbits was calculated as 275 µg/kg (Schwetz et al. 1973).  Deaths 
occurred within 12–22 days, but the cause of death was not specifically indicated.  Decreased survival was 
observed in Swiss Webster mice exposed 3 days a week to 2,3,7,8-TCDD at 0.05 µg for 13 weeks and 
0.001 µg for chronic duration (NTP 1982a).  In the subchronic study (NTP 1982a), male mice exhibited a 
higher mortality rate than females; lethal doses in males caused marked effects in lymphoid and hemato­
poietic tissues as well as on the liver and lung. The cause of death in the chronic study (NTP 1982a) was 
not specified. No increase in lethality was reported in HRS/J hairless mice dermally exposed to 0.0025 µg, 
2 days a week, for 20 weeks (Hebert et al. 1990).  
The LD50 value for rabbits and LOAEL values in mice for increased mortality for the intermediate- and 
chronic-duration categories are recorded in Tables 2-4 and 2-5. 
2.2.3.2 Systemic Effects 
The highest NOAEL values and all reliable LOAEL values for each systemic effect in each species and 
duration category for each congener are recorded in Table 2-4 and 2-5. 
Respiratory Effects. Bronchiolar adenomatoid changes were found in Swiss Webster mice exposed 
3 days a week to 0.05 µg 2,3,7,8-TCDD for 13 weeks, but no respiratory effects were observed in mice 
exposed 3 days per week to 0.01 µg for a chronic exposure period (NTP 1982a). 
Cardiovascular Effects. Information regarding cardiovascular effects in animals after dermal 
exposure to CDDs is limited.  Chronic dermal exposure of Swiss Webster mice to 2,3,7,8-TCDD at 
0.005 µg, 3 days per week, did not induce any cardiovascular changes observable under histopathological 
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Gastrointestinal Effects. Information regarding gastrointestinal effects in animals after dermal 
exposure to CDDs is limited.  No histopathological changes were observed in the gastrointestinal tract of 
Swiss Webster mice chronically exposed to 0.005 µg 2,3,7,8-TCDD 3 days per week (NTP 1982a). 
Hematological Effects. Hematological examination of Swiss Webster mice chronically exposed to 
0.005 µg 2,3,7,8-TCDD 3 days per week did not reveal any differences between exposed and control 
groups (NTP 1982a). 
Musculoskeletal Effects. No studies were located regarding musculoskeletal effects in animals after 
dermal exposure to CDDs. 
Hepatic Effects. Hepatic effects have been observed in animals after dermal exposure to 
2,3,7,8-TCDD. Necrosis, peripheral fibrosis, and bile duct proliferation were observed in rabbits acutely 
exposed to 2,3,7,8-TCDD on the ear surface (Kimbrough et al. 1977).  Increased liver/body weight ratio 
and hepatocellular hypertrophy were seen in HRS/J hairless mice topically exposed to 0.0025 µg 
2,3,7,8-TCDD twice a week for 20 weeks (Hebert et al. 1990).  Fatty degeneration and hepatocellular 
necrosis were observed in the livers of Swiss Webster mice exposed to 0.005 µg 2,3,7,8-TCDD 3 days a 
week for 13 weeks (NTP 1982a). No hepatic effects were found in mice chronically exposed to 
0.005 µg/day 2,3,7,8-TCDD (NTP 1982a).  The data indicated that 2,3,7,8-TCDD induced hepatotoxic 
effects similar to those observed after oral exposure. 
Renal Effects. Information regarding renal effects in animals after dermal exposure to 2,3,7,8-TCDD is 
limited.  No histopathological changes were found in Swiss Webster mice exposed to 0.005 µg 
2,3,7,8-TCDD 3 days per week for 99–104 weeks (NTP 1982a). 
Dermal Effects. Dermal effects of several CDD congeners have been studied in animals.  Acute dermal 
exposure to 0.01 µg (newborn) and 0.1 µg 2,3,7,8-TCDD (adult) per animal caused hyperkeratosis and 
epidermal hyperplasia in hairless HRS/J mice (Puhvel and Sakamoto 1988).  An involution of sebaceous 
glands was found in both (haired and hairless) strains.  Similar results were found following intermediate-
duration exposure (Puhvel et al. 1982). Furthermore, acne-like lesions in the ears were found in CD-1 mice 
following exposure to 0.1 µg 2,3,7,8-TCDD applied on the pre-shaved back 2 days a week for 30 weeks 
(Berry et al. 1978, 1979).  In contrast, no dermal effects were observed in Swiss Webster mice exposed to 
0.005 µg 2,3,7,8-TCDD/application, 3 days a week for up to 104 weeks (NTP 1982a). 
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Ocular Effects. A single application of 2,000 µg 2,7-DCDD, 2,3,7,8-TCDD, mixed HxCDD, or OCDD 
into the conjunctival sac of rabbits caused transient pain and conjunctival inflammation (Schwetz et al. 
1973). Delayed conjunctival chemosis was observed with 2,3,7,8-TCDD.  None of the CDDs caused 
corneal injury or iritis.  
Body Weight Effects. In animal studies, decreased body weight was observed in HRS/J and Skjh:HR­
1 mice following intermediate-duration dermal exposure to 0.1 µg 2,3,7,8-TCDD (Puhvel et al. 1982) and 
in Swiss Webster mice following chronic exposure to 0.005 µg 2,3,7,8-TCDD 3 days per week (NTP 
1982a). 
2.2.2.3 Immunological Effects 
The only information regarding immunological effects in animals after dermal exposure to CDDs was 
obtained from an intermediate-duration study in HRS/J mice (Hebert et al. 1990).  Mice dermally exposed 
to 0.01 µg 2,3,7,8-TCDD 2 days per week for 20 weeks had decreased thymus/body weight ratio.  No 
effects were observed at 0.005 µg. 
The NOAEL and LOAEL values for immunological effects in mice after intermediate-duration exposure are 
recorded in Table 2-4. 
2.2.3.4 Neurological Effects 
No studies were located regarding neurological effects in animals after dermal exposure to CDDs. 
2.2.3.5 Reproductive Effects 
Data regarding reproductive effects following dermal exposure in animals are scarce.  No treatment-related 
changes were observed in the reproductive system of Swiss Webster mice after chronic exposure to 
0.005 µg 2,3,7,8-TCDD per application (NTP 1982a). 
2.2.3.6 Developmental Effects 
No studies were located regarding developmental effects in animals after dermal exposure to CDDs. 
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2.2.3.7 Genotoxic Effects 
No studies were located regarding genotoxic effects in animals after dermal exposure to CDDs. 
Genotoxicity studies are discussed in Section 2.5. 
2.2.3.8 Cancer 
Acute- and intermediate-duration studies in animals investigated the interactions of 2,3,7,8-TCDD with 
known carcinogens. A single dermal pretreatment of CD-1 Charles River mice with 0.01 µg 2,3,7,8-TCDD 
inhibited the development of skin papillomas otherwise initiated by 1,3-dimethylbenz(o)anthracene 
(DMBA) (Berry et al. 1979). In intermediate-duration experiments, 2,3,7,8-TCDD did not promote skin 
tumors initiated by DMBA (Berry et al. 1978, 1979).  In contrast, the promoting ability of 2,3,7,8-TCDD at 
0.0025 µg/day (and higher), 2 days a week, for 20 weeks, was reported in HRS/J hairless mice following 
the initiation with N-methyl-N-nitro-N-nitrosoguanidine in intermediate-duration experiments (Hebert et al. 
1990; Poland et al. 1982). The effect was not observed in mice heterozygous for the hairless trait (Poland et 
al. 1982). In a chronic study, significantly increased incidence of fibrosarcoma of the integumentary system 
was found in Swiss Webster female mice following dermal exposure to 2,3,7,8-TCDD at 0.005 µg, 3 days a 
week for 2 years (NTP 1982a).  The cancer effect level (CEL) from this study is shown in Table 2-4. 
2.3 TOXICOKINETICS 
Data regarding toxicokinetics of CDDs in humans are limited to information derived from exposures that 
occurred after industrial accidents, exposures of Vietnam veterans, and ingestion of 2,3,7,8-TCDD by a 
volunteer. Humans can absorb CDDs by the inhalation, oral, and dermal routes of exposure. CDDs, when 
administered orally, are well absorbed by experimental animals, but they are absorbed less efficiently when 
administered by the dermal route.  Limited data in rats showed that transpulmonary absorption of 
2,3,7,8-TCDD may be at least as efficient as oral absorption.  In a human volunteer, >86% of the 
administered single oral dose appeared to have been absorbed.  In general, absorption is vehicle-dependent 
and congener-specific. Passage across the intestinal wall is predominantly limited by molecular size and 
solubility.  These parameters are most significant for hepta- and octachlorinated congeners, which exhibit 
decreased absorption in mammals.  The predominant CDD carriers in human plasma are serum lipids and 
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lipoproteins, but chlorine substitution plays a role in the distribution in these fractions.  For most 
mammalian species, the liver and adipose tissue are the major storage sites of CDDs; in some species, skin 
and adrenals also can act as primary deposition sites.  2,3,7,8-Substituted CDDs are the predominant 
congeners retained in tissues and body fluids.  Tissue deposition is congener-specific and depends on the 
dose, the route of administration, and age.  CDDs are very slowly metabolized by the microsomal 
monooxygenase system to polar metabolites that can undergo conjugation with glucuronic acid and 
glutathione. The major routes of excretion of CDDs are the bile and the feces; smaller amounts are excreted 
via the urine. In mammalian species, lactation is an effective way of eliminating CDDs from the liver and 
other extrahepatic tissues. Physiologically based pharmacokinetic (PBPK) models have been developed to 
describe disposition of 2,3,7,8-TCDD in humans and animals.  Some of these models included parameters 
to describe complex interactions of 2,3,7,8-TCDD with cellular proteins that lead to specific biological 
responses. 
2.3.1 Absorption 
2.3.1.1 Inhalation Exposure 
No quantitative data were located regarding absorption of CDDs in humans following inhalation exposure. 
However, based on data from studies with structurally related chemicals it is reasonable to assume that 
CDDs are absorbed by this route.  Furthermore, data on levels of CDDs in blood from populations with 
above-background exposures (occupational, accidental) also suggest that transpulmonary absorption occurs 
in humans; see Section 2.1 for more information. 
Systemic effects (hepatic aryl hydrocarbon hydroxylase [AHH] and cytochrome P-450 induction, hepatic 
histological alterations) were observed in rats following a single intratracheal instillation of 2,3,7,8-TCDD 
in a corn oil vehicle or as a laboratory-prepared contaminant of gallium oxide particles (Nessel et al. 1990). 
In a subsequent study, the same group of investigators (Nessel et al. 1992) using a similar protocol found 
that the relative pulmonary bioavailability of 2,3,7,8-TCDD on respirable soil particles was 100% as 
compared to the gallium oxide vehicle.  One and 7 days post-treatment, 13.9 and 11.9% of the administered 
dose were detected in the liver, respectively, and this was similar to the percentage found after instillation of 
contaminated gallium oxide particles.  Twenty-eight days after treatment, 5.2% of the administered dose 
was detected in the liver from soil-treated rats and 2.9% in liver from gallium oxide-treated rats suggesting 
that redistribution and retention of 2,3,7,8-TCDD differed in the two treatment groups.  Recently, Diliberto 
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et al. (1996) reported that 3 days after intratracheal application of a single dose of 0.32 µg 2,3,7,8-TCDD/kg 
to male Fischer 344 rats, 95% of the applied dose was absorbed, suggesting that inhalation can be an 
effective route of exposure. The extent of inhalation absorption was higher than when the same dose was 
administered orally (88%) or dermally (40%).  The available data suggest that inhaled CDDs will be 
absorbed. However, the degree of absorption and the rate will depend on the media on which the CDDs are 
adsorbed and the degree of chlorination. 
2.3.1.2 Oral Exposure 
The absorption of 2,3,7,8-TCDD was estimated to be >87% in a human volunteer following ingestion of a 
single radioactively labeled dose of 0.00114 µg 2,3,7,8-TCDD/kg in corn oil (Poiger and Schlatter 1986). 
Data regarding absorption of CDDs from breast milk in nursing infants are provided in Section 2.3.4.4. 
Gastrointestinal absorption of radiolabeled 2,3,7,8-TCDD has been investigated in rodents.  About 73.5% of 
the total dose of 2,3,7,8-TCDD (administered by gavage in corn oil vehicle) was absorbed in Syrian 
hamsters, the species most resistant to acute 2,3,7,8-TCDD toxicity (Olson et al. 1980b).  In Sprague-
Dawley rats given a single gavage dose of 50 µg/kg 2,3,7,8-TCDD in corn oil, at least 70% was absorbed 
(Piper et al. 1973). Rose et al. (1976) found a mean of 84% of a single oral gavage dose of 1 µg/kg 
absorbed within a day in a similar study and a steady-state body burden was achieved after dosing with 
0.01, 0.1, or 1 µg/kg in corn oil, 5 days a week for 7 weeks.  When 14C-2,3,7,8-TCDD was fed to Sprague-
Dawley rats at 0.35 µg/kg/day or 1 µg/kg/day in the diet for 42 days, about 60% of the consumed dose was 
absorbed (Fries and Marrow 1975). Intestinal absorption of 2,3,7,8-TCDD did not vary with age of 
Fischer 344 rats (13 weeks, 13 or 26 months) when in vivo absorption was studied with an in situ intestinal 
perfusion technique (Hebert and Birnbaum 1987).  When ICR/Ha Swiss mice were given a single dose of 
radioactively labeled 2,3,7,8-TCDD, 67–76% of the administered dose was excreted in feces and 1–2% in 
urine within the first 24 hours (Koshakji et al. 1984). The authors (Koshakji et al. 1984) concluded that 
most of the dose was not absorbed.  The more highly chlorinated CDD congeners are absorbed from the 
gastrointestinal tract to a lesser extent than 2,3,7,8-TCDD. 
Gastrointestinal absorption of 2,3,7,8-TCDD may differ depending on the vehicle used.  When hepatic 
concentrations were used as a measure of absorbed dose, the levels observed in rats 24 hours after 
2,3,7,8-TCDD administration in 50% ethanol were higher than in an aqueous suspension of soil (Poiger and 
Schlatter 1980). Use of activated carbon as a vehicle almost completely eliminated 2,3,7,8-TCDD 
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absorption. It was further demonstrated that the absorption of 2,3,7,8-TCDD from the gastrointestinal tract 
of rats was .50% less from contaminated soil than from corn oil (Lucier et al. 1986), which is supported by 
the finding that 2,3,7,8-TCDD-contaminated soil was less toxic to guinea pigs than an equivalent amount of 
2,3,7,8-TCDD in oil (Umbreit et al. 1985).  Gastrointestinal absorption of OCDD was <10% of the 
administered dose in Sprague-Dawley and Fischer 344 rats following single or repeated (3-week) exposures 
by gavage in oil vehicle (Birnbaum and Couture 1988; Norback et al. 1975).  Low doses (50 µg/kg) in a 
o-dichlorobenzene:corn oil (1:1) vehicle were found to give the best oral bioavailability for this extremely 
insoluble compound (Birnbaum and Couture 1988).  The bioavailability of CDDs (2,3,7,8-TCDD, 
1,2,3,7,8-PCDD, 1,2,3,6,7,8-HxCDD, and 1,2,3,7,8,9-HxCDD) to rats was lower on fly ash (0.4% for 
2,3,7,8-TCDD) as compared to extracts of the same fly ash administered in an oily vehicle (45% for 
2,3,7,8-TCDD) (Van den Berg et al. 1983, 1987c). The differences in hepatic levels between fly ash- and 
extract-treated rats were greater for the more highly chlorinated congeners.  
2.3.1.3 Dermal Exposure 
No quantitative data were located regarding absorption of CDDs in humans following dermal exposure. 
However, based on data from studies with structurally related chemicals it is reasonable to assume that 
CDDs are absorbed by this route.  Furthermore, data on levels of CDDs in blood from populations with 
above-background exposures (i.e., occupational, accidental) also suggest that dermal absorption occurs in 
humans.  Due to the relatively low vapor pressure and high lipid solubility, dermal uptake of 2,3,7,8-TCDD 
in the workplace may be a significant source of occupational exposure (Kerger et al. 1995). 
Kerger et al. (1995) examined the potential contribution of dermal exposure to 2,3,7,8-TCDD for three 
different occupational exposure scenarios: 1) trichlorophenoxy herbicide manufacturing worker (20-year 
exposure), 2) contract maintenance mechanic exposed by repairing a trichlorophenol reactor after an 
explosion accident (6-week exposure), and 3) trichlorophenoxy applicator handling only diluted 
trichlorophenoxy herbicides (seasonal exposure for 20 years).  In their evaluation, the authors used a 
conceptual model of workplace exposure, dermal bioavailability/uptake calculations, and simple 
pharmacokinetic modeling techniques (details of the model were not provided).  The contribution of 
background uptake of 2,3,7,8-TCDD from dietary sources in the United States was accounted for in the 
estimates of steady-state adipose concentrations.  The results of the modeling  showed that considerable 
occupational uptake can occur following both long-term continuous exposure and short-term high exposure. 
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body burden is measured within a 10-year period following cessation of exposure.  In contrast, seasonal 
exposure to dilute 2,3,7,8,-TCDD residues may result in little or no change in 2,3,7,8-TCDD body burden. 
The in vitro penetration of 3H-labeled 2,3,7,8-TCDD into human cadaver skin was studied at concentrations 
of 6.5 and 65 ng 2,3,7,8-TCDD/cm2 of skin (Weber et al. 1991). Two vehicles were used: acetone to 
simulate exposure to 2,3,7,8-TCDD as a dry material, and mineral oil to simulate exposure in an oily 
medium.  The experiments were conducted in intact skin and in skin with stripped stratum corneum and 
penetration was monitored for 30, 100, 300, and 1,000 minutes.  The results showed that acetone as a 
vehicle allowed 2,3,7,8-TCDD to penetrate deeply into the loose surface of the lamellae of the stratum 
corneum, but there was little further penetration.  On the other hand, mineral oil appeared to compete with 
lipophilic constituents of the stratum corneum for 2,3,7,8-TCDD, thus slowing its penetration even more. 
Removal of the stratum corneum increased the amount of 2,3,7,8-TCDD absorbed into layers of the skin. 
Rates of absorption were calculated in two ways: a worst case scenario where 2,3,7,8-TCDD absorbed into 
any layer of skin including the stratum corneum was used for analysis; and a physiological approach where 
only the amount of 2,3,7,8-TCDD which had penetrated beyond the epidermis into the region of dermal 
vascularization was considered absorbed.  In the former case, the stratum corneum appeared to mediate 
dermal absorption of 2,3,7,8-TCDD since the rates decreased when stripped skin was exposed to 
2,3,7,8-TCDD. With the physiological approach, the rate of absorption was a function of the amount 
applied suggesting that the rate of absorption per unit time was a first-order function.  The amount of 
2,3,7,8-TCDD that penetrated the skin also correlated with exposure duration.  The rate of 2,3,7,8-TCDD 
penetration with acetone as vehicle ranged from 100 to 800 pg 2,3,7,8-TCDD per hour-cm2 (worst-case 
scenario), or 6–170 pg per hour-cm2 with the physiological approach.  The corresponding values with 
mineral oil as a vehicle were 20–220 pg and 1.4–18 pg per hour-cm2, respectively.
Data regarding dermal absorption of CDDs in animals are limited.  When 200 pmol 2,3,7,8-TCDD was 
applied to the skin of Fischer 344 rats, absorption followed first-order kinetics with an absorption rate 
constant of 0.005 hour-1 (Banks and Birnbaum 1991).  Within 120 hours postexposure, about 0.026 µg 
2,3,7,8-TCDD was absorbed (less than 50% of the applied dose); at each interval of measurement, about 
70% of detected radioactivity on the skin could be removed by swabbing with acetone. About 15% of the 
dose was detected in the liver of rats 24 hours after dermal exposure to 26 ng of 2,3,7,8-TCDD in 50% 
methanol (Poiger and Schlatter 1980).  It was estimated that the amount absorbed from the dermal 
exposure represents .40% of the amount absorbed from an equivalent oral dose.  Absorption of 
2,3,7,8-TCDD was significantly reduced by application in Vaseline or polyethylene glycol and practically
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eliminated  in soil or activated carbon. Dermal absorption of radioactively labeled 2,3,7,8-TCDD in soil 
vehicle was reported to be only 1% of the administered dose during a 24-hour contact in rats (Shu et al. 
1988). The dermal absorption of 2,3,7,8-TCDD after 4 hours of contact was about 60% of that after 
24-hour contact. The uptake was not influenced by the 2,3,7,8-TCDD concentration in soil, nor were 
there any differences between normal and hairless rats. 
Dermal absorption in rats was found to be age-related.  Banks et al. (1990) found that in Fischer 344 rats, 
the percutaneous absorption was decreased in middle-aged (36-week-old) and senescent (120-week-old) 
rats compared to that in young adults (10-week-old) 72 hours after application of a dose of 40 nmol 
(approximately 12.9 µg) of 3H-labeled 2,3,7,8-TCDD. The authors suggested a decrease in blood flow 
through the skin between 3 and 4 months of age as a possible explanation for their findings.  In a 
subsequent and similar study, the same group of investigators examined the dermal absorption of 
2,3,7,8-TCDD in 3-, 5-, 8-, 10-, and 36-week-old Fischer 344 rats 72 hours after application of 200 pmol 
2,3,7,8-TCDD in acetone (Banks et al. 1993). Dermal absorption was greatest in 3-week-old rats 
(approximately 64% of the applied dose), decreased to about 40% of the applied dose in 5-, 8-, and 
10-week-old rats and to about 22% in 36-week-old rats.  In each age group, 70–80% of the radioactivity 
remaining at the application site 72 hours after dosing could be removed with acetone swabs. 
2.3.2 Distribution 
As discussed in Section 2.1, occupational or environmental human exposure to CDDs is not readily 
classifiable as to route of exposure. Human data regarding distribution obtained at autopsy indicated that 
accumulation in the liver following low levels of exposure is based in part on lipid solubility (Leung et al. 
1990a). However, this may not be the case with higher exposure levels that cause hepatic enzyme 
induction (see Section 2.4.1). When human hepatic and adipose tissues were examined for the presence 
of 2,3,7,8-TCDD, the concentration detected in the liver was about 1/10 of that in the adipose tissue on a 
whole-tissue-weight basis. However, on the basis of the total tissue lipid, the concentration in adipose 
tissue lipid was one-half that in the liver lipid (Thoma et al. 1990).  It was further demonstrated that over 
a wide range of concentrations, the serum 2,3,7,8-TCDD levels highly correlated with adipose tissue 
2,3,7,8-TCDD levels when both are expressed on a lipid weight basis (Patterson et al. 1988).  Adipose 
tissue serves as a storage depot for 2,3,7,8-TCDD in the body, and detectable levels (up to 20.2 ppt) were 
found in the general population with no known risk of high exposure to CDDs (Andrews et al. 1989).  An 
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population (Orban et al. 1994). The distribution of highly chlorinated CDDs among tissue lipid fractions 
is not equal. For example, the distribution of OCDD is 12:1 (Thoma et al. 1990) between liver and 
adipose tissue lipid factions and 2:1 between serum and adipose tissue lipid fractions (Schecter et al. 
1990). 
Increased adipose tissue levels of CDDs were reported in populations with known high residential or 
occupational exposure (Beck et al. 1989c; Fingerhut et al. 1989; Patterson et al. 1989b; Schecter et al. 
1994). For example, high levels of 2,3,7,8-TCDD were found in fat (42–750 ppt) and serum lipid 
(61–1,090 ppt) of Missouri chemical workers (Patterson et al. 1989b).  Measurable CDDs and CDFs 
levels were reported in the liver tissue of human stillborn neonates suggesting that the transplacental 
intrauterine transfer of these persistent chemicals resulted from environmentally exposed mothers 
(Schecter et al. 1990). In addition, CDDs are distributed to human milk (i.e., Fürst et al. 1994; Schecter et 
al. 1987a, 1987b, 1989e) and numerous studies have published concentrations of various congeners in 
human milk samples (see section 5.5.1).  Levels of CDDs in human milk have been found to be 
significantly and positively associated with of proximity of residence to waste sites and to dietary fat 
intake per week (Schaud et al. 1995). 
2.3.2.1 Inhalation Exposure 
The tissue distribution of 2,3,7,8-TCDD-derived radioactivity was recently examined in male Fischer 344 
rats 3 days after intratracheal application of a single dose of 0.32 µg 2,3,7,8-TCDD/kg (Diliberto et al. 
1996). The liver and adipose tissue were the major tissue depots for 2,3,7,8-TCDD-derived radioactivity 
with 33 and 15% of the applied dose distributing to these respective tissues.  The skin (ear) and muscle 
followed with 4.3 and 1.3%, respectively.  All other tissues had less than 0.5% of the administered dose. 
The 2/1 liver/adipose ratio was in contrast to the approximately 1/1 ratio found after gavage 
administration of the same dose. 
2.3.2.2 Oral Exposure 
Following an ingested dose of 3H-2,3,7,8-TCDD of 0.00114 µg/kg by a volunteer, the concentration of 
2,3,7,8-TCDD in the adipose tissue were 3.09 and 2.86 ppt at 13 and 69 days following exposure, 
respectively (Poiger and Schlatter 1986).  The authors estimated that about 90% of the body burden was 
distributed to the fatty tissue.  Increased radioactivity was detected in the blood only during the first 2 days
 
CDDs 194 
2. HEALTH EFFECTS 
postexposure; no radioactivity was detected in serum lipid after 5 days, but was in the feces for several 
months. 
Studies in animals have shown that 2,3,7,8-TCDD distributes preferentially to the liver and adipose tissue. 
In Sprague-Dawley rats, the highest levels of radioactivity (expressed as percentage of dose per gram of 
tissue) were located in the liver (3.18, 4.49, and 1.33% at days 3, 7, and 21 post-exposure, respectively) and 
adipose tissues (2.6, 3.22, and 0.43% at days 3, 7, and 21, respectively) following a single oral dose of 
labeled 2,3,7,8-TCDD at 50 µg/kg (Piper et al. 1973).  Much smaller amounts were found in muscles, 
testes, lungs, stomach, and other organs.  In male Fischer 344 rats administered a single gavage dose of 
0.32 µg 2,3,7,8-TCDD/kg, 24.4 and 26.2% of the administered dose was found in the liver and adipose 
tissue, respectively, 3 days after dosing (Diliberto et al. 1996); skin and muscle had 7.3 and 1.8%, 
respectively.  2,3,7,8-TCDD accumulated mainly in the liver and adipose tissue, with smaller amounts in 
the brain of pregnant Wistar rats after 10 daily doses of 2 µg/kg (Khera and Ruddick 1973).  Similarly, the 
highest levels of radioactivity were found in the liver, adipose tissue, and the adrenals of Golden Syrian 
hamsters after a single gavage dose of 650 µg/kg labeled 2,3,7,8-TCDD (Olson et al. 1980b).  In addition, 
about 36% of the total radioactivity administered remained in the adipose tissue by day 45 postexposure in 
Hartley guinea pigs; only about 7% (each) was found in the liver, muscles, and carcass (Olson 1986). 
Essentially all of the administered dose was unchanged 2,3,7,8-TCDD. When pregnant NMRI mice were 
exposed to a single oral, intraperitoneal, or subcutaneous dose of 2,3,7,8-TCDD, hepatic levels were about 
the same, indicating that there is no major first pass effect after oral 2,3,7,8-TCDD exposure (Nau and Bass 
1981). Liver, then adipose tissue and skin, were the major depots of OCDD in Fischer 344 rats treated with 
single oral doses of this congener (Birnbaum and Couture 1988). 
The dose- and time-dependent tissue distribution of 2,3,7,8-TCDD in mice has been recently examined 
(Diliberto et al. 1995). Female B6C3F1 mice were administered a single dose of 0.1, 1, or 10 µg 
[3H]-2,3,7,8-TCDD/kg by gavage in corn oil and the distribution of radioactivity was followed in 18 tissues 
for up to 35 days after dosing.  The results showed dose-dependent distribution of 2,3,7,8-TCDD-derived 
radioactivity in all tissues.  The highest concentrations of radioactivity were found in liver and adipose 
tissues, and both tissues accounted for 50% of the body burden.  Relatively high concentrations of 
2,3,7,8-TCDD-derived radioactivity were also found in skin, adrenal glands, thyroid, pancreas, olfactory 
epithelium, spleen, mesenteric lymph nodes, thymus, lung, and bone marrow.  The liver concentration of 
radioactivity increased disproportionally with increasing doses, whereas relative concentration and 
percentage dose/total tissue in extrahepatic tissues decreased with increasing dose and over time.  
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Liver/adipose tissue concentration ratios were shown to be dose- and time-dependent.  At the low-, mid-
and high-dose, the ratios ranged from 0.6 to 0.2, 2.3–0.5, and 3.1–1.4 over time, respectively.  This 
variation over time was thought to have been due to redistribution of 2,3,7,8-TCDD between the two 
storage sites and/or hepatic metabolism and subsequent excretion.  
The effect of age of the animal on 2,3,7,8-TCDD tissue distribution has also been examined.  Pegram et al. 
(1995) administered a single dose of 0.015, 0.5 or 15 µg [3H]2,3,7,8-TCDD/kg to 10-week- and 28-month­
old male C57BL/6N mice and monitored 2,3,7,8-TCDD-derived radioactivity in blood, liver, skin, kidney, 
and muscle 7 days after dosing.  The results showed that in young mice given the low- and high-dose, the 
concentration of 2,3,7,8-TCDD in blood relative to all other tissues was significantly greater than in older 
mice.  Also, in older mice, the concentration of 2,3,7,8-TCDD in skin and the percentage of the dose in the 
skin were greater than in the young mice.  The same trend was observed in kidney and muscle.  The 
concentration of 2,3,7,8-TCDD in liver, as well as the percentage of the dose in the liver, were greater in 
young than old animals at both the mid- and high-doses.  In both young and old mice the ratios of liver to 
adipose tissue increased with increasing doses.  According to the authors, the higher hepatic concentration 
of 2,3,7,8-TCDD in young mice could be due to the old mice having a larger fat compartment, such that the 
hepatic 2,3,7,8-TCDD sequestering action of CYP1A2 or other inducible binding factors may have been 
less effective in the more obese older mice.  In addition, decreased perfusion in the liver and adipose 
compartments in the old mice may have limited the effectiveness of hepatic 2,3,7,8-TCDD accumulation. 
The greater accumulation of 2,3,7,8-TCDD in the skin, muscle, and kidney from old mice were attributed to 
altered perfusion and possibly greater lipid infiltration in these tissues. 
The subcellular distribution of 2,3,7,8-TCDD-derived radioactivity in the liver, lungs, and kidneys from 
female Sprague-Dawley rats and B6C3F1 mice was studied by Santostefano et al. (1996).  In the liver of 
rats given a single oral dose of 0.1, 1, or 10 µg [3H]-2,3,7,8-TCDD/kg, radioactivity accumulated equally in 
the supernatant (S9, cytosol, and microsomes) and pellet (P9, nucleus, lysosomes, and mitochondria) 
fractions; within the S9 fraction, accumulation was predominantly in the microsomal fraction.  In contrast, 
in kidneys and lungs radioactivity accumulated preferentially in P9, but radioactivity detected in S9 was 
mostly in the cytosolic fraction.  The pattern of distribution of radioactivity in liver and lungs from mice 
was similar to that found in rats, but in mice kidneys, 2,3,7,8-TCDD detected in S9 was equally distributed 
between the microsomal and cytosolic fractions.  Accumulation of 2,3,7,8-TCDD in the various fractions in 
this single-dose study was not dose-dependent.  The investigators also conducted a 17-week oral dosing 
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accumulation between liver S9 and P9 fractions, whereas the kidney P9 had the most radioactivity 
regardless of the dose. In addition, liver S9 accumulated  2,3,7,8-TCDD in the microsomal fraction, 
whereas kidney S9 did it predominantly in the cytosol.  These results are consistent with the hypothesis 
that hepatic microsomal sequestration of 2,3,7,8-TCDD is mediated by cytochrome P-4501A2 (CYP1A2), a 
dioxin-inducible protein. This hypothesis was subsequently confirmed by experiments in transgenic mice 
lacking expression of CYP1A2 (CYP1A2-/-) (Diliberto et al. 1997). These mice, as judged by
2,3,7,8-TCDD liver/fat concentration ratios, failed to sequester 2,3,7,8-TCDD in the liver after 
administration of a single dose of 2,3,7,8-TCDD. 
Intermediate-duration exposure to 2,3,7,8-TCDD in the feed has been shown to produce higher liver 
accumulation in male (85%) than in female rats (70%) (Fries and Marrow 1975).  The percentage retained 
was related to intake, and at steady state, the total amount retained was about 10.5 times the average daily 
intake.
 Intermediate-duration studies have also been conducted with radioactively labeled OCDD.  OCDD had 
similar patterns of distribution and similar half-lives as 2,3,7,8-TCDD in Sprague-Dawley (Norback et al. 
1975) and Fischer 344 rats (Birnbaum and Couture 1988; Birnbaum et al. 1989a).  Most of the absorbed 
amount (50–97%) was found in the liver and was associated with the microsomal fractions.  Skin- and 
adipose-tissue levels were much lower.  Radioactivity was also detected in the kidneys, heart, testes, 
skeletal muscle, and serum. 
2.3.2.3 Dermal Exposure 
Male Fischer 344 rats absorbed 40% of a single dermal dose of 0.32 µg of radioactive 2,3,7,8-TCDD/kg 
over a period of 120 hours after dosing (Banks and Birnbaum 1991).  The major depots for 2,3,7,8-TCDD­
derived radioactivity were the liver and adipose tissue.  Seventy-two hours after dosing, the liver and 
adipose tissue retained approximately 21 and 8% of the administered dose, respectively.  Distribution to the 
liver increased significantly between 4 and 8 hours and between 12 and 72 hours after dosing.  Distribution 
in fat increased significantly between 12 and 120 hours after dosing.  Skin and muscle accumulated 
considerably less 2,3,7,8-TCDD-derived radioactivity than liver and fat.  Within 120 hours of dosing, less 
than 4% of the administered dose was found in either of these tissues. When 2,3,7,8-TCDD was dermally 
applied to HRS/J hairless mice for an intermediate duration, about 5–6% of the total administered dose 
(0.0025–0.01 µg/kg, 2 days a week, for 20 weeks) was detected in the liver (Hebert et al. 1990). 
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2.3.3 Metabolism 
No data were located regarding metabolic pathways of CDDs in humans.  However, there is some evidence 
that 2,3,7,8-TCDD is partially excreted in the feces in the form of metabolites (Wendling et al. 1990). 
Studies in animals indicate that 2,3,7,8-TCDD is metabolized slowly in mammals (Koshakji et al. 1984). 
Metabolic transformation by phase I metabolizing enzymes includes oxidation and reductive dechlorination, 
as well as oxygen bridge cleavage.  This is followed by conjugation reactions catalyzed by phase II type 
enzymes, which facilitate excretion by adding more polar groups to the molecule.  For example, a study in 
guinea pigs showed that only 28% of the radioactivity in the tissues 45 days following exposure to 
3H-2,3,7,8-TCDD was in the form of metabolites (Olson 1986).  Results from high performance liquid 
chromatography (HPLC) suggested the presence of at least five 3H-labeled metabolites of 2,3,7,8-TCDD, 
but their structure was not established. The results indicated that in the guinea pig, the metabolites of 
2,3,7,8-TCDD may not leave the body rapidly.  In rats and hamsters, metabolism appears to be required for 
urinary and biliary excretion (Olson et al. 1980a).  Metabolites of 2,3,7,8-TCDD are not generally detected 
in tissues, suggesting that for most species, 2,3,7,8-TCDD is readily eliminated following metabolism.  An 
in vitro study with isolated rat hepatocytes identified 1–hydroxy-2,3,7,8-TCDD and 8-hydroxy-
2,3,7-TrCDD as metabolites (Sawahata et al. 1982).  2-Hydroxy-1,3,7,8-TCDD was found to be the major 
metabolite of 2,3,7,8-TCDD in dogs but not in rats (Poiger et al. 1982).  The metabolites from dogs 
administered to rats were eliminated as conjugates in the bile (Weber et al. 1982).  Self induction of 
2,3,7,8-TCDD metabolism was reported in both species (Poiger and Schlatter 1985; Weber et al. 1982).  A 
single 10 µg/kg dose of unlabeled 2,3,7,8-TCDD 9 days prior to administration of 3H-2,3,7,8-TCDD 
resulted in a doubling of the amount of radioactivity eliminated in the bile of dogs.  When the 
2,3,7,8-TCDD metabolites, 2-hydroxy-2,3,7-TrCDD and 2-hydroxy-1,3,7,8-TCDD, were synthesized and 
injected intraperitoneal into Wistar rats, no toxic effects were observed (Mason and Safe 1986).  This 
supports the observation that the extract from the bile of 2,3,7,8-TCDD-treated dogs is about 100 times less 
toxic to rats and guinea pigs than pure 2,3,7,8-TCDD (Poiger et al. 1982). The lack of toxicity of the 
2,3,7,8-TCDD metabolites suggests that autoinduction of its own metabolism in animals is a detoxification 
mechanism. 
Data regarding other 2,3,7,8-substituted  CDDs are limited.  Wacker et al. (1986) found at least three 
phenolic radiolabeled metabolites of 14C-1,2,3,7,8-PeCDD in rat bile after treatment with glucuronidase and 
methylation, indicating the probability of formation of hydroxymetabolites.  Results from studies in 
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rats revealed no metabolites of OCDD, as expected from the fully chlorinated molecule (Birnbaum and 
Couture 1988; Tulp and Hutzinger 1978). 
CDDs induce both phase I and phase II drug-metabolizing enzymes including AHH, EROD, ACOH, 
glucuronosyl transferase, glutathione S-transferase, and DT-diaphorase (Van den Berg et al. 1994).  These 
enzymes are responsible for the metabolism of a variety of exogenous and endogenous substances. 
Pretreatment of C57BL/6J mice with 2,3,7,8-TCDD increased hepatic accumulation of a subsequent 
radiolabeled dose (total liver burden increased about 50%), whereas distribution to the kidney, fat, heart, 
lung, and gastrointestinal tract were reciprocally decreased (Curtis et al. 1990).  The data indicated that an 
inducible, saturable system is involved in 2,3,7,8-TCDD toxicokinetics.  The pretreatment, however, did not 
alter the hepatic metabolism of 2,3,7,8-TCDD in exposed mice.  Similarly, the rate of metabolism of 
2,3,7,8-TCDD in hepatocytes from 2,3,7,8-TCDD-pretreated (induced) guinea pigs and mice was 
unchanged from that in untreated animals (Olson and Wroblewski 1985; Shen et al. 1989; Wroblewski and 
Olson 1985). In contrast, the rate of metabolism in hepatocytes from 2,3,7,8-TCDD-pretreated rats was 
3.2-fold greater than the rate in hepatocytes from control rats and about 9 times greater than in hepatocytes 
from 2,3,7,8-TCDD-pretreated guinea pigs.  The difference between the 2,3,7,8-TCDD ability to induce its 
own rate of metabolism in rats and guinea pigs could be a factor in the difference between the susceptibility 
to 2,3,7,8-TCDD-induced toxicity in these two species, because the parent compound rather than 
metabolites is the toxic agent (Poland and Glover 1979).  A generalized scheme of metabolic pathways for 
CDDs based on information from in vivo mammalian studies was proposed by Van den Berg et al. (1994) 
and is presented in Figure 2-3. 
2.3.4 Elimination and Excretion 
A median half-life of 7.1 years was estimated for 2,3,7,8-TCDD in a group of 36 Vietnam veterans (CDC 
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were measured in these individuals in 1982 and again in 1987.  The individual half-life values varied from 
2.9 to 26.9 years.  In an expanded half-life study of 343 Vietnam veterans participating in Operation Ranch 
Hand, which included the subjects of the Pirkle et al. (1989) study, a half-life estimate of 8.7 years (95% CI 
of 8.0–9.5 years) was calculated (Michalek et al. 1996).  The half-life estimate was calculated using 
2,3,7,8-TCDD levels in blood samples collected in 1982, 1987, and 1992.  An earlier study of these subjects 
(Wolfe et al. 1994), which used data from two blood collection periods (1982 and 1987) estimated a half-
life of 11.3 years (95% CI of 10–14.1 years).  This half-life of 11.3 years was considered too high because it 
was based on restricted analysis of veterans with 2,3,7,8-TCDD levels above 10 ppt. By conditioning the 
data to lie above a line with slope equal to the negative of the decay rate, the analysis yielded a revised half-
life of 8.7 years.  The Michalek et al. (1996) half-life estimate of 8.7 years supersedes other estimates for 
this group of veterans because it includes an additional measurement of serum lipid 2,3,7,8-TCDD levels 
and controls for potential biases. 
Several other studies have calculated 2,3,7,8-TCDD half-lives.  A mean half-life of 5.8 years was estimated 
from repeated samples from 29 BASF AG facility workers whose initial 2,3,7,8-TCDD serum lipid 
concentrations ranged from 29 to 553 ppt (Ott and Zober 1996).  In a study of 48 German workers at a 
pesticide facility who were exposed to a mixture of CDDs/CDFs, a median half-life of 7.2 years was 
estimated for 2,3,7,8-TCDD (Flesch-Janys et al. 1996).  Needham et al. (1994) estimated a half-life of 
8.2 years in 27 Seveso residents with initial serum 2,3,7,8-TCDD levels of 130 to 3,830 ppt.  Using data 
from a human subject ingesting a single dose of 1.14 ng/kg 2,3,7,8-TCDD, Poiger and Schlatter (1986) 
calculated a half-life of 2,120 days (5.8 years).  Geyer et al. (1986a) noted that they calculated a half-life of 
3.5-6.9 years, but did not describe the basis of this estimation.  Overall, there is good agreement between 
the 2,3,7,8-TCDD half-lives estimated in 4 different populations (Vietnam veterans, BASF AG cohort, 
German pesticide workers, and Seveso residents); the half-lives ranged from 5.8 to 8.7 years (Flesch-Janys 
et al. 1996; Michalek et al. 1996; Needham et al. 1994; Ott and Zober 1996).  Several studies have found 
correlations between percentage of body fat and 2,3,7,8-TCDD elimination half-times (Flesch-Janys et al. 
1996; Michalek et al. 1996; Ott and Zober 1996; Wolfe et al. 1994).  Ott and Zober (1996) estimated half-
lives of 5.1 and 8.9 years in subjects with 20 and 30% body fat, respectively. 
There are limited data available on the elimination of other CDD congeners in humans.  In the Flesch-Janys 
et al. (1996) study of 48 workers at a German pesticide facility, elimination half times were estimated for 
several CDD congeners. The estimated half-lives were 15.7 years for 1,2,3,7,8-PeCDD, 8.4 years for 
1,2,3,4,7,8-HxCDD, 13.1 years for 1,2,3,6,7,8-HxCDD, 4.9 years for 1,2,3,7,8,9-HxCDD, 3.7 years for 
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1,2,3,4,6,7,8-HpCDD, and 6.7 years for OCDD.  In a study of six German workers with high CDD/CDF 
body burdens, elimination half-lives corrected for alterations in body weight ranged from 3.5 years for 
1,2,3,4,6,7,8-HpCDF to 7.9 years for 2,3,7,8-TCDD and 15 years for 1,2,3,4,7,8-HxCDD (Rohde et al. 
1997). In the same study, half-lives for elimination due only to fecal excretion ranged from 10 years for 
OCDD to 22 years for 2,3,7,8-TCDD and 27 years for 1,2,3,7,8-PeCDD.  The half-lives for 2,3,4,7,8­
PeCDF in humans exposed to contaminated rice oil in the Yusho incident range from 2 to 30 years, and 
were inversely dependent on adipose tissue concentrations above approximately 10 ng/kg body weight (i.e., 
the higher the body burden, the faster the elimination) (Ryan et al. 1993a). 
Elimination of CDDs through lactation is discussed in Section 2.3.4.4. 
2.3.4.1 Inhalation Exposure 
In male Fischer 344 rats administered a single intratracheal dose of 0.32 µg labeled 2,3,7,8-TCDD/kg, feces 
was the major route of excretion over a 3-day period after dosing (Diliberto et al. 1996).  The cumulative 
excretion of 26.3% of the administered dose was observed over 3 days following exposure.  Approximately 
4% of the dose was excreted in the feces on day 3.  The cumulative urinary excretion was only 1.3% of the 
administered dose. 
2.3.4.2 Oral Exposure 
The half-life for elimination of a single oral dose of 0.00114 µg/kg 3H 2,3,7,8-TCDD in a human volunteer 
was calculated as 5.8 years (Poiger and Schlatter 1986).  The excretion in feces was high during the first 
few days (up to day 6) probably because of elimination of unabsorbed material.  During these first few 
days, about 12% of the administered dose was excreted.  However, during days 7–125 only about 3.5% of 
the administered dose was eliminated.  Urinary levels of radioactivity did not exceed the background levels. 
Studies in animals indicated that elimination of 2,3,7,8-TCDD is a relatively slow process.  However, the 
results showed a great variability among species.  The half-life for 2,3,7,8-TCDD elimination was 
14.95 days in Syrian hamsters (Olson et al. 1980b), 12 and 14 days in male and female Sprague-Dawley 
rats, respectively (Fries and Marrow 1975), 17 days in male Sprague-Dawley rats in another study (Piper et 
al. 1973), and 94 days in guinea pigs, the most sensitive species to the acute toxicity of 2,3,7,8-TCDD 
(Olson 1986). In contrast, the elimination half-life was 391 days in monkeys chronically exposed to low 
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doses of 2,3,7,8-TCDD in the feed (Bowman et al. 1989b).  A similar half-life of about 1 year was observed 
in monkeys after a single-dose exposure (McNulty et al. 1982).  In addition, studies of 2,3,7,8-TCDD half-
life in highly exposed rats (Abraham et al. 1988), rhesus monkeys (McNulty et al. 1982) and marmoset 
monkeys showed that rates of excretion decreased with dose. 
The clearance of radioactivity after oral exposure to labeled 2,3,7,8-TCDD followed first-order kinetics in 
most studies.  Fecal elimination was the major route, though excretion in the urine, expired air, and milk 
was also reported. 
When Sprague-Dawley rats were given radioactively labeled 2,3,7,8-TCDD, a total of 53% of the 
administered radioactivity was excreted by feces in the first 21 days (Piper et al. 1973).  Elimination of 
2,3,7,8-TCDD-derived radioactivity in urine and expired air was 13 and 3% of the administered dose, 
respectively.  Thirty-two percent of a single gavage dose of 0.32 µg of 2,3,7,8-TCDD/kg was eliminated in 
the feces of male Fischer 344 rats over a 3-day period after dosing (Diliberto et al. 1996).  Only 1.4% of the 
administered dose was excreted in the urine over the same period.  About 20–30% of the total oral 
2,3,7,8-TCDD dose was eliminated in the bile of cholecystectomized and cannulated dogs (Poiger et al. 
1982). In addition, excretion of unchanged 2,3,7,8-TCDD in milk was demonstrated in NMRI mice (Nau et 
al. 1986) and in monkeys (Bowman et al. 1989b), after oral exposure. 
Of the other congeners, several have been studied. An elimination half-life of 29.5 days was estimated for 
1,2,3,7,8-PCDD in Sprague-Dawley rats following a single oral exposure (Wacker et al. 1986).  OCDD was 
more persistent in Fischer 344 rats with an estimated elimination half-life of 3–5 months following 10 daily 
oral doses (Birnbaum and Couture 1988).  These congeners were excreted primarily in the feces following 
biliary elimination as metabolites (1,2,3,7,8-PCDD, at least three phenolic metabolites) or parent 
compound.  A 13-week dosing study in which Sprague-Dawley rats were administered various mixtures of 
CDDs estimated liver half-lives of 14.5, 29.3, 45.6, and 100 days for 2,3,7,8-TCDD, 1,2,3,7,8-PCDD, 
1,2,3,4,7,8-HxCDD, and 1,2,3,4,6,7,8-HpCDD, respectively (Viluksela et al. 1998a). 
2.3.4.3 Dermal Exposure 
Within 120 hours after dermal administration of 0.32 µg/kg 2,3,7,8-TCDD to the clipped back skin of male 
Fischer 344 rats, 4% of the administered dose was excreted in the feces and <1% was excreted in the urine 
(Banks and Birnbaum 1991).  The rate of 2,3,7,8-TCDD elimination significantly increased over time. 
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2.3.4.4 Transfer of CDDs Through the Placenta and Breast Milk 
CDDs are lipophilic compounds which can concentrate in maternal milk.  Therefore, lactation provides an 
efficient mechanism for decreasing the body burden of these compounds (Schecter and Gasiewicz 1987a). 
CDD levels in breast milk samples from 193 German women ranged from 2.5 to 47 ng TEQ/kg milk fat 
(mean of 13 ng/kg) (Fürst et al. 1989b).  More than 50% of the total CDDs detected in samples was 
represented by OCDD, which was detected at a mean concentration of 195 ng/kg milk fat (range, 
13–664 ng/kg). The amounts of other congeners in human milk decreased with decreasing chlorination; the 
mean concentration of 2,3,7,8-TCDD in milk fat was 2.9 ng/kg (range, <1–7.9 ng/kg).  A more recent 
analysis of 526 individual milk samples from the German general population revealed a mean 
2,3,7,8-TCDD concentration of 3.2 ng/kg milk fat (Fürst et al. 1994).  The analysis also showed the 
presence of only 2,3,7,8-chlorine-substituted CDD congeners.  OCDD was the most concentrated congener 
with a mean level of 208 ng/kg milk fat.  In general, the levels in milk decreased with decreasing degree of 
chlorination from octa- to tetra-CDD.  Schecter and coworkers have published information on levels of 
dioxins in human breast milk from various countries (Schecter et al. 1989d, 1989e) (see also Section 2.6.1). 
In general, milk samples from industrial countries had higher CDD levels than those from less developed 
countries. Representative mean levels of CDDs in samples of human breast milk from various countries are 
presented in Table 2-6. 
Fürst et al. (1989b) also found that the levels of CDDs found in the milk of mothers breast-feeding their 
second child were about 20–30% lower than in those breast-feeding their first child.  It was further noted 
that the highest excretion of CDDs was during the first few weeks after delivery.  The sharpest decline was 
observed with OCDD; its excretion was reduced by half between the 1st and 5th week of lactation.  In 
contrast, there was no significant decline in total HxCDDs in milk during the first year of lactation.  The 
concentration of 1,2,3,4,6,7,8-HpCDD in milk fat showed a steady decline over the 1-year period, but its 
levels stayed relatively high.  2,3,7,8-TCDD represented the smallest portion of the total CDDs, and its 
levels in milk continuously declined over the year of lactation.  Levels of 2,3,7,8-TCDD, 1,2,3,7,8-PeCDD, 
1,2,3,4,7,8- and 1,2,3,6,7,8-HxCDD, 1,2,3,4,6,7,8-HpCDD, and OCDD were measured in a mother of twins 
prior to nursing and after 2 years of nursing (Schecter et al. 1996a).  There was a 49.5% decrease in the total 
amount of CDDs in the lipid fraction of the breast milk.  2,3,7,8-TCDD had the largest percent decline in 
CDD levels, a decrease of 83.9%. A 52.4% decrease in maternal serum lipid levels of total CDD was also 
observed; the largest percent decline was an 86.8% decline in 1,2,3,7,8-PeCDD levels.  
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Several studies have shown that CDDs in breast milk are readily absorbed by nursing infants.  In a 
19-week-old nursing infant, absorption was estimated as the difference between ingestion and the amount of 
CDDs found in the feces over a period of 12 days (McLachlan 1993).  The mother was 32 years old and 
nursing for the first time.  Several CDD congeners were determined in the milk: 2,3,7,8-TCDD, 1,2,3,7,8­
PeCDD, three hexacloro-substituted congeners, 1,2,3,4,6,7,8-HpCDD, and OCDD.  The percentage of dose 
absorbed ranged from 90 to 95% except for the hepta-substituted congeners and OCDD which exhibited 
absorption rates of 61 and 23%, respectively.  The percentage of the dose absorbed increased slightly if 
corrections were made for background levels in the diapers.  Similar results were reported by Pluim et al. 
(1993b) who measured the amount of CDDs consumed via breast milk and excreted in the feces in 3 infants 
at the ages of 4, 8, and 12 weeks. Because of the high content of CDDs of the diapers relative to the feces, 
the percentage of dose absorbed was not determined.  However, the results showed that, with the exception 
of OCDD, the bioavailability from breast milk was greater than 95%.  At 4 weeks of age, the average 
cumulative intake of CDDs from breast milk was 132.1 pg TEQ per kg body weight.  Of these, 37.4 
corresponded to 2,3,7,8-TCDD, 46.2 to 1,2,3,7,8-PCDD, and 24.4 to 1,2,3,6,7,8-HxCDD. With the 
inclusion of CDFs, the total TEQ at 4 weeks was approximately 257 pg/kg body weight.  Exposure to 
CDDs and CDFs from lactation decreased at 8 and 12 weeks mainly due to a decrease in their concentration 
in whole breast milk which resulted from a reduced fat content of the milk (the depletion of body burden of 
the mother while nursing may have also contributed).  Abraham et al. (1994, 1996) and Dahl et al. (1995) 
also reported almost complete absorption of lower chlorinated CDDs and CDFs in breast-fed infants during 
the first year of life.  It was also noticed that intake of CDDs and CDFs was up to 50 times higher in breast-
fed infants compared with a formula-fed infant (Abraham et al. 1996).  The latter study further showed that 
despite much lower intake of CDDs and CDFs after weaning, the concentration of these compounds in stool 
fat did not decrease substantially, suggesting that concentration in fecal fat more or less reflect that in body 
fat. Also, at 11 months of age, TEQ concentrations in blood from formula-fed infants were less than 25% 
of maternal values and about 10 times lower than in infants breast-fed for 6-7 months (Abraham et al. 
1996). 
Schecter et al. (1996b) recently presented data on the levels of CDDs and CDFs in human fetuses 
(8–14 weeks gestational age with placenta removed) and in placentas from women from the general 
population who had normal deliveries.  On a lipid basis, the total TEQs (CDDs plus CDFs) in a pool of 14 
placentas was 10.1 ng/kg; half this amount (5.3 ng/kg) was measured in a pool of 10 fetuses.  In an 
analysis of 43 samples of human milk, Schecter et al. (1996b) found that the total concentration of CDDs 
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the pooled fetal tissue was 0.034 ng/kg body weight; for pooled placentas, they calculated a total TEQ of 
0.086 ng/kg wet weight. These results suggest that the transfer of CDDs to the fetus may be somewhat 
limited.  
The influence of maternal transfer (placental and via breast milk) of CDDs/CDFs on the body burden of 
newborns and infants was further investigated by Kreuzer et al. (1997).  These investigators also 
developed a pharmacokinetic model for 2,3,7,8-TCDD that allowed them to simulate body and tissue 
burden for the entire human lifetime as a function of 2,3,7,8-TCDD uptake from contaminated nutrition. 
On a lipid basis, the concentrations of 2,3,7,8-TCDD in adipose tissue and liver of breast-fed infants who 
died of sudden infant death syndrome were 0.4–4 ppt and 0.5–4 ppt, respectively.  The corresponding 
values in nonbreast-fed infants were 0.2–0.8 ppt and 0.3–0.7 ppt.  Similar values were detected in adipose 
tissue and livers of three stillborns, confirming the placental transfer of these chemicals to the fetus.  The 
model developed by Kreuzer et al. (1997) reflected sex- and age-dependent changes in body weight, 
volumes of liver, adipose and muscle tissue, food consumption, and excretion of feces and was used to 
predict the half-life of elimination of 2,3,7,8-TCDD and its concentrations in adipose tissue, blood, liver, 
and feces at different ages. Also, the influence of breast-feeding on the 2,3,7,8-TCDD burden of the 
mother, her milk, and her child was simulated.  The authors used their own data, as well as those from 
others, to validate the model.  For nonbreast-fed infants, the model predicted a decrease in the 
concentration of 2,3,7,8,-TCDD in lipids during the first year, and this was supported by the empirical 
data. For infants exclusively breast-fed, the model predicted an increase in 2,3,7,8-TCDD burden 
followed by a decrease after weaning, and this was also confirmed by the measured data.  Model 
validation of 2,3,7,8-TCDD concentrations in liver for the 20 infants investigated and in adipose tissue, 
blood, and feces for data in infants published by others showed good agreement between the simulated 
and experimental values.  Since one of the model’s assumption was that the concentration of 
2,3,7,8-TCDD in fecal lipids reflected the concentration in lipids of the organism, the good correlation 
between predicted and empirical data validated the assumption.  Under the assumption that the 
2,3,7,8-TCDD concentration in lipids of breast milk equals the concentration in the maternal organism, 
the model predicted a value of 2.23 ng 2,3,7,8-TCDD/kg lipids for the beginning of the nursing period. 
The model further predicted that the concentration of 2,3,7,8-TCDD in milk decreases with duration of 
breast-feeding, such that after 6 months of daily nursing the concentration in milk and maternal body 
lipids is approximately 70% of the value at the time of delivery.  These predictions were in good 
agreement with published values.  Lastly, the investigators modeled the concentration of 2,3,7,8-TCDD in 
lipids or blood of a male subject for a time span of 60 years and compared it with literature values for 
German subjects.  One of two curves constructed was computed assuming breast-feeding for the first 
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6 months of life followed by formula up to 1 year and the other considering feeding only formula for the 
same period of time.  In both cases further nutrition was simulated to consist of the common diet.  The 
predicted curves differed considerably during the first years of life.  For the nonbreast-fed case, 
2,3,7,8-TCDD concentrations decreased during the first year and subsequently increased, reaching a 
maximum at 16 years.  For the breast-fed case, the simulation yielded a rapid rise of 2,3,7,8-TCDD in 
lipids followed by a 3-year decrease after weaning and merging at about 7 years with the concentrations 
of nonbreast-fed individuals. Subsequently, 2,3,7,8-TCDD concentrations leveled at between 2 and 3 ng 
2,3,7,8-TCDD/kg body lipids until the end of life.  The latter value was in agreement with average 
background levels for the German population.  The half-life of nonmetabolic elimination (unchanged 
2,3,7,8-TCDD) was calculated to be 0.42 years in newborns and 9.5 years in 40-year-old adults.  The 
half-life of the fraction metabolized by the liver ranged from 1.5 years for newborns to approximately
10 years for a 40-year-old individual.  The three times greater elimination half-life for the metabolized 
fraction relative to the nonmetabolized fraction in infants suggests that metabolic elimination does not 
play a major role in the elimination of 2,3,7,8-TCDD in infants.  A key finding from the Kreuzer et al. 
(1997) study is the model prediction that the increased 2,3,7,8-TCDD burden observed as a result of 
breast-feeding does not lead to a raised lifetime value. 
In rodents, placental transfer of CDDs to the fetus is relatively limited, but transfer during sensitive 
periods of organogenesis is biologically important as evidenced by effects on fetuses or offspring 
exposed in utero. Excretion into milk represents a major pathway for maternal elimination of CDDs 
and, therefore, for exposure to offspring. In C57BL/6N mice administered a single oral dose of 30 µg 
14C-2,3,7,8-TCDD/kg on Gd 11 the levels of 2,3,7,8-TCDD-derived radioactivity in the embryos on 
Gd 12, 13, or 14 were below 0.5% of the total 2,3,7,8-TCDD dose (Weber and Birnbaum 1985).  In 
the dams, the highest concentration of radioactivity was in the liver (50–67% of total dose), whereas 
embryos had a relatively higher concentration of radioactivity in the heads than in the rest of the 
body.  Approximately 0.03% of the administered dose was delivered to each embryo.  In a different 
study in NMRI mice, pregnant females were administered a single dose of 25 µg 14C-2,3,7,8-TCDD 
(oral, intraperitoneal, or subcutaneous) on Gd 16 and the distribution of radioactivity was examined in 
the pups on postnatal days 7–36 (Nau et al. 1986).  At all times, the highest concentration of 
radioactivity in the pups (per gram of tissue) was found in the liver; extrahepatic tissues such as 
intestines and skin had a concentration of radioactivity that was approximately one order of 
magnitude lower than the liver.  During the first postnatal week, 2,3,7,8-TCDD concentrations 
increased considerably in the pups.  It was also found that during the first two weeks the pups 
received doses of 2,3,7,8-TCDD through milk which were, on a body weight basis, similar to those 
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which had been administered to their mothers prior to birth.  In pups raised by untreated foster 
mothers, 2,3,7,8-TCDD tissue concentrations decreased rapidly due to organ growth with 
concomitant dilution of 2,3,7,8-TCDD.  Abbott et al. (1996) examined the distribution of 
2,3,7,8-TCDD in embryonic tissues of mice at times earlier than previous studies.  Pregnant mice 
were treated with 2,3,7,8-TCDD on Gd 12 and embryonic tissues were examined at various times 
from 0.5 to 24 hours after dosing.  The rate of accumulation of 2,3,7,8-TCDD reached a maximum in 
placental tissue in about 3 hours and, following a slight decline, remained relatively constant between 
8 and 24 hours. After 24 hours, 0.27% of the maternal dose was detected in the placenta.  In 
embryonic liver, 2,3,7,8-TCDD peaked approximately 8 hours after dosing and decreased thereafter, 
as opposed to maternal liver, where it remained constant after achieving an apparent maximum. The 
relative decrease in the rate of concentration in the embryonic liver was attributed to a rapid growth of 
the tissue during that time period.  Distribution of 2,3,7,8-TCDD to embryonic palates followed a 
pattern similar to that in embryonic liver.  Twenty-four hours after dosing, the secondary palates had 
0.0045% of the administered maternal dose. 
Van den Berg et al. (1987b) examined the transfer of CDDs and CDFs through the placenta and via the 
milk in Wistar rats.  Prenatal exposure of the fetus was studied by administering a diet containing a fly 
ash extract from a municipal incinerator to rats from day 8 until 17 of pregnancy, after which time the rats 
were sacrificed. Postnatal transfer was assessed in rats fed the same diet during the first 10 days after 
delivery while nursing their offspring.  Of the 49 tetra- to octa-CDDs, only 7 CDD congeners were 
detected and all had a 2,3,7,8-chlorine-substitution pattern.  In the fetus, 2,3,7,8-TCDD had the highest 
retention (0.13% of total dose, 0.0092% of the dose/g).  Retention decreased with the number of chlorine 
atoms; HpCDDs and OCDD were not detected.  In the liver of offspring, 2,3,7,8-TCDD, 1,2,3,7,8-PCDD, 
and the three 2,3,7,8-substituted HxCDDs had the highest retention (5.3–8.1% of total dose, 0.74–1.13% 
of dose/g). The 2,3,7,8-penta- and hexa-substituted congeners had the highest retention in the livers of 
pregnant and lactating rats (53.9–80.2% of total dose, 2.9–5.2% of dose/g).  No significant differences 
were found in liver retention of tetra- to octa-chlorinated congeners between pregnant and lactating rats, 
but lactating females stored less CDDs in their adipose tissue.  Similar results were reported by Li et al. 
(1995c) in Sprague-Dawley rats.  These authors administered a single intravenous dose of 5.6 µg 14C­
2,3,7,8-TCDD/kg to pregnant rats on Gd 18. Sacrifices were conducted on Gd 19 and 20, and 
postnatal days 1 and 5.  Groups of neonates were also cross-fostered between treated and nontreated dams 
to differentially assess transfer of 2,3,7,8-TCDD through the placenta and through nursing.  Only about 
0.01% of the dose administered to the dams was found in whole livers of fetuses one and two days after 
dosing (0.04 and 0.07% of dose/g fetal liver), indicating limited placental transfer.  In contrast, the 
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concentration of 2,3,7,8-TCDD in the liver of neonates after 1 day of lactation was 0.65% of the 
administered dose/g liver, and this increased to 2.88% after 4 days of nursing.  Four days after nursing, 
the liver concentration of 2,3,7,8-TCDD in neonates from dams dosed 1 day after parturition was 4.1% of 
the administered dose/g of liver, and this was higher than in the dam’s liver (3.32%).  As in earlier 
studies, the results from the cross-fostering experiments confirmed that nursing is a major pathway for 
transfer of 2,3,7,8-TCDD to the offspring. 
The transfer of CDDs and CDFs via placenta and through milk was also investigated in a marmoset 
monkey administered a defined mixture of CDDs and CDFs subcutaneously 11 weeks prior to delivery 
(Hagenmaier et al. 1990).  Concentrations of CDDs and CDFs were measured in a newborn 1 day after 
birth and in an infant of the same litter after a period of 33 days of lactation.  The highest deposition in 
newborn liver was observed for 2,3,7,8-TCDD and 1,2,3,7,8-PCDD (54 and 51 pg/g wet weight, 
respectively) and corresponded to about 0.15% of the administered dose/g tissue.  The concentration of all 
other congeners was <10% of the corresponding concentrations in adults.  In contrast to liver, the 
concentrations of 2,3,7,8-substituted CDDs in newborn adipose tissue were at least one third the levels in 
adults, and for OCDD, the concentration in adipose tissue was three times higher that in adult adipose 
tissue. Transfer of CDDs through milk was considerable, though selective.  The concentration of 
2,3,7,8-TCDD and 1,2,3,7,8-PCDD in the infant’s liver was 395 and 611 pg/g wet tissue, respectively; the 
corresponding concentrations in the mother’s liver were 107 and 326 pg/g.  However, the concentration of 
OCDD in infant’s liver was less than 10% that of the mother’s liver.  Bowman et al. (1989b) examined 
the transfer of 2,3,7,8-TCDD from mother to offspring in rhesus monkeys.  Female monkeys had been 
exposed to 2,3,7,8-TCDD for about 4 years to a diet (5 or 25 ppt) that provided an estimated 
0.0001–0.0006 µg 2,3,7,8-TCDD/kg/day before breeding.  Breeding started 10 months after exposure 
ceased. At weaning (4 months), the offspring had a concentration of 2,3,7,8-TCDD in mesenteric fat 4.3 
times higher than in subcutaneous fat from their respective mothers.  Bowman et al. (1989b) estimated 
that the mothers excreted between 17 and 44% of their 2,3,7,8-TCDD burden by lactation.  Based on 
measurements of 2,3,7,8-TCDD in fat at 4, 12, and 24 months of age, it was found that in the young 
monkeys the decline in 2,3,7,8-TCDD in fat followed first-order, single-compartment kinetics with a half-
life of approximately 181 days (Bowman et al. 1990).  For the purpose of comparison, the mean half-life 
in 7 adult female rhesus monkeys was 391 days with standard error of 88 days (Bowman et al. 1989b). 
In summary, CDDs can be transferred to the fetus across the placenta and, although the amounts may be 
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organogenesis. Due to their lipophilicity, CDDs can concentrate in human breast milk and can be 
transferred to infants through nursing. In general, the amount of individual congeners in breast milk 
decreases as chlorination decreases. Excretion via milk is highest during the first weeks after delivery.
Also, the concentration of CDDs in milk is higher in mothers breast-feeding their first child than in those 
breast-feeding their second child. CDDs transferred to infants through nursing are readily absorbed by 
the infants. A pharmacokinetic model predicted that the increased body burden in infants that results 
from breast-feeding does not translate into raised lifetime body burden.  Studies in animals have also 
shown transfer of CDDs across the placenta and via mother’s milk. 
2.3.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and 
disposition of chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994). PBPK models are also called biologically based tissue dosimetry 
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of 
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points. 
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target 
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen et al. 
1987; Andersen and Krishnan 1994). These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from 
route to route, between species, and between subpopulations within a species. The biological basis of 
PBPK models results in more meaningful extrapolations than those generated with the more conventional 
use of uncertainty factors. 
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model 
representation, (2) model parametrization, (3) model simulation, and (4) model validation (Krishnan and 
Andersen 1994). In the early 1990s, validated PBPK models were developed for a number of 
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993). PBPK models for a particular  substance require estimates of the chemical substance­
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specific physicochemical parameters, and species-specific physiological and biological parameters.  The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes. Solving these differential and algebraic equations 
provides the predictions of tissue dose. Computers then provide process simulations based on these 
solutions. 
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems.  If the uptake and disposition of the chemical substance(s) is 
adequately described, however, this simplification is desirable because data are often unavailable for many 
biological processes. A simplified scheme reduces the magnitude of cumulative uncertainty.  The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of 
PBPK models in risk assessment. 
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the 
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994). 
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in humans 
who are exposed to environmental levels (for example, levels that might occur at hazardous waste sites) 
based on the results of studies where doses were higher or were administered in different species. 
Figure 2-4 shows a conceptualized representation of a PBPK model. 
If PBPK models for CDDs exist, the overall results and individual models are discussed in this section in 
terms of their use in risk assessment, tissue dosimetry, and dose, route, and species extrapolations. 
PBPK models for 2,3,7,8-TCDD are discussed below.  The pharmacokinetic behavior of  2,3,7,8-TCDD, 
especially distribution, has been shown to be dose-dependent and involves protein binding and enzyme 
induction in hepatic tissue. Thus, terms describing these interactions have been included in the animal 
models described below.  Furthermore, since induction of these dioxin-binding proteins is a process 
mediated by the interaction of a dioxin-receptor (the Ah receptor) complex with specific binding sites on 
DNA additional terms were included in the models.  For a detailed explanation regarding the Ah receptor 
and its involvement in the mechanism of action of 2,3,7,8-TCDD and structurally related halogenated 
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2.3.5.1 Summary of PBPK Models. 
The elimination of 2,3,7,8-TCDD from humans was evaluated using a PBPK model developed by Kissel 
and Robarge (1988). The steady-state adipose tissue concentration predicted by the model was similar to 
the lipid-based blood levels reported in the general population with no known special exposure to 
2,3,7,8-TCDD. The model was also used to predict elimination of 2,3,7,8-TCDD from Ranch Hand 
Vietnam veterans.  The predicted half-lives were similar to an experimental value based on analysis of 
2,3,7,8-TCDD in blood of veterans with adipose burdens >10 ppt.  The apparent half-lives increased as the 
adipose tissue concentration approached the steady-state level associated with background exposure.  The 
model also predicted reasonably well the elimination of 2,3,7,8-TCDD from a volunteer who ingested a 
single 2,3,7,8-TCDD dose. 
Leung et al. (1988) developed a five compartment  PBPK model to describe the time course of 
2,3,7,8-TCDD distribution in tissues of both the Ah-responsive C57BL/6J and Ah-less responsive DBA/2J 
mice (C57BL/6J mice respond to 2,3,7,8-TCDD with an increase in AHH activity, at a dose less than 
required to elicit this response in DBA/2J mice). The model also included binding in blood and two hepatic 
sites, one in the cytosol and the other in microsomes.  It was found that the greater accumulation of 
2,3,7,8-TCDD in the liver of C57BL/6J mice, relative to DBA/2J mice, was not attributed to the greater fat 
content in the DBA/2J mice, but to the more avid microsomal binding (CYP1A2) in the liver of the 
C57BL/6J mice.  In the concentration range covered in the model simulations, the cytosolic receptor (Ah 
receptor) did not seem to play a major role in determining the overall tissue distribution pattern. 
The same group of investigators (Leung et al. 1990b) developed a PBPK model to describe the tissue 
disposition of 2,3,7,8-TCDD in Sprague-Dawley rats.  The description included the same compartments 
used in modeling the behavior of 2,3,7,8-TCDD in mice. The ratio of liver to fat concentration of 
2,3,7,8-TCDD was found to be primarily determined by the dissociation constant of the microsomal 
binding protein (CYP1A2) and the basal and induced concentration of this protein in the liver.  In general, 
there was agreement between the simulated data and experimental data from a single-dose study and a 7­
and 13-week repeated-dosing study.  However, the model underpredicted the concentration of 
2,3,7,8-TCDD in the fat at low dose and overestimated the concentration at high dose for a 2-year feeding 
study.  Induction of microsomal binding protein was necessary to account for the differences in disposition 
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Wang et al. (1997) and Santostefano et al. (1998) and included analyses of distribution and responses to 
2,3,7,8-TCDD exposure at early times and in multiple tissues. 
A receptor-mediated PBPK model was developed by Andersen et al. (1993).  The model included 
interactions of the Ah-TCDD complex with DNA and was used to examine the tissue disposition of 
2,3,7,8-TCDD and the induction of the dioxin-binding protein (presumably CYP1A2) and CYP1A1.  It 
was found that tumor promotion correlated more closely with predicted induction of CYP1A1 than with 
induction of the hepatic binding proteins (CYP1A2, AhR).  More recently, Andersen et al. (1997a, 1997b) 
developed a multicompartment geometric model of the liver that provided a better prediction of both total 
and regional induction of CYP450 proteins within the liver than conventional one-compartment models. 
A mechanistic model (known as the NIEHS model) was constructed to describe 2,3,7,8-TCDD-mediated 
alterations in hepatic proteins in the rat (Kohn et al. 1993).  This model included the tissue distribution of 
2,3,7,8-TCDD and its effects on concentrations of CYP1A2 and CYP1A1 and the effects of 2,3,7,8-TCDD 
on the Ah, estrogen, and epidermal growth factor (EGF) receptors over a wide range of 2,3,7,8-TCDD 
doses. The model predictions were compared to experimental data from 2,3,7,8-TCDD promotion studies. 
The biochemical response curves for the proteins examined were hyperbolic, indicating a proportional 
relationship between target-tissue dose and protein concentration at low 2,3,7,8-TCDD doses.  Also, the 
model successfully reproduced the observed tissue distribution of 2,3,7,8-TCDD, the concentration of 
CYP1A2 and CYP1A1, and the effects of 2,3,7,8-TCDD on the Ah, estrogen, and EGF receptors over a 
wide dose range. 
Carrier et al. (1995a) developed a model that describes the distribution kinetics of 2,3,7,8-TCDD and 
related chemicals (with chlorine substitutions in positions 2,3,7, and 8) in various mammalian species, 
including humans.  Their model takes into account cellular diffusion, binding of the chemicals with the Ah 
receptor and with proteins, and enzyme induction in the liver.  The model was used to describe the 
distribution of CDDs between liver and adipose tissue as a function of overall body concentration.  Model 
simulations showed that the fractions of the body burden contained in the liver and adipose tissue vary 
nonlinearly as a function of the overall body concentration; this was in agreement with published data in 
rodents, monkeys and humans.  The authors further modeled  the disposition kinetics of CDDs in liver, 
adipose tissue, and whole body as a function of time (Carrier et al. 1995b).  The results showed that the 
rate of change in CDD tissue concentrations varies as a function of total body burden such that whole body
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elimination rate decreases as body burden decreases, suggesting nonlinear disposition kinetics.  This was 
also in agreement with published data on absorption and elimination kinetics of CDDs in rats and humans. 
2.3.5.2 Comparison of  PBPK Models for 2,3,7,8-TCDD. 
Several models that describe the disposition of 2,3,7,8-TCDD in animals and one in humans were 
identified from the literature.  In the Leung et al. (1988, 1990b) models in mice and rats, tissue 
2,3,7,8-TCDD concentration ratios, particularly liver concentrations, were related both to intrinsic 
partitioning and to the presence of specific cytosolic and microsomal 2,3,7,8-TCDD-binding proteins. 
This is in contrast to other PBPK models developed for similar, persistent lipophilic chemicals, which 
distributed the chemicals between organs based on experimentally observed concentrations ratios under 
various dosing conditions. This could explain why two organs having the same partition coefficients 
contain very different 2,3,7,8-TCDD concentrations under a particular experimental condition.  Carrier et 
al. (1995a, 1995b) developed a similar model, which also included other 2,3,7,8-substituted dioxins and 
furans and simulated experimental data on rodents, monkeys, and humans.  The Andersen et al. (1993) 
model extended the Leung et al. (1988, 1990b) models by including induction of binding proteins/enzymes 
and of 2,3,7,8-TCDD metabolism in response to ternary interactions of 2,3,7,8-TCDD, the Ah receptor, 
and DNA binding sites and correlated various tissue dose measures with the promotional efficacy of 
2,3,7,8-TCDD. The five-compartment liver model described by Andersen et al. (1997a, 1997b) provided a 
better description of mRNA production and regional localization of induced proteins, consistent with 
immunohistochemical information, than conventional one-compartment models.  The model constructed 
by Kohn et al. (1993) suggested possible biochemical mechanisms which could explain a complex 
response to exposure to 2,3,7,8-TCDD such as cell proliferation in female rats.  This model not only 
included enzyme induction and the Ah receptor, but also the estrogen and EGF receptors, all of which 
seem to be involved in a complex sequence of events that lead to cell proliferation as a result of 
2,3,7,8-TCDD exposure. In contrast with the models developed for animals and described above, the 
Kissel and Robarge (1988) fugacity-based model for humans was used to predict vehicle-dependent uptake 
and elimination of 2,3,7,8-TCDD without including any Ah receptor-related terms. (Fugacity is defined as 
the “escaping tendency” of a substance in a phase.)  Pharmacokinetic parameters used in the various 
models are listed in Table 2-7. 
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2.3.5.3 TCDD Models 
The Kissel and Robarge Model
Description of the Model. The elimination of 2,3,7,8-TCDD from humans was described with a 
fugacity-based model using physiologically based parameters (Kissel and Robarge 1988).  In this model, 
transport of 2,3,7,8-TCDD was assumed to be perfusion-limited (flow-limited) and 2,3,7,8-TCDD was 
assumed to be uniformly distributed within each tissue group or fluid phase, and tissue levels were 
considered to be in equilibrium with exiting fluids (blood, urine, bile).  Because 2,3,7,8-TCDD appears to 
be poorly metabolized in humans, the model did not include terms for metabolites.  Transport between gut 
lumen and gut tissue was described as a diffusive process.  Included in the differential equations used to 
solve the system were data for several diets.  Body compartment sizes and densities used in the simulations 
of background exposure and of elimination from individuals with body burdens similar to those of Ranch 
Hand veterans were based on reference-man data.  Tissue perfusion rates and partition coefficients were 
obtained from the literature.  The diet used in all simulations was adapted from the literature and also 
included a typical intake of added fats and oils.  The fugacity capacity of the various diet components, 
gastric secretions, and fecal materials were either calculated or obtained from the literature.  The model 
was used to predict tissue levels resulting from background exposures, elimination of 2,3,7,8-TCDD from 
Ranch Hand veterans, and elimination of 2,3,7,8-TCDD from a human volunteer. 
Validation and Discussion. The steady-state adipose tissue concentrations predicted by the model, 
assuming no metabolism and a daily background exposure of 50 pg/day in North America, was 7.7 ppt. 
This value was similar to the lipid-based blood tissue levels reported in the general population with no 
known unusual exposure. The body burden projected for an intake of 100 pg/day fell outside the typical 
range associated with background sources. In simulating the elimination of 2,3,7,8-TCDD from Ranch 
Hand veterans the model assumed a background exposure of 50 pg/day and no metabolism.  Under these 
conditions, apparent half-lives of 4.4, 5.2, 5.9, 7.2, 9.1, and 20 years were estimated for individuals with 
2,3,7,8-TCDD adipose tissue concentrations of 100, 50, 30, 20, 15, and 10 ppt, respectively.  This was in 
good agreement with a half-life of 7.1 years determined by analysis of blood lipids of veterans with adipose 
burdens >10 ppt (Pirkle et al. 1989). The results showed that the apparent half-lives increased greatly as 
tissue concentrations approached the steady-state level associated with background exposure.  The model 
also approximated the uptake efficiency and  elimination of 2,3,7,8-TCDD from a volunteer as reported by 
Poiger and Schlatter (1986). The fact that the predicted uptake efficiency was similar to that found 
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experimentally indicated that the estimated gut-lumen/gut-tissue mass transfer coefficient used was in the 
appropriate range. The reported half-life was 5.8 years and the model estimated a value of 6.7 years. 
Overall, the result suggested that a fugacity-based model can provide a viable method for describing overall 
elimination of 2,3,7,8-TCDD from humans, but it does not provide much insight regarding why elimination 
occurs in a particular manner. 
The Leung et al. Model in Mice
Description of the Model. The model described by Leung et al. (1988) in mice provides quantitative 
descriptions of the time-course of elimination and levels of 2,3,7,8-TCDD in various organs of C57BL/6J 
mice and DBA/2J mice, a less responsive strain with higher body-fat content.  The model contains five 
compartments: blood, liver, fat, richly perfused tissues, and slowly perfused tissues.  To account for the 
2,3,7,8-TCDD binding to receptor in the liver, the model contained two hepatic binding sites, one 
corresponding to the high affinity/low capacity cytosolic Ah receptor and the other to the inducible, low 
affinity/high capacity microsomal protein (CYP1A2).  To simulate the intraperitoneal dose route used by 
Gasiewicz et al. (1983a), 2,3,7,8-TCDD was assumed to be absorbed into the liver compartment by a first-
order uptake process. Bioavailability was assumed to be 100%. Partition coefficients, physiological 
parameters, and biochemical constants were obtained or calculated from the literature for each mouse strain. 
The kidney was assumed to be representative of the richly perfused tissue, whereas the slowly perfused 
tissue consisted mainly of muscle and skin.  The binding capacity of the Ah-less responsive DBA/2J mice 
was set to equal that of the Ah-responsive mice even though the binding affinity is extremely low.  Blood 
binding was described as a linear process with an effective equilibrium between bound and free 
2,3,7,8-TCDD given by a constant.  In blood, only one form of 2,3,7,8-TCDD is exchangeable in the 
tissues, which gives rise to kinetic behavior observed for diffusion-limited uptake into tissues.  
Validation and Discussion. The simulation of the time-course of 2,3,7,8-TCDD concentration in the 
liver and fat of C57BL/6J mice after a single 10 µg/kg intraperitoneal injection generated by the model 
was in good agreement with the empirical data of Gasiewicz et al. (1983a).  In trying to simulate the 
3-times-higher liver/fat ratio of 2,3,7,8-TCDD in the C57BL/6L mice than in the DBA/2J mice, Leung et 
al. (1988) varied the fat content parameter in the C57BL/6J mice from 3 to 12% of body weight.  The 
rationale was that the difference in hepatic concentration may have been due to greater capacity of the 
DBA/2J mouse to sequester the highly lipophilic 2,3,7,8-TCDD in adipose tissue.  However, the results 
showed that 2,3,7,8-TCDD concentration in the liver was relatively insensitive to body fat content, 
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indicating that this was not an important factor influencing the disposition of 2,3,7,8-TCDD in the liver 
between the two strains of mice.  The authors also found that the distribution of 2,3,7,8-TCDD was 
strongly influenced by the binding characteristics of the microsomal binding protein, especially the 
binding constant. The model gave good simulations of 2,3,7,8-TCDD excretion in both strains of mice. 
The simulation of the time-course of 2,3,7,8-TCDD concentration in the liver and fat of DBA/2J mice after 
a single 10 µg/kg intraperitoneal injection was not as good as that for the C57BL/6J mouse if the input was 
set to be consistent with the uptake and elimination.  As with the C57BL/6J mouse, disposition of 
2,3,7,8-TCDD in the liver of DBA/2J mice was greatly influenced by the microsomal protein binding 
constant and rather insensitive to changes in body fat content.  The best fit of the empirical data was 
obtained with a binding constant of 75 nM (20 nM for the C57BL/6J mice), indicating that the 2,3,7,8­
binding affinity to the hepatic microsomal protein in the DBA/2J mice was at least 3.5 times lower than 
that of the C57BL/6J mice. 
The Leung et al. Model in Rats
Description of the model. This model in the Sprague-Dawley rat (Leung et al. 1990b) is an 
extension of the mouse model previously described and contains the same five compartments and two 
types of binding proteins: one corresponding to the high-affinity, low-capacity cytosolic 2,3,7,8-TCDD 
(Ah) receptor, and the other to the inducible, lower-affinity, high-capacity microsomal protein (CYP1A2). 
In the rat model, both types of binding proteins are defined with their own binding capacities and 
dissociation constants. The model was used to analyze experimental data for the single-dose studies of 
McConnell et al. (1984) and Rose et al. (1976), the 7-week Rose et al. (1976) study, the 13-week multiple-
dose study of Kociba et al. (1978b), and the 2-year feeding study of Kociba et al. (1978a).  In simulating 
the single-dose gavage study, 2,3,7,8-TCDD was assumed to be absorbed from the gastrointestinal tract by 
a first-order uptake process with a rate constant of 0.2/hour.  In simulating the multidosing studies, 
bioavailability was assumed to be 100%.  Physiological parameters, partition coefficients, and biochemical 
constants were calculated or obtained from the literature.  Since there was no literature value for the 
binding capacity of the microsomal 2,3,7,8-TCDD-binding site in the rat, the value used was approximated 
by assuming it to be 10 times that of the mouse.  The total microsomal binding capacity was apportioned 
between a basal level and an induced level. Also, AHH activity was taken to be the sum of a basal and 
induced level. A first-order metabolic rate constant for 2,3,7,8-TCDD metabolism in the liver was 
adjusted to provide a biological half-life of about 25–30 days.  
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Validation and Discussion. When the simulation of the McConnell et al. (1984) data for AHH 
induction included a term for induction of microsomal binding protein there was good agreement between 
the simulation and the empirical data.  This had not been the case in an initial fitting which included a 
constant concentration of microsomal binding protein.  Rose et al. (1976) examined the accumulation of 
2,3,7,8-TCDD in adipose and liver tissues in rats administered 0.01, 0.1 and 1 µg 2,3,7,8-TCDD/kg/day 
5 days a week for 7 weeks; sampling was done at weeks 1, 3, and 7.  Model predictions of 2,3,7,8-TCDD 
concentrations were in good agreement with the experimental data except for concentration in fat at the 
0.01 µg/kg/day dose level, in which case the model overpredicted the tissue concentration.  Model 
formulations that had constant microsomal binding capacity overpredicted liver 2,3,7,8-TCDD 
concentrations at the lower-dose rates. Also, model formulations that contained final amounts of 
microsomal binding protein (CYP1A2) very different (much higher or lower) from the basal 200 
nmol/liver could not simulate 2,3,7,8-TCDD concentration in liver at the highest-dose rate.  Similar to the 
findings in mice, the liver/fat concentration ratio in rats was extremely sensitive to the dissociation 
constant of the microsomal binding protein.  The model simulated well the data from the 7- and 13-week 
studies (Rose et al. 1976; Kociba 1978b), but not as well for data from the 2-year feeding study (Kociba et 
al. 1978a). There was underprediction of 2,3,7,8-TCDD concentration in fat and liver at the low dose 
(0.001 µg/kg/day) and overprediction of the liver concentration at the high-dose level (0.1 µg/kg/day). 
However, the ratios of the concentrations were consistent with those observed experimentally (1/1 at low 
doses, much higher in liver at high doses).  According to Leung et al. (1990b), the underprediction at low 
dose may reflect the fact that the low-dose fat concentration in the 2-year study was close to the limit of 
detection and thus, subject to more error.  At the high dose, physiological parameters such as tissue 
volume, metabolic constants, and amounts of binding proteins may have been altered by weight loss and 
changes in body composition, known effects of chronic exposure to 2,3,7,8-TCDD.  Leung et al. (1990b) 
indicated that the overprediction at high dose could have been due to a loss of microsomal 2,3,7,8-TCDD­
binding sites in the chronically exposed rats.  The affinity of 2,3,7,8-TCDD for the microsomal binding 
protein appeared to be greater in the Sprague-Dawley rats than in C57BL/6J mice, which could account for 
the higher liver/fat concentration ratio in rats than in mice, assuming that the partitioning between tissues 
is approximately the same in the two species. 
Wang et al. (1997) extended the work of Leung et al. (1988, 1990b) and Andersen et al. (1993)  and 
developed an improved model to describe the disposition of 2,3,7,8-TCDD in multiple tissues from female 
Sprague-Dawley rats.  The model of Wang et al. (1997) improved previous modeling attempts in some 
specific areas such as 1) providing information on distribution of 2,3,7,8-TCDD at early time points 
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(important for determining unique parameters related to mass transfer such as permeability), 2) better 
handling of mass balance when considering 2,3,7,8-TCDD binding to plasma proteins, and 3) improved 
estimation of physical and biochemical parameters.  The Wang et al. (1997) model accurately described 
the time course distribution of 2,3,7,8-TCDD following a single oral dose, as well as the concentration of 
2,3,7,8-TCDD in eight target tissues on day 3 after six different doses.  The model described by Wang et 
al. (1997) was recently coupled to a biologically-based pharmacodynamic (BBPD) model to quantitatively 
describe the relationship between disposition and response in multiple tissues (Santostefano et al. 1998). 
This later model incorporated both pharmacokinetic and pharmacodynamic events to account for the 
ability to 2,3,7,8-TCDD to induce CYP1A1 and the fact that CYP1A2 is responsible for maintaining high 
concentrations of 2,3,7,8-TCDD in the liver. The results showed that the BBPD model accurately 
described the time course of CYP1A1 protein expression and EROD activity in the liver, skin, and 
kidneys.  It also confirmed that EROD activity can be an appropriate marker for CYP1A1 protein 
expression, and the shape of the induction curves supported the hypothesis that similar time-dependent 
mechanism of 2,3,7,8-TCDD-induced CYP1A1 protein expression and associated EROD activity occurs in 
multiple tissues.  This, in turn, suggested that parameter estimation in the study accurately described the 
Ah receptor-mediated mechanism on protein expression and enzymatic activities in multiple tissues. 
The Andersen et al. Model
Description of the Model. This model (Andersen et al. 1993) is an extension of the earlier PBPK 
models developed by Leung et al. (1988, 1990b) for 2,3,7,8-TCDD.  Like the earlier models, this model 
consists of five compartments.  Each of the four tissue compartments has a specified blood flow, tissue 
compartment volume, and a tissue blood volume.  Movement of chemical from blood to tissue was modeled 
to be proportional to the product of a permeation coefficient times surface area for the tissue.  When this 
product is lower that the specified blood flow for the tissue, tissue uptake is diffusion-limited.  Because of 
the diffusion-limited tissue compartments, the model did not require blood binding to match the time-course 
of tissue uptake. It was assumed that in the liver both the Ah receptor and the inducible binding protein act 
to sequester 2,3,7,8-TCDD through a capacity-limited binding process, and the binding protein was 
assumed to be CYP1A2.  Binding interactions with CYP1A2 and CYP1A1 were described by reversible 
equilibrium relationships, which is valid as long as the rate constants for association/dissociation are large. 
It was also assumed that the DNA sites to which the Ah-2,3,7,8-TCDD complex binds are present at much 
lower concentrations than the Ah-ligand complex.  For both CYP1A1 and CYP1A2 induction, it was 
assumed that the Ah-ligand complex formation was equivalent, but that the Hill term, n, (a measure of 
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interaction for multiple Ah-ligand complex binding sites) and the Hill binding constant were different for 
the two responses. The model also allowed for autoinduction of metabolism following 2,3,7,8-TCDD 
treatment.  Data from Abraham et al. (1988) and Krowke et al. (1989) were analyzed.  The former study 
provided dose-response characterization of concentrations of 2,3,7,8-TCDD in liver and of liver CYP1A1 
activity and time-course characterization of 2,3,7,8-TCDD concentration in tissues and enzyme activities in 
female Wistar rats.  Krowke et al. (1989) examined liver and fat concentrations in male Wistar rats dosed 
weekly for up to 6 months.  In addition, Andersen et al. (1993) examined the potential correlation between 
several measures of dose estimated by the model and the promotional efficacy and carcinogenicity of 
2,3,7,8-TCDD in Sprague-Dawley rats.  Cancer data from Kociba et al. (1978a) and Pitot et al. (1980) were 
analyzed. 
Validation and Discussion. Abraham et al. (1988) found that the disposition of 2,3,7,8-TCDD in 
liver and fat from rats administered a single subcutaneous dose (0.001–10 µg/kg) of the chemical was 
highly dose-dependent.  The disproportionately higher concentration in the liver at higher doses appeared 
to be due to induction of a dioxin-binding protein, presumably CYP1A2.  The model developed by 
Andersen et al. (1993) successfully simulated the experimental data.  The affinity of the binding protein 
was estimated to be 6.5 nmol, while a value of 1 for n suggested little interaction among 2,3,7,8-TCDD­
responsive DNA-binding sites involved in the expression of CYP1A2.  For describing induction of 
CYP1A1, an n of 2.3 was required, which suggested possible interactions among DNA-binding sites for 
the Ah-ligand complex with this gene.  The simulation of the time-course of elimination from liver and of 
induction of CYP1A1 was in good agreement with the empirical data, but required the inclusion of time-
dependent growth parameters over the 100 days of the experiment.  The model also successfully simulated 
the data from the repeated-dosing study by Krowke et al. (1989) after small adjustments were made to fat 
and slowly perfused tissue parameters.  The measures of dose that were used for comparison with the 
promotional and carcinogenic properties of 2,3,7,8-TCDD were integrated total liver concentration during 
the treatment period, or integrated free liver 2,3,7,8-TCDD concentration.  Also, measures of tissue dose 
related to enhanced expression of CYP1A1 and hepatic binding proteins were calculated and examined for 
correlation with promotional activity.  Results of the analysis revealed that under the exposure conditions, 
the tumor promotional response of 2,3,7,8-TCDD in the rat liver most closely correlated with integrated 
expression of the CYP1A1 gene. However, Andersen et al. (1993) indicate that since there is no 
expectation of causality between tumor responses and induction of CYP1A1 (or CYP1A2), the correlation 
should be regarded cautiously.  Consistent with the findings of Leung et al. (1988, 1990b), the results from
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the Andersen et al. (1993) study showed that over a certain dose range (e.g., at doses several fold above 
background), protein (CYP1A2) induction greatly alters 2,3,7,8-TCDD disposition. 
Recently, Andersen and co-workers developed a model of hepatic enzyme zonation that was combined 
with the PBPK model of protein induction (Andersen et al. 1993) to create a multicompartmental 
representation of the liver architecture that can be used to predict the degree of induction in both the whole 
liver and in specific regions (Andersen et al. 1997a, 1997b).  A geometric representation was used to 
divide functional units (based on enzyme distribution) within the liver into five zones.  The primary 
objective was to compare model predictions for regional induction with regional protein induction as 
visualized by immuno-histochemistry.  The data set modeled included analysis of tissue distribution of 
2,3,7,8-TCDD in the first days or weeks after a single dose, time course studies for about 100 days after a 
single dose, and initiation-promotion studies in rats dosed for up to 6 months.  The results showed that the 
five-compartment model was more successful than conventional homogeneous one-compartment liver 
models not only in simulating low-dose behavior for mRNA in whole liver but also in representing 
immunohistochemical observations.  Five or more compartments were required to give a sharp boundary 
between induced and noninduced regions of the liver.  When the five-compartment liver model was used 
to account for CYP1A1 and CYP1A2 induction and regional distribution of induced enzymes, the low-
dose behavior appeared to be nonlinear and was better described, with a large n value (Hill coefficient) and 
a range of affinities in the liver covering about 81-fold differences between centrilobular and periportal 
regions. 
The Kohn et al. (NIEHS) Model
Description of the Model. Kohn et al. (1993) constructed a mathematical model (the NIEHS model) 
to describe 2,3,7,8-TCDD tissue distribution and 2,3,7,8-TCDD-mediated alterations in hepatic proteins in 
the rat. The model assumed that 2,3,7,8-TCDD mediates increases in liver concentration of transforming 
growth factor-α (TGF-α) by a mechanism which requires the Ah receptor.  TGF-α subsequently binds to 
the EGF receptor, a process which is known to cause internalization of the receptor in hepatocytes.  This is 
thought to be an early event in the generation of a mitogenic signal.  The model included equations for the 
Ah receptor-dependent induction of CYP1A1 and CYP1A2 activity and of the Ah receptor itself.  Because 
it was also assumed that estrogen action is required for 2,3,7,8-TCDD-mediated induction of TGF-α, 
production of the estrogen receptor, CYP1A2-catalyzed formation of catechol estrogens, and deactivation 
of estrogens by glucuronidation were included in the model.  The model predictions were compared to the 
two-stage initiation-promotion data of Tritscher et al. (1992) and  Sewall et al. (1993). Gavage doses 
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equivalent to 3.5–125 ng 2,3,7,8-TCDD/kg/day for 30 weeks were used in these studies.  Data from 
Abraham et al. (1988) were also analyzed.  Model parameters were obtained from the literature or 
calculated from experimental data and adjusted to make the model reproduce the observations of Tritscher 
et al. (1992) and Sewall et al. (1993). 
Validation and Discussion. The model prediction for the percentage of absorption (>90%) from 
ingestion of 2,3,7,8-TCDD was in good agreement with experimental data of Rose et al. (1976).  The model 
also predicted that 92.2% of the metabolite appears in the feces and 7.8% in the urine at a dose of 
125 ng/kg/day.  The dose of 2,3,7,8-TCDD did not have a significant effect on these predictions.  From the 
fit to the data of Abraham et al. (1988), the model predicted an initial and overall half-time clearance from 
liver of 11.8 and 13.5 days, respectively, which is very close to the experimentally obtained 11.5 and 
13.6 days.  Similar good agreement was obtained for half-time elimination from fat (22.3 days versus 
24.5 days).  The model predicted a linear relationship between administered dose and the concentration of 
2,3,7,8-TCDD in the liver at doses between 3.5 and 125 ng/kg/day, which was in good agreement with the 
data of Tritscher et al. (1992). The relationship between 2,3,7,8-TCDD dose and induction of both 
CYP1A1 and CY1A2 was best fit by an hyperbolic curve suggesting lack of cooperative interactions among 
binding sites. The hyperbolic curve was consistent with the experimental data for induction of these 
proteins from Tritscher et al. (1992).  The model also predicted that the fractional occupancy of the Ah 
receptor by 2,3,7,8-TCDD rises from 13.4% at a dose of 3.5 ng/kg/day to 69.3% at 125 ng/kg/day.  The 
model prediction of the degree of internalization of the EGF receptor as a function of the concentration of 
TGF-α was also hyperbolic in shape and successfully reproduced the experimental data of Sewall et al. 
(1993). Kohn et al. (1993) indicate that as this response may be involved in the mechanism of 
tumorigenesis in 2,3,7,8-TCDD-treated rats, it would be expected that it would correlate with tumor 
incidence better than does tissue dose.  If so, extrapolation of effects at high dose to low doses may 
underestimate low-dose effects.  However, extrapolation from low dose to extremely low dose would still 
be valid. The model predicted that 10 days after administration of a single dose of 1 µg 2,3,7,8-TCDD/kg 
there should be a greater decrease in plasma membrane EGF receptor in female rat liver than in male rat 
liver, which is consistent with the observed lower sensitivity of the male.  Consistent with the experimental 
data, the model reproduced the decrease in hepatic estrogen receptor (ER) level resulting from exposure to 
2,3,7,8-TCDD, and the relationship between concentration of 2,3,7,8-TCDD and amount of receptor was 
also hyperbolic.  Overall, the model’s success in reproducing the observed responses to 2,3,7,8-TCDD for 
the various proteins included in the model supports the proposed mechanism that internalization of the EGF 
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receptor in response to induction of TGF-α may be the origin of the mitogenic signal important for 
carcinogenesis. 
The Carrier Model
Description of the Model. The first part of this model provides a quantitative description of the 
distribution of 2,3,7,8-substituted CDDs (and CDD-like compounds) between liver and adipose tissues as a 
function of overall body concentration at any given time (Carrier et al. 1995a).  In a second step, differential 
equations were used to describe the disposition of CDDs in liver, adipose tissues, and whole body as a 
function of time (Carrier et al. 1995b).  The first step of the model was based on several hypotheses: 1) 
changes in overall CDD concentration are slow relative to intertissue diffusion exchanges, protein 
induction, and binding of CDDs in the liver; 2) CDDs are mainly in adipose tissue and in the liver, but 
exchanges between these two sites are mediated via the blood; 3) the liver synthesizes proteins that bind 
free CDDs according to standard mass action association-dissociation mechanisms; 4) synthesis of binding 
proteins in the liver is linked to binding of free CDDs to the Ah receptor; 5) CDDs in fat deposits within the 
liver contribute to the overall liver burden and is taken into account; and 6) small amounts of CDDs are 
contained in organs other than the liver and adipose tissues and this fraction is assumed to be constant.  In 
the second step, CDDs were assumed to be eliminated mainly by hepatic clearance; elimination by lactation 
or transplacental distribution was not considered. Model simulations of various experimental data sets, as 
specified below, were conducted. When not readily available, anatomical and physicochemical parameters 
were obtained from laboratory or clinical data. 
Validation and Discussion. The model successfully simulated data from Abraham et al. (1988), who 
provided dose-response characterization of concentrations of 2,3,7,8-TCDD in the liver of rats after a single 
dose of the compound.  Analysis of the data showed that the higher the body burden, the higher the 
proportion of the burden contained in the liver. However, the model predicted that a plateau is reached 
when body burden is >1 mg 2,3,7,8-TCDD/kg body weight.  The model predictions were also in good 
agreement with experimental data from Van den Berg et al. (1986a), who administered a single dose of a 
mixture of CDDs and CDFs to rats and hamsters and with data in monkeys administered a single oral dose 
of 2,3,7,8-TCDD (McNulty et al. 1982).  Results from simulations conducted on data from chronic studies 
in rats (Kociba et al. 1978a; Rose et al. 1976) and on human data from Yusho patients also showed that 
increasing the body burden results in an increase in the fraction of the body burden present in the liver and 
in an increase in the liver/adipose concentration ratio.  These changes in fractional distributions were 
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attributed to the affinity of specific liver proteins for binding of  free hepatic CDDs and the saturable 
capacity of the binding proteins at high concentration of free CDDs.  Model simulations of elimination data 
in rats after single (Abraham et al. 1988) or repeated doses (Kociba et al. 1978a; Rose et al. 1976) of 
2,3,7,8-TCDD, as well as data from a Yu-Cheng patient agreed well with the empirical data and showed 
that disposition kinetics of 2,3,7,8-substituted CDDs are nonlinear (i.e., as body burden decreases with time, 
liver and adipose tissue half-lives increase). According to the model, an additional factor that can influence 
the disposition kinetics of 2,3,7,8-CDDs is a rapid change in body weight and/or adipose tissue mass.  A 
rapid loss of adipose tissue whether by dieting or in patients experiencing anorexia, would result in a higher 
concentration of the chemical in the remaining adipose tissue, particularly if the loss of tissue is much faster 
than whole body elimination via the liver.  
2.3.5.4 Risk Assessment. 
In early efforts to model the disposition of persistent halogenated aromatic hydrocarbons, disposition was 
described by simple partitioning between the blood and the various tissues with first-order metabolism in 
the liver. In those studies, the role that extensive tissue binding to particular cellular proteins might play in 
determining the overall disposition of the chemical was not accounted for.  In contrast, the descriptions of 
Leung et al. (1988, 1990b) and Carrier et al. (1995a, 1995b) attempted to provide a biochemical basis for 
the observed tissue distribution. The use of this type of model may help explain interspecies differences in 
2,3,7,8-TCDD sensitivity and carcinogenicity. The rodent PBPK model for 2,3,7,8-TCDD revealed very 
consistent behavior between species, and some of the predictions of high dose-low dose behavior were 
verified. 
One advantage of a description that explicitly includes protein binding is the ultimate ability to develop 
pharmacodynamic models for 2,3,7,8-TCDD (and related chemicals) toxicity based on Ah receptor 
occupancy or Ah-TCDD complex concentration in vivo and to realistically couple it with the biologically 
based cancer models (or with models for other 2,3,7,8-TCDD responses).  This was attempted by Andersen 
et al. (1993) and Kohn et al. (1993), who included estimates of binding constants between the Ah receptor 
and 2,3,7,8-TCDD and between the Ah receptor-dioxin complex and sites on DNA.  Santostefano et al. 
(1998) extended previous modeling attempts by determining parameter values based on time course of 
CYP1A1 and CYP1A2 responses in multiple tissues using a simultaneous PBPK and BBPD models. 
However, as noted by Andersen et al. (1993), in order to develop a complete biologically motivated risk-
assessment model, these dosimetry models need to be combined with quantitative descriptions of cell and 
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tissue responses. Kohn et al. (1993) used the NIEHS model to successfully predict tissue concentrations of 
2,3,7,8-TCDD and of various induced proteins involved in the carcinogenic response to 2,3,7,8-TCDD and 
suggested that such a model might permit extrapolation of responses beyond the range obtained from 
experimental data and lead to scientifically sound approaches for estimating risks of adverse health effects 
of exposure to 2,3,7,8-TCDD. The importance of the results of Kohn et al. (1993) can be illustrated by the 
finding that the dose-response curves for various proteins were hyperbolic rather than sigmoid. 
Sigmoidicity in the response requires a higher concentration to produce a given response at low dose than 
does a hyperbolic response having the same concentration for half-maximal effect.  This implies that the 
response is approximately linear at very low doses. 
2.4 MECHANISMS OF ACTION 
2.4.1 Pharmacokinetic Mechanisms 
The mechanism of absorption of CDDs by the inhalation and dermal routes of exposure is not known. 
Transfer of CDDs from the aqueous environment of the intestine across cell membranes is predominantly 
limited by molecular size and lipid solubility.  The overall evidence indicates that 2,3,7,8-substituted tetra-
and pentachlorinated congeners are well absorbed.  In contrast, OCDD was poorly absorbed from the 
gastrointestinal tract of rats (Birnbaum and Couture 1988), but absorbed more on chronic exposure 
(Birnbaum et al. 1989a).  Absorption is also vehicle-dependent (Poiger and Schlatter 1980).  Highly 
chlorinated congeners, although absorbed in small amounts, can accumulate in the liver.  Results from 
studies in thoracic duct-cannulated rats showed that 2,3,7,8-TCDD was transported primarily via the 
lymphatic route and was predominantly associated with chylomicrons (Lakshmanan et al. 1986).  Several 
studies have examined the distribution of CDDs between blood and adipose tissue.  Patterson et al. (1989d) 
showed that on a lipid basis the serum/adipose ratio for 2,3,7,8-TCDD in humans was approximately 1:1, 
and this correlation held over a concentration range of almost three orders of magnitude.  They also found 
that in blood <10% of 2,3,7,8-TCDD was associated with red blood cells, which according to Patterson et 
al. (1989d), suggested that most of 2,3,7,8-TCDD in blood was bound to serum lipids and lipoproteins. 
However, the distribution between plasma lipid and adipose tissue increased with chlorine substitution, 
which indicated that higher chlorinated congeners have a higher binding affinity for plasma proteins 
(Patterson et al. 1989d; Schecter et al. 1990). Experiments of in vivo binding of CDD congeners to various 
serum fractions revealed that as chlorine content increased, binding to lipoproteins gradually decreased, 
75% of 2,3,7,8-TCDD was found bound to lipoprotein compared to 45% for OCDD (Patterson et al. 
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1989b). However, binding to other proteins increased with chlorine content (20% for 2,3,7,8-TCDD versus 
50% for OCDD).  Also, fewer CDDs (<10%) were bound to the chylomicrons in serum.  In studies in vitro 
with human whole blood, 80% of the applied amount of 2,3,7,8-TCDD was associated with lipoproteins, 
15% with proteins, and 5% with cellular components (Henderson et al. 1988).  Also, there is some evidence 
that 2,3,7,8-TCDD and related stereoisomers may be associated with plasma prealbumin (McKinney et al. 
1985a; Pedersen et al. 1986). Within the lipoprotein fraction and per mole of lipoprotein, 2,3,7,8-TCDD 
has highest affinity for very low density lipoprotein (VLDL), followed by LDL and HDL (Marinovich et al. 
1983). A study using cultured human fibroblasts presented some evidence that specific binding to LDL and 
the LDL receptor pathway may explain in part the rapid early uptake of 2,3,7,8-TCDD with LDL entry 
(Weisiger et al. 1981). 
2,3,7,8-substituted CDDs are the predominant congeners retained in tissue and body fluids from 
rodents and monkeys (Abraham et al. 1989b; Van den Berg et al. 1983), although minor retention of 
non-2,3,7,8-substituted congeners has been reported in the rat (Abraham et al. 1989b).  In general, the 
tissue distribution of CDDs is congener-specific and depends on the dose and route of administration 
(see Van den Berg et al. 1994 for review). In rats, for any particular organ or tissue, distribution 
within 24 hours of dosing depends on blood perfusion rate and relative tissue size, such that relatively 
high initial CDD concentrations are found in the adrenal glands and skeletal muscle (Pohjanvirta et al. 
1990). Shortly thereafter, the liver and adipose tissue become the major storage sites (Allen et al. 
1975; Lakshmanan et al. 1986; Rose et al. 1976).  Data from studies in humans, marmoset monkeys 
and rats suggest that the distribution ratio between liver and adipose tissue increases with increasing 
degree of chlorination (Abraham et al. 1989c; Neubert et al. 1990a; Thoma et al. 1990), but also 
depends on the dose, metabolic rate, route of administration, and the time of observation after dosing. 
In non-human primates and in humans, the liver appears to be a less significant storage site than in 
rodents (Van Miller et al. 1976). In mice, the Ah receptor does not appear to play a significant role in 
2,3,7,8-TCDD body distribution for adipose tissue, skin, kidney, and total-body concentration 
(Birnbaum 1986).  However, it plays some role in liver retention (Birnbaum 1986; Gasiewicz et al. 
1983a) and this was found to be related to inducibility of cytochrome P-450 (Leung et al. 1988), in 
particular CYP1A2. Distribution of 2,3,7,8-TCDD in mice has been shown to be age-dependent 
(Pegram et al. 1995).  The greater fat content of some tissues in old mice enhances partitioning of 
2,3,7,8-TCDD into the tissues, while decreased perfusion prolongs clearance (Pegram et al. 1995). 
Some acute- and chronic-duration studies in rats have demonstrated a disproportionate dose-dependent 
distribution of 2,3,7,8-TCDD in liver and adipose tissue (Abraham et al. 1988; Kociba et al. 1978b). 
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dose-dependent distribution has also been demonstrated in mice (Diliberto et al. 1995). 
2,3,7,8-TCDD-derived radioactivity in the liver was found associated preferentially with the 
microsomal fraction (Allen et al. 1975).  Information summarized by Van den Berg et al. (1994) 
suggests that the disproportionately greater hepatic concentration of 2,3,7,8-TCDD after exposure to 
higher doses may be explained in part by the induction of a hepatic-binding species, CYP1A2.  This 
distribution parameter is also explained by the Carrier et al. (1995a,b) model in humans. 
There is some experimental data to suggest that the fetal/neonatal period may be more sensitive to the 
toxicity of CDDs than the adult animal.  Several studies have shown that limited placental transfer of 
CDDs takes place in rodents (Li et al. 1995c; Nau et al. 1986; Van den Berg et al. 1987b; Weber and 
Birnbaum 1985) and in humans (Schecter et al. 1996a).  However, little is known about the 
mechanisms responsible for the transfer of CDDs across the placenta, the dependence of these 
mechanisms on the gestational period, and the distribution of these compounds in fetal tissue. 
However, CDDs and related chemicals are able to concentrate in breast milk, and limited human 
(Abraham et al. 1994; McLachlan 1993; Pluim et al. 1993b) and animal (Nau et al. 1986) data have 
indicated considerable absorption of these compounds by the nursing infant.  Thus, while the in utero 
exposure of fetal tissues to CDDs may represent only a small percentage of the maternal body burden 
of CDDs, the breast-fed infants will receive a higher daily dose per body weight than adults.  Further 
information regarding placental transfer and elimination of CDDs through breast milk is presented in 
Section 2.3.4.4. 
As mentioned in Section 2.3.3, metabolic transformation of CDDs in vivo includes oxidation and 
reductive dechlorination as well as glutathione conjugation.  Studies in two rat strains which differ 
greatly in sensitivity to 2,3,7,8-TCDD did not provide evidence for a role of toxicokinetics and 
metabolism in the difference in sensitivity (Pohjanvirta et al. 1990).  Also, studies in various mice 
strains showed no significant Ah receptor-related differences in metabolic pathways (Gasiewicz et al. 
1983a). While in vitro studies have shown similarities between most species regarding metabolite 
profile, the rate of 2,3,7,8-TCDD metabolism and the number of metabolites were reduced in 
hepatocytes in suspension culture from guinea pigs, a highly sensitive species (Wroblewski and Olson 
1985). The overall evidence suggests that 2,3,7,8-TCDD can induce its own metabolism in vivo, but 
only at doses that could cause overt signs of toxicity (Van den Berg et al. 1994).  It is important to 
consider the possibility of autoinduction at high doses because data obtained with exposure levels 
associated with a significant induction of CYP1A1 and CYP1A2 may not necessarily reflect 
toxicokinetic behavior at low-exposure levels. 
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Elimination of 2,3,7,8-substituted CDDs occurs mainly via the bile and the feces as polar metabolites; 
much smaller amounts are excreted via the urine.  Moreover, in almost all mammalian species studied, 
the 2,3,7,8-TCDD-derived radioactivity in tissues is associated with the parent compound, suggesting 
that the hydroxylated and/or conjugated metabolites are rapidly eliminated from the body.  Studies in 
mice showed that a strain of mice having a low affinity Ah receptor eliminate 2,3,7,8-TCDD at a much 
slower rate than mice with an Ah receptor of high affinity for the ligand (Gasiewicz et al. 1983a). 
These strain differences in body distribution and elimination could be explained not only by the 
differences in adipose tissue content, but also by the presence of a hepatic microsomal binding protein 
(Leung et al. 1988). Further studies in congenic mice suggested that the distribution and excretion of 
2,3,7,8-TCDD is controlled primarily by the total genetic background and not by the allele present at 
the Ah-locus (Birnbaum 1986).  Guinea pigs eliminate 2,3,7,8-TCDD considerably slower than other 
rodents (Olson 1986). This may reflect the relatively limited ability of the guinea pig to metabolize 
2,3,7,8-TCDD and may contribute to the greater persistence and greater acute toxicity of 
2,3,7,8-TCDD in this species. Results from a repeated-dosing study in rats showed that the rate-
constant defining the approach to steady-state concentrations was independent of the dose over the 
range tested (Rose et al. 1976). This was consistent with evidence suggesting that autoinduction of 
2,3,7,8-TCDD metabolism does not occur following exposure to sublethal doses.  Autoinduction of 
metabolism could explain cases of dose-related excretion in which longer half-lives for elimination are 
seen at lower-exposure levels which are not associated with enzyme induction.  
2.4.2 Mechanisms of Toxicity 
The mechanism(s) of toxicity for CDDs is not completely understood but has been extensively studied, 
particularly for 2,3,7,8-TCDD, and numerous reviews are available on this subject (Birnbaum 1994a; 
Goldstein and Safe 1989; Kerkvliet 1995; Landers and Bunce 1991; Okey et al. 1994; Poland and 
Knutson 1982; Safe 1986, 1990; Silbergeld and Gasiewicz 1989; Whitlock 1987, 1993).  Many CDDs, 
CDFs, coplanar PCBs, and other structurally related halogenated aromatic hydrocarbons are believed 
to share a common mechanism of action intimately related to similarities in their structural 
configuration. Most of what is known regarding the mechanism of action of these compounds is based 
on research in three main areas:  structure-activity relationships for receptor binding and induction of a 
variety of biochemical and toxicological responses; genetic studies using inbred mouse strains; and 
studies at the molecular level which have elucidated key events in the actions of the receptor.  Most of 
the studies providing this information used parenteral routes of exposure and/or in vitro tests systems. 
It is beyond the scope of this profile to discuss these studies in detail. 
CDDs 231 
2. HEALTH EFFECTS 
The extraordinary potency of 2,3,7,8-TCDD in evoking a dose-related induction of cytochrome P-450­
associated AHH activity, the stereospecificity among related halogenated aromatic compounds to 
evoke this response, and the tissue specificity of enzyme induction, led Poland and Glover (1973b) to 
postulate the existence of an induction receptor.  This receptor, the Ah receptor (Ah for aromatic 
hydrocarbon), was later identified in the cytosol of mouse liver cells (Poland et al. 1976) and, 
subsequently, in hepatic and extrahepatic tissues of a variety of laboratory animals, mammalian cell 
cultures, human organs and cell cultures, and also nonmammalian species (Okey et al. 1994).  Results 
from structure-binding relationships for a series of CDD congeners using mouse hepatic cytosol 
showed that not all the congeners had the same affinity for the Ah receptor; affinity was found to be 
determined by the chlorine-substitution pattern (Mason et al. 1986; Poland et al. 1976, 1979).  The 
most active compound was 2,3,7,8-TCDD, which is substituted in all four lateral positions.  Addition 
of one, two, or four nonlateral chlorine substituents, or removal of lateral chlorine substituents, 
resulted in congeners with lower binding affinities. The stereospecific nature of the binding suggested 
the existence of a cytosolic receptor as a mediator in responses caused by 2,3,7,8-TCDD and related 
compounds. 
2,3,7,8-TCDD and structurally related halogenated aromatic compounds induce a variety of 
microsomal enzymes primarily in the liver.  The most widely studied of these responses are induction 
of hepatic AHH and EROD (markers of CYP1A1 activity) in mammalian cell cultures and in 
laboratory rodents (Goldstein and Safe 1989; Poland and Glover 1973a; Safe 1986, 1990).  Several 
studies have examined the in vitro and in vivo structure-activity relationships for CDDs as inducers of 
hepatic and extrahepatic CYP1A1 activity (Bradlaw and Casterline 1979; Harris et al. 1990; Mason et 
al. 1986; Poland and Glover 1973a; Poland and Knutson 1982; Poland et al. 1979).  The most active 
CDDs were substituted in their 2,3,7, and 8 positions, and the structure-activity relationships for 
induction and receptor binding assay were comparable.  The molecular dimensions of the binding site 
was initially estimated to fit ligands that were approximately 3×10D (Poland and Knutson 1982), 
which would accommodate molecules such as 2,3,7,8-TCDD; however, approximate dimensions of 
12x14x5D would be required to accommodate other chemicals (e.g., 3-MC or β-naphthoflavone), 
known to bind (Landers and Bunce 1991; Rannug et al. 1991; Waller and McKinney 1995).  Although 
results from these experiments provided further evidence for a receptor-mediated mechanism of action, 
there was not strictly a linear correlation between Ah receptor binding and enzyme induction.  Mason 
et al. (1986) suggested that a number of factors, including differential solubilities of the CDDs in the 
assay buffer system at higher concentrations, may contribute to the nonlinearity.  They also suggested 
that structure-dependent receptor protein-ligand interactions which occur after the initial binding event 
may have played a role in the nonlinearity of the data sets.  
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Furthermore, differential rates of metabolism and elimination of particular CDDs also likely account 
for the comparative differences between studies in vivo and in vitro (Birnbaum 1985). 
Numerous studies have examined the structure-toxicity relationships for CDDs.  For example, 
examination of lethality data in guinea pigs revealed that the fully lateral-substituted tetra- to 
hexachloro-substituted isomers were the most toxic congeners, and the structure-activity relationships 
were comparable to those observed for their AHH-induction and receptor-binding activities (Eadon et 
al. 1986). Similar results have been reported for responses such as body weight loss and thymic 
atrophy (Mason et al. 1986; Safe 1987).  Furthermore, there was an excellent correlation between the 
in vitro AHH induction potencies and the in vivo responses. Additional end points for which structure-
toxicity relationships correlate well with structure-induction potencies and/or Ah receptor-binding 
affinities are epidermal responses such as the keratinization of the mouse teratoma XB cells and the 
production of skin lesions in genetically inbred haired and hairless mice (Knutson and Poland 1980, 
1982), suppression of the splenic antibody response to SRBC (Kerkvliet et al. 1985), antiestrogenicity 
(Gierthy et al. 1987; Krishnan and Safe 1993), and teratogenicity (Weber et al. 1985).  Taken together, 
these results, and others, strongly supported the role of the Ah receptor in mediating the toxicity of 
2,3,7,8-TCDD and related halogenated aromatic hydrocarbons. 
As previously mentioned, 2,3,7,8-TCDD and structurally related compounds induce a wide range of 
biological responses, including alterations in metabolic pathways, body weight loss, thymic atrophy, 
impaired immune responses, hepatotoxicity, chloracne and related skin lesions, developmental and 
reproductive effects, and neoplasia. The expression of these responses is thought to be initiated by 
the binding of individual congeners (or ligands) with the Ah receptor.  However, responsiveness of 
certain mouse strains to aromatic hydrocarbons is inherited in a simple autosomal-dominant mode 
and both enzyme induction and the toxic responses to 2,3,7,8-TCDD appear to segregate with the Ah 
locus (Poland and Glover 1980). For example, certain mouse strains, typified by C57XBL/6J, have 
an Ah receptor protein with a relatively high binding affinity for inducers of AHH such as 
3-methylcholanthrene, β-naphthoflavone, 2,3,7,8-TCDD, and other isostereomers of 2,3,7,8-TCDD, 
and are sensitive to the toxic effects of these chemicals.  In contrast, other mouse strains, such as 
DBA/2J, have an Ah receptor protein that has a lower ligand affinity (Okey et al. 1989), and are 
much less sensitive to the toxic effects of these compounds.  The use of these mouse strains and 
strains differing only the Ah locus (congenic) has suggested that many of the responses elicited by 
these chemicals (e.g., enzyme induction, thymic involution, cleft palate formation, hepatic porphyria, 
and immunotoxicity) segregate with this Ah locus (Birnbaum et al. 1990; Kerkvliet et al. 1990b; Lin 
et al. 1991a, 1991b; Poland and Knutson, 1982; Swanson and 
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Bradfield 1993). More recent investigations using an Ah receptor-deficient mouse 
(Fernandez-Salguero et al. 1996) also support the role of this protein in mediating the toxicity of 
2,3,7,8-TCDD and related halogenated aromatic hydrocarbons. 
These genetic data strongly support the role of the Ah receptor in mediating the toxicity of 
2,3,7,8-TCDD and related halogenated aromatic hydrocarbons.  However, it has become clear that a 
comparison of the properties of the Ah receptor across species and tissues indicates that it is difficult 
to account for the species-specific sensitivity and diversity of the biological effects of 2,3,7,8-TCDD 
by characteristics of the receptor alone.  There are several different forms of this protein in mice 
encoded by several different alleles of the same locus (Poland and Glover 1990; Poland et al. 1994). 
By analogy with the existence of multiple receptor forms in mice, it is reasonable to anticipate that 
the human population will also have different receptor forms.  The extent to which these forms in 
mice and humans affect the types of responses elicited and the sensitivity to TCDD is not known. 
As indicated above, the Ah receptor has been identified in several human tissues and cell lines (Cook 
and Greenlee 1989; Harper et al. 1991; Harris et al. 1989a; Lorenzen and Okey 1991; Roberts et al. 
1990). Although the general properties and function of the human Ah receptor (Harper et al. 1991) 
appear to be very similar to the rodent and other species (Denison et al. 1986a; Gasiewicz and Rucci 
1984), some differences exist.  For example, the molecular mass from a variety of human cell lines 
or tissues ranges from 106 to 110 kDa (Harper et al. 1991; Poland and Glover 1987; Wang et al. 
1991), compared to approximately 95 kDa for C57XBL/6J mice or from Hepa-1 cells (Landers et al. 
1989; Poland and Glover 1987, 1990; Prokipcak and Okey 1990), and 124 kDa from the hamster 
(Poland and Glover 1987). The same parameter for the nonresponsive DBA/2J mouse is 
approximately 104 kDa (Poland and Glover 1990).  There is no known correspondence between 
molecular mass of the protein and its affinity for any ligand and/or ability to mediate a biological or 
toxicological response. Apparent affinity constants (measured under in vitro conditions) for 
2,3,7,8-TCDD-human Ah receptor binding from various cell lines range from 3 to 15 nM compared 
with about 1 nM in cytosol from C57XBL/6J mice, 16 nM for the DBA/2J mouse, 0.1 nM for the 
guinea pig and 0.3 nM for the hamster (Cook and Greenlee 1989; Gasiewicz and Rucci 1984; Harper 
et al. 1991; Okey et al. 1989). 
While the use of structure-activity relationships and mouse genetics are consistent with the notion that the 
binding of 2,3,7,8-TCDD and structurally-related chemicals to the Ah receptor is the initial event that leads 
to the induced synthesis of certain enzymes, it has only been through the work at the cellular and molecular 
biological levels that this has been substantiated. Furthermore, these investigations indicate that complex 
series of events regulate the activity of the receptor and it is likely that the differential regulation of these 
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may, at least in part, be responsible for the tissue- and species-specific nature of the response observed in 
mammals following the exposure to 2,3,7,8-TCDD and related compounds.  Immunohistochemical studies 
have shown that in intact mouse hepatoma cells, the unliganded receptor resides in the cytoplasm, and that 
exposure to 2,3,7,8-TCDD leads to an accumulation of the receptor within the nucleus (Pollenz et al. 1994). 
However, the precise location of the unoccupied (i.e., without 2,3,7,8-TCDD bound) receptor in intact cells 
is still unresolved. The unoccupied AhR exists as a heteromeric complex with 2 molecules of another 
protein called 90 kDa heat-shock protein (hsp90) and another 43-kDa protein (Chen and Perdew 1994). 
Hsp90 appears to be necessary for maintaining the proper folding of the Ah receptor so it can bind ligand 
and limit the presence of another receptor form that is able to bind to DNA (Pongratz et al. 1992).  The 
exact role of the 43-kDa protein is not yet known. 
Binding of the Ah receptor by 2,3,7,8-TCDD initiates a series of as yet undefined events resulting in the 
dissociation of hsp90 and nuclear localization (Henry and Gasiewicz 1993; Pollenz et al. 1994; Pongratz et 
al. 1992). Results from experiments in genetically variant cells that respond poorly to 2,3,7,8-TCDD 
revealed a defect in 2,3,7,8-TCDD binding that results in an altered receptor.  Other variants exhibited 
normal binding, but the liganded receptors do not bind DNA and do not accumulate in the nucleus 
(Hankinson 1979; Miller and Whitlock 1981). The finding that these variants have a defect in a protein, 
termed Arnt (Ah receptor nuclear transport protein) (Reyes et al. 1992), suggested that 2,3,7,8-TCDD 
responsiveness requires both a ligand-binding protein (the Ah receptor) and a second protein which 
mediates the binding of the liganded receptor to DNA (Whitlock 1993).  Furthermore, the ligand-bound Ah 
receptor does not itself bind DNA (Gasiewicz et al. 1991). The Arnt protein does not bind 2,3,7,8-TCDD, 
nor does it bind to DNA in the absence of the liganded Ah receptor protein (Whitelaw et al. 1993).  The role 
of the Arnt protein as a translocator of the receptor from cytoplasm to the nucleus has been questioned; 
instead, it has been shown that Arnt interacts with the liganded Ah receptor to form a heterodimeric 
DNA-binding protein complex that can bind DNA and activate gene transcription (Whitlock 1993).  Other 
investigations have shown that phosphorylation/dephosphorylation of the Ah receptor and the Arnt protein 
may influence both heterodimerization and the binding of this complex to DNA (Berghard et al. 1993; 
Mahon and Gasiewicz 1995; Okino et al. 1992; Pongratz et al. 1991). 
Most of the information regarding the sequence of events that follow 2,3,7,8-TCDD binding to the Ah 
receptor is based on analyses of induction of AHH activity, which results from enhanced transcription of the 
corresponding cytochrome P-450 1A1 (CYP1A1) gene.  Stimulation of transcription occurs within minutes 
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discovery of a dioxin-responsive regulatory DNA domain which has the properties of a transcriptional 
enhancer (Fisher et al. 1990; Jones et al. 1986; Neuhold et al. 1986). These specific DNA elements have 
been termed dioxin-responsive elements (DREs) and require both receptor protein and Arnt protein for 
enhancer function. DREs function in a chromosomal location distinct from that of the CYP1A1 gene 
(Fisher et al. 1989). In addition to the enhancer, the DNA upstream of the CYP1A1 gene has a second 
control element (a transcriptional promoter), which ensures that transcription is initiated at the correct site. 
Neither enhancer nor promoter functions in the absence of the other (Jones and Whitlock 1990).  The fact 
that enhancer function requires both the receptor and Arnt protein, and that the liganded heteromeric form 
of the receptor shows increased affinity for the specific DNA sequence within the enhancer region 
suggested that the activation of the CYP1A1 gene involves the binding of the receptor heteromer to the 
DRE. This has been shown for the purified Ah receptor-Arnt protein complex (Henry et al. 1994). 
Analysis of the interaction of the Ah receptor with specific DNA domains indicates that the heteromer binds 
in a 1:1 ratio to the DRE (Denison et al. 1989). There is, however, no strict relationship between the 
affinity of the receptor heteromer for the DRE and the extent of enhancer activation (Neuhold et al. 1989; 
Shen and Whitlock 1992), which suggests that additional events, including DNA bending (Elferink and 
Whitlock 1990), must take place to activate transcription. 
The use of many in vitro techniques for these studies has required removing the DNA regulatory elements 
from the chromosome environment, and this may produce misleading results.  This led researchers to 
examine the protein-DNA interactions at the dioxin-responsive enhancer in intact cells.  Results from these 
studies suggested that the inactive enhancer is relatively inaccessible to DNA-binding proteins in vivo and 
that exposure to 2,3,7,8-TCDD leads to a rapid binding of six receptor heteromers and other proteins to the 
enhancer upstream of the CYP1A1 gene (Wu and Whitlock 1993).  It has also been shown that the CYP1A1 
promoter, like the enhancer, is inaccessible in uninduced cells, and that exposure to 2,3,7,8-TCDD increases 
its accessibility to constitutively expressed proteins (Durrin and Whitlock 1989; Wu and Whitlock 1992). 
The 2,3,7,8-TCDD-induced change is not dependent on protein synthesis and is receptor- and 
Arnt-dependent. It has been suggested that the inaccessibility of the enhancer/promoter region in 
uninduced cells is due to its organization into nucleosomes (Ko et al. 1996; Morgan and Whitlock 1992). 
The mechanism by which the binding of liganded receptor heteromers to the enhancer alters chromatin 
structure leading to activation of transcription is unknown.  Whitlock (1993) suggested that the DRE-bound 
receptor complex affects histones, thereby weakening the histone-DNA interactions and destabilizing 
nucleosomal structures.  They also proposed that the receptor-enhancer interaction may alter the DNA 
structure of the enhancer/promoter region stabilizing it in a non-nucleosomal configuration. 
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The information resulting from the cloning and sequencing of the Ah receptor and Arnt has also expanded 
our knowledge of the molecular mechanisms whereby these proteins influence transcriptional activity 
(Hankinson 1995; Whitlock 1993). Both proteins are members of a class of transcription factors containing 
a basic helix-loop-helix (bHLH) structural motif as well as a PAS (Per-Arnt-Sim) domain.  Both of these 
regions are involved in dimerization.  The bHLH motif is also required for DNA sequence recognition, 
while the PAS domain contains the ligand-binding site (in the Ah receptor) and interacts with hsp90 
(Coumaileau et al. 1995; Dolwick et al. 1993; Fukunaga et al. 1995; Whitelaw et al. 1993).  Both the Ah 
receptor and Arnt have C-terminal regions that function in transcriptional activation, although their relative 
contributions may depend on the gene involved (Ko et al. 1996).  Other members of the HLH-PAS family 
include hypoxia-inducible factor 1 alpha (HIF-a) and Drosophila protein Sim (Huang et al. 1993; Wang et 
al. 1995). All of the bHLH proteins identified to date are involved in transcriptional regulation, and have a 
variety of roles in tissue growth and differentiation processes.  It is not yet clear whether the 
ligand-activated Ah receptor modulates gene expression only through its interaction with Arnt; it may have 
other dimerization partners.  It is known that multiple heterodimerizations occur among several 
transcription factors, and that this multiplicity provides for the recognition of other DNA sequences and 
diversity of regulation of responsive genes.  Arnt has been shown to dimerize with HIF-1a and Sim, and 
there appear to be several different isoforms of Arnt, two of which have been shown to interact with the Ah 
receptor (Henry et al. 1994; Hirose et al. 1996; Ireland et al. 1995; Swanson et al. 1995; Wang and Semanza 
1995). However, as of yet, Arnt is the only protein that has been demonstrated to be a functional partner to 
the Ah receptor. Furthermore, the Ah receptor and Arnt appear to be co-expressed in a variety of tissues 
that have been examined (Abbott and Probst 1995; Abbot et al. 1995; Carver et al. 1994), suggesting 
co-dependence. 
As indicated above, much of our understanding of the interaction of 2,3,7,8-TCDD with the Ah receptor 
and how it modulates gene expression has come mainly from the analysis of the regulation of the CYP1A1 
gene. However, other studies have observed the presence of functional DREs in the genes that encode for 
CYP1A2 (Quattrochi et al. 1994), glutathione S-transferase Ya (Paulson et al. 1990), 
aldehyde-3-dehydrogenase (Takimoto et al. 1994), and NAD(P)H:quinone oxidoreductase (Favreau et al. 
1991). In addition, an imperfect DRE is present in the regulatory region of the cathepsin D gene.  In this 
case, the Ah receptor-Arnt complex may act as a repressor to prevent the binding of other transcription 
factors to nearby enhancer sequences (Safe 1995).  
CDDs 237 
2. HEALTH EFFECTS 
As discussed below, 2,3,7,8-TCDD-elicited activation of the Ah receptor has been shown to alter the 
transcription of a number of genes.  However, only a few of these, as indicated above, are as yet known to 
contain functional DREs (Lai et al. 1996). While in some cases the regulatory regions of all of the genes 
known to be altered by 2,3,7,8-TCDD have not been thoroughly examined; in other cases, the regulatory 
regions are known not to contain the conserved consensus sequence for the DRE.  It is possible that other 
dimerization partners exist and that different DNA sequences might be recognized.  It is also possible that 
the 2,3,7,8-elicited modulation of many of these genes and processes may be secondary subsequent to the 
induction/repression of a DRE-containing gene. However, there is some evidence to suggest that other Ah 
receptor-dependent pathways may exist for the alteration of gene expression that may not be dependent 
upon the interaction of the Ah receptor with nuclear elements.  It has been suggested that the interaction of 
2,3,7,8-TCDD with the Ah receptor may initiate a phosphorylation/dephosphorylation cascade that may 
subsequently activate other transcription factors (Matsumura 1994).  Enan and Matsumura (1995) reported 
an increase in protein kinase activity within 1–10 minutes following the addition of 2,3,7,8-TCDD to 
nuclear-free preparations of guinea pig adipose tissue.  These results are consistent with previous 
investigations showing increased tyrosine kinase activity within minutes of 2,3,7,8-TCDD exposure 
(Bombick et al. 1988; Clark et al. 1991a; DeVito et al. 1994).  Hsp90 has been found associated with a 
protein of 50 kDa (Chen and Perdew 1994; Whitelaw et al. 1993), and both have been shown to regulate the 
activity of pp60v-src, a tyrosine kinase (Brugge et al. 1983; Mimnaugh et al. 1995).  c-Src has recently been 
reported to be a component of the unoccupied Ah receptor complex (Enan and Matsumura 1996).  Thus, 
2,3,7,8-TCDD may modulate signal transduction processes and gene expression by at least two pathways: 
through the direct interaction of the Ah receptor and its heterodimer partners with gene regulatory elements, 
and from the initiation of a phosphorylation/dephosphorylation cascade and the subsequent modulated 
activity of other nuclear transcription factors.  It has yet to be determined which pathways may be more 
important in acute versus chronic responses to these compounds and/or during particular developmental 
periods. Nevertheless, together these data indicate that well regulated and conserved pathways exist for the 
transduction of cellular signals through the binding of 2,3,7,8-TCDD-like chemicals to the Ah receptor. 
Since the modulation of these pathways results in toxicity in response to 2,3,7,8-TCDD and related 
compounds, it is presumed that these chemicals cause these responses by either interfering with the normal 
function of some unknown endogenous ligand, and/or stimulating the signal transduction process at an 
inappropriate time and/or for an inappropriately long period of time. 
As indicated in the preceding sections, cell/tissue death and necrosis are not prominent features of effects 
resulting from 2,3,7,8-TCDD exposure in vivo or in vitro. Hyperplasia, hypoplasia, metaplasia, and 
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dysplasia are the most common histopathological changes observed in animals (McConnell and Moore 
1979). Likewise, under conditions in vitro, 2,3,7,8-TCDD-like compounds are potent in altering cellular 
differentiation and growth patterns for a number of different cell types including embryonic palatal 
epithelial cells (Abbott et al. 1989), keratinocytes (Gaido and Maness 1994), osteoblasts (Gierthy et al. 
1994) and preimplantation embryos (Blankenship et al. 1993).  
Despite the numerous tissue- and species-specific responses that have been observed and the elegant work 
on the molecular mechanisms mediating some of these, there exists a considerable gap between knowledge 
of these changes and the degree to which they are related to the biological and toxicological end points 
elicited by 2,3,7,8-TCDD and related compounds.  These chemicals have been shown to alter the 
transcription and/or translation of a number of genes, including several oncogenes and those encoding 
growth factors, receptors, hormones, and drug-metabolizing enzymes (Birnbaum 1994a, 1994b).  More 
recent investigations have noted effects on certain enzymes and proteins (e.g., kinases) involved in various 
signal transduction processes as well as cell cycle control (Birnbaum 1994a, 1994b; Weib et al. 1996).  The 
elicited induction of certain drug metabolizing enzymes such as CYP1A1, CYP1A2, and CYP1B1 are some 
of the most sensitive responses observed in a variety of different animal species, including humans. 
Significantly increased levels of CYP1A1 mRNA have been observed as dosages as low as 0.1 ng/kg body 
weight (Kohn et al. 1993). However, the precise 2,3,7,8-TCDD-induced biochemical alterations that are 
causally responsible for the abnormal growth processes observed are not known.  This is due predominantly 
to our incomplete understanding of the complex and coordinate molecular, biochemical, and cellular 
interactions that regulate tissue processes during development and under normal homeostatic conditions. 
Nevertheless, there is some evidence that many of these biochemical alterations may be relevant to altered 
growth responses observed. For example, changes in the EGF receptor have been seen in tissues from 
2,3,7,8-TCDD-exposed animals and humans (Abbott and Birnbaum 1990a; Sewall et al. 1993; Sunahara et 
al. 1987). EGF and its receptor possess diverse functions relevant to cell transformation and tumorigenesis, 
and changes in these functions may be related to a number of dioxin-induced responses including neoplastic 
lesions, chloracne, and a variety of developmental effects.  Likewise, the known ability of 2,3,7,8-TCDD 
directly or indirectly to alter the levels and/or activity of other growth factors and hormones, such as 
estrogen and thyroid hormone and their respective receptors, as well as enzymes involved in the control of 
cell cycle, may affect growth patterns in cells/tissues leading to adverse consequences.  Thus, both the 
biochemical and biological data are consistent with the notion that 2,3,7,8-TCDD and related compounds 
are growth regulators. 
CDDs 239 
2. HEALTH EFFECTS 
2,3,7,8-TCDD and structurally related compounds elicit a wide range of adverse effects.  Of the many 
adverse responses observed both in humans and experimental animals after exposure to 2,3,7,8-TCDD, the 
ones that appear at the lowest dose (more sensitive) are perhaps developmental/reproductive effects, 
alterations in the immune response, and neoplasia.  An overview of the mechanism(s) involved in these 
effects is presented below. Detailed mechanistic explanations are beyond the scope of this profile.  Some of 
the information has been extracted from recent reviews on these subjects (Kerkvliet 1995; Lucier et al. 
1993a; Peterson et al. 1993). 
Some common developmental effects attributed to 2,3,7,8-TCDD exposure in most laboratory mammals are 
thymic hypoplasia, subcutaneous edema, decreased prenatal growth, and prenatal mortality (Couture et al. 
1990). In addition, there are other species-specific effects, such as cleft palate in mice.  Any of these effects 
may result from actions on the mother, embryo/fetus, placenta, or any combination of these sites (Peterson 
et al. 1993). In general, developmental effects can be induced at exposure levels that are not maternally 
toxic; however, prenatal mortality appears to be associated with maternal toxicity.  Structure-activity results 
for 2,3,7,8-TCDD and related halogenated hydrocarbons for overt fetotoxicity are consistent with an Ah 
receptor-mediated mechanism.  Hydronephrosis is the most sensitive developmental response induced by 
2,3,7,8-TCDD in mice and it can be observed at maternal doses that do not cause cleft palate or overt 
maternal toxicity (Abbott and Birnbaum 1989a; Abbott et al. 1987a, 1987b; Couture-Haws et al. 1991b; 
Neubert and Dillman 1972; Weber et al. 1985).  Hydronephrosis in vivo is induced by a direct hyperplastic 
action of 2,3,7,8-TCDD on the uretic epithelium.  This results in occlusion of the ureter and subsequent 
accumulation of urine in the kidney (Abbott et al. 1987a).  As for cleft palate formation, 2,3,7,8-TCDD and 
related compounds seem to allow the palatal shelves to grow and make contact, but prevent the subsequent 
epithelial-to-mesenchyme transformation (Peterson et al. 1993; Pratt et al. 1984).  Susceptibility to both 
hydronephrosis and cleft palate formation segregate with the Ah locus, and structure-activity relationships 
for dioxin-like compounds are consistent with those for Ah receptor binding (Safe 1990; Weber et al. 1985). 
Further details on the mechanism of 2,3,7,8-TCDD-induced hydronephrosis and cleft palate formation and 
the involvement of various growth factors in these responses can be found in Section 2.5. 
Another sensitive system for 2,3,7,8-TCDD toxicity is the male reproductive system, and many of the 
effects observed were originally thought to be related to the ability of 2,3,7,8-TCDD to decrease plasma 
androgen concentrations (Mably et al. 1992a, 1992b, 1992c; Moore et al. 1985).  The fact that 
2,3,7,8-TCDD is transferred from mother to fetus and to neonates during lactation has a great impact on 
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the male reproductive system during early development.  Testosterone and its metabolite dihydro­
testosterone (DHT) are essential prenatally and/or early postnatally for imprinting and development of 
accessory sex organs and for initiation of spermatogenesis.  Mably et al. (1992b) suggested that the 
demasculinization and feminization of sexual behavior and feminization by LH secretion is due to the fact 
that perinatal exposure to 2,3,7,8-TCDD impairs sexual differentiation of the central nervous system, which 
is dependent on the presence of androgens during early development.  However, results from more recent 
studies suggest that the 2,3,7,8-TCDD-induced effects on the male reproductive system may be related to 
alterations in other systems such as brain amine content or in the expression of growth factors and receptors 
involved in urogenital cell system differentiation and proliferation (Bjerke et al. 1994a; Gray et al. 1995). 
Results from recent studies have also delineated the role of the Ah receptor in the development of 2,3,7,8­
TCDD-induced alterations in the male reproductive tract (Roman and Peterson 1998; Roman et al. 
1998a,b). A more detailed discussion of the mechanisms involved in these responses is presented in 
Section 2.5. 
2,3,7,8-TCDD has been shown to block some estrogenic effects both in vivo and in vitro, and the relative 
potencies of 2,3,7,8-TCDD and related congeners are consistent with their relative binding affinities with 
the Ah receptor (Safe et al. 1991). Estrogens are necessary for normal uterine development and for 
maintenance of the adult uterus.  The mechanism of these antiestrogenic effects  seems to be related to a 
decrease in gonadal tissue responsiveness to estrogen (DeVito et al. 1992) rather than to increased 
metabolism of estrogen.  Studies in cultured MCF-7 cells (estrogen-responsive cells derived from a human 
breast adenocarcinoma) revealed that the antiestrogenic activity of 2,3,7,8-TCDD could result from the 
increased metabolism of estrogens due to Ah receptor-mediated enzyme induction and/or a decreased 
number of estrogen receptors in the nucleus (Gierthy et al. 1987; Harris et al. 1989a, 1990; Safe et al. 1991; 
Zacharewski et al. 1991, 1992). More recent data indicates that in some cases 2,3,7,8-TCDD may block the 
effects of estrogen through the ability of the 2,3,7,8-TCDD-bound Ah receptor-Arnt complex to interfere 
with the estrogen receptors binding to enhancer elements within the regulatory regions of 
estrogen-responsive genes (Krishnan et al. 1995; Safe 1995).  Thus, the mechanism by which 
2,3,7,8-TCDD and related compounds may block certain effects of estrogen may be varied depending on 
the particular gene, response, and tissue. Under some conditions, 2,3,7,8-TCDD may also cause 
estrogen-like responses. For example, the treatment of mice with an appropriate dosage of  2,3,7,8-TCDD 
or estrogen results in thymic involution and modulation of particular bone marrow stem cell markers 
(Silverstone et al. 1994). However, the mechanism by which these compounds act are clearly different 
since potent antiestrogens block the effects of estrogen treatment without affecting 2,3,7,8-TCDD-elicited 
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responses (Frazier et al. 1994). Similarly, the effects of 2,3,7,8-TCDD on the development of external 
genitalia in rats are similar to the effects observed in animals exposed to potent estrogen-like chemicals 
(Gray and Ostby 1995). 
Extensive evidence suggests that the immune system is a sensitive target for toxicity of 2,3,7,8-TCDD and 
structurally related halogenated aromatic hydrocarbons (Kerkvliet 1995).  Exposure to 2,3,7,8-TCDD can 
increase susceptibility to bacterial (Thigpen et al. 1975; Thomas and Hinsdill 1979; White et al. 1986), viral 
(Clark et al. 1983; House et al. 1990), parasitic (Tucker et al. 1986), and neoplastic disease (Luster et al. 
1980). However, the specific immunological functions affected by 2,3,7,8-TCDD in most of the host-
resistance models have not been fully defined.  Thymic involution is characteristic of exposure to 
2,3,7,8-TCDD and structurally related chemicals in all species examined.  There is experimental evidence 
showing that immune suppression in rodents occurs at lower doses of 2,3,7,8-TCDD when the animals are 
exposed perinatally as compared with rodents exposed as adults, and that the prenatal effects are selective 
for T-cell-mediated immunity (Clark et al. 1983; Faith and Moore 1977; Vos and Moore 1974).  The 
mechanism for 2,3,7,8-TCDD-induced thymic atrophy is not completely understood.  There is evidence in 
rats suggesting that the 2,3,7,8-TCDD-induced effect is not mediated by an effect on the pituitary or adrenal 
glands, or from decreased production of thymic hormones (Van Logten et al. 1980; Vos et al. 1978).  There 
appear to be multiple mechanisms involving alterations in thymocyte differentiation (Blaylock et al. 1992; 
Cook et al. 1987a; Denker et al. 1985; Greenlee et al. 1985), thymocyte proliferation (Lundberg et al. 
1990), and migration of lymphocyte stem cells (Fine et al. 1990). 
A commonly used assay for immunotoxicity is the suppression of the antibody response to SRBC.  The 
magnitude of the anti-SRBC response depends on the interactions of antigen-presenting cells (i.e., 
macrophages), regulatory T-lymphocytes (i.e., helper and suppressor T cells), and B-lymphocytes (i.e., 
antibody-producing cells).  Results from experiments in vivo suggested that the target for 2,3,7,8-TCDD in 
the antibody response to either SRBC or tumor cells is the T-cell and/or macrophage components rather 
than the B-cell (Kerkvliet and Brauner 1987; Kerkvliet et al. 1996).  Although the effects of 2,3,7,8-TCDD 
on B-cell function in vivo have not been examined, in vitro studies suggest that 2,3,7,8-TCDD inhibits the 
terminal differentiation of B cells via alteration of an early activation event, perhaps increased protein 
phosphorylation and tyrosine kinase activity (Clark et al. 1991a; Kramer et al. 1987; Luster et al. 1988; 
Morris et al. 1991). Macrophage functions, examined ex vivo, generally have been found to be resistant to 
suppression by 2,3,7,8-TCDD (Mantovani et al. 1980; Vos et al. 1978).  There is also evidence suggesting 
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that inflammatory cells may be activated by 2,3,7,8-TCDD via enhanced production of inflammatory 
mediators such as interleukin 1 and tumor necrosis factor (Clark et al. 1991b; Taylor et al. 1992). 
Extensive research has been conducted on the role of the Ah locus in immunotoxicity of 2,3,7,8-TCDD and 
related compounds, and overall, the data linking 2,3,7,8-TCDD-induced immunotoxicity to the Ah receptor 
are convincing. For example, Vecchi et al. (1983a) reported that the antibody response to SRBC was 
greatly suppressed by 2,3,7,8-TCDD in C57BL/6J mice, but not as much in DBA/2J mice.  Results from 
structure-activity studies for the SRBC response with CDDs that contaminate technical grade pentachloro­
phenol supported an Ah receptor-mediated effect (Kerkvliet et al. 1985).  The Ah receptor was also found to 
be involved in the suppression of the antibody response to lipopolysaccharide (Kerkvliet et al. 1990a); and 
the cytotoxic T-lymphocyte response, and suppression of the latter by dioxin-like PCBs, correlated with 
relative-binding affinities for the Ah receptor (Kerkvliet et al. 1990b).  An additional response found to 
segregate with Ah-responsiveness was the cytotoxic response to activated neutrophils (Ackermann et al. 
1989). It is important to mention that results from some studies suggest that suppression of the in vitro 
antibody response may not be Ah receptor-mediated.  For example, Holsapple et al. (1986a) reported that 
the magnitude of the response was comparable using cells from responsive mice relative to nonresponsive 
mice.  Also, 2,7-dichlorodibenzo-p-dioxin, a congener with little affinity for the Ah receptor, was 
equipotent with 2,3,7,8-TCDD in suppressing the in vitro response. A similar conclusion was reached by 
Davis and Safe (1991), who found that a series of halogenated aromatic hydrocarbons, which had a 
>14,900-fold difference in in vivo immunotoxic potency, were equipotent in vitro in suppressing the anti-
SRBC response using cells from either responsive or nonresponsive mice.  Although these results suggest a 
possible role of non-Ah receptor mechanisms, the studies fail to rule out a role of the Ah receptor.  The 
variable effects of 2,3,7,8-TCDD in vitro may have been due to factors such as media components or 
procedures used to prepare cell suspensions. Kerkvliet (1994) suggested that "the difficulty in 
demonstrating consistent, direct effects of 2,3,7,8-TCDD in vitro on lymphocytes, the dependence of those 
effects on serum components, and the requirements for high concentrations of 2,3,7,8-TCDD are all 
consistent with an indirect mechanism of 2,3,7,8-TCDD on the immune system."  One potentially important 
indirect mechanism operates through effects on the endocrine system.  Glucocorticoids, sex steroids, T4, 
growth hormone, and prolactin have been shown to regulate immune responses, and 2,3,7,8-TCDD has 
been shown to alter the activity of all of them (see also sections on endocrine and reproductive effects). 
There is sufficient evidence that 2,3,7,8-TCDD is carcinogenic in animals, and the overall epidemiological 
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2,3,7,8-TCDD (Hardell et al. 1994; Lucier et al. 1993a). The mechanism of 2,3,7,8-TCDD carcinogenicity 
has not been fully elucidated, but there is considerable evidence indicating that it does not involve direct 
damage to DNA through formation of DNA adducts.  The criteria for designating 2,3,7,8-TCDD as a 
nongenotoxic carcinogen are based on the following: studies using extraordinarily sensitive analytical 
methods have been unable to detect DNA adducts in rodent tissue after exposure to 2,3,7,8-TCDD 
(Randerath et al. 1988; Turteltaub et al. 1990), numerous studies have demonstrated that 2,3,7,8-TCDD is 
not mutagenic in the Salmonella/Ames test with or without an activating system (Giri 1986; Wassom et al. 
1978), and 2,3,7,8-TCDD is a potent tumor promoter and a weak initiator or noninitiator in the two-stage 
models for liver (Flodstrom and Ahlborg 1989; Lucier et al. 1991; Pitot et al. 1980) and skin (Poland et al. 
1982). Instead, it has been proposed that 2,3,7,8-TCDD might alter the capacity of both exogenous and 
endogenous substances to damage the DNA by inducing CYP1A1- and CYP1A2-dependent drug-
metabolizing enzymes.  In some cases, enzyme induction will lead to increased formation of DNA-
damaging metabolites, as appears to be the case in the two-stage model in rat liver and mouse skin 
(Flodstrom and Ahlborg 1992; Hebert et al. 1990; Poland and Knutson 1982; Poland et al. 1982).  A recent 
study suggested that the induction of CYP1A1 may also lead to an increase in oxygen radicals and 
consequent oxidative DNA damage that could lead to mutation and cancer (Park et al. 1996).  However, in 
many cases in which induction leads to increased rate of detoxification, the opposite will occur, as 
demonstrated by Cohen et al. (1979) for benzo[a]pyrene.  The protection afforded by preinduction of 
CYP1A1 by 2,3,7,8-TCDD appears to be Ah receptor-mediated since it does not occur in mice deficient 
with low-affinity Ah receptor (Kouri et al. 1978).  It should be noted that results from structure-activity 
studies for 2,3,7,8-TCDD and related compounds strongly suggest that the hepatocarcinogenic actions of 
2,3,7,8-TCDD are Ah receptor-dependent (Flodstrom and Ahlborg 1992; Hebert et al. 1990; Poland et al. 
1982; Poland and Knutson 1982). The role of CYP1A2 induction is less clear than for CYP1A1.  Some 
have suggested that the liver carcinogenicity of 2,3,7,8-TCDD in intact female rats, but not male rats or 
ovariectomized female rats, could be explained in part by the formation of toxic catechol estrogens from 
17β-estradiol, a reaction catalyzed by CYP1A2 (Lucier et al. 1993a).  This is also consistent with the 
finding that CYP1A2 is induced in liver but not in extrahepatic organs. 
The role of the EGF receptor in 2,3,7,8-TCDD-induced carcinogenicity has also been examined.  EGF is a 
mitogen that stimulates the generation of mitotic signals in both normal and neoplastic cells, and its receptor 
and ligands have a variety of functions involved in cell transformation and tumorigenesis.  It has been 
shown that 2,3,7,8-TCDD decreases the binding capacity of the plasma membrane EGF receptor for its 
ligand without changing the affinity constant (Abbott and Birnbaum 1990a; Hudson et al. 1985; Lin et 
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al. 1991a; Madhukar et al. 1984). The mechanism involved is not completely understood, but it appears 
that 2,3,7,8-TCDD does not decrease EGF receptor mRNA (Lin et al. 1991a).  The effects of 2,3,7,8-TCDD 
on the EGF receptor have been shown to require the Ah receptor (Lin et al. 1991a).  The EGF receptor-like 
response produced by 2,3,7,8-TCDD is consistent with the idea that 2,3,7,8-TCDD increases the generation 
of cellular mitotic signals which may, in part, be responsible for the tumor-promoting actions of 
2,3,7,8-TCDD. 
The possible role of UDP-glucuronyltransferases (UDPGT) on the carcinogenicity of 2,3,7,8-TCDD has 
also been studied. UDPGTs are thought to be a deactivation pathway for many environmental chemicals 
and endogenous substances such as steroid hormones by increasing their water solubility, thereby
facilitating excretion by a conjugation reaction.  2,3,7,8-TCDD induces synthesis of at least one UDPGT 
isozyme (Lucier et al. 1986) by a Ah receptor-mediated mechanism (Bock 1991).  For example, the 
oncogenic effect of prolonged stimulation of the thyroid by TSH has been attributed to decreased levels of 
T4 due to UDPGT induction. Decreased T4 levels induce the pituitary gland to respond by secreting 
increased amounts of TSH.  This is consistent with results from rodent studies in which 2,3,7,8-TCDD and 
other inducers of UDPGT decreased T4 levels in blood, which is associated with increased TSH levels 
(Henry and Gasiewicz 1987).  Lucier et al. (1986) showed that in rats, the shape of the dose-response curve 
for induction of UDPGT by 2,3,7,8-TCDD is similar to that of CYP1A1 induction.  Kohn et al. (1996) 
constructed a physiologically based model to investigate the hypothesis that induction of UDPGT by 
2,3,7,8-TCDD may ultimately lead to a tumorigenic response in the thyroid of rats.  The model included 
compartments for the thyroid and thyroxine-sensitive tissues, secretion and tissue uptake of thyroid 
hormones, binding of T3 and T4 to proteins in blood and tissues, iodination of iodothyronines, and 
glucuronidation of T4 by hepatic UDPGT.  The model accurately predicted the effects of 2,3,7,8-TCDD on 
blood thyroid hormone concentrations, hepatic UDPGT activity, and the consequent increase of serum 
TSH. This was consistent with the observation that induction of UDPGT results in increased 
glucuronidation and biliary excretion of T4.  The results of Kohn et al. (1996) provided further support to 
the hypothesis that induction of UDPGT is an early event in the generation of thyroid tumors by 
2,3,7,8-TCDD in the rat. 
There is evidence that some carcinogenic responses to 2,3,7,8-TCDD are related to effects of 
2,3,7,8-TCDD on the estrogen receptor (ER) and on estrogen metabolism.  The responses appear to be 
tissue-specific as illustrated by the fact that in rats 2,3,7,8-TCDD increases liver tumor incidence, but 
decreases tumor incidence in mammary glands, the uterus, and pituitary gland (Kociba et al. 1978a).  In 
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rats, a single dose of 2,3,7,8-TCDD decreases the binding capacity of the hepatic ER for estrogens 
(Romkes and Safe 1988; Zacharewski et al. 1991, 1992).  This response seems to be Ah receptor-
mediated since 2,3,7,8-TCDD was much more effective in decreasing hepatic ER binding in C57BL/6J 
mice (responsive strain) than in congenic mice with low-affinity Ah receptor (Lin et al. 1991b). 
2,3,7,8-TCDD also decreased rat hepatic ER in a 30-week-duration study (Clark et al. 1991b).  The 
single ED50 for decreasing hepatic ER binding is similar to that for CYP1A1 induction, loss of plasma 
membrane EGF receptor, and induction of UDPGT (Lucier et al. 1993a).  The relationship, however, 
between changes in concentration and cell proliferation have yet to be fully evaluated.  In reproductive 
tract tissues, 2,3,7,8-TCDD decreases tumor incidences by a mechanism possibly involving increased 
estrogen metabolism as a consequence of UDPGT induction.  Increased estrogen degradation was also 
observed in the MCF-7 breast cancer cell line after addition of 2,3,7,8-TCDD (Gierthy et al. 1988). 
As indicated above, a substantial body of evidence is consistent with the premise that the Ah receptor 
mediates the biological effects of 2,3,7,8-TCDD.  Furthermore, this evidence indicates that a response to 
this chemical requires the formation of a ligand-receptor complex.  2,3,7,8-TCDD-receptor binding 
appears to obey the law of mass action and, therefore, depends on the concentrations of both ligand and 
receptor in the target cell, and the binding affinity of the ligand for the receptor.  In principle, and 
according to the law of mass action, some active 2,3,7,8-TCDD-Ah receptor complexes may form even 
at very low levels of exposure.  In reality, however, it is likely that at some finite concentration of 
2,3,7,8-TCDD, the formation of 2,3,7,8-TCDD-receptor complexes will be insufficient to elicit 
detectable or biologically relevant effects due to dependence on other factors (e.g., Arnt binding and 
DRE binding) and events (e.g., mRNA transcription and protein synthesis) necessary for the cascade of a 
signal transduction process to occur. Recent studies have indicated no evidence of a threshold for some 
relatively simple biochemical responses to 2,3,7,8-TCDD such as CYP1A1 induction (Kohn et al. 1993). 
However, this cannot yet be interpreted as an absence of a threshold since it is possible that either 
insufficiently low concentrations of 2,3,7,8-TCDD were used, or the background level of 2,3,7,8-TCDD 
equivalents (including any putative endogenous ligand) is already above the threshold level (even in 
experimental animals).  Events leading to a toxic response that are subsequent to 2,3,7,8-TCDD-receptor 
binding and the induction of a particular biochemical event such as CYP1A1 activity, may or may not 
exhibit a linear response to 2,3,7,8-TCDD since these events are likely additionally dependent on 
multiple and complex biochemical, cellular, and tissue changes that may or may not be dependent on 
saturable processes. Further information will be required to determine if other responses to 
2,3,7,8-TCDD, both biochemical and biological, do or do not demonstrate threshold behavior. 
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It is generally accepted that the toxicity of CDDs, including 2,3,7,8-TCDD, is due mainly to the parent 
compound.  Hydroxylated metabolites lack the activity of the parent compound, suggesting that 
metabolism is a detoxification process necessary for the biliary and urinary excretion of these 
compounds.  For instance, dog metabolites of 2,3,7,8-TCDD administered to guinea pigs had at least 100 
times less acute toxic potency than the parent compound (Weber et al. 1982).  In another study, two 
hydroxylated metabolites of 2,3,7,8-TCDD showed no significant effect on Ah receptor-mediated 
responses, such as body weight loss, thymus atrophy, or liver or spleen weight in male Wistar rats at 
doses as high as 5,000 µg/kg (Mason and Safe 1986a). One of the metabolites, 2-hydroxy-3,7,8-TrCDD, 
induced CYP1A1-related enzyme activities only at very high dose levels (1,000 and 5,000 µg/kg), 
whereas the other metabolite, 2-hydroxy-1,3,7,8-TCDD, lacked inducing capacity.  Structure-activity 
studies of 7-substituted 2,3-CDDs, including the hydroxylated congeners, showed that the binding 
affinities of the hydroxylated congeners for the Ah receptor were significantly lower than those of the 
corresponding chlorine analogs (Denomme et al. 1985).  Similar results were obtained in an additional 
study using hepatic cytosol from rat, mouse, hamster, and guinea pig (Romkes et al. 1987).  
There is some evidence that hydroxylated metabolites of CDDs interfere with the transport of T4 in 
blood by a mechanism unrelated to the Ah receptor (Lans et al. 1993, 1994).  These investigators showed 
that hydroxy-CDDs with chlorine substitution adjacent to the hydroxy group (e.g., 7-hydroxy-
2,3,8-TrCDD, 2-hydroxy-1,3,7,8-TCDD, and 3-hydroxy-2,6,7,8-TCDD) showed similar or higher 
relative binding potency than T4 for the thyroid hormone transport protein transthyretin (TTR) in an in 
vitro assay using purified human TTR (Lans et al. 1993).  In a subsequent study, they found that none of 
several hydroxylated CDDs tested inhibited T4 binding to thyroxin-binding globulin, the major 
T4-transporting plasma protein in humans, as opposed to TTR in rodents (Lans et al. 1994).  This clearly 
indicated that hydroxylated CDDs may cause different effects in rodents and humans. 
The possibility exists that reactive epoxide intermediates of 2,3,7,8-TCDD that may be formed as a 
result of metabolism are involved in 2,3,7,8-TCDD-induced carcinogenicity by covalently binding to 
DNA. However, this appears unlikely since, as previously mentioned, studies using extraordinarily 
sensitive analytical methods have been unable to detect DNA adducts in rodent tissue after exposure to 
2,3,7,8-TCDD (Randerath et al. 1988; Turteltaub et al. 1990), and the fact that 2,3,7,8-TCDD is not 




2. HEALTH EFFECTS 
2.4.3 Animal-To-Human Extrapolations 
As discussed in the introduction to Section 2.1, there are a number of limitations in the human database; 
for most health effects, the data are inadequate to assess the potential for humans having a particular 
effect. Because the human data are incomplete, hazard and risk must be extrapolated across species.  A 
large number of adverse effects have been observed in animals, and most have been observed in every 
experimental animal species tested, if the appropriate dose is administered.  This is illustrated in Table 2­
8 for 8 major effects associated with CDD toxicity (acute lethality, hepatotoxicity, wasting syndrome, 
chloracne, immunotoxicity, reproductive toxicity, developmental toxicity, and cancer).  With the 
exception of acute lethality in humans, positive responses have been observed in each tested species, 
when a response has been investigated.  Despite the similarities in hazard response between different 
species, large species differences in sensitivity have been observed.  Comparisons of species sensitivity 
demonstrate that no species is consistently sensitive or refractory for all effects and, for some effects, 
there is a small range of species sensitivity.  As presented in Table 2-9, the range of LD50 values for 6 
commonly tested animal species spans several orders of magnitude.  Guinea pigs have the lowest LD50 
value (0.6 µg/kg) and hamsters have the largest (1,157 µg/kg).  However, if these outliers are removed, 
the range of LD50 values for mice, monkeys, rabbits, and rats is less than an order of magnitude 
(22–115 µg/kg).  In contrast, the range of LOAELs for reproductive toxicity (abortions, resorptions, pre-
and post-implantation losses) spans approximately an order of magnitude with rats (0.125 µg/kg) being 
the most sensitive and guinea pigs the least sensitive (1.5 µg/kg; NOAEL of 0.15 µg/kg).  These data 
suggest that even though some effects have wide ranges of sensitivity, for most of the effects, the 
LOAELs for the majority of species cluster within an order of magnitude (Table 2-9). 
It is generally accepted that the Ah receptor plays a role in mediating many toxic responses attributed to 
exposure to CDDs (for additional information on the mechanisms of toxicity, see Section 2.4.2).  For some 
responses, receptor binding appears necessary but may not be sufficient to result in downstream biological 
effects. Ah receptors have been found in most species, including humans, monkeys, rats, mice, hamsters, 
rabbits, and guinea pigs (Denison et al. 1986a; Landers and Bunce 1991).  A simple way to explain 
sensitivity differences among species to 2,3,7,8-TCDD and related compounds, at least for Ah receptor-
mediated responses, would be to assume that they are related to differences in receptor levels in target 
tissues and/or to differences in the affinity of binding of the specific CDD congeners.  However, experi­
mental data indicate that differences in such parameters cannot explain marked differences to CDD toxicity 
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hamsters, but the affinity with which 2,3,7,8-TCDD binds to the Ah receptor from guinea pigs is not 
significantly different from the affinity with which 2,3,7,8-TCDD binds to the hamster Ah receptor 
(Denison et al. 1986a). In addition, there are no significant differences in the level of the hepatic Ah 
receptor between the two species, suggesting that in addition to species differences in receptor levels and in 
their affinities for the ligand, differences in species sensitivity to 2,3,7,8-TCDD may be determined by some 
event or events occurring after the initial binding of 2,3,7,8-TCDD to the Ah receptor.  These late events 
may involve a complicated interplay between genetic and environmental factors which may be key 
determinants of 2,3,7,8-TCDD biological potency and toxicity.  Factors unrelated to the Ah receptor, such 
as toxicokinetic differences, may also account for some of the observed species differences (for additional 
information, see Section 2.4.2).  The Ah receptor has been identified in many human tissues and human cell 
lines (Okey et al. 1994).  However, considerable individual differences in the expression levels of both Ah 
receptor and Arnt mRNAs have been found in human tissues (Hayashi et al. 1994).  Furthermore, based on 
findings in inbred mice, polymorphism in the Ah receptor probably exists in humans, so that a concen­
tration of TCDD that produces a response in one individual may not do the same in another (Whitlock 
1993). This could explain why there was a wide range of serum 2,3,7,8-TCDD levels among Seveso 
residents where the occurrence of chloracne was sporadic over a generally wide range of doses (Mocarelli et 
al. 1991). 
The weight of evidence from animal species comparisons and mechanistic data indicates that caution should 
be exercised when extrapolating from animals to humans.  Some theoretical models indicate a basis for 
extrapolating from animals to humans, but such models have not been validated; there is wide variation in 
the results of different models; and a great deal of uncertainty remains regarding whether valid, predictive 
extrapolations can be made.  It is reasonable to assume that humans will not be the most sensitive responder 
or be refractory to all effects, and that they will have a wider range of response due to increased 
heterogeneity.  Levels of exposure to CDDs that produce toxicity in experimental animals cannot be 
directly compared to levels associated with adverse health effects in humans because most epidemiologic 
studies do not provide adequate data to estimate CDD exposures in the studied populations.  However, the 
CDD body-burden history can sometimes be estimated in epidemiology studies from reported serum or 
adipose concentrations and empirically based assumptions regarding whole-body elimination kinetics of 
CDDs (as discussed in the introduction to Section 2.1).  Comparisons between estimated adverse body 
burdens of CDDs and related compounds (CDFs, PCBs) in experimental animals and humans have shown 
that humans and animals appear to respond to similar body burdens (DeVito et al. 1995).  As presented in 
Table 2-10, the adverse effect levels identified in humans are typically within a factor of 10 of the body
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burdens associated with similar effects in animals.  The data in Table 2-10 should be interpreted cautiously 
and should not be taken to suggest that humans are more sensitive than experimental animals.  The human 
body burdens were estimated from serum 2,3,7,8-TCDD levels measured many years after exposure 
termination using empirically based assumptions; small differences in one or more assumption can result in 
large differences in the estimated body burdens.  For example, the body burden of 945 ng/kg in the Manz et 
al. (1991) study was estimated using a half-life of 8.5 years; if the half-life of 7.1 years were used, the 
estimated body burden would have been 1606 ng/kg.  Additionally, individual serum 2,3,7,8-TCDD levels 
and length of time between exposure termination and measurement of serum 2,3,7,8-TCDD levels (latency) 
were not available for a few epidemiology studies, and mean serum levels and latency periods were used to 
estimate body burdens.  The use of mean values rather than individual values and empirically based 
assumptions may have resulted in an over- or underestimation of actual body burdens.  Conversely, in the 
animal studies, actual exposure levels were known and there is greater confidence in the estimated body 
burdens. An acute high-dose exposure would produce higher peak serum lipid 2,3,7,8-TCDD and target 
tissue levels than chronic exposure to lower levels, although the body burdens may be similar.  Thus, it may 
be misleading to compare adverse-effect body burdens from acute studies to those identified in chronic 
studies. Another issue which needs to be considered in comparing the human and animal adverse-effect 
body burdens is that this is comparison of LOAELs not a comparison of threshold levels, and free-standing 
LOAELs may not accurately predict threshold levels. 
2.5 RELEVANCE TO PUBLIC HEALTH 
Overview
The primary route of exposure to CDDs for the general population is the food supply.  This type of 
exposure is the main contributor to the background exposure.  Background exposure refers to exposure of 
the general population who are not exposed to readily identifiable point-sources of CDDs that result in 
widespread, low-level circulation of CDDs in the environment.  It is generally accepted that the contribution 
of inhalation and direct contact with CDDs to the body burden of the general population is not more than a 
few percent. However, inhalation and direct contact represent major exposure routes in cases of 
occupational or accidental exposures. A background exposure level of approximately 0.7 pg 
2,3,7,8-TCDD/kg/day (assuming a 70 kg reference body weight) has been estimated for the general 
population in the United States (Travis and Hattemer-Frey 1987).  If other CDD and CDF congeners are 
included, the background exposure level increases to approximately 18–192.3 pg TEQ/day (0.26–2.75 
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pg/kg/day using a 70 kg reference body weight) (Schecter et al. 1994b) (for additional information on TEQ, 
see the Toxic Equivalency Factor [TEF] and Toxic Equivalents [TEQ] subsections).  The inclusion of 
dioxin-like PCBs further raises the estimate to 3–6 pg TEQ/kg/day (Beck et al. 1989a; WHO 1991).  The 
average concentration of 2,3,7,8-TCDD in the adipose tissue of the U.S. population is 5.8 pg/g lipid (Orban 
et al. 1994). For all TEQ congeners, excluding dioxin-like PCBs, the national average was approximately 
28 pg TEQ/g lipid. In humans, the partitioning ratio of 2,3,7,8-TCDD between adipose tissue lipid and 
serum lipid is approximately 1 and remains near unity over at least a 1,000-fold concentration range over 
background levels (Patterson et al. 1988). This makes serum lipid an accurate and more practical measure 
of body burden than adipose tissue lipid. 
Data on human health effects of CDDs are derived from a variety of sources, including case reports and 
epidemiologic studies using case-control, cross-sectional, and cohort designs.  While case-control and 
cohort studies have been used to investigate increases in the incidence of cancers among populations 
exposed to 2,3,7,8-TCDD, nonmalignant effects have been examined in cross-sectional medical studies.  In 
many of the earliest studies, the magnitude of exposure-response relationships could not be adequately 
assessed for a number of reasons, including small sample size, poor participation, selection of inappropriate 
controls, the inability to identify confounding exposures, and short latency periods (especially important for 
assessment of cancer).  A long interval between exposure and examination (up to 40 years in some cases) is 
a serious limitation when assessing noncancer responses since responses that resolve with time might not be 
detected at the time of the examination.  On the other hand, health conditions that may be present at the 
time of examination may be totally unrelated to past exposure to 2,3,7,8-TCDD.  An additional limitation 
was the inability to quantify exposure.  However, serum or adipose tissue levels of 2,3,7,8-TCDD have 
been measured in more recent cross-sectional studies of U.S. chemical workers (Sweeney et al. 1989), 
Ranch Hand veterans (USAF 1991), and Missouri residents (Webb et al. 1989).  Using a standard half-life 
equation and assuming a one-compartment model and first-order kinetics, the half-life for 2,3,7,8-TCDD in 
humans has been estimated to be 8.7 years (Michalek et al. 1996).  By knowing the half-life, estimates of 
body burdens at the time of exposure can be back-calculated.  These estimates, however, should be used 
with caution since little information exists regarding the metabolism of 2,3,7,8-TCDD in humans.  In 
addition, there are considerable differences in the elimination half-lives for these chemicals among 
individual humans. 
For 2,3,7,8-TCDD, the majority of the effects have been reported among occupationally exposed 
individuals such as producers or users of chemicals in which 2,3,7,8-TCDD might have occurred as 
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impurities, and among residents of communities contaminated with 2,3,7,8-TCDD.  Effects that have been 
associated with exposure to materials contaminated with 2,3,7,8-TCDD in some studies include cancer; 
dermal, hepatic and thyroid effects; effects on serum lipids; diabetes; and cardiovascular, respiratory, 
immunologic, neurologic, and reproductive effects.  A number of studies have consistently found increases 
in cancer mortalities (all types combined) in the highest exposed workers with long latency periods, but the 
data on site-specific cancer are inconclusive. Among the dermal effects, chloracne is clearly a response 
associated with exposure to 2,3,7,8-TCDD and structurally related chemicals, but the threshold level of 
2,3,7,8-TCDD at which it occurs has not been established.  Moreover, there seems to be a great deal of 
innate human variability in the chloracne response between individuals (see Section 2.1.2).  Hepatic 
changes observed in exposed populations include hepatomegaly, increased hepatic enzyme (GGT, AST, 
ALT) levels, induced hepatic microsomal activity (measured as increased D-glucaric acid excretion), 
alterations in porphyrin metabolism, and increases in serum lipid (cholesterol, triglycerides) levels.  With 
the exception of long-lasting changes in GGT (Calvert et al. 1992; USAF 1991) and in serum cholesterol 
(USAF 1991) in some exposed groups, hepatic effects were transient and appeared to have been associated 
with acute exposure to high 2,3,7,8-TCDD concentrations.  Few long-term thyroid effects were found in 
Ranch Hand veterans (USAF 1991), but a recent study of nursing infants suggests that ingestion of breast 
milk containing CDD and CDF levels somewhat higher than those reported in most general population 
studies, may alter thyroid function (these data are not conclusive because the measure thyroid hormone 
levels were within the normal range) (Koopman-Esseboom et al. 1994; Pluim et al. 1992).  Slightly 
increased risk of diabetes and abnormal glucose tolerance tests have been reported in populations exposed 
to high 2,3,7,8-TCDD concentrations (Sweeney et al. 1992; USAF 1991).  In the former study, however, 
age and body mass index, both known risk factors for diabetes, appear to have a greater influence than 
2,3,7,8-TCDD level. Dose-related trends for deaths from cardiovascular disease and ischemic heart 
disease were observed in individuals exposed to CDDs during the BASF accident (Flesch-Janys et al. 
1995). However, other studies found no relationship between 2,3,7,8-TCDD exposure and cardiovascular 
deaths (Bertazzi et al. 1989b) or other cardiovascular effects (Hoffman et al. 1986; Wolfe et al. 1985).  A 
few case reports indicate that acute exposure to high 2,3,7,8-TCDD levels can produce respiratory 
irritation, but there is no indication that exposure to 2,3,7,8-TCDD produces chronic respiratory effects. 
Although there have been some reports of alterations in some immune end points in populations exposed 
to 2,3,7,8-TCDD, there has not been a consistent pattern, and the clinical significance of the effects is not 
totally clear.  The overall evidence for neurologic effects suggests that although neurologic effects are 
reported to have occurred shortly after exposure in occupationally exposed individuals, even high exposure 
to 2,3,7,8-TCDD caused no long-term sequelae (Goetz et al. 1994; Sweeney et al. 1993).  More recent data 
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suggests that exposure to 2,3,7,8-TCDD and related chemicals in humans during the pre- and neonatal 
periods may affect neurological development (Huisman et al. 1995a), but these data need to be interpreted 
cautiously because the neurological optimality score in infants was within the normal range and CDD/CDF 
levels may have only contributed a small amount to the variance in scores.  Of the many reproductive end 
points studied in populations exposed to 2,3,7,8-TCDD, the available data provide suggestive evidence of 
altered sex ratios in children of exposed parents (Basharova 1996; Dimich-Ward et al. 1996; Mocarelli et 
al. 1996) and possibly alterations in reproductive hormone levels in males (Egeland et al. 1994) are 
associated with increased serum 2,3,7,8-TCDD levels.  
Most of the toxicity studies of 2,3,7,8-TCDDs in animals have involved oral exposure, and numerous 
effects have been documented after short- and long-term exposure including lethality, and cardiovascular, 
gastrointestinal, hematological, hepatic, renal, endocrine, dermal, body weight, immunologic, 
reproductive, and developmental effects.  In addition, 2,3,7,8-TCDD is a potent carcinogen in various 
species, and produces tumors in multiple sites in rodents of both sexes.  However, as shown in Table 2-2, 
these effects occurred at doses several orders of magnitude higher than estimates of background exposure 
for CDDs. The most reliable and consistent sign of 2,3,7,8-TCDD toxicity in experimental animals is 
weight loss or decreased weight gain in growing rodents.  Animal responses to 2,3,7,8-TCDD exposure are 
species- and strain-dependent, although almost all responses can be induced in every species and strain if 
the appropriate dose is used. The animal data suggest that the most sensitive effects of 2,3,7,8-TCDD 
exposure are immunotoxicity, and reproductive and developmental toxicity. 
In recent years considerable advances have been made regarding the mechanisms of toxicities of 
2,3,7,8-TCDD and related chemicals, as well as the pharmacokinetics of dioxins in experimental animals. 
For CDDs, toxicity and toxicokinetics cannot be dealt with separately.  Based on results from research in 
these fields, it has become apparent that the comparison of  responses from animals to humans (or even 
between animal species) should be done on the basis of body-burden or target-tissue dose, rather than on 
the basis of administered dose.  By doing so, species-specific toxicokinetic considerations such as dose-
dependent distribution, the existence of tissue-specific sequestering chemical entities (i.e., CYP1A2), and 
body composition (i.e., percent fat) can be taken into account.  A discussion of relationships between 
administered dose, body burden, and biological responses is presented below. 
Issues relevant to children are explicitly discussed in Section 2.6, Children’s Susceptibility, and Section 
5.6, Exposures of Children. 
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Toxic Equivalency Factors (TEFs) and Toxic Equivalents (TEQs).  Humans are exposed to 
complex mixtures of CDDs and other halogenated aromatic hydrocarbons such as CDFs and PCBs which 
are found in the environment (including food).  The toxicological concerns resulting from exposure to 
these mixtures, as well as the gaps in available information with which to evaluate the potential risks from 
such exposures, led the EPA Chlorinated Dibenzo-p-dioxins/Chlorinated Dibenzofurans Technical Panel 
of the Risk Assessment Forum to recommend an interim method for assisting in estimating the risk from 
exposure to these mixtures that can be used until the data gaps are filled (Barnes 1991; EPA 1989e).  Since 
for many of these chemicals very limited data on toxicity exist, TEFs were developed and validated in 
studies in animals (Eadon et al. 1986; Silkworth et al. 1989a; Viluksela et al. 1998a, 1998b).  
The TEF approach involves assessment of the comparative effects of individual halogenated aromatic 
hydrocarbons congeners on various biological end points and derivation of TEFs based on the upper range 
of potency data for these effects  The key assumptions unifying the diverse types of data that are 
considered in the derivation of TEFs are: that congeners exert toxicity through a common receptor-
mediated mechanism, and that the effects of mixtures are additive (Safe 1990).  The TEF approach 
compares the relative toxicity of individual congeners to that of 2,3,7,8-TCDD, which is the most 
extensively studied of the halogenated aromatic hydrocarbons that interact with the Ah receptor.  The TEF 
for 2,3,7,8-TCDD is defined as unity; and TEFs for all other CDD congeners, CDFs, and dioxin-like PCBs 
are less than one, thus reflecting their lower toxic potency (see Kennedy et al. [1996] for an exception to 
this general rule). TEFs proposed earlier by EPA (1989) are presented in Table 2-11; recently revised 
values are presented in Table 2-12 (WHO 1998). The recent update also assigned a TEF of 1 to 1,2,3,7,8­
PeCDD. The toxic potency of a mixture of congeners (i.e., the TEQ) is the sum of the products of the 
TEFs for each congener and its concentration in the mixture.  Thus, TEQs represent 2,3,7,8-TCDD toxic 
equivalents for mixtures of  CDDs, CDFs, and/or dioxin-like PCBs. 
The TEF approach facilitates site-specific assessments that account for changes in congener composition 
due to differential environmental partitioning and transformation, as well as differences in congener profiles 
between sites and co-exposure to related halogenated aromatic hydrocarbons.  The TEF approach, however, 
has several shortcomings.  One problem is that very little data may be available for estimating the TEF and 
the available data are often from in vitro or single-exposure acute in vivo studies. Furthermore, there is a 
wide range in relative potency estimates derived from the literature.  For example, Safe (1990) estimated 
2,3,7,8-TCDD/1,2,3,4,7,8-HxCDD potency ratios of 33/1 for rat body weight loss, 12/1 for rat thymic 
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differences in pharmacokinetics between two chemicals result in different estimates of the relative potency 
depending upon the exposure protocol (DeVito and Birnbaum 1995).  These investigators demonstrated that 
published TEFs for 2,3,7,8-TCDD (TEF 1) and 2,3,7,8-TCDF (TEF 0.1) accurately estimated the relative 
potencies for liver EROD induction in female B6C3F1 mice after 4 weeks of treatment, but failed to do so 
after 13 weeks of treatment.  The inability to estimate relative potencies after the longer treatment duration 
was attributed to the difference in half-lives between the two compounds (2 days for 2,3,7,8-TCDF and 
15 days for 2,3,7,8-TCDD).  Steady-state levels of 2,3,7,8-TCDF were achieved within 4 weeks and, thus, 
EROD remained constant from 4 to 13 weeks.  Steady-state levels of 2,3,7,8-TCDD were not attained 
within 4 weeks, which explained the increased hepatic EROD between 4 and 13 weeks.  The results showed 
that TEFs for congeners with a short half-life may overestimate their potency and that the opposite may be 
true for congeners with a long half-life. Based on their results, DeVito and Birnbaum (1995) suggested that 
“present TEFs should be reevaluated to determine whether values have adequately incorporated 
pharmacokinetic differences between the test compound and 2,3,7,8-TCDD.”  In a more recent study, the 
same group of investigators compared the relative potencies for enzyme induction of 2,3,7,8-TCDD, 
1,2,3,7,8-PeCDD, 2,3,7,8-TCDF, 1,2,3,7,8-PeCDF, 2,3,4,7,8-PeCDF, OCDF, and 2,3,7,8­
tetrabromodibenzo-p-dioxin (2,3,7,8-TBDD) in mice based on daily administered or final tissue dose 
following gavage dosing for 90 days (DeVito et al. 1997).  The enzymes monitored were EROD (liver, 
lung, and skin) and ACOH (liver). After the 90-day administration period, the chemicals were assumed to 
be at or approaching steady-state conditions.  Since ED50 values could not be estimated for all the 
congeners, the authors used an alternative method of comparison that fitted a function to the 2,3,7,8-TCDD 
dose-response data. The function was then used to predict the 2,3,7,8-TCDD equivalent dose of a chemical 
based on the enzymatic activity induced at a given dose of the test compound.  A linear regression of the 
predicted dose of 2,3,7,8-TCDD and the actual congener dose provided the relative potency estimate.  The 
results showed that, when based on administered dose, the relative potencies for the specific congeners did 
not vary substantially among tissues.  However, for congeners with a much shorter half-life than 
2,3,7,8-TCDD, the relative potencies increased for all enzymes when estimated from tissue concentrations. 
For example, for 2,3,7,8-TCDF the relative potency based on administered dose varied by less than a factor 
of 2 between endpoints, ranging from 0.0076 for skin EROD to 0.014 for ACOH.  The relative potency 
increased by 4- to 14-fold when based on tissue dose and varied between tissues by a factor of 4, from 
0.028 to 0.11. Because 2,3,7,8-TCDF is metabolized much faster than 2,3,7,8-TCDD, to achieve an 
equivalent tissue concentration of these chemicals, higher doses of 2,3,7,8-TCDF must be administered 
relative to 2,3,7,8-TCDD. Overall, the results confirmed their previous observations that differences in 
absorption and metabolism modulate the relative potency of this class of chemicals.  DeVito et al. (1997) 
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suggested that it might be useful to derive two sets of TEF values, one used for estimating intake 
equivalents and the other for estimating tissue equivalents. 
Viluksela et al. (1998a, 1998b) recently examined a wide range of endpoints in rats administered either a 
mixture of CDDs with a given TEQ or single CDD congeners at the same TEQ dose level as the mixture. 
The TEFs for the various congeners were derived from acute experiments.  The dosing period was 
13 weeks. The results showed effects of similar magnitude in response to administration of the CDD 
mixture or single CDD congeners.  This supported the validity of the TEF method and the notion of 
additive toxicity for the CDDs evaluated.  Moreover, the concentration ratios for the various congeners in 
the liver were very similar to the ratios at which the congeners were administered. 
Neubert and coworkers (Neubert et al. 1992c) have also examined the issue of TEFs and proposed that a 
number of prerequisites need to be fulfilled in order to consider the TEF approach from a scientific point of 
view: 
•	 The actions of the congeners must be strictly additive in the dose range to be evaluated. 
•	 The organotropic manifestations in different species must be identical over the relevant dose ranges. 
•	 Dose-response curves for various toxicological end points for a given congener must run parallel. 
•	 The dose-response curves for a given toxicological end point must run parallel for the various 
congeners. 
•	 For extrapolations between species, the kinetics must be identical, or differences have to be taken into 
consideration. 
•	 With respect to a risk assessment relevant to humans, toxic or biological manifestations in the lower 
dose ranges are of special interest, and LD50 or ED50 values or effects induced by highly toxic dose are 
of minor importance. 
•	 Effects to be expected at low exposures must be identical with those observed at the high doses 
studied. 
After discussing each one of these seven points, Neubert et al. (1992c) concluded that the toxicological 
background for using the TEF approach for risk assessment must be increased considerably.  A similar 
conclusion was reached by a scientific panel that examined the feasibility of developing a TEF approach 
that would be applicable to PCB mixtures (Barnes et al. 1991).  In the case of PCBs, the study group 
concluded that “the application of TEF approach for PCBs would be less straightforward than it was in the 
case of chlorinated dibenzo-p-dioxins and dibenzofurans.” 
In 1992, a group of scientists met in Belgium under the auspices of the European Environmental Research 
Organization to discuss the impact of CDDs, CDFs, and PCBs on human and environmental health with 
special emphasis on application of the TEF concept.  The main conclusions, relevant to the TEF concept, 
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were that TEFs may be useful for risk management (i.e., quantitative estimation of Ah receptor-mediated 
toxic potential) of mixtures of CDDs, CDFs and the coplanar non-ortho and mono-ortho PCBs, but that the 
TEF concept is not applicable for the various toxic responses whose mechanisms do not involve the Ah 
receptor (Ahlborg et al. 1992, 1994). 
The TEF approach in relation to cancer risk estimation has also been examined Rao and Unger (1995). 
First, the authors used the standard approach of multiplying TEF doses by the cancer slope factor for 
2,3,7,8-TCDD to estimate lifetime incremental cancer risks for a mixture of CDDs and CDFs.  This method 
was compared with a modified approach in which the TEF dose was adjusted for differences in the 
probability of formation of bound receptor-ligand complexes.  Briefly, using algorithms from a competitive 
binding model, the fractions of Ah receptor bound to congeners were derived.  This fraction was defined as 
competitive binding ratios (CBR) in mixtures and represents the maximum likelihood estimate for the 
formation of a congener-receptor bound complex in the presence of other competing ligands.  Two distinct 
risk scenarios were used for comparison: (1) human adipose tissue residue data from the national human 
adipose tissue survey (Stanley et al. 1986) were used to generate potential lifetime incremental cancer risks, 
and (2) lifetime cancer risk was characterized for a potentially exposed population ingesting contaminated 
carp. In the modified TEF approach, CBR values for individual congeners computed from the competitive 
binding algorithms were used to derive the tissue concentrations.  The main findings of this analysis were 
that TEF doses calculated by using the model algorithms were lower than the combined TEF dose for all 
congeners estimated by the TEF method without considering the competitive binding.  In addition, the 
combined incremental cancer risks for all congeners were generally lower when model algorithms were 
used in the dose-response analysis.  Also, the standard TEF method tended to overestimate the risks of 
higher congeners with low toxicity and underestimated  the risk of more toxic congeners.  
One further concern regarding the use of TEQs for risk assessment is the fact that the human diet also 
contains Ah receptor agonists, such as indole-3-carbinol and related compounds in vegetables, polynuclear 
aromatic hydrocarbons (PAHs), aromatic amines formed during cooking.  These natural Ah receptor 
agonists elicit responses in humans that are consistent with a receptor-mediated pathway, but the response-
specific potencies of natural Ah receptor versus xenodioxins are unknown. Therefore, a TEF/TEQ 
approach based solely on intake of xenodioxins does not take into account the background of natural 
dioxins that may influence responses associated with persistent low-level occupation of the Ah receptor (see 
Safe 1998a, 1998b for review on this issue). 
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Minimal Risk Levels for 2,3,7,8-TCDD 
It is ATSDR’s policy (see Appendix B) to use health guidance values (i.e., MRLs, EMEGs) derived for 
2,3,7,8-TCDD for other dioxin-like compounds, expressed in total TEQs. 
Inhalation MRLs 
MRLs were not derived for inhalation exposure. 
Oral MRLs 
An MRL of 0.0002 (2×10-4) µg/kg/day has been derived for acute-duration oral exposure 
(14 days or less) to 2,3,7,8-TCDD.  
The acute duration oral MRL was based on a NOAEL of 0.005 µg/kg and a LOAEL of 0.01 µg/kg for 
immunological effects in female mice (Burleson et al. 1996).  In this study, groups of 20 female B6C3F1 
mice were administered a single gavage dose of 0, 0.001, 0.005, 0.01, 0.05, or 0.1 µg/kg 2,3,7,8-TCDD in 
corn oil. Seven days after 2,3,7,8-TCDD exposure, the mice were infected intranasally with influenza 
A/Hong Kong/8/68 (H3N2) virus diluted at 10-48, 10-50, 10-52, or 10-54. In a separate experiment, groups of 
18 female mice received a single gavage dose of 0, 0.001, 0.01, or 0.1 µg/kg 2,3,7,8-TCDD and were 
infected 7 days later with influenza A virus at a dose not known to cause mortality (10-54 and 10-58) or were 
sham-infected.  Body weight, thymus weight, and wet lung weights were measured 3, 9, or 12 days 
postinfection. Pulmonary virus titers were determined in groups of 72 mice exposed to 0, 0.001, 0.01, or 
0.01 µg/kg 2,3,7,8-TCDD and infected with influenza A virus seven days later.  For the virus titer study, 
groups of mice were killed 2 hours, 1, 4, 6, 7, 8, 9, 10, and 11 days post-infection. 
Statistically significant increases in mortality were observed in the influenza A infected mice exposed to 
0.01, 0.05, or 0.1 µg/kg 2,3,7,8-TCDD. However, no between group differences in mortality were observed 
at these 2,3,7,8-TCDD dosages. Mortality in mice receiving 0.001 or 0.005 µg/kg did not significantly 
differ from the mortality in the control group.  Exposure to 2,3,7,8-TCDD did not enhance the increase in 
relative lung weight normally seen in mice infected with influenza A virus.  As compared to controls, no 
significant alterations in thymus weights were observed in 2,3,7,8-TCDD-exposed mice  sham-infected or 
those infected with influenza A virus. 2,3,7,8-TCDD exposure did not result in a significant increase in 
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lack of dose-response in mortality and the lack of effect on the relative lung weight, thymus weight, and 
viral titers suggest that 2,3,7,8-TCDD may be exerting an effect via an indirect mechanism such as through 
an effect on cytokines.  The 0.005 µg/kg dose was considered a NOAEL for immunotoxicity.  As described 
in the footnote to Table 2-2, an uncertainty factor of 30 (3 for extrapolation from animals to humans and 10 
for human variability) and modifying factor of 0.7 (to adjust for the difference in higher bioavailability of 
2,3,7,8-TCDD from an oil gavage vehicle than from food) were used to derive the MRL from the NOAEL 
value. 
An MRL of 0.00002 (2×10-5) µg/kg/day has been derived for intermediate-duration oral exposure 
(15–364 days) to 2,3,7,8-TCDD. 
The intermediate-duration oral MRL was based on a NOAEL of 0.0007 µg/kg/day for immunological 
effects in Hartley guinea pigs fed 2,3,7,8-TCDD in the diet for 90 days (DeCaprio et al. 1986).  In that 
study, groups of weanling Hartley guinea pigs (10 per sex) were administered a diet that provided an 
average of 0.0001, 0.0007, 0.005, or 0.028 µg 2,3,7,8-TCDD/kg/day. This corresponds to 2, 10, 76, and 
430 ppt 2,3,7,8-TCDD in the food. A control group was fed a diet without added 2,3,7,8-TCDD. The 
recovery following treatment was studied in groups of 10 guinea pigs fed a diet containing 430 ppt 
2,3,7,8-TCDD for 11, 21, or 35 days and  allowed to recover for 79, 69, or 55 additional days, respectively. 
The highest dietary level of 2,3,7,8-TCDD caused net body weight loss and mortality.  Four males and four 
females died, and additional animals had to be sacrificed due to poor health.  Food consumption was 
significantly reduced in the highest-dose group only.  Body weight gain in the 0.0007 and 0.005 µg/kg/day 
male groups was reduced by 9 and 20%, respectively. In the corresponding female groups, body weight 
gain was reduced by 6 and 15%.  Gross lesions were observed only in the highest-dose group and included 
thymic atrophy, depletion of body fat, and liver enlargement. Significant changes in organ weights included 
a decrease in absolute kidney weight and in absolute and relative thymus weight in males dosed with 
0.005 µg/kg/day, increase in relative liver weight in males and females at the 0.005 µg/kg/day level, and 
increase in relative brain weight in males at this same dose level. Organ weights from high-dose animals 
were not monitored. Administration of 2,3,7,8-TCDD did not cause any significant hematological effect 
(blood was not collected from the highest-dose group). In the 0.005 µg/kg/day groups, serum ALT was 
significantly reduced in females, and triglycerides were elevated in males. No other significant changes in 
clinical chemistries were observed. Treatment-related histological alterations were observed only in the two 
higher-dose groups and consisted of hepatocellular cytoplasmic inclusion bodies and atrophy of the thymic 
cortex. In the recovery study there was 10% mortality in the groups treated for 11 and 21 days, and 70% 
mortality in the group treated for 35 days. Surviving animals in all groups exhibited significantly
C 
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reduced body weight gain. The 0.0007 µg/kg/day dose represents a NOAEL for decreased thymus weight, 
and the 0.005 µg/kg/day dose is a LOAEL.  As described in the footnote to Table 2-2, an uncertainty factor 
of 30 (3 for extrapolation from animals to humans and 10 for human variability) was used to derive the 
MRL from the NOAEL. 
An MRL of 0.000001 (1×10-6) µg/kg/day has been derived for chronic-duration oral exposure 
(365 days or more) to 2,3,7,8-TCDD. 
The chronic-duration oral MRL is based on a LOAEL of 0.00012 µg/kg/day for developmental toxicity in 
rhesus monkeys (Schantz et al. 1992).  In this study, groups of 8 female rhesus monkeys were fed a diet 
containing 0, 5, or 25 ppt 2,3,7,8-TCDD for a total of 16.2 months (the results of the neurodevelopmental 
portion of this study were published in papers by Bowman et al. [1989a], Schantz and Bowman [1989], 
Schantz et al. [1992]).  After 7 months of exposure, the monkeys were mated with unexposed males. (Only 
1 monkey in the 25 ppt group delivered a viable offspring; this offspring was not studied behaviorally.) The 
monkeys were fed the 2,3,7,8-TCDD diet throughout the mating period, gestation, and lactation.  When the 
offspring (3 males and 3 females per exposure group) were 8.6 months of age, they were placed in 3 peer 
groups of 4 monkeys and allowed to play for 1.5 hours without interference.  The peer groups consisted of 
two 2,3,7,8-TCDD-exposed monkeys and two control monkeys.  Behavioral patterns (social interactions 
and other behaviors such as vocalization, locomotion, self-directed behavior, and environmental 
exploration) were monitored 4 days a week for 9 weeks.  No overt signs of toxicity were observed in the 
mothers or offspring, and birth weights and growth were not adversely affected by 2,3,7,8-TCDD exposure. 
Significant alterations were observed in play behavior, displacement, and self-directed behavior in the 
2,3,7,8-TCDD-exposed offspring. 2,3,7,8-TCDD-exposed monkeys tended to initiate more rough-tumble 
play bouts and retreated less from play bouts than controls, were less often displaced from preferred 
positions in the playroom than the controls, and engaged in more self-directed behavior than controls.  No 
other significant alterations in behavior or alterations in reflex development, visual exploration, locomotor 
activity, or fine motor control were found (Bowman et al. 1989a).  In tests of cognitive function, object 
learning was significantly impaired, but no effect on spatial learning was observed (Schantz and Bowman 
1989). As described in the footnote to Table 2-2, an uncertainty factor of 90 (3 for the use of a minimal 
LOAEL, 3 for extrapolation from animals to humans, and 10 for human variability) was used to derive the 
MRL. 
It should be also noted that 10 years after termination of 2,3,7,8-TCDD exposure in the Schantz et al. 
(1992) study, Rier et al. (1993) reported a dose-related increase in the incidence and severity of 
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endometriosis in these same rhesus monkeys.  Rier et al. (1993) identified a less serious LOAEL of 5 ppt 
(0.00012 µg/kg/day) for moderate endometriosis.  However, monkeys appear to be more susceptible to 
endometriosis, based on a background incidence of endometriosis in monkeys of 30% (Rier et al. 1993) 
compared to a background incidence of 10% in humans (Wheeler 1992).  Thus, derivation of a chronic oral 
MRL based on endometriosis would necessitate using an uncertainty factor of less than 1 (or at most, 1) to 
account for the increased sensitivity of monkeys to endometriosis as compared to humans.  If the Rier et al. 
(1993) study were used to calculate an oral MRL, the LOAEL of 0.00012 µg/kg/day would be divided by 
an uncertainty factor of 100 (10 to extrapolate from a LOAEL, 10 for human variability and 1 for 
interspecies differences). This would result in a computed MRL essentially the same as the chronic oral 
MRL of 1 pg/kg/day based on developmental toxicity as described in the preceding paragraph.  Moreover, 
(1) the clinical history for these rhesus monkeys during the 10-year period between the Schantz et al. (1992) 
study and examination by Rier et al. (1993) is unknown (not reported); (2) Boyd et al. (1995) did not find 
an association between exposure to CDDs, CDFs, or PCBs and endometriosis in a clinical study in women; 
and (3) the EPA (1997) concluded that “the evidence for supporting the hypothesis that CDDs and PCBs 
are causally related to human endometriosis via an endocrine-disruption mechanism is very weak.”  So, 
even though there is information to indicate that endometriosis may also be a sensitive toxicological end 
point for 2,3,7,8-TCDD exposure, the developmental end point (altered social behavior) reported in the 
Schantz et al. (1992) study was determined to be the most appropriate end point for derivation of an MRL 
for chronic oral 2,3,7,8-TCDD exposure. 
Comparison of Estimated Body Burdens Associated with Effects in Experimental Animals 
and Humans. Estimated average body burdens of 2,3,7,8-TCDD in human populations in which 
various health effects of 2,3,7,8-TCDD are suspected range from 31 to 6,600 ng/kg (estimated body 
burdens at the time of exposure termination).  See Table 2-1 for more information.  The human body burden 
expected in populations exposed to background environmental levels of 2,3,7,8-TCDD  has been estimated 
to be 1 ng TCDD/kg body weight (DeVito et al. 1995; Orban et al. 1994).  This would suggest that effects 
of 2,3,7,8-TCDD in humans may occur at body burdens that are 30 to 6,600 times greater than background 
burdens for 2,3,7,8-TCDD. 
The similarities in response of humans and experimental animals to similar body burdens of CDDs and 
related chemicals (Table 2-10), along with our understanding of common mechanisms of actions of CDDs 
in humans and experimental animals lends support to both the relevance of experimental animal toxicology 
to humans and the use of experimental animal data for establishing MRLs (see Section 2.4.3 for more 
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information on the animal-to-human extrapolations).  Acute, intermediate and chronic MRLs for 
2,3,7,8-TCDD were derived from experimental animal studies that identified the highest NOAELs or lowest 
LOAELs for the respective exposure-duration category (Table 2-2).  The MRLs, and the NOAELs and 
LOAELs on which they are based, have been converted to their corresponding equivalent body burdens and 
are compared to background 2,3,7,8-TCDD body burdens in humans and body burdens associated with 
adverse health effects (Table 2-13). This comparison shows that the NOAELs for acute, intermediate, and 
LOAEL for chronic exposure to 2,3,7,8-TCDD in experimental animals are generally below the low end of 
the 31–6,600 ng TCDD/kg of body weight range of body burdens that is suspected to be adverse to humans 
based on the epidemiologic evidence.  Body burdens that correspond to the MRLs are 2-6 times lower than 
the estimated background body burden in humans, suggesting that adverse health effects are unlikely in 
humans exposed to background levels of 2,3,7,8-TCDD.  However, because of the magnitude of uncertainty 
in dose-response relationships for 2,3,7,8-TCDD, the possibility that current background exposures may be 
sufficient to contribute to a risk of adverse health effects in human populations cannot be completely 
excluded. 
Death. Information regarding mortality in humans after exposure to CDDs is limited to epidemiological 
studies in populations exposed occupationally or environmentally (Bertazzi et al. 1989b; Cook et al. 1986, 
1987b; Fingerhut et al. 1991; Ott et al. 1980, 1987; Pesatori et al. 1998; Thiess et al. 1982; Vena et al. 
1998; Wolfe et al. 1985; Zack and Suskind 1980; Zober et al. 1990). These studies did not find a 
significant increase in the overall mortality rate in populations exposed to 2,3,7,8-TCDD or other CDD 
congeners for acute or chronic durations. However, several studies did find significant increases in cause-
specific mortality (i.e., cancer and cardiovascular disease).  These increases in cause-specific mortality are 
discussed under the specific effect. 
Several studies provided data regarding lethality following CDDs exposure in animals.  Oral LD50 values 
for 2,3,7,8-TCDD were calculated in rats (NTP 1982b; Schwetz et al. 1973; Walden and Schiller 1985), 
minks (Hochstein et al. 1988), rabbits (Schwetz et al. 1973), guinea pigs (McConnell et al. 1984; Schwetz et 
al. 1973), and hamsters (Henck et al. 1981) following gavage doses in corn oil or corn oil:acetone vehicle. 
Doses that produced death were in the µg/kg range.  Differences in the susceptibility to the lethality of 




2. HEALTH EFFECTS 
within the same species, and even in the same strain of rat bred in different laboratories (Walden and 
Schiller 1985). The use of rats of different ages may have played a role in the interlaboratory differences in 
susceptibility between rats of the same strain. Toxicity results from acute- and intermediate-duration 
categories indicated that the guinea pig is the most sensitive species to 2,3,7,8-TCDD toxicity leading to 
death (DeCaprio et al. 1986; McConnell et al. 1984; Schwetz et al. 1973; Vos et al. 1973), and that the 
hamster is the most resistant (Hanberg et al. 1989; Henck et al. 1981).  Experiments with mice that were 
injected with 2,3,7,8-TCDD intraperitoneally showed that the C57BL/6J mice responsive to 2,3,7,8-TCDD­
induced toxicity were twice as sensitive to 2,3,7,8-TCDD-induced lethality as the less-responsive DBA/2J 
strains (Gasiewicz et al. 1983a). Increased mortality was also recorded in mice following intermediate-
duration dermal exposure to 2,3,7,8-TCDD (NTP 1982a). 
Toxicity data in animals indicated that similar effects occur after exposure to CDDs by oral, dermal, or 
parenteral routes. Toxicokinetic data in mice showed that 2,3,7,8-TCDD hepatic levels were similar 
following oral, intraperitoneal, and subcutaneous exposure (Nau and Bass 1981).  However, recent data in 
rats showed that intratracheal administration of a 2,3,7,8-TCDD dose resulted in a relatively higher 
accumulation of 2,3,7,8-TCDD in the liver than after oral administration of the same dose (Diliberto et al. 
1996). Intraperitoneal administration of 2,3,7,8-TCDD was less toxic than oral dosing in acute-exposure 
experiments with hamsters (Olson et al. 1980a).  
Following acute oral exposure to 2,3,7,8-TCDD, death occurred within 6–42 days depending on the dose 
and species tested, indicating a delayed type of toxicity.  Death was usually preceded by significant weight 
loss in all duration categories. However, weight loss did not appear to be the only cause of death.  A total 
parenteral nutrition fluid given to 2,3,7,8-TCDD-exposed rats and guinea pigs protected the animals against 
wasting syndrome, but not against 2,3,7,8-TCDD-induced lethality (Gasiewicz et al. 1980; Lu et al. 1986). 
Specifically, biochemical changes indicative of severe liver damage were found in moribund rats. 
2,3,7,8-TCDD was found not only to be more toxic than its isomer 1,2,3,4-TCDD (Courtney 1976) but also 
more toxic than any other congener tested (2,7-DCDD, 1,2,3,7,8-PeCDD, 1,2,3,6,7,8-HxCDD, 
1,2,3,7,8,9-HxCDD, 1,2,3,4,6,7,8-HpCDD, and OCDD) (Courtney 1976; NCI/NTP 1980; NTP 1982b; 
Viluksela et al. 1994, 1998a). LD50 values for acute oral exposure to a mixture of 1,2,3,6,7,8-HxCDD and 
1,2,3,7,8,9-HxCDD derived for rats and mice (NCI/NTP 1980) were higher by more than 2 orders of 
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magnitude than LD50 values for 2,3,7,8-TCDD. However, 1,2,3,4,6,7,8-OCDD and 2,7-DCDD did not 
cause death in mice even at doses as high as 4,000 and 2,000 mg/kg, respectively.
Systemic Effects.
Respiratory Effects. No exposure-related respiratory effects were found in a group of Air Force Vietnam 
veterans exposed to 2,3,7,8-TCDD during aerial spraying studied sometime after exposure (Wolfe et al. 
1985). No respiratory effects clearly attributable to 2,3,7,8-TCDD have been found in workers potentially 
exposed (Calvert et al. 1991). In rhesus monkeys, intermediate-duration exposure to a lethal oral dose of 
2,3,7,8-TCDD caused nose bleeding (McNulty 1984), hemorrhage, and hyperplasia of the bronchial 
epithelium (Allen et al. 1977).  Bronchiolar adenomatoid changes were seen in mice chronically exposed 
dermally (NTP 1982a).  Furthermore, hyperplastic changes in the lungs were recorded in rats exposed orally 
to a mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD (NCI/NTP 1980).  However, mostly negative 
results were obtained in other oral studies in animals regardless of duration of exposure (Holsapple et al. 
1986b; Kociba et al. 1978a; NCI/NTP 1979a; NTP 1982a, 1982b).  The relevance of the animal findings to 
human health is unclear.  Intense acute exposure to 2,3,7,8-TCDD can produce respiratory irritation, but the 
findings from controlled epidemiologic studies do not support an association between 2,3,7,8-TCDD 
exposure and chronic respiratory disease.  It should be noted, however, that chronic bronchitis and related 
effects were observed in many Yusho and Yu-Cheng patients, who were exposed to the structurally related 
CDFs (ATSDR 1994). 
Cardiovascular Effects. While some studies have found an association between CDD exposure and 
cardiovascular disease, most studies have not found a clear association between exposure to 2,3,7,8-TCDD 
and diseases of the heart and circulatory system (Bond et al. 1983; Calvert et al. 1998; Hoffman et al. 1986; 
Moses et al. 1984; Reggiani 1980; Suskind and Hertzberg 1984; Wolfe et al. 1985). However, human 
studies have suffered from limitations such as examination of the cohorts after exposure has ended, thus 
allowing for tissue repair to occur; lack of good exposure data; and inability to examine the relationship 
between serum 2,3,7,8-TCDD levels and cardiovascular disease in most studies.  In the Ranch Hand study 
(USAF 1991), a weak association was found between decreased mean diastolic blood pressure, cardiac 
arrhythmias, and decreases in peripheral pulses and exposure to 2,3,7,8-TCDD.  Bertazzi et al. (1989b) and 
Pesatori et al. (1998) found increases in deaths from ischemic heart disease and cardiovascular disease in 
men and chronic rheumatic heart disease in women in the 10-year period following the Seveso accident. 
However, the authors attributed these findings to post-accident stress rather than the 2,3,7,8-TCDD 
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exposure. In workers exposed occupationally to 2,3,7,8-TCDD and other CDD congeners at the Boehringer 
Hamburg plant, a statistically significant trend for increased risk of cardiovascular disease and ischemic 
heart disease mortalities with increasing serum lipid levels of 2,3,7,8-TCDD or TEQ (CDDs and CDFs) was 
found (Flesch-Janys et al. 1995).  An international study of more than 20,000 workers followed from 1939 
to 1992 found an increased risk for death from cardiovascular disease, especially ischemic heart disease, 
among exposed workers, but the authors did not rule out the influence of risk factors such as cigarette 
smoking, high fat diet, obesity, physical inactivity, and serum lipids (Vena et al. 1998). 
Experiments in animals demonstrated that exposure to relatively high doses of 2,3,7,8-TCDD can cause 
various pathophysiological effects.  Acute oral exposure of rats increased the basal tension of the left 
cardiac atria (Kelling et al. 1987) or decreased the basal rate for spontaneous beating, depending on the dose 
used (Hermansky et al. 1988; Kelling et al. 1987).  Reduced blood pressure and increased myocardial 
peroxidase activity were also recorded.  All of the effects on the heart in these two studies were attributed to 
a hypothyroid condition caused by near-lethal doses (Hermansky et al. 1988).  Other studies have suggested 
a direct effect of 2,3,7,8-TCDD on cardiac muscle, as for example an intraperitoneal injection of 
2,3,7,8-TCDD to guinea pigs reduced the contractive responsiveness of isolated myocardium (Brewster et 
al. 1987; Canga et al. 1988). 
Reports of histological findings are few. Myocardial degenerative changes were reported in rats after 
chronic oral exposure to a lethal dose of 2,3,7,8-TCDD (Kociba et al. 1978a), and hemorrhages were 
reported in monkeys after intermediate-duration dietary exposure to near-lethal doses (Allen et al. 1977). 
However, most studies did not find any histopathological changes in rats and mice following chronic oral 
exposure to 2,3,7,8-TCDD (NTP 1982b), 2,7-DCDD (NCI/NTP 1979a), or a mixture of 1,2,3,6,7,8-HxCDD 
and 1,2,3,7,8,9-HxCDD (NCI/NTP 1980). Similarly, no changes were reported after chronic dermal 
exposure of mice to 2,3,7,8-TCDD (NTP 1982a).  There is no conclusive evidence that the cardiovascular 
system is a target for 2,3,7,8-TCDD toxicity. 
Gastrointestinal Effects. Limited information is available regarding gastrointestinal effects of 
2,3,7,8-TCDD in humans.  Earlier studies of individuals with exposure to substances contaminated with 
2,3,7,8-TCDD found significant elevations in self-reported ulcers (Bond et al. 1983; Suskind and Hertzberg 
1984), but a study of Vietnam veterans (USAF 1991) failed to find such effect.  A more recent cross-
sectional medical study of workers employed more than 15 years earlier in the production of 
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2,3,7,8-TCDD-contaminated chemicals found no association between 2,3,7,8-TCDD exposure (body 
burden) and gastrointestinal disease (Calvert et al. 1992). 
Only a few of the numerous animal studies found any effects.  Gastrointestinal ulcerations were reported in 
minks after an acute oral exposure to a lethal dose of 2,3,7,8-TCDD (Hochstein et al. 1988), and 
hemorrhages were reported in rats following chronic exposure (Van Miller et al. 1977).  Ileitis and 
peritonitis were observed in hamsters receiving a single lethal dose of 2,3,7,8-TCDD (Olson et al. 1980a). 
A trophic effect on the antral mucosa was found in 2,3,7,8-TCDD treated rats, in contrast to atrophy found 
in pair-fed control animals (Theobald et al. 1991).  Although these authors attempted to relate the 
mechanism of action to hormonal effects, a definitive mechanism was not established.  Changes progressing 
from epithelial hyperplasia and metaplasia of gastric mucosa to stomach ulcerations were observed in 
rhesus monkeys with prolonged oral exposure (Allen et al. 1977; McConnell et al. 1978a; McNulty 1984). 
These data indicate that primates are particularly sensitive to 2,3,7,8-TCDD-induced gastrointestinal 
toxicity; however, the effects are seen at doses which caused severe toxicity at multiple sites.  In contrast, 
most studies in rodents did not find any gastrointestinal effects after oral or dermal exposure to 
2,3,7,8-TCDD (Christian et al. 1986a; Henck et al. 1981; Kociba et al. 1978a; NTP 1982a, 1982b), or after 
oral exposure to a mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD (NCI/NTP 1980) and 2,7-DCDD 
(NCI/NTP 1979a). The available information suggests that the gastrointestinal tract is not a target for 
2,3,7,8-TCDD toxicity in humans.  
Hematological Effects. Limited human data were located regarding hematological effects following 
exposure to CDDs. Increases in leukocyte and platelet counts were reported in Vietnam veterans involved 
in Operation Ranch Hand (USAF 1991), which suggested the presence of a low-level, chronic inflammatory 
response related to higher levels of 2,3,7,8-TCDD exposure.  Increased prevalence of high white blood cell 
counts was found in a population exposed to 2,3,7,8-TCDD in the environment, but the increase was not of 
clinical importance (Hoffman et al. 1986), and other epidemiological studies reported negative results 
(Stehr et al. 1986; Wolfe et al. 1985). 
Increased packed-cell volume was found in guinea pigs following a single intraperitoneal injection of 
2,3,7,8-TCDD; however, this was considered to be secondary to progressive dehydration of exposed 
animals with decreased water consumption (Gasiewicz and Neal 1979).  Several studies in animals reported 
hematological effects after intermediate-duration exposure to 2,3,7,8-TCDD. Among the effects observed 
were reduced leukocytes in guinea pigs at 0.001 µg/kg/day (Vos et al. 1973), thrombocytopenia and 
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hemoconcentration in rats at 0.8–1 µg/kg/day (Viluksela et al. 1994; Zinkl et al. 1973), and anemia and 
bone marrow hypoplasia in rhesus monkeys at 0.1 µg/kg/day (McNulty 1984).  Reduced erythrocytes was 
reported in rats chronically exposed to 0.1 µg 2,3,7,8-TCDD/kg/day in the feed (Kociba et al. 1978a). 
Splenic changes include reduced germinal centers after acute (Christian et al. 1986a) and splenic atrophy 
after chronic (Van Miller et al. 1977) oral exposures in rats.  Furthermore, splenic hyperplasia was found in 
rats orally exposed to a mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD for an intermediate duration 
(NCI/NTP 1980). Whether or not the splenic changes were secondary to hematopoietic effects is unclear. 
No hematological effects were found after acute oral exposure in minks (Hochstein et al. 1988) and mice 
(Holsapple et al. 1986a), intermediate oral exposure in guinea pigs (DeCaprio et al. 1986), chronic oral 
exposure in rats and mice (NTP 1982a; Oughton et al. 1995), chronic dermal exposure in mice (NTP 
1982a), and acute intraperitoneal exposure in rats (Mason and Safe 1986a).  Similarly, no effects were 
reported in rodents exposed chronically to 2,7-DCDD (NCI/NTP 1979a) or a mixture of 1,2,3,6,7,8­
HxCDD and 1,2,3,7,8,9-HxCDD (NCI/NTP 1980) by the oral route, but thrombocytopenia was reported in 
male Sprague-Dawley rats exposed for 13 weeks to 1,2,3,4,6,7,8-HpCDD (Viluksela et al. 1994). 
Decreased hematocrit and reduced platelet counts were reported in rats administered 1,2,3,7,8-PeCDD or 
1,2,3,4,7,8-HxCDD for 13 weeks at dose levels that caused lethality (Viluksela et al. 1998a). 
No clear picture regarding hematologic effects of 2,3,7,8-TCDD emerges from the studies in animals.  From 
the limited data, it appears, however, that mice are less sensitive than other species.  The relevance of the 
findings in animals to human health is difficult to ascertain. 
Musculoskeletal Effects. No relevant information was located  regarding musculoskeletal effects in 
humans exposed to CDDs.  However, evidence from case reports in the Yu-Cheng incident (which involved 
oral exposure to the structurally related CDFs and PCBs) indicate that musculoskeletal effects may occur 
after oral exposure to CDDs. Guo et al. (1994) reported that Yu-Cheng children were smaller and had less 
total lean mass and soft-tissue mass compared to matched control subjects.  Hemorrhages in the 
musculoskeletal system of monkeys were observed following an oral intermediate-duration exposure to 
2,3,7,8-TCDD (Allen et al. 1977). However, monkeys in this experiment were in terminal stages, and 
hemorrhages were found in several other systems.  There is no evidence that would indicate that the 
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Hepatic Effects. Exposure to 2,3,7,8-TCDD induces liver microsomal enzymes in both humans and 
animals, regardless of the route or duration of exposure.  Increased urinary δ-glucaric acid (UGA) excretion, 
an indirect index of enzyme induction, was found in children with chloracne living in the Seveso area 
following the 1976 industrial accident (Ideo et al. 1982). Biochemical changes (increased cholesterol and 
bilirubin levels, induced GGT and ALT activities) indicated liver effects in exposed humans (Hoffman et al. 
1986; Mocarelli et al. 1986). Biochemical changes indicative of a subclinical effect on lipid metabolism 
were found in Vietnam veterans involved in Operation Ranch Hand (USAF 1991).  Biochemical 
examinations found disorders in the metabolism of porphyrins, lipids, carbohydrates, and plasma proteins in 
workers exposed to 2,3,7,8-TCDD during the manufacture of herbicides (Jirasek et al. 1976; Pazderova-
Vejlupkova et al. 1981). In addition, histopathological changes (steatosis, fibrosis) were also documented. 
A more recent and better-designed study of workers employed at 2 chemical plants in the manufacture of 
sodium trichlorophenol and its more than 15 years earlier derivatives found no evidence of an elevated risk 
for long-term clinical hepatic disease (Calvert et al. 1992). Exposure was assessed by measuring lipid-
adjusted serum 2,3,7,8-TCDD levels, and exposed workers had serum 2,3,7,8-TCDD levels significantly 
higher than unexposed controls. The negative findings, however, are not necessarily inconsistent with 
results from earlier studies, but suggest that hepatic effects observed in humans immediately after exposure 
probably resolve with time.  A follow-up study of the same cohort found a positive association between 
serum 2,3,7,8-TCDD levels and the concentration of triglycerides and a negative correlation with HDL 
cholesterol; these associations were small when compared with the influence of many other factors (Calvert 
et al. 1996). 
Studies in animals have shown that exposure to 2,3,7,8-TCDD can induce hepatotoxicity in several species 
administered the chemical by various exposure routes for several exposure durations.  The severity of the 
lesion is dependent not only on the species, but also on the strain.  In general, it appears that rats exhibit 
more signs of hepatotoxicity than guinea pigs and hamsters.  Histological alterations of the liver are 
common findings observed in animals exposed to 2,3,7,8-TCDD.  These effects have been reported after 
acute exposure in rats (Christian et al. 1986; Hermansky et al. 1988), mice (Greig 1984; Greig et al. 1987; 
Kelling et al. 1985), and guinea pigs (Turner and Collins 1983); after intermediate-duration exposure in rats 
(NTP 1982b; Van Miller et al. 1977), mice (Thigpen et al. 1975), guinea pigs (DeCaprio et al. 1986), and 
monkeys (Allen et al. 1977; McNulty 1984); and after chronic exposure in rats (Kociba et al. 1978a). 
Hepatic lesions in rats are characterized by degenerative and necrotic lesions with the appearance of 
mononuclear cell infiltration, multinucleated giant hepatocytes, and increased number of mitotic figures and 
intracytoplasmic lipid droplets.  Markers of hepatic damage such as serum ALT and AST activities usually
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increase in animals that exhibit altered liver histology (Greig 1984; Rosenthal et al. 1989; Smith et al. 
1981). DBA/2J mice developed hepatic necrosis and inflammation without fatty changes after acute 
intraperitoneal exposure to 2,3,7,8-TCDD (Shen et al. 1991). Only slight lipid accumulation was found 
after exposure to a high dose (600 µg/kg).  In contrast, severe fatty changes were observed in C57BL/6J 
mice, indicating that the steatitic effect may depend on the Ah locus.  Histological lesions may be severe 
enough to be a contributing factor in death. Dose-related increases in intracellular and paracellular 
permeability of the biliary tree was observed in rats administered ip doses of 2,3,7,8-TCDD (Davidson and 
Fujimoto 1987). 
2,3,7,8-TCDD has been found to be porphyrogenic in both rats and mice (Cantoni et al. 1981; Goldstein et 
al. 1977, 1982; Jones and Sweeney 1977, 1980).  The mechanism of induction of porphyria is not known. 
2,3,7,8-TCDD is a potent inducer of the initial and rate-limiting enzyme involved in heme synthesis, ALA­
synthetase, but no increased activity was seen in mice which exhibited porphyria after treatment with 
2,3,7,8-TCDD for 11 weeks (Jones and Sweeney 1980).  A more likely explanation is that the primary 
event in 2,3,7,8-TCDD-induced porphyria is inhibition of  hepatic porphyrinogen decarboxylase (Jones and 
Sweeney 1980).  Crossbreeding experiments have shown that porphyrinuria was inherited together with 
AHH inducibility (Jones and Sweeney 1980), indicating that the Ah locus is involved in the porphyrogenic 
response to 2,3,7,8-TCDD. 
Enzyme induction is one of the most sensitive responses to 2,3,7,8-TCDD exposure, and has been one of 
the most extensively studied biochemical responses produced by 2,3,7,8-TCDD.  The MFO system is the 
most thoroughly investigated, and AHH and EROD (CYP1A1 markers) and acetanilide-4-hydroxylase 
(ACOH) (CYP1A2 marker) are the most frequently assayed enzyme activities.  The lowest single oral dose 
of 2,3,7,8-TCDD shown to induce AHH activity in rats was 0.002 µg/kg (Kitchens and Woods 1979). 
Similarly, the induction of EROD was observed in the liver in Wistar rats (Abraham et al. 1988) and 
C57BL/6 mice (Harris et al. 1990) following subcutaneous and intraperitoneal injection, respectively.  In 
female B6C3F1 mice, administration of a single oral dose of $0.1 µg 2,3,7,8-TCDD/kg significantly 
increased liver, lung, and skin EROD activities and liver acetanilide-4-hydroxylase activity (CYP1A2 
marker) (Diliberto et al. 1995).  In the three tissues examined, induction of EROD was dose-dependent. 
Also in B6C3F1 female mice, repeated oral administration of doses as low as 1.5 ng 2,3,7,8-TCDD/kg day 
significantly increased liver, lung, and skin EROD activities and liver acetanilide-4-hydroxylase activity 
(DeVito et al. 1994). In both studies (DeVito et al. 1994; Diliberto et al. 1995), liver, lung, and skin 
exhibited different sensitivities for enzyme induction.  In male C57BL/6J and DBA/2J mice, the ED50 
CDDs 275 
2. HEALTH EFFECTS 
values for induction of hepatic EROD after a single dose of 2,3,7,8-TCDD were 1.1 and 16 µg/kg, 
respectively (Weber et al. 1995).  In an intermediate-duration dietary study in  Sprague-Dawley rats, doses 
as low as 0.014 µg/kg/day induced both EROD and acetanilide-4-hydroxylase (Van Birgelen et al. 1995). 
Enzyme induction is a reversible process dependent on the dose and the dosing regime (Fan and Rozman 
1995; Li and Rozman 1995).  In male C57BL/6N mice, Pegram et al. (1995) showed that induction of 
acetanilide-4-hydroxylase by 2,3,7,8-TCDD was age-dependent, as it was significantly greater in old than 
in young mice. 
In addition to altering the activities of enzymes from the MFO system in the liver, 2,3,7,8-TCDD also alters 
the activities of some key liver enzymes of the intermediary metabolism.  These effects are intimately 
related with the wasting syndrome as discussed below (see Body Weight Effects).  For example, 
2,3,7,8-TCDD decreased the activities of hepatic PEPCK and G-6-Pase (key enzymes of gluconeogenesis) 
in mice and rats (Fan and Rozman 1995; Li and Rozman 1995; Viluksela et al. 1994; Weber et al. 1995) 
and also reduced the activity of TdO (key enzyme of tryptophan metabolism) in rats (Li and Rozman 1995; 
Viluksela et al. 1994), but not in mice (Weber et al. 1995). 
Vitamin A (retinol) is essential for normal growth and cell differentiation, particularly for epithelial cells. 
2,3,7,8-TCDD has been shown to decrease the storage of vitamin A in rodents.  Decreased ability to store 
vitamin A (retinol) was found in rats and guinea pigs; however, partial recovery of the retinol content by 
week 16 postexposure was reported only in rats.  A single oral dose of 2,3,7,8-TCDD caused a 70% 
reduction in the liver storage of retinol in rats when measured 2 months postexposure (Thunberg et al. 
1979). The reduction was dose-related within the dose range studied (0.1–10 µg/kg) (Thunberg et al. 
1980). Reduction of hepatic retinol by 2,3,7,8-TCDD was greater (87%) in younger rats with lower initial 
weights (Thunberg et al. 1984) than in more mature rats (60%) (Thunberg et al. 1979, 1980).  In a 13-week 
dietary study in female Sprague-Dawley rats, dose of $0.014 µg/kg/day produced a dose-dependent 
reduction in hepatic retinol (Van Birgelen et al. 1995).  In addition to reducing hepatic retinol storage, 
2,3,7,8-TCDD exposure induced the activity of UDPGT and AHH in the rat, results obtained with other 
compounds (polychlorinated phenols, methylcholanthrene, phenobarbital) suggest that the effect is not 
mediated by the Ah receptor (Thunberg et al. 1984). Experiments with Sprague-Dawley rats showed that 
pretreatment with 2,3,7,8-TCDD influenced not only the storage, but also urinary and fecal excretion of a 
subsequent dose of radioactively labeled retinyl acetate.  Retinol-content was also altered in various tissues; 
liver, intestine, and epididymis content decreased by 39–53, 19–67, and 18–44%, respectively, while renal 
content increased 3–30 times (Håkansson et al. 1989b).  The 2,3,7,8-TCDD pretreated rats, though not 
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retinol-deficient, used a subsequently administered dose of retinyl acetate in a manner similar to retinol-
deficient animals. 
Mild-to-moderate hepatic effects of 2,3,7,8-TCDD exposure were also found after intermediate-duration 
dermal exposure in mice (Hebert et al. 1990; NTP 1982a), after acute intratracheal instillation in rats 
(Nessel et al. 1990, 1992), after acute intraperitoneal exposure in rats (DiBartolomeis et al. 1986; Mason 
and Safe 1986a), hamsters (Olson et al. 1980a), and guinea pigs (Gasiewicz and Neal 1979; Holcomb et al. 
1988; Lu et al. 1986), and after acute subcutaneous exposure in mice (Courtney 1976).  Some effects 
(increased plasma albumin, total protein) were considered to be secondary to progressive dehydration of 
exposed animals with decreased water consumption (Gasiewicz and Neal 1979). 
Hepatotoxicity was observed in rats and mice chronically exposed by gavage to a mixture of 1,2,3,6,7,8­
HxCDD and 1,2,3,7,8,9-HxCDD (NCI/NTP 1980). Liver effects were also found in rats exposed by diet to 
HpCDD (Viluksela et al. 1994), 1,2,3,7,8-PeCDD and 1,2,3,4,7,8-HxCDD (Viluksela et al. 1998b), and 
OCDD for subchronic durations (Birnbaum et al. 1989a; Couture et al. 1988), and to 2,7-DCDD for a 
chronic duration (NCI/NTP 1979a). 
It is clear that the liver is a target for 2,3,7,8-TCDD toxicity in animals.  In humans, hepatic alterations have 
been observed sometimes following exposure to high 2,3,7,8-TCDD levels.  In general, the effects are mild 
and transient, which might explain the negative findings of Calvert et al. (1992). 
Renal Effects. The overall evidence from studies of populations exposed to high concentrations of 
2,3,7,8-TCDD suggests that the kidney is not a target for 2,3,7,8-TCDD toxicity in humans (Stehr et al. 
1986; USAF 1991; Wolfe et al. 1985). 
Likewise, the kidney is not a target organ in adult animals.  No effects were found in mice exposed acutely 
(Holsapple et al. 1986a; Weber et al. 1995) and in rats exposed chronically (Kociba et al. 1978a; NTP 
1982b) to 2,3,7,8-TCDD by the oral route or in mice exposed by the dermal route (NTP 1982a).  Similarly, 
no changes were found in rodents exposed chronically to 2,7-DCDD (NCI/NTP 1979a) or a mixture of 
1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD (NCI/NTP 1980) by the oral route. 
Renal effects which were seen at near-lethal doses and considered secondary to frank toxicity included pale 
kidneys in minks after acute oral exposure to 2,3,7,8-TCDD (Hochstein et al. 1988), and enlarged 
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convoluted tubules and Bowman's spaces together with epithelial hyperplasia in rats (Christian et al. 1986) 
and monkeys (McConnell et al. 1978a) orally exposed for acute durations and in monkeys orally exposed 
for intermediate durations (Allen et al. 1977).  An increased incidence of renal inflammatory changes 
recorded in mice after chronic oral exposure to 2,3,7,8-TCDD (NTP 1982b) was not a primary effect. 
Decreased glomerular filtration rate (Anaizi and Cohen 1978; Pegg et al. 1976) and increased tubular 
filtration rate (Anaizi and Cohen 1978) were reported in rats treated with a single intraperitoneal dose of 
2,3,7,8-TCDD. The authors concluded that observed renal effects were probably secondary to the general 
toxic reaction to 2,3,7,8-TCDD (Pegg et al. 1976). However, renal effects (mainly hydronephrosis) were 
found in pups of 2,3,7,8-TCDD-exposed pregnant rodents (Abbott et al. 1987a, 1987b; Courtney 1976; 
Schwetz et al. 1973) indicating special ability of CDDs to induce effects in the developing kidneys. 
Endocrine Effects.  No biochemical evidence of thyroid dysfunction, as evaluated by serum levels of T4, 
triiodothyronine, and TSH, were reported in a group of 18 workers examined 17 years after an industrial 
accident during the manufacture of 2,4,5-T (Jennings et al. 1988).  The small sample size, the fact that no 
measure of exposure was provided, and the long period of time between exposure and examination preclude 
any conclusion regarding possible effects of 2,3,7,8-TCDD.  Zober et al. (1994) found a significant increase 
in the incidence of thyroid disease (no further details provided) 35 years after the BASF accident.  An 
increased incidence of diabetes and subclinical decreases in thyroid function were found in Vietnam 
veterans who participated in operation Ranch Hand (USAF 1991).  
A strong positive association was found between glucose intolerance or increased risk of diabetes and 
2,3,7,8-TCDD serum levels (USAF 1991).  The diabetes finding remained significant even after adjusting 
for body fat.  Furthermore, subclinical effects in thyroid function (significant decrease in mean T3 % uptake 
and increases in mean TSH) were reported for Operation Ranch Hand veterans with high 2,3,7,8-TCDD 
serum levels (USAF 1991).  However, the magnitude of the differences was not considered physiologically 
significant. Diabetes and glucose intolerance were also found in workers exposed occupationally 
(Pazderova-Vejlupkova et al. 1981; Sweeney et al. 1992).  However, in the Sweeney et al. (1992) study, age 
and body mass index, both known risk factors for diabetes, appear to have a greater influence on the 
increase in both the risk of diabetes and elevated fasting serum glucose levels than 2,3,7,8-TCDD level.  A 
follow-up study of Operation Ranch Hand veterans confirmed earlier findings of glucose abnormalities and 
increased risk of diabetes mellitus in exposed subjects (Henriksen et al. 1997).  Furthermore, a follow-up of 
Seveso residents found a significant increase in deaths from diabetes among women from zone B (Pesatori 
et al. 1998). 
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The evidence available from epidemiological studies suggests that exposure to high concentrations of CDDs 
may induce long-term alterations in glucose metabolism and subtle alterations (of unknown clinical 
relevance) in thyroid function. 
Numerous studies in rodents have reported alterations in thyroid status after exposure to 2,3,7,8-TCDD. 
End points commonly examined included serum levels of T4, T3, TSH, and activity of hepatic microsomal 
UDPGT, an enzyme which increases glucuronation of T4 and clearance.  The effects on T4 levels are dose-
dependent and also appear to be species-dependent.  For example, serum T4 was decreased in rats after 
acute (Bastomsky 1977; Fan and Rozman 1995; Gorski and Rozman 1987; Henry and Gasiewicz 1987; 
Hermansky et al. 1988; Potter et al. 1986) and intermediate exposure (Li and Rozman 1995; Sewall et al. 
1995; Van Birgelen et al. 1995; Viluksela et al. 1994). In contrast, the response of serum T3 levels ranged 
from increased (Bastomsky 1977; Potter et al. 1986) to no change or inconsistent change (Fan and Rozman 
1995; Henry and Gasiewicz 1987; Potter et al. 1983; Sewall et al. 1995) to decreased (Pazdernik and 
Rozman 1985).  In hamsters, a species less susceptible to 2,3,7,8-TCDD toxicity than rats, T4 serum levels 
were increased by 2,3,7,8-TCDD even though hepatic microsomal UDPGT activity was significantly 
increased, suggesting that mechanisms other than induction of this enzyme must account for the species-
specific alterations in T4 (Henry and Gasiewicz 1987).  A further species-specific response was noted by 
Weber et al. (1995) who reported that in C57BL/6J and DBA/2J mice, both T4 and T3 levels were 
decreased in a parallel fashion as a result of a single dose of 2,3,7,8-TCDD.  According to Weber et al. 
(1995), the decrease in T3 in mice would reduce the de novo synthesis of fatty acids, thus improving the 
balance of metabolic energy which might explain, at least in part, the reduced susceptibility of mice to 
2,3,7,8-TCDD toxicity compared to rats.  It is interesting to note that Long Evans rats exhibited a dose-
related increase in T4 and T3 90 days after single doses of 2,3,7,8-TCDD that decreased T4, but did not 
significantly alter T3 4 days after dosing (Fan and Rozman 1995).  The significance of this finding was not 
entirely clear, but according to the authors it indicated that sustained effects of 2,3,7,8-TCDD on thyroid 
homeostasis trigger adaptive responses which persist even after most of the 2,3,7,8-TCDD has been cleared. 
Decreased levels of serum T4 have also been reported in rats administered other CDD congeners such as 
1,2,3,7,8-PeCDD and 1,2,3,4,7,8-HxCDD in intermediate exposure duration studies (Viluksela et al. 
1998b). 
The reduction in circulating T4 levels observed in rats appears, in part, to be due to the increased activity of 
UDPGT (Bastomsky 1977; Sewall et al. 1995), but other possibilities have also been discussed.  McKinney 
et al. (1985b) proposed that T4 and T3 might be endogenous ligands for the Ah receptor, and 
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that 2,3,7,8-TCDD might be an agonist for the T4 receptor.  Although some evidence was presented in 
support for this hypothesis, the weight of evidence, summarized by Goldstein and Safe (1989), argues 
against 2,3,7,8-TCDD being a thyroid agonist.  Lans et al. (1993, 1994) have explored the possibility that 
hydroxylated 2,3,7,8-TCDD metabolites competitively interact with plasma thyroid hormone transport 
proteins, thus facilitating clearance and excretion of T4.  They tested various hydroxy-CDDs in an in vitro 
competitive-binding assay using purified human TTR and found that  those with chlorine substitution 
adjacent to the hydroxy group (7-OH-2,3,8-TrCDD and 2-OH-1,3,7,8-TCDD) showed similar or higher 
relative-binding potency than T4 (Lans et al. 1993).  8-OH-2,3-DCCD, which did not contain chlorine 
substitution adjacent to the OH group, did not displace T4. In a subsequent study, Lans et al. (1994) studied 
the displacement of T4 from globulin, the major T4-binding protein in humans by hydroxy CDD 
metabolites (in contrast to TTR in rodents).  The results showed than none of the tested hydroxylated CDD 
metabolites inhibited binding of T4 by T4-binding globulin and suggested that hydroxylated CDD 
metabolites can cause different effects in rodents and humans.  
The overall evidence suggests that in rodents, thyroid hormones modify 2,3,7,8-TCDD toxicity, but a 
reduction in T4 (at least in rats) does not mediate toxicity. 
Administration of 2,3,7,8-TCDD to rodents was also shown to reduce blood corticosterone levels (Balk and 
Piper 1984; DiBartolomeis et al. 1987; Mebus and Piper 1986).  This effect has been attributed to decreased 
corticosterone synthesis by decreasing cholesterol side-chain cleavage in the adrenal gland.  More recent 
studies suggested that 2,3,7,8-TCDD may interfere with secretion or synthesis of appropriate, bioactive 
ACTH from the anterior pituitary gland, which could compromise adrenal steroidogenenesis (Bestervelt et 
al. 1993). 
Administration of 2,3,7,8-TCDD to animals results in a wide range of endocrine responses which are not 
only species-dependent, but also exhibit variability within species.  Endocrine effects observed in humans 
have not been limited to thyroid effects and diabetes; alterations in levels of reproductive hormones, as 
summarized in the sections on reproductive effects have also been observed.  The wide array of endocrine 
effects induced by CDDs and structurally-related chemicals has triggered increased interest within the 
scientific community and the term “endocrine disruptors” is currently being used to describe some members 
of this class of chemicals.  The available information suggests that CDDs may cause adverse endocrine 
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Dermal Effects. Chloracne is the most easily recognized effect of exposure to 2,3,7,8-TCDD and 
structurally related chlorinated organic chemicals.  Chloracne is a high-dose response in animals and 
humans; and its presence in humans indicates exposure to CDDs and other chlorinated organic compounds, 
but its absence does not preclude such exposure. Furthermore, the variability of the response in more 
highly exposed individuals suggests that susceptibility varies among individuals.  Chloracne can first occur 
on the face, particularly under the eyes and behind the ears.  With increasing exposure, the rest of the face 
and neck, upper arms, chest, back, abdomen, outer thighs, and genitalia may be affected.  When severe, 
chloracne can cover the entire body.  Clinically, changes vary from an eruption of comedones to occurrence 
of papules and pustules. Histologically, the lesions consist of keratinous cysts caused by squamous 
metaplasia of sebaceous glands.  The acute stage is followed by vermiculite skin atrophy.  The incidence of 
other dermal effects, including hyperpigmentation and hirsutism, correlates with the intensity of chloracne 
(Poland et al. 1971). Chloracne has been reported to have occurred in at least a small number of workers in 
all accidents at TCP-production facilities (Jansing and Korff 1994; May 1973; Schecter et al. 1993; Suskind 
1985; Zober et al. 1990); among subjects involved in production of 2,3,7,8-TCDD-contaminated products 
(Bond et al. 1989a; Moses and Prioleau 1985; Pazderova-Vejlupkova et al. 1981; Poland et al. 1971; 
Suskind and Hertzberg 1984); in laboratory workers exposed to 2,3,7,8-TCDD (Oliver 1975); and among a 
small percentage of Seveso residents (Assennato et al. 1989; Caramaschi et al. 1981; Mocarelli et al. 1986; 
Reggiani 1980). Chloracne, however, was not observed among Missouri residents (Hoffman et al. 1986; 
Webb et al. 1989) examined 10 years after exposure or among Ranch Hand veterans (Burton et al. 1998; 
USAF 1991). 
The dermal changes induced by 2,3,7,8-TCDD may appear as soon as 2 days after exposure (Ott et al. 1993; 
Zober et al. 1990) or within months (Caramaschi et al. 1981; Reggiani 1980).  The lesions may heal within 
a few months after cessation of exposure (Assennato et al. 1989) despite high serum 2,3,7,8-TCDD levels 
(Mocarelli et al. 1991) or persist for over 15 years, depending upon severity (Crow 1978; Jansing and Korff 
1994; Moses and Prioleau 1985; Schecter et al. 1993; Suskind and Hetzberg 1984).  Children exposed to 
2,3,7,8-TCDD appear to be more sensitive than adults, and individuals similarly exposed have variable 
susceptibility to chloracne (Mocarelli et al. 1991).  Data from analyses of cases among chemical workers 
suggested that the risk for developing chloracne was highest among workers who were exposed at younger 
ages, among those who had been exposed for the longest periods, and among workers whose jobs rated at 
the highest intensity of exposure (Ott et al. 1987).  The variability in the chloracneic response can be 
illustrated the following evidence from the Seveso incident:  no chloracne was observed in subjects with 
initial serum lipid 2,3,7,8-TCDD levels of <800 ppt, chloracne was present at serum lipid levels of 
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>12,000 ppt; and between 800 and 12,000 ppt the occurrence of chloracne was sporadic (Mocarelli et al. 
1991); this suggested that, in this population, 8,000 to 10,000 ppt 2,3,7,8-TCDD in blood was necessary for 
expression of chloracne. German workers involved in TCP production who had chloracne had estimated 
adipose levels $200 ppt 2,3,7,8-TCDD and $2,000 ppt HxCDD at the time of diagnosis (Beck et al. 1989a). 
In another study of German workers, 80% of the severe chloracne cases had 2,3,7,8-TCDD levels of 
$250 ppt; however, 26% of the workers without chloracne also had 2,3,7,8-TCDD levels of $250 ppt (Ott 
et al. 1993). Schecter et al. (1993) provided the first reported incidence of chloracne in females with 
elevated dioxin blood levels from occupational exposure.  Their observation that one worker diagnosed 
with chloracne in their study had the lowest 2,3,7,8-TCDD blood concentration, whereas two workers with 
the higher levels did not display chloracne, confirmed the view that chloracne indicates exposure to dioxin, 
but its absence does not preclude such exposure. 
No studies were located regarding dermal effects in humans exposed specifically to CDDs by the oral route. 
Evidence from human case reports in the Yusho/Yu-Cheng incidents (which involved exposure to CDFs, 
PCBs, and CDDs) and from animal studies, however, indicates that dermal effects could occur after 
exposure by the oral route (ATSDR 1994). 
Oral studies of 2,3,7,8-TCDD showed the development of rough hair in hamsters (Henck et al. 1981) and 
skin thickening in A2G-hr/+ mice (Greig 1984) after acute exposure.  Chronic oral exposure to 
2,3,7,8-TCDD caused dermatitis in B6C3F1 mice (Della Porta et al. 1987) and amyloidosis in Swiss mice 
(Toth et al. 1979). Rhesus monkeys proved to be very sensitive to 2,3,7,8-TCDD-induced dermal effects. 
The changes consisted of swollen eyelids, nail loss, facial alopecia, and acneform lesions after both acute­
(McConnell et al. 1978a) and intermediate-duration oral exposures (Allen et al. 1977; McNulty 1984). 
Dermal exposure to 2,3,7,8-TCDD induced hyperkeratosis and epidermal hyperplasia in hairless HRS/J 
mice after acute- (Puhvel and Sakamoto 1988) and intermediate-duration (Puhvel et al. 1982) exposures. 
While acneiform lesions were reported in CD-1 mice after intermediate-duration dermal exposure to 
2,3,7,8-TCDD (Berry et al. 1978, 1979), no effects were found in Swiss Webster mice chronically exposed 
to lower levels (NTP 1982a). 
The data available suggest that 2,3,7,8-TCDD is a dermal toxicant both in humans and animals. 
Erythematous skin rashes and chloracne are considered one of the hallmarks of 2,3,7,8-TCDD toxicity, 
although it can be caused also by exposure to other polyhalogenated aromatic compounds.  It is also worth 
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mentioning that although in humans chloracne indicates exposure to chlorinated or halogenated aromatics, 
lack of chloracne does not indicate that exposure has not occurred. 
Ocular Effects.  The incidence of eye irritation correlated with the intensity of chloracne in a study of 
workers employed in a 2,4,5-T factory (Poland et al. 1971), but the role of 2,3,7,8-TCDD, if any, cannot be 
established. No studies were located regarding ocular effects in humans exposed specifically to CDDs by 
the oral route. Evidence from the human case reports in the Yusho/Yu-Cheng incidents (which involved 
exposure to CDFs, PCBs, and less so CDDs) and from animal studies, however, indicates that ocular effects 
could occur after exposure by the oral route (ATSDR 1994).  Ocular effects observed in the Yusho and Yu-
Cheng victims included hypersecretion of the Meibomian glands, abnormal pigmentation of the 
conjunctiva, and swelling of the eyelids (Hsu et al. 1994; Masuda 1994). 
Topical application of 2,7-DCDD, with no toxic 2,3,7,8-chlorine pattern, 2,3,7,8-TCDD, and mixed 
HxCDD, or OCDD into the conjunctival sac of rabbits caused transient pain and conjunctival inflammation 
(Schwetz et al. 1973). 
Based on adverse ocular effects observed in humans and animals exposed to chemicals structurally-related 
to CDDs and animals (monkeys) exposed to 2,3,7,8-TCDD itself, it is reasonable to assume that CDDs will 
cause similar effects under similar exposure conditions. 
Body Weight Effects.  A transient weight loss was reported in a small number of subjects exposed to 
2,3,7,8-TCDD in the workplace (Jirasek et al. 1976; Oliver 1975). However, due to the lack of data from 
controlled studies, the role of 2,3,7,8-TCDD, if any, is difficult to ascertain.  Although weight loss has not 
been well documented in humans following exposure to 2,3,7,8-TCDD, numerous animal studies provide 
evidence that exposure to CDDs causes the wasting syndrome.  Acute oral exposure to 2,3,7,8-TCDD 
induced weight loss in rats (Christian et al. 1986a; Moore et al. 1985; Roth et al. 1988; Seefeld and Peterson 
1984; Seefeld et al. 1984a, 1984b; Walden and Schiller 1985), mice (Hanberg et al. 1989; Kelling et al. 
1985; Smith et al. 1976; Weber et al. 1995), guinea pigs (Hanberg et al. 1989; Umbreit et al. 1985), 
hamsters (Hanberg et al. 1989), and monkeys (McConnell et al. 1978a).  Similarly, body weight changes 
were found after intermediate-duration oral exposure to 2,3,7,8-TCDD in rats (Diliberto et al. 1996; NTP 
1982b; Van Birgelen et al. 1995; Viluksela et al. 1994; Vos et al. 1973), guinea pigs (DeCaprio et al. 1986; 
Vos et al. 1973), mice (Thigpen et al. 1975; Vos et al. 1973), and monkeys (McNulty 1984), and after 
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Porta et al. 1987). In addition, milder changes, represented usually by decreases in body weight gain, were 
seen after oral exposure to other congeners (NCI/NTP 1979a, 1980; Schwetz et al. 1973).  The wasting 
syndrome does not appear to be a route-specific effect since body weight changes were observed in mice 
exposed to 2,3,7,8-TCDD dermally (NTP 1982a; Puhvel et al. 1982), and numerous studies reported body 
weight changes in animals that were injected with 2,3,7,8-TCDD subcutaneously or intraperitoneally 
(Canga et al. 1988; Chahoud et al. 1989; Della Porta et al. 1987; Gorski et al. 1988b; Holcomb et al. 1988; 
Kelling et al. 1985; Lu et al. 1986; McConkey and Orrenius 1989; Pohjanvirta et al. 1989). 
The mechanism of the wasting syndrome has been extensively investigated.  Results of studies in C57BL/6 
mice, guinea pigs, and Fischer 344 rats showed that 2,3,7,8-TCDD exposure induces appetite suppression 
resulting in loss of adipose and lean tissue, and eventually death (Kelling et al. 1985).  However, by using 
pair-fed animals as controls, it was clear that body weight loss alone was not the cause of death.  This is 
also supported by the fact that the weight loss, but not the lethality of 2,3,7,8-TCDD, can be prevented by 
parenteral feeding of rats and guinea pigs (Gasiewicz et al. 1980; Lu et al. 1986).  Seefeld and Peterson 
(1984) showed that in rats, fecal energy loss as a percentage of daily feed energy uptake was not 
significantly altered by treatment with 2,3,7,8-TCDD.  Furthermore, the percentage of feed energy absorbed 
by the gastrointestinal tract was not changed by 2,3,7,8-TCDD, which ruled out the possibility of a 
2,3,7,8-TCDD-induced gross malabsorption syndrome.  The same group of investigators (Seefeld et al. 
1984a, 1984b) showed that 2,3,7,8-TCDD does not impair the animals' capacity to feed since rats that lost 
weight prior to treatment with 2,3,7,8-TCDD ate and gained weight after treatment with 2,3,7,8-TCDD. 
Based on their results, Seefeld and coworkers (Seefeld and Peterson 1984; Seefeld et al. 1984a, 1984b) 
proposed that 2,3,7,8-TCDD lowers a “set point” for regulated body weight, and hypophagia serves as a 
secondary response to reduce the animal’s body weight to the lower regulation level determined by the dose 
of 2,3,7,8-TCDD administered.  The ability of an animal to recover from the 2,3,7,8-TCDD-induced 
hypophagia may be species- and/or strain-specific (Tuomisto and Pohjanvirta 1991).  Within 1-2 weeks 
after a single dose of 2,3,7,8-TCDD, feed intake increased in Hans/Wistar rats but not in Long Evans rats; 
the Long Evans rats died by week 3.  Although Hans/Wistar and Long Evans rats have similar Ah receptor 
binding and cytochrome P-450 induction properties, the wide differences in sensitivity to 2,3,7,8-TCDD 
suggest that other mechanisms may be involved in the wasting syndrome.  
Numerous studies have examined the possibility that the wasting syndrome results from 2,3,7,8-TCDD­
induced alterations in intermediate metabolism.  For example, it has been shown that in male Sprague-
Dawley rats, lethal doses of 2,3,7,8-TCDD severely alter glucose homeostasis (Gorski and Rozman 1987; 
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Gorski et al. 1990; Potter et al. 1983). Hypoglycemia was not the result of hyperinsulinemia since insulin 
levels were also depressed with 2,3,7,8-TCDD treatment (Potter et al. 1983).  Also, hypophagia did not 
account for hypoglycemia since pair-fed rats also exhibited hypoglycemia (Potter et al. 1983).  Further 
studies showed that decreased gluconeogenesis was the result of significantly reduced activity of hepatic 
PEPCK, the rate-determining enzyme in the pathway (Weber et al. 1991a).  Other gluconeogenic enzymes 
such as glucose-6-phosphatase and pyruvate carboxylase were also decreased by treatment with 
2,3,7,8-TCDD, but pyruvate kinase, a glycolytic enzyme, was not affected (Weber et al. 1991a).  It was also 
shown that changes in gluconeogenic enzyme activities preceded hormonal changes (insulin, 
corticosterone) by at least 2 days (Weber et al. 1991b), which led the authors to suggest that 2,3,7,8-TCDD­
induced changes in hormonal homeostasis are adaptive responses of the organism to stimulate 
gluconeogenesis. Reduced liver PEPCK activity as a result of 2,3,7,8-TCDD treatment has also been 
observed in Long Evans rats (Fan and Rozman 1995) and in C57BL/6J and DBA/2J mice (Weber et al. 
1995). 
Some investigators suggested that the wasting syndrome may be linked to 2,3,7,8-TCDD-induced effects on 
the thyroid (Rozman 1984; Rozman et al. 1985).  In thyroidectomized rats, the weight loss after 
2,3,7,8-TCDD exposure was slow, suggesting that the lack of thyroid hormone reduced the rate of stored fat 
utilization (Rozman et al. 1985).  Thyroidectomy protected rats from immunotoxicity induced by an 
intraperitoneal dose of 2,3,7,8-TCDD (Pazdernik and Rozman 1985).  Replacement therapy with T4 
partially reversed the effects of thyroidectomy on T4 and triiodothyronine serum levels, body weight, and 
immune function.  The authors suggested that 2,3,7,8-TCDD-induced hypothyroidism may be a protective 
mechanism against 2,3,7,8-TCDD-induced wasting syndrome and lethality.  Thyroid hormones regulate fat 
mobilization and use of fatty acids in adipose tissue and influence norepinephrine-mediated nonshivering 
thermogenesis that is also linked to brown adipose tissue.  It was also suggested that the effect of 
2,3,7,8-TCDD on the thyroid causes activation of thyrotropin-releasing hormone, which results in anorexia 
(Aust 1984). Anorexia and 2,3,7,8-TCDD-induced retinol depletion would then lead to the body weight 
loss. 
Based on the findings that 2,3,7,8-TCDD administered into the lateral cerebral ventricles does not cause 
death or decreased feed intake in rats (Stahl and Rozman 1990), Rozman et al. (1991) examined the 
possibility that 2,3,7,8-TCDD suppresses appetite via peripheral mechanisms acting on the central nervous 
system.  The results of experiments of transfusion of blood from rats with 2,3,7,8-TCDD-induced appetite 
suppression and normal satiated rats suggested that 2,3,7,8-TCDD-treated rats are not satiated, rather than 
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that they are not hungry.  In a second experimental series, the possible role of norepinephrine, dopamine, 
and serotonin as central mediators of appetite suppression induced by 2,3,7,8-TCDD was investigated.  No 
changes were found in epinephrine and dopamine in the hypothalamus or in dopamine and its metabolites in 
the striatum. However, tryptophan (a precursor of serotonin) levels in plasma and brain were increased and 
this was paralleled by increases in brain serotonin and 5-hydroxyindolacetic acid (the major serotonin 
metabolite) (Rozman et al. 1991).  Based on the results of these experiments, Rozman et al. (1991) 
proposed that decreased PEPCK activity decreases gluconeogenesis and leads to increased plasma 
concentrations of glycogenic amino acids, such as tryptophan.  Increased tryptophan leads to increase in 
serotonin release in the brain and to appetite suppression.  It was subsequently shown, however, that  lethal 
doses of 2,3,7,8-TCDD reduces the activity of TdO, the key enzyme of the major tryptophan degradation 
pathway (Weber et al. 1992c, 1994).  Whether due to reduction in TdO activity, reduced glyconeogenesis, 
or both, Weber et al. (1994) proposed that an initial increase in tryptophan levels result in some initial feed 
refusal, which in turn initiates the wasting of body mass and increases the supply of tryptophan with which 
the animals cannot deal.  A vicious cycle develops which results in strongly elevated tryptophan levels and 
increased serotonin turnover, which acts as an appetite suppressant. 
Alternative explanations for the increased levels of plasma-free tryptophan in 2,3,7,8-TCDD-treated rats 
have been offered. Four possibilities were discussed by Unkila et al. (1994):  2,3,7,8-TCDD may reduce 
the binding capacity of the blood, i.e., may decrease plasma albumin levels; 2,3,7,8-TCDD may stimulate 
the production of some competing factor in the blood (e.g., nonesterified fatty acids or bilirubin) which are 
also bound to albumin; 2,3,7,8-TCDD might affect the binding properties of the albumin molecule; and 
2,3,7,8-TCDD might inhibit tryptophan catabolism.  Of the four factors examined that might affect the 
binding of tryptophan to albumin, Unkila et al. (1994) indicated that the most important is probably plasma 
bilirubins and suggested that disturbances in liver function may be involved in the changes in tryptophan 
metabolism.  
The wasting syndrome is a characteristic effect of exposure to 2,3,7,8-TCDD in animals and, in its most 
severe form, is usually associated with lethality, particularly in rodents.  The fact that the wasting syndrome 
has not been demonstrated in humans does not necessarily indicate that humans are insensitive to this effect 
of dioxins, but may indicate that human exposure has not approached acutely high enough levels.  
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Immunological and Lymphoreticular Effects. No consistent exposure-related effects on the 
immune system have been observed in human populations exposed to above-background levels of 
2,3,7,8-TCDD (Ernst et al. 1998; Jansing and Korff 1994; Jennings et al. 1988; Jung et al. 1998; Mocarelli 
et al. 1986; Neubert et al. 1993, 1995; Svensson et al. 1994; Tonn et al. 1996; USAF 1991; Webb et al. 
1989; Zober et al. 1994). The immunological effects of 2,3,7,8-TCDD were recently reviewed by Kerkvliet 
(1995) who identified a number of factors on which the results of immunological assessments may be 
dependent. One of these factors, perhaps the most notable, is the inherent difficulty in assessing subclinical 
immunological effects in an outbred human population.  In addition, the wide range of normal responses of 
most immunological assays diminishes the sensitivity to detect small changes.  Another factor to consider is 
that assays used to assess immune function in humans exposed to 2,3,7,8-TCDD and related chemicals have 
been based for the most part on what was clinically feasible rather than on assays proven to be sensitive in 
animal studies (i.e., the antibody response to SRBC).  Therefore, the lack of consistent or significant 
immunotoxic effects in humans exposed to 2,3,7,8-TCDD may be a function of both the type of assay and 
the immune status of the population studied.  Furthermore, often the cohort exposure is not validated and 
the immune status has been examined long after exposure allowing for recovery from any immunotoxic 
effect that may have occurred shortly after exposure. 
A potentially useful approach to studying the sensitivity of the human immune system to 2,3,7,8-TCDD 
has been to examine the direct in vitro effects of 2,3,7,8-TCDD on human cell cultures.  For example, 
Cook et al. (1987a) observed concentration dependent immunosuppressive responses of cultured human 
thymic epithelial cell and thymocytes exposed to 2,3,7,8-TCDD.  The proliferative response of human 
lymphocytes in vitro to stimulation with mitogens is extremely sensitive to 2,3,7,8-TCDD.  Concentrations 
of 2,3,7,8-TCDD as low as 10-12 to 10-14 M reduced the percentage of CD20+ B cells and CD4+CDw29+ 
T cells (Neubert et al. 1991). However, these results could not be corroborated in a similar study by Lang 
et al. (1994) who used 2,3,7,8-TCDD concentrations ranging from 10-7 to 10-11 M. In another study, 
proliferation of human tonsillar lymphocytes (HTLs) cultured in vitro was inhibited by 3×10-8 M 
2,3,7,8-TCDD, but pokeweed mitogen (PWM) induced proliferation was not affected by 2,3,7,8-TCDD 
concentrations ranging from 3×10-8 to 10-10 M (Wood et al. 1992). However, when low density ß cells 
from HTLs were purified and cultured in vitro in the same laboratory and stimulated with 
lipopolysaccharide and TRF (T-cell replacing factor), 3×10-8 to 10-10 M 2,3,7,8-TCDD suppressed the IgG 
secretion in a dose related manner.  HTLs possess the Ah receptor as indicated by the induction of 
7-ethoxycoumarin-o-deethylase (EROD) in a dose-related manner at the above doses when the HTLs are 
stimulated with phytohemagglutenin (PHA) or PWM (Wood et al. 1993).  A promising animal model for 
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assessing the potential immunotoxicity of CDDs in humans is the SCID mice, which can be engrafted with 
human fetal thymus and liver tissue fragments under the kidney capsule.  Using the SCID mice model, it 
was shown that human thymus cells are as sensitive to 2,3,7,8-TCDD as the thymus of Wistar rats (De 
Heer et al. 1995). 
The immune system appears to be one of the most sensitive targets for CDDs in animals.  However, it is 
difficult to make interspecies or congener comparisons due to interlaboratory variability of functional tests 
and use of different end points in various studies. Thymic atrophy was observed in rats, mice, guinea pigs, 
(De Heer et al. 1994a; Hanberg et al. 1989), hamsters (Hanberg et al. 1989; Olson et al. 1980a), and 
monkeys (McConnell et al. 1978a) after acute exposure; in guinea pigs (Vos et al. 1973) after 
intermediate-duration exposure; and in rats (Kociba et al. 1978a) after chronic oral exposure to 
2,3,7,8-TCDD. Furthermore, lymph node atrophy (Allen et al. 1977) and bone marrow degeneration 
(Hong et al. 1989) were reported in monkeys after intermediate- and chronic-duration exposure to 
2,3,7,8-TCDD, respectively.  In support of these data, thymic atrophy was also induced by a single 
intraperitoneal injection of 2,3,7,8-TCDD in Sprague-Dawley rats (Gorski et al. 1988b), Syrian hamsters 
(Olson et al. 1980a), and C57BL/6J mice (Poland and Glover 1980). Only increased thymus/body weight 
ratio was found in HRS/J mice exposed to 2,3,7,8-TCDD dermally (Hebert et al. 1990).  Effects on 
peripheral lymphocytes following acute subcutaneous and in vitro exposure, particularly changes in 
percentages of lymphocyte subpopulations, suggest that marmoset monkeys may be particularly sensitive 
to immunologic effects of 2,3,7,8-TCDD (Neubert et al. 1990a, 1991).  In general, relatively high doses 
cause lymphoid depletion, lower doses cause thymic cellular depletion in young animals, and much lower 
doses affect specific immune receptor functions. 
Administration of total parenteral nutrition did not protect rats from thymic atrophy with decreased 
numbers of cortical lymphocytes that developed after acute intraperitoneal 2,3,7,8-TCDD  exposure 
(Gasiewicz et al. 1980). 2,3,7,8-TCDD-induced thymic atrophy in BALB/CJ and DBA/2J mice correlated 
with a reduction in thymic and bone marrow terminal deoxynucleotidyl transferase synthesis (Fine et al. 
1990b). The prothymocyte activity was severely damaged by 2,3,7,8-TCDD exposure.  The authors 
concluded that 2,3,7,8-TCDD produces atrophy by damaging the capability of bone marrow prethymic 
stem cells to seed the thymus.  In addition to bone marrow effects, 2,3,7,8-TCDD may also inhibit normal 
thymocyte maturational processes.  When B6C3F1 mice were exposed in utero by dosing the dam at 
3 µg/kg/day between Gd 6–14 and foster-nursing the offspring with unexposed females, thymic atrophy 
was seen at Gd 18 or on postnatal day 6, but the thymic effects were no longer seen by day 14.  In utero
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effects on the thymus were at much lower doses than effects in animals exposed postnatally.  Rodents are 
born with an immature immune system which develops in the first few days after birth.  These mice were 
tested for immune function at 7–8 weeks of age; the cytotoxic T-lymphocyte was still suppressed, but the 
mitogen response to SRBC was not suppressed (Holladay et al. 1991).  Humans, in contrast to rodents, 
have a more mature immune system at birth.  The role of the thymus is important in prenatal and perinatal 
development of the immune system, but its role in adult life has not been established.  Concentrations of 
140 fg 2,3,7,8-TCDD/mg in the thymus of mice at Gd 18 were associated with thymic atrophy (Fine et al. 
1990a). 
In addition to causing lymphoid organ weight changes, 2,3,7,8-TCDD has been shown to cause functional 
alterations in the immune response (Vecchi et al. 1980a).  Studies have shown that suppressed antibody 
response (Holsapple et al. 1986a; Vecchi et al. 1980a, 1983b) decreased host resistance to Streptococcus 
pneumoniae or influenza A virus (Burleson et al. 1996; White et al. 1986), and suppressed serum 
complement activity (White et al. 1986) occur in B6C3F1 mice after single or repeated oral dose(s) of 
2,3,7,8-TCDD. Immunological effects occurred at the lowest LOAEL in acute- and intermediate-duration 
exposure studies and indicated that the immunological system is very sensitive to 2,3,7,8-TCDD-induced 
toxicity.  The dose of 0.01 µg/kg for impaired resistance was the lowest LOAEL for acute oral exposure 
(Burleson et al. 1996). The NOAEL of 0.005 µg/kg identified in this study was used to derive an acute 
oral MRL of 2×10-4 µg/kg/day. The 0.0007 µg/kg/day dose for reduced thymus weight for intermediate-
duration oral exposure (DeCaprio et al. 1986) was used to derive an intermediate-duration oral MRL for 
2,3,7,8-TCDD of 2×10-5 µg/kg/day.  Immunosuppression as evidenced by increased mortality when 
challenged with bacteria was demonstrated in C57BL/6J mice after administration of a dose of 1 µg 
2,3,7,8-TCDD/kg/week over a period of 4 weeks (Thigpen et al. 1975); this occurred without any other 
apparent signs of toxicity.  In addition, an intermediate-duration exposure to 2,3,7,8-TCDD induced 
decreased cell-mediated (mice and guinea pigs) and humoral (guinea pigs) immunity (Vos et al. 1973). 
The results indicated that guinea pigs are the most sensitive species tested. 2,3,7,8-TCDD-induced 
suppression of humoral immunity was also reported in animals exposed parenterally.  
In general, the route of exposure does not affect the immune response.  Several tests of immunotoxicity 
dosed the animals by parenteral routes (intravenous, subcutaneous, or intraperitoneal).  Acute 
intraperitoneal 2,3,7,8-TCDD exposure inhibited the primary and secondary humoral response to 
T-dependent (SRBC) and T-independent (pneumococcal polysaccharide) antigens in C57BL/6 mice 
(Vecchi et al. 1980b, 1983b); doses were comparable to those causing effects by the oral route.  A dose­
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related suppression of IgM and IgG antibody-forming cells was induced by exposure to a single 
intraperitoneal injection of 2,3,7,8-TCDD in B6C3F1 mice (House et al. 1990).  Furthermore, doses as low 
as 0.1 µg/kg decreased survival after influenza virus infection, and exposure at 10 µg/kg suppressed 
production of antibody to viral hemagglutinin.  Cytolytic and NK-cell-mediated immunity was impaired in 
C57BL/6 mice after a single intraperitoneal injection of 2,3,7,8-TCDD due to the decreased number of 
peritoneal macrophages and splenocytes (Mantovani et al. 1980).  However, the immune function per unit 
was not damaged.  In addition, an in vitro study demonstrated that 2,3,7,8-TCDD induces tumor necrosis 
factor in human keratinocytes that could affect tumor promotion and affect immune parameters (Choi et al. 
1991). 
The role of the Ah receptor in the immune responses to CDDs has been examined in several studies.  A 
correlation between the AHH inducibility and suppression of humoral immunity caused by 2,3,7,8-TCDD 
injection was observed in several strains of mice (Vecchi et al. 1983a).  Similarly, when three strains of Ah 
responsive mice (C57BL/6nQdj, BALB/cCrj, C3H/HeNQdj) were compared with nonresponsive 
(AKR/JSea, DBA/2JCrj, DDD:Qdj) strains of mice, decreased thymus weight was found only in the 
responsive animals (Nagayama et al. 1989).  The C57 strain also had decreased lymphocyte counts. 
Results of an in vitro experiment supported these observations (Dencker et al. 1985).  Thymus cultures 
from Ah locus responsive C57BL/6 mice were very sensitive to the toxicity of 2,3,7,8-TCDD compared 
with thymus cultures from the nonresponsive DBA/2J mice.  2,3,7,8-TCDD exposure of cultures of thymic 
epithelial cells from responsive C57BL/6 mice indicated that 2,3,7,8-TCDD alters the maturation of 
thymocytes (Greenlee et al. 1985).  It was further demonstrated that 2,3,7,8-TCDD toxicity in human 
thymic epithelial cells was mediated by a protein receptor (Cook and Greenlee 1989).  Similarly, in vitro 
studies with lymphocytes, spleen cells, and bone marrow cells from 2,3,7,8-TCDD-pretreated mice 
indicated that 2,3,7,8-TCDD acts by an Ah locus-dependent mechanism to obstruct the formation of 
cytotoxic T cell generation from their precursors (Dooley et al. 1990; Holladay et al. 1991; Nagarkatti et 
al. 1984). A brief summary of the possible mechanisms of 2,3,7,8-TCDD immunotoxicity can be found in 
Section 2.4.2. 
Oral experiments with other congeners reported suppressed antibody response in B6C3F1 mice after acute 
exposure to 2,7-DCDD, a non 2,3,7,8-chlorine substituted CDD (Holsapple et al. 1986b) and splenic 
hyperplasia in rats after intermediate-duration exposure to a mixture of 1,2,3,6,7,8-HxCDD and 
1,2,3,7,8,9-HxCDD (NCI/NTP 1980). 
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Although human exposure studies to date found no conclusive evidence of immunotoxicity, the animal 
data show that the immune system is a target for CDD toxicity in many species.  However, a defined 
2,3,7,8-TCDD-induced immune deficiency syndrome has not emerged largely because in animals, the 
immune response depends on the species studied, the dose of 2,3,7,8-TCDD, and the antigen and exposure 
protocol studied. 
Neurological Effects. Some psychological effects were reported in Vietnam veterans potentially 
exposed to 2,3,7,8-TCDD-contaminated herbicides.  These included depression in Air Force and ground 
troop veterans (Levy 1988; Wolfe et al. 1985) and hypochondria and hysteria in Air Force veterans (Wolfe 
et al. 1985). In contrast, a more recent study did not find any association between 2,3,7,8-TCDD exposure 
and neurological or psychological diseases in Air Force personnel (USAF 1991). These psychological 
effects could be due to a number of stress-related factors in the veterans.  Recently, a group of 16 scientific 
experts from the National Academy of Sciences’ Institute of Medicine, who evaluated the strength of 
evidence for human health effects among veterans exposed to herbicides used in Vietnam, found no strong 
evidence establishing an association between herbicide use in Vietnam and clinical neurologic disorders 
(Goetz et al. 1994). However, psychological changes were reported in relatively small cohorts of exposed 
individuals (Oliver 1975; Pazderova-Vejlupkova et al. 1981; Peper et al. 1993).  Subclinical peripheral 
neuropathy, encephalopathy, and sensory impairment were reported in workers exposed to higher levels of 
2,3,7,8-TCDD (Goldman 1973; Jirasek et al. 1976; Pazderova-Vejlupkova et al. 1981) and in the general 
population exposed to 2,3,7,8-TCDD after an industrial accident (Barbieri et al. 1988; Filippini et al. 1981; 
Pocchiari et al. 1979). Decreased nerve conduction velocity was observed in phenoxy herbicide 
production workers (Singer et al. 1982). In contrast, exposure to 2,3,7,8-TCDD (confirmed by elevated 
serum levels) was not related to chronic peripheral neuropathy in a group of workers exposed 15–37 years 
earlier compared to referent controls (Sweeney et al. 1993).  These authors suggest that the finding of 
peripheral neuropathy in the earlier studies indicate that this condition may occur shortly after exposure 
and resolve over time.  
Data regarding neurological or neurophysiological effects following exposure to CDDs in animals are 
limited.  Decreased motor activity was seen in rats at 2,3,7,8-TCDD dose levels of #5 µg/kg (Giavini et al. 
1983; Seefeld et al. 1984a). Time-dependent increases in tryptophan (amino acid precursor of the 
neurotransmitter serotonin) levels in plasma and brain (hypothalamus, striatum) correlated with elevations 
in brain serotonin and 5-hydroxyindoleacetic acid levels in rats after a single intraperitoneal injection of 50 
or 120 µg 2,3,7,8-TCDD/kg (Rozman et al. 1991; Tuomisto et al. 1990).  Furthermore, slight changes 
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were observed in levels of noradrenaline, dopamine, dihydroxyphenylacetic acid (DOPAC), homovanillic 
acid (HVA), 5-hydroxytryptamine (5-HT), and 5-hydroxyindoleacetic acid (5-HIAA) (Tuomisto et al. 
1990). Results from a more recent study in rats showed that 2,3,7,8-TCDD increases neuronal serotonin 
turnover in TCDD-susceptible Long Evans rats, but not in TCDD-resistant Han/Wistar rats or in food-
restricted Long Evans rats (Unkila et al. 1994). By using much lower intraperitoneal doses of 
2,3,7,8-TCDD (2.2–8.8 µg/kg) in adult male Han/Wistar rats, thus avoiding manifestation of the wasting 
syndrome, Grahmann et al. (1993) and Grehl et al. (1993) observed electrophysiological (decreased 
conduction velocity) and histological signs (nerve degeneration) of peripheral neuropathy several months 
after a single injection of 2,3,7,8-TCDD. The possible mechanism of 2,3,7,8-TCDD  neurotoxicity was 
not discussed. The existing information suggests that 2,3,7,8-TCDD causes minor alterations in brain 
neurotransmitter systems.  
The overall evidence suggests that adverse neurological effects may occur in subjects exposed to relatively 
high levels of dioxins, or at least to levels that cause frank dermal effects.  The neurological effects, 
however, may be transient and therefore, difficult to diagnose if examination is conducted several years 
after exposure. The nervous system in adults does not seem to be a particularly sensitive target for CDDs 
toxicity, but CDDs may represent a neurological hazard to the developing organism by, for example, 
altering hormone levels at critical times during the maturation of the central nervous system. 
Reproductive Effects. The weaknesses of the epidemiology studies examining reproductive end points 
limits drawing conclusions regarding the reproductive toxicity of 2,3,7,8-TCDD in humans.  Some common 
weaknesses include lack of exposure data (many of the studies rely on self-reported 2,3,7,8-TCDD 
exposure; CDC (1987) found that 2,3,7,8-TCDD blood levels of Vietnam veterans reporting direct or 
indirect exposure to Agent Orange were not significantly different from levels in non-Vietnam veterans), 
concomitant exposure to other chemicals, and lack of data on 2,3,7,8-TCDD levels at the time of 
conception. Several studies looked for an association between 2,3,7,8-TCDD exposure and an increased 
risk of spontaneous abortions, most did not find any statistically significant alterations following paternal 
exposure to 2,3,7,8-TCDD (Aschengrau and Monson 1989; Smith et al. 1982; Wolfe et al. 1995).  An 
increased incidence of spontaneous abortions, was observed in women living near an herbicide 
manufacturing facility (Forsberg and Nordstrom 1985).  However, this study has been criticized for its 
small sample size, inadequate discussion of sample selection, and concomitant exposure to other chemicals, 
including dibenzofurans (Sweeney 1994).  In Vietnamese residents living in areas sprayed with Agent 
Orange, an increased incidence of hydatiform moles was observed (Phuong et al. 1989a).  A later case­
 
CDDs 292 
2. HEALTH EFFECTS 
control study by Ha et al. (1996) did not confirm the results of the Phuong et al. (1989a) study.  In the 
7½-year period after the Seveso accident, the number of female children born to parents living in area A 
was significantly higher than the number of male children (48 versus 26) (Mocarelli et al. 1996).  An 
increased ratio of female to male children was also reported in workers of a 2,4,5-T production facility in 
Ufa, Russia (Basharova 1996) and in men exposed to chlorophenate wood preservatives contaminated with 
CDD (Dimich-Ward et al. 1996; James 1997).  No alterations were found in the Missouri cohort of women 
living in 2,3,7,8-TCDD-contaminated areas (Stockbauer et al. 1988).  Although several studies provide 
suggestive evidence of a relationship between CDD exposure and alterations in the sex ratio, the data are 
inadequate to establish a causal relationship. Additionally, it is not known how 2,3,7,8-TCDD affects the 
sex ratio. It has been postulated that the effect may be due to an alteration in hormonal balance or a 
disproportional number of miscarriages of male fetuses. 
Data on 2,3,7,8-TCDD-induced alterations in gonads and reproductive endocrine function in humans are 
limited to effects observed in males.  Decreased testicular size without any hormonal changes was found in 
Air Force Vietnam veterans exposed to 2,3,7,8-TCDD during Operation Ranch Hand (USAF 1991). This 
finding (decreased testicular size) was not confirmed when a more sensitive measurement device (ultra­
sound) was used (Henriksen et al. 1996). Wolfe et al. (1985) found no alterations in sperm count or 
morphology in veterans involved in Operation Ranch Hand.  Henriksen et al. (1996) assessed the possible 
relationship between 2,3,7,8-TCDD exposure and alterations in testosterone levels, FSH, LH, testicular 
abnormalities, sperm abnormalities, and sperm counts in the Operation Ranch Hand cohort (reproductive 
parameters were assessed in 1982, 1987, and 1992) and found no consistent, statistically significant 
alterations. Increases in FSH and LH levels and decreases in testosterone levels were observed in males 
working in 2,4,5-trichlorophenol manufacturing facilities (NIOSH cohort); however the magnitude of the 
changes in hormone levels was small (Egeland et al. 1994).  The study authors note that increases in LH 
levels and decreases in testosterone levels were not found in the same men, suggesting that 2,3,7,8-TCDD 
may result in subtle alterations rather than primary gonadal failure. 
A number of reproductive effects, including decreased fertility, damage to the gonads, and alterations in 
hormone levels, have been observed in male and female animals orally exposed to 2,3,7,8-TCDD.  In male 
rats, a dose- and time-dependent reduction of serum testosterone and dihydrotestosterone levels was 
observed after acute oral exposure to 2,3,7,8-TCDD (Mebus et al. 1987; Moore et al. 1985, 1991). 
Furthermore, male rats had decreased weight of seminal vesicles following oral exposure to 2,3,7,8-TCDD 
(Al-Bayati et al. 1988; Moore et al. 1985) and reduced spermatogenesis after oral and subcutaneous 
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exposure (Al-Bayati et al. 1988; Chahoud et al. 1989; Van Miller et al. 1977).  Biochemical changes in rat 
testes included dose- and time-dependent decreases in 17-hydroxylase activity and 20-lyase activity and 
reduced microsomal cytochrome P-450 (Mebus et al. 1987).  Decreases in testicular superoxidase dismutase 
and glutathione peroxidase activities, and increases in protein kinase C activity and lipid peroxidation were 
also found in 2,3,7,8-TCDD-exposed rats (Al-Bayati et al. 1988).  On the basis of the above data, it was 
postulated that the androgen deficiency is due to decreased androgen synthesis.  It was further suggested 
that the morphological changes in rat testes may be due to changes in lipid peroxidation. 
Pre- and/or postimplantation losses have been observed in rats (Giavini et al. 1983; Sparschu et al. 1971a), 
mice (Neubert and Dillman 1972; Smith et al. 1976), and rabbits (Giavini et al. 1982) following acute oral 
exposure to 2,3,7,8-TCDD. A single intraperitoneal injection of 2,3,7,8-TCDD (100 µg/kg) given between 
Gd 2–6 caused a high incidence of resorptions in C57BL/6J mice (Pratt et al. 1984).  Similarly, increased 
resorptions were reported in rats exposed to mixed HxCDD during gestation, but not in those exposed to 
2,7-DCDD or OCDD (Schwetz et al. 1973). In addition, abortions were observed in monkeys exposed to 
2,3,7,8-TCDD for 3 weeks by gavage (McNulty 1984), and reduced reproduction was observed in those 
exposed chronically in the feed (Bowman et al. 1989b; Hong et al. 1989; Schantz et al. 1992).  Finally, 
significantly decreased fertility in F1 and F2 generations was reported in a 3-generation reproductive study 
in rats exposed to 2,3,7,8-TCDD (Murray et al. 1979).  
Investigations into the mechanism of CDD-induced decreased fertility revealed blocked estrous cycle in 
female mice exposed orally to 2,3,7,8-TCDD for an intermediate duration (Umbreit et al. 1987) and dose-
dependent decreases in uterine and hepatic cytosolic, and nuclear estrogen and progesterone receptor levels 
in rats after intraperitoneal 2,3,7,8-TCDD injection (Romkes and Safe 1988).  Furthermore, 2,3,7,8-TCDD 
antagonized the estradiol-mediated increases in these levels.  In addition, a dose-related reduction of uterine 
peroxidase activity and decreased uterine wet weight were seen after a single 2,3,7,8-TCDD injection in rats 
(Astroff and Safe 1990). 2,3,7,8-TCDD application also antagonized the treatment with estradiol.  The 
authors concluded that 2,3,7,8-TCDD antagonized the estrogen-induced uterine response and that the Ah 
receptor was involved in mediating the reaction.  Other authors suggest that the anti-estrogen effect is 
mediated by 2,3,7,8-TCDD-induced metabolism of estrogens (Gierthy et al. 1987). 
In non-pregnant female rats, decreases in ovarian weight, estrous cyclicity, ovulation rate, and the number 
of ova released were observed following a single dose of 2,3,7,8-TCDD (Li et al. 1995a, 1995b). Increases 
in LH and follicle stimulating hormone levels were also observed.  The mechanisms involved in these 
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effects are thought to involve direct effects on the ovaries and effects on the hypothalamus/pituitary axis. 
The normal preovulatory surge of LH was not observed in the 2,3,7,8-TCDD-exposed rats, suggesting that 
2,3,7,8-TCDD inhibited the positive feedback action of 17β-estradiol at the hypothalamic-pituitary axis (Li 
et al. 1995a). In hypophysectomized rats, 2,3,7,8-TCDD exposure resulted in a reduction of ovulation; Li et 
al. (1995a) suggests that this may be the result of a direct effect on the ovary, although the mechanism has 
not been elucidated. 
Endometriosis has been observed in monkeys chronically exposed to 2,3,7,8-TCDD in the diet (Rier et al. 
1993). A possible association between 2,3,7,8-TCDD and endometriosis is supported by rat and mouse 
studies using surgically induced models of endometriosis (Cummings et al. 1996; Johnson et al. 1997).  In 
contrast, Foster et al. (1997) found that 2,3,7,8-TCDD exposure diminished endometrial tissue growth in 
mice.  These studies used different models of surgically induced endometriosis and highlight the complexity 
of the disease. In the Cummings et al. (1996) and Johnson et al. (1997) studies, the animals were exposed 
to 2,3,7,8-TCDD prior to the development of endometriosis, and immune suppression probably facilitated 
the growth of endometrial tissue.  In the Foster et al. (1997) model, 2,3,7,8-TCDD was administered after 
endometriosis development and 2,3,7,8-TCDD, via its anti-estrogenic effects, inhibited tissue growth.  The 
relationship between CDD exposure and endometriosis in humans has not been adequately studied.  In 
humans, the etiology of endometriosis likely involves a complex interplay between a number of diverse 
physiological factors including altered cell-mediated immunity and increased levels of growth hormone. 
Although the human data regarding reproductive effects are inconsistent, a number of reproductive effects 
have been observed in animals, including deceased fertility, altered hormone levels, and gonad damage in 
males and females.  The similarity between some of the effects observed in humans and animals suggest 
that reproductive effects may also occur in humans. 
Developmental Effects. The developmental toxicity of 2,3,7,8-TCDD has been investigated in 
several human populations, with conflicting results.  Most studies did not find increases in the number of 
birth defects in the children of men exposed to 2,3,7,8-TCDD in a chlorophenols manufacturing facility 
(Townsend et al. 1982) or during the Vietnam war (Aschengrau and Monson 1990; Erickson et al. 1984; 
Wolfe et al. 1995); or the children of parents living in Seveso, Italy (Bisanti et al. 1980; Mastroiacovo et 
al. 1988). Some studies did find increases in the incidence of specific defects (e.g., talipes, ventricular 
septal defect) in the infants of exposed fathers or mothers and fathers (Aschengrau and Monson 1990; 
Erickson et al. 1984; Hanify et al. 1981; Wolfe et al. 1995), but there was little consistency regarding the 
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type of defect or the target organ/system.  The lack of exposure data, small sample sizes, and the lack of 
reliable data for birth defect rates prior to 2,3,7,8-TCDD exposure precludes drawing conclusions from 
these human studies.  A section below summarizes information on health effects in humans associated with 
exposure to CDDs in utero and/or via breast milk. 
Developmental toxicity has been observed in rats, mice, rabbits, hamsters, and monkeys exposed to 
2,3,7,8-TCDD and other CDD congeners.  Perinatal exposure to 2,3,7,8-TCDD results in structural 
malformations, functional alterations, decreased growth, and fetal/newborn mortality.  Many of the effects 
occurred at 2,3,7,8-TCDD doses which were not maternally toxic.  Acute oral exposure to 2,3,7,8-TCDD 
during gestation caused an increased incidence of cleft palate and skeletal anomalies in offspring of rats 
(Giaviani et al. 1983; Huuskonen et al. 1994), mice (Abbott and Birnbaum 1989a; Courtney 1976; 
Dasenbrock et al. 1992; Neubert and Dillman 1972; Smith et al. 1976; Weber et al. 1985), and rabbits 
(Giavini et al. 1983). These effects were also observed in fetuses of mice that received subcutaneous 
injections of 2,3,7,8-TCDD during gestation (Courtney 1976; Poland and Glover 1980).  The 
2,3,7,8-TCDD-induced cleft palate is caused by the failure of the opposing palatal shelves to fuse (Pratt et 
al. 1984); 2,3,7,8-TCDD does not alter the size of the palatal shelves or interfere with the opposing shelves 
coming into contact.  Under normal conditions, there is a cessation of medial cell proliferation, a 
degeneration of peridermal medial cells, and a transformation of basal cells to mesenchymal cells as the 
opposing palatal shelves come into contact and fuse (Abbott and Birnbaum 1989b).  2,3,7,8-TCDD 
exposure alters medial cell proliferation and differentiation resulting in the formation of stratified 
squamous epithelium.  Abbott and Birnbaum (1990a) suggest that the altered proliferation and 
differentiation of the medial cells is due to 2,3,7,8-TCDD-induced reductions of several growth factors 
(EGF, TGF-α, and TGF-β1) and increases in EGF receptor expression. EGF and TGF-α (which both bind 
to the EGF receptor) stimulate epithelial proliferation and differentiation and TGF-β1 inhibits epithelial 
proliferation. The increased levels of EGF receptor appear to compensate for the decreased EGF and TGF­
α levels resulting in continued proliferation. Abbott et al. (1994a, 1994b) suggest that the altered 
expression of growth factors may be mediated by the Ah receptor.  Exposure to 2,3,7,8-TCDD resulted in 
a dose-dependent downregulation of the Ah receptor throughout the palate; this probably occurs at the 
transcriptional level as decreases in mRNA were also observed (Abbott et al. 1994b).  There is no evidence 
for direct Ah regulation of growth factors; rather, transcriptional regulation of related genetic activity may 
indirectly influence growth factor expression.  Data which support an association between Ah receptor and 
cleft palate include a correlation between 2,3,7,8-TCDD binding to the Ah receptor and altered growth 
factor expression (Abbott et al. 1994b); finding of 2,3,7,8-TCDD-induced altered Ah receptor expression 
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and altered growth factor expression at doses which do not induce cleft palate (Abbott et al. 1994b); and 
the inability of 2,3,7,8-TCDD to induce cleft palate in strains of mice which have low affinity for Ah 
receptors (Pratt et al. 1984; Silkworth et al. 1989b). 
Kidney malformations, particularly hydronephrosis, were observed in the offspring of rats (Giavini et al. 
1983; Huuskonen et al. 1994), mice (Abbott et al. 1987a, 1987b; Courtney 1976; Moore et al. 1973; 
Silkworth et al. 1989b), and hamsters (Gray et al. 1995) orally exposed to 2,3,7,8-TCDD during gestation. 
Kidney defects were also observed in mouse offspring following in utero subcutaneous exposure to 
2,3,7,8-TCDD (Courtney 1976) and in mice postnatally exposed to 2,3,7,8-TCDD via contaminated 
mothers' milk (Couture-Haws et al. 1991b).  The hydronephrosis observed in these offspring is the result 
of occlusion of the ureter and subsequent accumulation of urine in the kidney (Abbott et al. 1987a). 
Prenatal exposure to 2,3,7,8-TCDD results in hyperplasia of the epithelium in the ureter, obstruction of the 
ureteric lumen, and a restriction of the flow of urine.  Abbott and Birnbaum (1990b) found that 
2,3,7,8-TCDD interfered with the normal decline in EGF receptors in the ureteric epithelia, resulting in 
excessive proliferation. In the bladder, 2,3,7,8-TCDD exposure also resulted in an increase in the 
epithelial thickness and continued expression of EGF receptors.  2,3,7,8-TCDD also appears to directly 
damage the kidney.  Under normal conditions, there is an increase in laminin and type IV collagen levels 
and a thickening of the lamina densa of the glomerular basement membrane, which is important in 
establishing the filtration barrier. Following exposure to 2,3,7,8-TCDD, there is a decreased expression of 
laminin and type IV collagen and a diminished thickening of the lamina densa (Abbott et al. 1987b).  This 
immature filtration barrier is likely to result in proteinuria and may result in increased urine volume. 
A number of recently published studies have shown that the developing reproductive system is very 
sensitive to the toxicity of 2,3,7,8-TCDD.  In female rats, exposure to 2,3,7,8-TCDD on Gd 8 caused 
functional reproductive toxicity (accelerated onset of constant estrus, shortened reproductive lifespan, 
reduced ovarian weight, and cystic hyperplasia of the endometrium) (Gray and Ostby 1995).  Although 
there were no effects on fertility or estrous cyclicity when 2,3,7,8-TCDD exposure occurred after 
organogenesis (exposure on Gd 15) (Gray and Ostby 1995), external urogenital malformations (clefting, 
hypospadias, vaginal thread, and delayed vaginal opening) were observed (Flaws et al. 1997; Gray and 
Ostby 1995; Gray et al. 1997a; Heimler et al. 1998).  These malformations to external genitalia are likely 
to interfere with mating (Gray and Ostby 1995).  The authors note that the effects on the external genitalia 
are similar to effects observed in animals exposed to potent estrogen-like chemicals (e.g., DES, estradiol), 
although it likely that these effects occur by a different mechanism.
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In male rats, perinatal exposure to 2,3,7,8-TCDD resulted in alterations in androgen status (decreased 
plasma testosterone levels, delay in testes descent, delay in external signs of puberty, and decreased ventral 
prostate and seminal vesicle weights), testes and cauda epididymis weights, and spermatogenesis 
(decreased daily sperm production, amount of mature sperm in cauda epididymis, and amount of sperm 
ejaculated), and in demasculinization and partial feminization of sexual behavior following exposure on 
Gd 15 (Bjerke and Peterson 1994; Bjerke et al. 1994a, 1994b; Gray et al. 1995; 1997b;  Mably et al. 
1992a, 1992b, 1992c; Sommer et al. 1996).  In most of these studies, the experimental protocol involved 
gavaging the dams with a single dose of 2,3,7,8-TCDD on Gd 8 (Gray et al. 1995) or 15 (Bjerke and 
Peterson 1994; Bjerke et al. 1994a, 1994b; Gray et al. 1995; Mably et al. 1992a, 1992b, 1992c) and 
assessing a number of indices of reproductive development and function in newborn, juvenile, pre­
pubescent, post-pubescent, and mature male rats.  Because 2,3,7,8-TCDD is lipophilic and has a relatively 
long half-life, a single dose on Gd 15 will result in transplacental exposure from Gd 15 to birth and 
exposure via contaminated milk.  Bjerke and Peterson (1994) compared the reproductive effects of 
2,3,7,8-TCDD in rats exposed in utero to the effects observed in rats exposed to 2,3,7,8-TCDD only 
during lactation. Both in utero and lactational exposure resulted in decreased plasma testosterone level, 
decreased seminal vesicle and ventral prostate growth, and decreased epididymal sperm reserves. 
Exposure in utero only also resulted in decreased daily sperm production and delayed puberty; and 
exposure by lactation only resulted in partial feminization of sexual behavior.  These data suggest that the 
timing of the 2,3,7,8-TCDD exposure is important.  The mechanism by which 2,3,7,8-TCDD disrupts the 
development of the reproductive system and whether all of the reproductive effects have similar 
mechanisms is not known.  Early investigators of the effects of 2,3,7,8-TCDD on sexual behavior 
suggested that perinatal exposure to 2,3,7,8-TCDD resulted in impaired sexual differentiation of the central 
nervous system (Mably et al. 1992b).  The results of the Bjerke et al. (1994b) study suggest that the 
2,3,7,8-TCDD-induced alterations in sexual behavior were not due to 2,3,7,8-TCDD acting as an estrogen 
antagonist or altering ER capacities of hypothalamic nuclei.  The volume of the sexually dimorphic 
nucleus in the preoptic area of the hypothalamus (SDN-POA), which is dependent upon testosterone-
derived estradiol in the brain during perinatal development, was not altered in 2,3,7,8-TCDD-exposed rats. 
Additionally, the sexual differentiation of ER concentration in brain nuclei which exhibit sexual 
dimorphism (ventromedial nuclei, medial preoptic nuclei, bed nucleus of the stria terminalis, 
periventricular preoptic area nucleus, cortical and medial amygdala, and arcuate nucleus) were not affected 
by 2,3,7,8-TCDD.  Thus, 2,3,7,8-TCDD effects did not parallel those of either estrogen or androgen 
antagonists. Gray et al. (1995) also support the theory that 2,3,7,8-TCDD does not interfere with 
testosterone- and estrogen-dependent central nervous system sexual differentiation.  In their study, no 
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hamsters, masculinization of the central nervous system requires perinatal exposure to testosterone). 
Bjerke et al. (1994b) proposed that 2,3,7,8-TCDD may affect other systems, such as brain amine content or 
growth factor expression of function, which would indirectly impact sexual differentiation.  Similarly, 
Gray et al. (1995) suggested that 2,3,7,8-TCDD-induced alterations in the growth factors and receptors 
involved in urogenital system cell differentiation and proliferation may result in alterations in 
morphological sexual differentiation.  Bjerke et al. (1994a) also found that the 2,3,7,8-TCDD-induced 
inhibition of ventral prostate weight and protein content imprinting was not due to perinatal reductions in 
plasma androgen levels because no effect on imprinting of the seminal vesicle, penis, or pituitary were 
observed in the 2,3,7,8-TCDD-exposed rats. Using a treatment regime that consisted of administration of 
a loading subcutaneous dose of 2,3,7,8-TCDD to female rats prior to mating, followed by weekly 
maintenance subcutaneous doses during mating, pregnancy, and lactation, Faqi et al. (1998) reported that 
sperm parameters were the most susceptible end points in male offspring examined at puberty (70 days 
old) and adulthood (170 days old).  Based on pharmacokinetic considerations, the authors estimated that 
the lowest effective dose was <0.8 ng/kg/day.  The sperm parameters that were altered were sperm number 
from cauda epididymis, daily sperm production, sperm transit rate, and percent abnormal sperm (more so 
in adults than in pubertal rats). No significant and/or consistent effects were observed on litter size, sex 
ratio, body weights, developmental landmarks, weight of sex organs, and sexual behavior.  Testosterone 
levels were significantly reduced at age 170 days but not at age 70 days.  In spite of sperm alterations, all 
exposed males exhibited normal reproductive performance and successfully impregnated untreated female 
to produce viable fetuses. 
Recent studies have also focused on the role of the Ah receptor in the 2,3,7,8-TCDD-induced alterations in 
the development of the male reproductive system.  Roman et al. (1998a) recently demonstrated the presence 
of both the Ah receptor and the receptor nuclear translocator (Arnt) in the testis, epididymis, vas deferens, 
ventral and dorsolateral prostate, and seminal vesicles from adult Holtzman rats.  Arnt was localized in all 
organs in a variety of cell types; subcellular localization varied across organs and cell types within these 
organs. Unfortunately, technical difficulties precluded the evaluation of the Ah receptor distribution in the 
various organs. The authors also showed that a single oral dose of 25 µg 2,3,7,8-TCDD/kg produced 
significant induction of CYP1A1 in the ventral and dorsolateral prostate.  CYP1A1 expression was 
localized in the epithelial cells of the ventral and lateral lobes of the prostate.  Less CYP1A1 induction was 
seen in selected epithelial cells from other tissues, and no induction was detected in the testis.  Also, 
2,3,7,8-TCDD had no effect on Arnt protein expression, but Ah receptor expression was significantly 
reduced in all organs examined.  In another study from this series, Roman and Peterson (1998) found that, 
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relative to controls, in utero exposure to 2,3,7,8-TCDD (1 µg/kg) transiently decreased the amount of 
several prostate-specific androgen-regulated mRNAs, all of which are markers of a differentiated ductal 
epithelium.  This was in contrast with observations in adults, in which 2,3,7,8-TCDD induced CYP1A1 
mRNA without altering the amount of prostate-specific, androgen-regulated mRNAs.  These results 
suggested that the developing prostate can directly respond to in utero and lactational exposure to 
2,3,7,8-TCDD, and that this exposure not only impairs prostate growth but also delays prostate luminal 
epithelial cell differentiation. In yet an additional study from this series, Roman et al. (1998b) reported that 
in the most severely affected animals, 2,3,7,8-TCDD produced alterations in the histological arrangement of 
epithelial and stromal cells and in the spatial distribution of androgen receptor expression. 
Other developmental effects that have been observed in animals include immunotoxicity (thymic atrophy, 
immunosuppression, and alterations in thymocyte phenotypes) (Fine et al. 1989; Gehrs et al. 1997a, 1997b; 
Håkansson et al. 1987; Huuskonen et al. 1994; Luster et al. 1980; Madsen and Larsen 1989; Thomas and 
Hinsdill 1979), decreased fetal and newborn body weight (Abbott et al. 1992; Bjerke et al. 1994a; Bjerke 
and Peterson 1994), fetal/newborn mortality or decreased survival (Bjerke et al. 1994a; Bjerke and Peterson 
1994; Huuskonen et al. 1994; McNulty 1984; Murray et al. 1979; Nau et al. 1986), and altered social 
behavior (Schantz et al. 1992). 
Developmental toxicity has also been observed in animals exposed to other CDDs.  These effects include 
heart defects in rats exposed to 2,7-DCDD (Schwetz et al. 1973); decreased thymic weight in rats exposed 
to 1,2,3,7,8-PCDD (Madsen and Larsen 1989); subcutaneous edema, decreased fetal growth, delayed 
ossification, dilated renal pelvis, and cleft palate in rats exposed to HxCDD (Schwetz et al. 1973); and 
subcutaneous edema in rats exposed to OCDD (Schwetz et al. 1973). 
The animal database provides strong evidence that developmental toxicity is a sensitive end point following 
2,3,7,8-TCDD exposure. Structural malformations, functional alterations (including impaired development 
of reproductive system), decreased growth, and fetal/newborn mortality have been observed in several 
animal species.  Limited human data on the developmental toxicity of CDDs is available.  Most of these 
studies examined the occurrence of birth defects in children of males exposed to 2,3,7,8-TCDD. 
Deficiencies in the human data preclude drawing firm conclusion on the potential of 2,3,7,8-TCDD to 
induce developmental effects in humans.  However, the animal data suggest that 2,3,7,8-TCDD is a likely 
human developmental toxicant. 
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Health Effects Associated with Exposure to CDDs in Breast Milk. The developing organism is very 
susceptible to the toxicity of CDDs, in particular 2,3,7,8-TCDD.  Prenatal or perinatal exposure has resulted 
in structural malformations (e.g., cleft palate, hydronephrosis), functional alterations (e.g., damage to the 
immune system, impaired development of the reproductive system), decreased growth, and fetal/newborn 
mortality in several animal species.  Additionally, several animal studies (summarized in Table 2-14) 
provide evidence that lactation-only exposure to 2,3,7,8-TCDD can adversely affect the developing animal. 
Impaired development of the reproductive system (Bjerke and Peterson 1994), increased incidence of 
hydronephrosis (Couture-Haws et al. 1991a, 1991b), decreased weight gain, thymic atrophy (Faith and 
Moore 1977; Håkansson et al. 1987), and suppression of cell-mediated immunity (Faith and Moore 1977) 
have been observed in rats and mice exposed to 2,3,7,8-TCDD during lactation but not during gestation. 
The authors of these studies noted that most of the effects observed following lactation-only exposure were 
similar to those observed in animals exposed to 2,3,7,8-TCDD during gestation. 
Because CDDs are efficiently absorbed following ingestion of breast milk (approximately 95% absorption 
efficiency for most congeners, see Section 2.3.4.4 for more information) and animal studies have found that 
lactation-only exposure can result in developmental effects, there is concern that breast-fed infants of 
women with high background levels of CDDs may be at risk.  Ayotte et al. (1996) predicted that exposure 
to CDDs and related chemicals from breast milk will strongly influence the body burden of these chemicals 
during childhood and adolescence. Several human studies have examined the possible association between 
background CDD and CDF levels from in utero exposure and exposure from breast milk, and adverse 
health effects in infants. These studies (summarized in Table 2-15) found alterations in the levels of some 
markers of liver function (plasma ALT and AST) (Pluim et al. 1994a), thyroid function (thyroxine, thyroid 
stimulating hormone) (Koopman-Esseboom et al. 1994; Pluim et al. 1993b), and immune function (T-cell 
markers [TcRγδ+, CD3+CD8+, and TcRαβ+] and monocyte) (Weisglas-Kuperus et al. 1995), and the 
neurological optimality score in infants (Huisman et al. 1995a) which significantly correlated with CDD 
and CDF TEQ levels in breast milk.  In follow-up studies and studies of older infants or children, no 
relationship between high levels of CDDs, CDFs, and PCBs in breast milk and neurological development, 
neurological optimality score, and/or reflexes was found at ages 6 (Pluim et al. 1996), 18 (Huisman et al. 
1995b), or 31 months (Ilsen et al. 1996).  Although the Ilsen et al. (1996) study of 31-month-old children 
did not find any alterations in overall neurological optimality or suboptimality scores, significant 
alterations, indicative of enhanced neuromuscular maturation and higher reflexes, were found in some tests 
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received higher than background levels of CDDs and CDFs in breast milk (Alaluusua et al. 1996).  Other 
studies have not found a relationship between higher background levels of CDDs, CDFs, and PCBs in 
breast milk and adverse health effects (summarized in Table 2-15); decarboxylated prothrombin and 
vitamin K levels in 11-week-old infants (Pluim et al. 1994b); birth weight (Pluim et al. 1996; Vartiainen et 
al. 1998), head circumference, and body weight at 1, 10, and 26 weeks of age (Pluim et al. 1996); or liver 
size (Pluim et al. 1996) were not adversely affected.  Although significant correlations were found, the data 
should be interpreted cautiously because the levels of these markers were within the normal range and the 
correlation coefficients were low suggesting that only a small amount of the variance in the marker 
concentrations can be attributed to CDD and CDF levels. 
The animal data suggest that lactation-only exposure to relatively high concentrations of CDDs can result in 
serious health effects. However, the human data show that the risk of CDD-induced health effects in infants 
exposed to background levels of CDDs and CDFs in breastmilk is small and this risk, in most cases, does 
not outweigh the benefits of breast-feeding. 
Genotoxic Effects. In vivo genotoxicity studies are summarized in Table 2-16.  Human studies have 
been conducted on populations exposed to 2,3,7,8-TCDD.  An increased incidence of chromosomal 
aberrations was found in the fetal tissues, but not in the maternal tissues, following induced abortions in a 
group of women exposed to 2,3,7,8-TCDD in the Seveso accident (Tenchini et al. 1983).  However, cases 
treated for chloracne in the area did not have an elevated frequency of chromosomal aberrations (Reggiani 
1980). Results of a higher incidence of chromosomal aberrations were inconsistent in groups of Vietnam 
veterans (Kaye et al. 1985) or no cytogenetic changes were reported (Mulcahy et al. 1980).  Fewer birth 
defects due to chromosomal abnormalities in children of Vietnam veterans were reported in another study 
(Erickson et al. 1984). Human studies cited above were limited by several factors.  Generally, the levels of 
exposure to 2,3,7,8-TCDD were not known and coexposure to other potentially active compounds occurred 
in all studies. In the case of Vietnam veterans, a long postexposure period passed before the cytogenetic 
analysis was done.  Furthermore, most of the studies used groups that were too small (less than 20 
individuals) to have the statistical power to detect any changes.  
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In a study in which current 2,3,7,8-TCDD blood levels of previously exposed workers were approximately 
25 times higher than in referents, there was no evidence of increased incidence of chromosomal aberrations 
or sister chromatid exchanges (Zober et al. 1993). 
Animal studies on the genotoxicity of CDDs are inconclusive.  When Osborne-Mendel rats were given 
2,3,7,8-TCDD (0.25, 0.5, 1, 2, or 4 µg/kg) by gavage twice a week for 13 weeks, increased incidence of 
chromosomal aberrations was observed in the highest-exposure group (Green et al. 1977).  Increased 
incidences of gaps and chromatid aberrations were observed in bone marrow cells of CD-1 mice following 
an intraperitoneal injection of 10 µg/kg 2,3,7,8-TCDD (Loprieno et al. 1982). Positive results were 
obtained at 96 hours, but not 24 hours, posttreatment.  In contrast, no induction of structural chromosomal 
changes was found in CD-COBS rats orally exposed to 1.0, 0.1, or 0.01 µg/kg 2,3,7,8-TCDD once a week 
for 45 weeks (Loprieno et al. 1982). In addition, no differences in the frequency of sister chromatid 
exchanges and chromosomal aberrations in peripheral lymphocytes were observed in a group of rhesus 
monkeys receiving 0.001 µg/kg 2,3,7,8-TCDD in the feed for 4 years and their matching controls (Lim et 
al. 1987). Furthermore, no induction of chromosomal aberrations or sister chromatid exchanges, or 
increases in the frequency of micronuclei, were found in bone marrow cells of C57BL/6J (with high-affinity 
2,3,7,8-TCDD receptor) or DBA/2J mice (with low-affinity 2,3,7,8-TCDD receptor) following a single 
intraperitoneal injection of 2,3,7,8-TCDD at doses of 50, 100, or 150 µg/kg (Meyne et al. 1985).  The 
samples were examined within 8–48 hours.  The negative results may, however, have been due to the time-
dependent detectability of chromosomal changes after CDD exposure reported earlier (Loprieno et al. 
1982). 
In addition to studies dealing with structural chromosomal changes, effects on DNA were also investigated. 
Oral exposure to 1 µg/kg/week of 2,3,7,8-TCDD or 1,2,3,7,8-PCDD for up to 6 months did not increase the 
formation of DNA adducts in Sprague-Dawley rats (Randerath et al. 1989).  A single oral dose of 
2,3,7,8-TCDD (25–100 µg/kg) caused time-dependent increases in the induction of DNA single-strand 
breaks (and lipid peroxidation) in hepatic cells of Sprague-Dawley rats terminated within 3–14 days after 
the treatment (Wahba et al. 1989). 
Negative results were obtained in reproductive tests including a dominant-lethal test following 7 daily oral 
doses of 2,3,7,8-TCDD (4, 8, or 12 µg/kg/day) to male Wistar rats (Khera and Ruddick 1973) and a sex-
linked recessive-lethal test with 2,3,7,8-TCDD in Drosophila melanogaster (Zimmering et al. 1985).  
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In vitro genotoxicity studies are summarized in Table 2-17.  Eukaryotic cell systems were used for detecting 
the effects of 2,3,7,8-TCDD exposure on DNA. Exposure to 2,3,7,8-TCDD did not stimulate the 
unscheduled DNA synthesis in cultural human cells (Loprieno et al. 1982), but inhibited DNA, ribonucleic 
acid (RNA), and protein synthesis in mouse lymphocytes (Luster et al. 1979); caused gene mutations in 
mouse lymphoma cells (Rogers et al. 1982); and induced sister chromatid exchanges in Chinese hamster 
cells (Toth et al. 1984). 
Several researchers used the Ames test with Salmonella typhimurium to assess the mutagenicity of 
2,3,7,8-TCDD in prokaryotic organisms.  Predominantly negative results were obtained with tester strains 
G46, TA 1530, TA 1535, TA 100, TA 1950, and TA 1975, revealing base pair substitutions; and with 
strains TA 1531, TA 1532, TA 1534, TA 1538, TA 98, and TA 1978, revealing frame shift mutations 
(Geiger and Neal 1981; Gilbert et al. 1980; Mortelmans et al. 1984; Toth et al. 1984).  However, some of 
the studies were limited by using 2,3,7,8-TCDD concentrations in excess of its solubility in water.  Only 
two early studies reported positive results (Hussain et al. 1972; Seiler 1973).  However, the results were 
limited by failure to demonstrate a dose-response relationship and by low bacterial survival rates.  In 
addition, 2,3,7,8-TCDD exposure induced reverse mutations in Escherichia coli (Hussain et al. 1972) and in 
Saccharomyces cerevisiae (Bronzetti et al. 1983). The conflicting data obtained in the above studies may 
result from technical difficulties in testing 2,3,7,8-TCDD rather than from a lack of biological activity. 
Testing difficulties arise from an extreme insolubility of this compound and a high toxicity observed in 
some test systems, which would be anticipated to result in a very narrow window for effective genotoxic 
doses. 
Considering the inconclusive results reported above and the severe limitations of some studies, there is no 
strong evidence for 2,3,7,8-TCDD genotoxicity.  The information regarding the mutagenic potential of 
other CDDs is even more limited. 
Cancer. Numerous epidemiological studies investigated the effects of 2,3,7,8-TCDD exposure on the 
development of cancer.  A number of large-scale retrospective cohort mortality studies (Becher et al. 1996; 
Fingerhut et al. 1991; Hooiveld et al. 1998; Kogevinas et al. 1993, 1997; Manz et al. 1991; Ott and Zober 
1996; Zober et al. 1990) have found significant increases in cancer mortalities (all types of cancers 
combined).  These increases were typically found in the highest exposed workers and in workers with the 
longest latency periods.  In general, the SMRs were low (less than 1.5); however, the high degree of 
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risks of several specific types of cancer have also been found, but the data are somewhat inconsistent.  The 
site-specific cancers with elevated possible risks include soft-tissue sarcoma (Eriksson et al. 1981, 1990; 
Fingerhut et al. 1991; Hardell and Eriksson 1988; Hardell and Sandrom 1979; Hardell et al. 1995; 
Kogevinas et al. 1995, 1997; Saracci et al. 1991; Smith et al. 1984a), non-Hodgkin's lymphoma or 
malignant lymphoma (Becher et al. 1996; Cantor 1982; Hardell et al. 1981; Kogevinas et al. 1995), 
respiratory tract cancer (Fingerhut et al. 1991; Kogevinas et al. 1997; Manz et al. 1991; Zober et al. 1990), 
and gastrointestinal organ cancers (Axelson et al. 1980; Thiess et al. 1982).  Furthermore, an increased risk 
of benign systemic neoplasms was reported in Vietnam Air Force veterans involved in Operation Ranch 
Hand (USAF 1991). There is some uncertainty regarding the interpretation of the epidemiology study 
results. In most studies, the cohort was also exposed to chemicals other than 2,3,7,8-TCDD and exact 
levels of exposure were not known.  Furthermore, in some studies the exposure data were based solely on 
questionnaires and some recall bias could have been present.  Other studies suffered from examining small 
cohorts or investigating the effects after a short latency period.  The long latency period is important for 
detecting increases in soft-tissue sarcomas, presumably a major cancer outcome of CDD exposure in 
humans. 
Several studies provided evidence of CDD-related carcinogenicity in animals.  In general, the effects were 
dependent on the congener, species, sex, and route of administration, and were seen at doses that were close 
to doses that are toxic in the same animal species.  Intermediate- and chronic-duration oral exposure to 
2,3,7,8-TCDD induced multiple-site carcinomas and/or sarcomas in rats (Kociba et al. 1978a; NTP 1982b) 
and mice (Della Porta et al. 1987; NTP 1982a, 1982b; Toth et al. 1979).  Similarly, chronic oral exposure to 
a mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD induced carcinomas in mice and rats (NCI/NTP 
1980), and exposure to 2,7-DCDD caused carcinomas and sarcomas in mice (NCI/NTP 1979a).  However, 
no cancer effects were found following chronic exposure to 2,7-DCDD in rats (NCI/NTP 1979a). 
Furthermore, squamous cell carcinoma developed in hamsters (Rao et al. 1988) following  intermediate-
duration intraperitoneal exposures. 
Short-term dermal studies with 2,3,7,8-TCDD had controversial results.  Some studies reported its 
inhibitory effects on the development of skin tumors in mice otherwise initiated by 13-dimethylbenz­
(o)anthracene (Berry et al. 1978, 1979).  Others cited its ability to promote tumors initiated by N-methyl­
N-nitro-N-nitrosoguanidine (Hebert et al. 1990; Poland et al. 1982).  Further, intraperitoneal injection of 
2,3,7,8-TCDD given 2 days prior to or concurrently with methylcholanthrene did not affect methyl­
cholanthrene-induced carcinogenicity in C57BL/6 mice (Kouri et al. 1978); in contrast, 2,3,7,8-TCDD 
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pretreatment (intraperitoneal or subcutaneous) of DBA/2 mice slightly increased the carcinogenic index.  In 
support of these data, promotion of GGT-positive hepatic foci and/or development of tumors was observed 
after initiation with nitrosodiethylamine in rats (Flodstrom and Ahlborg 1989; Flodstrom et al. 1991; Pitot 
et al. 1980) that were injected with 2,3,7,8-TCDD for an intermediate duration.  A recent study of the 
promoting activity of 2,3,7,8-TCDD in the liver from female Sprague-Dawley rats showed that increased 
tissue burden of 2,3,7,8-TCDD, which correlated with increased CYP1A1 activity, did not necessarily lead 
to increased cell proliferation (Walker et al. 1998). Experimentally, cell proliferation was increased after 30 
or more weeks of treatment, but not after only 14 weeks of treatment, whereas both tissue burden and 
CYP1A1 activity  exhibited similar significant increases at both time points.  Walker et al. (1998) noted that 
a dose metric such as the area under the curve, which measures total dose over time, did not correspond to 
either 2,3,7,8-TCDD-induced changes in cell proliferation or changes in CYP1A1 expression.  This, 
according to the authors, suggested that for a number of 2,3,7,8-TCDD-induced responses, particularly 
those involving integrated signal transduction pathways such as altered cell/tissue growth and 
differentiation, dose metrics that incorporate not only magnitude of exposure, but also duration of exposure 
and temporal windows of sensitivity for the response, may be more appropriate. 
The available data provided sufficient evidence that 2,3,7,8-TCDD is a carcinogen in animals and its action 
is not solely dependent upon initiation by other substances. This is in conflict with the inconclusive geno­
toxicity data.  Significant binding of radioactivity derived from labeled 2,3,7,8-TCDD to liver proteins was 
observed in several studies. However, covalent binding to hepatic DNA was four times less than the levels 
of binding with other carcinogens (Poland and Glover 1979).  This indicates that the typical mutation 
mechanism model (covalent binding/DNA alteration) may not be applicable in the case of CDDs.  In 
addition, there is an evidence that 2,3,7,8-TCDD acts as a tumor promoter (Hebert et al. 1990; Poland et al. 
1982), which is consistent with the increases in multiple-site tumors observed in exposed humans and 
animals.  
2,3,7,8-TCDD is an atypical chemical because of its accumulation and long persistence in the body. 
Several studies demonstrated that 2,3,7,8-TCDD affects the adrenals, thymus (DiBartolomeis et al. 1987; 
Gorski et al. 1988b; Greenlee et al. 1985; Hochstein et al. 1988), and thyroid (Henry and Gasiewicz 1987; 
Hermansky et al. 1988; Hong et al. 1987; Lu et al. 1986; Rozman et al. 1985) and also alters the estradiol 
(Umbreit et al. 1987), testosterone, and dihydrotestosterone (Mebus et al. 1987; Moore et al. 1985) levels in 
the organism.  A study with intact and ovariectomized rats indicated that ovarian estrogens are involved in 
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between the 2,3,7,8-TCDD Ah receptor protein function and the steroid and thyroid receptor protein 
functions, 2,3,7,8-TCDD would interact with various hormone receptors (Holder and Menzel 1989).  It has 
been proposed that 2,3,7,8-TCDD is a hormonal carcinogen causing effects in targeted organs and in 
secondary targets through hormonal imbalance.  Furthermore, 2,3,7,8-TCDD may also promote the meta­
bolism of procarcinogens to active intermediates by the induction of metabolizing enzymes as demonstrated 
in vitro in cultured human lymphocytes (Jaiswal et al. 1985; Kouri et al. 1974, 1978).  The induction of 
these enzymes appears to be the subject of genetic polymorphism such that individuals who are highly 
inducible may be at high risk for the development of tumors.  
Taken together, the results of the epidemiology studies and the animal studies suggest that 2,3,7,8-TCDD 
may be a human carcinogen.  This is consistent with conclusions of several regulatory agencies.  NTP 
(1998) considers 2,3,7,8-TCDD to be a substance that may reasonably be anticipated to be a carcinogen 
(limited evidence in humans, sufficient evidence in animals); NTP is currently considering a reclassification 
of 2,3,7,8-TCDD and the decision is pending. IARC (1997) has recently classified 2,3,7,8-TCDD in Group 
1 based on limited evidence of carcinogenicity in humans and sufficient evidence in animals.  EPA had 
classified 2,3,7,8-TCDD as a Group B2 carcinogen when considered alone and a Group B1 carcinogen 
when considered in association with phenoxyherbicides and/or chlorophenols (EPA 1985d, 1989d, 1991a). 
The Group B2 classification indicates that although evidence in humans is inadequate, the evidence in 
animals is sufficient to consider 2,3,7,8-TCDD a probable human carcinogen.  The Group B1 classification 
indicates that there are not only sufficient animal data but also limited human data to support the 
consideration that 2,3,7,8-TCDD, in association with phenoxyherbicides and/or chlorophenols, is a probable 
human carcinogen.  Moreover, in a proposed rule to add “Dioxin and Dioxin-Like Compounds” to the list 
of chemicals subject to release reporting requirements, EPA reiterated that, “Based on the EPA weight of 
evidence classification criteria, there is sufficient evidence to conclude that 2,3,7,8-TCDD is a probable 
human carcinogen” (EPA 1997c). 
2.6 CHILDREN’S SUSCEPTIBILITY 
This section discusses potential health effects from exposures during the period from conception to maturity 
at 18 years of age in humans, when all biological systems will have fully developed.  Potential effects on 
offspring resulting from exposures of parental germ cells are considered, as well as any indirect effects on 
the fetus and neonate due to maternal exposure during gestation and lactation.  Relevant animal and in vitro 
models are also discussed. 
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Children are not small adults.  They differ from adults in their exposures and may differ in their 
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the extent 
of their exposure. Exposures of children are discussed in Section 5.6, Exposures of Children. 
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is a 
difference depends on the chemical (Guzelian et al. 1992; NRC 1993).  Children may be more or less 
susceptible than adults to health effects, and the relationship may change with developmental age (Guzelian 
et al. 1992; NRC 1993). Vulnerability often depends on developmental stage. There are critical periods of 
structural and functional development during both pre-natal and post-natal life and a particular structure or 
function will be most sensitive to disruption during its critical period(s).  Damage may not be evident until a 
later stage of development. There are often differences in pharmacokinetics and metabolism between 
children and adults. For example, absorption may be different in neonates because of the immaturity of 
their gastrointestinal tract and their larger skin surface area in proportion to body weight (Morselli et al. 
1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants and young children (Ziegler 
et al. 1978). Distribution of xenobiotics may be different; for example, infants have a larger proportion of 
their bodies as extracellular water and their brains and livers are proportionately larger (Altman and Dittmer 
1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 1966; Widdowson and Dickerson 1964).  The 
infant also has an immature blood-brain barrier (Adinolfi 1985; Johanson 1980) and probably an immature 
blood-testis barrier (Setchell and Waites 1975). Many xenobiotic metabolizing enzymes have distinctive 
developmental patterns and at various stages of growth and development, levels of particular enzymes may 
be higher or lower than those of adults and sometimes unique enzymes may exist at particular 
developmental stages (Komori 1990; Leeder and Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether 
differences in xenobiotic metabolism make the child more or less susceptible also depends on whether the 
relevant enzymes are involved in activation of the parent compound to its toxic form or in detoxification. 
There may also be differences in excretion, particularly in the newborn who has a low glomerular filtration 
rate and has not developed efficient tubular secretion and resorption capacities (Altman and Dittmer 1974; 
NRC 1993; West et al. 1948). Children and adults may differ in their capacity to repair damage from 
chemical insults.  Children also have a longer lifetime in which to express damage from chemicals; this 
potential is particularly relevant to cancer. 
Certain characteristics of the developing human may increase exposure or susceptibility while others may 
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kilogram of body weight than adults may be somewhat counterbalanced by their alveoli being less 
developed, so there is a disproportionately smaller surface area for absorption (NRC 1993). 
There is a limited amount of information available on the toxicity of CDDs in children.  Most of the 
available data come from a series of studies on children living in Seveso during the accidental release of 
airborne trichlorophenol contaminated with 2,3,7,8-TCDD.  Shortly after the accident, early irritative 
dermal lesions (this effect may not have been related to 2,3,7,8-TCDD exposure) and chloracne were 
observed in a number of children.  Erythema and edema, the main clinical features of the early irritative 
lesions, were only observed in children and young adults (less than 20 years old) (Caputo et al. 1988). 
Chloracne was observed in 187 individuals, 88% of them were children aged 0 to 14 years (Bisanti et al. 
1980). Based on serum 2,3,7,8-TCDD levels measured in 30 Seveso residents with and without chloracne, 
Mocarelli et al. (1991) suggested that children may develop chloracne at lower 2,3,7,8-TCDD body burdens 
than adults following acute exposure to 2,3,7,8-TCDD.  Other effects observed in the exposed children 
include a significant increase in the number of children with chloracne having clinical and 
electrophysiological signs of peripheral nervous system involvement (assessed 6 years after the accident) 
(Barbieri et al. 1988) and slight transient increases in serum γ-glutamyltransferase and alanine 
aminotransferase levels in boys aged 6-10 years (Mocarelli et al. 1986).  Although the serum enzyme levels 
were higher than in non-exposed children, the values were within the normal range and were elevated 1, 2, 
and 3 years after the accident, but not after 4 or 5 years.  Increased risks of Hodgkin’s lymphoma, myeloid 
leukemia, and thyroid cancer were also reported among children who were 0–19 years old at the time of the 
Seveso accident (Pesatori et al. 1993). However, the differences in relative risks (RRs) for these cancer 
types between the Seveso residents and the control population did not reach statistical significance.  Similar 
results were found in a 15-year follow-up study of this cohort (Bertazzi et al. 1997). 
A wide variety of effects have been observed in adults exposed to 2,3,7,8-TCDD at work or following an 
accidental release of 2,3,7,8-TCDD into the environment.  The primary targets appear to be the skin, liver, 
thyroid, and cardiovascular, endocrine, and immune systems; an increased cancer risk has also been 
observed. In the absence of data to the contrary, it is likely that these organs/systems will also be sensitive 
targets in children. 
A number of human studies have investigated the potential of 2,3,7,8-TCDD to induce developmental 
effects. No significant increases in the incidence of birth defects have been observed in the children of 
parents living in Seveso at the time of the accident or during the next 6-year period (Bisanti et al. 1980; 
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Mastroiacovo et al. 1988) or in the children of men involved in the manufacture of chlorophenols 
(Townsend et al. 1982). In contrast, other studies have found increases in specific types of defects, 
although the total number of defects was not significantly altered.  It is difficult to interpret these data 
because there is little consistency regarding the type of defect or the target organ/system.  For example, a 
significant association between nervous system defects and paternal serum 2,3,7,8-TCDD levels was 
observed in the Ranch Hand cohort (Wolfe et al. 1995) and facial clefts were observed in Arkansas 
residents exposed to sprayed 2,4,5-T.  The lack of exposure data, small sample sizes, and the lack of reliable 
data for birth defect rates prior to 2,3,7,8-TCDD exposure limits the power of the human studies to 
determine if an association between 2,3,7,8-TCDD exposure and developmental toxicity exists in humans.  
The toxicity of 2,3,7,8-TCDD has been extensively examined in animal oral toxicity studies, and effects 
have been observed in most organs/systems.  The animal studies clearly demonstrate that the developing 
organism is very sensitive to the toxicity of 2,3,7,8-TCDD.  The types of effects observed in the offspring 
of animals exposed to 2,3,7,8-TCDD include fetal/newborn mortality, decreased growth, structural 
malformations, kidney anomalies, immunotoxicity, thymic atrophy impaired development of the repro­
ductive system, and neurodevelopmental effects.  The LOAELs for developmental effects are among the 
lowest identified in animals, and the chronic oral MRL is based on a developmental effect.  The most 
sensitive developmental effects are impaired development of the reproductive system and neurobehavioral 
effects. In utero exposure to 2,3,7,8-TCDD adversely affects the development of the reproductive system in 
male and female offspring; studies have shown alterations in androgen levels, secondary sex organs, 
spermatogenesis, fertility, and sexual behaviors (Bjerke and Peterson 1994; Bjerke et al. 1994a, 1994b; 
Chaffin et al. 1996, 1997; Flaws et al. 1997; Gray and Ostby 1995; Gray et al. 1995, 1997a, 1997b; Heimler 
et al. 1998; Mably et al. 1992a, 1992b, 1992c).  Gray and Ostby (1995) found decreased fertility in the 
female offspring exposed on Gd 8; no effects on fertility have been observed in female offspring exposed 
on Gd 15 (Gray et al. 1997a) or in male offspring (Gray et al. 1995; Mably et al. 1992c).  Schantz and 
Bowman (Bowman et al. 1989b; Schantz et al. 1986, 1992; Schantz and Bowman 1989) found neuro­
behavioral alterations in the offspring of monkeys chronically exposed to dietary 2,3,7,8-TCDD (7 months 
prior to mating and during mating and lactation).  Altered peer group behavior, cognitive deficits, and 
prolonged maternal care were observed.  There are some data to suggest that other CDDs (2,7-DCDD, 
1,2,3,7,8-PCDD, OCDD, and HxCDD) are also toxic to the developing organism (Madse and Larsen 1989; 
Schwetz et al. 1973). The observed developmental effects appear to be similar to those observed following 
in utero exposure to 2,3,7,8-TCDD. More details about these studies can be found in Sections 2.2.2.6, 
Developmental Effects, and 2.4.2, Mechanisms of Toxicity.  
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There is a limited amount of data on the toxicokinetic properties of CDDs in children or immature animals. 
A toxicokinetic model was constructed that accurately predicted the lifetime concentrations of 
2,3,7,8-TCDD in adipose tissue, blood, liver, and feces at different ages (Kreuzer et al. 1997).  In formula-
fed infants, the model predicted that 2,3,7,8-TCDD lipid levels would decrease during the first year and 
subsequently increase, reaching a maximum at 16 years of age.  In contrast, the model predicted an initial 
increase in 2,3,7,8-TCDD lipid levels in exclusively breast-fed infants followed by a 3-year decrease after 
weaning and merging at about 7 years with concentrations in formula-fed individuals.  The half-life of 
nonmetabolic elimination (unchanged 2,3,7,8-TCDD) was calculated to be 0.42 years in newborns and 
9.5 years in 40-year-old adults.  The half-life of the fraction metabolized by the liver ranged from 1.5 years 
for newborns to approximately 10 years for a 40-year-old individual.  The three times greater elimination 
half-life for the metabolized fraction relative to the nonmetabolized fraction in infants suggests that 
metabolic elimination does not play a major role in the elimination of 2,3,7,8-TCDD in infants. 
2,3,7,8-TCDD accumulates preferentially in liver and adipose tissue.  Accumulation in the liver is due to 
sequestration by the microsomal binding protein, CYP1A2.  To the extent that this protein is develop­
mentally regulated (Leeder and Kerns 1997), infants (<4 months old) might accumulate relatively less 
2,3,7,8-TCDD in their livers than adults. Little is known about the metabolism of 2,3,7,8-TCDD in humans 
and it is unknown whether the metabolism of 2,3,7,8-TCDD or other CDDs differs between adults and 
children. In animals, phase II enzymes play an important role in the biotransformation and elimination of 
2,3,7,8-TCDD. If this were the case in humans, it would be expected that very young infants would 
metabolize and eliminate 2,3,7,8-TCDD slower than adults since glucuronosyltransferase activity achieves 
adult levels by 6–18 months of age (Leeder and Kearns 1997).  
CDDs are transferred from mother to offspring through the placenta and breast milk.  Although there are 
human data indicating placental transfer of 2,3,7,8-TCDD (Kreuzer et al. 1997; Schecter et al. 1996b), 
quantitative data are not available. A study in mice administered a single dose of 2,3,7,8-TCDD on Gd 12 
showed that the rate of accumulation of 2,3,7,8-TCDD in placental tissue reached a maximum in about 
3 hours (Abbott et al. 1996); after 24 hours, 0.27% of the maternal dose was detected in the placenta.  This 
issue is discussed in more detail in Section 2.3.4.4, Transfer of CDDs Through the Placenta and Breast 
Milk. 
CDDs are lipophilic compounds that can concentrate in maternal milk and be transferred to the nursing 
infant. Numerous studies have examined the transfer of 2,3,7,8-TCDD and related chemicals to infants via 
breast milk and for the most part, the results showed that infants may absorb up to 95% of the administered 
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dose (Abraham et al. 1994, 1996; Dahl et al. 1995; McLachlan 1993; Pluim et al. 1993b).  This percentage 
is similar to the percent of 2,3,7,8-TCDD absorbed (>87%) by an adult volunteer after ingestion of a single 
oral dose of 2,3,7,8-TCDD (Poiger and Schlatter 1986). As stated previously, it has also been shown that 
breast-fed infants have a larger 2,3,7,8-TCDD burden during the first year of life compared to formula-fed 
infants (Kreuzer et al. 1997). However, this initial higher burden does not translate into a higher lifetime 
burden. A number of human studies have examined breast-fed infants of mothers with high background 
levels of CDDs. These studies have found alterations in some markers of liver, thyroid, and immune 
function and neurodevelopment (neurological optimality score) (Huisman et al. 1995a; Koopman-Esseboom 
et al. 1994; Pluim et al. 1993b, 1994a; Weisglas-Kuperus et al. 1995); however, all of the markers were 
within the normal range.  The impaired neurological optimality score that was observed in newborns was 
not significantly altered in children aged 6, 18, or 31 months (Ilsen et al. 1996; Huisman et al. 1995b; Pluim 
et al. 1996). 
Subsequent sections of this chapter (Sections 2.7, 2.8, and 2.10) discuss the available information on 
biomarkers, interactions, and methods for reducing toxic effects.  Most of the available information is from 
adults and mature animals; no child-specific information was identified, with the possible exception of 
biomarker data.  However, there are some data to suggest that interactions with PCBs and CDFs may 
influence the developmental toxicity of 2,3,7,8-TCDD.  Data from children living in Seveso suggest that 
serum 2,3,7,8-TCDD levels are reflective of exposure levels and are a sensitive indicator of past exposure. 
Likewise, it is likely that the available information in adults on interactions and methods for reducing toxic 
effects will also be applicable to children. 
As discussed previously, children appear to be unusually susceptible to the dermal toxicity of 
2,3,7,8-TCDD. The data are inadequate to assess whether they will also be more sensitive to other CDD 
effects. Additionally, the available animal data suggest that the developing fetus is very sensitive to 
2,3,7,8-TCDD-induced toxicity.  2,3,7,8-TCDD appears to interfere with the development of the 
reproductive, immune, and nervous systems; the mechanisms of action for these toxic effects have not been 
elucidated. 
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2.7 BIOMARKERS OF EXPOSURE AND EFFECT 
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples.  They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 1989). 
Due to a nascent understanding of the use and interpretation of biomarkers, implementation of biomarkers 
as tools of exposure in the general population is very limited.  A biomarker of exposure is a xenobiotic 
substance or its metabolite(s), or the product of an interaction between a xenobiotic agent and some target 
molecule(s) or cell(s) that is measured within a compartment of an organism (NRC 1989).  The preferred 
biomarkers of exposure are generally the substance itself or substance-specific metabolites in readily 
obtainable body fluid(s) or excreta.  However, several factors can confound the use and interpretation of 
biomarkers of exposure.  The body burden of a substance may be the result of exposures from more than 
one source. The substance being measured may be a metabolite of another xenobiotic substance (e.g., high 
urinary levels of phenol can result from exposure to several different aromatic compounds).  Depending on 
the properties of the substance (e.g., biologic half-life) and environmental conditions (e.g., duration and 
route of exposure), the substance and all of its metabolites may have left the body by the time samples can 
be taken. It may be difficult to identify individuals exposed to hazardous substances that are commonly 
found in body tissues and fluids (e.g., essential mineral nutrients such as copper, zinc, and selenium). 
Biomarkers of exposure to CDDs are discussed in Section 2.7.1. 
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that, depending on magnitude, can be recognized as an established or potential health impairment 
or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of tissue 
dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial cells), 
as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung capacity. 
Note that these markers are not often substance specific.  They also may not be directly adverse, but can 
indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused by CDDs are 
discussed in Section 2.7.2. 
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability to 
respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or 
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
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biologically effective dose, or a target tissue response.  If biomarkers of susceptibility exist, they are 
discussed in Section 2.9, Populations That Are Unusually Susceptible. 
2.7.1 Biomarkers Used to Identify or Quantify Exposure to CDDs 
Methods for measuring CDDs in biological fluids and tissues are available.  Adipose tissue and liver are the 
primary storage site for CDDs and tissue samples have been analyzed in several studies.  It was 
demonstrated that the relative (lipid-based) levels of 2,3,7,8-TCDD are similar in hepatic and adipose 
tissues (Leung et al. 1990a) and between adipose tissue and serum (Patterson et al. 1988; Schecter et al. 
1990) from the same patients.  However, this was not the case for more highly chlorinated dioxins; for 
example, for OCDD there is a 2:1 ratio between serum and adipose tissue lipid fractions (Schecter et al. 
1990) and a 12:1 ratio between liver and adipose tissue levels (Thoma et al. 1990).  However, the important 
TEQ variable was close to 1:1 ratio. 
In the general population, adipose tissue levels of 2,3,7,8-TCDD ranged from non-detectable to 20.2 ppt in 
128 Kansas City, St. Louis, and Springfield, Missouri, residents with no known special exposure to CDDs 
(Andrews et al. 1989). Similarly, 2,3,7,8-TCDD levels in adipose tissues were between 5 and 10 ppt in a 
sample of the general population in Canada, while OCDD levels ranged from 600 to 800 ppt in the cohort 
(Ryan et al. 1985a).  Increased environmental exposure to CDDs was reflected by increased levels in 
adipose tissues. Residents of two California households who had eaten dioxin-contaminated beef and eggs 
had significantly elevated serum levels of 2,3,7,8-TCDD, PCDD, and HxCDD, compared with rural 
Californians who did not eat contaminated beef and eggs (Goldman et al. 1989).  2,3,7,8-TCDD serum lipid 
levels ranged from 2.8 to 750 ppt in individuals with possible recreational, residential, or occupational 
exposure in Missouri (Patterson et al. 1986a). Several other studies reported increased concentrations of 
2,3,7,8-TCDD in adipose tissues (Beck et al. 1989c; Fingerhut et al. 1989; Patterson et al. 1989b) or serum 
lipid (Fingerhut et al. 1989; Patterson et al. 1989b) of occupationally exposed workers.  The highest 
2,3,7,8-TCDD levels reported ranged between 42 and 750 ppt in adipose tissue lipid and between 61 and 
1,090 ppt in the serum lipid of Missouri chemical workers (Patterson et al. 1989b).  Based on a mean of 
208 ppt 2,3,7,8-TCDD in the serum lipid of chemical workers measured at least 17 years postexposure, and 
a mean biological half-life level of 7 years, it was estimated that the serum lipid level shortly after exposure 
would have been approximately 2,313 ppt (range, 6.4–14,673) (Fingerhut et al. 1989).  The major 
disadvantage of these studies is a lack of information regarding actual 2,3,7,8-TCDD exposure.  Studies in a 
population exposed to 2,3,7,8-TCDD in the Seveso industrial accident found serum lipid 
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2,3,7,8-TCDD levels in exposed individuals as high as 56,000 ppt in the highly contaminated zone where 
soil samples ranged from 956 to 1,185 µg 2,3,7,8-TCDD/m2 (Mocarelli et al. 1991); these serum samples 
were collected about a month after exposure and were recently analyzed.  Chloracne did not always develop 
in the individuals with highly elevated serum 2,3,7,8-TCDD levels, although it did occur in all who had 
levels above 12,000 ppt. In the most recent National Human Adipose Tissue Survey (NHATS), conducted 
in fiscal year 1987, it was found that the average concentration of 2,3,7,8-TCDD in the adipose tissue of the 
U.S. population was 5.38 ppt, increasing from 1.98 ppt in children under 14 years of age to 9.4 ppt in adults 
over 45 (Orban et al. 1994). The average concentration of 2,3,7,8-TCDD was found to increase at an 
average rate of 0.83 ppt per decade for individuals under age 31, and at an average rate of 1.52 ppt per 
decade for the older population. The study also found no statistical evidence of differences in the average 
levels for populations representing different sexes and racial groups nationwide.  Furthermore, a 
comparison of mean concentrations of 2,3,7,8-TCDD and OCDD between the 1982 and 1987 NHATS 
revealed no statistically significant differences between the two surveys.  For OCDD the values were 768 
and 724 ppt in the 1982 and 1987 surveys, respectively (Orban et al. 1994).  
Similarly, no exact exposure data were available in Vietnam veteran studies.  In general, tissue samples for 
analyses were taken several (approximately 10–20) years after exposure, which represents another 
limitation of these studies.  Increased adipose 2,3,7,8-TCDD levels (up to 99 ppt) were recorded in Vietnam 
War veterans involved in Operation Ranch Hand (Gross et al. 1984; Schecter et al. 1989a).  In a small 
group of potentially exposed Vietnam veterans, adipose tissue 2,3,7,8-TCDD levels ranged from non-
detectable to 11 ppt with a mean of 5.8 ppt (Schecter et al. 1989a).  Schecter et al. (1989a) noted that the 
veterans with adipose tissue levels of $8 ppt were considered to have slightly elevated values or values 
within the normal range.  In another study of 646 ground troop veterans, only two individuals had serum 
2,3,7,8-TCDD levels above 20 ppt in the lipid fraction (CDC 1988).  In the rest of the cohort, the median 
2,3,7,8-TCDD levels ranged from 3.2 to 4.3 ppt and did not differ significantly from the levels found in the 
control group of non-Vietnam veterans (CDC 1988; MMWR 1987).  It was concluded that those who did 
not handle or spray herbicides were not highly exposed to 2,3,7,8-TCDD (CDC 1988).  With regard to the 
long time period between exposure and serum analysis, the authors argued that, assuming first-order 
kinetics and 2,3,7,8-TCDD's half-life of 7 years in humans, the study had enough statistical power to detect 
differences between the exposed and control groups (CDC 1988).  Elevated CDD levels were also measured 
in some patients treated in a hospital in South Vietnam (Phiet 1989; Phuong et al. 1989b).  However, these 
reports involved too few patients to give any conclusive results.  In a more recent expanded half-life study 
of 337 Vietnam veterans, a median observed half-life of 11.5 years was calculated for 
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2,3,7,8-TCDD (Wolfe et al. 1994). The nonparametric 95% CI was 10–14.1 years.  A review of CDD 
levels in human tissues from various populations can be found in Schecter et al. (1994c). 
CDDs have also been detected in breast milk of women exposed to high levels of CDDs and in women 
presumably exposed to background levels.  High 2,3,7,8-TCDD levels (mean of 484 pg/g milk fat; 18 pg/g 
whole milk) were found in the milk of mothers from South Vietnam in 1970; the levels dropped to a mean 
of 12 pg/g milk fat (0.47 pg/g milk) by 1985 (Schecter et al. 1987a) and 7.5 pg/g milk fat in samples 
collected between 1984 and 1992 (Schecter et al. 1995). Mean 2,3,7,8-TCDD levels in breast milk samples 
(collected in 1984) in mothers from South Vietnam, North Vietnam, and the United States were 0.68, not 
detectable, and 0.19 pg/g whole milk (Schecter and Gasiewicz 1987b).  The total CDD and CDF levels 
(expressed as TEQs) in these samples were 1.11, 0.065, and 1.04 pg/g milk.  Results from the analysis of 
526 individual milk samples from the German general population revealed a mean 2,3,7,8-TCDD 
concentration of 3.2 pg/g milk fat (Fürst et al. 1994).  The analysis also showed the presence of only 
2,3,7,8-chlorine-substituted congeners. OCDD was the most concentrated congener with a mean level of 
208 pg/g milk fat.  In general, the levels in milk decreased with decreasing degree of chlorination from 
octa- to tetra-CDD. The total TEQs, including CDFs, was 29.3 pg/g milk fat.  Fürst et al. (1994) estimated 
that the average daily intake of 2,3,7,8-TCDD via human milk for an infant weighing 5 kg is 15.4 
pg/kg/day, and the mean total dioxin equivalents amounted to 140.6 pg/kg/day.  Both parity and the length 
of time the woman has been lactating influence the CDD concentration in breast milk. 
A reverse transcriptase polymerase chain reaction (RT-PCR) method was developed to quantitate CYP1A1 
mRNA levels on total RNA extracts from mitogen-stimulated human blood lymphocytes cultured in the 
presence or absence of 10 nM 2,3,7,8-TCDD (Van den Heuvel et al. 1993). Although CYP1A1 gene 
expression can be monitored by measuring EROD activity (CYP1A1) or mRNA expression (using 
conventional RNA hybridization), RT-PCR is a much more sensitive approach.  The average CYP1A1 
mRNA levels in the cultured, 2,3,7,8-TCDD-treated cells was approximately 21 times higher than that in 
the non-2,3,7,8-TCDD-treated cells. In uncultured, nonstimulated lymphocytes from volunteers, CYP1A1 
mRNA could be reproducibly measured at levels that were 10–40-fold lower than in mitogen-stimulated 
lymphocytes.  In comparison, EROD activity measured in uncultured, nonstimulated lymphocytes was 
indistinguishable from measurements on reagents controls, which proved the high sensitivity of the RT­
PCR approach. In a group of 6 smokers, the average level of CYP1A1 message was approximately 2 times 
higher than in a group of 6 nonsmokers, although there was great variability in the group of smokers. 
Based on these preliminary results, Van den Heuvel et al. (1993) suggested that CYP1A1 gene expression 
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in peripheral blood lymphocytes may be used as a human exposure marker for 2,3,7,8-TCDD and related 
compounds. 
For more information on biomarkers for renal and hepatic effects of chemicals, see the ATSDR/CDC 
Subcommittee Report on Biological Indicators of Organ Damage (1990), and for information on biomarkers 
for neurological effects, see OTA (1990). 
2.7.2 Biomarkers Used to Characterize Effects Caused by CDDs 
Chloracne is one effect that is clearly associated with exposure to high levels of CDDs and other 
halogenated organic chemicals, and has been observed in some individuals who were exposed 
occupationally or in the environment to increased levels of 2,3,7,8-TCDD or chemicals contaminated with 
2,3,7,8-TCDD. However, while the presence of chloracne indicates exposure to CDDs or other halogenated 
organic compounds, its absence does not preclude such exposure.  For example, in a cohort from the Seveso 
incident, no chloracne was observed below an initial serum lipid 2,3,7,8-TCDD level of 800 ppt (body 
burden of 2.5 µg/kg, assuming 22% body fat and 70 kg body weight); above 12,000 ppt (body burden of 
38 µg/kg) chloracne was always observed; and between 800 and 12,000 ppt the occurrence of chloracne 
was sporadic (Mocarelli et al. 1991). In the Yu-Cheng population, chloracne was associated with a body 
burden in 2,3,7,8-TCDD equivalents of 2–3 µg/kg body weight, or about 140–210 µg for a 70-kg adult 
(Ryan et al. 1990). 
Biochemical changes (raised serum hepatic enzyme levels, disorders of lipid and carbohydrate metabolism, 
unbalanced porphyrin metabolism) and/or an enlarged liver can indicate effects induced by 2,3,7,8-TCDD 
exposure, but these effects are not specific for this or other compounds.  Light and electron microscope 
changes in the liver (e.g., lipid droplets in parenchymal cells, increased endoplasmic reticulum, enlarged 
and pleomorphic mitochondria) are also sensitive but nonspecific biomarkers for exposure to CDDs 
(Schecter et al. 1985b). When biochemical changes in the placenta of women exposed in the Yu-Cheng 
incident were evaluated for use as possible biomarkers, the EGF receptor autophosphorylation effect was 
found to be associated with decreased birth weight in the neonates (Lucier et al. 1986). The authors 
suggested using this response as a biomarker of effect for all toxic chlorinated aromatic compounds. 
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2.8 INTERACTIONS WITH OTHER CHEMICALS 
Several studies were located regarding interactions that affect the toxicity of CDDs.  Probably the most 
important interactions that have an impact on human health are those involving CDDs, CDFs, and PCBs.  It 
has been recognized that chloroaromatics cause a complex of similar effects that vary in severity depending 
on the number of chlorine atoms, positional substitution, and species susceptibility.  Sufficient information 
is available for assessment of risk associated with exposure to 2,3,7,8-TCDD.  However, exposure to a 
mixture of chloroaromatics is common in the general environment.  The assessment of health risk resulting 
from exposure to chemical mixtures of chloroaromatics was enabled by the development of TEFs 
(2,3,7,8-TCDD equivalence factors) that relate the relative toxic potency for CDDs and CDFs to that of 
2,3,7,8-TCDD (EPA 1989). It was assumed based on previous literature data (Eadon et al. 1986) and in 
animal dosing studies (Van den Berg et al. 1989), that CDDs and CDFs have an additive effect in the 
organism when weighted for relative toxicity compared to 2,3,7,8-TCDD (for further information see 
Sections 2.4 and 2.5). The assumption of additivity was later supported by experimental data.  The concept 
of TEFs was used, for example, to assess the potential toxicity of background levels of CDFs and CDDs in 
general populations based on body burdens of indicator CDDs that were associated with chloracne and 
other effects in the Yusho and Yu-Cheng rice oil poisoning incidents (Ryan et al. 1990). 
However, some recent studies further investigated the interactions of various chloroaromatics and indicated 
that the interactions may be more complicated.  In vitro studies compared relative toxicity of various 
chloroaromatics in human cell lines monitoring enzyme induction and binding to the Ah receptor that 
mediates the induced responses (Nagayama et al. 1985; Safe 1987).  In vivo studies concentrated on 
monitoring of enzyme induction, inhibition of body weight gain and immunotoxic and teratogenic effects. 
Coexposure of Long Evans rats to 6-methyl-1,3,8-trichlorodibenzofuran (MCDF) and 2,3,7,8-TCDD 
induced a partial inhibition of the monooxygenase enzyme-induction response caused by 2,3,7,8-TCDD 
treatment alone (Harris et al. 1989b).  Although MCDF did not decrease the levels of occupied nuclear 
2,3,7,8-TCDD Ah receptors, it inhibited the effects of 2,3,7,8-TCDD on the cytosolic Ah receptor (Harris et 
al. 1989b). 
Other studies further indicated that PCBs may antagonize Ah receptor-mediated responses to 
2,3,7,8-TCDD. In a recent review, Van den Berg et al. (1994) suggested that toxicokinetic factors 
contribute to the observed nonadditive toxicological and biological effects. Co-treatment of C57BL/6 mice 
with various commercial Aroclors (PCB mixtures) and 2,3,7,8-TCDD resulted in antagonizing the 
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2,3,7,8-TCDD-mediated inhibition of the splenic plaque-forming cell response (Bannister et al. 1987; Davis 
and Safe 1989). Similarly, significant antagonism of 2,3,7,8-TCDD and Aroclor 1254 was observed in the 
induction of cytochrome P-450-dependent monooxygenases in C57BL/6J mice (Bannister et al. 1987).  The 
effects were dependent on the dose of both 2,3,7,8-TCDD and Aroclor 1254 and on their respective ratios. 
The ratios of Aroclor 1254/2,3,7,8-TCDD that induced antagonist reactions were comparable to the ratios of 
PCBs/CDDs found in human tissues and environmental samples.  The authors speculated that less-toxic 
chlorinated compounds may have a protective effect against the more-toxic compounds in the environment. 
However, by comparing the immune sensitivities of both Ah responsive and Ah less-responsive mouse 
strains, it was demonstrated that a complex mixture of contaminants taken from the Love Canal site was 
immunosuppressive and that this effect was primarily due to the 2,3,7,8-TCDD component of the mixture, 
although 2,3,7,8-TCDD was a very minor component, and there was little interaction with the other 
hydrocarbon components of the mixture (Silkworth et al. 1989a). 
Experimental studies have shown that interactions of 2,3,7,8-TCDD and CDFs or PCBs resulted in fetotoxic 
and teratogenic effects in the offspring of exposed animals.  Exposure of pregnant mice to 2,3,7,8-TCDF 
resulted in cleft palates and hydronephrosis in the offspring (Hassoun et al. 1984).  The results obtained in 
different strains of mice indicated an association with the Ah locus.  Comparable results were obtained 
previously in mice exposed to 2,3,7,8-TCDD (Abbott and Birnbaum 1989a; Abbott et al. 1987a, 1987b; 
Courtney 1976).  When C57BL/6N mice were treated orally with 2,3,7,8-TCDD and 2,3,7,8-TCDF on 
gestational day (Gd) 10, hydronephrosis and cleft palates were observed in the offspring (Weber et al. 
1985). The effects of both chemicals were additive.  Similarly, an increased incidence (10-fold) of cleft 
palates was observed in offspring of C57BL/6N mice after a combined treatment with 2,3,7,8-TCDD and 
2,3,4,5,3',4'-hexachlorobiphenyl during gestation, as compared with those treated with 2,3,7,8-TCDD alone 
(cleft palate was not observed when 2,3,4,5,3',4'-hexachlorobiphenyl was administered alone) (Birnbaum et 
al. 1985). In contrast, no potentiation of CDD-mediated effect was found with 2,4,5,2',4',5'-hexachloro­
biphenyl.  Furthermore, co-treatment of pregnant C57BL/6J mice with Aroclor 1254 and 2,3,7,8-TCDD 
resulted in a sharp decrease in the incidence of cleft palate per litter (8.2%) compared with those treated 
with 2,3,7,8-TCDD alone (62%) (Haake et al. 1987).  
Similarly, 2,3,7,8-TCDD-induced fetotoxicity and teratogenicity were altered by co-exposure to other 
chemicals.  A synergistic effect on the induction of cleft palates was observed in offspring of C57BL/6N 
mice treated orally with 2,3,7,8-TCDD and retinoic acid on Gd 10 or 12 (Abbott and Birnbaum 1989b; 
Birnbaum et al. 1989b).  However, the co-administration of retinoic acid did not influence the incidence of 
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2,3,7,8-TCDD-induced hydronephrosis, nor did 2,3,7,8-TCDD affect the incidence or severity of limb-bud 
defects induced by retinoic acid (Birnbaum et al. 1989b).  A synergistic effect was observed when 
2,3,7,8-TCDD (orally) and hydrocortisone (subcutaneously) were administered to C57BL/6N mice on 
Gd 10–13 (Birnbaum et al. 1986).  The incidence of cleft palate in the offspring increased to 100% 
following the combined treatment.  Pretreatment of pregnant NMRI mice with benzo(a)pyrene 
subcutaneously 5 hours prior to an intraperitoneal injection of 2,3,7,8-TCDD caused an increase in CDD-
induced lethality but did not alter the rate of cleft palate formation (Hassoun 1987).  Offspring of male 
mice, treated with chlorinated phenoxy acids and 2,3,7,8-TCDD in their feed for 8 weeks before the mating, 
did not differ in their development or survival from offspring in the control group (Lamb and Moore 1981). 
Results in B6C3F1 mice indicated that α-naphthoflavone antagonizes 2,3,7,8-TCDD in induction of 
splenocyte EROD activity (Blank et al. 1987).  It was further suggested that α-naphthoflavone impedes 
2,3,7,8-TCDD suppression of B lymphocyte differentiation by competing for binding to the Ah receptor. 
The mechanism of interaction of these chemicals was studied in vitro using rat hepatic cytosol or mouse 
hepatoma cells (Gasiewicz and Rucci 1991).  The results indicated that α-naphthoflavone acts as a 
2,3,7,8-TCDD antagonist by binding to the Ah receptor and forcing on it a conformation that cannot 
identify the DNA recognition sequence contained in the dioxin-responsive enhancer element of the 
CYP1A1 gene. In contrast, in vitro experiments showed that co-exposure of a thymus organ culture with 
the weakly toxic β-naphthoflavone and 2,3,7,8-TCDD results in a significant increase in the lymphoid 
inhibitory effect mediated by 2,3,7,8-TCDD (Hassoun 1987). 
Hexachlorobenzene acted like a weak Ah receptor agonist and caused an up to 40% decrease in specific 
hepatic cytosol binding of 2,3,7,8-TCDD in rat cells (Hahn et al. 1989b).  Similarly, 2,3,7,8-TCDD-induced 
myelotoxicity and enzyme induction was antagonized by 1-amino-3,7,8-trichlorodibenzo-p-dioxin in 
B6C3F1 mice presumably by competitive binding to the cytosolic Ah receptor (Luster et al. 1986). 
Comparable effects were observed in vitro in murine bone-marrow-cells cultures.  Treatment of Fischer 344 
rats orally with di(2-ethylhexyl)phthalate (DEHP) before or after oral administration of 2,3,7,8-TCDD 
reduced the hyperlipidemia induced by the latter compound (Tomaszewski et al. 1988).  Furthermore, 
DEHP pretreatment followed by daily doses of this hypolipidemic substance was partially protective against 
2,3,7,8-TCDD-induced mortality, wasting, and liver fatty changes. 
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The addition of activated charcoal or dehydrocholic acid to the feed, protected animals (C57BL/6J mice, 
CD-COBS rats, and guinea pigs) from increased mortality caused by a single lethal dose of 2,3,7,8-TCDD 
(Manara et al. 1984). In the case of the former agent, the effect was probably due to the general high 
binding ability of superactivated charcoal; since no other antidote is known, its use for therapeutic purposes 
was recommended.  Protective effects of ascorbic acid (administered orally) and butylated hydroxyanisole 
(BHA) (administered orally) against 2,3,7,8-TCDD given by gavage were investigated in Sprague-Dawley 
rats (Hassan et al. 1987). BHA administration partially protected rats from losses in organ weights and 
2,3,7,8-TCDD-induced lipid peroxidation and inhibition of glutathione peroxidase activity.  In contrast, 
ascorbic acid had no protective effects. 
Data regarding interactions affecting the toxicity or toxicokinetics of other chemicals by 2,3,7,8-TCDD 
were limited.  Dermal pretreatment with 2,3,7,8-TCDD inhibited the induction of skin tumors by 
subsequently applied benzo(a)pyrene or dimethylbenz(a)anthracene in Sencar mice (Cohen et al. 1979).  It 
was proposed that 2,3,7,8-TCDD caused qualitative alteration of hydrogen binding to DNA.  In addition, 
2,3,7,8-TCDD may also promote the metabolism of procarcinogens (e.g., 3-methylcholanthrene) to active 
metabolites by the induction of metabolizing enzymes (Kouri et al. 1974, 1978). 
2.9 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceptible population will exhibit a different or enhanced response to CDDs than will most persons 
exposed to the same level of CDDs in the environment.  Reasons may include genetic makeup, age, health 
and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke).  These parameters may 
result in reduced detoxification or excretion of CDDs, or compromised function of target organs affected by 
CDDs. Populations who are at greater risk due to their unusually high exposure to CDDs are discussed in 
Section 5.6, Populations With Potentially High Exposure. 
No data were located regarding unusually susceptible subpopulation in humans.  Animal data showed 
developmental effects of 2,3,7,8-TCDD in fetuses and newborns exposed in utero and via breast-feeding, 
respectively (Abbott and Birnbaum 1989b; Giavini et al. 1982, 1983; Håkansson et al. 1987; Weber et al. 
1985) (see Section 2.2.2.6). The experimental data suggest that the prenatal and postnatal population may 
be more sensitive to 2,3,7,8-TCDD-induced effects; however, the levels of exposure necessary to induce 
such effects are not known. Data in mice indicated that strain differences in sensitivity to 2,3,7,8-TCDD 
toxicity exist and are associated with the Ah receptor (Poland and Glover 1980).  It has been shown that 
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the Ah receptor exists in human lymphoid tissue and that its concentration is variable between persons 
(Hayashi et al. 1994; Lorenzen and Okey 1991).  As noted in Section 2.4, 2,3,7,8-TCDD may promote the 
metabolism of procarcinogens (e.g., contained in cigarette smoke) to active intermediates by the induction 
of metabolizing enzymes.  The induction of these enzymes in humans appears to be subject to genetic 
polymorphism so that individuals who have an Ah receptor with high affinity for 2,3,7,8-TCDD and related 
chemicals may be at the highest risk for the development of lung tumors (Antilla et al. 1991; Bartsch et al. 
1990; Kawajiri et al. 1990; McLemore et al. 1990; Uematsu et al. 1991). 
2.10 METHODS FOR REDUCING TOXIC EFFECTS 
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to CDDs. However, because some of the treatments discussed may be experimental and 
unproven, this section should not be used as a guide for treatment of exposures to CDDs.  When specific 
exposures have occurred, poison control centers and medical toxicologists should be consulted for medical 
advice. 
No texts were found that provided specific information about treatment following exposures to CDDs. 
2.10.1 Reducing Peak Absorption Following Exposure 
No specific information was located regarding the reduction of peak absorption of CDDs by the oral and 
inhalation routes of exposure in humans.  Weber et al. (1992d) examined the effect of four decontamination 
protocols on the residency time of 2,3,7,8-TCDD in intact or damaged human post-mortem skin in vitro. 
Damage was simulated by stripping of the stratum corneum.  2,3,7,8-TCDD was applied to the skin for 
100 minutes and one of the following protocols was performed: the sample was wiped with dry, adsorbent 
material (cotton balls); a 10-minute topical treatment with mineral oil was followed by dry wiping with 
cotton balls; a 10-minute topical treatment with mineral oil was followed by wiping with acetone-soaked 
cotton balls; and the sample was washed with water and soap.  In intact skin, mineral oil treatment and 
acetone wipes reduced by about two-fold the amount of 2,3,7,8-TCDD in the stratum corneum.  Mineral oil 
plus dry wipes reduced the amount of 2,3,7,8-TCDD in the stratum corneum by about 33%, whereas dry 
wiping alone was ineffective. However, all protocols were equally effective in reducing the amount of 
2,3,7,8-TCDD in the epidermis and upper dermis by factors of up to 10.  In damaged skin, by dry wiping 
with adsorbent material 2,3,7,8-TCDD was rubbed into the skin, leading to increased concentrations in the 
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various layers of the skin.  In contrast, mineral oil treatment followed either by dry wipes or by acetone 
wipes, and washing with water and soap decontaminated the damaged skin quite effectively.  The authors 
(Weber et al. 1992d) noted that the effect of decontamination was most pronounced at a skin depth between 
160 and 500 µm, which is the depth at which vascularization begins and, therefore, the protocols discussed 
should be particularly effective in reducing systemic absorption of 2,3,7,8-TCDD from the skin.  
2.10.2 Reducing Body Burden 
Limited information was located regarding reducing body burden following exposure to CDDs in humans. 
A recent study examined the influence of short-term dietary measures on CDD and CDF concentrations in 
human milk (Pluim et al. 1994c).  The authors hypothesized that mobilization of fatty acids from adipose 
tissue cause the concomitant release of CDDs and CDFs, which will then be eliminated in the breast milk. 
Two diets were tested for their ability to reduce the concentration of CDDs and CDFs in human milk: a 
low-fat/high carbohydrate/low CDD and CDF diet (16 women), and a high-fat/low carbohydrate/low CDD 
and CDF diet (18 women).  The authors also analyzed the fatty acid pattern of the milk to determine 
whether the dietary changes were sufficient to change the milk-fat composition.  The test diets were 
followed for 5 consecutive days in the fourth week after delivery.  Body weights were not affected by the 
experimental diets.  The results showed that the fat content of the milk did not decrease in either group 
during the test diet. Furthermore, there was no significant change in CDD and CDF concentration in milk 
fat after treatment with the experimental diets.  However, the percentage of medium-chain fatty acids 
(MCFA) changed significantly.  In the low-fat/high carbohydrate diet group, the percentage of MCFA 
increased while the percentage of C18:1ω9 fatty acids (fatty acid with 18 straight-chain carbon atoms, 
1-methylene-interrupted double bond and 9 carbon atoms from the terminal methyl group to the nearest 
double bond) decreased. In the high-fat/low carbohydrate diet group the changes were in the opposite 
direction. According to the authors, the results would indicate that the concentration of CDDs and CDFs in 
milk fat may be independent of the source of the fatty acids.  Alternatively, they indicate that the dieting 
period may have been too short or the dietary changes in fat and carbohydrate intake may have not been 
large enough. 
Using a fugacity-based PBPK model to evaluate elimination of 2,3,7,8-TCDD from humans, assuming a 
background 2,3,7,8-TCDD intake of 50 pg/day, Kissel and Robarge (1988) estimated that daily 
consumption of 10 g of a nonabsorbable oil would reduce the steady-state adipose tissue concentration of 
2,3,7,8-TCDD from 7.7 ppt to 3 ppt.  At an adipose tissue level of 50 ppt, the apparent half-life of 
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2,3,7,8-TCDD would be decreased by consumption of the nonabsorbable oil from 5.2. to 2.1 years. 
However, this is a theoretical assumption based on the PBPK model. 
Zober and Päpke (1993) reported that serum lipid 2,3,7,8-TCDD levels increased from 17 ppt to 32 ppt in a 
patient who lost >7 kg of weight in a 5-month period.  The serum lipid concentrations of 
1,2,3,6,7,8-HxCDD, 1,2,3,4,5,7,8-HpCDD, and OCDD also increased during this period. Fasting appeared 
to relieve signs and symptoms of intoxication in a group of patients who ingested rice oil contaminated with 
the structurally related PCBs and CDFs (Yu-Cheng incident) (Imamura and Tung 1984).  The authors 
suggested that fasting may stimulate mobilization of the chemicals from adipose tissue to the liver where 
they are then metabolized, which would facilitate excretion and reduce body burden.  However, the findings 
of that study should be interpreted with caution because a control group was not used, small number of 
subjects were evaluated, the patients volunteered for the study, and some of the end points that were 
evaluated were subjective. Promotion of fecal excretion of CDFs and PCBs by cholestyramine, a 
hypercholesterolemia therapeutic agent used in the treatment of poisoning by chlorinated organic 
agricultural chemicals, was inconclusive in a clinical trial with six Yusho patients (Iida et al. 1991; Murai et 
al. 1991). 
In experimental animals, administration of a diet containing 2.5 or 5% activated charcoal substantially 
reduced mortality due to a single lethal oral dose of 2,3,7,8-TCDD in rats, mice, and guinea pigs (Manara et 
al. 1984). Also, feed with 0.25 or 0.5% cholic acid had a similar protective action in mice (Manara et al. 
1984). The effect of activated charcoal was attributed to increased clearance of unabsorbed 2,3,7,8-TCDD 
from the body; the mechanism of protection by cholic acids was unclear.  
2.10.3 Interfering with the Mechanism of Action for Toxic Effects 
There are no established methods for interfering with the mechanism of action of CDDs.  Many of the toxic 
effects of 2,3,7,8-TCDD and structurally related halogenated aromatic hydrocarbons have been shown to be 
mediated through the Ah receptor (see Section 2.4 for details).  The sequence of events associated with the 
receptor-mediated mechanism involve entry of 2,3,7,8-TCDD into the cell, binding to the cytosolic Ah 
receptor, binding of the receptor-ligand complex to DNA recognition sites, and expression of specific genes 
and the translation of their protein products. Although speculative, it is possible that interference with this 
mechanism may lead to a more specific treatment for reducing some of the toxic effects of 2,3,7,8-TCDD 
and structurally related chemicals.  Future research on Ah receptor antagonists may provide new insights 
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for clinical treatment of the Ah receptor-mediated toxicity of 2,3,7,8-TCDD and other Ah receptor agonists. 
2.11 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate 
information on the health effects of CDDs is available.  Where adequate information is not available, 
ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the initiation of 
a program of research designed to determine the health effects (and techniques for developing methods to 
determine such health effects) of CDDs.  
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean that 
all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
2.11.1 Existing Information on Health Effects of CDDs 
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to CDDs 
are summarized in Figures 2-5 and 2-6.  The purpose of this figure is to illustrate the existing information 
concerning the health effects of CDDs. Each dot in the figure indicates that one or more studies provide 
information associated with that particular effect.  The dot does not necessarily imply anything about the 
quality of the study or studies, nor should missing information in this figure be interpreted as a "data need." 
A data need, as defined in ATSDR's Decision Guide for Identifying Substance-Specific Data Needs Related 
to Toxicological Profiles (ATSDR 1989), is substance-specific information necessary to conduct 
comprehensive public health assessments.  Generally, ATSDR defines a data gap more broadly as any 
substance-specific information missing from the scientific literature. 
As seen in Figures 2-5 and 2-6, information is available regarding death, systemic, immunological, 
neurological, developmental, reproductive, and genotoxic effects and cancer in humans.  Most of the 
available information is for 2,3,7,8-TCDD.  Most of this information is negative or inconclusive except for 
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dermal effects and cancer.  As previously mentioned, exposure to humans probably occurs by a 
combination of the inhalation, oral, and dermal routes.  No information is available regarding effects of a 
single route of exposure in humans.  However, food is the major source of human exposure in the general 
population; therefore, the oral route is the most significant exposure route. 
Oral and dermal studies in animals provide data on death, systemic effects after acute-, intermediate-, and 
chronic-duration exposure, and immunological, reproductive, and cancer effects.  Furthermore, data exist 
regarding neurological, developmental, and genotoxic effects after oral exposure.  No data were located 
regarding effects in animals after inhalation exposure to CDDs. 
2.11.2 Identification of Data Needs 
As discussed in Section 2.5, the EPA and other agencies and scientists are using the TEF scheme as an 
alternative interim approach for hazard evaluation of CDDs and CDFs.  Since toxicological data for other 
CDD congeners is more limited, additional congener-specific studies would provide valuable data for 
validating the TEF approach. In vitro and short-term parenteral injection studies using sensitive end points 
(i.e., enzyme induction, immune alterations) have been used for this purpose, but studies using other end 
points, the oral route, and/or longer durations of exposure would be more informative.  Since the database 
for CDD effects not mediated through the Ah receptor is limited, additional studies may be relevant to 
understanding whether acute versus chronic responses to 2,3,7,8-TCDD occur by different mechanisms. 
CDDs and the structurally related CDFs and dioxin-like PCBs are of concern to ATSDR because of the 
potential of these chemicals to harm health at relatively low doses.  As discussed in Section 2.5, many of 
the toxic effects of these compounds appear to be mediated by a common mechanism, and CDDs frequently 
occur with CDFs in the environment.  Therefore, due to the common mechanism of toxicity, total toxicity 
of a CDD/CDF mixture probably results from the added contribution (not necessarily linear) of both classes 
of chemicals.  Because of this, the complex issue of appropriate methodology for quantitatively assessing 
health risks of CDDs and CDFs is currently being evaluated by ATSDR.  Additional information on toxic 
interactions between CDDs and CDFs, as well as PCBs, would facilitate health risk assessment of this class 
of chemicals. 
Acute-Duration Exposure Acute exposure of humans to 2,3,7,8-TCDD can cause chloracne and 
hepatic effects (Goldman 1973; Reggiani 1980).  Specifying the route of exposure in these human cases is 
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difficult because the individuals were probably exposed by a combination of routes.  Furthermore, human 
data did not provide any information regarding exposure levels and co-exposure to other chemicals 
confounds the results. Also, in most cases, the exposed subjects were examined long after exposure 
occurred. Acute oral exposure to 2,3,7,8-TCDD caused delayed type of death in all animal species tested, 
and LD50 values have been determined for rats (NTP 1982b; Schwetz et al. 1973; Walden and Schiller 
1985), minks (Hochstein et al. 1988), rabbits (Schwetz et al. 1973), guinea pigs (McConnell et al. 1984; 
Schwetz et al. 1973), and hamsters (Henck et al. 1981).  Furthermore, an acute LD50 was calculated for rats 
and mice exposed to a mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD (NCI/NTP 1980).  No deaths 
were observed with other congeners (2,7-DCDD, 1,2,3,4,6,7,8-HpCDD, 1,2,3,4,6,7,8,9-OCDD) (NTP 
1982b) tested, and 2,3,7,8-TCDD proved to be the most toxic CDD.  However, interspecies and interstrain 
differences were found in the susceptibility to CDDs.  Systemic effects observed in animals after acute oral 
exposure to 2,3,7,8-TCDD included cardiovascular (Hochstein et al. 1988; McConnell et al. 1978b), 
gastrointestinal (Theobald et al. 1991), hematological (Christian et al. 1986), hepatic (Christian et al. 1986; 
Kelling et al. 1985; Walden and Schiller 1985), renal (Christian et al. 1986; McConnell et al. 1978b), 
endocrine (Bastomsky 1977; Bestervelt et al. 1993; Fan and Rozman 1995; Potter et al. 1986; Weber et al. 
1995), dermal effects (Greig 1984; McConnell et al. 1978b), and body weight loss (Kelling et al. 1985; 
Moore et al. 1985; Seefeld and Peterson 1984; Weber et al. 1994, 1995).  Hepatic and body weight effects 
were the main signs of 2,3,7,8-TCDD toxicity and occurred also after exposure to a mixture of 1,2,3,6,7,8­
HxCDD and 1,2,3,7,8,9-HxCDD (NCI/NTP 1980). Furthermore, immunological effects were observed 
following low oral doses of 2,3,7,8-TCDD (Burleson et al. 1996; White et al. 1986), and an acute oral MRL 
was based on a NOAEL for immunological effects (Burleson et al. 1996).  In addition, the dermal LD50 for 
2,3,7,8-TCDD has been determined in rabbits (Schwetz et al. 1973).  Since only dermal changes were 
investigated following acute dermal exposure (Puhvel et al. 1982), further studies could provide useful 
information regarding additional endpoints; dermal contact is a relevant route of exposure at waste sites 
where CDDs may be stored.  Limited data were located regarding effects in animals after acute inhalation 
exposure to CDDs (Diliberto et al. 1996; Nessel et al. 1992). Further studies by the inhalation route of 
exposure would be useful since toxicokinetic data in rats suggest that this could be an important route for 
systemic absorption of CDDs (Diliberto et al. 1996).  
No information was located regarding health effects of other congeners in humans, and limited data exist 
about effects caused by an acute exposure to these congeners in animals.  The information would be useful 
for populations living near hazardous waste sites who may be exposed to CDDs for acute durations. 
Should a case of high acute exposure to 2,3,7,8-TCDD occur in humans, prompt comprehensive 
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examination of those exposed would provide greatly needed information.  Furthermore, follow-up medical 
surveillance of such a population should be conducted for as long as possible. 
Intermediate-Duration Exposure. Intermediate-duration exposure of humans to CDDs has occurred 
after industrial accidents or in population groups (e.g., Vietnam veterans, Vietnamese, and pesticide 
production workers and applicators) exposed to CDD-contaminated herbicides.  As stated above, the route 
of exposure and exposure levels cannot be exactly determined.  Hepatic and dermal changes were the main 
effects noted, and an association between incidence of diabetes and exposure to 2,3,7,8-TCDD has been 
reported (Jirasek et al. 1976; USAF 1991). More toxicokinetic data for various routes of exposure with 
relevant congeners would be useful.  These data would help in extrapolation from one route of exposure to 
another, since no information is available in humans on exposure via the oral route, which is the major 
exposure route to CDDs. The main adverse effects in animals following intermediate-duration oral and 
dermal exposure to 2,3,7,8-TCDD included chloracne (Allen et al. 1977; Berry et al. 1978; McNulty 
1984), wasting syndrome (DeCaprio 1986; NTP 1982b; Vos et al. 1973), and liver effects (Hebert et al. 
1990; NTP 1982a). Similar effects were observed with a mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9­
HxCDD (NCI/NTP 1980), and 1,2,3,7,8-PeCDD and 1,2,3,4,7,8-HxCDD (Viluksela et al. 1998a, 1998b). 
As with acute-duration exposure, the immune system proved to be a very sensitive end point for 
intermediate-duration exposure to 2,3,7,8-TCDD, and an intermediate-duration oral MRL was derived 
from a NOAEL value for immunological effects (DeCaprio et al. 1986).  No data were located regarding 
toxicity or toxicokinetics in animals after intermediate-duration inhalation exposure to CDDs.  Information 
obtained from a 90-day inhalation exposure study would be relevant to people living near hazardous waste 
sites who may be exposed to CDDs for similar durations or much longer time periods.  
Chronic-Duration Exposure and Cancer. A number of epidemiology studies have examined the 
toxicity of CDDs following chronic exposure to phenoxy herbicides and chlorophenols contaminated with 
2,3,7,8-TCDD (Calvert et al. 1991, 1992, 1996, 1998; Cook et al. 1987b; Egeland et al. 1994; Henriksen et 
al. 1997; Pesatori et al. 1998; Sweeney et al. 1993).  Although a number of effects have been observed, 
interpretation of the results is confounded by a number of factors including lack of adequate exposure 
information, long postexposure periods, concomitant exposure to other chemicals, and small cohorts. 
Follow-up medical surveillance of subjects with known past high exposure to 2,3,7,8-TCDD would provide 
information on the possibility that adverse effects could manifest themselves later in adult life when 
compounded by normal age-related changes.  In addition, further research is needed in areas for which the 
animal data have demonstrated exposure related effects, but the human data are inconclusive.  Such 
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research in exposed humans should focus on diseases of the circulatory system, reproductive effects, 
immunological effects, effects on serum lipids, and effects on thyroid function.  Hepatic effects were 
observed in animals after chronic exposure to CDDs (including 2,3,7,8-TCDD, mixed HxCDD isomers, and 
2,7-DCDD) by the oral route (NCI/NTP 1979a, 1980; NTP 1982b) and to 2,3,7,8-TCDD by the dermal 
route (Schwetz et al. 1973). The 2,3,7,8-TCDD congener was the most toxic.  Studies in monkeys 
demonstrated their high susceptibility to 2,3,7,8-TCDD-induced toxicity.  Developmental behavioral effects 
were seen in offspring of monkeys chronically exposed to low oral doses (Bowman et al. 1989a; Schantz 
and Bowman 1989;  Schantz et al. 1992). The lowest dose tested in this series of studies was used to derive 
a chronic-duration oral MRL. 
No studies were located regarding chronic effects of CDD exposure by the inhalation route.  Toxicokinetic 
inhalation data and chronic-duration studies would be useful for assessing the risk levels for people living 
near municipal, medical, and industrial waste incinerators who can be exposed for chronic durations to 
CDDs by this route. 
Several epidemiological studies of phenoxy herbicide and chlorophenol producers found increases in cancer 
mortality in populations exposed to 2,3,7,8-TCDD (Fingerhut et al. 1991; Kogevinas et al. 1993; Manz et 
al. 1991; Zober et al. 1990). 2,3,7,8-TCDD exposure has been especially associated with the development 
of soft-tissue sarcoma after a prolonged latency period (Eriksson et al. 1981, 1990; Fingerhut et al. 1991; 
Hardell and Eriksson 1988; Hardell and Sandrom 1979; Kogevinas et al. 1995; Smith et al. 1984a).  The 
human data suggest that 2,3,7,8-TCDD may be a human carcinogen; however, the interpretation of many of 
these studies is limited by confounding factors (e.g., small cohorts, short latency periods, co-exposure to 
other chemicals, inadequate exposure data).  Since these factors are inherent to epidemiological studies, it is 
unlikely that new human studies would clarify this issue.  There are no reliable human studies on the 
carcinogenicity of other CDDs.  Animal studies provided sufficient evidence that 2,3,7,8-TCDD is a 
carcinogen after oral (Kociba et al. 1978a; NTP 1982b; Toth et al. 1979) and dermal (Della Porta et al. 
1987; Rao et al. 1988) exposure. Furthermore, 2,3,7,8-TCDD has promoting ability on tumors initiated by 
diethylnitrosourea (Hebert et al. 1990; Poland et al. 1982).  Similarly, chronic oral exposure of rodents to a 
mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD or to 2,7-DCDD resulted in carcinogenic effects 
(NCI/NTP 1979a, 1980). No studies were located regarding cancer effects in animals following inhalation 
exposure to CDDs. However, at this time, it is unlikely that such a study would add any new information 
regarding the potential carcinogenicity of CDDs in animals. 
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Genotoxicity. Inconclusive results were obtained regarding genotoxicity of CDDs in human as well as 
in animal studies.  Structural chromosomal changes were found in some groups of exposed individuals 
(Kaye et al. 1985).  However, the studies were confounded by small cohorts and unknown exposures. 
Positive and negative results at the chromosomal level (Green et al. 1977; Loprieno et al. 1982; Meyne et al. 
1985) as well as at the gene level (Randerath et al. 1989; Wahba et al. 1989) were reported in animal 
studies. Furthermore, negative results were obtained in dominant-lethal tests (Khera and Ruddick 1973) 
and sex-linked recessive-lethal tests in rats and Drosophila (Zimmering et al. 1985), respectively.  In 
addition, mostly negative results were obtained in prokaryotic organisms (Geiger and Neal 1981; Gilbert et 
al. 1980; Toth et al. 1984). Some studies indicated that the covalent binding of 2,3,7,8-TCDD to DNA is 
low, and that this mechanism does not operate in CDD genotoxicity.  Further studies on the mechanism of 
CDDs would be useful to evaluate the best possible method for detecting CDD genotoxicity. 
Reproductive Toxicity. Data from studies on reproductive effects in humans (Aschengrau and Monson 
1989; Egeland et al. 1994; Forsberg and Nordstrom 1985; Henriksen et al. 1996; Phuong et al. 1989a; 
Smith et al. 1982; USAF 1991; Wolfe et al. 1985, 1995) are inconclusive and are limited by confounding 
factors such as small cohorts, co-exposure to other chemicals, and inadequate exposure data.  Better 
controlled epidemiological studies measuring 2,3,7,8-TCDD exposure levels or 2,3,7,8-TCDD body 
burdens would be useful to assess the human reproductive toxicity risk. Reproductive effects have been 
observed in oral animal studies.  Increased incidences of pre- and post-implantation losses were observed in 
2,3,7,8-TCDD-exposed rodents (Giavini et al. 1983; Neubert and Dillman 1972; Smith et al. 1976; 
Sparschu et al. 1971a), rabbits (Giavini et al. 1982), and monkeys (McNulty 1985).  Adverse effects have 
also been observed in the reproductive organs (decreased weight), hormone levels, and gametes of male rats 
(Khera and Ruddick 1973; Moore et al. 1985) and non-pregnant female rats (Li et al. 1995a, 1995b).  None 
of the acute-duration exposure studies assessed the potential of CDDs to impair fertility; data on fertility 
would be useful in assessing potential effects in humans exposed to CDDs for a short period of time. 
Reduced fertility (Bowman et al. 1989b; Hong et al. 1989; Murray et al. 1979; Schantz et al. 1992), 
increased incidence of abortions (Bowman et al. 1989b; Hong et al. 1989; McNulty 1984; Schantz et al. 
1992), altered estrus cycle (Umbreit et al. 1987), and endometriosis (Rier et al. 1993) were observed in 
animals exposed for intermediate or chronic durations.  Reproductive effects have also been observed in 
animals exposed to mixed HxCDD (Schwetz et al. 1973), but not following exposure to 2-MCDD, 
2,3-DCDD, 2,7-DCDD, 1,2,3,4-TCDD, or OCDD (Khera and Ruddick 1973).  Data on the reproductive 
toxicity of CDD following dermal exposure is limited to a single animal study which found no adverse 
effects on reproductive organs of mice chronically exposed to 2,3,7,8-TCDD (NTP 1982a).  No animal 
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inhalation reproductive toxicity studies were located.  Additional animal inhalation and dermal reproductive 
studies, particularly studies which assessed reproductive performance, would be useful to assess the 
possible risk in humans exposed to CDDs by these routes. 
Developmental Toxicity. Studies in humans and animals indicated that 2,3,7,8-TCDD can cross the 
placenta and is excreted in milk (Fürst et al. 1989b; Schecter et al. 1989d, 1989g, 1990).  Studies on the 
developmental toxicity of 2,3,7,8-TCDD in humans are inconclusive.  Some studies have found significant 
increases in the risk of certain birth defects (Aschengrau and Monson 1990; Erickson et al. 1984; Hanify et 
al. 1981; Nelson et al. 1979; Phuong et al. 1989a; Wolfe et al. 1985, 1995), while other studies have found 
no significant alterations (Bisanti et al. 1980; Mastroiacovo et al. 1988; Townsend et al. 1982).  However, a 
number of limitations (e.g., lack of exposure data, small sample sizes, and the lack of reliable data for birth 
defects prior to 2,3,7,8-TCDD exposure) limits the interpretation of the results of these studies. 
Epidemiology studies which measure exposure concentrations or body burdens would be useful to 
determine if 2,3,7,8-TCDD and other CDD congeners are human developmental toxicants.  Developmental 
toxicity has been observed in animals orally exposed to 2,3,7,8-TCDD (Abbott and Birnbaum 1989a; 
Abbott et al. 1992; Bjerke and Peterson 1994; Bjerke et al. 1994a, 1994b; Bowman et al. 1989a, 1989b; 
Brown et al. 1998; Courtney 1976; Couture-Haws et al. 1991b; Giaviani et al. 1983; Gordon et al. 1995; 
Gray and Ostby 1995; Gray et al. 1995; Håkansson et al. 1987; Huuskonen et al. 1994; McNulty 1985; 
Moore et al. 1973; Neubert and Dillman 1972; Roman et al. 1998a, 1998b;  Schantz et al. 1992; Silkworth 
et al. 1989b; Smith et al. 1976; Thomas and Hinsdill 1979; Weber et al. 1985), 2,7-DCDD (Khera and 
Ruddick 1973; Schwetz et al. 1973), mixed HxCDD (Schwetz et al. 1973), and OCDD (Schwetz et al. 
1973). The most common effects were cleft palate, hydronephrosis, impaired development of the 
reproductive system, immunotoxicity, and death.  No studies were located regarding developmental effects 
in animals after inhalation and dermal exposure.  Such studies would be useful for extrapolating the 
possible risk to human populations exposed environmentally by these routes. 
Immunotoxicity. Studies in humans did not provide conclusive evidence regarding immunotoxicity of 
CDDs (Ernst et al. 1998; Jansing and Korff 1994; Jennings et al. 1988; Jung et al. 1998; Mocarelli et al. 
1986; Neubert et al. 1993, 1995; Reggiani 1980; Stehr et al. 1986; Svensson et al. 1994; Tonn et al. 1996; 
USAF 1991; Webb et al. 1989; Wolfe et al. 1985). Studies in animals indicated that CDDs are immuno­
suppressive (Kerkvliet 1995). 2,3,7,8-TCDD induced thymic atrophy or thymic weight changes after oral 
(Hanberg et al. 1989; McConnell et al. 1978b), dermal (Hebert et al. 1990), and parenteral exposure (Gorski 
et al. 1988b; Olson et al. 1980a). Bone marrow degeneration was reported in orally exposed 
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monkeys (Hong et al. 1989).  Suppressed cell-mediated and humoral immunity was found in rodents after 
intermediate-duration exposure (Vos et al. 1973).  Similarly, immunotoxic effects were found after oral 
exposure of rodents to 2,7-DCDD or to a mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD 
(Holsapple et al. 1986b; NCI/NTP 1980). At least in mice, differences in responsiveness to CDDs’ 
immunotoxicity in vivo segregated with the Ah locus (Nagayama et al. 1989; Vecchi et al. 1983a).  
Studies in animals aimed at identifying 2,3,7,8-TCDD-sensitive immune end points that can also be 
measured in humans would be valuable to determine correlative changes in the biomarker and immune 
function. However, this can be done only after establishing a database of normal values for the clinical 
immunology end points that may be used as biomarkers of immune-function in immunotoxicity 
assessments.  It also important to determine in animals how well changes in lymphoid organs correlate with 
changes in the expression of lymphocyte subset/activation markers in peripheral blood. The role of the Ah 
receptor in the immunotoxicity of 2,3,7,8-TCDD needs to be researched in species other than mice.  In 
addition, the role of Ah receptor-independent processes in 2,3,7,8-TCDD-induced immunotoxicity needs to 
be examined further.  Such actions may include changes in intracellular calcium or in the activity of 
kinase/phosphatase systems, or interactions with hormone systems.  A battery of immune function tests in 
human cohorts exposed to CDDs would be useful for detecting the immunotoxic responses in exposed 
individuals. The ability of CDD-exposed individuals to mount an integrated functional response to a novel 
antigen, such as hepatitis B vaccine, would provide a broad measure of immune function in exposed human 
populations. 
Neurotoxicity. Studies in Vietnam veterans could not conclusively demonstrate cognitive or other 
central nervous system deficits (Goetz et al. 1994).  Neurological examinations revealed neurological 
effects in humans exposed to a CDD-contaminated environment (Pocchiari et al. 1979) and in occupational 
settings (Goldman 1973; Jirasek et al. 1976; Klawans 1987; Pazderova-Vejlupkova et al. 1981) shortly 
following exposure, but reports with comparison groups do not offer clear evidence that exposure to 
2,3,7,8-TCDD is associated with chronic peripheral neuropathy (Suskind and Hertzberg 1984; Sweeney et 
al. 1993). No notable neurological effects were found in laboratory animals after oral and dermal exposure. 
The existing information suggests that in adults, no long-term neurologic affects were even caused by high 
exposure to 2,3,7,8-TCDD-contaminated materials.  However, the possibility exists that subtle central 
nervous system changes acquired in early adulthood could manifest themselves later in adult life when 
compounded by normal age-related changes in the central nervous system (Goetz et al. 1994).  Thus, it 
would be of interest to include tests of neurological function in ongoing prospective studies of 
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2,3,7,8-TCDD-exposed populations to determine if neurological effects occur as the exposed population 
ages. 
Epidemiological and Human Dosimetry Studies. Epidemiology studies have investigated the 
toxicity of 2,3,7,8-TCDD in populations exposed in the workplace or in the contaminated environment 
(after industrial accidents or herbicide spraying) (Bertazzi et al. 1993; Calvert et al. 1992, 1996, 1998; 
Egeland et al. 1994; Eriksson et al. 1981, 1990; Fingerhut et al. 1991; Flesch-Janys et al. 1995; Hardell and 
Eriksson 1988; Hardell and Sandrom 1979; Manz et al. 1991; Mastoiacovo et al. 1988; Mocarelli et al. 
1991; Pesatori et al. 1993, 1998; Saracci et al. 1991; Smith et al. 1984a; Sweeney et al. 1993; Vena et al. 
1998; Zober et al. 1990) and in Vietnam veterans exposed to Agent Orange (Burton et al. 1998; Henriksen 
et al. 1997; USAF 1991; Wolfe et al. 1985, 1995). The interpretation of the results of most of these studies 
is confounded by such factors as unknown levels of exposure, too short or too long postexposure periods, 
and small cohorts.  Well conducted epidemiological and occupational studies that quantify exposure levels 
would be useful to assess the risk for the main end points of concern (i.e., reproductive, developmental, 
immunotoxic effects, and cancer).  Some of the more recent studies have measured the levels of 
2,3,7,8-TCDD and related compounds in serum lipid; these levels can then be used to estimate body burden 
at the time of exposure.  There are a number of drawbacks associated with extrapolating body burdens back 
to the time of the original exposure using current serum 2,3,7,8-TCDD levels; these include uncertainty 
associated with 2,3,7,8-TCDD half-life in humans and having to use average serum 2,3,7,8-TCDD levels 
and average exposure durations and reference body weights and percentage of body fat.  There is a lack of 
consensus on the half-life of 2,3,7,8-TCDD in humans, half-lives ranging from 5 to 12 years have been 
estimated (Pirkle et al. 1979; Schecter et al. 1994b; Wolfe et al. 1994).  Additional human studies 
measuring 2,3,7,8-TCDD half-life would be useful in establishing dose-response relationships for human 
effects. All of the above limitations for assessing the body burden of 2,3,7,8-TCDD also apply to other 
CDDs where far less human toxicokinetic data are available.  Thus, it would be useful to have congener-
specific human toxicokinetic data on other CDDs and related compounds.  Furthermore, human dosimetry 
studies would be useful in occupational settings to obtain results regarding levels of CDDs in the 
environment as opposed to levels in serum or adipose tissues. 
Biomarkers of Exposure and Effect.
Exposure.  Several studies reported results of measurements of CDD levels in the lipid fraction of adipose 
tissue, milk, and serum from members of the general population with unknown CDD exposure (Andrews et 
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al. 1989; Ryan et al. 1985a; Schecter et al. 1987b).  The gas chromatography-mass spectrometry (GS/MS) 
tests used to detect CDD levels are sensitive and specific.  Analytical testing for levels in biological fluids 
and tissues can be used for monitoring exposed populations.  While chloracne is a known, readily 
identifiable effect of exposure to CDDs, it is not useful as a biomarker of exposure because of its variable 
expression in individuals with even very high levels of exposure to these agents.  Further information on 
how aging and changes in body composition can influence the distribution of CDDs in tissues and body 
fluids would be valuable. A reverse transcriptase polymerase chain reaction method has been used to 
quantify CYP1A1 mRNA levels on total RNA extracts from human blood lymphocytes (Van den Heuvel et 
al. 1993). This method was found to be much more sensitive than, for example, measuring EROD activity, 
and could potentially be used as a human exposure marker for CDDs and structurally related compounds. 
However, EROD activity measurements can be useful as a marker of exposure to the agents. 
Effect.  There are no specific biomarkers of effects for CDDs.  Exposure to relatively high concentrations of 
CDDs can lead to the development of chloracne in humans.  However, while the presence of chloracne 
indicates CDD or similar halogenated-chemical exposure, lack of chloracne does not indicate that exposure 
has not taken place, as evidenced in a cohort from the Seveso incident (Mocarelli et al. 1991).  Additional 
studies could evaluate the feasibility of using body burden as a biomarker for predicting other effects of 
CDDs. Although the results of an earlier study suggested that 2,3,7,8-TCDD may form adducts with DNA, 
albeit at an extremely low rate (Poland and Glover 1979), more recent studies that have rigorously looked 
for 2,3,7,8-TCDD-DNA adducts have been negative (Randerath et al. 1988; Turteltaub 1990).  Expression 
of CYP1A1 mRNA, protein, and/or activity are sensitive biological responses in human tissues which can 
be observed following exposure to 2,3,7,8-TCDD and related compounds, and may be useful biomarkers of 
effects. Further studies to identify biomarkers of effects of CDDs would facilitate medical surveillance 
leading to early detection of potentially adverse health effects and possible treatment. 
Absorption, Distribution, Metabolism, and Excretion. There are no quantitative data regarding 
absorption in humans by the inhalation and dermal routes, but data from accidentally exposed individuals 
suggest that exposure by these routes may lead to a significant increase in body burden of CDDs (Patterson 
et al. 1994; Schecter 1994b). Results from one human study indicated that more than 87% of an oral 
2,3,7,8-TCDD dose in an oil vehicle was absorbed (Poiger and Schlatter 1986).  Also, results from studies 
of absorption of CDDs from maternal milk by nursing infants showed that 90–95% of the dose of CDDs 
can be absorbed; hepta-substituted congeners and OCDD exhibited lower absorption rates (Abraham et al. 
1994, 1996; Dahl et al. 1995; McLachlan 1993; Pluim et al. 1993b).  The data indicate that 2,3,7,8-TCDD 
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is effectively absorbed and that absorption is vehicle-dependent (Fries and Marrow 1975; Lucier et al. 1986; 
Poiger and Schlatter 1980); oil vehicles were most effective (Olson et al. 1980b; Piper et al. 1973). 
Transpulmonary absorption of 2,3,7,8-TCDD also occurs in animals (Diliberto et al. 1996; Nessel et al. 
1992). Dermal absorption of 2,3,7,8-TCDD in rats was found to be age-dependent (Banks et al. 1993).  In 
rats, following single equivalent intratracheal, oral, and dermal 2,3,7,8-TCDD doses, absorption was 
calculated as 95, 88, and 40% of the administered dose, respectively (Diliberto et al. 1996).  The available 
information shows that absorption of 2,3,7,8-TCDD has been fairly well characterized in animals. 
Based on analysis of CDDs in adipose tissue, milk, and blood, it appears that humans store exclusively 
2,3,7,8-chlorine substituted congeners (Fürst et al. 1987; Rappe et al. 1987; Van den Berg et al. 1986b). 
Data are available on tissue distribution of 2,3,7,8-TCDD in rats after inhalation, oral, and dermal exposure 
(Diliberto et al. 1996). The liver and adipose tissue are the major storage sites in animals.  In general, 
distribution of CDDs is congener specific, and depends on the dose and route of administration (Diliberto et 
al. 1996; Van den Berg et al. 1994). Age was also a factor in the distribution of 2,3,7,8-TCDD in mice 
(Pegram et al. 1995).  The distribution of 2,3,7,8-TCDD-derived radioactivity in subcellular liver fractions 
has also been studied (Santostefano et al. 1996). 2,3,7,8-Chlorine substituted CDDs are the predominant 
congeners retained in tissue and body fluids from humans, rodents, and monkeys (Abraham et al. 1989c; 
Van den Berg et al. 1983). Further dosimetry studies of various durations in which levels of 2,3,7,8-TCDD 
and related compounds are monitored in tissues suspected of being targets for 2,3,7,8-TCDD toxicity would 
provide valuable information.  These data can be used to establish correlations between target-tissue doses 
and adverse effects. 
Data regarding the biotransformation of CDDs in humans are limited to a self-dosing experiment that 
provided some evidence that 2,3,7,8-TCDD is partially excreted in the feces in the form of metabolites 
(Wendling et al. 1990). The use of human cell systems in culture might be considered a useful addition to 
whole-animal studies for examining the metabolic fate of CDDs.  Biotransformation of CDDs has been 
examined in several species, but the structure of metabolites has been elucidated only in the rat and dog 
(Poiger and Buser 1984). Although information regarding metabolism following inhalation or dermal 
exposure is lacking, there is no reason to believe that different pathways would operate after exposure by 
these routes. 
Only one study was located that provide limited evidence of fecal excretion of 2,3,7,8-TCDD metabolites in 
adult humans (Wendling et al. 1990).  Several studies provided information regarding fecal excretion of 
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CDDs in infants exposed through breast milk (Abraham et al. 1994; McLachlan 1993; Pluim et al. 1993b). 
Elimination of CDDs through maternal milk is well documented (Fürst et al. 1994; Rappe et al. 1985; 
Schecter and Gasiewicz 1987a; Schecter et al. 1989d, 1989e).  Fecal excretion is the main route of excretion 
of CDDs in animals after all routes of exposure (Diliberto et al. 1996).  Estimates of 2,3,7,8-TCDD half-life 
in humans are available (Pirkle et al. 1989; Poiger and Schlatter 1986; Wolfe et al. 1994), but further 
information regarding the relationships between aging, fat redistribution, and half-lives in humans would be 
valuable. 
Comparative Toxicokinetics. CDDs are efficiently absorbed from the gastrointestinal tract of 
mammals, but the vehicle plays an important role (Olson et al. 1980b; Piper et al. 1973; Poiger and 
Schlatter 1986; Van den Berg et al. 1987c). Distribution data in orally exposed rodents indicated that the 
highest postexposure levels were in the liver followed by the fat (Diliberto et al. 1996; Khera and Ruddick 
1973; Olson 1986), but distribution is highly dose- and species-dependent.  The studies to date suggest that 
compared with rodents, primates, including humans, accumulate significantly less CDDs in the liver than in 
adipose tissue (Neubert et al. 1990a; Ryan et al. 1986; Van Miller et al. 1976).  With the exception of the 
guinea pig, mammals retain only 2,3,7,8-substituted congeners.  The high liver retention of 2,3,7,8­
substituted congeners by rodents has been attributed to the presence of inducible storage sites, presumably 
CYP1A2 (Leung et al. 1990b). In all mammalian species studied, exposure by breast-feeding has a much 
greater contribution to the offspring 2,3,7,8-TCDD body burden than placental transfer.  Metabolic 
capacities are species-dependent. Rats, hamsters, and mice metabolize and eliminate CDDs much faster 
than the guinea pig. The metabolites were excreted predominantly via the bile and feces, with minor 
amounts excreted in the urine in all species (Diliberto et al. 1996; Fries and Marrow 1975; Weber and 
Birnbaum 1985).  Whole-body half-lives ranged from 11 days in hamsters (Olson et al. 1980b) to more than 
1 year in monkeys (Bowman et al. 1989b; McNulty et al. 1982), and approximately 7–12 years in humans 
(Wolfe et al. 1994). The toxicity of CDDs has been associated with the parent compound and not the 
metabolites (Mason and Safe 1986a; Weber et al. 1982); therefore, metabolism and excretion represent a 
detoxification process. The data collected in recent years indicate differences in species susceptibility to 
CDDs cannot be explained by differences in toxicokinetics alone; it is likely that genetic factors have an 
important role.  Based on this information, species-, congener-, and dose-specific toxicokinetic data need to 
be factored in human risk assessment for CDDs.  Several models that describe the disposition of 
2,3,7,8-TCDD in animals and humans were identified from the literature (Andersen et al. 1993, 1997a, 
1997b; Carrier et al. 1995a, 1995b; Kissel and Robarge 1988; Kohn et al. 1993; Leung et al. 1988, 
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1990b). Although each new model that is published usually fills data gaps identified in earlier models, 
further research is necessary to increase their reliability for use in human risk assessment. 
Methods for Reducing Toxic Effects. The mechanism by which CDDs enter the blood stream in 
humans is not known; consequently, there are no established methods for reducing absorption.  In 
experimental animals, however, administration of a diet containing activated charcoal reduced mortality in 
an acute-duration study presumably by preventing gastrointestinal absorption and the reabsorption of the 
chemical from biliary secretions (Manara et al. 1984). Identification of additional substances that could 
prevent or delay absorption and that do not represent a toxic risk per se would be valuable. Increasing the 
fact content of the diet by ingesting non-absorbable lipids has been suggested as a method for increasing the 
elimination rate (Rohde et al. 1997).  These authors estimated that if the normal feces excretion of 5 g 
fat/day was quadrupled and the lipid based distribution of CDDs/CDFs between the body and the intestine 
stayed the same, the overall elimination rate would at least double.  There are no established methods for 
reducing body burden in humans, but data from a study of Vietnam veterans suggested that persons with 
more fat tend to eliminate 2,3,7,8-TCDD more slowly (Wolfe et al. 1994).  It was suggested that metabolic 
or other factors that change with age (i.e., redistribution of fat stores) affect 2,3,7,8-TCDD elimination. 
Studies examining the effect of fasting in animals exposed to CDDs would provide useful information that 
can be used to characterize the effectiveness of this approach better.  Although, in recent years, great 
advances have been made related to the understanding of the mechanism of action of CDDs, no methods 
exist to block the toxic response due to exposure to CDDs.  Further characterization of the Ah receptor 
protein and understanding of physiological effects of interfering with the chain of events that follow 
binding of CDDs to the Ah receptor would be useful for the possible identification of blockers of those 
events. Further studies aimed at elucidating the non Ah receptor-mediated mechanisms of action of CDDs 
would also be valuable. There are no established methods for mitigation of health effects resulting from 
exposure to CDDs. 
Children’s Susceptibility. A limited number of human studies have examined health effects of CDDs 
in children. Data from the Seveso accident suggest that children may be more susceptible to the dermal 
toxicity of 2,3,7,8-TCDD (chloracne), but it is not known if this would be the case for other effects. 
Follow-up medical surveillance of the Seveso children (including measurement of serum 2,3,7,8-TCDD 
levels) would provide information on whether childhood exposure would pose a risk when the individual 
matures and ages.  The available human and animal data provide evidence that 2,3,7,8-TCDD can cross the 
placenta and be transferred to an infant via breast milk.  Although information on the developmental 
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toxicity of CDDs in humans is limited, there are extensive animal data that the developing organism is very 
sensitive to the toxicity of 2,3,7,8-TCDD.  Several human studies have found significant alterations in 
markers of liver, thyroid, immune, and neurological function in young breast-fed infants of mothers with 
higher current background or general population CDD levels.  Recent data suggest that the neurological 
effects are reversible; prospective studies of the breast-fed individuals would provide useful information on 
whether these children are at risk of developing additional effects as they age.  Further data needs relating to 
developmental effects are discussed above under Developmental Toxicity. 
In general, the available toxicokinetic data did not examine potential differences between adults and 
children; toxicokinetic studies examining how aging and changes in body composition can influence 
distribution and turnover rates would be useful in assessing children’s susceptibility to CDD toxicity.  Most 
of the available mechanism of action data suggest that the toxicity of 2,3,7,8-TCDD is mediated through the 
Ah receptor. We do not know if there are any age-related differences in receptor binding or expression; 
studies in animals would be valuable to fill this information gap.  No age-specific biomarkers of exposure 
or effect were identified for CDDs; the long half-life of 2,3,7,8-TCDD in humans, suggests that there may 
not be a way to assess whether adults were exposed as children to 2,3,7,8-TCDD.  Additionally, there are 
no data to determine whether there are any interactions with other chemicals which would be specific for 
children. There is very little available information on methods for reducing 2,3,7,8-TCDD toxic effects or 
body burdens; it is likely that research in adults would also be applicable to children.  
Child health data needs relating to exposure are discussed in Section 5.8.1, Identification of Data Needs: 
Exposures of Children. 
2.11.3 Ongoing Studies 
Ongoing studies regarding the health effects of CDDs were reported in the Federal Research in Progress 













3. CHEMICAL AND PHYSICAL INFORMATION
 
CDDs are a class of related chlorinated hydrocarbons which are structurally similar.  The basic structure is a 
dibenzo-p-dioxin (DD) molecule, which is comprised of 2 benzene rings joined at their para carbons by 
2 oxygen atoms.  There are 8 homologues of CDDs, monochlorinated through octachlorinated.  The class of 
CDDs contains 75 congeners, consisting of 2 monochlorodibenzo-p-dioxins (MCDDs), 10 dichlorodibenzo­
p-dioxins (DCDDs), 14 trichlorodibenzo-p-dioxins (TrCDDs), 22 tetrachlorodibenzo-p-dioxins (TCDDs), 
14 pentachlorodibenzo-p-dioxins (PeCDD), 10 hexachlorodibenzo-p-dioxins (HxCDDs), 2 hepta­
chlorodibenzo-p-dioxins (HpCDDs), and a single octachlorodibenzo-p-dioxin (OCDD) (Ryan et al. 1991). 
The general structure of the dibenzo-p-dioxins is shown below. The numbers indicate the positions for 










Not all congeners have been studied for their chemical and physical properties, but basic properties are 
known for the CDDs as a chemical family and for the homologous groups.  Chlorinated dioxins exist as 
colorless solids or crystals in the pure state.  They have a low solubility in water and a low volatility. 
Chlorinated dioxins have an affinity for particulates and readily partition to particles in air, water, and soil. 
The more toxic compounds appear to be the 2,3,7,8-substituted tetra-, penta-, and hexachloro compounds 
(i.e., 2,3,7,8-TCDD, 1,2,3,7,8-PeCDD, 1,2,3,4,7,8-HxCDD, 1,2,3,6,7,8-HxCDD, and 1,2,3,7,8,9-HxCDD). 
These are also the congeners, along with OCDD, that have the greatest tendency to bioaccumulate.  One of 
the most toxic congeners in mammals is believed to be 2,3,7,8-TCDD; this compound has also been the 
most studied of the TCDD congeners.  
3.1 CHEMICAL IDENTITY 
Information regarding the chemical identities of CDDs is presented in Table 3-1. 
3.2 PHYSICAL AND CHEMICAL PROPERTIES 














4. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
4.1 PRODUCTION 
CDDs are not manufactured commercially in the United States except on a small scale for use in chemical 
and toxicological research. CDDs are unique among the large number of organochlorine compounds of 
environmental interest in that they were never intentionally produced as desired commercial end products 
(Zook and Rappe 1994). Typically, CDDs are unintentionally produced during various uncontrolled 
chemical reactions involving the use of chlorine (EPA 1990c) and during various combustion and 
incineration processes (Zook and Rappe 1994). In the process of making white paper products, for 
example, chlorine or chlorine derivatives are often used as the primary bleaching agent.  As a result, several 
chlorinated organic compounds are formed, including small amounts of CDDs (EPA 1990c).  These 
chlorinated compounds not only leave the mills in the pulp and paper products, they are also released 
through waste waters (effluents from the mills) and sludge produced as a result of waste water treatment 
(EPA 1990c). CDDs are also produced as undesired by-products during the manufacture of chlorinated 
phenols such as pentachlorophenol, 2,4,5-trichlorophenol, and related chemicals, and during incineration of 
chlorinated wastes (IARC 1977; NTP 1989; Podoll et al. 1986). By far the greatest unintentional 
production of CDDs occurs via various combustion and incineration processes including all forms of waste 
incineration (municipal, industrial, and medical), many types of metal production (iron, steel, magnesium, 
nickel, lead, and aluminum), and fossil fuel and wood combustion (Czuczwa and Hites 1986a, 1986b; 
Oehme et al. 1987, 1989; Zook and Rappe 1994).  More extensive information on sources of CDDs released 
to the environment can be found in Chapter 5. 
In general, there are two conventional methods for the preparation of CDDs for research purposes: 
condensation of a polychlorophenol and direct halogenation of the parent dibenzo-p-dioxin or a 
monochloro-derivative.  For example, 2,3,7,8-tetrachlorodibenzo-p-dioxin (2,3,7,8-TCDD) is generally 
synthesized by the condensation of two molecules of 2,4,5-trichlorophenol in the presence of a base at high 
temperatures or by chlorination of dibenzo-p-dioxin in chloroform in the presence of iodine and ferric 
chloride (EPA 1987k; IARC 1977). Other methods of 2,3,7,8-TCDD synthesis include the following: 
pyrolysis of sodium α-(2,4,5-trichlorophenoxy) propionate at 500 EC for 5 hours; reaction of 
dichlorocatechol salts with o-chlorobenzene by refluxing in alkaline dimethyl sulfoxide; ultraviolet 
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pyrolysis of chlorinated phenolates and chlorinated phenols; and heating 1,2,4-trichloro-5-nitrobenzene and 
4,5-dichlorocatechol in the presence of a base (EPA 1984a; IARC 1977). 
1,2,3,4-TCDD has been prepared by refluxing a mixture of catechol, potassium carbonate, pentachloronitro­
benzene and acetone in nitrogen (IARC 1977). 
DCDD can be synthesized by two methods.  In the first method, 2-bromo-4-chlorophenol and potassium 
hydroxide are dissolved in methanol and evaporated to dryness.  The residue is then mixed with 
bis(2-ethoxyethyl) ether, ethylene diacetate, and a copper catalyst; and then heated, cooled, and eluted from 
a chromatographic column with chloroform.  This residue is evaporated and then sublimed.  DCDD can also 
be synthesized by heating the potassium salt of 2,4-dichlorophenol in the presence of copper powder in a 
vacuum sublimation apparatus (IARC 1977). 
1,2,4,6,7,9-HxCDD has been made by heating the potassium salt of 2,3,5,6-tetrachlorophenol with 
powdered copper and potassium carbonate in a vacuum sublimation apparatus (IARC 1977). 
1,2,3,4,7,8-HxCDD has been prepared by mixing 1,2,3,4-TCDD, ferric chloride, chloroform, and a crystal 
of iodine and then adding a solution of chlorine in carbon tetrachloride (IARC 1977). 
OCDD has been synthesized by the following methods: irradiation of aqueous solutions of CDD-free 
sodium pentachlorophenol with ultraviolet light; heating the potassium salt of pentachlorophenol; heating 
pentachlorophenol in the presence of an initiator, such as chlorine, bromine, iodine, or 2,3,4,4,5,6-hexa­
chloro-2,5-cyclohexadienone; and heating hexachlorocyclohexadienone in an atmosphere of carbon dioxide 
for 30 minutes (Crosby and Wong 1976; EPA 1984a; IARC 1977). 
At present, the only reported producers of CDDs are Eagle Picher Industries, Inc., located in Lenexa, 
Kansas, and Cambridge Isotope Laboratories, located in Andover, Massachusetts.  Eagle Picher Industries 
produces 2,3,7,8-TCDD and OCDD for research purposes (SRI 1991).  Cambridge Isotope Laboratories 
produced unlabeled chlorodioxin standards (TCDD through HpCDD) and C13 labeled chlorodioxin 
standards (DCDD through OCDD) for use in chemical analyses and in toxicological research (Cambridge 
Isotope Laboratories 1995). 
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Since CDD releases are not required to be reported under Superfund Amendments and Reauthorization Act 
(SARA) Section 313, there are no data on CDDs in the 1994 Toxics Release Inventory (TRI) (EPA 1995g). 
4.2 IMPORT/EXPORT 
2,3,7,8-TCDD is not imported into the United States (NTP 1989).  There were no data located pertaining to 
the export of 2,3,7,8-TCDD or any other CDD for research purposes. 
4.3 USE 
The only reported use of CDDs/CDFs is as research chemicals (NTP 1989).  A large diversified group of 
researchers use various CDDs in studies of toxicology, environmental fate, transformation, and transport, 
and in residue analysis of a variety of contaminated media.  CDDs have been tested for use in flame-
proofing polymers such as polyesters and against insects and wood-destroying fungi; however, there are no 
data reporting its commercial production or use for these purposes (IARC 1977). 
4.4 DISPOSAL 
The 1994 estimates on the degree of TCDD contamination in the environment indicated that approximately 
500,000 tons of soil and sediment in the United States were contaminated with 2,3,7,8-TCDD (Hilarides et 
al. 1994). The development of treatment technologies for CDD-contaminated soils and wastes needed to 
address unique problems associated with CDDs: for example, they are insoluble in water, only slightly 
soluble in organic solvents, have a strong affinity for adsorption on organic matter, and are biologically and 
environmentally stable (U.S. Congress 1991).  In order to meet the clean-up standards established for 
CDDs, the treatment system must be capable of removing the CDDs from the contaminated matrix (U.S. 
Congress 1991). Several treatment or disposal methods for CDDs and CDD-contaminated materials have 
been investigated, including land disposal, thermal destruction, and chemical and biological degradation. 
Each of these methods has limitations regarding economics, technical feasibility, and acceptability (HSDB 
1995). 
Land disposal of CDD-containing wastes is currently prohibited (EPA 1986f, 1988f).  The Toxic 
Substances Control Act (TSCA) regulates the use, disposal, and distribution in commerce of process waste 
water treatment sludges intended for land application from pulp and paper mills employing chlorine or 
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chlorine derivative-based bleaching processes (EPA 1991b, 1991c).  Also, under the Marine Protection 
Research and Sanctuaries Act, ocean dumping of CDD-containing wastes is prohibited except when only 
trace amounts are present (EPA 1977a, 1977b). 
Thermal destruction technologies offer the most straightforward approach to treating or disposing of CDD-
contaminated materials because under the appropriate conditions the breakdown of the CDDs is assured 
(U.S. Congress 1991). The thermal treatment technologies that are currently used to treat waste containing 
hazardous or toxic constituents and that have demonstrated potential use toward the treatment of CDD-
contaminated waste include rotary kiln incineration, liquid injection incineration, fluidized-bed incineration, 
advanced electric reactor (AER), infrared incineration, plasma arc pyrolysis incineration, supercritical water 
oxidation, and in situ vitrification (U.S. Congress 1991). In addition to kiln incinerators, the technologies 
that have been field-tested for treating CDD-contaminated media under EPA’s  Superfund Innovative 
Technology Evaluation (SITE) program include dechlorination, stabilization, and in situ vitrification (U.S. 
Congress 1991). Although some alternatives look promising and have been shown effective in the 
laboratory or in application to other pollutants, more development and testing is needed to demonstrate 
viability for large-scale treatment of CDD contamination. 
Incineration, involving the high-temperature oxidation of CDD molecules, is the most extensively tested 
method for disposal of CDDs.  CDDs such as TCDD, PeCDD, and HxCDD are classified by EPA as 
Principal Organic Hazardous Constituents (POHCs) and are required to be incinerated under conditions that 
achieve a destruction and removal efficiency of 99.99% (EPA 1990b; Sedman and Esparza 1991). 
Incinerator operating conditions currently considered adequate for destruction of 2,3,7,8-TCDD and most 
other chlorinated organics require a temperature of at least 1,500–2,600 EF, with residence times of at least 
30 minutes (although 1.5 hours is a more common residence time) to ensure complete destruction (EPA 
1990a). Thermal destruction of CDDs that are adsorbed on fly ash can be accomplished through the use of 
a rotary kiln furnace combined with a baghouse filter for the recycling of entrained fly ash and an activated 
carbon filter for adsorption of CDD traces transported in the gas phase.  This method is capable of 
destroying 99.5% of CDDs in fly ash, which is considered a high level of efficiency (Kahr et al. 1990). 
EPA's Mobile Incineration System, a transportable rotary kiln system, was judged to be more than adequate 
for detoxifying CDD-contaminated solids and liquids after it was performance-tested with a variety of 
uncontaminated soils and other solid wastes, and thus could be expected to accomplish a successful CDD 
trial burn. The system, which has been extensively modified for field use, consists of a 
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rotary-kiln, a secondary combustion chamber, an air pollution control unit, and separate continuous stack-
gas analysis capabilities (HSDB 1995).  In 1977, the U.S. Air Force disposed of Agent Orange 
contaminated with 2,3,7,8-TCDD by high temperature incineration at sea (Bumb et al. 1980).  The high 
flame temperature reached 1,500 EC in the incinerator, and EPA determined a combustion efficiency of 
99.9% for 2,3,7,8-TCDD. 
Kiln incinerators have been used to treat a variety of containerized and noncontainerized solid and liquid 
wastes. Since the waste can be treated individually or simultaneously, the versatility of this technology has 
made it popular in the United States for disposing of hazardous waste.  For the disposal of CDD-containing 
waste, however, kiln incineration is more commonly practiced in Europe than in the United States (U.S. 
Congress 1991). Although liquid injection incineration has been used for ocean-based incineration of 
Agent Orange, certain limitations must be considered before applying the technology to treating CDD 
contamination.  These limitations include the applicability of the technology only to combustible low-
viscosity liquids and slurries that can be pumped; atomizing the waste prior to injection into the combustor; 
and the importance of particle size because burners are susceptible to clogging (U.S. Congress 1991). 
Fluidized-bed combustion (FBC) systems have traditionally been used to treat the sludge produced by 
municipal waste treatment plants and waste generated from oil refineries, pulp and paper mills, and the 
pharmaceutical industry.  The system consists of a vertical refractory-lined vessel which holds a perforated 
plate. A bed of granular material, usually sand, is placed on the perforated plate.  The system uses forced 
hot air to fluidized the bed and cause a highly turbulent zone that ensures the mixing of the waste with bed 
particles and the combustion air.  Combustion is facilitated by an overhead burner (U.S. Congress 1991). 
The type and size of materials to be treated are critical because variations in gravity and density could be 
deleterious to the process (U.S. Congress 1991). Modification of the traditional FBC system for treatment 
of chlorinated wastes continues to be investigated by researchers in the private sector.  A modified system 
designed by Waste-Tech Services, Inc. uses a granular bed composed of a mixture of combustion catalyst 
and limestone.  The results of the trial burn for the Waste-Tech Services system which used chlorinated 
waste containing carbon tetrachloride, tetrachloroethane, p-dichlorobenzene and some CDDs and CDFs, 
showed no measurable amount of any of the chlorinated pollutants treated and no 2,3,7,8-TCDD in any of 
the samples tested (U.S. Congress 1991).  In situ vitrification (ISV), which treats waste in place, solidifies 
all materials not volatilized or destroyed.  Bench-scale testing of ISV on soils containing 10 ppb CDDs 
showed destruction removal efficiency (DRE) values of 99.9999% (U.S. Congress 1991). 
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Since the early 1970s, several chemical methods have been investigated for the degradation of CDDs. 
Treatment of CDD-contaminated materials with alkali polyethylene glycolate (APEG) reagents at 
hazardous waste sites has been demonstrated to successfully destroy CDDs in liquid wastes and to be viable 
even under difficult circumstances.  This method involves the reaction of potassium hydroxide with 
polyethylene glycol to form an alkoxide that reacts with one of the chlorine atoms on the CDD to produce 
an ether and potassium chloride.  Bioassays indicate that the by-products produced by treating 
2,3,7,8-TCDD with APEG reagents do not bioaccumulate or bioconcentrate, do not cause mutagenicity, and 
are far less toxic than 2,3,7,8-TCDD (Klee 1988). Cleavage of the ether linkages with the formation of 
halophenols may be achieved by treatment with strong acids or quaternary ammonium salts, but the 
dibenzodioxin nucleus is resistant to chemical attack. Oku et al. (1995) investigated the dechlorination of 
polychlorinated dibenzo-p-dioxins (CDDs) and polychlorinated dibenzofurans (CDFs) using a modified 
alkali-metal hydroxide method.  The destruction reagent, prepared by dissolving either potassium hydroxide 
or sodium hydroxide in 1,3-dimethyl-2-imidazolidinone (DMI) destroyed all components regardless of the 
difference in the number of chlorine atoms or isomers of CDDs and CDFs (Oku et al. 1995).  The efficiency 
of the methods was evaluated under varying conditions; in the presence and absence of water, at 90 and 
50 EC, for 0.5 and 5 hours. Although the degree of CDD destruction (99.95–99.80%) was less than that for 
CDFs (99.99–99.98%), overall, the investigators considered the DMI reagent to be more useful than the 
polyethylene glycols because of its stability under strongly basic conditions and its efficiency in the 
presence of water (Oku et al. 1995). 
Ruthenium tetroxide treatment can cause oxidative degradation of CDDs.  This method can be used for 
detoxification of glassware and artifacts, or for the periodic purging of industrial reactors to counteract the 
accumulation of CDD residues (HSDB 1995).  There is no available evidence on the nature of fragments 
formed during oxidation of the CDDs; however, the related chlorophenols undergo extensive 
decomposition to yield chlorine ions and no significant levels of organic products (HSDB 1995).  Other 
chemical methods of detoxification include exposure to ultraviolet light or gamma radiation, the use of 
ozone or special chloroiodide compounds, and the use of solvents or adsorbents to concentrate CDDs into 
smaller volumes for final disposal by incineration (HSDB 1995). 
Dougherty et al. (1993) conducted a theoretical analysis of a proposed in situ method for decontaminating 
soil by photodegradation.  Up to 86% of TCDD in the soil can be degraded by this process (Zhong et al. 
1993). Because of its extremely low water solubility and volatility, TCDD is a very persistent soil 
contaminant.  With the method, based on the physical properties that facilitate photolysis of TCDD by
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sunlight, an organic solvent mixture (2:1 w/w) of tetradecane and 1-butanol is applied to the contaminated 
soil (Dougherty et al. 1993).  The controlling factors in TCDD photodegradation are desorption of the 
compound from the soil, the transport mechanism to the soil surface, and the availability of sunlight.  As the 
solvents remove the tightly bound TCDD from the soil, convective upward movements of the compound 
are caused by the evaporation of the solvent (Dougherty et al. 1993; Zhong et al. 1993).  The effectiveness 
of the process also depends on a balance between the convective movement and sunlight availability for 
degradation (Dougherty et al. 1993).  Modeling conducted by Zhong et al. (1993) identified and quantified 
the controlling factors governing the TCDD photodegradation process.  Following the concentration 
variation of TCDD in the top 2 mm of soil through sunlight/night cycles over an exposure period of 
15 days, the model showed that during the daytime of the first few days, there is little accumulation of 
TCDD as the losses due to photodegradation were almost equal to the convective flux in magnitude but 
with different signs. Although the losses due to photodegradation  drop to zero at night, the convective flux 
effected a build-up of TCDD. The losses due to photodegradation  held steady while the convective 
movements decreased as evaporation slowed down (Zhong et al. 1993).  A balance between the build-up of 
TCDD concentration at night and the drop in concentration during the day did not occur until the eleventh 
day of exposure (Zhong et al. 1993). 
Hilarides et al. (1994) investigated degradation of TCDD in the presence of surfactants.  Their results 
indicated that radiolytic destruction of TCDD using γ radiation can be achieved. Greater than 92% of the 
TCDD was destroyed in soils amended with 100 ppb TCDD, 25% water, and 2% nonionic surfactant using 
60Co at high radiation doses (800 kGy or 80 Mrad).  The use of 60Co as a source avoids the temperature 
increases and power requirements of other sources of ionizing radiation such as an electron beam.  It is also 
better suited for soil application because of its greater penetration depths (Hilarides et al. 1994). 
Biotreatment systems which use microorganisms for degradation of refractory organopollutants, like CDDs, 
are also being considered. Phanerochaete chrysosporium, a white rot fungus, has shown the ability to 
slowly degrade 2,3,7,8-TCDD in the laboratory (Bumpus et al. 1985; Des Rosiers 1986).  The ability of this 
fungus to metabolize 2,3,7,8-TCDD is thought to be related to its extracellular lignin degrading enzyme 
system (Bumpus et al. 1985; Des Rosier 1986). 
Other proposed methods of disposal are burial in salt mines and inclusion of these chemicals with nuclear 





5. POTENTIAL FOR HUMAN EXPOSURE 
5.1 OVERVIEW 
Chlorinated dioxins (CDDs) are a family of compounds that includes some extremely toxic and potent 
congeners. The two most toxic of the CDDs in mammals are 2,3,7,8-TCDD and 1,2,3,7,8-PeCDD (Buser 
1987; Poland and Knutson 1982; Safe 1986; WHO 1997).  In general, the more toxic congeners to mammals 
appear to be the 2,3,7,8-substituted tetra-, penta-, and hexachloro- compounds, (e.g., 2,3,7,8-TCDD, 
1,2,3,7,8-PeCDD, 1,2,3,4,7,8-HxCDD, 1,2,3,6,7,8-HxCDD, and 1,2,3,7,8,9-HxCDD) (Poland and Knutson 
1982; Safe 1986; WHO 1997). A more detailed discussion of the relative toxicities of the different CDD 
congeners is given in Section 2.5, Relevance to Public Health. 
CDDs usually occur in the environment concurrently with other chemicals such as chlorinated dibenzo­
furans (CDFs). CDDs and CDFs are highly persistent compounds and have been detected in air, water, 
soil, sediments, animals, and foods.  CDFs include 135 congeners, which are structurally similar to CDDs 
and which elicit a number of similar toxicological and biochemical responses in animals (for more 
information on CDFs see ATSDR 1994).  CDDs and CDFs are released to the environment during 
combustion processes (e.g., municipal solid waste, medical waste, and industrial hazardous waste 
incineration, and fossil fuel and wood combustion); during the production, use, and disposal of certain 
chemicals (e.g., PCBs, chlorinated benzenes, chlorinated pesticides); during the production of bleached 
pulp by pulp and paper mills; and during the production and recycling of several metals  (Buser et al. 
1985; Czuczwa and Hites 1986a, 1986b; Oehme et al. 1987, 1989; Zook and Rappe 1994).  The EPA 
has developed procedures for estimating risks associated with exposures to mixtures of CDDs and CDFs 
in environmental matrices (EPA 1989e).  This approach is based on the assignment of 2,3,7,8-TCDD 
toxic equivalence factors (TEFs) to CDD/CDF congeners or homologues in complex mixtures.  The 
rationale behind the use of TEFs is explained in Section 2.5, Relevance to Public Health.  Although the 
focus of this profile is CDDs, it should be recognized that most exposure scenarios involve exposure 
to CDDs, CDFs, and the non-ortho polychlorinated biphenyls (PCBs) that have CDD-like toxicity; 
many of these exposure scenarios are discussed in this chapter.  These exposures are usually reported 
in TEQs (for more information see Section 2.5, Relevance to Public Health, Toxic Equivalency Factors 
[TEFs] and Toxic Equivalents [TEQs]).  Over the past several years sets of TEFs have been 
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developed, varying slightly from one to another.  The reader is encouraged to consult the original literature 
for specific details on TEQs computation. 
CDDs (TCDD, PeCDD, HxCDD, HpCDD, OCDD) are ubiquitous in the environment (Podoll et al. 1986). 
Although all of the sources or processes that contribute to CDDs in the environment have not been 
identified, CDDs are known to be formed in the manufacture of chlorinated intermediates and pesticides, 
during smelting of metals (EPA 1998j), in the incineration of municipal, medical, and industrial wastes 
(Podoll et al. 1986), and from the production of bleached wood pulp and paper (Fletcher and McKay 1993). 
CDDs are also found in emissions from the combustion of various other sources, including coal-fired or oil-
fired power plants, wood burning, and home heating systems (Chiu et al. 1983; Czuczwa and Hites 1984; 
EPA 1998j; Gizzi et al. 1982; Thoma 1988).  Generally, the more highly  chlorinated CDDs are the most 
abundant congeners present in the emissions from these combustion sources.  CDDs also occur in other 
combustion products (e.g., cigarette smoke) (Bumb et al. 1980; Lofroth and Zebuhr 1992; Muto and 
Takizawa 1989), automobile exhaust from cars running on leaded gasoline with chlorine scavengers and to 
a lesser extent from cars running on unleaded gasoline (Bingham et al. 1989; Marklund et al. 1987, 1990), 
and diesel exhaust (Jones 1995; Cirnies-Ross et al. 1996). CDDs/CDFs can form during the synthesis and 
combustion of chlorine-containing materials, such as polyvinylchloride (PVC), in the presence of naturally 
occurring phenols, vegetation treated with phenoxy acetic acid herbicides, paper and wood treated with 
chlorophenols, and pesticide-treated wastes (Arthur and Frea 1989). 
CDDs occur as contaminants in the manufacture of various pesticides and, as a result, have been released 
to the environment during use of these pesticides.  2,3,7,8-TCDD is a by-product formed in the manu­
facture of 2,4,5-trichlorophenol (2,4,5-TCP) (Arthur and Frea 1989).  2,4,5-TCP was used to produce the 
bactericide, hexachlorophene, and the chlorophenoxyherbicide, 2,4,5-trichlorophenoxy acid (2,4,5-T). 
Trichlorophenol-based herbicides have been used extensively for weed control on crops, rangelands, 
roadways, right-of-ways, etc.  Various formulations of 2,4-dichlorophenoxy acetic acid (2,4-D) 
contaminated mainly with higher chlorinated CDDs/CDFs and 2,4,5-T contaminated mainly with 
2,3,7,8-TCDD were used extensively for defoliation and crop destruction by the American military during 
the Vietnam War.  Although six herbicides were used (Orange, Purple, Pink, Green, White, and Blue), 
herbicide Orange (Agent Orange) was the primary defoliant (Wolf et al. 1985).  Hexachlorophene use has 
been restricted by the FDA and its disposal is regulated by EPA under the Resource Conservation and 
Recovery Act (RCRA).  In 1983, EPA canceled registration for all chlorophenoxy herbicides used on 
foods, rice paddies, pastures, and rangelands (IARC 1986b).  2,4,5-T can no longer be used legally in the 
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United States for any purpose (IARC 1986b). Other countries, including Canada, Sweden, the Netherlands, 
Australia, Italy, and the Federal Republic of Germany, have also canceled registrations for 2,4,5-T (IARC 
1986b), but many other countries have not.  Currently, 2,4,5-T can be produced with lower 2,3,7,8-TCDD 
concentrations than were previously possible.  2,4,5-TCP production has been discontinued in many 
countries, including the United States, Canada, the United Kingdom, the Federal Republic of Germany, 
and Austria (IARC 1986a). HxCDD, HpCDD, and OCDD are known contaminants of pentachlorophenol 
(PCP), primarily a wood preservative and pesticide, which was used extensively in the 1970s and is still 
used today (to a lesser extent) in the lumber industry.  PCP is currently registered as a restricted-use 
pesticide in the United States (Sine 1990). 
Although little definitive data exist to prove or disprove that CDDs form during natural processes, results 
from dated sediment cores have shown that there were significant increases in CDDs and CDFs after about 
1940 (Czuczwa and Hites 1984, 1986b, 1986b) and lower levels of CDDs are currently found in persons 
from less industrialized countries (Schecter et al.1991a).  The congener/homologue profile of the 
sediments was similar to that of atmospheric samples, strongly suggesting that combustion processes were 
the source of CDDs in the sediments.  The historical increase in CDDs/CDFs also was similar to the trends 
for the production, use, and disposal of chlorinated organics, suggesting that accumulation of these 
compounds in the environment is a recent phenomenon related to the production, use, and subsequent 
incineration of chlorinated organic chemicals (Schecter et al. 1988). 
CDDs are ubiquitous in the environment and are found at low background levels (parts per trillion [ppt] or 
parts per quadrillion [ppq]) in the air, water, and soil.  Lower levels are found in biological and environ­
mental samples from less industrialized rural regions than in those from more industrialized urban regions 
(Czuczwa and Hites 1986a; Des Rosiers 1987; Edgerton et al. 1989; Schecter et al. 1989e, 1989g, 1991a, 
1994d; Tiernan et al. 1989b). HpCDD and OCDD are the most common CDDs found in environmental 
samples (Christmann et al. 1989b; Clement et al. 1985, 1989; Pereira et al. 1985; Reed et al. 1990; Tashiro 
et al. 1989a; Tiernan et al. 1989b). 
The environmental fate and transport of CDDs involve volatilization, long-range transport, wet and dry 
deposition, photolysis, bioaccumulation, and biodegradation (Kieatiwong et al. 1990).  CDDs strongly 
partition to soils and sediments.  Due to their low vapor pressure and low aqueous solubility and their 
strong sorption to particulates, CDDs are generally immobile in soils and sediments.  Although most 
biological and nonbiological transformation processes are slow, photolysis has been shown to be relatively
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rapid. Photolysis is probably the most important transformation process in environmental systems into 
which sunlight can penetrate (Kieatiwong et al. 1990).  Estimates of the half-life of 2,3,7,8-TCDD on the 
soil surface range from 9 to 15 years, whereas the half-life in subsurface soil may range from 25 to 
100 years (Paustenbach et al. 1992).  CDDs have been shown to bioaccumulate in both aquatic and 
terrestrial biota. CDDs have a high affinity for lipids and, thus, will bioaccumulate to a greater extent in 
organisms with a high fat content.  
Over the past decade, typical concentrations of CDDs in urban air in the United States have averaged 
2.3 pg/m3, with OCDD and HpCDD homologues predominating and 2,3,7,8-TCDD being the least 
common congener (Smith et al. 1992).  CDD concentrations range as follows: OCDD, 0.44–3.16 pg/m3; 
HpCDD, 0.21–4.4 pg/m3; HxCDD, 0.6–0.63 pg/m3; PeCDD, not detected to 0.1 pg/m3; and 2,3,7,8-TCDD, 
<0.04–0.18 pg/m3 (Edgerton et al. 1989; Eitzer and Hites 1989a, 1989b; Hunt and Maisel 1992; Smith et 
al. 1992). Although 2,3,7,8-TCDD has been detected in some urban air, it is rarely detected in rural areas 
(Reed et al. 1990). Ambient air concentrations of 2,3,7,8-TCDD detected in the vicinity of a Superfund 
clean-up site were on the order of 1 pg/m3 (Fairless et al. 1987). CDDs have been detected almost 
exclusively in raw surface waters, rather than in finished drinking water (Jobb et al. 1990).  This is not 
unexpected because CDDs are hydrophobic, and the compounds tend to be adsorbed onto particulate 
matter in the water column.  Conventional water treatment processes appear to be effective in removing the 
CDDs along with the particulates (Jobb et al. 1990; Meyer et al. 1989).  OCDD is the congener most often 
detected in water supplies at concentrations ranging from 9 to 175 ppq (raw water) and from 19 to 46 ppq 
(finished water). 2,3,7,8-TCDD concentrations have not been detected in finished drinking water, but 
were detected in one raw sample at a concentration of 1.7 ppq (Meyer et al. 1989).  Concentrations of 
2,3,7,8-TCDD in most soils are <12 ppt (Des Rosiers 1987; Nestrick et al. 1986); however, levels in 
contaminated soils can be several orders of magnitude higher (1,750 ppb) (Tiernan et al. 1985). 
2,3,7,8-TCDD and other CDDs, have also been detected in measurable amounts in the sediments of 
industrialized waterbodies throughout the United States  (Bopp et al. 1991; Wenning and Erickson 1994; 
Wenning et al. 1992, 1993a, 1993b). 
In the National Study of Chemical Residues in Fish conducted by the EPA between 1986 and 1989, four 
CDDs (2,3,7,8-TCDD, 1,2,3,7,8-PeCDD, 1,2,3,6,7,8-HxCDD, and 1,2,3,4,6,7,8-HpCDD) were detected at 
over 50% (54 to 89%) of 388 sites surveyed nationwide (EPA 1992).  The most frequently detected CDD 
compound (1,2,3,4,6,7,8,-HpCDD) was found in fish tissues at 89% of the sites.  This compound was also 




5. POTENTIAL FOR HUMAN EXPOSURE 
and 1,2,3,7,8-PeCDD, the CDDs currently believed to be most toxic to vertebrates (WHO 1997), were 
found in fish tissue at 70% and 54% of the sites, respectively.  2,3,7,8-TCDD was found at a mean 
concentration of 6.9 ppt and a maximum concentration of 204 ppt, and 1,2,3,7,8-PeCDD was found at a 
mean concentration of 2.38 ppt and a maximum concentration of 54 ppt.  With respect to source 
categories, fish collected near pulp and paper mills using chlorine had the highest median 2,3,7,8-TCDD 
concentration (5.66 ppt), compared to the second highest median 2,3,7,8-TCDD concentrations of 1.82 ppt 
at refinery/other industrial sites, and the third highest median 2,3,7,8- TCDD concentration of 1.27 ppt at 
Superfund sites. Similarly, with respect to source categories, fish collected near pulp and paper mills using 
chlorine had the highest median 1,2,3,7,8-PeCDD concentration (1.52 ppt), compared to the second 
highest median concentrations of 1.35 ppt at refinery/other industrial sites, and the third highest median 
concentration of 1.09 ppt at industrial/urban sites. 
The detection of CDDs in blood, adipose tissue, breast milk, and other tissue samples from the general 
population indicates universal exposure to CDDs from environmental sources (Fürst et al. 1994; Orban et 
al. 1994; Patterson et al. 1986a; Ryan et al. 1986, 1993a; Schecter and Gasiewicz 1987a, 1987b; Schecter 
et al. 1986b, 1989e; Stanley 1986; Stanley et al. 1986).  The general population is exposed to CDDs 
released from industrial and municipal incineration processes; exhausts from automobiles using leaded 
gasoline; cigarette smoke; and foods, including human milk (Pohl and Hibbs 1996; Schecter et al. 1994e). 
The major source (>90%) of exposure for the general population, however, is primarily associated with 
meat, dairy products, and fish (Beck et al. 1989a; Schaum et al. 1994; Schecter et al. 1994d, 1994e, 
1996a). CDDs are transferred through the placenta to the fetus, by breast milk to infants and young 
children, and by lifelong dietary ingestion.  Workers involved with incineration operations or those who 
have been or may be involved in the production, use, or disposal of trichlorophenol, phenoxyherbicides, 
hexachlorophene, pentachlorophenol and other compounds that contain impurities of CDDs are at a greater 
risk from exposure to CDDs and TEQs (Päpke et al. 1992; Schecter and Ryan 1988; Schecter et al. 1991). 
Individuals in the general population who may be exposed to potentially higher levels of CDDs include 
recreational and subsistence fishers (including many native Americans) and their families living in CDD-
contaminated areas who consume large quantities of fish from contaminated waters (CRITFC 1994; Ebert 
et al. 1996), subsistence hunters such as the Inuit of Alaska who consume large quantities of wild game 
(particularly marine mammals) (Dewailly et al. 1993; Hebert et al. 1996; Norstrom et al. 1990), 
subsistence farmers and their families living in areas contaminated with CDDs who consume their own 
farm-raised beef and dairy products (EPA 1996b; McLachlan et al. 1994), individuals who live in the 
vicinity of an industrial or municipal incinerator, or individuals who live in the vicinity of the 
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126 hazardous waste sites where CDDs (and more especially where  2,3,7,8-substituted CDDs) have been 
detected (Gough 1991; Liem et al. 1991; Pohl et al. 1995; Riss et al. 1990; Wuthe et al. 1993). 
2,3,7,8-TCDD has been identified in at least 91 of 1,467 current or former EPA National Priorities List 
(NPL) hazardous waste sites (HazDat 1998). However, the number of sites evaluated for 2,3,7,8,-TCDD is 
not known. The frequency of these sites within the United States can be seen in Figure 5-1.  Of these sites, 
90 are located in the United States and 1 is located in the Commonwealth of Puerto Rico (not shown). 
Total CDDs (including TCDDs, PeCDDs, HxCDDs, HpCDDs, and OCDD) have been identified in 126, 
105, 34, 43, 49, and 53 sites, respectively, of the 1,467 hazardous waste sites on the NPL.  The frequency 
of these sites within the United States for total CDDS, TCDDs, PeCDDs, HxCDDs, HpCDDs, and OCDD, 
respectively, can be seen in Figures 5-2 through 5-7. Of the 126 sites with total CDD detections, 125 are 
located in the United States and 1 site is located in the Commonwealth of Puerto Rico (not shown).  Of the 
105 sites with total TCDD detections, 104 are located in the United States and 1 site is located in the 
Commonwealth of Puerto Rico (not shown).  Of the sites with PeCDD, HxCDD, HpCDD, and OCDD 
detections, all 34, 43, 49, and 53 sites, respectively, are located in the United States. 
5.2 RELEASES TO THE ENVIRONMENT 
CDDs have been measured in all environmental media including ambient air, surface water, groundwater, 
soil, and sediment.  While the manufacture and use of chlorinated compounds, such as chlorophenols and 
chlorinated phenoxy herbicides, were important sources of CDDs to the environment in the past, the 
restricted manufacture of many of these compounds has substantially reduced their current contribution to 
environmental releases.  It is now believed that incineration/combustion processes are the most important 
sources of CDDs to the environment (Zook and Rappe 1994).  Important incineration/combustion sources 
include: medical waste, municipal solid waste, hazardous waste, and sewage sludge incineration; industrial 
coal, oil, and wood burning; secondary metal smelting, cement kilns, diesel fuel combustion, and 
residential oil and wood burning (Clement et al. 1985; Thoma 1988;  Zook and Rappe 1994). 
Emissions to the atmosphere from incineration and combustion sources result in the wide-spread 
distribution of CDDs. Consequently, CDDs are found at low levels in rural soils as well as in sediments of 
otherwise pristine waterbodies. Much of the CDD deposits from wet and dry deposition ultimately 
become components of urban runoff which enter rivers, streams, and estuaries directly or through 
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pattern matching techniques (principal components analysis) to evaluate CDD congener patterns in 
sediment samples collected adjacent to several CSOs.  According to these authors, the presence of these 
unique CDD/CDF congener patterns in sediment adjacent to CSOs suggested that these CSOs were a likely 
source given the industrial, residential, and stormwater inputs to the combined sewer overflow system. 
Such statistical techniques have been applied elsewhere to CDD congener pattern matching in an effort to 
identify specific sources of CDDs.  Wenning et al. (1993a, 1993b) also applied principal components 
analysis to Newark Bay Estuary sediments and found that most of the congener fingerprint patterns were 
related to combustion/incineration sources.  More recently, Ehrlich et al. (1994) applied polytopic vector 
analysis, a fingerprinting technique that “unmixes” the CDD/CDF patterns, and concluded that the primary 
sources of CDD/CDFs in Newark Bay Estuary sediments were combustion/incineration, sewage-related 
sources, and PCB-related sources. Statistical techniques that have proven useful for identifying sources of 
CDDs have recently been reviewed (Wenning and Erickson 1994).  Future efforts to reduce the release of 
CDDs to the environment will require additional analysis of the distributional patterns of CDDs in 
environmental media, which may also provide information on  sources still to be identified. 
5.2.1 Air 
The key sources of CDD releases to air are from anthropogenic combustion processes and the production 
and use of chemicals contaminated with CDDs.  Some evidence suggests that natural combustion 
processes (e.g., forest fires or volcanic activity) may also be sources of CDDs, but to a much smaller 
extent. Toxics Release Inventory (TRI) data are not available for CDDs since CDD releases are not 
required to be reported (EPA 1995g). 
Combustion Processes. Combustion processes generate CDDs, CDFs, and other halogenated 
aromatic compounds (Czuczwa and Hites 1984, 1986a, 1986b).  Most of the direct releases of CDDs and 
CDFs from combustion processes are to the air (Czuczwa and Hites 1984, 1986a, 1986bc).  CDDs and 
CDFs may be found in particulates released from the combustion of most types of organic material and 
limited evidence suggests that they may also result from trace chemical reactions in fire (Bumb et al. 1980; 
Crummett 1982; Safe 1990).  The processes involved in the formation of CDDs and CDFs consist of 
numerous chemical reactions that occur during combustion of organic compounds in the presence of 
chlorinated material. The EPA has recently identified stationary source categories that release 
2,3,7,8-TCDD TEQ to the atmosphere (EPA 1998j).  The percentage contribution of the five highest 
source categories are: 68% from municipal waste incineration, 12.3% from medical waste incineration, 
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8.9% from Portland cement manufacture hazardous waste kilns, 3.5% from secondary aluminum smelting, 
and 3.0% from other biological incineration.  These five source categories account for 95.9% of all 
stationary emissions of 2,3,7,8-TCDD TEQ to the air. 
The "Trace Chemistries of Fire Hypothesis" suggests that CDDs and CDFs can also form during a variety 
of combustion processes including natural ones, such as forest fires and volcanic eruptions (Crummett 
1982). However, there is very limited evidence suggesting that such natural processes could be minor 
sources of these compounds in the environment. Only data from one study were found that directly 
measured CDD/CDFs in actual emissions from forest fires.  Tashiro et al. (1990) detected the concen­
tration of total CDD/CDFs in air ranging from 15 to 400 pg/m3. The samples were collected from fixed 
collectors 10 m above the ground and from aircraft flying through the smoke.  Soil samples collected 
before the burn detected 43 ppt of OCDD in 1 of 4 samples tested.  After the burn, OCDD was detected in 
3 of 4 soil samples at concentrations of 46, 100, and 270 ppt.  Because the small sample size precluded 
statistical analysis, no further conclusions were drawn by the authors. Thomas and Spiro (1995), however, 
estimated that forest and agricultural burning accounted for the third largest emission of CDD/CDF in the 
United States (30 kg/year), behind municipal waste incineration (200 kg/year) and hospital incinerators 
(40 kg/year) although the inclusion of agricultural burning, which may include acreage treated with long-
lived organochlorine pesticides, may skew the values higher than would be expected from forest fires 
alone. Failure to find CDDs in ancient mummies or ancient frozen Eskimo tissues is another indication 
that the “Trace Chemistries of Fire Hypothesis” may have little bearing on human exposure (Ligon et al. 
1989; Schecter et al. 1988; Tong et al. 1990). The EPA recently found elevated levels of 2,3,7,8-TCDD in 
two chickens that were traced to clay (used as an anti-caking additive in soybean animal meal) derived 
from clay deposits mined at the Kentucky-Tennesse Ball Clay Company in Crenshaw, Mississippi. 
(Chemical Regulation Reporter 1997a, 1997b). However, no information on the origin of the 2,3,7,8­
TCDD, either natural or anthropogenic, was presented. 
The issue of natural sources of CDD/CDF is interesting, but historical deposition records strongly 
implicate anthropogenic activity as the major source of CDD/CDFs (Thomas and Spiro 1996).  These 
authors further suggest that the historic record on CDD/CDF deposition provided by sediment cores 
strongly implies that anthropogenic sources have been overwhelmingly dominant.  Sediment cores from 
Siskwit Lake on a remote island in northern Lake Superior, provide a historic record of atmospheric CDD 
fluxes (Czuczwa and Hites 1986a). An 8-fold increase in the CDD/CDF deposition rate (from approx 
imately 4–30 pg/cm2/year) occurred between 1940 and 1970, corresponding to a great expansion in the 
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industrial use of chlorine (Thomas and Spiro 1996). The decrease in deposition rate of about 30% (from 
30 to 24 pg/cm2 /year) from 1970 to the mid 1980s parallels decreased production and use of chlorophenols 
(pesticide registrations for 2,4,5-T and Silvex were discontinued in 1983 and 1984, respectively) (IARC 
1977; Sine 1990) and reductions in municipal incinerator emission resulting from improvements in design, 
pollution controls, and operation of these facilities (Thomas and Spiro 1996).  It is difficult to reconcile 
these trends with predominantly natural sources, especially since the total area of U.S. forests consumed by 
forest fires diminished by more than a factor of 4 between 1940 and 1970 through more effective fire 
control (Thomas and Spiro 1996). 
Although the production of CDDs during combustion processes are highlighted here, most samples from 
combustion sources show a complex mixture of isomers and congeners of CDDs and CDFs which vary in 
their relative concentrations (Kolenda et al. 1994; Nestrick and Lamparski 1983; Vikelsoe et al. 1994). 
CDDs have been detected in emissions (flue gas and fly ash) from municipal, hazardous waste, and 
industrial incinerators (Buser 1987; Oppelt 1991; Sedman and Esparza 1991; Schecter 1983).  Combustion 
of materials, such as vegetation treated with phenoxy acetic acid herbicides, paper and wood treated with 
chlorophenols, pesticide-treated wastes, and polyvinylchloride (PVC) in the presence of naturally 
occurring phenols, may lead to CDDs and CDD precursors (Arthur and Frea 1989).  PVC is known to 
yield a small amount of chlorobenzene upon pyrolysis, which in turn thermally decomposes to CDDs and 
CDFs (Lustenhouwer et al. 1980). CDDs have also been detected in fly ash from an oil-fired power plant, 
in city dust, in commercial sludge fertilizer, in particulate deposits in car and truck mufflers, in exhaust 
from vehicles powered with leaded and unleaded gasoline and diesel fuel, in cigarette smoke, and in soot 
from home fireplaces and from PCB and chlorinated benzene contaminated transformer fires (Bumb et al. 
1980; Hutzinger et al. 1985; Lofroth and Zebuhr 1992; Marklund et al. 1987, 1990; Muto and Takizawa 
1989; Schecter 1983; Thoma 1988).  Dichloroethane, the chlorinated additive in leaded gasoline, is also a 
source of CDDs (Marklund et al. 1987). The dichloroethane acts as a scavenger to prevent the deposition 
of lead compounds in engines (Safe 1990).  Although the data indicate that CDDs result from diverse 
processes, the relative contributions of these sources and other unidentified sources to the presence of 
CDDs in the atmosphere are not known. 
A mixture of CDDs (TCDD, PeCDD, HxCDD, HpCDD, OCDD) has been found in emissions (both 
particles and flue gases) from various combustion sources, including municipal incinerators, power plants, 
wood burning, home heating systems, and petroleum refining (Chiu et al. 1983; Czuczwa and Hites 1984; 
Gizzi et al. 1982; Nessel et al. 1991; Thoma 1988; Thompson et al. 1990).  In individual samples of 
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emissions from an urban incinerator, HxCDDs and OCDD were often the most abundant CDDs found, 
although the homologue pattern can be quite variable (Gizzi et al. 1982).  Emission of TCDD from 
municipal waste combustion ranged from 0.018 ng/m3 to 62.5 ng/m3 depending on the type of combustion 
facility (Roffman and Roffman 1991).  A municipal solid waste incinerator sampled in 1988 contained an 
average TCDD concentration of 0.0012 ng/m3, where OCDD was present at 1.2 ng/m3, and HxCDD was 
present at >1 ng/m3 (Nessel et al. 1991). In another study, no TCDDs were found in emissions from 
hazardous waste or municipal waste incinerators; the levels of PeCDD found in the emissions from 
municipal waste incinerators were three orders of magnitude higher than from hazardous waste 
incinerators (Oppelt 1991). Fly ash from a municipal incinerator and from coal-fired power plants was 
analyzed to study the CDD congener distributions typical of combustion samples (Czuczwa and Hites 
1984). OCDD was the most abundant CDD in all fly ash samples.  Coal fly ash samples differed 
significantly from municipal incinerator fly ash samples.  Although some CDDs were detected in coal fly 
ash, no TCDDs or PeCDDs were detected. CDDs were present in much lower concentrations in fly ash 
from coal-fired power plants than in fly ash from a municipal incinerator.  The levels of OCDD in the coal 
fly ash samples (2.2 ppb and 3.8 ppb) were at least 100 times lower than those found in the municipal 
incinerator fly ash (400 ppb).  No isomers of TCDD were detected in municipal incinerator fly ash samples 
with a detection limit of 100 ppt (Czuczwa and Hites 1984). 
CDDs have been detected in chimney soot samples from various home heating systems using unleaded 
heating oil, coal, and wood in Germany (Thoma 1988).  A Canadian study of wood-burning stoves 
detected only OCDD in particulates from the stack emissions (Wang et al. 1983).  Open-air burning of 
PCP-treated wood produced levels of CDDs ranging from 2 ppb (TCDD) to 187 ppb (OCDD) (Chiu et al. 
1983). Combustion of untreated wood also produces CDDs (TCDD, PeCDD, HxCDD, HpCDD, OCDD) 
(Clement et al. 1985).  Samples of bottom ash and chimney ash from 2 wood-burning stoves, 1 open 
fireplace, and outdoor open-air burning had detectable levels of CDDs ranging from 0.3 to 33 ppb.  For 
each homologous class, the total concentrations ranged from not detectable to 11 ppb.  Detection limits 
were equal to 10 ppt for TCDD and PeCDD and 50 ppt for HxCDD, HpCDD, and OCDD.  The open-air 
burning ash produced the highest total CDD concentration of 33 ppb, with HpCDD (11 ppb) and OCDD 
(10 ppb) being the most abundant (Clement et al. 1985). 
Fires involving capacitors or transformers containing chlorobenzene and PCBs are also sources of CDDs 
and CDFs. For example, in the transformer fire in the New York State Office Building in Binghamton, 
NY, TCDD, PeCDD, HxCDD, HpCDD, and OCDD were found in soot samples at levels ranging from 
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<2 ppm (PeCDD) to 7 ppm (HpCDD) (Tiernan et al. 1985).  CDFs were more abundant and were detected 
at higher concentrations ranging from 28 to 1,920 ppm in soot. 
Recently, Wikstrom et al. (1996) studied formation of CDDs, CDFs, and chlorobenzenes in the 
combustion process.  These authors monitored combustion of an artificial fuel where the chlorine level and 
source were varied in the artificial waste. Different levels of organic chlorine (PVC) and inorganic 
chlorine (CaCl2@6H20) were added to the fuel. When the level of chlorine in the fuel was <1%, there was 
no correlation between the quantities of CDDs, CDFs, and chlorobenzenes present.  However, when the 
chlorine level was >1%, increased formation rates were noted for CDDs, CDFs, and chlorobenzenes. 
Production and Use of Contaminated Chemicals and Certain Herbicides. CDDs are known 
trace contaminants of certain chlorinated industrial chemicals like chlorophenols (Buser 1987).  CDDs can 
inadvertently form as by-products during the manufacture of chlorophenols.  Since the 1930s, PCP and the 
tri- and tetrachlorophenols have gained recognition as fungicides, herbicides, insecticides, and precursors 
in the synthesis of other pesticides.  
PCP was developed primarily for use as a wood preservative but has also been used as an herbicide on 
pineapple and sugarcane plantations. It has also been employed as a molluscicide against schistosomiasis, 
a severe human parasitic disease prevalent in much of tropical Asia, Africa, and South America (Hutzinger 
et al. 1985). The major contaminant of commercial PCP is OCDD, which may be present at concentrations 
between 500 and 1,500 mg/kg (ppm) (Dobbs and Grant 1979; Miller et al. 1989a).  PCP may also contain 
mixed isomers of HxCDD and HpCDD (Pereira et al. 1985).  It is currently registered as a restricted-use 
pesticide for use as a wood preservative (Sine 1990). 
2,3,7,8-TCDD forms during the manufacture of 2,4,5-TCP.  2,4,5-TCP has been used in cooling towers 
and in paper, pulp, and leather processing (Hutzinger et al. 1985).  2,4,5-TCP was used to produce the 
bactericide hexachlorophene and phenoxy-herbicides like 2,4,5-trichlorophenoxy acids (2,4,5-T).  2,4,5-T, 
in turn, was used in the production of a wide variety of herbicides including Silvex (2-[2,4,5-trichloro­
phenoxy]propionic acid) and Agent Orange (Hutzinger et al. 1985).  Hexachlorophene, which is currently 
under EPA suspension, is reported to contain <15 µg/kg (ppb) 2,3,7,8-TCDD (IARC 1977; Sine 1990). 
2,3,7,8-TCDD is an unwanted by-product formed during the production of hexachlorophene (Freeman et 
al. 1986). The 2,3,7,8-TCDD produced is primarily contained in still-bottom waste (waste oils) remaining 
after hexachlorophene is purified (Freeman et al. 1986).  Still-bottom waste and other oils were used in the 
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early 1970s for dust control on roads, parking lots, horse arenas, and other sites around Missouri (Freeman 
et al. 1986). The herbicide 2,4,5-T produced commercially prior to 1965 contained up to 30 mg/kg (ppm) 
or more 2,3,7,8-TCDD (IARC 1977).  The level of 2,3,7,8-TCDD in commercial 2,4,5-T was reduced to 
<0.05 mg/kg (ppm), and most of the commercial 2,4,5-T available before its registration was discontinued 
in the United States in 1983 contained <0.02 mg/kg (ppm) 2,3,7,8-TCDD (IARC 1977; Sine 1990). 
Chlorophenoxy herbicides, such as 2,4-D, are typically formulated as esters or amine salt derivatives 
(IARC 1986b). Of 16 samples of 2,4-D formulations from Canada analyzed for CDDs in the early 1980s, 
8 of 9 ester formulations and 4 of 7 amine salt formulations were contaminated (IARC 1986b).  The 2,4-D 
ester formulations contained 0.2–1.8 mg/kg (ppm) 1,3,6,8-TCDD (the only TCDD isomer detected), while 
the 2,4-D amine salt formulations contained 0.02–0.3 mg/kg (ppm) 1,3,6,8-TCDD (IARC 1986b).  It 
should be noted that 1,3,6,8-TCDD is not one of the toxic CDDs with respect to mammals; however, 
2,3,7,8-substituted CDDs/CDFs have been reported in 2,4-D from Russia (Schecter et al. 1993). 
Agricultural and wartime uses of trichlorophenol-based herbicides such as 2,4,5-T and Silvex also have 
resulted in release of 2,3,7,8-TCDD at low concentrations in many countries (EPA 1987k).  2,4,5-T was 
used in aerial spraying operations for weed control on crops, along fence rows, ditch banks, farm road­
ways, pastures, and rangeland (Bovey 1980).  Non-farm uses of 2,4,5-T included tree and bush control on 
rights-of-way, roadways, fire lanes, and railroads (Bovey 1980).  Agent Orange, used as a defoliant in the 
Vietnam War from 1962 to 1970, was contaminated with an average of 2 ppm of 2,3,7,8-TCDD (Czuczwa 
and Hites 1986a, 1986b; Wolfe et al. 1985). An estimated 10–11 million gallons were applied in South 
Vietnam (EPA 1987k; Wolfe et al. 1985).  This volume of Agent Orange contained an estimated 
368 pounds of 2,3,7,8-TCDD (Wolfe et al. 1985). Agent Orange is an equal parts mixture of the butyl 
esters of 2,4,5,-T and 2,4-dichlorophenoxyacetic acid (2,4-D) (Josephson 1983).  These herbicides were 
used extensively in silviculture for control of deciduous trees in conifer forests before their use was 
discontinued (EPA 1987k). The use of Silvex, a herbicide closely related to 2,4,5-T, was discontinued in 
the United States in 1984 (Sine 1990). 
Industrial accidents have also released high levels of CDDs into the air.  In 1976, at least 1.3 kg 
(2.87 pounds) of 2,3,7,8-TCDD was released into the air as a result of an industrial accident at the 
ICMESA chemical plant near Seveso, Italy, that was involved in 2,4,5-TCP synthesis (Cerlisi et al. 1989; 
Mocarelli et al. 1991). The 2,3,7,8-TCDD release contaminated a populated area of about 2.8 km2 
(1.08 mi2) (Mocarelli et al. 1991). 
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2,3,7,8-TCDD has been detected in air samples collected at 9 of the 91 NPL hazardous waste sites where it 
has been detected in some environmental media (HazDat 1998).  Total CDDs have been detected in air 
samples collected at 10 of the 126 NPL sites where they have been detected in some environmental media. 
Total TCDDs, PeCDDs, HxCDDs, HpCDDs, and OCDD have been detected in air samples at 10, 3, 3, 3, 
and 1 sites of the 105, 34, 43, 49, and 53 sites, respectively, where they have been detected in some 
environmental media (see Table 5-1). 
5.2.2 Water 
CDDs can enter water by a number of different mechanisms including urban runoff, combined sewer 
overflows (CSOs), and direct discharge by industrial facilities and publicly-owned treatment works 
(POTWs); deposition of particulates from combustion sources, runoff and drift from the use of 
chlorophenol-based pesticides; and leaching from chlorophenol-containing waste sites (Huntley et al. 
1997; Muir et al. 1986a; Periera et al. 1985; Shear et al. 1996). Direct application or drift of 2,4,5-T or 
Silvex into water has also resulted in release of TCDD to surface water (Norris 1981); however, the 
contribution of CDDs from pesticide drift is now negligible since most CDD-containing pesticides have 
been banned. The migration of chemical wastes containing CDDs from disposal sites has resulted in 
contamination of surface water and groundwater (HazDat 1998). 
CDDs/CDFs, specifically 2,3,7,8-TCDD and 2,3,7,8-TCDF, are also present in effluent and sludges from 
pulp and paper mills that employ the bleached kraft process (Clement et al. 1989; EPA 1991b; Swanson et 
al. 1988). 2,3,7,8-TCDD was detected in 7 of 9 bleached pulps at concentrations ranging from not 
detected (<1 ppt) to 51 ppt (median 4.9 ppt; mean 13 ppt) (Amendola et al. 1989).  It was also detected in 
waste waters from 4 of 5 paper mills at levels ranging from not detected (<0.006 ppt) to 3.6 ppt (Amendola 
et al. 1989). 
During 1988, the EPA and the U.S. pulp and paper industry jointly conducted a survey of 104 pulp and 
paper mills in the United States to measure concentrations of CDDs in effluent, sludge, and paper (EPA 
1990d). This study is commonly called the 104-Mill Study and includes all U.S. mills where wood pulps 
are bleached with chlorine or chlorine derivatives. Higher chlorinated CDDs/CDFs are typically found in 
effluent when chlorine dioxide is used, but not when elemental chlorine is used. In 1992, the pulp and 
paper industry conducted its own survey (NCASI 1993).  As part of an effort to develop revised effluent 
guidelines and standards for the pulp and paper industry, the EPA recently published the development 
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document for the guidelines and standards being proposed for this industry (EPA 1993a).  This 
development document presents estimates of annual discharges of two congeners, 2,3,7,8-TCDD and 
2,3,7,8-TCDF in effluents (from wastewater treatment systems) from this industry as of January 1993. 
The joint EPA/paper industry study of 104 pulp and paper mills provides an estimate of the release of 
2,3,7,8-TCDD and 2,3,7,8-TCDF in bleached pulp, waste water sludge, and waste water effluent from the 
U.S. pulp and paper industry as of mid-to-late 1988 (EPA 1990d).  This was a time in the industry’s 
history when only limited use of pulping and bleaching technologies and operating practices that 
demonstrated potential to reduce the formation of TCDDs and TCDFs had been implemented.  In this 
study 2,3,7,8-TCDD was detected at 90 and 56% of the kraft and sulfite mills, respectively, that were 
surveyed, and no mill was found to be free of 2,3,7,8-TCDD/TCDF.  For bleached pulp, the mean 
2,3,7,8-TCDD concentration was 7.5 ppt (maximum 56 ppt) for kraft hardwoods, 12 ppt (maximum 
116 ppt) for kraft softwoods, 7.1 ppt (maximum 15 ppt) for sulfite hardwoods, and 3.5 ppt (maximum 
3.5 ppt) for sulfite softwoods. Mean waste water effluent concentrations of 2,3,7,8-TCDD were 0.076 ppt 
for kraft mills (maximum 0.64 ppt) and 0.013 ppt (maximum 0.023 ppt) for sulfite mills.  Waste water 
sludges contained mean 2,3,7,8-TCDD concentrations of 101 ppt for kraft mills (maximum 1,390 ppt) and 
13 ppt (maximum 58 ppt) for sulfite mills.  Furthermore, for all kraft mills, about 38% of the 
2,3,7,8-TCDD was partitioned to pulps, 33% to waste water sludges, and 29% to waste water effluents. 
The NCASI (1993) report found that <10% of pulp and paper mills had 2,3,7,8-TCDD and 2,3,7,8-TCDF 
concentrations in effluent above the detection limits of 10 ppq and 100 ppq, respectively; however, none of 
the more highly congener groups were measured.  Similar results were obtained in the short- and long-term 
sampling reported for 18 mills (EPA 1993a).  2,3,7,8-TCDD and 2,3,7,8-TCDF were detected at four and 
nine mills, respectively.  Waste water sludges at 75–90% of all mills contained <10 ppt of 2,3,7,8-TCDD 
and <100 ppt of 2,3,7,8-TCDF (NCASI 1993). Similar results were reported in the EPA (1993a) report 
except that 2,3,7,8-TCDD and 2,3,7,8-TCDF were found in sludges in 64 and 85%, respectively, of the 
mills sampled.  NCASI (1993) reported that almost 90% of bleached pulps contained <2 ppt of 
2,3,7,8-TCDD and <20 ppt of 2,3,7,8-TCDF. For bleached pulps, the mean 2,3,7,8-TCDD concentration 
was 0.9 ppt (maximum 10 ppt) and the mean 2,3,7,8-TCDF concentration was 6 ppt (maximum 323 ppt). 
The mean waste water effluent concentration of 2,3,7,8-TCDD was 0.006 ppt (maximum 0.08 ppt) and 
0.031 ppt (maximum 0.510 ppt) for 2,3,7,8-TCDF.  Waste water sludges contained a mean 2,3,7,8-TCDD 
concentration of 11 ppt (maximum 133 ppt) and 11 ppt (maximum 735 ppt) for 2,3,7,8-TCDF.  In this 
study, mean pulp, waste water effluents, and waste water sludge concentrations of 2,3,7,8-TCDD all 
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declined by a factor of about 10 from those cited in the 104 Mill Study (EPA 1990d).  Overall, NCASI 
(1993) reports a 90% reduction in TEQs generated by pulp and paper mills from 1988 to 1992 for all 
2,3,7,8-TCDDs and 2,3,7,8-TCDFs. 
2,3,7,8-TCDD has been detected in surface water and groundwater samples collected at 9 and 15 sites of 
the 91 NPL hazardous waste sites where it has been detected in some environmental media (HazDat 1998). 
Total CDDs have been detected in surface and groundwater samples collected at 14 and 32 of the 126 NPL 
sites where they have been detected in some environmental media.  Total TCDDs, PeCDDs, HxCDDs, 
HpCDDs, and OCDD have been detected in surface water samples collected at 10, 1, 4, 4, and 6 sites and 
in groundwater samples collected at 21, 3, 10, 14, and 16 of  the 105, 34, 43, 49, and 53 NPL sites, 
respectively, where these homologues have been detected in some environmental media (see Table 5-1). 
5.2.3 Soil 
Historically, CDDs have been deposited onto soil through pesticide applications and disposal of CDD-
contaminated industrial wastes, and via land application of paper mill sludges (EPA 1991b).  Currently, 
however, atmospheric fall-out of CDD-laden particulates and gases appears to be the predominant source 
of CDDs to soil (Hutzinger et al. 1985). 
The commercial production of trichlorophenol, as well as various derivative products such as 2,4,5-T and 
other biocides, has yielded large quantities of waste products containing substantial concentrations of 
CDDs. Extensive contamination of the environment with 2,3,7,8-TCDD occurred in Missouri in the early 
1970s as a result of the spraying of horse arenas, roads, and parking lots with mixtures of used oil and 
chemical waste (Tiernan et al. 1985).  The chemical waste, formed during the manufacture of 2,4,5-TCP 
and then used to make hexachlorophene, contained several hundred ppm of 2,3,7,8-TCDD (Tiernan et al. 
1985). Several thousand gallons of this waste were dispersed over a sizable area of southwestern and 
eastern Missouri during the 1970s. Concentrations of 2,3,7,8-TCDD in soil samples from selected 
contaminated sites throughout Missouri ranged from 30 to 1,750 ppb (Tiernan et al. 1985).  Concentrations 
of 2,3,7,8-TCDD in soil samples from Times Beach, Missouri, which had been heavily contaminated, 
ranged from 4.4 to 317 ppb (Tiernan et al. 1985). 
In Seveso, Italy, an explosion occurred during the production of 2,4,5-T and a cloud of toxic material 
including 2,3,7,8-TCDD was released (Cerlisi et al. 1989; MMWR 1988; Mocarelli et al. 1991). Debris 
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from the cloud covered an area of approximately 700 acres (2.8 km2). The total amount of 2,3,7,8-TCDD 
released during the accident was estimated to be 1.3 kg.  Soil samples from this industrial accident were 
measured in three areas: Zone A, the most contaminated zone where residents were evacuated; Zone B, the 
moderately contaminated area where residents were advised not to eat locally raised produce; and Zone R, 
where 2,3,7,8-TCDD contamination in soil was lowest of the three areas.  Mean soil concentrations in 
these 3 areas were: 230 µg/m2 (maximum 5,477 µg/m2) in Zone A, 3 µg/m2 (maximum 43.9 µg/m2) in 
Zone B, and 0.9 µg/m2 (maximum 9.7 µg/m2) in Zone R (MMWR 1988). 
The migration of chemical waste containing CDDs from disposal sites has also resulted in environmental 
contamination of sediment.  For example, at Love Canal in Niagara Falls, New York, where an estimated 
200 tons of 2,4,5-TCP production waste were disposed of during the 1940s and early 1950s, 
2,3,7,8-TCDD was detected at high concentrations (up to several hundred ppb) in storm sewer sediments 
(Smith et al. 1983; Tiernan et al. 1985). 
2,3,7,8-TCDD has been detected in soil and sediment samples collected at 61 and 17 sites of the 91 NPL 
hazardous waste sites where it has been detected in some environmental media (HazDat 1998).  Total 
CDDs have been detected in soil and sediment samples collected at 94 and 31 of the 126 NPL sites where 
they have been detected in some environmental media.  Total TCDDs, PeCDDs, HxCDDs, HpCDDs, and 
OCDD have been detected in soil samples at 71, 21, 29, 34, and 38 sites and in sediment samples at 22, 7, 
10, 9, and 13 sites of the 105, 34, 43, 49, and 53 NPL sites, respectively, where these homologues have 
been detected in some environmental media (see Table 5-1). 
5.3 ENVIRONMENTAL FATE 
Combustion generated CDDs may be transported long distances (as vapors or associated with particulates) 
in the atmosphere (Czuczwa and Hites 1986a, 1986b; Tysklind et al. 1993).  They may eventually be 
deposited on soils, surface waters, or plant vegetation as a result of dry or wet deposition.  CDDs 
(primarily MCDD, DCDD, TrCDD) will slowly volatilize from the water column, while the more highly 
chlorinated CDDs will adsorb to suspended particulate material in the water column and be transported to 
the sediment (Fletcher and McKay 1993; Muir et al. 1992).  CDDs deposited on soils will strongly adsorb 
to organic matter.  CDDs are unlikely to leach to underlying groundwater but may enter the atmosphere on 
soil dust particles or enter surface waters on soil particles in surface runoff.  Low water solubilities and 
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binding to suspended organic matter the actual uptake by such organisms may be less than predicted.  This 
is also true of uptake and bioconcentration by plants, although foliar deposition and adherence may be 
significant. 
5.3.1 Transport and Partitioning 
Combustion processes appear to have contributed to the ubiquity of CDDs in the environment (Hites and 
Harless 1991; Tysklind et al. 1993).  CDDs have relatively long residence times in the atmosphere, and 
combustion-generated CDDs associated with particulates can become distributed over large areas 
(Tysklind et al. 1993).  During transport in the atmosphere, CDDs are partitioned between the vapor phase 
and particle-bound phase (Hites and Harless 1991). However, because of the very low vapor pressure of 
CDDs, the amount present in the vapor phase generally is negligible as compared to the amount adsorbed 
to particulates (Paustenbach et al. 1991). The two environmental factors controlling the phase in which the 
congener is found are the vapor pressure and the atmospheric temperature (Hites and Harless 1991). 
Congeners with vapor pressure <10-8 mm Hg will be primarily associated with particulate matter while 
congeners with a vapor pressure >10-4 mm Hg will exist primarily in the vapor phase.  Those chemicals 
with vapor pressures between these values can be found in both the vapor phase and associated with 
particulates (Eisenreich et al. 1981). With a reported vapor pressure ranging from 7.4x10-10 to 
3.4x10-5 mm Hg, 2,3,7,8-TCDD falls into the intermediate category.
The detection of CDDs in sediments from Siskiwit Lake, Isle Royale, suggests that CDDs can be 
transported great distances in air (Czuczwa and Hites 1986a, 1986b).  Because this lake is landlocked on a 
wilderness island in Lake Superior, the only way that CDDs could reach these sediments is by atmospheric 
fall-out (i.e., by wet and dry deposition).  Similar amounts of CDDs were also found in Lake Huron and 
Lake Michigan sediments, which indicates that atmospheric transport is a source of CDDs found on these 
Great Lake sites (Czuczwa and Hites 1986a, 1986b; Hutzinger et al. 1985).  Atmospheric deposition of 
TCDD to Lake Erie may contribute up to 2% of the annual input of TCDD to the lake (Kelly et al. 1991). 
Through pattern analysis of herring gull monitoring data, Hebert et al. (1994) provided evidence that the 
sources of CDDs in Great Lakes food chains were mainly atmospheric, with the exception of 
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CDDs are physically removed from the atmosphere via wet deposition (scavenging by precipitation), 
particle dry deposition (gravitational settling of particles), and gas-phase dry deposition (sorption of CDDs 
in the vapor phase onto plant surfaces) (Rippen and Wesp 1993; Welschpausch et al. 1995).  Precipitation 
(rain, sleet, snow) is very effective in removing particle-bound CDDs from the atmosphere (Hites and 
Harless 1991; Koester and Hites 1992). Table 5-2 summarizes the average ppt scavenging ratios and 
percentage of washout due to particulates for congener groups of both CDDs and CDFs collected at two 
sites in Indiana. The scavenging ratio is the ratio of the concentration of the congener group in rain to the 
atmospheric concentration of the congener group and is a measure of the effectiveness of rain in removing 
the congener groups from the atmosphere.  Table 5-2 also summarizes the percentages of the congener 
groups scavenged as particles in rain rather than as dissolved solutes in rain.  Total rain scavenging ratios 
ranged from 10,000 to 150,000; HpCDDs and OCDD (the congeners most strongly associated with 
particulates) were the congeners scavenged most efficiently (Hites and Harless 1991; Koester and Hites 
1992). 
Environmental fate modeling of CDDs requires knowledge of a number of fundamental physical and 
chemical parameters, such as water solubility, vapor pressure, Henry's law constant, octanol-water 
partition coefficient (Kow), and organic carbon partition coefficient (Koc). CDDs are a class of high 
molecular weight, highly hydrophobic compounds.  Although the class contains 8 homologues (congener 
groups) and 75 congeners, solubility values are available for only a handful of these congeners (Doucette 
and Andren 1988). CDDs have very low water solubilities, with solubility decreasing with increasing 
chlorine substitutions (Doucette and Andren 1988).  The water solubility of 2,3,7,8-TCDD ranges from 
7.9x10-6 to 33.2x10-4 mg/L (Shiu et al. 1988).  See Table 3-2 for the water solubilities for specific 
congeners. Water solubilities at 25 EC for the congener groups have been estimated as follows:  MCDD, 
0.278–0.417 mg/L; DCDD, 3.75x10-3–1.67x10-2 mg/L; TrCDD, 4.75x10-3–8.41x10-3; TCDD, 7.9x10-6 to 
6.3x10-4 mg/L; PeCDD, 1.18x10-4 mg/L; HxCDD, 4.42x10-6 mg/L; HpCDD, 2.4x10-6–1.9x10-3 mg/L; and 
OCDD, 0.1x10-9–7.4x10-8 mg/L (ASTER 1995; Doucette and Andren 1988; HSDB 1997; McCrady and 
Maggard 1993; Shiu et al. 1988). 
CDDs generally exhibit very low vapor pressures, with the tendency of decreasing vapor pressure with 
increasing chlorine substitution (Friesen et al. 1985; Rordorf 1986, 1989). At 25 EC, the vapor pressure of 
2,3,7,8-TCDD ranges from 7.4x10-10 to 3.4x10-5 mm Hg (HSDB 1997; Rordorf 1989).  See Table 3-2 for 
the vapor pressures of specific congener groups. Vapor pressures at 25 EC for the other congener groups 
have been estimated as follows: MCDD, 9.0x10-5–1.3x10-4 mm Hg; DCDD, 9.0x10-7–2.9x10-6 mm Hg;
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6.46x10-8–7.5x10-7; TCDD, 7.4x10-10–4.0x10-3 mm Hg; PeCDD, 6.6x10-10 mm Hg; HxCDD, 3.8x10-11 mm 
Hg; HpCDD, 5.6x10-12–7.4x10-8 mm Hg; and OCDD, 8.25x10-13–1.68x10-12 mm Hg (HSDB 1997; 
McCrady and Maggard 1993; Rordorf 1989; Shiu et al. 1988).  CDDs can be found in both the vapor and 
particle-bound phases (Eitzer and Hites 1989a; Hites and Harless 1991), with the low vapor pressure of 
OCDD resulting in its enrichment in the particulate phase in the atmosphere.  When this particulate matter 
is deposited on water, OCDD-enriched sediments will result (Eitzer 1993).  The less chlorinated CDD 
congeners (TCDD and PeCDD) occur in greater proportion in the vapor and dissolved phases of air and 
rain, whereas the more chlorinated congeners (HpCDD and OCDD) are associated with the particulate-
bound phases (EPA 1991d). Data from one study of CDDs in the ambient atmosphere of Bloomington, 
IN, found that vapor-to-particle ratios for individual CDDs ranged from 0.01 to 30 and were dependent on 
the ambient temperature and the compound's vapor pressure (Eitzer and Hites 1989b).  Since the less-
chlorinated CDDs have higher vapor pressures, they are found to a greater extent in the vapor phase (Eitzer 
and Hites 1989a). As air moves, photodegradation of the vapor-phase CDDs occurs and they are lost more 
readily than the particulate-bound CDDs.  Vapor-phase CDDs are not likely to be removed from the 
atmosphere by wet or dry deposition (Atkinson 1991), although this is a primary removal process for 
particulate-bound CDDs. Wet or dry deposition could result in greater concentrations of the more 
chlorinated CDDs reaching soil or water surfaces and eventually sediment (EPA 1991d).  All CDDs are 
found to some extent in both the vapor phase and bound to particulates.  At warmer temperatures (28 EC), 
CDDs, particularly the MCDDs, DCDDs, TrCDDs, and TCDDs will have a greater tendency to exist in the 
vapor phase. At cooler temperatures (16–20 EC and <3 EC), all CDDs will have less propensity to exist in 
the vapor phase and greater propensity to adsorb to particulates (Shroy et al. 1985).  At a constant 
temperature, there is a positive relationship between increasing numbers of chlorine atoms on the molecule 
and decreased propensity to exist in the vapor phase relative to particulate adsorption (Eitzer and Hites 
1989b; Paustenbach et al. 1991; Shroy et al. 1985).  
CDDs are removed from the water column to a minor extent by volatilization to the atmosphere, with 
binding to particulates and sediment, or bioaccumulation by aquatic biota being more significant processes 
(Fletcher and McKay 1993; Muir et al. 1992; Paustenbach et al. 1992).  CDDs have Henry's law constants 
ranging from 1.31×10-6 to 146×10-6 atm-m3/mol (Shiu et al. 1988).  These values indicate that volatil­
ization from water is likely to be a slow, with the transfer rate controlled by the gas-phase resistance (i.e., 
the rate is controlled by slow diffusion through the air) (Lyman et al. 1982; Shiu et al. 1988).  The more 
chlorinated homologous classes (TCDD, PeCDD, HxCDD, HpCDD, OCDD) have lower Henry's law 
constant values than the less chlorinated homologous classes (MCDD, DCDD, TrCDD).  Thus, 
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volatilization from the water column is not expected to be a very significant loss process for the TCDD 
through OCDD congeners as compared to adsorption to particulates.  In general, the Henry's law constants 
decrease with increasing chlorine number as a result of the decrease in vapor pressure and water solubility 
(Shiu et al. 1988). Volatilization half-lives for 2,3,7,8-TCDD were calculated for ponds and lakes 
(32 days) and for rivers (16 days) (Podoll et al. 1986).  The primary removal mechanism for CDDs from 
the water column is sedimentation, with 70–80% of the CDDs being associated with the particulate phase 
(Muir et al. 1992). The remainder was associated with dissolved organic substances.  CDDs bound to 
sediment particles may be resuspended in the water column if the sediments are disturbed.  This could 
increase both the transport and availability of the CDDs for uptake by aquatic biota (Fletcher and McKay 
1993). 
Generally, CDDs are characterized by low vapor pressure, low aqueous solubility, and high hydro­
phobicity, suggesting that these compounds strongly adsorb to soil and that their vertical mobility in the 
terrestrial environment is low (Eduljee 1987b).  In general, higher chlorinated CDDs also volatilize more 
slowly from soil and water surfaces than do lower chlorinated ones (Hutzinger et al. 1985).  Nash and 
Beall (1980) reported that only 12% of 2,3,7,8-TCDD applied to bluegrass turf as a component of 
emulsifiable Silvex volatilized over a 9-month period.  Because CDDs (particularly the more highly 
chlorinated PCDD, HxCDD, HpCDD, and OCDD) strongly adhere to soil and exhibit low solubility in 
water, leaching of CDDs would be unlikely if water were the only transporting medium.  Instead, wind and 
erosion can cause the mixing and transport of CDD-contaminated soil.  As a result of erosion, surface soil 
contaminated with CDDs is either blown away by wind or washed via surface water runoff into rivers, 
lakes, and streams, with burial in the sediments being the predominant fate of CDDs sorbed to soil 
(Hutzinger et al. 1985). 
Adsorption is an important process affecting transport of hydrophobic compounds such as CDDs.  The 
organic carbon fraction of the soil is believed to be the most important factor governing the degree of 
adsorption of hydrophobic organic contaminants.  CDDs adsorb more strongly to soils with a higher organic 
carbon content than to soils with low organic carbon content (Yousefi and Walters 1987).  Because of their 
very low water solubilities and vapor pressures, CDDs found below the surface soil (top few mm) are 
strongly adsorbed and show little vertical migration, particularly in soil with high organic carbon content 
(Yanders et al. 1989). Vertical movement of CDDs in soil may result from the saturation of sorption sites 
of the soil matrix, migration of organic solvents, or human or animal activity (Hutzinger et al. 1985). 
Adsorption/desorption of 2,3,7,8-TCDD in contaminated soils was studied by Des Rosiers (1986).  Soil 
samples were taken from an abandoned 2,4,5-T manufacturing facility and a scrap metal yard in New 
CDDs 406 
5. POTENTIAL FOR HUMAN EXPOSURE 
Jersey and from horse arenas, roadways, and residential property in Missouri.  Historically, these samples 
were contaminated with either chemical residues or waste oils containing 2,3,7,8-TCDD.  Mean log organic 
carbon partition coefficient (Koc) values ranged from 7.39 to 7.58 (Des Rosiers 1986).  This Koc range 
indicates that 2,3,7,8-TCDD is immobile in soil (Swann et al. 1983).  However, the mobility of 
2,3,7,8-TCDD in soil will increase if organic co-solvents that can solubilize 2,3,7,8-TCDD are present in 
the soil (Podoll et al. 1986). This situation might occur at a hazardous waste site.  In one study, only 1.5% 
of the CDDs applied to soil surfaces had leached to a depth of 2.5 cm below the soil surface after 
15 months.  Leaching of the CDDs through the soil was primarily associated with carriers such as petroleum 
oil (Orazio et al. 1992). 
Most CDDs entering surface waters are associated with particulate matter (dry deposition of atmospheric 
particles) and eroded soil particulates contaminated with CDDs (Hallett and Brooksbank 1986).  In the 
aquatic environment, significant partitioning of CDDs from the water column to sediment and suspended 
particulate organic matter may occur.  Dissolved CDDs will partition to suspended solids and dissolved 
organic matter (detritus, humic substances) and are likely to remain sorbed once in the aquatic environment. 
From suspended sediment and water data collected from the Niagara River on the New York-Canada 
border, it was found that CDDs were strongly associated with suspended sediment (Hallett and Brooksbank 
1986). Concentrations of total TCDDs, PeCDDs, HxCDDs, HpCDDs, and OCDD in raw water ranged 
from below detection limits to 3.6 pg/L (3.6 ppq), while the concentration of these same homologue groups 
in suspended sediments ranged from below detected limits to 228 pg/g (ppt) (Hallett and Brooksbank 1986). 
The more highly chlorinated congeners (HxCDD, HpCDD, and OCDD) predominated in both water and 
suspended sediment samples.  
A model has been developed to describe the vertical transport of low-volatility organic chemicals in soil 
(Freeman and Schroy 1986).  The model was used to make predictions on the transport of 2,3,7,8-TCDD at 
the Eglin Air Force Base Agent Orange biodegradation test plots (Freeman and Schroy 1986).  Trenches 
10 cm deep were dug in the soil, and Agent Orange containing 40 ppb of 2,3,7,8-TCDD was applied to the 
trench bottom.  The model predicted a vertical movement of 2,3,7,8-TCDD, buried in 1972, through the soil 
column.  Soil-column-profile data confirm the vertical movement of 2,3,7,8-TCDD from core samples taken 
in 1984 (Freeman and Schroy 1986).  The 2,3,7,8-TCDD in the Eglin Air Force Base biodegradation plots 
moved through the entire 10 cm of the soil column in 12 years (Freeman and Schroy 1986).  The rates of 
migration and loss of 2,3,7,8-TCDD in contaminated soil were studied under natural conditions in 
experimental plots at the Dioxin Research Facility, Times Beach, Missouri (Yanders et al. 1989).  The 
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TCDD concentration profiles of sample cores taken at Times Beach in 1988 (mean range 78–160 ppb) were 
virtually the same as those in cores taken in 1984 (mean range 76–162 ppb).  The results show that little 
movement and essentially no loss due to volatilization of 2,3,7,8-TCDD had occurred in the experimental 
plots in the four years since the Dioxin Research Facility was established (Yanders et al. 1989). 
CDDs are characterized by low water solubilities and high lipophilicities.  Kow values range from 104 to 1012 
for MCDD through OCDD, with Kow values increasing relative to increasing chlorination (Table 3-2). 
Because of these physicochemical properties, CDDs are expected to adsorb to bedded and suspended 
sediments and to bioaccumulate in aquatic organisms. 
The bioconcentration factor (BCF) is the ratio of the concentration of CDDs in an organism over the 
concentration of CDDs in water. The BCF values for CDDs can be estimated from their Kow values, and a 
number of regression equations are available for this purpose (Bysshe 1990).  Experimentally measured 
BCFs for selected CDD congeners in various aquatic species are summarized in Table 5-3. Measurements 
of the bioconcentration of CDDs tend to increase with the degree of chlorination up to TCDDs, and then 
decrease as chlorination continues to increase up to the OCDD congener (Loonen et al. 1993).  The more 
highly chlorinated congeners, such as OCDD, appear to have the lowest bioconcentration potential either 
because they are less bioavailable because of their rapid adsorption to sediment particles (Servos et al. 
1989a, 1989b) or because their large molecule size may interfere with transport across biological 
membranes (Bruggeman et al. 1984; Muir et al. 1986a, 1986b). 
The hydrophobic nature of CDDs, combined with their great affinity for organic carbon, suggests that a 
major proportion of CDDs in the aquatic environment is sorbed to organic matter and sediment.  Because 
only a minute fraction of CDDs are dissolved in the natural environment, bioconcentration is not the 
primary route of exposure for most aquatic organisms.  Whereas the term bioconcentration is defined as the 
uptake of a chemical from water only, the term bioaccumulation refers to the combined uptake of a 
chemical from both dietary sources (e.g., food) and water.  A bioaccumulation factor (BAF) that includes 
the ingestion route of uptake can be calculated based on fish uptake from water, food, and sediment 
(Sherman et al. 1992). 
The primary route of exposure to CDD congeners for lower trophic organisms (e.g., phytoplankton and 
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particles). Certain benthic organisms accumulate highly lipophilic compounds (e.g., PCBs and 
CDDs/CDFs) from water at the water/sediment interface (the concentration of a lipophilic compound is 
generally higher at this interface than in the water column) and via intake of phytoplankton, zooplankton, 
and suspended particulate materials that contain higher concentrations of these chemicals than the 
surrounding water (Porte and Albaiges 1993; Pruell et al. 1993; Secor et al. 1993).  For the higher trophic 
level organisms, such as foraging fish, predaceous fish, and piscivorous wildlife, the predominant route of 
exposure is via food chain transfer, with negligible contributions from CDDs in water and sediment (Muir 
and Yarechewski 1988). Exposure through direct consumption of CDD-contaminated sediment and detritus 
may occur in some bottom-feeding species such as carp and white suckers (Kuehl et al. 1987a, 1987b; 
Servos et al. 1989a, 1989b). Under natural conditions, in which a high proportion of these hydrophobic 
CDD compounds are sorbed to suspended and dissolved organic matter, direct uptake of these CDDs from 
water is not expected to be substantial (Muir et al. 1986a, 1986b).  The estimated BCFs in such cases may 
not be a good indicator of the experimental bioaccumulation measured in the field.  Another reason for the 
difference between estimated BCFs and experimentally measured bioaccumulation values is the ability of 
some aquatic organisms to metabolize and eliminate specific CDD congeners from their bodies and thereby 
change the congener profile pattern in their tissues. 
Preferential bioconcentration and bioaccumulation of 2,3,7,8-TCDD and other 2,3,7,8-substituted CDDs 
by aquatic organisms have been reported (Branson et al. 1985; Kuehl et al. 1985, 1987a, 1987b, 1987c; 
Opperhuizen 1986; Paustenbach et al. 1992). In water-only exposure studies, BCF values for fish exposed 
to 2,3,7,8-TCDD ranged from 37,900 to 128,000 (Cook et al. 1991; Mehrle et al. 1988).  Much lower BCF 
values ranging from 1,400 to 5,840 and 34 to 2,226 have been reported for fish exposed to 1,3,6,8,-TCDD 
and OCDD, respectively (Muir et al. 1986a, 1986b).  These BCF values are approximately two orders of 
magnitude less than would be predicted using the Kow values. Similarly, the lower BCFs for HpCDD in 
fathead minnows and OCDD in rainbow trout fry relative to the other CDDs tested resulted from lower 
uptake efficiencies from water.  Elimination half-lives for TCDDs and PeCDDs were similar and rapid, 
averaging about 2.6 days in trout fry and 3 days in minnows.  Elimination half-lives for HxCDD and 
HpCDD were longer, averaging about 16 days in rainbow trout and 20 days in fathead minnows (Muir et 
al. 1986b). The results of these studies also indicate that BCFs of the higher chlorinated CDDs (HxCDD, 
HpCDD, OCDD) from water are much lower than would be predicted based on their Kow values. Servos et 
al. (1989a, 1989b) also noted that the BCF values were less than predicted based on the Kow values, and 
these authors suggest that BCFs reported in the literature may underestimate the true BCF, unless the BCFs 
were calculated using truly dissolved CDD concentrations in the water column rather than 
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total dissolved concentrations, which would include complexes with large molecules of dissolved organic 
carbon. 
BCF values measured in fish exposed to both water and sediment were much lower than equivalent 
exposures to water only and ranged from 2,500 to 5,800 (Adams et al. 1986; Cook et al. 1991; Tsushimoto 
et al. 1982) (Table 5-3). Loonen et al. (1993) also reported that bioaccumulation of CDDs was reduced in 
the presence of sediment and that the effects of sediment increased with increasing hydrophobicity (degree 
of chlorination) of the congeners. BCFs were reduced by 15–82% for various CDD/CDF congeners, with 
the greatest reduction associated with OCDD. 
The bioavailability of CDDs/CDFs from municipal incinerator fly ash and sediment to freshwater fish has 
been studied in experimental situations.  Like the BCF and BAF values, the biota-sediment-accumulation 
factor (BASF) (ratio of contaminant concentration in the organism normalized to lipid content to the 
concentration in fly ash or sediment, normalized to organic carbon content) generally decreased with an 
increasing degree of chlorination (Kuehl et al. 1985, 1987b, 1987c).  The BASF values for benthic 
(bottom-dwelling) fish (e.g., carp, catfish) are generally higher than for those pelagic (water column) 
species (e.g., bass, trout, sunfish) because of the higher lipid content and increased exposure to 
contaminated sediments for the benthic species (Paustenbach et al. 1992). 
Several authors have studied the disposition and metabolism of CDDs in fish.  Studies on the disposition of 
2,3,7,8-TCDD in rainbow trout and yellow perch indicate that fatty tissues (visceral fat, carcass, skin, and 
pyloric caeca) typically contain the bulk of 2,3,7,8-TCDD (78–90%) with only a small percentage (2–5%) 
associated with the skeletal muscle (Kleeman et al. 1986a, 1986b).  For other congeners, such as 
1,3,6,8-TCDD and OCDD, the greatest proportion of the total body burden is concentrated in the bile, with 
lesser concentrations in liver > caeca > kidney > spleen > skin > muscle (Muir et al. 1986a, 1986b). 
Differences in the distribution among various species may be a function of the exposure pathway (i.e., 
dietary versus water uptake) and differences in metabolic breakdown rates.  For example, both the parent 
compound and metabolites of 2,3,7,8-TCDD and 1,3,6,8-TCDD were present in the bile of fish exposed 
under laboratory conditions (Branson et al. 1985; Muir et al. 1986a, 1986b).  Kleeman et al. (1986b) 
reported the presence of several polar metabolites in the gall bladder of yellow perch exposed to a single 
dose of 14 C- 2,3,7,8-TCDD. One week later, the gall bladder, skin, skeletal muscle, and kidneys were 
removed.  In contrast to liver, muscle, and kidney where the parent compound accounted for 96–99% of the 
extractable 14 C, the gall bladder contained almost entirely 2,3,7,8-TCDD metabolites, at least one of which 
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was a glucuronide conjugate. Although the metabolic breakdown was slow, it is clear that CDDs can be 
transformed by fish to polar metabolites that are subsequently excreted in the bile. 
Freshwater aquatic invertebrates have been shown to bioaccumulate CDDs/CDFs through water, sediment, 
and food pathways  (Isensee 1978; Muir et al. 1983; Yockim et al. 1978).  The range in experimentally 
determined BCF values for freshwater invertebrates is presented in Table 5-3.  As discussed previously, 
exposure to CDDs from sediment and water containing dissolved organic material markedly decreases the 
BCF values, especially for the more highly chlorinated CDDs.  Sediment-dwelling organisms (e.g., 
Chironomous sp. larvae and Hexagenia sp. nymphs), stoneflies, and other predaceous nymphs showed poor 
accumulation of OCDD in comparison to 1,3,6,8-TCDD (Muir et al. 1983).  The lower bioaccumulation of 
OCDD was attributed to greater adsorption of the OCDD onto sediment particles and organic matter, and 
the reduced uptake across biological membranes due to large molecular size.  The potential ingestion of 
sediments during burrowing activities by sediment-dwelling insects was believed to result in greater tissue 
concentrations of CDDs than those observed for predaceous insects.  It is also possible that predaceous 
insects may metabolize 1,3,6,8-TCDD more effectively, leading to a greater rate of elimination.  Sediment-
dwelling organisms are important food sources for fish and other predaceous insects; consequently, if rapid 
elimination of 1,3,6,8-TCDD and low accumulation of OCDD occur in the natural environment, 
bioaccumulation of these congeners in trophically higher-level organisms may not be significant (Muir et al. 
1983). 
Marine invertebrates have also shown an ability to bioaccumulate CDDs/CDFs to varying degrees  in their 
tissues (Brown et al. 1994; Cai et al. 1994; Conacher et al. 1993; Hauge et al. 1994; Rappe et al. 1991), 
although no information on BCF values was found in the literature.  Interestingly, several investigators have 
reported that shellfish species (crustaceans and molluscs) are better indicators of CDD/CDF contaminant 
levels than fish because their tissues contain larger numbers and higher residues of CDD/CDF congeners in 
addition to the 2,3,7,8-TCDD congeners and other 2,3,7,8-substituted congeners that are selectively 
accumulated in fish species (Brown et al. 1994; Conacher et al. 1993; Rappe et al. 1991).  This is in contrast 
to what is observed in fish and fish-eating birds, in which there is selective retention of congeners with the 
2,3,7,8-substitution positions occupied, which may be due to an increased ability to metabolize and 
eliminate non-2,3,7,8-substituted CDD/CDF congeners (Brown et al. 1994; Rappe et al. 1991).  The use of 
shellfish species as target organisms in CDD/CDF-monitoring studies is recommended as these species 
provide a better overall representation of both the magnitude and congener-specific nature of the 
environmental contamination (Petreas et al. 1992).  Conacher et al. (1993) present an example where 
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use of a shellfish species provides a much higher estimate of exposure to CDDs/CDFs as well as to total 
CDD equivalent toxicity (TEQs) than use of a fish species.  This difference in congener bioaccumulation 
profiles between fish and shellfish species is a result of the ability of fish to metabolize CDDs/CDFs.  Both 
the parent congeners and metabolites of 2,3,7,8-TCDD and 1,3,6,8-TCDD were present in the bile of fish 
exposed under laboratory conditions (Branson et al. 1985; Muir et al. 1986a).  Kleeman et al. (1986a, 
1986b) reported the presence of several polar metabolites, including glucuronide conjugates, in various fish 
exposed to 2,3,7,8-TCDD. Despite the slowness of the metabolic breakdown processes, it is clear that 
CDDs can be transformed within fish to polar metabolites that are subsequently excreted with the bile.  It 
does not appear from the results obtained in studies conducted to date that shellfish species have the same 
ability to metabolize and eliminate non-2,3,7,8-substituted CDDs/CDFs (Brown et al. 1994; Cai et al. 
1994). 
It is apparent from the available data regarding the substantial bioaccumulation potential of CDDs/CDFs in 
aquatic organisms  (particularly the 2,3,7,8-substituted congeners) as well as data on the extent of 
contamination of fish and shellfish in various freshwater and marine waterways, that ingestion of 
contaminated fish and shellfish is an important exposure pathway for CDDs/CDFs in humans.  
CDDs have been found to accumulate in both surface and rooted aquatic vegetation, with BCF values 
ranging from 208 to 2,083 (Table 5-3) (Isensee 1978; Tsushimoto et al. 1982; Yockim et al. 1978).  Corbet 
et al. (1983) reported that a rooted plant species (Potemageton pectimatus) and a surface-dwelling 
duckweed (Lemna sp.) accumulated concentrations of 1,3,6,8-TCDD of 280 and 105 ng/g (dry weight), 
respectively, following exposure to water containing 1,000 ng/L (ppt).  The maximum concentrations were 
observed 8 days post-application and represented 6% of the total TCDD applied.  These results are similar 
to those reported by Tsushimoto et al. (1982) in an outdoor pond study, in which a maximum bioaccumu­
lation of 2,3,7,8-TCDD in the pond weeds Elodea nuttali and Ceratophyllon demersum equivalent to a BCF 
of 130 occurred after 5 days of exposure.  In both studies, the tissue concentrations reached equilibrium in 
approximately 20 days and remained constant until the end of the experiment (approximately 58 and 
170 days, respectively).  These experimental data indicate that CDDs can accumulation in aquatic plant 
species through waterborne exposure. 
Like many fish, several species of fish-eating birds have shown the ability for preferential bioaccumulation 
of 2,3,7,8-TCDD and other 2,3,7,8-substituted CDDs and TCDFs.  Jones et al. (1994) monitored TEQ 
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and Huron. Biomagnification factors (BMF, the ratio of the concentration of TCDD-equivalents in bird 
eggs to concentrations in forage fish) were found to range from 11.7 to 56.8 (mean, 31.3).  In another study, 
all of the CDDs and CDFs detected in double-crested cormorant and Caspian tern eggs were 2,3,7,8­
substituted (Yamashita et al. 1992).  Concentrations of 2,3,7,8-TCDD, 1,2,3,7,8-PeCDD, 1,2,3,4,7,8­
HXCDD, 1,2,3,6,7,8-HXCDD, 1,2,3,7,8,9-HXCDD, 1,2,3,4,6,7,8-HpCDD, and OCDD ranged from 5.3 to 
20, 3.2 to 9.4, 10 to 20, 3.6 to 11, and 7.8 to 16 pg TEQ/g, respectively, for double-crested cormorant eggs, 
and 8.2 to 22, 3.3 to 6.4, 8.7 to 17, 2.4 to 6.0, and 9.7 to 21 pg TEQ/g, respectively, for Caspian tern eggs. 
This same pattern was also reported to occur in California peregrine falcons and their eggs (Jarman et al. 
1993). For this species, mean concentrations of 2,3,7,8-TCDD, 1,2,3,7,8-PeCDD, 1,2,3,4,7,8-HxCDD, 
1,2,3,6,7,8-HxCDD, 1,2,3,7,8,9-HxCDD, 1,2,3,4,6,7,8-HpCDD and OCDD in eggs were 5.7, 11, 2, 11, 1.3, 
3.8, and 5.3, respectively.  Fish-eating birds are exposed to CDDs primarily through their diet.  A rapid 
decline in contaminant levels in eggs of fish-eating birds, therefore, reflects a rapid decrease in contaminant 
levels of their prey.  This has been shown to occur in Great blue heron chicks in British Columbia 
(Sanderson et al. 1994) in areas where CDD/CDF levels in pulp and paper mill effluents decreased 
substantially within a few years.  The Great blue heron chicks also showed an increased hepatic microsomal 
ethoxyresorufin O-deethylase (EROD) activity in the areas of highest contamination.  This indicates that the 
induction of cytochrome P-450 1A1 has occurred, and that the Ah-receptor-mediated process, by which 
2,3,7,8-TCDD and related chemicals exert their toxicities, has been activated. 
Ankley et al. (1993) studied the uptake of persistent polychlorinated hydrocarbons by four avian species at 
upper trophic levels of two aquatic food chains.  Concentration of 2,3,7,8-TCDD toxic equivalents (TEQs) 
were evaluated in Forster’s tern and common tern chicks and in tree-swallow and red-winged-blackbird 
nestlings from several areas in the watershed.  Young birds accumulated small concentrations of 
2,3,7,8-TCDD and several other 2,3,7,8-substituted CDDs and CDFs, including 1,2,3,6,7,8-HxCDD, 
2,3,7,8-TCDF, 1,2,3,6,7,8-HxCDF, 1,2,3,4,6,7,8-HpCDF, 1,2,3,7,8-PeCDD, 1,2,3,4,6,7,8-HpCDD, and 
OCDD. The general trend in concentrations of CDDs from the greatest to least was Forster’s tern ­
common tern > tree swallow > red-winged blackbird.  The similarity in concentrations between the two tern 
species is expected given that they are both piscivores and their similar life histories and the close proximity 
of the two colonies. The greater concentrations in the tree swallows than in the red-winged blackbirds were 
somewhat unexpected given the presumed similarity of the diets (both species are insectivores).  The 
authors suspect that the red-winged blackbirds foraged more on relatively uncontaminated upland food 
sources than the tree swallows, which fed primarily on chironomids emerging from the bay.
 
CDDs 415 
5. POTENTIAL FOR HUMAN EXPOSURE 
2,3,7,8-TCDD is generally considered to be bioavailable to terrestrial birds primarily through ingestion of 
TCDD-laden food items and soil particles (Nosek et al. 1992).  These authors, using H3TCDD-administered 
suspensions in various environmental matrices, found that 30% of the dose absorbed from suspensions of 
earthworms, 33% absorbed from soil suspensions, 41% absorbed from suspensions of paper mill sludge 
solids, and 58% absorbed from a suspension of crickets.  These authors also reported that the percentage of 
the cumulative TCDD dose translocated to an individual egg was 1.1% for the first 15 eggs laid and that the 
percentage was not affected by the order in which the eggs were laid.  Assuming an adult female could lay 
30 eggs, 35% of the hen TCDD body burden could be translocated to all eggs laid.  Results of these studies 
suggest that TCDD can be orally bioavailable from earthworms and crickets, important dietary sources for 
this species and other terrestrial species, as well as from nonfood items such as orally ingested soil and 
paper mill sludge solids.  
For terrestrial mammals, the BCF value is the quotient of the concentration of CDD in the tissues divided 
by the concentration in food (Geyer et al. 1986a, 1986b).  BCF values for 2,3,7,8-TCDD were calculated in 
the liver and/or fat of rats, cows, and monkeys (Geyer et al. 1986a; Kociba et al. 1978a).  BCF values 
ranged from 10.9 to 24.5 in liver tissue and from 3.7 to 24.5 in fat tissue of rats fed 2,200, 210, or 22 ng/kg 
of 2,3,7,8-TCDD in their diet for 2 years (Geyer et al. 1986a; Kociba et al. 1978a).  The BCF value 
calculated for this rat study, increased as the concentration in the animals’ food decreased.  In a cattle-
feeding study, 24 ng 2,3,7,8-TCDD in the diet was fed to cows for 28 days after which time the BCF of 
2,3,7,8-TCDD in the liver was 0.7 and in the fat was 3.5.  Using a linear one compartment model, Geyer et 
al. (1986a) calculated that a steady state would be reached in 499 days and that the cattle fatty tissue would 
contain 594 ng/kg. The calculated BCF value for 2,3,7,8-TCDD would then be 24.8 (Geyer et al. 1986a; 
Jensen et al. 1981). This value is in good agreement with the BCF of 24.5 calculated for rats that received 
22 ng TCDD/kg in their diet for years.  This is a much higher BCF than has been reported by Fries and 
Paustenbach (1990). After 4 years of chronic exposure to 25 ng/kg 2,3,7,8-TCDD in their diet, the 
calculated BCF in fatty tissue of monkeys ranged from 24 to 40 (Geyer et al. 1986a).  Using the 
2,3,7,8-TCDD concentration in human adipose tissue (10.7 ppt whole weight) and in food 
(0.052–0.103 ng/kg), the calculated BCF is between 104 and 206 on a whole-weight basis, or between 
115 and 229 on a lipid basis (90% lipid) (Geyer et al. 1986a).  Using a pharmacokinetics model, the 
calculated BCF value is 153 (Geyer et al. 1986a).  The authors further point out that the calculated BCFs for 
2,3,7,8-TCDD in human adipose tissue are of the same order of magnitude as those calculated for PCBs, 
DDT, and hexachlorobenzene which are also persistent compounds with comparable lipophilicity 
(n-octanol/water partition coefficients). Based on this BCF range, 2,3,7,8-TCDD was ranked as having a 
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high bioconcentration potential in human adipose tissue (Geyer et al. 1986b).  The half-life in humans was 
estimated to be approximately 7 years (Pirkle et al. 1989).  
The primary mechanisms by which CDDs enter terrestrial food chains are by atmospheric wet and dry 
deposition of vapor-phase and particulate-bound chemicals (McCrady and Maggard 1993).  Uptake of 
CDDs from soils by vegetables and other plants may occur (Schroll and Scheunert 1993).  Accumulation of 
CDDs on vegetation may involve both of these mechanisms.  Since 2,3,7,8-TCDD is lipophilic, adsorbs 
strongly to soil, and is not very soluble in water, root uptake and translocation to upper plant parts is only a 
minor source of vegetative contamination (Travis and Hattemer-Frey 1987) except perhaps for plant species 
belonging to the Cucurbitaceas (e.g., zucchini and pumpkin).  For zucchini and pumpkin plants, root uptake 
of CDD/CDFs and subsequent translocation to the shoots and into the fruits is a main contamination 
pathway (Hulster et al. 1994).  Hulster and Marschner (1993) reported that CDD levels in foliage were not 
related to CDD levels in soil. The contamination of plant foliage via atmospheric deposition is a more 
important contamination mechanism than root uptake and translocation to plant foliage (McCrady et al. 
1990). Welschpausch et al. (1995) determined that dry deposition was the main pathway of uptake in grass 
of CDDs/CDFs from the atmosphere.  Particles <2.9 µm in diameter were not important in atmospheric 
deposition, but large particles may contribute to HpCDD and OCDD accumulation.  McCrady et al. (1990) 
conducted experiments with plants growing in nutrient solutions containing TCDD in a closed-laboratory 
system.  These authors demonstrated that translocation from roots to shoots did not occur, but shoot 
contamination was associated with foliar uptake from the air.  In general, there is little bioaccumulation of 
CDDs in plants (Hutzinger et al. 1985). BCFs for TCDD in plants have been estimated to be 0.0002, 
although most absorption occurs in the plant root with little or no translocation through the plant to the 
foliage (Wild and Jones 1992). A concentration of 0.06 ppm 2,3,7,8-TCDD was applied to the soil and root 
uptake from soil was then measured in oats and soybeans (Kearney et al. 1971).  Oat and soybean plants (at 
all growth stages) accumulated very small quantities of 2,3,7,8-TCDD.  A maximum of 0.15% (0.12 ppm) 
of 2,3,7,8-TCDD present in soils was translocated to the aerial portion of the oat and soybean plants.  No 
detectable amounts of the compound were found in the oat or soybean plants harvested at maturity.  The 
amount of 2,3,7,8-TCDD applied to these soils was many thousands of times greater than that which would 
occur in soils from herbicide applications containing a few ppm of 2,3,7,8-TCDD as an impurity.  Even 
upon exposure to these high concentrations in the soil, significant amounts of 2,3,7,8-TCDD could not be 
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Maize (corn) and bean cultivations grown in soils spiked with 22–1,066 ppt 2,3,7,8-TCDD showed 
2,3,7,8-TCDD concentrations in roots ranging from 16 to 1,278 ppt for maize and from 37 to 1,807 for 
beans (Fachetti et al. 1986). The soil-grown crops did not show a significant increase of 2,3,7,8-TCDD in 
above-ground parts, either as a function of time or with increasing concentration of the pollutant in the soil 
(Fachetti et al. 1986). 
Uptake of 14C-labeled OCDD was studied in a closed, aerated-soil plant system for 7 days after application 
of the OCDD to soil (Schroll et al. 1994). The BCF (concentration of 14C equivalent to the OCDD in plant 
dry matter divided by 14C-labeled OCDD in dry soil) was 0.742 in carrot root and 0.085 in carrot shoots 
grown on OCDD-contaminated soil as compared to a BCF of not determinable and 0.084 in the control 
carrot root and shoots, respectively.  There was no transport of 14C-labeled OCDD between the roots and 
shoots or vice versa. The residues in roots were due only to root uptake from the soil; those in shoots were 
due only to foliar uptake from the air. 
Muller et al. (1993) studied transfer pathways of CDD/CDFs to fruit.  These authors found that homologue 
patterns of CDDs/CDFs in soil were different from those in both apples and pears grown in the contam­
inated soil. Concentrations of CDDs/CDFs ranged from 1 to 4 ng/kg (fresh weight) and were 4–8 times 
higher in the peel than in the pulp. These authors suggest that airborne CDDs/CDFs are a major source of 
contamination of fruits grown in contaminated soil.  Muller et al. (1994) conducted field studies of CDD 
transfer pathways from soil to several edible plant varieties (carrots, lettuce, and peas).  Plants were grown 
in soil with 5 ng TEQ/kg or total CDD/CDF concentrations of 363 ng/kg dry weight (control plots) and 
56 ng TEQ/kg or total CDD/CDF concentrations of 3,223 ng/kg dry weight on the contaminated plots. 
CDD/CDF concentrations in carrot peels were three times higher on the contaminated plots than on the 
control plots. This was the result of a 10-fold increase in the CDD/CDF levels in the carrot peel. 
CDD/CDF concentrations in lettuce (17.7 and 21.1 ng/kg dry weight) and in peas (7.1 ng/kg dry weight) 
were not any higher when grown on the contaminated plot as compared to the control plots and were much 
lower than concentrations in the carrots (47.3 and 47.5 ng/kg, dry weight).  This indicates that the 
CDD/CDFs in the lettuce and peas from both plots were of atmospheric origin.  The CDD/CDF homologue 
pattern in the contaminated soil showed OCDFs and HpCDFs were the two most prevalent congeners, while 
the CDD/CDF homologue pattern from the peel of carrots grown on the contaminated plots contained 
TCDF, PeCDF, and HxCDF. Levels of TCDD were the lowest of all CDD/CDF homologues in both 
contaminated soils and carrot peels.  The homologue profile in lettuce samples was largely dominated by 
lower chlorinated CDFs (TCDF and PeCDF) and higher chlorinated CDDs (HpCDD and OCDD), a 
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profile often found in samples of atmospheric deposition (Eitzer and Hites 1989a, 1989b).  The lowest 
CDD/CDF levels of this study were found in peas with pea pods showing higher levels than seeds.  The 
homologue profiles was dominated by lower chlorinated CDFs and higher chlorinated CDDs similar to the 
profile found in lettuce. 
Since most of the CDDs released into the atmosphere settle onto water and soil surfaces, foliar deposition is 
the major route of vegetative contamination (Travis and Hattemer-Frey 1987).  The translocation of foliar­
applied 2,3,7,8-TCDD has been studied (Kearney et al. 1971).  Labeled 2,3,7,8-TCDD was applied to the 
center leaflet of the first trifoliate leaf of 3-week-old soybean plants and the first leaf blade of 12-day-old 
oat plants. The compound was applied in an aqueous surfactant solution to enhance leaf adsorption and to 
keep the water-insoluble TCDD in solution. Plants were harvested 2, 7, 14, and 21 days after treatment, 
dissected into treated and untreated parts, and analyzed.  2,3,7,8-TCDD was not translocated from the 
treated leaf to other plant parts. Very little 2,3,7,8-TCDD was lost from soybean leaves, while a gradual 
loss (38% in 21 days) did occur from oat leaves (Kearney et al. 1971).  The authors considered 
volatilization to be a possible mechanism for removal of 2,3,7,8-TCDD, but photolysis may also have 
contributed to the loss. 
McCrady and Maggard (1993) measured the uptake and elimination mechanisms for 2,3,7,8-TCDD applied 
to grass foliage in a closed-laboratory system using [3H]TCDD.  The [3H]2,3,7,8-TCDD was injected into 
the chamber as a vapor originating from a [3H]2,3,7,8-TCDD generator.  The total recovered radioactivity 
was 74%. Plant foliage accounted for 59% and the air and other chamber components accounted for 6 and 
9%, respectively.  This indicated that plant foliage was a major sink for [3H]2,3,7,8-TCDD vapor.  Less than 
0.2% was recovered from the soil and associated with root tissues, further verifying an airborne mechanism 
of [3H]2,3,7,8-TCDD uptake and negligible translocation.  The authors also demonstrated that both 
photodegradation and volatilization were primary loss mechanisms for [3H]2,3,7,8-TCDD.  The 
photodegradation half-life (first-order kinetics) of 2,3,7,8-TCDD sorbed to grass and exposed to natural 
sunlight was 44 hours, while the half-life for volatilization of 2,3,7,8-TCDD from grass foliage was 
128 hours. 
In conclusion, CDDs may be transported long distances in the atmosphere.  They eventually may be 
deposited on soils or surface water as a result of wet or dry deposition.  CDDs will slowly volatilize from 
the water column or, more likely, will adsorb to suspended particulate materials in the water column and be 
transported to the sediment.  CDDs deposited on soils will strongly adsorb to organic matter.  They are 
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unlikely to leach to underlying groundwater, but may enter the atmosphere on soil or dust particles or enter 
surface water in runoff. Low water solubilities and high lipophilicity indicate that CDDs will biocon­
centrate in aquatic organisms, although as a result of their binding to suspended organic matter, actual 
uptake by these organisms may be less than predicted.  This is also true of uptake and bioconcentration by 
plants, although foliar deposition and adherence may be significant. 
5.3.2 Transformation and Degradation 
CDDs belong to a class of highly lipophilic compounds with low water solubility and low chemical 
reactivity that are resistant to microbial degradation.  The dominant transformation processes affecting their 
fate have been shown to be surface photolysis and gas-phase diffusion/volatilization with subsequent 
photolysis (Yanders et al. 1989). 
5.3.2.1 Air 
The primary transformation reaction for CDDs in the atmosphere depends on whether the CDD is in the 
vapor or particulate phase. Vapor-phase CDDs are not likely to undergo reactions with atmospheric ozone, 
nitrate, or hydroperoxy radicals; however, reactions with hydroxyl radicals may be significant, particularly 
for the less-chlorinated congeners (MCDD through TCDD) (Atkinson 1991).  Based on the photolysis 
lifetimes of CDDs in solution, it is expected that vapor-phase CDDs will also undergo photolysis in the 
atmosphere, although reactions with hydroxyl radicals will predominate.  For TCDD, the photolytic lifetime 
ranges from 1.3 to 7.1 days, depending on the season (faster in summer), whereas the hydroxyl radical 
reaction lifetime is estimated to be 2 days (Atkinson 1991).  A half-life of 8.3 days was estimated for the 
gas-phase reaction of 2,3,7,8-TCDD with photochemically produced hydroxyl radicals in the atmosphere 
(Podoll et al. 1986). Using the gas-phase hydroxyl radical reaction rate constant of 1×10-11 cm3-molecule-1 
sec-1 and an average 12-hour daytime hydroxyl radical concentration of 1.5×106 molecules cm-3, the 
atmospheric lifetimes of CDDs are estimated to range from 0.5 days for MCDD to 9.6 days for OCDD, with 
TCDD having a lifetime of 0.8–2 days (Atkinson 1991). 
Particulate-bound CDDs are removed by wet or dry deposition with an atmospheric lifetime $10 days 
(Atkinson 1991) and, to a lesser extent, by photolysis.  Miller et al. (1987) measured photolysis of 
2,3,7,8-TCDD sorbed onto small-diameter fly ash particulates suspended in air.  The results indicated that 
fly ash confers photostability to the adsorbed 2,3,7,8-TCDD.  The authors reported little (8%) to no loss of 
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2,3,7,8-TCDD on the fly ash samples after 40 hours of illumination in simulated sunlight.  Koester and 
Hites (1992) studied the photodegradation of CDDs naturally adsorbed to five fly ash samples (two from 
coal-fired plants, two from municipal incinerators, and one from a hospital incinerator).  Although the 
authors reported that CDDs underwent photolysis in solution and on silica gel, no significant degradation 
was observed in 11 photodegradation experiments conducted for periods ranging from 2 to 6 days. 
The selected transformation of the more and less chlorinated CDDs has been demonstrated by the analysis 
of CDDs found in soil samples compared with atmospheric concentrations of CDDs at the emission source 
(Marklund et al. 1991; Yamamoto and Fukushima 1993).  Soil samples contained progressively greater 
concentrations of HpCDD and OCDD with increasing distance from the emission source, indicating that 
photolysis of the less chlorinated congeners was occurring (Eitzer 1993).  In the air, the low vapor pressure 
of OCDD results in its partitioning primarily to the particulate phase rather than the vapor phase; therefore, 
atmospheric photodegradation is less likely to occur for this tightly bound congener (Eitzer 1993). 
5.3.2.2 Water 
Photolysis is the major route of CDD disappearance in aqueous solutions (Hutzinger et al. 1985).  While 
photolysis is a relatively slow process in water, CDDs are rapidly photolyzed under certain conditions, (i.e., 
when exposed to ultraviolet light of the appropriate wavelength and in the presence of an organic hydrogen 
donor). These hydrogen donors can be expected to be present in chlorophenol pesticides either as 
formulation solvents (e.g., xylene or petroleum hydrocarbons), as active constituents of the formulation 
(e.g., the alkyl esters of 2,4-D and 2,4,5-T), or as natural organic films on soils (Crosby et al. 1973).  The 
photolytic behavior of CDDs in an organic solvent or in a water-organic solvent, however, may not 
accurately reflect the photolytic behavior of these compounds in natural waters (Hutzinger et al. 1985).  For 
example, Choudry and Webster (1989) reported that photolysis of 1,3,6,8-TCDD was slower in natural 
pond-water solutions than was predicted from studies with laboratory solutions.  Conversely, Friesen et al. 
(1990) reported that photolysis of PeCDD and HpCDD proceeds faster in a pond or lake-water solutions 
than was predicted or measured in a laboratory solution.  In general, however, lower chlorinated CDDs are 
degraded faster than higher chlorinated congeners. Chlorine atoms in the lateral positions (e.g., 2, 3, 7, 8) 
are also more susceptible to photolysis than are chlorine atoms in the para positions (e.g., 1, 4, 6, 9) 
(Choudhry and Hutzinger 1982; Crosby et al. 1973; Hutzinger et al. 1985). 
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Podoll et al. (1986) used the quantum yield data of Dulin et al. (1986) for a water:acetonitrile solution to 
calculate seasonal half-life values for dissolved 2,3,7,8-TCDD at 40 degrees north latitude in clear near-
surface waters. Photolysis half-lives for dissolved 2,3,7,8-TCDD in sunlight range from 118 hours in 
winter, to 51 hours in fall, to 27 hours in spring, to 21 hours in summer (Podoll et al. 1986).  Choudhry and 
Webster (1989) studied photolysis of a series of CDDs in a water:acetonitrile solution (2:1 v/v).  These 
authors estimated the midday midsummer sunlight photolysis half-lives values at 40 degrees north latitude 
in clear near-surface waters as follows: 1,3,6,8-TCDD (0.3 days), 1,2,3,7-TCDD (1.8 days), 
1,2,3,4,7-PeCDD (15 days), 1,2,3,4,7,8-HxCDD (6.3 days), 1,2,3,4,6,7,8-HpCDD (47 days), and OCDD 
(18 days) near the surface of water bodies (Choudhry and Webster 1989).  Sunlight photolysis half-lives 
were also reported for the spring, fall, and winter for 1,2,3,4,6,7,8-HpCDD (57, 88, and 156 days, 
respectively) and for OCDD (21, 31, and 50 days, respectively) (Choudhry and Webster 1989).  Photolysis 
half-lives for 1,2,3,4,6,7,8-HpCDD and OCDD in water-acetonitrile solutions irradiated at 313 nm were 
reported to be 8 and 7.7 days, respectively (Choudhry and Webster 1987, 1989).  The half-lives of 
1,3,6,8-TCDD and OCDD in lake water are 2.6 and 4 days, respectively, with removal by partitioning to the 
lake sediments (Servos et al. 1992). 
The photodegradation profiles of 2,3,7,8-TCDD, 1,3,6,8-TCDD, and 1,2,3,4-TCDD in 1,4-dioxane 
solutions at various wavelengths under xenon lamp irradiation were studied (Koshioka et al. 1989a, 1989b, 
1989c). Reductive dechlorination reactions were observed in the photolysis of TCDD isomers.  After 
200 minutes of irradiation with a xenon lamp, 2,3,7,8-TCDD formed 2,3,7-TrCDD, 2,7-DCDD, 2,8-DCDD, 
2-MCDD, and DD. Photodegradation half-lives of 2,3,7,8-TCDD at the maximal photodegradation 
wavelengths of 252.6 nm and 318.6 nm were 72.6 minutes and 29.7 minutes, respectively (Koshioka et al. 
1989b, 1989c). After 267 minutes of irradiation with a xenon lamp, 1,3,6,8-TCDD formed 1,3,6-TrCDD, 
1,3-DCDD, 1,6-DCDD, 1-MCDD, 2-MCDD, and DD, while 1,2,3,4-TCDD formed 1,2,3-TrCDD, 
1,2,4-TrCDD, 1,2-DCDD, 1,3-DCDD, 1,4-DCDD, 2,3-DCDD, 1-MCDD, 2-MCDD, and DD (Koshioka et 
al. 1989a). 
The photolytic half-life of 2,3,7,8-TCDD in isooctane was estimated to be 40 minutes with a light source at 
0.5 meters and 3 hours with a light source at 1 meter (Stehl et al. 1973).  Very little change was observed in 
OCDD on exposure to artificial sunlight. Approximately 20% photolysis of OCDD was observed in 
isooctane at the end of 18 hours and about 6% photolysis of OCDD after 20 hours of exposure in 1-octanol 
(Stehl et al. 1973). Irradiation of pentachlorophenol (PCP) dissolved in sodium hydroxide at a wavelength 
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of 300 nm (equivalent to sunlight) for 16 hours produced OCDD (Crosby and Wong 1976).  OCDD then 
underwent photoreduction to HpCDD as a PCP photolysis product (Crosby and Wong 1976). 
Under equivalent light exposure conditions, photolytic half-lives were determined for each of the individual 
TCDD isomers in dilute hydrocarbon solution and as a diffuse molecular dispersion on a clean soft-glass 
surface (Nestrick et al. 1980). The photolytic behavior of 2,3,7,8-TCDD was atypical compared to other 
TCDD isomers.  In a hydrocarbon solution, 2,3,7,8-TCDD had the fastest decomposition rate (half-life 
56.8 minutes) and 1,4,6,9-TCDD had the slowest decomposition rate (half-life 8,400 minutes [5.8 days]). 
The half-lives of the remaining TCDD isomers ranged from 153 to 1,388 minutes (2.55–23.1 hours). 
However, as a diffuse molecular dispersion on a glass surface, the 2,3,7,8-TCDD had the slowest 
decomposition rate (half-life 8,400 minutes [5.8 days]), and 1,4,6,9-TCDD had the second slowest 
decomposition rate (half-life 830 minutes [13.8 hours]).  The half-lives of the remaining TCDDs ranged 
from 121 to 560 minutes (2–9.3 hours).  The majority of TCDD isomers photolytically decomposed faster 
on a glass surface than in a hydrocarbon solution under conditions of equivalent light intensity. 
2,3,7,8-TCDD and 1,4,6,9-TCDD possess the highest degree of symmetry within the group, and these 
isomers demonstrated the largest change in the photodecomposition rate for surface and solution reactions, 
with the changes being in opposite directions. Additional photolysis tests were conducted using more 
highly chlorinated CDD congeners.  In a hydrocarbon solution, the half-lives of 1,2,3,4,6,7,8-HpCDD, 
1,2,3,4,6,7,9-HpCDD, and OCDD were 1,800 minutes (1.3 days), 3,300 minutes (2.3 days), and 
1,460 minutes (1.01 days), respectively, and 3,140 minutes (2.18 days), 2,400 minutes (1.67 days), and 
48,900 minutes (33.96 days), respectively, on a glass surface (Nestrick et al. 1980). 
2,3,7,8-TCDD decomposed rapidly when dissolved in methanol and exposed to ultraviolet (UV) light 
(Plimmer et al. 1973).  Rate measurements showed that 2,3,7,8-TCDD is more rapidly photolyzed in 
methanol than OCDD (Plimmer et al. 1973).  The photolysis half-lives for 2,3,7,8-TCDD, 
1,2,3,4,6,7,8-HpCDD, 1,2,3,4,6,7,9-HpCDD, and OCDD in n-hexadecane solution were 56.8 minutes, 
1,800 minutes (1.25 days), 3,300 minutes (2.29 days), and 1,460 minutes (1.01 days), respectively 
(Mamantov 1984). 
Solution-phase photolysis of HpCDD and OCDD has been reported (Dobbs and Grant 1979).  Solutions of 
these CDDs in hexane (approximately 1 µg/mL) were exposed to natural sunlight as well as to fluorescent 
blacklight. The photolytic half-life for OCDD exposed to both types of radiation was 16 hours.  HpCDD 
was generated by photolysis of OCDD (Dobbs and Grant 1979).  The photolytic half-lives of 
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1,2,3,4,6,7,9-HpCDD and 1,2,3,4,6,7,8-HpCDD were 28 hours and 11 hours, respectively (Dobbs and 
Grant 1979). 
It has been suggested that the potential for biological degradation of 2,3,7,8-TCDD in a wide variety of 
environmental samples is low (Arthur and Frea 1989).  The fate of 2,3,7,8-TCDD in sediment and water 
from two lakes in Wisconsin was examined (Ward and Matsumura 1978).  After incubation periods of up to 
589 days, little metabolism of 2,3,7,8-TCDD was detected.  The slight metabolism that was detected was 
stimulated by the presence of sediment and the addition of nutrients (Ward and Matsumura 1978).  Also, 
2,3,7,8-TCDD does not hydrolyze in water (Mabey et al. 1982; Miller et al. 1987). 
5.3.2.3 Sediment and Soil 
Photolysis of 2,3,7,8-TCDD on soils is a relatively slow process compared to photolysis in an aqueous 
media (Kieatiwong et al. 1990).  2,3,7,8-TCDD applied to soil or a solid surface seems to be extremely 
resistant to the action of sunlight and decomposes very slowly (Plimmer et al. 1973).  A methanol solution 
of 2,3,7,8-TCDD (2.4 ppm) applied to glass plates coated with soil and illuminated 96 hours with a 
fluorescent UV lamp remained unchanged at the end of the period (Plimmer et al. 1973).  Organic solvents 
added to the soil, however, can enhance the extent of photolysis.  Use of a solvent mixture of tetradecane 
and 1-butanol to TCDD-treated soil, combined with exposure to sunlight, resulted in 61–85% 
photodegradation of TCDD after 60 days.  The solvent was effective in transporting TCDD from deeper in 
the soil column (60 cm) to the soil surface via evaporation.  At the soil surface, photodegradation could 
occur. TCDD concentrations at 60 cm decreased from 23.8 ng/g (ppb) to 7.1 ng/g (ppb) after 60 days 
(McPeters and Overcash 1993). 
Photolysis of OCDD (10 mg/kg) on soils resulted in production of the lower chlorinated CDDs, notably 
2,3,7,8-TCDD, 1,2,3,7,8-PeCDD, three HxCDD isomers substituted at the 2,3,7,8-positions, and 
1,2,3,4,6,7,8-HpCDD. Photolysis of OCDD occurred in mean soil depths between 0.06 and 0.13 mm 
(Miller et al. 1989). Approximately 30–45% of OCDD was lost by day 5 of irradiation; no further 
significant loss of OCDD was observed following 10 additional days of irradiation.  Although photolysis 
only occurred at shallow soil depths and the conversion of OCDD to the more toxic TCDD, PeCDD, and 
HxCDD homologues was small (0.5–1%) compared with the photodechlorination to HpCDD (67%), 
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The loss of 2,3,7,8-TCDD in contaminated soil has been studied under natural conditions in experimental 
plots at the Dioxin Research Facility, Times Beach, Missouri (Yanders et al. 1989).  The 2,3,7,8-TCDD 
concentration profiles of sample cores taken at Times Beach in 1988 were virtually the same as those in 
cores taken in 1984. The authors concluded that the loss of 2,3,7,8-TCDD due to photolysis at Times 
Beach was minimal in the 4 years covered by the study (Yanders et al. 1989).  Estimates of the half-life of 
TCDD on the soil surface range from 9 to 15 years, whereas the half-life in subsurface soil may range from 
25 to 100 years (Paustenbach et al. 1992). 
A white rot fungus (Phanerochaete chrysosporium) has demonstrated the ability to degrade 2,3,7,8-TCDD 
in laboratory experiments (Bumpus et al. 1985; Des Rosiers 1986).  In cultures containing 1.25 nmol of the 
2,3,7,8-TCDD substrate, 27.9 pmol were mineralized to CO2 in 30 days (2.23% metabolism) increasing to 
49.5 pmol in 60 days (3.96% metabolism) (Des Rosiers 1986).  It was suggested that the ability of this 
fungus to metabolize 2,3,7,8-TCDD is dependent on its extracellular lignin-degrading enzyme system 
(Bumpus et al. 1985; Des Rosiers 1986).  More recently, Valli et al. (1992) reported that 2,7-DCDD also 
was degraded by P. chrysosporium via the removal of both aromatic chlorines before aromatic ring 
cleavage took place. 
Cultures of Pseudomonas testosteroni, of an unidentified bacterium isolated from soil from Seveso, Italy, 
and of a mixture of 6 unidentified bacterial strains isolated from Seveso soil were incubated aerobically 
with 14C-2,3,7,8-TCDD for 35, 54, and 12 weeks, respectively (Philippi et al. 1982).  Results showed the 
occurrence of a metabolite of 14C-2,3,7,8-TCDD in all three cultures. The polar metabolite amounted to 
approximately 1% of the input material and was found to be a hydroxylated derivative of 14C-2,3,7,8-TCDD 
(Philippi et al. 1982). 
Approximately 100 strains of pesticide-degrading microorganisms were tested for their ability to degrade 
2,3,7,8-TCDD (Matsumura and Benezet 1973).  The organisms were maintained in liquid axenic culture, 
and the production of metabolites from ring-labeled 14C-2,3,7,8-TCDD was measured.  Five strains were 
identified that showed some ability to degrade 14C-2,3,7,8-TCDD. The degradative organisms included a 
fungus (Trichoderma viride), a bacterium (Pseudomonas putida), and three organisms referred to by coded 
numbers (Matsumura and Benezet 1973). 
To determine the persistence of 2,3,7,8-TCDD, concentrations of 1, 10, and 100 ppm of unlabeled 
2,3,7,8-TCDD were added to 300-g samples of silty loam and sandy soils and then assayed periodically for 
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residues (Kearney et al. 1971).  Measurements of 2,3,7,8-TCDD residues after 20, 40, 80, 160, and 
350 days of incubation at 28 EC in foil-sealed beakers indicated a relatively slow degradation process in 
both soils. After 350 days, 56% of the initially applied 2,3,7,8-TCDD was recovered from the sandy soil, 
while 63% was recovered from the silty clay loam for all concentrations (Kearney et al. 1971). 
Parsons (1992) studied the influence of suspended sediment on the biodegradation of several CDDs.  In this 
study, aqueous solutions of a mixture of 2-chloro-, 1,3-dichloro, 2,8-dichloro-, and 1,2,4-trichloro CDDs 
were incubated for 24 days with 100 mg/L suspended sediment.  Subsequently, the degradation of the 
CDDs in the sediment suspensions by Alcaligenes sp. strain JB1 was compared to that in solutions without 
sediment.  The amounts of all four CDD compounds degraded in the sediment suspensions after 7 days 
were greater than those initially present in the dissolved phase, based on their calculated sediment-water 
partition coefficients. The sorbed fractions were, therefore, sufficiently desorbed to be partly degraded. 
However, the biodegradation rates were slower in the sediment suspensions than in the solutions.  The 
results indicate that sorbed fractions of CDDs formed after relatively short incubation periods are 
sufficiently labile to be available for biodegradation after desorption.  Evidence that the presence of 
sediment lowers biodegradation rates in sediment suspension, however, implies that longer residence times, 
such as those observed under field conditions, may also lead to a significant lowering of the biodegradation 
rates in soil. This will apply even more to the more highly chlorinated CDD congeners.  In another study, 
the degradation of highly chlorinated CDD congeners (5–7 chlorine/molecule) was studied for a period of 
6 months in anaerobic microcosm incubations using PCB-contaminated Hudson River sediments and 
creosote-contaminated aquifer samples from Pensacola, Florida (Adriaens and Grbic-Galic 1994).  The 
authors reported (pseudo-first-order) half-life values for 1,2,3,4,6,7,8-HpCDD of 4.1 and 2.9 years for the 
Hudson River and Pensacola aquifer-incubated microcosm samples, respectively.  The half-life values for 
1,2,3,4,7,8-HxCDD were 2 and 2.9 years for the Hudson River and Pensacola aquifer-incubated microcosm 
samples, respectively.  The 1,2,4,6,8,9/ 1,2,4,6,7,9-HxCDD congeners were found not to be degraded, 
which was presumably due to the low concentration spiked.  The authors reported that tentative 
identification of the degradation products indicate that para-dechlorination was the preferential route of 
reduction, as has been observed with 1,2,3,4,5,6,7,8-HpCDD in aquifer microcosms.  This observation is 
contrary to photolytic dechlorination patterns of soil-sorbed CDDs. 
Beurskens et al. (1995) reported that an anaerobic microbial consortium enriched from Rhine River 
sediments was able to remove chlorine substituents from CDDs.  A model CDD, 1,2,3,4-TCDD, was 
reductively dechlorinated to both 1,2,3- and 1,2,4-TrCDD.  These TrCDD compounds were further 
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dechlorinated to 1,3- and 2,3- DCDD and trace amounts of 2-MCDD.  The TrCDD compounds were 
detected at low concentrations, but the 1,3- and 2,3- DCDD were detected at higher concentrations.  The 
anaerobic culture dechlorinates 1,2,3,4-TCDD at a relatively rapid rate with a half-life value estimated at 
15.5 days (first-order kinetics).  The formation of metabolites with a conserved 2,3-substitution pattern from 
1,2,3,4-TCDD indicates that dechlorination of highly chlorinated CDDs may result in metabolites that are 
potentially more toxic than the parent compounds. 
5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT 
Reliable evaluation of the potential for human exposure to CDDs depends in part on the reliability of 
supporting analytical data from environmental samples and biological specimens.  Historically, CDD 
analysis has been both complicated and expensive, and the analytical capabilities to conduct such analysis 
have been available through only a relatively few analytical laboratories.  Limits of detection have 
improved greatly over the past decade with the use of high-resolution mass spectrometry, improvements in 
materials used in sample clean-up procedures, and with the use of known labeled and unlabeled chemical 
standards. Problems associated with chemical analysis procedures of CDDs in various media are discussed 
in greater detail in Chapter 6. In reviewing data on CDD levels monitored or estimated in the environment, 
it should be noted that the amount of the chemical identified analytically is not necessarily equivalent to the 
amount that is bioavailable (see Section 2.3) and that every measurement is accompanied with a certain 
analytical error. 
5.4.1 Air 
Indoor household dust samples gathered by a vacuum cleaner from rooms with furniture treated with a 
wood-preserving formulation were analyzed for CDDs (Christmann et al. 1989b).  The wood-preserving 
formulation contained PCP, which is known to be contaminated with CDDs, particularly HxCDD, HpCDD, 
and OCDD. OCDD was the most abundant congener found in the dust samples at an average concentration 
of 191 µg/kg (ppb), followed by HpCDD (20 µg/kg), HxCDD (2.5 µg/kg), PeCDD (0.9 µg/kg), and TCDD 
(0.2 µg/kg) (Christmann et al. 1989b). 
Indoor air concentrations of CDD/CDFs were measured in kindergarten classrooms in West Germany to 
evaluate releases from wood preservatives (e.g., PCP) that may have been used in building materials (Päpke 
et al. 1989a). Measured indoor air concentrations of total CDD/CDF ranged from 1.46 to 
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4.27 pg/m3, while measured outdoor air concentrations ranged from 0.61 to 78.97 pg/m3. The 2,3,7,8­
substituted congeners predominated with mean concentrations as follows: OCDD (131.5 pg/m3), 
1,2,3,4,6,7,8-HpCDD (77 pg/m3), 1,2,3,4,6,7,8-HpCDF (51 pg/m3), and OCDF (25.3 pg/m3). 
Measured indoor air samples collected in an office building in Binghamton, New York, 2 years after a fire 
in an electrical transformer that contained PCBs and tri- and tetra-chlorobenzenes had concentrations of 
2,3,7,8-TCDD ranging from 0.23 to 0.47 pg/m3 (0.017–0.036 ppq) (Smith et al. 1986a).  The 2,3,7,8-TCDD 
isomer constituted 23–30% of the 1.0–1.3 pg/m3 (0.076–0.099 ppq) total TCDDs. The limit of detection for 
these samples was approximately 0.003 pg/m3 (Smith et al. 1986a). 
Background levels of CDD in air were measured in a semi-rural location in Elk River, Minnesota, located 
about 25 miles northwest of Minneapolis-St. Paul (Reed et al. 1990).  No major industrial or commercial 
activity occurred in the area at the time of the study.  Ambient air samples were collected in the winter and 
summer of 1988.  2,3,7,8-TCDD was not detected in any of the ambient air samples taken in the summer 
(detection limits for 2,3,7,8-TCDD ranged from 0.005 to 0.065 pg/m3 [0.0004–0.0046 ppq]). 
2,3,7,8-TCDD was noted in a wintertime sample at concentrations of 0.015 pg/m3 (0.0011 ppq) and 
0.019 pg/m3 (0.0014 ppq). Detection limits in the remaining wintertime samples for 2,3,7,8-TCDD ranged 
from 0.005 to 0.01 pg/m3 (0.0004–0.0007 ppq). Wintertime CDD concentrations were greater than those 
observed for summertime.  The authors noted that this may be a result of increased numbers of combustion 
sources operating during the winter months.  The wintertime CDD congener profile showed increasing 
concentrations with increasing chlorine substitutions.  Average wintertime ambient air concentrations of 
HpCDD and OCDD ranged from approximately 0.5 to 4.1 pg/m3 (0.029–0.236 ppq) and 0.74 to 8.2 pg/m3 
(0.039–0.436 ppq), respectively (Reed et al. 1990).  Average summertime ambient air concentrations of 
HpCDD and OCDD ranged from approximately 0.204 to 0.246 pg/m3 (0.011–0.014 ppq) and 0.018 to 
0.024 pg/m3 (0.001–0.0013 ppq), respectively (Reed et al. 1990). The authors found that, in general, the 
more highly chlorinated congeners were present at higher concentrations that the less chlorinated 
congeners. 
A long-term study (1985–1988) of CDDs in the ambient atmosphere of Bloomington, IN (a suburban area), 
was carried out in order to provide base-line data against which the impact of a future incinerator on local 
CDD concentrations could be judged (Eitzer and Hites 1989b).  Ambient air samples were analyzed for the 
presence of CDDs in both the particulate-bound phase and the vapor-phase forms.  At the four sites 
sampled, the concentrations of CDDs (TCDD, PeCDD, HxCDD, HpCDD, and OCDD) increased with an 
increasing level of chlorination. All sites showed that the less chlorinated CDDs have a higher vapor-phase 
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fraction than the more chlorinated CDDs.  In addition, all sites show OCDD to be the most abundant CDD, 
averaging from 0.44 to 0.69 pg/m3 (0.023–0.032 ppq) (detection limit 0.001 pg/m3 [5.3×10-5 ppq]) (Eitzer 
and Hites 1989b). A seasonal effect was seen on the proportion of the total atmospheric burden present in 
the vapor phase. During the warm summer months, the total vapor-to-particle bound ratio (V/P) was as 
great as 2, whereas in the winter it was <0.5. At warm temperatures, most of the less chlorinated CDDs are 
found in the vapor phase, whereas at cooler temperatures more of the CDDs were associated with the 
particle phase (Eitzer and Hites 1989b). 
CDDs have been found in urban air particulates from Washington, D.C., and St. Louis, Missouri; OCDD 
was the predominant congener at concentrations of 200 ppb and 170 ppb for Washington and St. Louis, 
respectively (Czuczwa and Hites 1986a).  Combustion of municipal and chemical wastes was the most 
likely source of these compounds.  CDDs were detected in air samples from Albany, Binghamton, Utica, 
and Niagara Falls, NY (Smith et al. 1990b).  Concentrations of CDD congener groups for all 4 cities were 
as follows: total TCDD, not detected (<0.21 pg/m3 [0.016 ppq]); total PeCDD, <0.04–0.62 pg/m3 
(<0.003–0.043 ppq); total HxCDD, 0.10–2.4 pg/m3 (0.007–0.15 ppq); total HpCDD, <0.21–4.4 pg/m3 
(0.012–0.25 ppq); and OCDD <0.54–4.6 pg/m3 (0.029–0.244 ppq) (Smith et al. 1990b).  In 1988–89, total 
CDDs measured downwind from an industrial source in Niagara Falls, NY, ranged from 0.3 pg/m3 to 
133 pg/m3 and were approximately 2.5 times higher than upwind concentrations (Smith et al. 1990b). 
Between 1986 and 1990, total CDD concentrations averaged 2.3 pg/m3, of which 65% was OCDD (Smith et 
al. 1992). 
An extensive multi-year monitoring program for CDDs/CDFs was conducted at eight sampling locations in 
the Los Angeles South Coast Air Basin from 1987 to 1989 (Hunt and Maisel 1992).  The monitoring 
network, which monitored for both vapor and particulates, included several sites situated in residential areas 
as well as sites in the vicinity of suspected CDD/CDF sources.  Monitoring results indicated that 
2,3,7,8-TCDD was virtually undetected.  The most commonly detected 2,3,7,8-substituted congener was 
OCDD followed by 1,2,3,4,6,7,8-HpCDD.  The predominance of 1,2,3,4,6,7,8-HpCDD as the most 
persistent congener is associated with stationary or mobile combustion source emissions. 
1,2,3,4,6,7,8-HpCDD was found at all 7 sampling sessions at a mean concentration of 1.140 pg/m3. OCDD 
also was found at all 7 sampling sessions at a mean concentration of 2.883 pg/m3. The mean total TCDD 
concentration was 0.114 pg/m3 and was measured during only 3 sampling sessions (Hunt and Maisel 1992). 
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The concentrations of CDDs in the ambient air at several sites in metropolitan Dayton, Ohio, have been 
determined (Tiernan et al. 1989b).  No CDDs (TCDD, PeCDD, HxCDD, HpCDD, and OCDD) were found 
in rural regions, with average detection limits ranging from 0.03 pg/m3 (TCDD) to 1.44 pg/m3 (OCDD). 
The rural area was outside the impact zone of air pollutants from any regional industrial sources.  CDDs in 
the industrialized regions appear to originate from a combination of sources, including municipal waste 
incinerators, motorized vehicles, and a PVC-coated metal incinerator, the latter being a major source of 
these pollutants. Suburban/roadside area samples were taken at ground level at a distance of about 3 meters 
from a street intersection through which approximately 60,000 cars passed each day.  Other sampling 
sources were on the roofs of buildings in the downtown Dayton area, which lay in the emissions path from 
municipal solid-waste incinerators.  TCDDs and PeCDDs (detection limits 0.01 and 0.03 pg/m3, 
respectively) were not detected in the suburban/roadside area but were detected in the municipal waste-
incinerator areas at 0.24 and 0.38 pg/m3, respectively.  HpCDD was detected in both the suburban/roadside 
areas and the municipal waste-incinerator areas at concentrations of 0.41 pg/m3 (0.024 ppq) and 3.34 pg/m3 
(0.19 ppq), respectively.  OCDD was also detected in the suburban/roadside areas (1.09 pg/m3 [0.058 ppq]) 
and the municipal waste incinerator areas (4.69 pg/m3 [0.25 ppq]).  Concentrations of HxCDD were lower 
than HpCDD and OCDD, 0.05 pg/m3 (0.003 ppq) in the suburban/ roadside areas and 2.56 pg/m3 
(0.160 ppq) in the vicinity of the municipal waste incinerators (Tiernan et al. 1989b). 
Air samples were collected in Ohio in 1987 at an industrial area, an urban area downwind of a municipal 
incinerator, a high-traffic density area, and a rural area (Edgerton et al. 1989).  No 2,3,7,8-TCDD was 
detected in any of the air samples with detection limits of <0.24 pg/m3 (0.02 ppq) in any of the areas.  The 
ambient concentrations of CDDs collected in the urban area were as follows:  total HpCDD, 1.0–1.1 pg/m3 
(0.058–0.063 ppq); OCDD, 1.0–1.2 pg/m3 (0.053–0.064 ppq); PeCDD, 0.1 pg/m3 (0.03 pg/m3); and total 
HxCDD, 0.6–0.63 pg/m3 (0.038–0.039 ppq) (detection limit not specified).  Concentrations of CDDs in the 
industrial area were: total HpCDD, 0.41–1.0 pg/m3 (0.024–0.058 ppq), OCDD, 0.51–1.1 pg/m3 
(0.027–0.058 ppq), and total HxCDD, 0.43–0.78 pg/m3 (0.027–0.049 ppq). Concentrations of total 
HpCDD, OCDD, total HxCDD in the high-traffic density area were 0.56 pg/m3 (0.032 ppq), 0.96 pg/m3 
(0.051 ppq), and 0.15 pg/m3 (0.008 ppq), respectively.  Ambient air concentrations of total HpCDD, 
OCDD, and total HxCDD in the rural area were 0.48 pg/m3 (0.028 ppq), 0.5 pg/m3 (0.027 ppq), and 
0.33 pg/m3 (0.021 ppq), respectively.  PeCDD was not detected in the industrial, high-traffic, or rural areas 
(Edgerton et al. 1989). 
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Air monitoring at Windsor, Ontario, downwind of a proposed municipal solid-waste incinerator in Detroit, 
Michigan, between 1987 and 1988 found a mean total CDD concentration of 2.12 pg/m3. A sampling 
station located in a rural area 30 miles away provided background total CDD concentrations of 0.51 mg/m3. 
At both stations, the primary congeners were HpCDD and OCDD in the particulate phase, whereas TCDD 
and PeCDD were not detected in the vapor or particulate phases above the detection limit (Bobet et al. 
1990). 
A mixture of CDDs (TCDD, PeCDD, HxCDD, HpCDD, OCDD) has been found in emissions from the 
combustion of various sources, including municipal incinerators, power plants, wood burning, house-
heating systems, and petroleum-refining operations (Chiu et al. 1983; Clement et al. 1985; Thoma 1988; 
Thompson et al. 1990).  CDDs were found in stack and fly ash samples from the following combustion 
sources (ranges given): municipal incinerator, 8 ppb (OCDD) to 390 ppb (HxCDD) (TCDD was found at 
10 ppb); open-air burning of PCP-treated wood, 2 ppb (TCDD) to 187 ppb (OCDD); coal-fired power plant, 
1 ppb (TCDD) to 6 ppb (PeCDD and HxCDD); hydroelectric power plant, 0.5 ppb (OCDD) to 5.2 ppb 
(TCDD) (Chiu et al. 1983); and petroleum refining, 0.8 (OCDD) to 3.4 ng/m3 (PeCDD) (Thompson et al. 
1990). Samples of ash from wood-burning stoves, a fireplace, and open-air wood burning contained 
detectable levels of CDDs ranging from 0.3 to 33 ppb (Clement et al. 1985).  The open-air burning ash 
contained the highest total CDD concentration (33 ppb), with HpCDD being the most abundant homologue 
(11 ppb). The total CDD concentrations in 4 samples from wood-burning stoves ranged from 0.3 to 15 ppb, 
with the relative amounts of each homologue varying for each sample.  Ash samples from the fireplace 
contained total CDD concentrations ranging from 3.1 to 5.4 ppb, with HxCDD (0.3–1.7 ppb) and OCDD 
(0.4–3.1 ppb) being the most abundant homologues present (Clement et al. 1985).  TCDD was present in 
ash samples from open-air burning (0.8 ppb) and was detected in ash from the fireplace. 
Ambient air monitoring in the vicinity of a Superfund clean-up site detected 2,3,7,8-TCDD levels on the 
order of 1 pg/m3 (0.08 ppq) (Fairless et al. 1987). The surface and subsurface soils at the site were tested 
and found to contain 2,3,7,8-TCDD at concentrations above 1 ppb at most locations within the site.  
2,3,7,8-TCDD has been detected in air samples (concentrations unspecified) collected at 9 of the 91 NPL 
hazardous waste sites where it has been detected in some environmental media (HazDat 1998).  CDDs have 
been detected in air samples (concentrations unspecified) collected at 10 of the 126 NPL sites where they 
have been detected in some environmental media.  TCDDs, PeCDDs, HxCDDs, HpCDDs, and OCDD 
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have been detected in air samples (concentrations unspecified) at 10, 3, 3, 3, and 1 sites of the 105, 34, 43, 
49, and 53 sites, respectively, where they have been detected in some environmental media (see Table 5-1). 
In conclusion, most of the measurements of CDDs in air tend to be very close to current detection limits. 
CDDs are found at the greatest concentrations in urban air with OCDD being the most prevalent congener 
(up to 0.100 ppq), HpCDDs being the next most common congener, and 2,3,7,8-TCDD being the least 
common congener (0.014 ppq).  Concentrations of all CDDs are highest in the air near industrial areas. 
Rural areas usually have very low or unquantifiable levels of all CDDs.  In urban and suburban areas, 
concentrations of CDDs may be greater during colder months of the year when furnaces and wood stoves 
are used for home heating. 
5.4.2 Water 
Precipitation samples collected in a rural location (Dorset, Ontario) over an 8-month period between 1986 
and 1987 were analyzed for CDDs (Tashiro et al. 1989a, 1989b).  No TCDDs were found in any samples at 
detection limits of 4–30 ppq.  OCDD concentrations were found in 3 samples in the 60–1,200 ppq range. 
Lower concentrations of HpCDD (70 ppq) were also found (Tashiro et al. 1989a).  Precipitation samples 
were also collected in 1987–88 in urban and rural locations in Canada (Tashiro et al. 1989b).  Varying 
levels of OCDD were detected throughout the sampling period, mainly at the rural location.  OCDD was the 
only CDD detected at the rural site.  OCDD concentrations ranged from 35 to 230 ppq, with the median 
value being slightly below 100 ppq.  No seasonal pattern of OCDD concentrations was observed.  OCDD 
was detected in only 2 of the urban precipitation samples at concentrations of 33 and 15 ppq (Tashiro et al. 
1989b). Rain collected at Bloomington, IN, between June 1987 and July 1988 showed low concentrations 
of total CDDs, although OCDD was the most prominent congener in all samples at concentrations ranging 
from below the detection limit of 0.1 pg/L to 220 pg/L.  Total TCDD was detected in only 3 of 28 samples 
at concentrations <9 pg/L (EPA 1991d). 
An analysis of EPA's STORET (STOrage and RETrieval) database for 1980–82 showed that based on the 
statistical criteria used, 2,3,7,8-TCDD was detected but at concentrations too low to be quantified in 
surface-water samples collected at sampling sites (Staples et al. 1985).  The sampling sites in the STORET 
database included both ambient and pipe sites.  Ambient sites included streams, lakes, ponds, wells, 
reservoirs, canals, estuaries, and oceans and were intended to be indicative of general U.S. waterway 
conditions. Pipe sites referred to municipal or industrial influents or effluents (Staples et al. 1985). 
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Treated effluents from various Ontario pulp and paper plants using either the bleached kraft (8 mills) or 
sulfite bleaching process (2 mills) were analyzed for CDDs (Clement et al. 1989).  2,3,7,8-TCDD was not 
detected in any of the effluent samples with detection limits ranging from 0.07 to 0.7 ppt.  A few samples 
contained a TCDD isomer (not 2,3,7,8-TCDD) at concentrations ranging from 0.06 to 0.12 ppt.  PeCDD 
(0.07 ppt) was detected in one effluent sample, and OCDD (0.05–0.79 ppt) was detected in 4 effluent 
samples.  Suspended particulates were collected from the final effluent from two plants.  2,3,7,8-TCDD and 
OCDD were detected in the particulates at a concentration range of 200–660 ppt and 180–210 ppt, 
respectively.  The concentration of 2,3,7,8-TCDD determined in the particulates represents levels in the 
final effluent of 5–10 ppq, suggesting that 2,3,7,8-TCDD is associated with suspended particulate materials 
in the effluents (Clement et al. 1989). 
In 1983, Jobb et al. (1990) conducted a survey of 49 drinking water supplies in Ontario, Canada, including 
supplies in the vicinity of chemical plants and pulp and paper mills.  OCDD was detected in 36 of 
37 positive samples ranging from concentrations of 9 to 175 ppq in raw samples (33 positive samples) and 
from 19 to 46 ppq in treated (filtered) water samples (4 positive samples).  These low concentrations were 
found primarily in water obtained downstream of industrial areas in the St. Clair/Detroit River system. 
Concentrations of 2,3,7,8-TCDD were not detected in any sample.  Because CDDs are hydrophobic, 
concentrations of these compounds in water tend to be adsorbed onto particulate matter in water. 
Conventional water treatment processes are expected to be effective in removing the CDDs along with the 
particulates. This is substantiated by the fact that only 4 of the 37 positive detections were found in treated 
drinking water, while 33 detections were found in raw water samples.  
During 1986, a survey of 20 community water systems throughout the state of New York was conducted to 
evaluate CDD/CDF concentrations (Meyer et al. 1989).  The sampling sites selected were representative of 
major surface water sources in the state used to obtain drinking water.  The sites included surface water 
sources receiving industrial discharges and those known to contain CDD-contaminated fish, as well as 
water sources from more remote areas.  Raw water sampled at the Lockport, NY, facility contained 
concentrations of TCDDs (1.7 ppq) as well as concentrations of TCDFs to OCDFs (18, 27, 85, 210, and 
230 ppq, respectively).  These data show that the CDF congener group concentrations increased with 
increasing chlorine numbers.  TCDFs were also detected in finished water sampled at the Lockport facility 
(duplicate samples contained 2.1 and 2.6 ppq).  Except for a trace of OCDF detected at one other location, 
no other CDDs/CDFs were detected in finished water at any of the other 19 community water systems 
surveyed. 
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Utility telecommunication and railway right-of-ways may be contaminated by leaching of CDDs associated 
with chlorophenol-treated railway ties and utility poles.  A study in British Columbia showed that CDDs 
and CDFs were not detected in parkland ditch water (control area), but were detected in farmland, utility, 
and railway right-of-way ditch water (Wan and van Oostdam 1995).  Total mean CDD concentrations 
(mainly OCDD and HpCDD) measured in farm ditch water, and railway ditch water, without and with 
utility poles were 2.22 µg/L, 45 µg/L, and 9,627 µg/L respectively.  Mean total concentrations of CDDs 
were much higher in ditch water adjacent to utility poles (13,142 ng/L) than in ditch water 4 meters 
downstream  (4,880 ng/L) or 4 meters upstream of  the utility  poles (2.72 ng/L). The authors concluded 
that utility poles and railway ties are a potential constant source of CDD/CDF contamination to both water 
and sediment in aquatic environment through ditch runoff. 
2,3,7,8-TCDD has been detected in surface water samples collected at 9 sites of the 91 NPL hazardous 
waste sites where it has been detected in some environmental media (HazDat 1998).  CDDs have been 
detected in surface water samples collected at 14 of the 126 NPL sites where they have been detected in 
some environmental media.  TCDDs, PeCDDs, HxCDDs, HpCDDs, and OCDD have been detected in 
surface water samples at 10, 1, 4, 4, and 6 sites of the 105, 34, 43, 49, and 53 NPL sites, respectively, where 
they have been detected in some environmental media (see Table 5-1). 
Groundwater in the vicinity of an abandoned wood treatment facility was sampled from monitoring wells 
constructed at depths ranging from 6.1 to 30.5 meters and was analyzed for CDDs in January 1984 (Pereira 
et al. 1985). Concentrations of HxCDD, HpCDD, and OCDD in groundwater samples taken from wells at a 
depth of 6.1 meters were 61 ppt, 1,500 ppt, and 3,900 ppt, respectively.  The authors noted that the high 
concentrations of CDDs in the sample from a depth of 6.1 meters probably resulted from the presence of 
microemulsions of oil that were difficult to separate from the sample.  Groundwater samples collected from 
deeper wells (12.2–30.5 meters) contained HxCDD, HpCDD, and OCDD at concentration ranges of not 
detected to 21 ppt, not detected to 34 ppt, and not detected to 539 ppt, respectively (Pereira et al. 1985). 
2,3,7,8-TCDD has been detected in groundwater samples collected at 15 sites of the 91 NPL hazardous 
waste sites where it has been detected in some environmental media (HazDat 1998).  CDDs have been 
detected in groundwater samples collected at 32 of the 126 NPL sites where they have been detected in 
some environmental media.  TCDDs, PeCDDs, HxCDDs, HpCDDs, and OCDD have been detected in 
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groundwater samples at 21, 3, 10, 14, and 16 sites of the 105, 34, 43, 49, and 53 NPL sites, respectively, 
where they have been detected in some environmental media (see Table 5-1). 
In conclusion, CDDs are rarely detected in drinking water at ppq levels or higher.  Raw water samples 
generally have higher concentrations of CDDs (9–175 ppq) than finished drinking water samples 
(19–46 ppq) because conventional water treatment processes remove the CDDs along with the particulates 
from raw water.  CDDs have been detected in treated effluent samples collected at pulp and paper mills 
using the bleach kraft or sulfite bleaching process. In groundwater samples collected near industrial sites, 
CDDs have been detected at concentrations up to 3,900 ppt. 
5.4.3 Sediment and Soil 
Soil. As part of this National Dioxin Study, EPA conducted a 2-year nationwide study to assess the 
extent of 2,3,7,8-TCDD contamination (EPA 1987n).  Environmental samples (including soil, sediment, 
water, and fish) were analyzed for 2,3,7,8-TCDD concentrations at seven different tiers of sites (including 
NPL, various industrial, urban, and pristine rural sites).  Soil concentrations at most of the Tier 1 and 2 sites 
(i.e., sites classified as or expected to be classified as NPL sites) were in the ppb range, although at a few of 
the sites where 2,4,5-TCP production waste storage or disposal occurred, concentrations were as high as 
2,000 ppm.  Offsite soil contamination of concern (in the ppb range) was confirmed at 7 of these 100 Tier 
1 and 2 sites. At 11 of 64 Tier 3 sites (facilities and associated disposal sites where 2,4,5-TCP and its 
derivatives were formulated into pesticide products), soil concentrations exceeded 1 ppb, but in 7 of the 
11 sites where contamination was found, only 1 or 2 samples exceeded 1 ppb.  At 15 of 26 Tier 5 sites 
(areas where 2,4,5-TCP and other pesticide derivatives had been or were currently being used), soil 
concentrations were generally above 1 ppt with one detection at 6 ppb. Two-thirds of all detections at the 
Tier 5 sites were below 5 ppt. At 3 of 18 Tier 6 sites (organic chemical and pesticide manufacturing 
facilities where production processes could have resulted in 2,3,7,8-TCDD being introduced into the waste 
streams), soil concentrations exceeded the 1 ppt detection limit, although these concentrations were limited 
to one or two samples per site.  In general, 2,3,7,8-TCDD was detected infrequently and at very low 
concentrations in background soil samples taken at sites (urban and rural areas) that did not have previously 
known sources of 2,3,7,8-TCDD contamination (1 ppt detection limit).  Only 17 of 221 urban sites and 1 of 
138 rural sites in Tier 7 (background sites not expected to have contamination) had detectable levels of 
2,3,7,8-TCDD, with 11.2 ppt being the highest concentration reported (Des Rosiers 1987; EPA 1987n). 
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Background levels of CDDs in soil were measured at Elk River, Minnesota, a semi-rural area located about 
25 miles northwest of Minneapolis-St. Paul (Reed et al. 1990).  No major industrial or commercial activity 
occurred in the area at the time of the study.  The soil data reflected generally low background 
concentrations of CDDs. 2,3,7,8-TCDD, total TCDD, and PeCDD were not detected (detection limit range 
0.75–2.9 ppt). OCDD represented the highest baseline levels, ranging from 340 to 3,300 ppt.  Levels of 
total HpCDD ranged from 62 to 640 ppt, while levels of total HxCDD ranged from 12 to 99 ppt (Reed et al. 
1990). 
Birmingham (1990) analyzed soil samples from industrial, urban, and rural sites in Ontario, Canada, and 
some Midwestern U.S. states for CDDs and CDFs.  The concentrations of CDD/CDF in rural soils were 
generally not detectable, although HpCDDs and OCDD were found in a few samples.  In urban soils, the 
tetra- through octa-congener groups were measured for both CDDs and CDFs.  The HpCDDs and OCDD 
dominated the homologue profile and were two orders of magnitude greater than concentrations in rural 
soils. These urban soils also contained measurable quantities of TCDDs, PeCDDs, and HxCDDs. 
Industrial soils did not contain any TCDDs or PeCDDs, but they did contain the highest concentrations of 
the HpCDDs, OCDD, TCDFs, HpCDFs, and OCDFs.  In an earlier study, soil concentrations of 
2,3,7,8-TCDD were measured in industrialized areas of a group of mid-western and mid-Atlantic states 
(Illinois, Michigan, New York, Ohio, Pennsylvania, Tennessee, Virginia, and West Virginia) (see 
Table 5-4) (Nestrick et al. 1986). Many of the samples were taken within one mile of major steel, 
automotive, or chemical manufacturing facilities or of municipal solid-waste incinerators.  The data show 
that in these typical industrialized areas, 2,3,7,8-TCDD soil concentrations are below 0.01 ppb (range, 
ND–9.4 ppt). The widespread occurrence of 2,3,7,8-TCDD in U.S. urban soils at levels of 0.001–0.01 ppb 
suggests that local combustion sources, including industrial and municipal waste incinerators, are the 
probable sources of the trace 2,3,7,8-TCDD soil concentrations found in those locations (Nestrick et al. 
1986). Soil samples collected in the vicinity of a sewage sludge incinerator were compared with soil 
samples from rural and urban sites in Ontario, Canada (Pearson et al. 1990).  Soil in the vicinity of the 
incinerator showed a general increase in CDD concentration with increasing degrees of chlorination.  Of the 
CDFs measured, only OCDFs was detected (mean concentration, 43 ppt).  Rural woodlot soil samples 
contained only OCDD (mean concentration, 30 ppt).  Soil samples from undisturbed urban parkland 
revealed only concentrations of HpCDDs and OCDD, but all CDF congener groups from TCDF to OCDF 
were present. The parkland samples showed an increase in concentrations from the HpCDDs to OCDD and 
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A large-scale environmental survey was conducted by the Dow Chemical Company to determine soil levels 
of 2,3,7,8-TCDD on the Dow Midland Plant site and in the city of Midland, Michigan (Nestrick et al. 
1986). The Dow Midland Plant site manufactures a variety of chlorophenolic compounds.  Soil samples 
were taken from three different types of areas: locations known to be directly associated with current or 
historic chlorophenolic production and handling, locations known to be associated with incineration of 
chemical and conventional wastes and with ash storage, and locations away from established 2,3,7,8-TCDD 
sources that provide a measure of general background levels of 2,3,7,8-TCDD surface soil within the Dow 
property.  Soil samples taken from chlorophenolic production areas showed a range of 2,3,7,8-TCDD 
concentrations from 0.041 to 52 ppb.  Two localized areas of elevated concentrations (above 5 ppb) were 
identified with peaks at 34 ppb and 52 ppb. All other samples taken around this area had 2,3,7,8-TCDD 
soil concentrations below 1 ppb. Two of 10 surface soil samples with 2,3,7,8-TCDD concentrations above 
1 ppb (2.0 and 4.3 ppb) were found near the waste incinerator.  The concentrations observed there 
(0.018–4.3 ppb) closely matched the 2,3,7,8-TCDD content of the ash produced by the incinerator, which 
ranged up to 10 ppb. The background levels of 2,3,7,8-TCDD (0.0065–0.59 ppb) within the Dow Midland 
Plant site were well below 1 ppb. Soil samples taken within the city of Midland showed 2,3,7,8-TCDD soil 
concentrations below the 1 ppb concern level established by the U.S. Public Health Service, Centers for 
Disease Control and Prevention (CDC), for residential areas (Kimbrough et al. 1984).  2,3,7,8-TCDD soil 
concentrations in the city of Midland (0.6–450 ppt) were higher in areas nearer the Dow Chemical 
Company Midland Plant site (22–450 ppt) (Nestrick et al. 1986).  This gradient suggests that operations on 
the Midland Plant site are associated with the appearance of the trace levels of 2,3,7,8-TCDD in the nearby 
environment.  
Several studies have analyzed soil samples in the State of Missouri for 2,3,7,8-TCDD contamination and all 
reported values are comparable.  Concentrations of 2,3,7,8-TCDD in soil samples from contaminated sites 
throughout Missouri ranged from 30 to 1,750 ppb and concentrations in Times Beach, MO, a heavily 
contaminated site ranged from 4.4 to 317 ppb (Tiernan et al. 1985). In another study, soil core samples 
taken from a roadside in Times Beach, MO, contained levels of 2,3,7,8-TCDD ranging from 0.8 to 274 ppb. 
Many roadways in Times Beach had been sprayed with waste oil containing CDDs for dust control 
(Freeman et al. 1986).  In a third study conducted by Hoffman et al. (1986), 2,3,7,8-TCDD was measured in 
soil samples from the Quail Run Mobile Home Park in Gray Summit, MO.  A maximum soil concentration 
of 2,200 ppb (single non-composited sample) was detected at one site; however, concentrations typically 
ranged from 39 to 1,100 ppb in composite soil samples.  
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2,3,7,8-TCDD has been detected in soil samples collected at 61 sites of the 91 NPL hazardous waste sites 
where it has been detected in some environmental media (HazDat 1998).  CDDs have been detected in soil 
samples collected at 94 of the 126 NPL sites where they have been detected in some environmental media. 
TCDDs, PeCDDs, HxCDDs, HpCDDs, and OCDD have been detected in soil samples at 71, 21, 29, 34, and 
38 sites of the 105, 34, 43, 49, and 53 NPL sites, respectively, where they have been detected in some 
environmental media (see Table 5-1). 
In conclusion, soil concentrations of CDDs are typically higher in urban areas than in rural areas.  Soil 
concentrations associated with industrial sites are clearly the highest, with CDD levels ranging from the 
hundreds to thousands of ppt. In general, as the degree of chlorination increases, the concentrations 
increase. HpCDD and OCDD congeners are generally found at higher concentrations in soil and sediments 
than the TCDD, PeCDD, and HxCDD congeners. 
Sediment. Highly stratified sediments from Green Lake in upstate New York had CDD concentrations 
that could be correlated with atmospheric deposition.  CDDs could be detected as far back as 1860–1865 at 
a total CDD concentration of 7 ppt; 98% of all CDDs detected were OCDD.  The CDD sediment profile 
showed a strong increase after 1923 and continued to increase until 1984 (the last year analyzed), with a 
maximum concentration of >900 ppt, of which 75% was OCDD (Smith et al. 1992). 
In another study, surficial (surface) sediment samples taken from the Saginaw River and Bay and from 
southern Lake Huron showed that CDDs are ubiquitous in the samples studied, including the most remote 
locations (Czuczwa and Hites 1984). The concentrations were highest in those sediments collected closest 
to urban areas and lowest in open-lake cores. This indicates that the most of the CDDs found in these 
samples are anthropogenic in origin (Czuczwa and Hites 1984).  The CDDs found closest to urban areas 
may be related to point source industrial inputs as well as atmospheric deposition, while CDDs found at the 
remote sites are likely to be only atmospheric in origin.  In dated sediment cores, CDDs were absent before 
1940. Thus, the authors suggest that accumulation of CDDs in the environment is a recent phenomenon and 
is related to industrial activities (Czuczwa and Hites 1986a, 1986b).  Surface sediments taken from the 
Great Lakes showed that CDDs were ubiquitous in the sediments.  OCDD was predominant at concen­
trations ranging from 560 to 4,800 ppt (dry weight) (Czuczwa and Hites 1986a, 1986b).  The sediments also 
contained relatively high concentrations of HpCDD. The less chlorinated CDDs were not found in the 
sediments (Czuczwa and Hites 1986a).  Sediment samples were collected from five sampling stations in the 
western basin of Lake Ontario near the mouth of the Niagara River and were analyzed for 2,3,7,8-TCDD 
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(Onuska et al. 1983). Measurable quantities of 2,3,7,8-TCDD were present in sediment at two of the 
stations. The highest concentration of 2,3,7,8-TCDD (13 ppt) was found at a depth of 3–5 cm, followed by 
a concentration of 4 ppt at a depth of 3 cm, and 3 ppt at a depth of 13–14 cm.  Concentrations of 
2,3,7,8-TCDD in the rest of the sediment samples were below the detection limit (0.1 ppt) (Onuska et al. 
1983). 
Surficial sediments collected from Jackfish Bay on the north shore of Lake Superior, near a pulp and paper 
manufacturer, contained moderate concentrations of the TCDFs (range of geometric mean, 2.4–6,223 pg/g) 
and OCDD congeners (range of geometric mean, 12–250 pg/g), with trace (< 60 ppt) concentrations of 
other congeners (Sherman et al. 1990).  The OCDF and OCDD profile for a sediment core collected from 
Moberly Bay was similar to the surficial sediment pattern.  These congener groups predominated at all 
sediment depths where detectable concentrations occurred.  Low concentrations of the HpCDD, PeCDF, 
and HpCDF congeners also were detected. The concentration profile of the HpCDF congener group 
showed a relatively high value that dropped abruptly to nondetectable (<60 ppt) below a sediment depth of 
10 cm.  This abrupt change corresponded to a date of 1973 that reflected an operational change at the pulp 
mill. 
Surficial harbor sediments collected near a PCP wood preserving plant in Thunder Bay, Ontario, Canada on 
the north shore of Lake Superior were found to contain CDDs and CDFs (McKee et al. 1990).  The highest 
concentrations were detected at stations closest to the plant docking area and lower concentrations occurred 
at stations further from the source (McKee et al. 1990).  No CDDs or CDFs were detected below the 
surficial layer.  Concentrations of TCDD and PeCDD congeners were below detection limits (<1 ppt)  in all 
samples.  The concentrations of the HxCDD and OCDD congeners increased with the degree of 
chlorination. The maximum concentrations of the HxCDDs to OCDD ranged from 5,600 ppt (HxCDDs) to 
980,000 ppt (OCDD). As with the CDD distribution profile, the concentrations of HxCDFs and OCDFs 
increased with the degree of chlorination. 
Sediment samples taken from Love Canal storm sewers in Niagara Falls, NY, contained from 0.9 to 
312 ng/g of 2,3,7,8-TCDD (0.9–312 ppb) (Smith et al. 1983).  The highest concentration of 2,3,7,8-TCDD 
(312 ppb) was found immediately adjacent to the canal at its southern end; the next highest concentration 
(120 ppb) was found just upstream.  A sample taken one street away from the canal, near the high altitude 
division of the storm sewer system where only a small amount of canal runoff occurs, contained only 
0.9 ppb 2,3,7,8-TCDD (Smith et al. 1983). 
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Surface sediment samples were collected from various estuaries in the United States: Black Rock Harbor 
(an urban industrialized estuary in Connecticut), Long Island Sound (a relatively clean reference site in 
New York), Narragansett Bay (an estuary affected by input from chemical industries in Rhode Island), New 
Bedford Harbor (an estuary within a Superfund site boundary in Massachusetts), and Eagle Harbor (a 
creosote wood-treatment facility in Washington) (Norwood et al. 1989).  2,3,7,8-TCDD was detected in 
sediment from Black Rock Harbor (56–57 ppt), Narragansett Bay (15–19 ppt), and in some of the sediment 
samples found in New Bedford Harbor (4.2–4.6 ppt).  1,2,3,7,8-PeCDD was detected in estuarine sediments 
from Black Rock Harbor (79–95 ppt), New Bedford Harbor (21–29 ppt), and Eagle Harbor (5 ppt). 
HxCDD, HpCDD, and OCDD were also detected in sediments from all estuaries at concentrations ranging 
from approximately 10–100 ppt, 500–3,000 ppt and 2,000–37,000 ppt, respectively.  The highest 
concentrations of HpCDD (>1,000 ppt) were detected in Narragansett Bay sediments, while the highest 
concentration of OCDD (37,000 ppt) was detected in Eagle Harbor sediments.  The levels of CDDs 
reported for all samples were for dry weight (air dried) concentrations (Norwood et al. 1989). 
Sediment samples collected in 1985–86 from estuarine areas (Passaic River and Newark Bay), near a 
Newark, NJ, facility that manufactured 2,4,5-T between 1948 and 1969, contained high concentrations of 
2,3,7,8-TCDD and OCDD (Bopp et al. 1991). Concentrations of OCDD in the sediment were many times 
higher than concentrations of 2,3,7,8-TCDD. The study indicated that there probably was a significant 
regional source (i.e., combustion and/or use of the wood preservative PCP) for OCDD, a source that is 
lacking in significant concentrations of 2,3,7,8-TCDD relative to the local industrial source.  A high 
correlation was found between 2,3,7,8-TCDD and 2,3,7,8-TCDF concentrations, suggesting that the 
industrial site was a major source of 2,3,7,8-TCDF to the natural waters of the area.  Sediment core samples 
from a depth of 108–111 cm contained 2,3,7,8-TCDD at a concentration of 21,000 ppt, the highest 
concentration measured in the study.  This residue value corresponds to deposition of sediments that 
occurred during the late 1950s to early 1960s during active 2,4,5-T production at the industrial site. 
Maximum concentrations of TCDD in the sediment cores corresponded to the period of maximum 2,4,5-T 
production, with more recently deposited sediments containing lower concentrations of TCDD.  This study 
established the persistence of 2,3,7,8-TCDD and 2,3,7,8-TCDF in anaerobic sediments on a time scale of 
several decades (Bopp et al. 1991). 
There has been considerable discussion about historic releases of CDDs/CDFs in Newark Bay, New Jersey. 
Bopp et al. (1991) suggested that a single source (pesticide production facility) is responsible for the 
presence of 2,3,7,8-TCDD/TCDF in the watershed.  Recently, Wenning et al. (1992, 1993a, 1993b), 
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using chemometric comparisons of CDD/CDF residues in surficial sediments, found that congener patterns 
in Newark Bay were closely related to those found in sediments from other industrialized waterways with 
several different pollutant sources (e.g., New Bedford Harbor, Massachusetts; Black Rock Harbor, 
Connecticut; Providence River, Rhode Island; Eagle Harbor, Washington, as well as several European 
waterways).  The similarities and differences among the various waterways examined in the analysis 
suggests that the presence of 2,3,7,8-substituted CDDs/CDFs in surficial sediments from Newark Bay are 
more likely due to multiple sources of contamination.  Most recently, Ehrlich et al. (1994) identified the 
relative contributions of various sources of CDDs/CDFs to recently deposited sediments of Newark Bay 
using polytopic vector analysis, a multivariate statistical technique.  These authors also concluded that the 
2,3,7,8-substituted CDD/CDF patterns in the sediments of Newark Bay are consistent with discharges from 
multiple sources.  In a recent study, Huntley et al. (1997) reported that combined sewer overflows may 
contribute substantially to surface sediment contamination of the nearby Passaic River.  Several such 
sources that have existed over the past century in the vicinity include scrap metal refineries, pulp and paper 
mills, copper smelters, chemical manufacturing plants, municipal sewage treatment plants, and industrial/ 
municipal incinerators (EPA 1987n).  2,3,7,8-TCDD sediment concentrations ranged from below the 
detection limit (22 ppt) to 21,000 ppt (21 ppb), whereas OCDD concentrations ranged from 3.1 ppb to 
42,000 ppt (42 ppb), although other sources of OCDD were thought to contribute to the elevated levels of 
OCDD (Bopp et al. 1991; Wenning et al. 1992). 
Sludges from various Ontario pulp and paper plants using either the bleached kraft (8 mills) or sulfite 
bleaching process (2 mills) were analyzed for CDDs (Clement et al. 1989).  2,3,7,8-TCDD was detected in 
sludge samples at a concentration range of 170–370 ppt.  Only one other TCDD isomer (180 ppt) was 
detected in a sludge sample, but it was not identified.  PeCDDs and HxCDDs were not detected in any 
sludge samples, whereas HpCDD (400 ppt) was found in 1 sludge sample and OCDD (120–1,800 ppt) was 
found in 6 sludge samples (Clement et al. 1989). 
Utility telecommunication and railway right-of-ways may be contaminated by leaching of CDDs associated 
with chlorophenol-treated railway ties and utility poles.  A study in British Columbia showed that CDDs 
and CDFs were not detected in parkland ditch sediments (control area), but were detected in farmland, 
utility, and railway right-of-way ditch sediments (Wan and van Oostdam 1995).  Total mean CDD 
concentrations (mainly OCDD and HpCDD) ranged from 18.8 to 277 ng/kg (ppt) (dry weight) in ditch 
sediments and ballasts respectively.  Concentrations of CDDs were much higher in ditch sediment adjacent 
to utility poles (mean 2,576 ng/kg (ppt) [dry weight]) than in sediment  4 meters downstream (14 ng/kg 
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[dry weight]) or 4 meters upstream of  the utility  poles (not detected).  CDD concentrations in ditch water 
were also higher close to the poles (mean 13,142 ng/L [ppt] than 4 meters downstream of the poles (mean 
4,880 ng/L [ppt]). The authors concluded that utility poles and railway ties are a potential constant source of 
CDD/CDF contamination to both water and sediment in aquatic environment through ditch runoff. 
2,3,7,8-TCDD has been detected in sediment samples collected at 17 sites of the 91 NPL hazardous waste 
sites where it has been detected in some environmental media (HazDat 1998).  CDDs have been detected in 
sediment samples collected at 31 of the 126 NPL sites where they have been detected in some environ­
mental media.  TCDDs, PeCDDs, HxCDDs, HpCDDs, and OCDD have been detected in sediment samples 
at 22, 7, 10, 9, and 13 sites of the 105, 34, 43, 49, and 53 NPL sites, respectively, where they have been 
detected in some environmental media (see Table 5-1). 
In conclusion, CDD congener profiles in sediment generally reflect those exhibited by the contamination 
source or sources. High concentrations of HxCDDs, HpCDDs, and OCDDs in sediment are usually the 
result of anthropogenic inputs via industrial processes and releases or urban runoff, and concentrations 
generally increase with the degree of chlorination, but decrease with distance from the source (McKee et al. 
1990). 
5.4.4 Other Environmental Media 
Foods. The FDA has conducted limited analyses for the higher chlorinated CDDs (HxCDD, HpCDD, 
and OCDD) in market-basket samples collected from 1979 to 1984 under the FDA's Total Diet Program 
(Firestone et al. 1986). Food samples found to contain PCP residues >0.05 µg/g (ppm) were analyzed for 
1,2,3,4,6,7,8-HpCDD and OCDD. In addition, selected samples of ground beef, chicken, pork, and eggs 
from the market-basket survey were analyzed for these CDD congeners (wet weight basis), regardless of the 
results of the PCP analysis.  HxCDD was not found in any of the foods sampled; however, the detection 
limit (10–40 pg/g [ppt]) was very high.  Generally low concentrations (<300 pg/g [ppt]) of HpCDD and 
OCDD were found in bacon, chicken, pork chops, and beef liver.  Several beef livers had higher concen­
trations of OCDD residues (614–3,830 pg/g), and one beef liver contained 428 pg/g (ppt) of HpCDD. 
HxCDD, HpCDD, and OCDD were not detected in milk, ground beef, or seafood samples, but the detection 
limits (10–40 ppt) were very high.  No CDDs were found in 17 egg samples collected in various parts of the 
United States. OCDD was detected in 2 of 18 pork samples (27 ppt and 53 ppt) and in 2 of the 16 chicken 
samples (29 ppt and 76 ppt).  One chicken sample with PCP residues (>0.05 µg/g) contained 
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concentrations of 1,2,3,4,6,7,8-HpCDD (28 ppt) and OCDD (252 ppt).  The CDD residues (21–1,610 pg/g) 
in eggs from Houston, Texas, and Mena, Arkansas, with PCP residues >0.05 µg/g collected in 1982 and 
1983–84, respectively, contained 1,2,3,4,6,7,8-HpCDD concentrations ranging from 21 to 588 ppt, and 
OCDD concentrations ranging from 80 to 1,610 ppt.  These residues were attributed to local PCP 
contamination problems in these areas (Firestone et al. 1986).  Milk samples contaminated with PCP at 
levels ranging from 0.01 µg/g to 0.05 µg/g PCP contained no detectable CDDs.  It should be noted that the 
reported limits of detection (10–40 ppt) for the FDA analyses from these older samples, are higher than 
concentrations of CDDs observed in foods from more recent studies.  Samples of beef liver, pork chops, 
chicken, ground beef, and eggs collected in the United States and analyzed for HpCDD and OCDD 
contained average concentrations of HpCDD (2.2–9.6 ppt) and OCDD (6.3–47.6 ppt) (Jasinski 1989).  Eggs 
contained the lowest levels of HpCDD and OCDD, and beef liver contained the highest levels. 
LaFleur et al. (1990) analyzed the concentration of 2,3,7,8-TCDD and 2,3,7,8-TCDF (wet weight basis) in a 
variety of food products collected randomly from grocery stores located in the southern, Midwestern, and 
northwestern regions of the United States. Concentrations of 2,3,7,8-TCDD ranged from 17 to 62 pg/kg for 
ground beef, were not detectable in ground pork, ranged from 12 to 37 pg/kg for beef hot dogs, and ranged 
from 7.2 to 9.4 pg/kg for canned corned beef hash on a whole-weight basis.  Concentrations of 
2,3,7,8-TCDF were generally much less than concentrations of 2,3,7,8-TCDD, with the exception of ground 
pork and corned beef hash. For ground pork, TCDD concentrations were not detectable and 2,3,7,8-TCDF 
concentrations ranged from 13 to 20 pg/kg and for corned beef hash, concentrations of TCDD ranged from 
7.2 to 9.4 pg/kg, while concentrations of TCDF ranged from 9.8 to 10 pg/kg. 
A study conducted by the province of Ontario, Canada analyzed concentrations of CDDs/CDFs in a variety 
of foods locally grown in Canada or imported from the United States and New Zealand (Birmingham et al. 
1989). Concentrations of OCDD in various foods ranged from 3 to 210 ppt (wet weight basis).  OCDD 
concentrations were detected in U.S. eggs (8 ppt), U.S. beef (24 ppt), Canadian hamburger (3 ppt), and 
Canadian chicken samples (210 ppt).  Chicken also contained 15 ppt HpCDD, but no other CDDs were 
detected in these samples.  Fruits and vegetables were generally free of CDD and CDF residues (detection 
limit = 1 ppt).  OCDD concentrations ranging from 0.6 to 8 ppt (wet weight) were also detected in samples 
of U.S. potatoes (3 ppt), apples (8 ppt), peaches (0.6 ppt), and wheat (0.7 ppt).  For these food items, OCDD 
was the only homologue detected.  No 2,3,7,8-TCDD was detected in any of the food samples tested 
(detection limits of 1–4 ppt). 
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Beck et al. (1989a) analyzed the concentrations of CDDs/CDFs in 22 samples of foodstuffs collected in the 
Federal Republic of Germany.  Twelve randomly collected food samples (chicken, eggs, butter, pork, 
redfish (ocean perch), cod, herring, vegetable oil, cauliflower, lettuce, cherries, and apples) were purchased 
in various stores in West Berlin. The highest 2,3,7,8-TCDD levels were observed in fish samples with 
concentrations of 4.7, 23, and 2.8 ppt (lipid basis) for herring, cod, and redfish, respectively. Concentrations 
of 2,3,7,8-TCDD (on a lipid basis) in meat, poultry, and dairy products were lower; with concentrations 
ranging from 0.01 ppt in sheep, 0.03 in pork, 0.2 in eggs, 0.3 in chicken, 0.6 in cattle, and 0.02 in cow's 
milk and 0.08 in butter (see Table 5-5).  The EPA TEQ values for CDDs/CDFs  calculated for these 
products ranged from 20.0–39.7 ppt in fish, 0.14–1.31 ppt in meat and poultry, and from 0.43 to 0.86 ppt in 
dairy products.  In all samples tested, the 2,3,7,8-substituted congeners predominated in the samples and 
non-2,3,7,8-substituted congeners were not detected in fish, chicken and eggs.  For meat, poultry, and dairy 
samples, the congener profile showed high concentrations of 1,2,3,4,6,7,8-HpCDD and OCDD with 
concentrations of most other congeners at or below 1 ppt (lipid basis).  In fish samples, high concentrations 
of the 2,3,7,8-substituted congeners, TCDDs (range 2.8–23 ppt), PeCDD (range 1.3–12 ppt), HxCDD 
(range 0.01–17 ppt), and OCDD (range 11–83 ppt) resulted in TEQ values for CDDs/CDFs ranging from 
20–40 ppt (lipid basis). In the five food samples of plant origin, no CDDs/CDFs were detected on a whole 
weight basis (detection limit . 0.01 ppt). 
Congener-specific analyses for CDDs and CDFs were performed on 18 dairy, meat, and fish products 
obtained from a supermarket in upstate New York (Schecter et al. 1994d).  Total CDD concentrations (on a 
wet weight basis) ranged from 0.35 to 2.91 ppt in fish, 0.6–59.3 ppt for meats, and 0.6–14 ppt in dairy 
products. A summary of the CDD/CDF concentrations and TEQ concentrations calculated for the 18 foods 
is presented in Table 5-6. The TEQ for both the CDDs and CDFs on a wet weight basis for these food 
samples ranged from 0.02 to 1.5 ppt, 0.02–0.13 ppt for fish products, 0.03–1.5 ppt for meat products, and 
0.04–0.7 ppt for dairy products, with the highest TEQ found in ground beef. 
Recently, the EPA and U.S. Department of Agriculture (USDA) completed the first statistically designed 
surveys of the occurrence and concentrations of CDDs/CDFs in beef fat (Ferrario et al. 1996; Winters et al. 
1996), pork fat (Lorber et al. 1997), poultry fat (Ferrario et al. 1997), and the U.S. milk supply (Lorber et al. 
1998). The congener specific results for various foods are shown in Table 5-7.  It is clear from the results, 
that two congeners (1,2,3,4,6,7,8-HpCDD and 1,2,3,4,6,7,8-OCDD) were typically found at the highest 
concentrations in all food samples.  Concentrations of 2,3,7,8-TCDD were highest in heavy fowl (0.43 ppt) 
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(0.10 ppt), young chickens (0.16 ppt), light fowl (0.03 ppt) and milk (0.07 ppt).  The total concentrations of 
CDDs/CDFs were highest in pork fat (75.67 ppt) and milk (15.43 ppt), and ranged from 5.68 to 14.09 ppt 
for all other types of foods tested.  The TEQ value for CDDs/CDFs combined was highest for pork fat (1.30 
ppt), heavy fowl (0.98 ppt), young turkeys (0.93 ppt), and beef fat (0.89 ppt), with lower TEQ values of 
0.40–0.82 ppt for young chickens, light fowl, and milk. 
CDDs have been found in infant formulas purchased in the United States (Schecter et al. 1989c).  The infant 
formulas were derived from cow's milk or soybeans.  In general, both types of infant formula had very low 
concentrations of CDDs. 2,3,7,8-TCDD and PeCDD were not detected in cow's milk or soybean formula at 
detection limits ranging from 0.5 to 1.0 ppt.  HxCDD was not detected in soybean formula at the same 
detection limits.  Whole and lowfat (2% fat) cow's milk contained total HxCDD at lipid-adjusted 
concentrations of 3.6 and 3.3 ppt, respectively.  Lipid-adjusted levels of HpCDD were found in whole cow's 
milk formula (6.5 ppt), lowfat (2%) cow's milk formula (8 ppt), and soybean formula (2.3–3.0 ppt).  OCDD 
was the most abundant congener in both cow's milk and soybean formula.  Concentrations of OCDD (lipid­
adjusted) were as follows: cow's milk formula (15 ppt), low fat (2%) cow's milk formula (21 ppt), and 
soybean formula (21–36 ppt) (Schecter et al. 1989c). 
In comparison, a study by LaFleur et al. (1990) reported the concentration of 2,3,7,8-TCDD and 
2,3,7,8-TCDF in whole milk and half and half.  These authors also measured the additional exposure that 
resulted from migration of these compounds from bleached paperboard containers into the milk over 
various storage periods. The concentrations of 2,3,7,8-TCDD in whole milk ranged from 24 to 25 pg/kg 
and in half-and-half ranged from 13 to 14 pg/kg.  The corresponding concentrations of 2,3,7,8-TCDF 
ranged from 260 to 280 pg/kg for whole milk and 146 to 195 pg/kg for half and half.  These authors also 
determined the concentration of 2,3,7,8-TCDD and TCDF for cow’s milk obtained directly from a dairy and 
for milk stored for various time periods in bleached paperboard cartons.  On a lipid basis, the concentration 
of 2,3,7,8-TCDD of control milk obtained directly from the dairy was 0.48 pg/g, and milk stored in 
paperboard cartons for 24, 48, 120, and 288 hours was 0.95, 1.4, 1.9, and 2.7 pg/g, respectively.  The 
2,3,7,8-TCDD and 2,3,7,8-TCDF concentrations in the paperboard carton were 4.3 and 25 ppt, respectively. 
Concentrations of 2,3,7,8-TCDF in the control milk was not detectable, but increased in milk stored in 
cartons for 24, 48, 120, and 288 hours to 6.8, 10.2, 20.1, and 35.1 pg/g, respectively.  The percent migration 
of the 2,3,7,8-TCDD ranged from 2 to 6%, while the percentage of migration of the 2,3,7,8-TCDF ranged 
from 4 to 18% over the same period (LaFleur et al. 1990). 
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Similar levels of CDD contamination were reported in two European studies.  CDDs were detected in 
8 samples of cow's milk in Germany at concentrations ranging from 0.2 ppt for 2,3,7,8-TCDD (detection 
limit 0.2 ppt) to <10 ppt of OCDD (detection limit not significantly higher than blanks) (Beck et al. 1987). 
In a Swedish study, only 1 of 10 samples of milk held in either glass bottles or paper cartons contained a 
detectable level of 2,3,7,8-TCDD (0.46 pg/g milk fat; paper carton; detection limit 0.4 pg/g).  Other CDDs 
were also detected (maximum 7.8 pg/g for OCDD) with the highest concentrations associated with milk 
packaged in paper cartons, indicating that leaching of CDDs from the paper carton into the milk can occur 
(Rappe et al. 1990). 
Fish and Wildlife. A survey of 2,3,7,8-TCDD contamination in benthic (bottom feeding) and predator 
fish from major U.S. watersheds was conducted for the EPA National Dioxin Study (Kuehl et al. 1989).  It 
was observed that 17 of 90 (19%) samples collected at sites statistically selected by the EPA had detectable 
levels of 2,3,7,8-TCDD, whereas 95 of 305 (31%) samples from sites chosen by EPA regional laboratories 
had detectable levels (detection limits 0.5–2 ppt on a wet weight basis).  Of the 112 sites where 
2,3,7,8-TCDD was detected, 74 samples (67%) were below 5 ppt, 34 samples (32%) were between 5 and 
25 ppt, and 4 samples (1%) were above 25 ppt.  A subset of samples collected at sites near the discharges 
from pulp/paper manufacturing facilities (n=28) had a higher frequency of 2,3,7,8-TCDD contamination 
above 5 ppt (38%).  This subset of samples also contained the sample with the highest level of 
2,3,7,8-TCDD contamination (85 ppt).  Of the 29 samples collected in the Great Lakes region, 23 (79%) of 
the sites were found to have detectable levels of 2,3,7,8-TCDD.  The most highly contaminated sample, 
with a concentration of 41 ppt, was collected from Lake Ontario near Oswego, NY.  Four of 57 (7%) 
estuarine or coastal sites had detectable 2,3,7,8-TCDD levels in either fish or shellfish.  The level of 
contamination in these 4 samples ranged from 1.08 to 3.5 ppt (Kuehl et al. 1989).  In another study, fish 
sampled downstream from a bleached kraft paper mill were found to contain higher concentrations of CDDs 
compared with fish sampled upstream of the paper mill (Hodson et al. 1992).  TCDD concentrations in the 
fish ranged from 1.47 pg/g (wet weight basis) in upstream areas to 15.6 pg/g in fish sampled 2 km 
downstream.  Fish sampled 95 km downstream contained only about half the residues (8.87 pg/g TCDD) of 
those collected immediately downstream of the facility (Hodson et al. 1992). 
Travis and Hattemer-Frey (1991) analyzed data collected as part of the National Dioxin Study regarding 
2,3,7,8-TCDD concentrations in fish. The TCDD levels measured in fish from lakes and rivers in the 
United States confirm that 2,3,7,8-TCDD is bioaccumulating in fish and that low-level contamination of 
fish is widespread (EPA 1987n). The fish survey included 304 urban areas in the vicinity of population 
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centers or areas with known commercial fishing activity, including sites in the Great Lakes region.  The 
results of this study indicate that only 29% of fish fillets collected at urban sites had detectable 
concentrations of 2,3,7,8-TCDD (detection limit =1 ppt).  The geometric mean for these fillet samples was 
0.3 ppt (wet weight basis). Fish samples from the Great Lakes area contained higher concentrations of 
2,3,7,8-TCDD than fish from urban areas (e.g., 67 versus 29% contained detectable levels, respectively).  In 
the Great Lakes area, the geometric mean concentrations of 2,3,7,8-TCDD in fish fillets (2.3 ppt) was 
almost 7 times higher than the concentrations in the fillets from fish collected from urban areas (0.3 ppt). 
Comparable concentrations of 2,3,7,8-TCDD were detected in bottom-feeding and predator species from 
the Great Lakes region. Approximately 74% of the fish fillet samples collected from sites near pulp and 
paper mills contained detectable concentrations of 2,3,7,8-TCDD.  The geometric mean concentration for 
these fillet samples was 0.9 ppt.  This geometric mean is 3 times higher than for urban fillet concentrations 
(0.3 ppt) but is approximately 2 times lower than for TCDD concentrations in fillets from the Great Lakes 
Region (2.3 ppt). 
From 1986 to 1989, the National Study of Chemical Residues in Fish (NSCRF) was conducted by the EPA 
as a follow-on study to the National Dioxin Study (EPA 1992).  The purpose of the NSCRF was to assess 
the concentrations of 60 toxic pollutants (including CDDs and CDFs) in the tissues of benthic and game 
fish nationwide. Benthic species were analyzed as whole-body samples, while game species were analyzed 
as fillet samples and all concentrations were on a wet weight basis.  A summary of the prevalence and 
concentrations of 6 CDDs and 9 CDFs detected at 388 sites surveyed nationwide in the NSCRF is presented 
in Table 5-8. Four of the CDDs and three of the CDFs analyzed were detected at over 50% (58–89%) of 
the sites surveyed.  The most frequently detected CDD/CDF compounds (1,2,3,4,6,7,8-HpCDD and 
2,3,7,8-TCDF) were both found at 89% of the sites. These compounds were also detected at the highest 
concentrations: 1,2,3,4,6,7,8-HpCDD at 249 ppt and 2,3,7,8-TCDF at 404 ppt (wet weight).  The mean 
concentrations of these 2 compounds were substantially lower at 10.5 and 13.6 ppt, respectively.  The CDD 
(2,3,7,8-TCDD) believed to be the most toxic congener to mammals, was found at 70% of the sites at a 
maximum concentration of 204 ppt and a mean of 6.8 ppt (wet weight basis).  The NSCRF report further 
shows that pulp and paper mills using chlorine bleach pulp appeared to be the dominant source of the 
2,3,7,8-TCDD and 2,3,7,8-TCDF. Fish collected at sites downstream of pulp and paper mills had 
significantly higher concentrations of 2,3,7,8-TCDD than fish collected near all other source categories. 
The statistical tests also showed the same result for 2,3,7,8-TCDF, with the exception that fish residue 
concentrations downstream of  Superfund sites also marginally met the statistical criteria.  With respect to 
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chlorine bleaching processes) had the highest median 2,3,7,8-TCDD concentrations (5.66 ppt), compared to 
the next highest source category, refinery/other industrial sites (1.82 ppt), industrial/urban sites (1.40 ppt), 
Superfund sites (1.27 ppt), and background sites (0.5 ppt). Source categories with the highest 
2,3,7,8-TCDD concentrations in fish also had the highest TEQ values.  OCDD and OCDFs were not 
analyzed in tissue because at the time the NSCRF study was initiated (1986), the TEFs were zero for these 
compounds.  In 1989, TEFs for OCDD and OCDFs were increased to 0.001.  Consequently, TEQ values 
presented in the NSCRF report may be underreported for samples collected at sites with sources of 
OCDD/OCDFs (e.g., wood preservers) (EPA 1992). 
De Vault et al. (1989) collected samples of lake trout and walleye for CDD and CDF analysis from each of 
the Great Lakes and Lake St. Clair. One of the conclusions of the National Dioxin Study was that fish from 
the Great Lakes region were among the most severely contaminated in the United States.  Fish were 
analyzed for 8 congeners of CDDs and 10 congeners of CDFs.  Total CDD concentrations ranged from 
7.2 ng/kg in lake trout from Lake Superior to 64.5 ng/kg in Lake Ontario (wet weight basis).  Concen­
trations of 2,3,7,8-TCDD ranged from 1 ng/kg in lake trout from Lake Superior to 48.9 ng/kg in lake trout 
from Lake Ontario.  The dominant congener in all but Lake Ontario was 1,2,3,7,8-PeCDD at concentrations 
ranging from 2.3 ng/kg in Lake Superior to 16.7 ng/kg in Lake Michigan.  The only other congener that 
significantly contributed to the total CDD concentration was 1,2,3,6,7,8-HxCDD, which ranged from 
1.3 ng/kg in Lake Superior to 10.9 ng/kg in Lake Michigan.  Substantial interlake differences exist in the 
percentage of total CDD contributed by the various congeners.  The 2,3,7,8-TCDD congener contributes a 
relatively small percentage of the total CDD in fish from Lakes Superior, Michigan, and Erie.  It is 
comparatively more important in Lake Huron (32%) and Lake St. Clair (36%) and contributes 76% of the 
total CDD in Lake Ontario. The results of this study support the widespread contamination of the Great 
Lakes ecosystem and clearly show that both the concentration of individual congeners and the congener 
composition of total CDDs in Great Lakes fish vary significantly between lakes and in Lake Michigan 
between sites. The authors suggest that these differences may be associated with different sources and 
loadings of these compounds to each of the Great Lakes (De Vault et al. 1989).  This is confirmed by the 
analysis of sources of CDDs in the Great Lakes which appear to be both from atmospheric deposition and 
industrial point sources (Hebert et al. 1994). 
In another study, CDDs and CDFs were measured in four species of salmonids (coho salmon, lake trout, 
rainbow trout, and brown trout) collected from Lake Ontario (Niimi and Oliver 1989a).  Total CDD 
concentrations ranged from 46 to 290 ng/kg (ppt) in whole fish and 60–366 ng/kg in muscle composite 
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samples.  Levels of 2,3,7,8-TCDD in whole fish ranged from 60–20 ppt (wet weight basis).  This 
represented 60% of total TCDDs and 10% of total CDDs.  The HxCDD congener group was most dominant 
in all fish species and represented approximately 39% of the total CDD concentrations.  High 
concentrations of OCDD were also detected in coho salmon (160 ng/kg whole fish and 280 ng/kg muscle) 
and lake trout (89 ng/kg whole fish and 28 ng/kg muscle) but not in brown or rainbow trout.  The authors 
could not explain this difference; however, OCDD is typically the CDD present at the highest concen­
trations in Lake Ontario water, suspended sediments, and sediments.  Although the total CDF concentra­
tions were 75% lower than the total CDD concentrations, the levels of 2,3,7,8-TCDF (11–20 ppt) were 
comparable to levels of 2,3,7,8-TCDD (6–20 ppt).  Results of another study by the same authors found that 
TEQ values for PCB concentrations in Lake Ontario salmonids were several fold higher than TEQ values 
for CDDs and CDFs in the same fish species (Niimi and Oliver 1989b). 
Background concentrations of CDDs in fish were measured in the Mississippi River and Lake Orono in Elk 
River, Minnesota, a semi-rural location (Reed et al. 1990).  No major industrial or commercial activity 
occurred in the area at the time of the study, and the survey was conducted as a baseline study prior to the 
operation of the Elk River Electric Generating Station (powered by refuse-derived fuel).  None of the fish 
collected contained measurable amounts of 2,3,7,8-TCDD; however, one of the composites from the 
Mississippi River contained 3.9 ppt of total TCDD (wet weight basis).  Detection limits ranged from 
0.28 ppt to 6.6 ppt on a congener-specific and sample-specific basis and were not individually reported for 
each result. OCDD was the most abundant congener (average 59 ppt, range 56–62 ppt), followed in 
decreasing order by total HpCDD (average 19.3, range 15–22 ppt), total HxCDD (average 6.87 ppt, range 
2.3–11 ppt), and total PeCDD (average 3.9 ppt, range 3.5–4.5 ppt) (Reed et al. 1990).  Lake Orono showed 
the same pattern, with OCDD being the most abundant congener (average 39 ppt, range 35–43 ppt), 
followed by total HpCDD (average 10.5, range 10–11 ppt), and total HxCDD (3.0 ppt).  PeCDDs were not 
detected in the Lake Orono samples (Reed et al. 1990). 
Contamination of the Spring River in southwest Missouri by 2,3,7,8-TCDD is believed to have resulted 
from several well defined point-source waste disposal sites (Crunkilton et al. 1987).  Analysis of 31 fish 
samples (11 different fish species) collected from 1981 to 1983 demonstrated a rapid decline in 
2,3,7,8-TCDD concentrations in fish at increasing distances both upstream and downstream from the area of 
contamination.  Mean concentrations of 2,3,7,8-TCDD 0.5 km downstream from the area of contamination 
were 38 ppt in whole fish and 20 ppt in fish fillets (wet weight basis).  Mean concentrations in fish 
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caught more than 14 km downstream were below 4 ppt in both whole fish and fillet samples (Crunkilton et 
al. 1987). 
Fish samples (butterfish, flounder, hake, and herring) collected in 1984 from the Atlantic Ocean off Long 
Branch, NJ, contained no detectable levels of 2,3,7,8-TCDD (detection limit <10 pg/g) (wet weight basis) 
(Firestone et al. 1986). Cod caught in the northwest Atlantic in November 1990 did not have detectable 
levels of any CDDs in their muscles or ovaries, although 5 of 10 liver samples had OCDD at a mean 
concentration of 0.8 ppt and TCDD was found in 3 of 10 samples at 0.1 ppt (Hellou and Payne 1993).  A 
4-year study of marine and freshwater fish and other edible aquatic organisms taken from Canadian waters 
that received effluents from pulp and paper mills indicated that 2,3,7,8-TCDD was the most prominent 
CDD found in the fish regardless of the tissue sampled or sampling location.  The maximum 2,3,7,8-TCDD 
concentration detected in the edible organisms sampled was for crab hepatopancreas tissue (>500 pg/g) (wet 
weight basis). Whole fish samples also contained greater CDD concentrations than fillet samples (Whittle 
et al. 1993). 
Several studies have been conducted to monitor 2,3,7,8-TCDD concentrations in fish and shellfish in 
northern New Jersey in the vicinity of a pesticide manufacturing site that allegedly released an estimated 
4–8 kg of 2,3,7,8-TCDD over a 20-year period (Bopp et al. 1991).  Samples of striped bass, blue crabs, 
and lobsters collected from Newark Bay and the New York Bight (marine waters directly offshore from 
New York Harbor) all contained high concentrations (up to 6,200 ppt) (wet weight basis) of 2,3,7,8­
substituted TCDD, PeCDD, and CDFs (Rappe et al. 1991). Concentrations of HxCDD and HpCDD 
ranged from <0.1 to 220.7 ppt and <0.7 to 244.9 ppt, respectively. The concentrations of 2,3,7,8-TCDD in 
these marine organisms were higher than any other New Jersey samples and represented the highest 
concentrations of 2,3,7,8-TCDD reported for aquatic species.  The two crustaceans sampled in the study 
had similar congener patterns; they all contained both a large number and large amounts of CDD and 
CDF congeners in addition to the 2,3,7,8-substituted chlorinated compounds.  In contrast, the striped bass 
samples contained primarily the 2,3,7,8-chlorine-substituted congeners.  The concentrations of 
2,3,7,8-TCDD in crab hepatopancreas tissue ranged from 3,700 to 6,200 ppt and from 100 to 120 ppt in 
crab meat.  Concentrations of 2,3,7,8-TCDD were lower in the lobster, ranging from 250 to 610 ppt in the 
hepatopancreas and 5 to 6 ppt in the meat.  Concentrations of 2,3,7,8-TCDD in striped bass muscle tissue 
ranged from 84 to 730 ppt.  In this study, the crustacean samples all contained very complex ion curves 
for the TCDDs showing 10 major and 5 minor peaks, while the striped bass samples primarily contained 
the 2,3,7,8-TCDD isomer and a few other isomers.  With respect to the PeCDDs, the crustacean samples 
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contained 5–6 peaks including the 1,2,3,7,8-PeCDD (100 ppt in hepatopancreas and 1–2 ppt in meat), 
while the major isomer found in the striped bass was 1,2,3,7,8-PeCDD (5–10 ppt).  Regarding the 
HxCDDs, the crustacean samples contained 3 major peaks one of which was 1,2,3,6,7,8-HxCDD 
(100–300 ppt in the hepatopancreas); while the striped bass samples contained concentrations <1 ppt. 
The HpCDD congeners (1,2,3,4,6,7,9- and 1,2,3,4,6,7,8-) were detected in crustacean hepatopancreas 
tissue ranging from 31.7 to 411.9 ppt, while meat samples contained 0.00-8.5 ppt.  Striped bass tissue 
samples contained 4–11.4 ppt.  Concentrations of OCDD ranged from 50.5 to 94.6 ppt in crustacean 
hepatopancreas tissues, 6.3–78.8 ppt in meat samples, while concentrations in striped bass ranged from 
5.1–49.5 ppt (Rappe et al. 1991). 
Cai et al. (1994) analyzed blue crab tissue (hepatopancreas and muscle) from Newark Bay and some adjacent 
areas of the New York Bight for 2,3,7,8-TCDDs and 2,3,7,8-TCDF and several other 2,3,7,8-substituted 
CDDs/CDFs. These authors found 2,3,7,8-TCDD concentrations in hepatopancreas tissue to be 10–20 times 
higher than muscle concentrations.  Lipid content of the hepatopancreas is 6–9% as compared to 1% for muscle 
tissue. The highest concentration of CDDs/CDFs was detected in crabs collected at the station closest to the 
pesticide production facility.  Crabs also had higher CDDs/CDF concentrations in September after feeding all 
summer than crabs collected in June.  Concentrations of 2,3,7,8-TCDD up to 1 ppb were detected in some crabs 
collected from Newark Bay (detection limit 0.5–1 ppt).  Hauge et al. (1994) conducted further studies of blue 
crabs and lobsters from three distinct fisheries in the Hudson-Raritan estuary.  The Ambrose fishery includes 
Raritan and Sandy Hook Bays and extends to a 7-nautical-mile radius from Ambrose Light near the entrance to 
New York Harbor. The Alongshore fishery is a box-shaped area extending from Long Branch, NJ, south to 
Point Pleasant, NJ, and then extending off-shore approximately 25 nautical miles.  The Offshore fishery extends 
eastward from the 50-fathom line to the 100-fathom line approximately 100 miles seaward to the edge of the 
continental shelf. Combined muscle/hepatopancreas samples of blue crabs from Raritan Bay and the lower 
Hudson River had a mean 2,3,7,8-TCDD concentration of 71.5 pg/g (range not detected to 260 pg/g) and a 
mean 2,3,7,8,-TCDF concentration of 67.1 pg/g (range not detected to 110 pg/g).  The mean total TEQ 
concentration was 78.2 pg/g (ppt) (wet weight basis). Both the mean 2,3,7,8-TCDD concentration and the mean 
TEQ values exceeded the FDA guidelines for "no consumption" (>50 ppt) (see Chapter 7). FDA “no 
consumption” guidelines advise consumers  that fish and shellfish should not be consumed when CDD 
concentrations exceed 50 ppt. 2,3,7,8-TCDD and TCDF were detected in 53 and 67% of crabs, respectively.
Levels of 2,3,7,8-TCDD in muscle and hepatopancreas of lobsters were similar in animals from the Ambrose 
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41 pg/g of 2,3,7,8-TCDD/TCDF. The mean total TEQ values were 38.5 pg/g (Ambrose fishery) and 44.4 pg/g 
(Alongshore fishery).  Mean 2,3,7,8-TCDD/TCDF levels thus exceeded the FDA "safe consumption" level 
(#25 ppt), but did not exceed the FDA "no consumption" level (>50 ppt).  None of the lobsters from the 
Offshore fishery contained detectable TCDD/TCDF.  Analysis of separate muscle and hepatopancreas tissues 
from individual lobsters yielded detectable concentrations of both contaminants only in the hepatopancreas 
(<26–410 pg/g for 2,3,7,8-TCDD and <33–380 pg/g for 2,3,7,8-TCDF).  Concentrations in lobster muscle 
tissues were all below detection limits of 6–20 pg/g for 2,3,7,8-TCDD and 10–25 pg/g for 2,3,7,8-TCDF. 
Concentrations of CDDs/CDFs were also evaluated in a bivalve mollusc, the soft-shelled clam (Mya arenaria) 
in Newark Bay, Arthur Kill, and Raritan Bay (Brown et al. 1994).  Clams from Newark Bay contained 
11–20 ppt TCDD, 3.5–5 ppt TCDF, and 13–25 ppt TEQ; those from Arthur Kill contained 4.8–7.7 ppt TCDD, 
3.1–5.1 ppt TCDF, and 6.8–11 ppt TEQ; and those from Raritan Bay contained 0.5–1.1 ppt TCDD, 2–4.6 ppt 
TCDF, and 1.2–2.1 ppt TEQ (wet weight basis). The maximum TEQ concentration of the Newark Bay clams 
(25 ppt) approached the upper limit of the FDA "safe consumption" level of #25 ppt. The FDA believes that 
consumption of fish or shellfish with CDD concentrations #25 ppt should not result in any serious health 
effects. Concentrations decreased with increasing distance from the suspected pesticide plant site near Newark 
Bay.  The authors also showed that the clams could eliminate TCDD and TCDF when they were removed to 
clean water sites. The half-lives of the TCDD, TCDF, and TEQ were calculated to be 45, 111, and 66 days, 
respectively.
Concentrations of CDDs and CDFs were also reported in wood ducks (Aix sponsa), species of migratory 
waterfowl collected near Bayou Meto, Arkansas (White and Hoffman 1995).  The EPA identified a former 
2,4,5-T chemical manufacturing plant as the source of the contamination and subsequently listed the areas on 
the NPL of hazardous waste sites in 1982. Residues in wood duck eggs based on 2,3,7,8-TCDD (TEQs) ranged 
up to 611 ppt, and the egg arithmetic means were 90-fold higher at the site nearest the point source discharge 
compared to the reference site.  The State of Arkansas has issued a wildlife consumption advisory for wood 
ducks in the Bayou Meto area (EPA 1998). 
CDDs were determined in pooled samples of ringed seal (Phoca hispida) blubber, beluga whale (Delphin-
apterus leucas) blubber, and polar bear (Ursus maritimus) liver and fat collected from several areas throughout 
the Canadian north (Norstrom et al. 1990).  All seal samples and all but one polar bear sample had detectable 
levels of 2,3,7,8-TCDD (wet weight) ranging from 2 to 37 ppt, but 2,3,7,8-TCDD was not 
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found in beluga blubber (<2 ppt). All seal samples and one of the three beluga whale samples contained 2,3,7,8­
TCDF (2-7 ppt), but 2,3,7,8-TCDF was not found in polar bear samples.  OCDD concentrations in seal blubber 
and polar bear samples ranged from not detected (<8 ppt) to 43 ppt.  No biomagnification of TCDD and OCDD 
occurred from seal to bear fat.  The highest concentrations of 2,3,7,8-TCDD and OCDD in seals and bears were 
found in the central Canadian Arctic Archipelago, and the lowest concentrations were found in the Hudson Bay 
area. The reason for higher concentrations of 2,3,7,8-TCDD and OCDD in the Arctic than in sub-Arctic areas is 
thought to be transpolar movement of aerosols from combustion-related sources originating in Eurasia 
(Norstrom et al. 1990).  CDDs and CDFs were determined in caribou tissue samples from 7 herds across the 
Canadian Arctic (Hebert et al. 1996). In contrast to marine mammals, concentrations for caribou were 
extremely low, sub-ng/kg (lipid basis), for all congeners except OCDD and 1,2,3,7,8-PeCDD in one herd. 
OCDD was found in most of the samples at concentrations ranging from < 0.2 ng/kg in fat to 4.7 ng/kg in 
adipose tissue. The one pooled liver sample analyzed from the Yukon had an OCDD concentration of 11 ng/kg 
(lipid basis). 2,3,7,8-TCDD was detected in adipose tissue samples of two herds in the eastern Canadian Arctic 
at levels of 0.73 and 0.14 ng/kg, but was not detected in tissue samples from other herds at detections limits as 
low as 0.03 ng/kg (lipid basis). CDF levels were sub-ng/kg in all cases.  TEQs were dominated by non-ortho 
substituted PCBs in all cases, and ranged from 0.33 ng/kg to 3.29 ng/kg in adipose tissue.  The authors 
concluded that caribou tissues are therefore less contaminated than tissues from marine mammals. 
Consumer products.
Cigarettes and Cigarette Smoke.  CDDs have been detected in cigarettes and cigarette smoke.  In a recent 
study, Lofroth and Zebuhr (1992) detected CDD/CDF concentrations in both mainstream (collected directly on 
a glass fiber filter) and sidestream smoke (emitted into an acrylic box and then collected on a glass fiber filter) 
from a single brand of commercially available Swedish cigarettes.  These authors reported that the mainstream 
smoke from 20 cigarettes contained about 18 pg TEQ (1 pg TEQ per cigarette), while sidestream smoke 
contained 39 pg TEQ (2 pg TEQ per cigarette).  No particular isomer contributed more than 20% to the total 
TEQ value. Most isomers were not present at concentrations above the detection limits (0.3–1.3 pg), with the 
exception of 1,2,3,4,6,7,8-HpCDD (6.8 pg), 1,2,3,4,6,7,8-HpCDF (4 pg), and OCDD (7.3 pg). An earlier study 
that used low-resolution mass spectrometry for analysis of CDDs in cigarette smoke obtained by a continuous 
smoking process (all cigarette tobacco gave rise to mainstream smoke) found that HpCDD was the most 
abundant homologue detected, accounting for >90% of the total CDDs (Muto and Takizawa 1989). 
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Paper Products.  CDDs are formed during pulp bleaching, and as a result they have been found in many 
different types of paper products.  2,3,7,8-Substituted CDDs were determined in different samples of coffee-
filter paper (Beck et al. 1988b, 1989d). 2,3,7,8-TCDD was the most abundant congener detected at a mean 
concentration of 3.85 ppt (range 1.6–7.3 ppt). OCDD was detected at a mean concentration of 2.05 ppt (range 
0.7–3.5 ppt). PeCDDs, HxCDDs, and HpCDDs were identified at concentrations ranging from 0.03 to 0.7 ppt. 
In an earlier study, HxCDD was the most abundant homologue detected in coffee filters (2.1 ppt) and 
2,3,7,8-TCDD was found at concentrations of 1 ppt (Beck et al. 1988b).  Coffee brewed without filters did not 
contain any detectable CDDs; however, coffee brewed with one filter showed leaching of TCDDs from the 
paper into the coffee. Carryover (leaching) rates were 25% for 2,3,7,8-TCDD, indicating that people who drink 
coffee brewed with paper filters containing 5 ppt 2,3,7,8-TCDD may ingest small quantities (<5 pg) of 
2,3,7,8-TCDD per day (Beck et al. 1989d).  Hashimoto et al. (1992) also analyzed CDD/CDF concentrations in 
coffee-filter paper available in Japan. These authors reported mean TEQ values of 0.89 pg/g (ppt) (range 
0.042–3.6 pg/g) for chlorine-bleached filters, 0.13 pg/g (range 0.079–0.18 pg/g) for oxygen-bleached filters, 
and 0.009 pg/g (range 0.00038–0.017 pg/g) for unbleached filters.  Chlorine-bleached filters also gave the 
highest mean TCDD and TCDF elutions (range <0.043–2.1 and <0.081–6 pg/g, respectively).  Oxygen-
chlorinated filters gave considerably lower elutions (range <0.085–0.14 and 0.23–0.26 pg/g, respectively), 
while unbleached filters produced elutions near the detection limits (<0.094 pg/g).  Approximately one-third of 
the total CDD/CDF contamination was eluted from the filter paper into the coffee during brewing; however, 
almost the same amount was eluted from the filters with hot water.  This leaching rate of approximately 30% 
agrees with that obtained by Beck et al. (1989d).  The elution ratio was almost constant for all CDD/CDF 
congeners and isomers.  Using the maximum TEQ value of 3.6 pg/g paper and the minimum TEQ value of 
0.00038 pg/g paper, the TEQ values for one cup of coffee were calculated to range from 0.000015 pg to 1.4 pg. 
The authors suggest that any potential health risk from CDD/CDF exposure from coffee-filter paper is small and 
can be further reduced by rinsing the filter prior to brewing the coffee. 
CDDs (TCDD, PeCDD, HxCDD, HpCDD, and OCDD) are also present in newsprint, facial (cosmetic) tissue, 
and recycled paper at levels ranging from <0.4 to 335 ppt (Beck et al. 1988b).  OCDD was the most abundant 
congener detected in newsprint (37 ppt). HxCDD was the most abundant homologue detected in cosmetic 
tissue (79 ppt) and recycled paper (335 ppt).  2,3,7,8-TCDD was found at lower concentrations in cosmetic 
tissue (1.1 ppt), and recycled paper (0.6 ppt) (Beck et al. 1988b).  Another study of CDDs in bleached and 
unbleached consumer paper products showed that the highest levels of 2,3,7,8-TCDD were found in bleached 
coffee filters (5 ppt), unbleached coffee filters (2.0 ppt), bleached shopping bags 
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(1.3 ppt), and cigarette paper (1.4 ppt) (Wiberg et al. 1989).  Concentrations were found to be lower in the 
unbleached products than in the corresponding bleached products (Wiberg et al. 1989).  2,3,7,8-TCDD has been 
measured in tea bags at concentrations ranging from not detected (0.36 ppt) to 4.79 ppt (Sullivan and Stanford 
1990). 
The use of newsprint for cow bedding was examined to determine if CDDs in the newsprint would find their 
way into the cow's milk as a result of the cow’s ingesting its bedding.  Although HxCDD and OCDD were 
detected in the milk, TCDD was not detected  (detection limit 0.5 ppt) (Shane et al. 1993). 
Ryan et al. (1992) analyzed the concentrations of CDDs/CDFs in Canadian bleached-paper milk containers 
from 1988 to 1989 and examined the resulting concentrations transferred to the milk.  Milk-carton paper 
manufactured prior to 1989 tested positive for 2,3,7,8-TCDF and 2,3,7,8-TCDD, with levels on a TEQ basis 
varying between 1.4 and 55 ng/kg of paper.  Bleached milk-carton paper produced after mid-1989 tested 
negative for these compounds at a limit of detection of 1 ng/kg paper.  Storage of 3 types of milk in the 
pre-1989 low- and high-level cartons resulted in the transfer of the TCDD/TCDF into the milk, most of which 
occurred within the first 7 days.  The TCDD/TCDF transfer varied between 3 and 25%, with whole and 2% fat 
milk accumulating about twice the concentrations of skim milk.  On the basis of these results, milk stored for up 
to 14 days at 5 EC in currently produced bleached-paper containers with less than 1 ng TEQ/kg of paper would 
not contain any detectable CDDs/CDFs (<0.005 ng TEQ/kg milk).  
An FDA study of the migration of TCDD from paper products that come in contact with food found that TCDD 
was present in all paper products at concentrations ranging from 0.5 ppt for coated paper trays to 13 ppt for 
coated paper cups (average 2–8.5 ppt).  Migration of TCDD from the paper into the food ranged from below 
detectable limits for coated juice cartons to 24% for coffee filters.  Most CDDs migrated in the range of 4–8%. 
The TEQ estimated concentration values ranged from 1.5 ppt for coffee filters to 140 ppt for paper plates 
(Cramer et al. 1991). 
LeBel et al. (1992) analyzed a wide variety of paper products purchased from retail stores in Canada in 1988 
and 1991 for TCDD/TCDF through OCDD/OCDF. The congeners exhibiting the highest concentrations in 
most paper products were 2,3,7,8-TCDF, OCDD, and 2,3,7,8-TCDD.  With respect to the TEQ values, the mean 
TEQ for disposable diapers increased from 1.4 to 2.0 pg/g from 1988 to 1991.  The TEQ values decreased 
during the same period for facial tissues (5.2–4.0 pg/g), paper plates (6.4–2.2 pg/g), paper cups 
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coffee filters in 1988 were similar to concentrations reported in the United States (Cramer et al. 1991) and in 
Germany (Beck et al. 1988b).  The authors cautioned that, given the small number of both paper products and 
samples analyzed, these data do not permit them to draw any conclusions regarding trends in CDDs/CDF levels 
in paper products. 
Dyes and Pigments.  Malisch (1994) reported the presence of CDDs/CDFs in colored candle wax produced 
with the dye pigment Violet 23, which is derived from chloranil.  The three candle samples with the highest 
contamination contained 1.8, 1.4, and 0.8 ng TEQ/kg (ppt).  The author also noted that candles of the same 
color could have highly different CDD/CDF concentrations based on the composition of dye pigments used in 
the manufacturing process. 
Three pigments used in fabric dyeing that are derived from chloranil include the dioxazine pigments Violet 23 
and Direct Blue 106 and 108 (Williams et al. 1992).  Concentrations of the congeners OCDD and OCDF 
predominated in the pigment Blue 106 and ranged from 18,066 to 41,953 ng/g (ppb) for OCDD and 
1,006–12,463 ng/g (ppb) for OCDF. Pigment Blue 108 contained much lower concentrations of CDDs/CDFs, 
although OCDD and OCDF were also the predominant congeners detected at 23 and 11 ng/g, respectively. 
Violet 23 contained higher CDD/CDF concentrations than Direct Blue 108 but lower concentrations than Direct 
Blue 106. OCDD concentrations ranged from 806 to 11,022 ng/g (ppb), while OCDF concentrations ranged 
from 125 to 3,749 ng/g (ppb).  The TEQ values for Direct Blue 106, Direct Blue 108, and Violet 23 were 35.4, 
0.1, and 9.1 ng/g (ppb), respectively. 
Textile Products.  A recent study has identified sources of CDDs/CDFs found in textiles.  Horstmann and 
McLachlan (1994a) detected CDD/CDF concentrations in new textile products ranging from less that 50 pg/g to 
as high as 290,000 pg/g. The authors believe that textile finishing processes are not the source of the high 
CDD/CDF concentrations because of the randomness of the textiles with high concentrations.  Since PCP is still 
being used in developing countries, especially for purposes of preserving cotton during sea transport, the 
authors hypothesize that this is a likely source.  
Dry Cleaning Fluid Residues.  Chemical analysis of dry cleaning solvent residues collected in Germany prior 
to 1993 indicated that residues from machines using perchloroethylene contained an average concentration of 
256 ppb CDD/CDF, with 2,3,7,8-TCDD being detected in 21 of 28 samples; however, the HpCDD and 
OCDD congeners comprised between 90 and 95% of the CDDs/CDFs found (Towara et al. 1992). 
Horstmann and McLachlan (1994b) detected CDD/CDF residues in used dry cleaning fluid and 
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concluded that the source of the CDDs/CDFs residues in the dry cleaning fluid were introduced by dry 
cleaning new, unwashed textiles that had been treated with pentachlorophenol (PCP). 
Motor Vehicle Exhaust.  CDDs have also been identified in automobile exhaust emissions (Marklund et al. 
1987, 1990). 2,3,7,8-TCDD was found in car exhaust from 4 Swedish cars running on leaded gasoline at 
levels ranging from <0.05 to 0.3 ng/24.8 km (0.002–0.01 ng/km) running cycle.  PeCDD was also found in 
the exhaust of cars running on leaded gasoline at levels ranging from 6 to 98 ng/24.8 km (0.24–3.95 ng/km). 
No CDDs were found in samples where unleaded gasoline was used at detection limits of 0.05 ng 
(2,3,7,8-TCDD) and 0.3 ng (PeCDD) (Marklund et al. 1987).  Another study of exhaust emissions from cars 
running on leaded and unleaded gasoline found total HpCDD concentrations ranging from not detected to 
0.482 ng/km and OCDD concentrations ranging from not detected to <0.510 ng/km for the cars running on 
leaded gasoline (Bingham et al. 1989).  HpCDD was not detected in car exhaust emissions from a single car 
running on unleaded gasoline. OCDD concentrations ranged from not detected to <0.110 ng/km (Bingham et 
al. 1989). Most recently, however, Cirnies-Ross et al. (1996) reported that using copper in diesel fuels to 
reduce soot generation in engines was accomplished at the expense of increasing CDD/CDF during 
combustion.  These authors reported that using the copper doped fuel significantly increased CDD/CDF 
particulate formation from < 20 ng/L TEQ in normal fuel to almost 60 ng/L TEQ in doped fuel at an engine 
output of 1 kW. The increased CDD/CDF particulate formation was most striking at low engine output (1 
kW). 
From the research conducted on CDD emissions from vehicles running on leaded and unleaded gasoline, it is 
clear that CDD emissions are typically less in cars running on unleaded gasoline.  It should be noted however, 
that because the use of leaded gasoline is no longer permitted in the vast majority of domestic automobiles in 
the United States, this source of CDD emissions to the air should have been significantly reduced in recent 
years (EPA 1996a). 
5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE 
5.5.1 General Population 
Currently, consumption of food (including human milk) is by far the most important  pathway for exposure to 
CDDs for the general population representing over 90% of the total daily intake.  Other pathways of exposure 
include inhalation of CDDs from municipal, medical, and industrial waste incinerators and other 
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incineration and combustion processes (-2% of the daily intake), and ingestion of drinking water(<0.1% of 
the daily intake) (Travis and Hattermer-Frey 1987; Schaum et al.1994). 
Foods. Food is the major source (>90%) of human exposure to CDDs (Beck et al. 1989a; Hattemer-Frey 
and Travis 1989; Liem and van Zorge 1995; Rappe 1992; Schaum et al. 1994;  Schecter et al. 1994d, 1994e, 
1996a). An estimate of the daily intake of 2,3,7,8-TCDD by adults in the general U.S. population from 
ingestion of contaminated food items and drinking water and inhalation of ambient air is given in Table 5-9. 
The average daily adult intake of 2,3,7,8-TCDD estimated by the model was 47 pg/day (Hattemer-Frey and 
Travis 1989) with a lower bound daily intake of 8 pg/day and an upper bound daily intake of 300 pg/day. 
Food, especially meat, and dairy products, accounted for 98% of the total daily intake of 2,3,7,8-TCDD. 
Hattemer-Frey and Travis (1989) estimated that  the average daily intake of 2,3,7,8-TCDD for an adult in the 
United States from meat alone was 23 pg/day, accounting for  50% of the total daily intake of 2,3,7,8-TCDD 
from food sources.  The average daily intakes of 2,3,7,8-TCDD from milk, produce, and fish were 13 pg/day 
(27%), 5 pg/day (11%), and 5 pg/day (10%), respectively of the total daily intake in the United States 
(Hattemer-Frey and Travis 1989).  However, for certain subpopulations (recreational and subsistence fishers), 
fish consumption may be a more important source of CDDs.  The maximum daily intake of 2,3,7,8-TCDD for 
residents of the Great Lakes region who regularly consume fish from the Great Lakes was estimated to range 
from 390 to 8,400 pg/day (EPA 1985a).  Inhalation of ambient air and ingestion of water are not major 
pathways of human exposure, accounting for only 2% (1 pg/day)  and <0.01% (6.5 x10-3 pg/day), 
respectively, of the total daily intake of 2,3,7,8-TCDD (Hattemer-Frey and Travis 1989).  The percentage of 
daily intake of 2,3,7,8-TCDD estimated by Hattemer-Frey and Travis (1989) from each exposure pathway 
agrees closely with more recent estimates made by Schaum et al. (1994) for intakes of total CDDs/CDFs 
(Table 5-10). However, quantitatively, the estimates differ by a factor of 2–3 because Hattemer-Frey and 
Travis (1989) considered only 2,3,7,8-TCDD, while Schaum et al. (1994) based their estimates on all CDDs 
and CDFs. 
Based on their congener-specific analysis of 18 food samples collected in Binghamton, New York, 
Schecter et al. (1994d), estimated the U.S. mean daily exposure to CDD equivalents for an adult (65 kg 
body weight) to range from 18 to 192 pg TEQs depending on how not-detected values were treated.  This 
is equal to a daily adult intake of CDDs/CDFs ranging from 0.3 to 3.0 pg TEQs/kg body weight.  These 
authors reported that total CDDs ranged from 0.35 to 2.91 ppt (wet weight) in fish, from 0.6 to 59.3 ppt in 
meat products, and from 0.6 to 14 ppt in dairy products.  The total CDD/CDF TEQ value ranged from 
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reported that a vegetarian diet (vegan diet with no consumption of dairy products) might have health 
advantages by lowering daily intakes to only 2% of the level estimated for persons consuming fish, meat, 
and dairy products (Schecter et al. 1994d, 1984e). An ovo-lacto vegetarian diet that contains eggs and 
dairy products would not achieve this same reduction level. More recently, these same authors estimated 
the U.S. mean daily exposure to CDD equivalents based on an expanded analysis of 100 food samples 
collected in supermarkets in Binghamton, New York; Chicago, IL; Louisville, Kentucky; Atlanta, 
Georgia; and San Diego, California (Schecter et al. 1996a). For 1995, these authors report that the 
estimated U.S. mean daily exposure to CDDs/CDFs TEQs for an adult (65 kg body weight) ranges from 
34 to 167 pg TEQs. This is equivalent to a daily adult intake of CDDs/CDFs ranging from 0.52 to 2.57 
pg TEQs/kg body weight.  If PCB TEQs are also considered (where TEF values are available), the daily 
adult intake ranges from 1.16 to 3.57 pg TEQ/kg body weight/day. A more recent survey of CDDs/CDFs 
in total diet food samples in Canada was conducted by Ryan et al. (1997).  These authors found, through 
analysis of more than 100 food samples collected from commercial outlets in 1992 and 1993, that the total 
TEQ intake for CDDs/ CDFs was about 0.8 pg TEQs/kg/day.  If all dioxin-like PCBs were also included, 
this TEQ value rose to approximately 1.2 pg TEQs/kg/day.   
In 1995, Schecter and Li (1997) conducted a congener-specific analysis of CDDs, CDFs, and dioxin-like 
PCBs in US fast foods. These authors reported TEQ values from 0.03–0.28 pg/g wet weight for 
McDonald’s Big Mac, 0.03–0.29 pg/g for Pizza Huts personal pan supreme pizza with all toppings, 
0.01–0.49 pg/g for Kentucky Fried Chicken 3 piece original recipe meal, and 0.3–0.31 pg/g for Haagen-
Daz chocolate-chocolate chip ice cream.  Daily TEQ consumption per kilogram body weight assuming a 
65-kg adult, from one serving of each of the fast foods tested ranged between 0.046–1.556 pg/kg.  This 
same value in  a 20-kg child (6-year-old) ranged from 0.15 to 5.05 pg/kg.  A child on average consumes 
three times more TEQs on a per kg/body weight basis as compared to adults eating any one of the fast 
foods tested. 
Studies conducted in other industrialized countries have reported similar values to those obtained for the 
United States. Estimated daily intakes of CDDs and CDFs from various foods were calculated in a 
Canadian study of foods domestically produced in Canada or imported from the United States (Birmingham 
et al. 1989). Based on contamination levels (CDDs and CDFs) in samples of meats, eggs, fruits, and 
vegetables from the United States and Canada, a total daily intake of 1.52 pg TEQs/kg body weight was 
calculated (for a 60-kg adult). The foods that contributed the most exposure to CDDs/CDFs TEQs were 
milk, eggs, and beef.  Approximately one-half (0.81 pg TEQs/kg) was contributed by milk products.  Eggs 
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and beef were also estimated to make substantial contributions (0.28 and 0.27 pg TEQs/kg, respectively). 
The total contribution from these animal products to the daily dietary intake is 1.5 pg TEQ/kg body weight 
(99% of the total). Plant products (fruits, vegetables, and wheat products) contribute only 0.068 pg TEQ/kg 
body weight/day (1% of the total).  The authors also estimated that consumption of freshwater fish was 
0.28 pg TEQ/day, thus the total daily intake of CDDs/CDFs amounted to 1.8 pg TEQ/kg body weight 
(Birmingham et al. 1989). 
In a German study where 22 samples of different foodstuffs (cow's milk, butter, pork, beef, lamb, chicken, 
eggs, and fish) were analyzed for CDDs/CDFs, the total average daily intake of 2,3,7,8-TCDD via food was 
0.35 pg/kg/day and for total CDDs/CDFs was 1.3 pg TEQs/kg body weight/day for a 70-kg adult (Beck et 
al. 1989a). Meat, milk and other dairy products, and fish were the most important food groups contributing 
17.9, 26.6, and 38.6 pg TEQ/day, respectively, to the body burden.  Eggs, vegetable oil, vegetables, and 
fruits contributed 3.1, 0.3, 2.4, and 1.3 pg TEQ/day, respectively, to the body burden (Beck et al. 1989a). 
In general, vegetation contamination from airborne sources of CDDs results in more substantial exposures 
to grazing animals due to the proportionally higher accumulation from foliar (leaf) deposition as compared 
to root uptake (Travis and Hattemer-Frey 1987).  OCDD is the CDD contaminant most concentrated by 
plants. This supports the contention that atmospheric deposition is the primary mechanism by which plants 
become contaminated, as OCDD is not readily available for root uptake or translocation in plants (Hulster 
and Marschner 1993; Muller et al. 1993). The concentration of 2,3,7,8-TCDD (due to root uptake and foliar 
deposition) on vegetation consumed by cows was estimated to be 0.11 ng/kg (97% due to foliar deposition). 
The estimated total concentration on exposed produce and vegetation consumed by humans was 0.02 ng/kg 
(67% resulting from foliar deposition) (Travis and Hattemer-Frey 1987).  A model has been developed that 
estimated the CDD content in cow's milk based on emissions from a nearby municipal solid-waste 
incinerator. The model includes three components that predict atmospheric transport and deposition, soil 
and grass concentrations, and uptake and bioavailability from fodder to cows.  Results indicate that models 
can be used to estimate CDD contamination in foods (Lorber et al. 1994; Slob and Jaarsveld 1993). 
Municipal and industrial incinerators and other combustion sources. Combustion processes 
are widely recognized as a source of CDDs/CDFs.  Using a model, Hattemer-Frey and Travis (1989) 
estimated a total daily intake of CDD/CDF of  3×10-4 ng TEQs/day associated with exposure to a typical, 
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state-of-the-art municipal solid-waste (MSW) incinerator, assuming a CDD/CDF emission rate based on the 
geometric mean from 11 proposed MSW facilities.  Daily intakes of CDD/CDF in TEQs associated with 
exposure to a typical state-of-the-art municipal waste incinerator were estimated to be 1.3x10-4 ng/day from 
inhalation, 1.1x10-4 ng/day from total ingestion, 5.7x10-5 ng/day for mother’s milk and 2.2x10-6 ng/day from 
dermal absorption.  This total daily intake value (3×10-4 ng TEQs/day) was 160 times lower than the 
estimated total daily background intake from all sources of CDDs  (0.047 ng/day) to which the general U.S. 
population is exposed. Thus, the authors concluded that MSW incinerators will not substantially increase 
human exposure to CDDs/CDFs above normal background levels (Hattemer-Frey and Travis 1989). 
Table 5-11 shows estimated average daily intakes of CDD/CDF TEQs from various exposure pathways. 
Fries and Paustenbach (1990) evaluated the effects of 2,3,7,8-TCDD from incinerator emissions to humans. 
These authors also concluded that airborne emissions of CDDs/CDFs from modern waste incinerators that 
are equipped with appropriate air pollution devices should not pose a significant health hazard via 
inhalation of CDD contaminated particles or via contamination of foods regardless of the incinerator 
location. Hattemer-Frey and Travis (1989) focused on ideal state-of-the-art incinerators. In a more recent 
analysis, Travis and Hattemer-Frey (1991) estimated that the total daily intake of CDDs/CDFs (TEQs) by a 
maximally exposed individual living near a modern municipal solid waste incinerator was 0.7 pg/day (0.9% 
of total daily intake) and 92.8 pg/day (99.1%of total daily intake) was from all other background exposures. 
 These estimates are supported by recent data of Schecter et al. (1995) who found that workers who operate 
municipal waste incinerators have blood levels of TEQs which do not differ significantly from background 
levels. 
The presence of CDDs in cigarette smoke is also of importance with respect to inhalation exposure since 
cigarette smoke is inhaled directly into the lungs.  Daily exposure to CDDs by smoking 20 cigarettes was 
estimated to be 18 TEQ pg/day equivalent to a daily intake of 0.26 pg/kg body weight/day (for a 70-kg 
adult) (Lofroth and Zebuhr 1992). 
Consumer products. The presence of CDDs in a variety of consumer products ranging from plastic 
packaging to colored candle wax, and from textiles to air filters for home-heating systems suggests that 
CDDs are virtually ubiquitous in the environment (Beck et al. 1989d; Berry et al. 1993; Horstmann and 
McLachlan 1994; Malisch 1994; Ryan et al. 1992).  2,3,7,8-TCDD and 2,3,7,8-TCDF have been found in 
many paper products, including coffee-filter paper, although present day paper products now contain less 
than 1 ng/kg TEQ. Under the preconditions of using 4 small coffee-filter papers (4×1 g) per day containing 
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2,3,7,8-TCDD and 32 pg 2,3,7,8-TCDF or nearly 10 pg TEQs (for these two compounds combined) were 
calculated for a coffee drinker consuming all the coffee (this is a worst-case assumption that an individual 
would consume all the coffee brewed) (Beck et al. 1989d).  TCDD, PeCDDs, HxCDD, HpCDD, and OCDD 
were found in all samples derived from consumer products (including plastic packaging, clothes dryer lint, 
vacuum cleaner dust, room and car air filters, and furnace filter dust), and bleached and unbleached paper 
products tested. In general, the more highly chlorinated congener groups (HxCDD, HpCDD and OCDD) 
exhibited the highest concentrations. The highest levels of most congeners were found in home-furnace 
filter dust, which contained HxCDD, HpCDD and OCDD at concentrations up to 135 ppt, 9,990 ppt, and 
24,600 ppt, respectively (Berry et al. 1993). Car air filters displayed a different CDD profile than the other 
products with the highest concentration detected for TCDD (2,080 ppt), PeCDD (1,320 ppt) and HxCDD 
(1,320 ppt). TEQ values for CDD/CDF were highest for the home furnace filter (170 ppt), car air filter (84 
ppt), and room air filter (29 ppt). 
Adipose tissue residues. The general population of the United States is continuously exposed to 
small amounts of CDDs, as exemplified by the fact that  all human adipose tissue samples contain CDDs 
(Orban et al. 1994; Patterson et al. 1986a; Ryan et al. 1986; Schecter et al. 1986b; Stanley 1986; Stanley et 
al. 1986). Results of the National Human Adipose Tissue Survey (NHATS) conducted in 1982, which 
estimated the general population exposure to toxic organic chemicals, showed that 2,3,7,8-TCDD was 
detected in 35 of 46 (76%) composite samples with an average lipid-adjusted concentration of 6.2±3.3 ppt 
(Stanley 1986; Stanley et al. 1986).  The average concentration of the other CDD compounds ranged from 
43.5 ppt for PeCDD (detected in 91% of the composites) to 694 ppt for OCDD (detected in 100% of the 
composites).  The congener distributions found in adipose tissue are similar to those found in human milk 
(i.e., OCDD was the most abundant and 2,3,7,8-TCDD the least abundant congener).  The analysis of 
46 composite adipose  samples verified the prevalence of the 2,3,7,8-substituted tetra- through octa CDDs 
in the U.S. population (Stanley 1986; Stanley et al. 1986).  The number of adipose samples in each 
composite was defined based on differences in age, gender, race, and regional affiliation of the individuals 
from whom the specimens were collected.  The results also suggested that adipose tissue concentrations 
tended to increase with age for the congeners tested, with the exception of PeCDD.  The NHATS study also 
showed regional differences in CDD concentrations in adipose tissue, with the greatest exposure occurring 
in the East North Central region of the United States (i.e., Ohio, Michigan, Indiana, Illinois, and 
Wisconsin). Exposure was also relatively high in the mid-Atlantic and East South Central regions (Phillips 
and Birchard 1991). 
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Results of the more recent 1987 NHATS Study were summarized by Orban et al. (1994).  Human adipose 
samples from autopsy cases were obtained through a network of pathologists to provide a representative 
sample of the general U.S. population.  NHATS samples collected during 1987 were analyzed for 7 CDDs 
and 10 CDFs and the results are summarized in Table 5-12.  Data were evaluated by census region, age 
group, sex, and racial group. The average concentration of 2,3,7,8-TCDD in adipose tissue in the U.S. 
population was estimated to be 5.38 pg/g (±6%).  The 1987 survey data clearly show that nearly all of the 
CDD/CDF congeners increased with the age of the donor (i.e., the highest concentrations occur in the 
45+ age group and the lowest concentrations occur in the 0–14 age group).  On a regional basis, only the 
average concentration of 2,3,4,7,8-PeCDF was statistically different in the Northeast (13.7 pg/g) compared 
to the national average (9.7 pg/g). Orban et al. (1994) also compared NHATS 1987 data to the NHATS 
1982 data. Because of slight differences in study design, the congeners that were most comparable between 
the two surveys were 2,3,7,8-TCDD and 2,3,7,8,-OCDD.  Statistical analysis of the two survey data sets 
revealed no significant differences between the national average concentration of 2,3,7,8, TCDD 
determined in 1982 and 1987.  There were also no significant differences in the profiles with respect to 
census region, sex, and race. With respect to age, however, there was a significant difference;  the 1987 
NHATS data demonstrated that the concentration of 2,3,7,8-TCDD consistently increased with the age of 
the donor. The average concentration of 2,3,7,8-TCDD in the 1987 survey increased from 1.98 pg/g in the 
0–14-year-old group, to 4.37 pg/g in the 15–44-year-old group, to 9.4 pg/g in the 45+-year-old group.  The 
average concentration of OCDD in the 1982 survey was 768 pg/g (±79.7 standard error) as compared to 
724 pg/g (± standard error 28.6) in the 1987 study. 
Analysis of human adipose tissue from 35 autopsy cases from Georgia and Utah found 2,3,7,8-TCDD in all 
of the samples at a concentration range (whole-weight) of 2.7–19 ppt (Patterson et al. 1986b).  The 
geometric mean value for 2,3,7,8-TCDD in these samples on a whole-weight basis was 7.1 ppt.  The 
geometric mean value for 2,3,7,8-TCDD in 31 of these samples on a lipid basis was 9.6 ppt.  The histories 
of exposure to 2,3,7,8-TCDD were not known for any of the autopsy cases (Patterson et al. 1986b). 
Blood residues. CDDs/CDFs were measured in the blood (lipid basis) of 10 individuals in Germany 
with no prior CDD exposure (Päpke et al. 1989b).  OCDD was the most abundant congener present (mean 
610.8 ppt; range 439–889 ppt), followed by 1,2,3,4,6,7,8-HpCDD (mean 88.2 ppt; range 30-142 ppt), 
HxCDD (mean 75.7 ppt; range 52–99.8 ppt), 1,2,3,7,8-PeCDD (mean 16.5 ppt; range 5.6–39 ppt), and 
2,3,7,8-TCDD (mean 4 ppt; range <1.5–9.1 ppt).  Mean blood levels of CDFs ranged from 24 to 46.3 ppt. 
Detection limits for 2,3,7,8-TCDD were 1–4 ppt (extractable lipids) which corresponds to 0.005–0.02 ppt 
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for whole blood with a lipid content of 0.5% (Päpke et al. 1989b).  These authors reported that blood levels 
of CDDs/CDFs from persons with no known exposure to CDDs corresponded to those levels measured in 
adipose tissue of unexposed individuals. Needham et al. (1996) reported reference range data for CDDs 
and CDFs in blood of individuals who presumably had not been exposed occupationally to these 
compounds. The range of means in ppt (lipid basis) in blood for 7 CDDs, 11 CDFs, and 4 PCBs are 
summarized in Table 5-13.  OCDD was the most abundant congener present (range of means 
560–1,000 ppt), followed by 1,2,3,4,6,7,8-HpCDD (range of means, 80.3–230 ppt), 1,2,3,6,7,8-HxCDD 
(range of means, 45–85 ppt), 1,2,3,7,8-PeCDD (range of means, 6.6–32 ppt), and 2,3,7,8-TCDD (range of 
means, 3.2–10.1 ppt).  Mean blood levels of CDFs ranged from not detected to 27 ppt.  The TEQ range in 
mean blood levels was 13.7–41.39 ppt for all CDDs and 15.1–58.0 ppt for CDDs/CDFs.  
Tepper et al. (1997) compared serum levels of CDD and CDF concentrations in 16 community residents 
who had no occupational exposure to these compounds.  OCDD was the most abundant congener present 
(range, 285–1,489 ppt), followed by 1,2,3,4,6,7,8-HpCDD (range, 64.1–115 ppt), 1,2,3,6,7,8-HxCDD 
(range, 48.3–101 ppt), 1,2,3,7,8-PeCDD (range, 2–7.8 ppt), and 2,3,7,8-TCDD (range, 1.5–3.5 ppt).  Mean 
blood levels of CDFs ranged from 0.8 to 31.3 ppt.  The mean in TEQs was 13.5 ppt (range, 9.5–19.1) for all 
CDDs, 5.0 ppt (range, 3.4–8.8 ppt) for all CDFs, and 19.1 ppt (range, 12.9–25.9 ppt) for CDD/CDFs. 
Most recently, Michalek et al. (1998) measured levels of 2,3,7,8-TCDD in 1,302 unexposed Air Force 
Vietnam-era veterans.  These veterans served as controls in the 20-year epidemiologic study of Air Force 
veterans of Operation Ranch Hand, the unit responsible for aerial spraying of Agent Orange in Vietnam. 
These authors reported mean 2,3,7,8-TCDD concentrations in blood of 4.32±2.53 ppt for the control group. 
The 99th percentile of the distribution was less than or equal to 10.4 ppt. 
Needham et al. (1991) also showed that human adipose tissue concentrations of CDDs may be correlated 
with blood serum levels after adjusting for total lipid content.  On a lipid basis, total CDD/CDFs are higher 
in blood than adipose tissue. Partitioning is not identical in these tissues;  2,3,7,8-TCDD levels are almost 
identical in blood and adipose tissues, but OCDD levels are higher in blood.  However, the presence of 
OCDD at levels of 5,000–10,000 pg/person when concentrations in food are generally in the low pg/g level 
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5.5.2 Occupational Exposure 
Occupational exposure to CDDs occurs primarily through inhalation and dermal contact of fire fighters and 
cleanup workers involved with transformers containing PCBs and polychlorobenzenes; in workers involved 
in incineration operations; in workers in metal reclamation facilities, and in workers producing and handling 
pesticides, hexachlorophene, trichlorophenol, or other chlorinated compounds (e.g., pentachlorophenol) that 
may contain small impurities of 2,3,7,8-TCDD or other CDDs (Päpke et al. 1992).  In addition, these 
authors reported that the CDD/CDF homologue profiles in whole blood of workers engaged in a variety of 
different chemical processes or in occupational accidents exhibited distinct CDD/CDF patterns (Päpke et al. 
1992). 
A dust sample collected from the ambient atmosphere of a municipal incineration plant in Europe over a 
6-day period was analyzed for CDDs.   The concentrations of 2,3,7,8-substituted congeners ranged from 
0.9 ppb (2,3,7,8-TCDD) to 310 ppb (1,2,3,4,6,7,8-HpCDD) (Tong et al. 1989a).  These results indicate that 
the ambient atmosphere of a municipal incinerator can be contaminated by CDDs by means of fly ash and 
possibly other incineration products; thus, municipal incinerator workers are at risk of exposure to CDDs 
(Tong et al. 1989a). Blood analysis of 10 workers at a municipal solid-waste incinerator in Germany 
showed elevated CDD levels of 4 workers whose work was associated with exposure to fly ash and slag 
(Päpke et al. 1993). In several individuals studied, the higher chlorinated CDDs/CDFs especially the 
2,3,7,8-substituted HxCDD, HpCDD, and OCDD congeners showed slightly elevated levels. 
Compared with background 2,3,7,8-TCDD levels (3.6 ppt), workers involved in trichlorophenol 
production had elevated 2,3,7,8-TCDD blood levels, with a mean concentration of 332 ppt (Päpke et al. 
1992). PCP manufacturing resulted in the greatest increases for workers with respect to all congeners, 
with OCDD blood levels of approximately 300,000 ppt. PeCDF, HxCDF, and HpCDF levels in the blood 
were elevated in workers at a metals reclamation plant (Päpke et al. 1992).  Workers exposed to CDD as a 
result of an industrial accident had mean 2,3,7,8-TCDD blood levels of 53 ppt almost 36 years after the 
incident (Päpke et al. 1992). In one documented case, a U.S. domestic agricultural worker was exposed to 
2,3,7,8-TCDD during spraying of 2,4,5-T herbicide on pasture land and hay ground.  A sample of the 
herbicide that he used contained 7.7 ppb 2,3,7,8-TCDD.  2,3,7,8-TCDD levels measured in the worker's 
adipose tissue 5 years post-exposure were 72 ppt (whole weight) or 77 ppt (lipid basis) (Tong et al. 
1989b). Thirty-two years after an industrial accident in a chemical plant manufacturing trichlorophenol, 
the average lipid-adjusted concentration of 2,3,7,8-TCDD in the adipose tissue of exposed workers who 
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developed symptoms (chloracne and other illnesses) was 49 ppt (range of 11-141 ppt) (Schecter and Ryan 
1988). 
In a recent study by Tepper et al. (1997), serum levels of CDDs and CDFs were measured in pulp and 
paper mill workers in the United States.  These authors reported that serum levels of CDDs and CDFs 
among 46 long-term workers at a pulp and paper mill were not appreciably different among three exposure 
groups studied (community residents, low-exposure-potential worker group, and high-exposure-potential 
worker group). Serum CDD TEQs were 13.5 ppt (range, 9.5–19.1 ppt), 15.9 ppt (range, 6.5–31.8 ppt), and 
13.3 ppt (range, 7.5–24.9 ppt) respectively.  Total TEQ for both CDDs and CDFs were similar for the three 
groups at 19.1 ppt, 21.2 ppt and 18.1 ppt, respectively.  Serum levels of CDDs and CDFs in this study 
were within the range previously reported for persons with no known occupational exposure. 
A series of adipose tissue samples collected from one exposed individual, as well as surgical and autopsy 
specimens from four control individuals, was analyzed for CDDs (TCDD, PeCDD, HxCDD, HpCDD, and 
OCDD) (Schecter et al. 1985a). All specimens were obtained from persons residing in urban or rural areas 
of upstate New York during 1983 or 1984. The worker who had been exposed to soot containing PCBs, 
CDFs, and small amounts of CDDS from the CDD/ CDF-contaminated Binghamton State Office Building 
in New York, had a total CDD concentration (whole-weight basis) of 1,015 ppt, whereas the average total 
CDD concentration for the controls was 765 ppt. Mean concentrations were highest for OCDD among all 
the CDD congener groups in both the controls (585 ppt) and the exposed person (690 ppt).  2,3,7,8-TCDD 
concentrations were lowest in both groups, an average of 6.3 ppt for the controls and 11.6 ppt for the 
exposed person. Intermediate levels were found for PeCDD (7.5–13.8 ppt), HxCDD (6.8–64.2 ppt), and 
HpCDD (2.6–119 ppt) in the control groups. Intermediate levels were also found in the exposed 
individual for PeCDD (15 ppt), HxCDD (7.3–72.6), and HpCDD (9.6–209 ppt) (Schecter et al. 1985a). 
An occupational study of workers exposed to CDDs at a Missouri chemical plant from 1968 to 1972 found 
a mean 2,3,7,8-TCDD concentration of 390 ppt in the adipose tissue of 4 exposed workers measured 
13–17 years post-exposure.  The chemical plant made 2,4,5-trichlorophenol (2,4,5-TCP), which was used 
as a feedstock to produce butyl esters of 2,4,5-trichlorophenoxyacetic acid (2,4,5-T esters) and hexachloro­
phene between 1968 and 1972. The 2,3,7,8-TCDD was generated as an unintended contaminant during 
the production of 2,4,5-TCP. Consequently, workers involved in these processes were potentially exposed 
to 2,3,7,8-TCDD. The mean concentration of 2,3,7,8-TCDD found in these workers was 45 times higher 
than the mean of 8.7 ppt reported for 7 unexposed Missouri residents (Patterson et al. 1989a).  
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Another group that is occupationally exposed to CDDs includes analytical chemists involved in the 
synthesis of CDDs for research purposes or those involved in analysis of environmental samples 
contaminated with CDDs.  Schecter et al. (1994b) reported that a chemist who had been involved in 
synthesizing 2,3,7,8-TCDD in 1956 at a university research laboratory had subsequently developed 
chloracne, headaches, backaches, and severe leg pains when he walked.  During 1990–91, approximately 
35 years after the chemist's initial exposure, blood CDDs analysis was performed to determine whether 
residual CDD levels still remained.  Schecter et al. (1994b) reported that blood TCDD levels (on a blood-
lipid basis) were 20 ppt as compared to 3–5 ppt measured in a control population of 100 individuals. 
Analytical laboratory personnel who are involved in analyzing CDD-contaminated samples also may be 
exposed to higher levels of CDD contamination than the general population (Hesso et al. 1992; Oliver 
1975). 
In a study conducted by NIOSH, serum levels of 2,3,7,8-TCDD were measured in 27 U.S. chemical 
workers previously exposed to CDDs-contaminated products (Fingerhut et al. 1989).  The workers were 
employed at two U.S. facilities that produced 2,4,5-TCP and 2,4,5-T between 1951 and 1972.  Serum 
levels of 2,3,7,8-TCDD were also measured in 19 unexposed controls.  A mean serum 2,3,7,8-TCDD level 
of 208.2 ppt found in the exposed workers exceeded (by more than 25 times) the mean background level of 
8.2 ppt found in the controls who did not produce these chemicals (Fingerhut et al. 1989).  
Workers who are involved with incineration operations may be exposed to levels of CDDs that are higher 
than background levels to which the general population is exposed.  Schecter et al. (1991b) measured CDD 
and CDF blood levels on a lipid basis in pooled blood samples from a group of 56 New York City 
incinerator workers and 14 controls. The levels of 11 of the 18 CDD/CDF congeners measured were 
increased in the incinerator workers as compared to the controls.  CDD levels in incinerator workers were 
48, 17, 27, 30, and 31% higher for 1,2,3,7,8-PeCDD, 1,2,3,6,7,8-HxCDD, 1,2,3,7,8,9-HxCDD, 
1,2,3,4,6,7,8-HpCDD, and OCDD, respectively.  Only 2,3,7,8-TCDD and 1,2,3,4,7,8-HxCDD were lower 
in incinerator workers’ blood than in controls (5 and 15% lower, respectively).  Overall, the total 
CDD/CDF level in workers’ blood was, 1,007.2 ppt (lipid basis) as compared to 747.3 ppt for the controls 
(Schecter et al. 1991b). In the past, workers involved in the production or use of hexachlorophene, 
trichlorophenol, 2,4,5-T, and other compounds that are no longer used were also exposed to 
2,3,7,8-TCDD. Workers in pulp and paper mills also have the potential for 2,3,7,8-TCDD exposure 
because of the occurrence of 2,3,7,8-TCDD in bleached kraft paper-making processes (Clement et al. 
1989; Kuehl et al. 1987a; Tepper et al. 1997); although exposure to this source has probably declined since 
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1990 with the implementation of bleach plant modifications at many pulp and paper mills (NCASI 1993). 
Workers in the sawmill industry who handle treated lumber may be exposed to chlorophenols, particularly 
PCP; consequently, they may be exposed to higher levels of the more highly chlorinated CDDs 
(Kalliokoski and Kauppinen 1990). Workers employed at sites of improper chemical waste disposal 
(trichlorophenol, hexachlorophene, 2,4,5-T) have a greater potential for exposure to 2,3,7,8-TCDD via 
inhalation or via oral or dermal contact than the general population.  
A current estimate of the number of workers in the United States that are potentially exposed to CDDs is 
not available. At-risk worker populations include incinerator personnel, those involved in production or 
use of chlorinated compounds containing CDD contamination (e.g., hexachlorophene, PCP, 
2,4,5-trichlorophenol, and 2,4-D), analytical research chemists, and workers at chemical waste disposal 
sites, electrical utility workers, and firefighters. 
5.6 EXPOSURES OF CHILDREN 
This section focuses on exposures from conception to maturity at 18 years in humans and briefly considers 
potential pre-conception exposure to germ cells.  Differences from adults in susceptibility to hazardous 
substances are discussed in Section 2.6, Children’s Susceptibility. 
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways. 
Children drink more fluids, eat more food, and breathe more air per kilogram of body weight, and  have a 
larger skin surface in proportion to their body volume.  A child’s diet often differs from that of adults.  The 
developing human’s source of nutrition changes with age: from placental nourishment to breast milk or 
formula to the diet of older children who eat more of certain types of foods than adults.  A child’s behavior 
and lifestyle also influence exposure.  Children crawl on the floor; they put things in their mouths; they 
may ingest inappropriate things such as dirt or paint chips; they spend more time outdoors.  Children also 
are closer to the ground, and they do not have the judgement of adults in avoiding hazards (NRC 1993). 
Children are primarily exposed to CDDs in the same manner as adults in the general population (i.e., via 
consumption of foods contaminated with small amounts of CDDs, particularly meat, milk and other dairy 
products, and fish). Children that are at additional risk of exposure primarily through dietary habits, 
include: infants and young children who are breast-fed; children of recreational and subsistence fishers, 
who typically consume larger amounts of locally caught fish and shellfish than the general population; 
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children of subsistence hunters, particularly those in the high latitudes, who typically consume large 
amounts of locally caught game especially marine mammals; and children of subsistence farmers living in 
areas contaminated with CDDs (either by waste incinerators or the use of CDD- contaminated sewage on 
their land) who exclusively consume their own farm-raised beef and dairy products (see Section 5.7). 
The human fetus is exposed to CDDs/CDFs through transplacental transfer from the mother.  Schecter et 
al. (1990a) reported 2,3,7,8-TCDD concentrations in liver tissue of three still-born infants ranging from 
0.03 to 0.18 ppt (whole weight basis) and 1.3 to 4.3 ppt (lipid weight basis).  Schecter et al. (1990a) also 
reported CDD/CDF concentrations in liver tissue of three stillborn infants ranging from 2.1 to 4.92 ppt 
(whole weight basis) and 98 to 104 ppt (lipid weight basis).  The TEQ for CDD/CDFs combined ranged 
from 0.14 to 0.49 ppt (whole weight basis) and 6.4 to 12 ppt (lipid weight basis).  In a more recent study, 
Schecter et al. (1996e) reported TEQs for CDDs/CDFs in placental material ranging from 8.4 to 17.6 ppt 
(lipid basis). In a pooled sample of fetal tissue (8–14 weeks), the TEQ was 5.3 ppt (lipid basis). 
Concentrations of 2,3,7,8-TCDD in adipose tissue and liver were also reported by Kreutzer et al. (1997) 
for stillborns at levels between 0.2 and 0.8 ppt and 0.3 to 0.7 ppt, respectively.  Kreutzer et al. (1997) 
developed a pharmacokinetic model for 2,3,7,8-TCDD that predicted a decrease in body burdens during 
the first year for non-breast-fed infants and this was supported by empirical data (see Section 2.3.4.4, 
Transfer of CDDs Through the Placenta and Breast Milk). 
In addition to transplacental transfer, CDDs and CDFs have been found in human milk (Fürst et al. 1992; 
Ryan et al. 1993a; Schecter and Gasiewicz 1987b; Schecter et al. 1986a, 1989d, 1989e, 1989g, 1991a); 
human milk is thus a potential source of CDDs for nursing infants and children (see Section 5.5).  In 
Binghamton, New York, and Los Angeles, California, human breast milk was found to contain almost 
identical levels of detectable CDDs on a lipid basis probably because food consumption and sources are 
similar across the United States (Schecter et al. 1989e).  Mean values of two pooled samples (n=42) from 
both cities showed that OCDD was the most abundant congener present (233 ppt), followed in decreasing 
order by total HxCDD (42.65 ppt), 1,2,3,4,6,7,8-HpCDD (42 ppt), 1,2,3,6,7,8-HxCDD (30.5 ppt), 
1,2,3,7,8-PeCDD (6.7 ppt), 1,2,3,7,8,9-HxCDD (6.2 ppt), 1,2,3,4,7,8-HxCDD (4.95 ppt), and 
2,3,7,8-TCDD (3.3 ppt). The total CDDs value was reported as 327 ppt.  The TEQ for CDDs/CDFs, but 
not PCBs in breast milk in the United States was 17 ppt (Schecter et al. 1989e).  Between 1986 and 1987, 
concentrations of CDDs found in breast milk sampled from Canadian women ranged from 2.2 ng/kg (ppt) 
(lipid basis) for TCDDs to 173 ppt for OCDD. In addition, the combined CDD/CDF mean TEQ of 
15.6 ppt (lipid basis) declined from a TEQ of 24.7 ppt  measured in 1981–1982 (Ryan et al. 1993a). 
CDDs 479 
5. POTENTIAL FOR HUMAN EXPOSURE 
CDD/CDF concentrations also have been measured in breast milk in several foreign studies. Concentra­
tions of CDDs/CDFs were also measured in preserved breast milk from 505 persons (both primiparas and 
multiparas) in Japan from 1978 to 1984 (Ogaki et al. 1987).  OCDD was a major component in primiparas' 
milk (789 ppt) and multiparas' milk (518 ppt) (Ogaki et al. 1987).  For the primiparas, average 
concentrations found for HpCDD, HxCDD, PeCDD, total TCDD, and 2,3,7,8-TCDD were 150, 76, 15, 37, 
and 13 ppt, respectively.   The average CDD concentrations found in the milk of multiparas were generally 
lower than the average concentrations found in the milk of primiparas.  For the multiparas, average 
concentrations for HpCDD, HxCDD, PeCDD, and TCDD (not 2,3,7,8) were 75, 56, 11, and 19 ppt, 
respectively (Ogaki et al. 1987).  A similar study in Germany between 1984 and 1991 found mothers 
nursing their second child had 20% less CDD TEQs in their milk than did primigravidae (Fürst et al. 
1992). CDD concentrations in human milk can be directly correlated with the age of the mother and the 
amount of animal (but not vegetable) fat and protein consumed, suggesting that meat, milk and other dairy 
products, and fish are the major sources of CDD intake (Pluim et al. 1993a).  The fact the CDD concen­
trations in milk fat were significantly related to age is in agreement with the results of  Stanley et al. (1986) 
and Orban et al. (1994) who reported a strong correlation between age group and CDD levels in adipose 
tissue in the general U.S. population. The positive correlation can be expected because of the long half-life 
of CDDs in humans (7–11.3 years) (Pirke et al. 1989; Wolfe et al. 1994). 
Estimated daily intakes of CDD/CDF TEQs by nursing infants in the United States have been reported by 
Schecter and Gasiewicz (1987a). The daily intake by nursing infants in the United States was estimated to 
be 83.1 pg TEQs/kg body weight/day. To determine this daily intake, various assumptions were made 
regarding infant body weight (10 kg), duration of nursing, average amount of milk consumed, and 
gastrointestinal absorption. It was also assumed that breast milk was the only source of  CDDs while the 
infant was nursing during the first year of life.  From results of earlier studies that determined the 
concentrations of CDDs/CDFs in human breast milk in the United States (Schecter et al. 1989e) and in 
cow’s milk and soybean-derived infant formula sold in the United States (Schecter el al. 1989c) (see 
Section 5.4.4), Schecter et al. (1994e) estimated slightly lower intakes of 35–53 pg TEQ/kg of body 
weight/day for infants (7.3 kg) that were breast-fed within the first year of life as compared to 0.07–0.16 
pg TEQ/kg of body weight for infants who were fed soy formula. 
Exposure of infants and young children to CDDs may be very high because of their relatively high 
consumption of milk, including breast milk (ECETOC 1992).  Schecter et al. (1994e) evaluated the intake 
of CDDs/CDFs from human breast milk and estimated that high levels reported for breast milk in the 
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United States (.17 ppt TEQ on a lipid basis) contribute 35–53 pg TEQ/kg of body weight per day to the 
nursing infant in its first year of life (Schecter et al. 1989e).  The CDD concentrations in cow’s milk and 
soy-based formula were much lower than in breast milk (327 ppt) (Schecter et al. 1991a).  The following 
concentrations for CDDs (on a lipid basis) were reported: cow’s milk (25.1 ppt), 2% cow’s milk (32.3 ppt), 
SimilactTM infant formula (39 ppt), IsomilTM infant formula (23.3 ppt), and ProsobeeTM infant formula (42.7 
ppt) (Schecter et al. 1989c). The TEQ values for cow's milk and soy-based infant formula were also much 
lower than for human breast milk (.17 ppt). The corresponding TEQ values for CDDs/CDFs (on a lipid 
basis) were reported: cow's milk (2.1 ppt), 2% lowfat cow's milk (0.79 ppt), Similac™ infant formula 
(0.08 ppt), Isomil™ infant formula (0.05 ppt), and Prosobee™ infant formula (0.127 ppt) (Schecter et al. 
1989c). Schecter and Gasiewicz (1987a, 1987b) calculated TEQ values for CDDs/CDFs in human milk in 
two populations in Vietnam and in the general population in the United States.  These authors reported 
mean values during the 1980s of 1.04 pg TEQ/g (whole milk basis) for the United States (maximum 
4.72 pg TEQ/g), a mean of 1.11 pg TEQ/g for South Vietnamese (maximum value 4.38 pg TEQ/g) 
exposed to Agent Orange sprayed between 1962 and 1970, and a mean of 0.065 pg TEQ/g (maximum 
value 0.18 pg TEQ/g) for a North Vietnamese population that was not exposed to Agent Orange.  These 
authors concluded that some infants in the United States (whose mothers had CDD milk concentrations in 
the upper range of measured values) were being exposed to mean concentrations comparable to levels 
observed in the South Vietnamese population exposed to Agent Orange (Schecter and Gasiewicz 1987a, 
1987b). 
The highest exposure to CDD-contaminated breast milk reported was associated with the widespread use 
of Agent Orange as a defoliant during the Vietnam War.  Human milk specimens from Ho Chi Minh City 
and Song Be Province in South Vietnam had lower 2,3,7,8-TCDD values in the late 1980s (7.1 and 17 ppt 
lipid basis) (TEQ values of 18.5 and 31.7 ppt), respectively, than they did in the 1970s when Agent Orange 
spraying occurred (Schecter et al. 1989e).  A 1970 mean value for 2,3,7,8-TCDD in human milk in South 
Vietnam was reported to be 484.9 ppt (range, not detectable to 1,450 ppt) (Baughman and Meselson 1973; 
Schecter et al. 1986a). These values serve as reference values for the highest levels of 2,3,7,8-TCDD 
documented in human milk (Schecter et al. 1989e).  Estimated daily intakes of TEQs by nursing infants 
from Vietnam have been reported (Schecter and Gasiewicz 1987a).  The estimated daily intake by nursing 
infants in southern Vietnam in 1970 was 908 pg TEQs/kg body weight/day, whereas the daily intakes in 
southern and northern Vietnam in 1984 were 88.7 and 5.1 pg TEQs/kg body weight/day, respectively. 
Analysis of 9 milk samples from individuals living in northern Vietnam showed no detectable 
concentrations of 2,3,7,8-TCDD (detection limit 2 ppt) (Schecter and Gasiewicz 1987a).  To determine 
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these daily intakes, various assumptions were made regarding infant weight, duration of nursing, average 
amount of milk consumed, and gastrointestinal absorption.  It was also assumed that breast milk was the 
only lifetime source of exposure to CDDs during the first year of life.  In another study, Tarkowski and 
Yrjanheikki (1989) evaluated the health risks associated with human milk.  These authors concluded that 
levels of CDD/CDFs in breast milk did not present a health risk to infants and children and that there was 
no justification for limiting breast-feeding.  However, these authors believed there was a need for primary 
prevention of CDD/CDF exposure in humans.  Because of the relatively short period of intake and the 
accepted benefits of breast-feeding, the World Health Organization did not recommend limitations on 
breast-feeding at the levels of background exposures to CDDs and CDFs (WHO 1991).  More recently, 
Pohl and Hibbs (1996) reviewed recent studies indicative of a possible link between development of subtle 
health effects in children and their exposure to CDDs and CDFs from maternal milk. It is the ATSDR 
position that for background exposures, the benefits of breast feeding outweigh any potential risk 
associated with exposure. For higher CDDs levels in breast milk, the safety of breast-feeding may be of 
concern in some cases. 
Two recent studies have looked at ways to reduce CDD exposure in breast-fed infants.  Koppe (1995) 
reported that exposure before and after birth to CDDs and PCBs has given rise to subtle abnormalities 
(disturbed cognitive development and delayed motor development) in approximately 10% of newborns 
in the Netherlands. This author examined possibilities of reducing this exposure by influencing the 
diet of the lactating mother.  Mobilization of fatty acids from adipose tissue will cause release of stored 
CDDs which will then be secreted in breast milk.  Two maternal diets were tested for their ability to 
reduce concentrations of CDDs in human milk.  One diet was a low fat/high carbohydrate/low CDD 
diet, while the second was a high fat/low carbohydrate/low CDD diet.  Despite significant changes in 
fatty acid profiles of the milk, no significant changes in CDD concentrations in breast milk were 
observed. The author concluded that short-term dietary measures will not reduce CDDs in breast milk. 
A lowering of CDD intake must occur years before the woman becomes pregnant.  An important food 
source for the women is cow’s milk and other dairy products and these are responsible for about half 
of the daily exposure CDDs and PCBs in women in the Netherlands, so levels of the compounds in 
dairy foods must be lowered.  In addition, the author believes that a lowering of CDD concentrations 
in fish is also necessary.  Based on the results of his dietary study, Koppe (1995) reported that daily 
dietary intake of CDDs during lactation represents only 14% of the daily secretion of CDD in breast 
milk, while 86% was derived from CDDs stored in adipose tissue.  Thus, reducing dietary intake of 
CDDs during lactation would only reduce CDDs in milk by 14%.  Schlaud et al. (1995) also reported 
that to reduce organochlorine residue levels including 
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CDDs in human breast milk in the short-term, nursing mothers should be advised not to try to reduce 
their body weight until after lactation.  These authors reported statistically significant positive 
associations between breast milk contamination and average dietary fat intake per week (P=0.001) and 
proximity of residence to hazardous waste sites (P<0.05) for CDDs.  These authors believe that public 
promotion of a lower dietary fat intake may reduce the lifetime accumulation of CDDs in human fatty 
tissues and in the long-term, resulting in lower concentrations in breast milk as well. 
In addition to exposure to CDDs through consumption of breast milk, cow’s milk, and soy-based 
infant formula, older children can be exposed through dietary practices similar to those of adults in the 
general population (see Section 5.4.4). One study has looked at the exposure that might occur in a 
6-year-old child who consumes “fast foods.”  In 1995, Schecter and Li (1997) conducted a congener-
specific analysis of CDDs, CDFs, and dioxin-like PCBs in U.S. fast foods.  These authors reported a 
CDD/CDF TEQ value, depending on the treatment of not detected congeners, from 0.03–0.28 pg/g wet 
weight for one McDonald’s Big Mac, 0.03–0.29 pg/g for one Pizza Hut personal pan pizza supreme 
with all toppings, 0.01–0.49 pg/g for one Kentucky Fried Chicken 3-piece original recipe meal, and 
0.3–0.31 pg/g for one Haagen-Daz chocolate-chocolate chip ice cream.  The daily intake from one 
serving of each of the fast foods tested, assuming a 20-kg child (6 years old), ranged between 0.15 and 
5.05 pg TEQ/kg body weight.  These authors calculated that, on average, a child (6 years old) 
consumes 3 times more TEQs on a per kg/body weight basis than an adult eating any one of the fast 
foods tested. 
As a result of the transfer of CDDs through the placenta to the fetus, by breast milk to infants and 
young children, and by lifelong dietary intakes from the consumption of meat, milk and dairy 
products, and fish, CDDs are found to be widespread in the adipose tissue of members of the general 
population (Orban et al. 1994). Human adipose samples from the recent 1987 NHATS Study  provide 
a representative sample of CDD body burden in the general U.S. population (see Section 5.5.1).  The 
average concentration of 2,3,7,8-TCDD in the U.S. population was estimated to be 5.38 pg/g (±6%). 
The 1987 survey data clearly show, however, that nearly all of the CDD/CDF congeners in adipose 
tissue increased with the age of the donor (i.e., the highest concentrations occur in the 45+ age group 
and the lowest concentrations occur in children in the 0–14 age group).  The average concentration of 
2,3,7,8-TCDD in the 1987 survey increased from 1.98 pg/g in the 0–14-year-old group, to 4.37 pg/g in 
the 15–44-year-old group, to 9.4 pg/g in the 45+-year-old group. 
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Children may be exposed to CDDs through a variety of lifestyle practices of their parents or of their 
own. For example, CDD/CDF concentrations have been reported in cigarette smoke (Lofroth and 
Zebuhr 1992; Muto and Takizawa 1989) (see Section 5.4.4). Young children and infants may be 
exposure to CDDs indirectly by inhalation of room air contaminated from cigarette smoking of their 
parents. In addition, older children and teenagers, may be directly exposed if they become smokers 
themselves. Malisch (1994) reported that some colored candle wax produced with certain dye 
pigments contained CDDs/CDFs.  By burning these candles, CDDs could be released into room air 
and be an additional source of inhalation exposure for children. 
Children may also be exposed to CDDs by dermal contact with some new, unwashed clothing, 
particularly those manufactured in some developing countries or from fabric shipped from developing 
countries where pentachlorophenol (PCP) is used for preserving cotton fabrics during sea transport 
(Horstmann and McLachlan 1994).  Exposures can be reduced by washing new clothes prior to 
wearing. 
Children could potentially be exposed to CDDs at home from a variety of incineration sources.  For 
example, if their parents routinely burn domestic garbage containing scrap wood treated with PCP 
(Chiu et al. 1983) or untreated wood (Clement et al. 1985), old pesticide containers that may have 
contained 2,4,5 T or 2,4-D or Silvex (Arthur and Frea 1989), or  polyvinylchloride (PVC) pipes or 
other plastics items  (Lustenhouwer et al. 1980), or extensively use a wood stove (Clement et al. 1985), 
children may be exposed to higher levels of CDDs in outdoor and/or indoor air. Time spent in a garage 
where cars or trucks are being repaired and the engines are running, exposes children and teenagers to 
exhaust products and engine soot that may also contain CDDs (Bingham et al. 1989; Cirnies-Ross et 
al. 1996). 
Although there are many studies on the effects of CDDs on adults that receive occupational exposures 
(Fingerhut et al. 1989; Hesso et al. 1992; Patterson et al. 1989a; Schecter et al. 1985a, 1994b; Tepper 
et al. 1997), no information was located on the potential for workers in the United States to bring 
CDDs home on their clothing or shoes, thus contaminating other family members, including children. 
It is conceivable, however, that because CDDs are present in a variety of diverse occupational settings 
(see Section 5.5.2 Occupational Exposures), that poor occupational hygiene could result in CDDs 
being brought home and contaminating domestic dwellings. 
Children in populations with potentially high exposure living in the vicinity of former or current production 
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hazardous waste sites) may be exposed to CDDs by several pathways (see Section 5.7).  Children may be 
exposed to CDDs in CDD-contaminated soils.  Dermal absorption from contaminated soil, however, is 
likely to be inefficient (Poiger and Schlatter 1980; Shu et al. 1988; Weber et al. 1991c).  Young children are 
potentially exposed to CDDs because of their tendency, through hand-to-mouth activity, to ingest soils 
(pica) that may be contaminated with CDDs (see Section 5.7 for further details) (Fries and Paustenbach 
1990; Kimbrough et al. 1984; Paustenbach et al. 1992; Pohl et al. 1995).  La Goy (1987) estimated the 
following average soil ingestion rates for children: age 0–1 years old, 50 mg/day (maximum 250 mg/day); 
1–6 years old, 100 mg/day (maximum 500 mg/day); 6–11 years old, 50 mg/day (maximum 250 mg/day); 
and over 11 years old, 50 mg/day (maximum 100 mg/day).  If children ingest between 50 and 100 mg of 
soil per day (LaGoy 1987) and the soil they ingest contains 1 pg/g (1 ppt) of CDDs, a child may be exposed 
to 0.05-0.1 pg of CDDs per day by this pathway alone (see Section 5.7). 
Children in high risk populations include children of recreational or subsistence fishers, children of 
subsistence hunters particularly those that consume tissues of marine mammals, and children of subsistence 
farmers that consume meat, milk and/or dairy products from their own farm raised animals (see Section 5.7 
for further details). For example, Native American and other subsistence fishing communities may be at 
greater health risks from CDDs in fish and children in these population often consume larger amounts of 
fish than adult members of the general population (CRITFC 1994; Mott 1995).  Children of recreational and 
subsistence fishers who routinely consume locally caught fish from CDD-contaminated waterbodies can be 
exposed to higher CDD concentrations than children who consume similar or larger amounts of 
commercially marketed fish from a variety of sources (Ebert et al. 1996; EPA 1995c; Mott 1995).  The 
exposure to CDDs will also be highest among children who regularly eat fish as compared to those who 
only occasionally or never eat fish.  Several recent studies have documented the higher fish consumption 
rates among subsistence fishers some of which are Native American populations (CRITFC 1994; Nobmann 
et al. 1992; Wolfe and Walker 1987). A study of fish consumption patterns among the Umatilla, Nez Perce, 
Yakama, and Warm Springs tribes of the Columbia River Basin in Washington and Oregon (CRITFC 1994) 
found that the consumption rate for these Native American children (5 years and younger) from these 
four tribes was 19.6 g/day (a consumption rate over 3 times higher than that for adults in the general 
population (6.5 g/day). 
This increased exposure has been demonstrated by serum CDD levels, which are found to be several times 
higher in people who regularly eat fish as compared to those who occasionally or never eat fish (Anderson 
et al. 1998; Svensson et al. 1991) (see Sections 5.5 and 5.9).  In addition, this same situation also applied 
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for consumption of wildlife, specifically marine mammals (Ayotte et al. 1997; Dewailly et al. 1992). 
Similar dietary situations exist for children of subsistence hunters that tend to consume tissues of marine 
mammals and children of subsistence farmers that consume beef, milk and other dairy products from their 
own farm raised animals.  In the case of subsistence fishers, subsistence hunters, and subsistence farmers, 
all three populations share one problem, that the source of their fish, meat, and/or milk and other dairy 
products, is typically restricted to a localized area, and if these food sources are contaminated with CDDs, 
adults and children in these populations will be exposed to higher levels of CDDs than members of the 
general population (see Section 5.7 for additional details on these populations at risk). 
In order to reduce exposure from consumption of CDD-contaminated fish and wildlife, consumption 
advisories are issued by states recommending that individuals restrict their consumption of specific fish, 
shellfish, and wildlife species from certain waterbodies where CDD concentrations in tissues of these 
species exceed the human health level of concern (EPA 1995c) (see Section 5.7 for additional information). 
Recreational and subsistence fishers typically consume larger quantities of fish and shellfish than the 
general population and frequently fish the same waterbodies routinely.  Because of this, children living in 
these populations are at greater risk of exposure to CDDs and other chemical contaminants if the waters 
they fish are contaminated.  Currently, 66 advisories have been issued by 21 states restricting the 
consumption of CDD-contaminated fish and shellfish (EPA 1998b) and one state Arkansas also has issued a 
consumption advisory for wood ducks, a species of migratory waterfowl. Three states (New Jersey, New 
York and Maine) also have statewide advisories for CDDs in their marine waters (EPA 1998a).  The 
number of waterbodies under advisory for CDD in each state is shown in Figure 5-8. 
5.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 
In addition to individuals who are occupationally exposed to CDDs (Section 5.5), there are several groups 
within the general population with potentially high exposures (higher-than-background-normal levels) to 
CDDs. Historically, populations that have been exposed to higher-than-normal background levels of CDDs 
in the air, water, soil, and/or food have included those who were exposed to 2,3,7,8-TCDD as a result of 
industrial accidents (e.g., Nitro, West Virginia; and Seveso, Italy) and those exposed through environmental 
contamination (e.g., Times Beach, MO; Binghamton, NY; Love Canal, NY; Newark, NJ; and Vietnam) 
(Kahn et al. 1988; Schecter 1985; Schecter and Tiernan 1985; Schecter et al. 1987a, 1989a; Umbriet et al. 
1986a, 1986b; Zook and Rappe 1994). 
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Currently, individuals living in proximity to sites where CDDs are produced as chemical by-products or 
sites where CDD-contaminated chemicals are disposed, individuals living near municipal and industrial 
incinerators, and individuals living near one of the 110 NPL hazardous waste sites where CDDs have been 
detected in some environmental media (HazDat 1998) are at risk of receiving potentially higher-than­
normal background levels of exposure.  Other populations at risk of exposure primarily through dietary 
habits, include recreational and subsistence fishers who typically consume larger amounts of locally caught 
fish and shellfish than the general population, subsistence hunters, particularly those in the high latitudes, 
who typically consume large amounts of locally caught game including marine mammals;  and subsistence 
farmers and their families living in areas contaminated with CDDs who exclusively consume their own 
farm-raised beef and dairy products.  
Individuals exposed through industrial accidents or environmental contamination. Very 
extensive residential contamination by 2,3,7,8-TCDD occurred in Seveso, Italy, when a 2,4,5-TCP reactor 
exploded in 1976 (Mocarelli et al. 1991). The contaminated area was divided into three zones based on the 
concentration of 2,3,7,8-TCDD in the soil. Families in zone A, the most heavily contaminated area based 
on soil 2,3,7,8-TCDD levels, were evacuated within 20 days of the explosion and measures were taken to 
minimize exposure of residents in nearby zones.  A recent analysis of 19 blood samples from residents of 
zone A, which were collected and stored shortly after the accident, showed serum lipid levels of 
2,3,7,8-TCDD that ranged from 828 to 56,000 ppt.  These serum lipid levels are among the highest ever 
reported for humans (Mocarelli et al. 1991).  
In a study conducted in Missouri, 2,3,7,8-TCDD was measured in the adipose tissue of 39 volunteers with a 
history of residential, recreational, or occupational exposure (14 years post-exposure) and in 57 persons in a 
control group (Patterson et al. 1986a). Based on questionnaire responses, the eligible exposed group for 
this study consisted of people who were exposed either to areas with 2,3,7,8-TCDD concentrations in soil 
between 20 and 100 ppb for 2 or more years or to 2,3,7,8-TCDD concentrations >100 ppb for at least 
6 months.  Persons who met these criteria were classified as having one of three types of exposure: 
residential (either living in close proximity to areas with 2,3,7,8-TCDD-contaminated soil or having 
evidence of contamination inside the home), recreational (riding or caring for horses in 2,3,7,8-TCDD­
contaminated stable arenas at least one time per week), or occupational (working either in a 
hexachlorophene production facility or at truck terminals where the grounds had been sprayed with 
2,3,7,8-TCDD-contaminated waste oil).  All study participants had detectable levels of 2,3,7,8-TCDD in 
their adipose tissue, but the group with known previous exposures had significantly higher levels than 
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controls. Nineteen (49%) of the 39 exposed persons had levels higher than the highest 2,3,7,8-TCDD 
concentration (20.2 ppt) detected in the 57 controls.  Six (15%) of the 39 exposed persons had 
2,3,7,8-TCDD concentrations >100 ppt. Five of the 6 values >100 ppt were from persons exposed to 
2,3,7,8-TCDD during the production of hexachlorophene.  The other high value (577 ppt) was found in a 
man exposed to 2,3,7,8-TCDD while horseback riding in a contaminated arena. 2,3,7,8-TCDD 
concentrations measured in the occupational group (average 136.2 ppt; range 3.5–750 ppt) were, in general, 
higher than those in the residential group (average 21.1 ppt; range 2.8–59.1 ppt), the recreational group 
(average 90.8 ppt; range 5.0–577 ppt), and the control group (average 7.4 ppt; range 1.4–20.2 ppt) 
(Patterson et al. 1986a). 
2,3,7,8-TCDD has been detected at concentrations ranging from 20 to 173 ppt in adipose tissue from 
3 Vietnam veterans reported to have been heavily exposed to Agent Orange (Gross et al. 1984).  Except for 
these few men, however, 2,3,7,8-TCDD concentrations in American Vietnam and non-Vietnam veterans 
were nearly identical with mean serum levels of approximately 4 ppt (CDC 1988).  Concentrations of 
2,3,7,8-TCDD in the controls (those who never served in Vietnam) ranged from not detected (4 ppt) to 
20 ppt. The veterans had served in Vietnam in 1967 and 1968 in areas where Agent Orange had been 
heavily used (CDC 1988).  In another study, 2,3,7,8-TCDD was detected in adipose tissue of 14 Vietnam 
veterans and 3 control patients at levels ranging from not detected (2–13 ppt) to 15 ppt.  No significant 
differences in the tissue levels of Vietnam veterans and the controls were found in this study (Weerasinghe 
et al. 1986). Air Force personnel associated with Operation Ranch Hand (spraying of Agent Orange) in 
Vietnam from 1962 to 1971 had serum CDD levels up to 10 ppt (521 persons).  A correlation was found 
between CDD concentrations and increased body fat (USAF 1991).  The median half-life of 2,3,7,8-TCDD 
in 36 veterans was estimated to be 7.1 years (Pirke et al. 1989).  In 1987, many of the exposed Air Force 
personnel had serum CDD concentrations >50 ppt and several had concentrations exceeding 300 ppt (CDC 
1987). Wolfe et al. (1994) reported a half-life value of 11.3 years for Air Force personnel involved in 
Operation Ranch Hand. Using individuals from two rice oil poisoning episodes (Yusho [Japan] and Yu-
Cheng [Taiwan]), Ryan et al. (1993a) have shown that the elimination of related CDFs is not constant, but 
variable, with faster clearance at higher doses followed by a slowing down in the rate of loss as body 
burden decreases. By analogy, the same may be true for CDDs.  It is also likely that individual congeners 
or those with the same degree of chlorination are excreted from the body at rates that differ from those 
estimated for 2,3,7,8-TCDD.  Because the rate of clearance is not constant, uncertainty in determining the 
half-life measurement may result, especially for estimates of the changing body burden of total CDDs 
measured as TEQs.  
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Individuals living in proximity to production or disposal sites. Individuals living in the vicinity 
of former or current production sites where CDDs are released as by-products, (such as incinerators, coal-
fired electric generating facilities, other waste disposal facilities, and hazardous waste sites) may be exposed 
to CDDs from several exposure pathways.  CDDs have been detected in soil at 94 of the 126 sites where 
they have been detected in some environmental media (HazDat 1998). 
Children and adults may receive higher CDD exposures from dermal contact if they play or work with 
CDD-contaminated soils.  Several studies have examined the bioavailability of 2,3,4,7-TCDD for uptake by 
dermal exposure.  In a study using in vitro human skin tissue, 2,3,7,8-TCDD did not readily penetrate into 
the human skin and the vehicle of exposure played an important role in the dermal penetration (Weber et al. 
1991c). These authors reported that when the exposure vehicle was acetone, the maximum 2,3,7,8-TCDD 
penetration into the in vitro human stratum corneum (30–45% of the dose) was reached within 100 minutes, 
with a tendency to decrease after 1,000 minutes.  Using mineral oil as the exposure vehicle, absorption of 
2,3,7,8-TCDD leveled off at 10% of the dose, and it took more than 300 minutes to reach the maximum. 
The data suggest that the rates of absorption of 2,3,7,8-TCDD into in vitro human skin are moderate (worst­
case scenario) to low when the 2,3,7,8-TCDD is applied in acetone; when applied in mineral oil, the 
adsorption rate was further reduced. Shu et al. (1988) reported that in rats, dermal absorption of 
2,3,7,8-TCDD in a soil vehicle was only 1% of the administered dose.  Similarly, Poiger and Schlatter 
(1980) reported that in rats, dermal absorption of 2,3,7,8-TCDD was almost eliminated when soil or 
activated carbon was used as vehicles. These data support the original Kimbrough et al. (1984) risk 
assessment of a contaminated site in which the authors estimated that the additional lifetime uptake of 
TCDD from soil above background uptake will consist of 95% from soil ingestion, 3% from dermal 
exposure to soil (assuming 1% dermal absorption), and 2% from inhalation of soil particles. 
Children and adults also may receive potentially higher oral exposures from ingestion of CDD-
contaminated soils from their unwashed hands while playing or working in CDD-contaminated areas (Fries 
and Paustenbach 1990; Kimbrough et al. 1984; Paustenbach et al. 1992; Pohl et al. 1995).  Bioavailability is 
an integral factor in the estimation of the internal dose (or dose at the target tissue) of the chemical.  Like 
dermal absorption, gastrointestinal absorption of 2,3,7,8-TCDD and related compounds is variable, 
incomplete, and congener- and vehicle-specific (see Section 2.3.1).  More lipid soluble congeners, such as 
2,3,7,8-TCDF, are almost completely absorbed, while the extremely insoluble OCDD is poorly absorbed. 
However, laboratory data suggest that there are no major interspecific differences in the gastrointestinal 
absorption of CDDs and CDFs. Results from animal studies indicate that bioavailability of 2,3,7,8-TCDD 
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from soil varies between sites because CDDs bind tightly to soil, and increasingly so with the passage of 
time and clay content of the soil (Gough 1991; Umbreit et al. 1986a;1986b).  Therefore, 2,3,7,8-TCDD soil 
concentrations alone may not be indicative of the potential for human health hazard from contaminated 
soils, and site-specific evaluation may be essential.  In their risk assessments, Kimbrough et al. (1984) 
assumed 30% bioavailability from ingestion of soil, but they point out that animal studies with 
contaminated Missouri soil indicated absorption as high as 30 to 50% (McConnell et al. 1984).  Pohl et al. 
(1995) assumed 40% bioavailability of 2,3,7,8-TCDD from soil.  In contrast, Paustenbach et al. (1986) 
assumed only 10–30% bioavailability.  However, unless toxicokinetic studies that use soil samples from the 
specific site are available, it is difficult to speculate on how much 2,3,7,8-TCDD as well as other CDDs will 
be bioavailable. ATSDR’s policy on CDDs contaminated soils is in Appendix B of this profile. 
Individuals may also receive higher doses from routine consumption of CDD-contaminated fish from local 
waters receiving runoff or leachates from the waste site (Paustenbach et al. 1992).  CDDs have been 
detected in fish collected at 12 of the 126 NPL sites where they have been detected in some environmental 
media (HazDat 1998). 
Lastly, individuals living near incinerator or hazardous waste sites may inhale vapors or particulates 
contaminated with CDDs from ambient outdoor air.  This, however, would be a relatively minor exposure 
pathway as only about 50% of all particles are of inhalable size (<10µm)  (Fries and Paustenbach 1990; 
Paustenbach et al. 1992). These authors concluded that since uptake of 2,3,7,8-TCDD from foods will be 
approximately 500–1,000-fold greater than that due to inhalation, that inhalation exposure was a relatively 
insignificant exposure pathway even for individuals living in proximity to an incinerator. 
Recreational and subsistence fishers. In general, concentrations of CDDs in sport fish and 
shellfish from CDD-contaminated waters can be at least an order of magnitude higher than in commercial 
fish and shellfish purchased in a supermarket (see Section 5.4.4).  Since CDDs have been found in fish from 
contaminated lakes and streams (Crunkilton et al. 1987; De Vault et al. 1989; EPA 1987n, 1992; Kuehl et 
al. 1989, 1994; Niimi and Oliver 1989a, 1989b; Reed et al. 1990) and fish and shellfish from estuarine 
waters (Bopp et al. 1991; Brown et al. 1994; Cai et al. 1994; Hauge et al. 1994; Rappe et al. 1991), 
populations that consume large quantities of fish or shellfish from these contaminated waters are also likely 
to have higher exposures to CDDs, although the method of preparation (edible fillets versus skin-on fillets 
or whole fish) and cooked versus raw consumption may substantially reduce the amount of CDDs ingested 
(Paustenbach et al. 1992; Schecter et al. 1996c). 
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Recreational (sport) and subsistence fishers (including some native American peoples) who consume locally 
caught fish from CDD-contaminated waterbodies can be exposed to higher CDD concentrations than 
individuals who consume similar or larger amounts of commercially marketed fish from a variety of sources 
(Ebert et al. 1996; EPA 1995c). The exposure to CDDs will also be highest among people who regularly 
eat large amounts of fish as compared to those who only occasionally or never eat fish.  This increased 
exposure has been demonstrated by serum CDD levels to be several times higher in people who regularly 
eat fish as compared to those who occasionally or never eat fish (Anderson et al. 1998; Svensson et al. 
1991). 
Several studies suggests there is a correlation between consumption of CDD-contaminated fish and/or 
marine mammal tissues and elevated levels of CDDs in blood (Anderson 1998; Ayotte et al. 1998; 
Svensson et al. 1991). Svensson et al. (1991) reported elevated blood levels of CDDs in Swedish fish 
consumers living near the Baltic Sea.  Three distinct groups of consumers were studied: individuals who did 
not consume any fish, moderate fish consumers (consumption rate of 220–500 g of fish/week 
[31–71 g/day]), and high fish consumers (consumption rate of 700–1,750 g of fish/week [100–250 g/day]). 
The highest fish consuming group was composed of fishermen or workers in the fishing industry who 
consumed primarily salmon (30–90 pg TEQ/g) and herring (8–18 pg TEQ/g) from the Baltic Sea.  The TEQ 
blood level was found to average 63.5 pg TEQ/g lipid for the high consumption group, 25.8 pg TEQ/g lipid 
for the moderate consumption group, and 17.5 pg TEQ/g lipid for the nonfish-eating group.  With respect to 
2,3,7,8-TCDD blood levels, the mean blood level detected was 1.8 pg/g (lipid basis) for individuals that 
consumed no fish, 2.5 pg/g for the moderate consumers, and 8.0 pg/g for the high consumer group.  It 
should be noted that even in those individuals who consumed no fish, detectable levels of CDDs were 
present in their blood. This indicates that other food sources (e.g., meat, milk, and other dairy products) are 
likely to be important contributors to the total body burden of CDDs (Rappe 1992). 
Recently, Anderson et al. (1998) completed a preliminary study of the levels of 8 CDDs, 10 CDFs, 36 
PCBs, and 11other persistent organochlorine pesticides in human serum samples from Great Lakes sport 
fish consumers.  Overall, the 31 fishers on average consumed 49 Great Lakes sport fish meals per year, for a 
mean of 33 years.  This is in contrast to the general population in the Great Lakes basin that typically 
consumes 6 meals of Great Lakes sport fish per year.  A summary of the distribution of CDDs is provided 
in Table 5-14. CDD congeners detected most often were 1,2,3,4,6,7,8-HpCDD (31 detects), OCDD (31 
detects), 1,2,3,6,7,8-HxCDD (30 detects), 2,3,7,8-TCDD (25 detects) and 1,2,3,7,8-PeCDD (20 detects). 
The overall mean concentration for 2,3,7,8-TCDD was 6.6 ppt.  Total CDD concentrations were highest 
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for Lake Huron fish consumers (1,259 ppt), intermediate for Lake Michigan consumers (1,087 ppt) and 
lowest for Lake Erie consumers (844 ppt).  The comparison group serving as a control included individuals 
residing in Arkansas and had a total CDD serum concentration of 1,198 ppt.  With respect to the TEQ 
values for CDDs, the pattern among Great Lakes fish consumers was similar to that for total CDD 
consumers with TEQs for Lake Huron fish consumers of 36 ppt, Lake Michigan consumers of 25.9 ppt, and 
Lake Erie consumers of 20.7 ppt. The TEQ values for the three Great Lakes sport fish consumer groups 
were statistically different (p<0.03).  Although the comparison population had CDD concentrations within 
the range of the Lake Michigan and Lake Huron fish consumers, the TEQ value for CDDs for this 
population was the lowest of the four groups at 15.5 ppt.  The authors concluded that Great Lakes anglers 
who are life-long frequent consumers of sport fish represent a subpopulation with the potential for 
significant exposure to CDDs as well as CDFs and PCBs.  The levels of CDDs, CDFs, and PCBs found in 
sportfish and human tissue residues were above those in the general population. 
Ayotte et al. (1998) measured concentrations of CDDs/CDFs and PCBs in plasma of adult Inuit living in 
Arctic Quebec, Canada. The Inuit consume large amounts of fish and marine mammal tissue.  The mean 
concentration of 2,3,7,8-TCDD was 8.4 ppt (range 2.5 to 36.0 ppt) in the Inuit population and < 2 ppt 
(range <2) for the control population in Southern Quebec. The TEQ values for all CDDs/CDFs was 39.6 ppt 
(range 17.1 to 81.8 ppt) in the Inuit population and 14.6 ppt (range 11.5 to 18.9 ppt) for the control 
population. When PCBs and CDDs/CDFs are considered together, the mean TEQ values for all dioxin-like 
compounds was 184.2 ppt in the Inuit population (range 55.8 to 446.7 ppt) and 26.1 ppt (range 20.1 to 31.7 
ppt) for the control population. 
Several recent studies have documented the higher fish consumption rates among subsistence fishers some 
of which are Native American populations.  In a study of Alaskan subsistence economies, Wolf and Walker 
(1987) reported daily fish consumption rates ranging from 6 to 1,536 g/day, with an average consumption 
rate of 304 g/day.  This average consumption rate for subsistence fishers is more than 46 times higher than 
the mean fish consumption rate of 6.5 g/day estimated for the general population (EPA 1995c).  In a study 
of 11 Alaskan communities, Nobmann et al. (1992) reported an average daily fish consumption rate of 
109 g/day.  This is more than 16.8 times higher than the mean fish consumption rate of 6.5 g/day estimated 
for the general population (EPA 1995c). A recent study of fish consumption patterns among the Umatilla, 
Nez Perce, Yakama, and Warm Springs tribes of the Columbia River Basin in Washington and Oregon 
(CRITFC 1994) found that adults in these 4 tribes consume an average of 58.7 g/day of fish and the 
95th percentile of fishers consume 170 g/day of fish.  This mean consumption rate is more than nine times 
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higher than the mean fish consumption rate estimated for the general population (EPA 1995c).  Fitzgerald et 
al. (1995) conducted a study to establish patterns of fish consumption of nursing Mohawk Indians residing 
in the vicinity of three hazardous waste sites located near Akwesasne, NY, compared to a control 
population of Caucasian women in New York state.  The dietary data showed that there was a significant 
past prevalence of local fish consumption among Mohawk mothers (23.5 meals per year) more than a year 
before pregnancy as compared to the controls (14.1 meals per year). 
In order to reduce CDD exposure from consumption of CDD-contaminated fish and shellfish, consumption 
advisories are issued by states recommending that individuals restrict their consumption of specific fish and 
shellfish species from certain waterbodies where CDD concentrations in fish and shellfish tissues exceed 
the human health level of concern.  This level of concern is set by individual state agencies, but many states 
use the FDA tolerance levels of >25 ppt, but <50 ppt to advise consumers to restrict consumption and levels 
>50 ppt to issue advisories recommending no consumption of contaminated fish and shellfish (see 
Table 7-1). These values are used despite the fact that they were designed to protect consumers from the 
health risks associated with consumption of fish and shellfish that are shipped in interstate commerce and 
are purchased in commercial markets.  In 1995, the EPA Office of Water  issued guidance to states on 
sampling and analysis procedures to use in assessing the health risks from  locally caught fish and shellfish. 
The risk assessment method proposed by EPA was specifically designed to assist states in developing fish 
consumption advisories for recreational and subsistence fishers (EPA 1995c).  These two groups within the 
general population consume larger quantities of fish and shellfish than the general population and 
frequently fish the same waterbodies routinely.  Because of this, these populations are at greater risk of 
exposure to CDDs and other chemical contaminants if the waters they fish are contaminated.  The EPA 
advises states to use a screening value of 7x10-7 ppm (0.7 ppt) of total TEQ value (wet weight) in fillets for 
the general population as a criteria to evaluate their fishable waterbodies (EPA 1995c).  Currently, 
66 advisories have been issued by 21 states restricting the consumption of CDD-contaminated fish and 
shellfish (EPA 1998b). Three states (New Jersey, New York, and Maine) also have statewide fish 
advisories in effect for their marine coastal waters.  In addition, the State of Arkansas also has issued a 
wildlife advisory for wood ducks, a species of waterfowl in Bayou Meto, a site contaminated by a point 
source discharge (White and Hoffman 1995).  The number of waterbodies under advisory for CDD in each 
state is shown in Figure 5-8. 
Subsistence hunters. Native American populations such as the Inuit of Alaska and other subsistence 
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CDDs in marine mammals, but not terrestrial mammals (i.e., caribou).  CDDs have been detected in seal 
and polar bear fat and liver tissues (Norstrom et al. 1990).  Recently, Ayotte et al. (1997) reported that in 
20 pooled samples of Inuit blood, the TEQ concentration supplied by CDDs/CDFs (combined) was 39.6 ppt 
as compared to 14.6 ppt in 3 pooled samples of blood from individuals in the general population in 
Southern Quebec. The mean 2,3,7,8-TCDD concentrations were 8.4 ppt for Inuit and <2 ppt for members of 
the general population. When planar PCBs, mono- and di- ortho PCBs were added, the mean TEQs were 
184.2 ppt and 26.1 ppt, respectively, for Inuit and members of the general population in Southern Quebec. 
In a related study, Dewailly et al. (1992) found that breast milk of these Inuit was more contaminated by 
CDDs, CDFs, and PCBs than milk of women in Southern Quebec. For CDDs and CDFs, differences were 
less impressive than for PCBs.  However, mean OCDD concentrations were 292 ppt versus 132 ppt and 
2,3,7,8-TCDD concentrations were 6.2 ppt versus 2.3 ppt for Inuit women and women in Southern Quebec, 
respectively.  Concentrations of OCDD and 2,3,7,8-TCDD were 2 to 3 times greater among the native Inuit 
population that consumed large amounts of fish and marine mammal tissue.  No data were located 
specifically for CDD concentrations in the adipose tissue, blood, or breast milk of native American 
populations in the United States. However, by analogy to CDDs in Canadian Inuit populations, it is 
anticipated that CDD concentrations in these tissues are likely to be higher among individuals who 
routinely consume large quantities of wild game species, especially marine mammal than among members 
of the general population. 
In a study of subsistence economies in the State of Alaska, Wolfe and Walker (1987) reported that total 
annual per capita consumption of wild game species (including land mammals, marine mammals, and fish) 
ranged from 10 to 1,498 pounds (median harvest of 252 pounds) as compared to 222 pounds of meat, fish, 
and poultry consumed each year by individuals in the western United States.  In the 1980s, the 98 Alaskan 
subsistence communities surveyed harvested wild game at levels from one-half to 4 times the U.S mean. 
The average daily per capita consumption was 0.67 pounds for fish and 0.23 pounds for land mammals 
based on all 98 communities, and 0.2 pounds for marine mammals based on the 41 coastal communities 
surveyed.  Land mammals consumed in these communities included moose, caribou, deer, black bear, 
snowshoe and tundra hare, beaver, and porcupine; while marine mammals included seal, walrus and whales. 
Subsistence hunters and their families are a population at potentially higher risk of CDD exposure when the 
wild game species particularly marine mammals they consume  are contaminated with CDDs.  It should be 
noted that concentrations of CDDs/CDFs were recently determined in caribou tissue samples from 7 herds 
across the Canadian Arctic (Hebert et al. 1996). In contrast to levels of 2,3,7,8-TCDD found in marine 
mammals which ranged from 2 to 37 ng/kg (ppt wet weight) (Norstrom et al. 1990), 
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concentrations of 2,3,7,8-TCDD in caribou were extremely low, sub ng/kg (lipid basis).  2,3,7,8-TCDD was 
detected in adipose tissue samples of two herds in the eastern Canadian Arctic at levels of 0.73 and 
0.14 ng/kg, but was not detected in tissue samples from other herds at detections limits as low as 0.03 ng/kg 
(lipid basis). CDFs were detected at sub-ng/kg levels in all cases.  TEQs were dominated by non-ortho 
substituted PCBs in all cases, and ranged from 0.33 ng/kg to 3.3 ng/kg in adipose tissue.  The authors 
concluded that caribou tissues are therefore less contaminated than tissues from marine mammals. 
Subsistence farmers that consume their own farm-reared meat and dairy products.
Subsistence farmers and their families living on farms where CDD concentrations may be high who 
exclusively eat meat and dairy products produced on their own farms may be exposed to higher levels of 
CDD in these foods than the general population. Grazing cattle in farming areas downwind of municipal or 
industrial incinerators where CDDs may be deposited as particulates on soil or forage crops or grazing 
cattle in areas with CDD-contaminated soil or soil amended with municipal sewage sludges or paper mill 
sludges contaminated with CDDs may result in higher CDD tissue residues in the animals (EPA 1991b; 
Fries and Paustenbach 1990). In an evaluation of potential transmission of 2,3,7,8-TCDD from incinerator 
emissions to humans via foods, Fries and Paustenbach (1990) determined that the amount of 2,3,7,8-TCDD 
accumulated in soil from airborne emissions was less important that the amount deposited in forage.  These 
authors further concluded that the airborne emissions of CDDs/CDFs from modern waste incinerators that 
have appropriate air pollution devices should not pose a significant health hazard regardless of the 
incinerator location. The authors, however, acknowledged that it would be desirable to measure 
2,3,7,8-TCDD in soil and crops around existing facilities to better evaluate their assessment results, 
although they felt it was likely that concentrations would be too low to reliably quantify.  More recently, 
Fürst et al. (1993) reported that soil levels up to 30 pg TEQ/g dry matter did not result in elevated CDD 
concentrations in cow’s milk.  However, these authors did show increasing concentrations of CDDs in grass 
resulted in slightly higher CDD concentrations in cow’s milk.  These authors, like Fries and Paustenbach 
(1990), believe that the pathway of air to grass to cow is more important than the pathway of soil to grass to 
cow. 
In a European survey of cow’s milk samples collected on dairy farms, elevated CDD/CDF milk 
concentrations were used to pinpoint the existence of certain “hotspots” of CDD contamination.  These 
“hotspots” were generally found near CDD/CDF emitting sources, such as cable waste incinerators or 
metal refining industries (Beck et al. 1990; Liem et al. 1991; Rappe et al. 1987).  Riss et al. (1990) 
analyzed blood from one farmer in a CDD/CDF-contaminated location in proximity to a metal reclamation 
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plant who consumed milk produced from his own farm, and found 2,3,7,8-TCDD blood levels (55 pg/g on 
a lipid basis) above expected background levels. 
Exposure to 2,3,7,8-TCDD from land application of municipal sewage sludge or paper mill sludge also can 
occur through the dietary pathway if people consume food grown or animals grazed on sludge-amended 
lands (EPA 1991b). Wild et al. (1993), using a human exposure assessment model, predicted that if all the 
produce consumed by a human is derived from agricultural land to which sewage sludge is applied at a rate 
of 10 tons/hectare and 0.5 ng/kg dry weight concentration, this would increase exposure to 2,3,7,8-TCDD 
by 0.0332 ng/day or 39% over background conditions.  This scenario assumes that the poultry, eggs, and 
fish CDD concentrations are unaffected by the sludge application.  Most recently, McLachlan et al. (1994) 
reported that the prolonged use of sewage sludge as a soil amendment on English farms under some 
conditions can lead to an increase in the concentrations of CDDs/CDFs in both the soil and in cow’s milk. 
Subsistence farmers and their families are a population at potentially higher risk of CDD exposure because 
meat and dairy products are substantial sources of CDDs in the U.S. diet (Schecter et al. 1994e, 1996a).  
5.8 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate 
information on the health effects of CDDs is available.  Where adequate information is not available, 
ATSDR, in conjunction with the NTP, is required to assure the initiation of a program of research designed 
to determine the health effects (and techniques for developing methods to determine such health effects) of 
CDDs. 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
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5.8.1 Identification of Data Needs 
Physical and Chemical Properties. The physical and chemical properties of 2,3,7,8-TCDD are 
sufficiently characterized to predict the environmental fate of 2,3,7,8-TCDD (IARC 1977; Sax and Lewis 
1987; Schroy et al. 1985; Shiu et al. 1988).  Of all the CDDs, 2,3,7,8-TCDD has been the compound most 
studied. Not all isomers within each homologous class have been equally well studied for many of the 
physical and chemical properties.  Information on physical and chemical properties of certain congeners 
(particularly 1,2,3,7,8,-PeCDD and 1,2,3,6,7,8-HxCDDs) would be helpful in better understanding the 
different fate and transport pathways of the homologous groups.  
Production, Import/Export, Use, Release, and Disposal. CDDs are not manufactured 
commercially in the United States except on a laboratory scale for use in chemical and toxicological 
research (Cambridge Isotope Laboratories 1995).  They are produced as undesired by-products during the 
manufacture of chlorophenols (e.g., PCP and 2,4,5-trichlorophenol) and during combustion processes 
(IARC 1977; NTP 1989; Podoll et al. 1986). CDDs are ubiquitous in the environment and have been 
found at low levels (ppt or lower) in air, water, soil, sediment, and foods.  Current disposal methods are 
efficient and are subject to EPA and state regulations. 
According to the Emergency Planning and Community Right-To-Know Act of 1986, 42 U.S.C. Section 
11023, industries are required to submit chemical release and off-site transfer information to the EPA.  The 
Toxics Release Inventory (TRI), which contains this information for 1994, became available in May of 
1996. This database will be updated yearly and should provide a list of industrial production facilities and 
emissions.  However, there are no TRI data for CDDs since CDD releases are not required to be reported 
(EPA 1995g). 
Environmental Fate. CDDs are subject to atmospheric transport and both wet and dry deposition 
(Kieatiwong et al. 1990). They are partitioned to air, water, sediment, and soil, and they accumulate in 
both aquatic and terrestrial biota. CDDs can volatilize to the atmosphere from water and soil surfaces. 
They adsorb strongly to soils and are not likely to leach into groundwater (Eduljee 1987b).  In the aquatic 
environment, CDDs partition to sediment or suspended particulates.  TCDD, HpCDD, and OCDD are 
subject to photolysis in air, water, and soil (Plimmer et al. 1973).  2,3,7,8-TCDD is biodegraded very 
slowly in soil and thus is likely to persist in the soil.  A better understanding of environmental behavior of 
CDDs is needed with respect to the importance of vapor-phase versus particulate transport, the 
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environmental behavior of different congeners, and the significance of processes that reintroduce CDDs 
into the atmosphere after deposition.  Information regarding the degradation of other congeners, 
specifically OCDD, and their degradation products in water, sediment, and soil would be useful in 
evaluating the various pathways of human exposure. 
Bioavailability from Environmental Media. Toxicokinetic data in humans regarding adsorption of 
CDDs following oral and dermal exposure are very limited (Poiger and Schlatter 1986).  CDDs can be 
absorbed following oral exposure in both humans and animals (Birnbaum and Couture 1988; Fries and 
Marrow 1975; Koshakji et al. 1984; Norback et al. 1975; Olson et al. 1980b; Piper et al. 1973; Poiger and 
Schlatter 1980). The more highly chlorinated CDD congeners are absorbed to a lesser extent than 
2,3,7,8-TCDD (Koshakji et al. 1984). Also, limited information is available on the bioavailability from fly 
ash (Van den Berg et al. 1983, 1985). 2,3,7,8-TCDD can be adsorbed following dermal contact (Banks 
and Birnbaum 1991; Poiger and Schlatter 1980; Shu et al. 1988); however, dermal absorption of 
2,3,7,8-TCDD from soil is very low (Shu et al. 1988).  More information is needed regarding oral and 
dermal exposure to determine the bioavailability of CDDs from food, water, and soil.  Additional 
information is needed to examine the discrepancy noted in the mass balance from CDDs ingested from 
foods and eliminated in feces.  For inhalation exposure, information on the bioavailability from fly ash and 
sediments would be useful.  Information is also needed on the selective uptake of the 2,3,7,8-substituted 
CDD congeners. 
Food Chain Bioaccumulation. CDDs are bioconcentrated in aquatic organisms, plants, and 
terrestrial animals.  Shellfish (including crustaceans and bivalve mollusks) appear to accumulate CDDs 
nonselectively to relatively high concentrations in their tissues (Bopp et al. 1991; Brown et al. 1994; Cai et 
al. 1994; Conacher et al. 1993; Hauge et al. 1994; Rappe et al. 1991).  In contrast, finfish appear to 
selectively accumulate primarily 2,3,7,8-TCDD and other 2,3,7,8-substituted isomers in their tissues 
(Rappe et al. 1991). Information from a larger number of species on the retention of 2,3,7,8-substituted 
CDD congeners and general information on retention and distribution of other CDDs would be useful in 
better understanding both aquatic and terrestrial food chains.  
Exposure Levels in Environmental Media. CDDs have been detected in air, water, soil, sediment, 
plant material, and foods.  Environmental monitoring studies show that the higher chlorinated CDDs are 
usually the ones most commonly found in environmental samples (Christmann et al. 1989b; Clement et al. 
1985, 1989; Pereira et al. 1985; Reed et al. 1990; Tashiro et al. 1989a; Tiernan et al. 1989b). Current 
 
    
 
CDDs 500 
5. POTENTIAL FOR HUMAN EXPOSURE 
monitoring studies are needed to determine CDD levels in media surrounding hazardous waste sites. 
Using a model, the total average daily intake of 2,3,7,8-TCDD (by air, water, and food) for the general 
population was estimated to be 0.05 ng/day (range 0.008–0.3 ng/day) (Travis and Hattemer-Frey 1987). 
Schecter et al. (1994d, 1994e, 1996a) and Schecter and Li (1997) have provided current information on 
CDD exposures from food.  Food consumption accounts for over 90% of background human exposure to 
2,3,7,8-TCDD and other CDDs/CDFs in the general U.S. population (Hattemer-Frey and Travis 1989; 
Schaum et al. 1994).  The average daily intake by nursing infants in the United States has been estimated 
to be 83 pg TEQs/kg (Schecter and Gasiewicz 1987a, 1987b). 
Reliable monitoring data for the levels of CDDs in contaminated media at hazardous waste sites are needed 
so that the information obtained on levels of CDDs in the environment can be used in combination with the 
known body burdens of CDDs to assess the potential risk of adverse health effects in populations living in 
the vicinity of hazardous waste sites. 
Exposure Levels in Humans. CDDs/CDFs have been found in blood (Fingerhut et al. 1989; 
Needham et al. 1991; Päpke et al. 1989b, 1992, 1993), adipose tissue (Orban et al. 1994; Patterson et al. 
1986a; Ryan et al. 1986; Schecter et al. 1986b; Stanley 1986; Stanley et al. 1986), and breast milk of both 
the general population and workers exposed through industrial accidents or environmental contamination 
(Fürst et al. 1992; Pluim et al. 1993a; Ryan et al. 1993b; Schecter and Gasiewicz 1987b; Schecter and 
Tiernan 1985a; Schecter et al. 1986a, 1986b; 1989e). Levels of 2,3,7,8-TCDD as well as other CDDs are 
generally higher in occupationally exposed individuals or those individuals exposed through industrial 
accidents or environmental contamination (Kahn et al. 1988; Schecter et al. 1986b; Schecter and Tiernan 
1985; Schecter et al. 1987a; Umbriet et al. 1986a, 1986b).  CDDs have also been detected in breast milk 
and blood of Canadian populations of native Inuit that consume large amounts of fish and marine 
mammals (Ayotte et al. 1997; Dewailly et al. 1992). Additional biological monitoring data are needed, 
however, for those U.S. populations surrounding hazardous waste sites or municipal, medical, or industrial 
incinerators, for urban versus rural exposures, and for other potentially exposed populations including 
subsistence fishers and hunters (Liem et al. 1991; Startin et al. 1989; Wuthe et al. 1993).  Information on 
tissue levels in the general population worldwide are for the most part lacking (Schecter et al. 1991a).  As 
they are identified, exposed populations should be evaluated to characterize exposure levels and health 
effects. This information is necessary for assessing the need to conduct health studies on these 
populations. 
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Exposures of Children. Children in the general population are exposed to CDDs primarily through 
dietary exposures in utero via placental blood and in newborn infants via breast-feeding. Despite the fact 
that studies on the concentrations of CDDs in human breast milk have been conducted in various other 
countries, there is a need to determine the levels of CDDs in human milk in the United States.  Additional 
exposure studies also are needed to determine whether dietary modifications in mothers can reduce total 
CDD exposures in newborns and whether dietary modifications of the infant can also reduce lifetime 
exposure. For children in populations with potentially high exposure to CDDs, the primary exposure 
pathway is  through their diet; however, additional exposure to CDDs via consumption of contaminated 
groundwater, contaminated soil, and dermal exposure to contaminated soil may increase their exposure 
levels. Studies of workers in various industrial settings that are exposed to CDDs (i.e., elevated CDD 
levels in adipose or blood serum) should be conducted to determine whether CDDs are routinely brought 
home by these workers on their clothing and shoes to assess in order to determine whether this is an 
important exposure route for children. 
Schecter and Li (1997) have calculated weight-adjusted intakes of CDDs derived from consumption of 
four types of fast foods for 6-year-old children.  Additional information on dietary intake of CDDs from 
other types of foods should be conducted for various age groups of children to help identify the magnitude 
and sources of dietary exposure during childhood.  Studies to verify these calculations would be helpful in 
assessing health risks to children. 
The primary childhood specific means to decrease exposure to CDDs involves placing the infant on a 
cow’s milk or soy-based baby formula and on maintenance of children on a long-term diet that is lower in 
animal fats (meat, dairy products, and fish) and higher in grains, fruits, and vegetables.  It should be noted 
however, that because of the relatively short period of intake and the accepted benefits of breast-feeding 
that maintenance of children on long-term diet low in animal fat would likely be more beneficial in 
decreasing total lifetime CDD body burdens than cessation of breast-feeding.  Additional means of 
reducing CDD exposures also should be investigated. 
Exposure Registries. Approximately 250 members were enrolled in the 2,3,7,8-TCDD Subregistry 
of the National Exposure Registry in 1991 (ATSDR 1996).  These individuals were chosen because they 
participated in one or more of the Missouri Dioxin Health Studies and were reportedly exposed to CDDs at 
one of the four Times Beach, MO area CDD sites.  Data collected for each member of the Dioxin 
Subregistry include demographic information, smoking and occupational histories, and self-reported 
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responses to 25 general health status questions. The data files for the Subregistry are established at the 
time baseline data are collected.  A follow-up survey is conducted 1 year after baseline data collection, and 
surveys are, in most cases, conducted at 2-year intervals after that to update the files.  For the Dioxin 
Subregistry, all interviews are conducted by means of computer-assisted telephone interviewing. 
Subregistry members will be questioned yearly about their health over the previous year.  This activity is 
carried out by ATSDR.  The data will become part of public-user data files maintained by ATSDR.  The 
information that is amassed in the National Exposure Registry facilitates the epidemiological research 
needed to assess adverse health outcomes that may be related to the exposure to this compound. 
The Air Force maintains an exposure registry of about 1,200 personnel previously involved in the spraying 
of Agent Orange (USAF 1991). The Air Force Health Study (AFHS) is an epidemiologic investigation of 
the association between occupational exposure to Agent Orange (and its CDD contaminants) and long-
term adverse health effects experienced by Air Force personnel who served in Operation Ranch Hand units 
in Vietnam from 1962 to 1971 and sprayed Agent Orange from fixed winged aircraft.  A comparison 
group, which was formed from Air Force veterans, is used as the unexposed cohort.  Evaluations were 
performed in 1982, 1985, and 1987.  In the 1987 examination, 1,670 participants were involved.  Health 
outcomes were evaluated with respect to serum CDD levels.  Additional evaluations are planned for 1997 
and 2002. 
5.8.2 Ongoing Studies 
The EPA is currently conducting a reassessment of the risk from exposure to CDDs, and other chlorinated 
dioxin-like compounds such as CDFs and PCBs.  This reassessment involves a literature reevaluation of 
existing studies and new laboratory studies addressing health and ecological risks from exposure to these 
compounds (LaFleur et al. 1990; Rappe 1992; Schecter et al. 1994d). Currently, the EPA dioxin 
reassessment document is undergoing final review. 
The National Institute of Environment Health Sciences and the Centers for Disease Control and Prevention 
are measuring levels of CDDs, CDFs, PCBs and other chemicals in blood of members of the general U.S. 
population as part of the NHANES program. 
In addition, an international “Dioxin” research conference meets annually to discuss developments 
regarding these environmental contaminants. The proceedings of this international symposium on CDDs 
and related compounds are published annually in extended abstract form and frequently in a proceedings 
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issue of the journal Chemosphere and are an extensive source for papers on a wide variety of 
environmental and health issues related to CDDs and dioxin-like compounds. 
A search of Federal Research in Progress (FEDRIP 1998) identified numerous research studies that are 









The purpose of this chapter is to describe the analytical methods that are available for detecting, and/or 
measuring, and/or monitoring CDDs, its metabolites, and other biomarkers of exposure and effect to 
CDDs. The intent is not to provide an exhaustive list of analytical methods.  Rather, the intention is to 
identify well-established methods that are used as the standard methods of analysis.  Many of the 
analytical methods used for environmental samples are the methods approved by federal agencies and 
organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH).  Other 
methods presented in this chapter are those that are approved by groups such as the Association of Official 
Analytical Chemists (AOAC) and the American Public Health Association (APHA).  Additionally, 
analytical methods are included that modify previously used methods to obtain lower detection limits, 
and/or to improve accuracy and precision. 
6.1 BIOLOGICAL SAMPLES 
The primary method of determining CDDs in biological samples is gas chromatography (GC) with mass 
spectrometry (MS).  Sample preparation is critical, and extensive extraction and sample clean-up are 
required to separate the CDD homologues/congeners from fatty material and other organic contaminants. 
Extreme care must also be used to ensure that all reagents and equipment used in analysis are free of CDD 
contamination.  Losses of CDDs can occur as a result of adsorption onto the surfaces of glassware used in 
sample preparation (EPA 1994c).  The routine baking of glassware as a part of the cleaning process should 
be avoided because this may cause active sites on the glass that will irreversibly adsorb CDDs.  The lack of 
interferences must be demonstrated under the conditions of analysis.  Analysts should avoid polyvinyl 
chloride (PVC) gloves (EPA 1994c). The basic steps of sample preparation include extraction of the 
sample with a lipophilic organic solvent (e.g., hexane) followed by several evaporation and column 
chromatography steps to concentrate, clean up, and fractionate the CDDs. 
Methods of measuring CDDs in biological samples are very sensitive, generally having method (sample 
matrix) detection limits  in the low- or sub-parts per trillion (ppt) level.  If rigorous sample preparation 
methods are meticulously followed, sensitivity, accuracy, selectivity, and precision can be good.  These 
parameters will vary with the analytical method used, the experience level of the technician, the nature of 
the sample matrix, the concentrations of the analyte(s) and possible interfering substances, and the specific 
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homologue/congener being measured.  High-resolution gas chromatography (HRGC) is used almost 
exclusively.  The MS method may be low resolution (LRMS), high resolution (HRMS), or tandem LRMS 
(MS/MS). Individual ionization techniques that have been commonly used with MS to determine CDDs 
include electron impact ionization (EI), chemical ionization (CI), and negative chemical ionization (NCI). 
Electron impact ionization instruments are the most common although the least sensitive.  The use of CI 
and NCI methods can improve instrumental sensitivity because less molecular fragmentation occurs, with 
the resulting ion current concentrated in fewer ions compared to EI.  NCI is very selective for those 
compounds that tend to capture electrons and form negative ions.  Both CI and NCI can greatly increase 
selectivity and sensitivity in complicated matrices.  Selected ion monitoring (SIM) is most frequently used 
for quantitation; however, multiple ion monitoring (MIM), also called multiple ion detection (MID), has 
also been employed.  Isotopically labeled internal standards (such as 13C- or 37Cl-labeled CDDs) are 
needed both for quantitation and to monitor method performance.  Table 6-1 is a summary of some of the 
most commonly used methods for detecting CDDs in biological samples.  Many of the methods for food 
and wildlife (Table 6-2) could have applicability to CDDs in human samples of similar composition. 
HRGC combined with HRMS has been used to determine parts per quadrillion (ppq) levels of CDDs in 
blood, serum, and plasma (Chang et al. 1993; Nygren et al. 1988; Patterson et al. 1987a, 1989b).  Method 
8290 (EPA 1994c) is applicable to adipose tissue with a limit of detection of 1 ppt.  Method 8290 has also 
been used to determine CDDs in blood and semen (Schecter 1996).  The methods differ in the solvent 
system used to extract the dioxins and the types of columns used to clean up and fractionate the samples. 
The method of Chang et al. (1993) used solid phase extraction for the initial step of the isolation. 
Detection limits were comparable for CDD, but the method used by Patterson et al. (1987a) gave better 
recovery of the analyte.  Precision was similar, with a coefficient of variation (CV) that ranged from 2 to 
22% for TCDD. 
2,3,7,8-TCDD has been detected (sub-ppt) in human feces using HRGC/LRMS (Wendling et al. 1990).  In 
rodent metabolism studies both parent compound and metabolite were detected in feces and metabolites 
were detected in urine using GC/LRMS. HRGC/LRMS has also been used successfully in determination 
of CDDs in rat feces (Abraham et al. 1989a).  Adequate comparisons of sensitivity, accuracy, and 
precision cannot be made because of the lack of these data for several methods and the differences in the 
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HRGC has been combined with LRMS, HRMS, and MS/MS for the detection of CDDs in tissues. 
Sensitivity is generally in the ppt range with the best sensitivity (2 ppt) reported with MS/MS using CI 
(Ryan et al. 1987a).  The limit of detection was higher for MS than for MS/MS (Schecter et al. 1985b; 
Stanley 1986; Takizawa and Muto 1987).  No recovery data were given for HRMS (Nygren et al. 1988). 
Precision for these methods is usually <20% (Takizawa and Muto 1987; Van den Berg et al. 1989).  
CDDs have been measured in breast milk using HRGC/MS in the SIM mode.  Reported detection limits 
are in the low- to sub-ppt (Van den Berg et al. 1986b), and recovery (75–89%) is good (Noren and Sjoevall 
1987). 
An additional screening test for TCDD-like (aryl hydrocarbon receptor, AhR, active) chemicals has been 
developed (Garrison et al. 1996) and is available commercially (Anonymous 1997).  Dubbed the CALUX 
(for chemically activated luciferase gene expression) system, the assay is based on recombinant cell lines 
into which researchers have inserted a firefly luciferase gene.  When exposed to dioxin-like compounds, 
the recombinant cells luminesce.  The method is sensitive to ppt levels of 2,3,7,8-TCDD equivalents in 
blood, serum, and milk (Anonymous 1997).  Samples testing positive can be subjected to more definitive 
and specific analytical testing.  
6.2 ENVIRONMENTAL SAMPLES 
As with biological samples, the most common method of determining CDDs in environmental samples is 
HRGC/HRMS. Other methods, including enzyme bioassays, and monoclonal antibody-based enzyme-
linked immunosorbent assays (ELISAs) have also been used or are under development.  Even in relatively 
simple matrices, such as air and water, detection and quantitation of CDDs require rigorous sample 
preparation procedures. Methods used to prepare environmental samples are similar to those used for 
biological samples: organic solvent extraction of CDDs from the sample and concentration, clean up, and 
fractionation of the dioxins using evaporative and column chromatography techniques.  The same MS 
techniques described for biological samples are available for environmental samples, with essentially the 
same results and limitations.  Table 6-2 describes some of the most common methods that have been used 
to determine CDDs in environmental samples, with specific MS techniques listed when known.  The 
following section describes the methods available for the different types of environmental samples. 
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HRGC/LRMS and HRGC/HRMS have been used to analyze for CDDs in ambient and hazardous waste 
site air, cigarette smoke, car exhaust, and gaseous waste emissions.  Sample preparation steps for gaseous 
samples are very similar for these two analytical methods.  The steps consist of collection of sample 
contaminants on a filter/trapping cartridge apparatus, organic solvent extraction of the cartridge, and clean 
up and fractionation of the extract using column chromatography (Bingham et al. 1989; Cooke et al. 1988; 
Fairless et al. 1987; Harless et al. 1992; Muto and Takizawa 1989; Oehme et al. 1986; Rappe et al. 1988; 
Smith et al. 1986).  A quartz fiber filter and polyurethane foam plug are commonly used to collect air 
samples (EPA 1988g; Harless et al. 1992; Kuwata et al. 1993), although XAD-2 has also been used 
(Hippelein et al. 1993). The sensitivity of these methods is in the low- to sub-pg/m3  range. Reported 
recovery and precision were generally good for measurements in air and gaseous waste emissions (Cooke 
et al. 1988; Fairless et al. 1987; Oehme et al. 1986), but severe sample loss can occur (Bingham et al. 
1989; Rappe et al. 1988). Electron capture, negative ionization, low resolution MS has also been used to 
quantify CDDs in ambient air; however, 2,3,7,8-TCDD is difficult to detect using this method and results 
must be confirmed with HRGC (Koester et al. 1992). 
Methods have been developed for detecting CDDs in liquid samples including drinking water (McCurvin 
et al. 1989; O'Keefe et al. 1986), groundwater (EPA 1986k, 1994a, 1994c; Pereira et al. 1985), fog 
(Czuczwa et al. 1989), liquid waste effluents (Cooke et al. 1988), an oil extract of landfill leachate (Först et 
al. 1988), pentachlorophenol (Singh et al. 1985), fuel oils, still bottoms, and reactor residues (EPA 1986k, 
1994a), and pyrolyzed transformer oil (Hardin et al. 1989).  HRGC was combined with either LRMS, 
HRMS, or MS/MS in these methods.  Not all methods reported on recovery, precision, and sensitivity, so 
it is difficult to compare these parameters.  Based on the data available, sensitivities range from sub-ppq 
(O'Keefe et al. 1986) to low-ppt levels (Först et al. 1988). Recoveries were usually >60% (Först et al. 
1988; O'Keefe et al. 1986), although some lower values were reported (Hardin et al. 1989). 
HRGC/LRMS, HRGC/HRMS, HRGC/MS/MS, and HRGC/ECD have been used to analyze for CDDs in 
soils and/or sediments (Bobbie et al. 1989; Creaser and Al-Haddad 1989; Donnelly et al. 1986; EPA 
1986k, 1994a, 1994c; Eschenroeder et al. 1986; Jasinski 1989; Pereira et al. 1985; Simon et al. 1989; 
Stalling et al. 1986), solid wastes (Donnelly et al. 1986; Först et al. 1988;  Popp et al. 1997), and other 
solid materials (Donnelly et al. 1986; Hardin et al. 1989; Korfmacher et al. 1985; Muto and Takizawa 
1989). Detection limits for the MS methods range from low-ppt to low-ppb levels.  The sensitivity cannot 
be compared to ECD because no detection limits were reported for the ECD methods.  For soil/sediments, 
recovery seemed to be better for GC/ECD (92–100%) (Jasinski 1989) than for the HRGC/MS methods 
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(40–102%) (Creaser and Al-Haddad 1989; Donnelly et al. 1986; Simon et al. 1989).  Polychlorinated 
biphenyls, polychlorinated diphenyl ethers, polychlorinated naphthalenes, and polychlorinated 
alkydibenzofurans may be found at concentrations several orders of magnitude higher than the analytes of 
interest (EPA 1994a) and could thus interfere with the CDDs.  Retention times must be verified using 
reference standards. 
A method for determining CDDs in municipal incinerator fly ash has been reported (Alexandrou and 
Pawliszyn 1990).  The method uses supercritical fluid extraction (SFE) to recover CDDs from fly ash 
samples prior to GC.  Supercritical fluid extraction is faster and less expensive than the typically used 
Soxhlet extraction and gives quantitative removal of CDDs and CDFs from fly ash.  Extracts obtained 
using SFE will still require additional clean-up steps prior to analysis.  Supercritical CO2 has also been 
used to assist solvent-based extraction of CDDs from soils (Friedrich and Kleiböhmer 1997).  In this case, 
the supercritical fluid was combined with accelerated solvent extraction (liquid extractions conducted 
under elevated temperature and pressure) to provide good recoveries relative to Soxhlet extractions.  
TCDD and other CDDs have been measured in foods (Jasinski 1989; Schecter et al. 1994; Takizawa and 
Muto 1987) and wildlife (birds and bird eggs, fish, and seals) (Bobbie et al. 1989; Buser et al. 1985; EPA 
1994a; Stalling et al. 1986) using HRGC/ECD or HRGC/LRMS.  Schecter et al. (1994) reported data as 
TCDD toxic equivalents with detection limits of approximately 0.01 ppt.  Ferrario et al. (1996) reported a 
new modification of EPA Method 1613 (EPA 1994a) for use in measuring CDDs and CDFs in beef fat; an 
LOD of 0.05 ppt was shown. A comparison of HRGC/LRMS methods conducted  using samples from 
fish, birds, and seals showed that NCI was substantially more sensitive than EI for some, but not all, 
congeners (Buser et al. 1985). A within-lab comparison of fish tissue analysis using HRGC combined 
with either LRMS, HRMS, or MS/MS showed HRMS to be the most sensitive of the three methods 
(Bobbie et al. 1989). However, the large variations in recovery obtained with these methods also 
demonstrated the significance of the problems of sample loss and sample contamination that can occur in 
the analyses of CDDs.  The data were not sufficient to permit a comparison of methods among different 
laboratories. 
Bioassays using induction of the enzymes ethoxyresorufin o-deethylase (EROD) and/or arylhydrocarbon 
hydroxylase (AHH) in rat hepatoma H-4-IIE cells (Zacharewski et al. 1989) and modified mouse liver 
cells (Schuman and Hunter 1988) have been developed and tested on water, soil, and fish samples.  The 
bioassays are based on induction of AHH or EROD enzymatic activity in the cell cultures.  Since the cells 
used in the bioassays are most sensitive to induction by 2,3,7,8-TCDD, this dioxin is used to generate a 
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standard curve for the bioassays, and induction of activity is expressed as TCDD equivalents.  These 
bioassays are highly sensitive to concentrations of Ah receptor-mediated cytochrome P-450 inducers 
(Holcomb et al. 1988; Zacharewski et al. 1989), and could be used to rapidly pre-screen environmental 
samples for 2,3,7,8-TCDD toxicity equivalents.  A major drawback to these assays is that they are not 
highly selective.  A number of halogenated aromatics other than CDDs can induce AHH and EROD 
activity (e.g., chlorinated dibenzofurans, polychlorinated biphenyls, and polychlorinated phenols), 
although none to the extent of TCDD induction. There is also a question about the possible effects of 
chemical mixtures, such as might be found in contaminated soil or fish, on the assay results (Zacharewski 
et al. 1989). An ELISA based on derivation of monoclonal antibodies specific to CDDs has also been 
investigated as a means of screening environmental samples for chlorinated dioxins (Stanker et al. 1987). 
Monoclonal antibodies (MAbs) developed using 1-amino-substituted 3,7,8-TrCDD derivatives could 
detect sub-ng levels of TCDD standards. The derived antibodies had a stronger affinity for CDDs 
substituted at the 1 position and for CDFs substituted at the 2, 3, 7, and 8 positions than for other CDDs 
including 2,3,7,8-TCDD. However, development of MAbs more specific for CDDs, especially 
2,3,7,8-TCDD would provide a rapid, inexpensive, sensitive, and reasonably selective method for 
screening samples for CDD contamination. Sugawara and coworkers (Sugawara et al. 1998) have recently 
described an ELISA-based method for polychlorinated dibenzo-p-dioxins that can detect as little as 0.5 
pg/well of 2,3,7,8-TCDD and shows great promise as a screening tool.  The cross reactivity for octachloro­
dibenzo-p-dioxin is very low (<0.1%), but it is much higher for compounds with three, four, or five 
chlorine atoms in a substitution pattern similar to the of 2,3,7,8-TCDD.  As with all screening approaches, 
more accurate chemical analysis would be needed to confirm the compounds present. 
The CALUX assay described in Section 6.1 has been applied to Ah receptor-active compounds (not 
limited to dioxins) in sediments and pore waters (Murk et al. 1996) and to blood with mixed results. 
Sensitivities as low as 0.5 fmol of 2,3,7,8-TCDD were reported.  Two polychlorinated terphenyl mixtures, 
the PCB-substituted Ugilec 141, polybrominated diphenyl ethers, and the PCB mixture Clophen 150 were 
tested in the CALUX assay and had induction potencies that were 10-4 to 10-7 compared to TCDD.  Thus, 
this assay is more selective than earlier, induction-based assays, although clearly not as selective as 
GC/MS. 
6.3 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate 
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information on the health effects of CDDs is available.  Where adequate information is not available, 
ATSDR, in conjunction with the NTP, is required to assure the initiation of a program of research designed 
to determine the health effects (and techniques for developing methods to determine such health effects) of 
CDDs. 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
6.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect. Methods exist for determining 
CDDs in human serum and plasma, feces, biological tissues, and milk (Abraham et al. 1989a; Anonymous 
1997; Chang et al. 1993; EPA 1994a, 1994c; Noren and Sjoevall 1987; Nygren et al. 1988; Patterson et al. 
1987a, 1987b; Ryan et al. 1987a; Schecter et al. 1985b; Stanley 1986; Takizawa and Muto 1987; Van den 
Berg et al. 1989; Wendling et al. 1990). These methods have been used to determine ppq to ppt levels of 
CDDs in biological samples.  The commonly used methods are sensitive enough to detect background 
levels of CDDs in most media,  especially adipose tissue.  The background concentration for non­
occupationally-exposed people has been reported to be on the order of 4 ppt in lipid (Michalek et al. 1998). 
Improved clean-up and instrument sensitivity could make blood a more useful monitoring medium, 
although it is usually reagent and background contamination that is most problematic; CDD concentrations 
in blood tend be quite low. Improvements in current methods or development of new methods to increase 
sensitivity and selectivity would help to decrease the time involved in sample preparation, and would 
reduce the high cost ($800–$1,000 per sample) and possible errors associated with current methods of 
determining exposure to CDDs. 
Several effects such as chloracne and alterations in hepatic metabolism have been associated with exposure 
to 2,3,7,8-TCDD in humans.  However, these effects are not specific for 2,3,7,8-TCDD or other CDDs, but 
may be induced by numerous other chlorinated hydrocarbons.  Determination of specific biomarkers of 
effect for CDD and development of reliable methods to quantify these effects would be useful in assessing 
the effects associated with exposure to CDDs. 
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Methods for Determining Parent Compounds and Degradation Products in Environmental 
Media. Methods exist for measuring CDDs in a variety of environmental media, including air, water, 
sediment, soil, chemical waste, foods, fish, and other solid matrices (Bingham et al. 1989; Bobbie et al. 
1989; Buser et al. 1985; Cai et al. 1994; Cooke et al. 1988; Creaser and Al-Haddad 1989; Donnelly et al. 
1986; EPA 1986k, 1988g, 1994a, 1994c; Fairless et al. 1987; Jasinski 1989; Marquis et al. 1994; 
McCurvin et al. 1989; Muto and Takizawa 1989; Oehme et al. 1986; O'Keefe et al. 1986; Pereira et al. 
1985; Rappe et al. 1988; Smith et al. 1986a).  Of the EPA methods, Method 8280 (EPA 1986k) and 8290 
(EPA 1994a) are both commonly used; Method 8290 is approximately three orders of magnitude more 
sensitive. Assuming an acute oral MRL of 20 pg/kg/day, an intermediate oral MRL of 7 pg/kg/day, and a 
70-kg individual, the limit of detection needed for water (2 L/day consumption) is 770 ppq for acute and 
245 ppq for intermediate exposure.  The methods of O'Keefe et al. (1986) (LOD reported to be 
0.5–1.1 ppq) and EPA (1994a, 1994c) (LODs reported to be 4 ppq to 10 ppq) are adequate for detecting 
CDDs in drinking water. If a 2 kg/day consumption of food is assumed, the needed method LODs will be 
700 ppq for acute and 245 ppq for intermediate exposure.  Of those method reporting LODs in foods, the 
methods of Bobbie et al. (1989) and of Ferrario et al. (1996) have the required LODs.  Since CDDs are 
typically determined on a fat weight basis, the method of Ferrario et al. (1996) should be suitable for most 
food types once the fat is extracted.  The sensitivity of the HRGC/MS methods is excellent, but because of 
the very low levels of these chemicals in the environment, increased sensitivity may be desirable in order 
to obtain detectable values. Increased accuracy and selectivity would help make analyses more reliable 
and possibly reduce the costly and time-consuming sample preparation steps that are currently required. 
Additional development of bioassays to detect CDDs could provide screening methods with sufficient 
sensitivity to detect the very low concentrations of toxicological importance. 
6.3.2 Ongoing Studies 
A collaborative study was identified in which researchers at CDC, NIEHS, University of Mainz in 
Germany and the German Cancer research Center in Heidelberg are studying biochemical markers of 
exposure and susceptibility to dioxin in human peripheral blood lymphocytes (Yang et al. 1997).  
The following information was obtained from a search of Federal Research in Progress (FEDRIP 1998). 
Under an SBIR (Small Business Innovative Research) grant, Xeonobiotic Detection Systems, Inc. of 
Durham, NC, is marketing the CALUX assay (Anonymous 1997) described in Section 6.1.  Hybrizyme 
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Corp, of Raleigh, NC, is working on a new test method for dioxins in human and animal samples.  This 
work is also being performed under an SBIR.  No other details were available.  Antibody-based methods 
for 2,3,7,8-TCDD analysis is the subject of a project lead by R. Carlson of Ecochem Research, Inc. 
(another SBIR) during which methods for gases will be developed.  Finally, G. Wheelock, Paracelsian, 
Inc., Ithaca, NY, is using SBIR funding to develop an Ah receptor-based assay for the determination of 
toxic equivalency factors. 
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The international, national, and state regulations and guidelines regarding CDDs in air, water, and other 
media are summarized in Table 7-1. 
It is ATSDR’s policy (see Appendix B) to use health guidance values (i.e., MRLs and EMEGs) derived for 
2,3,7,8-TCDD for other dioxin-like compounds expressed as total TEQs. 
ATSDR has derived an acute-duration oral MRL of 0.0002 µg/day (2×10-4 µg/kg/day) for 2,3,7,8-TCDD 
based on its ability to suppress serum total hemolytic complement activity in B6C3F1 mice (White et al. 
1986). 
An intermediate-duration oral MRL of 0.00002 µg/day (2×10-5 µg/kg/day) was derived based on observed 
decreases in thymus weight in guinea pigs (Decaprio et al. 1986).  
A chronic-duration oral MRL of 0.000001 µg/day (1×10-6 µg/kg/day) was derived for 2,3,7,8-TCDD based 
on altered social interactions with peers in monkeys exposed to 2,3,7,8-TCDD prenatally and during 
lactation (Schantz et al. 1992). 
Neither a reference concentration (RfC) nor a reference dose (RfD) is listed in IRIS (IRIS 1998) for any of 
the CDDs. 
The IRIS database does not contain a weight-of evidence cancer classification for 2,3,7,8-TCDD.  The 
EPA is currently in the final stages of re-evaluating the risks and hazards from exposures to CDDs and 
CDD-like-like compounds.  In its proposed rule to add a chemical category that includes dioxin and 
dioxin-like compounds to the list of toxic chemicals subject to release reporting requirements, EPA 
acknowledged that existing data shows “2,3,7,8-TCDD is a potent toxicant in animals and has the potential 
to a produce a wide spectrum of toxic effects in humans” (EPA 1997c).  In the preamble of the rule EPA 
further states that “Available human data cannot clearly demonstrate whether a cause and effect 
relationship exists between 2,3,7,8-TCDD exposure and increased incidence of cancer.  However, there are 
a number of epidemiological studies associating exposure to 2,3,7,8,-TCDD with cancer mortality” (EPA 
1997c). Making reference to the 1985 cancer slope factor (1.56 × 105 [mg/kg/day]-1) (EPA 1985d) for 
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2,3,7,8-TCDD and considering its own weight-of-evidence classification criteria, EPA states that “there is 
sufficient evidence to conclude that the compound is a probable human carcinogen” (EPA 1997c).  In 
February, 1997, the International Agency for Research on Cancer (IARC) evaluated the evidence for 
CDDs being risk factors for human cancer (IARC 1997).  Consequently, IARC currently identifies 2,3,7,8­
TCDD as being carcinogenic to humans;  Group 1 carcinogen (IARC 1997).  IARC concluded that there is 
limited evidence in humans for the carcinogenicity of 2,3,7,8-TCDD; however, data from studies involving 
experimental animals provided sufficient evidence of carcinogenicity.  Giving consideration to supporting 
evidence such as 2,3,7,8-TCDD being a multi-site carcinogen in experimental animals; its acting through a 
mechanism involving Ah receptor which functions the same way in humans as in experimental animals; 
and similar tissue concentrations both in heavily exposed human populations and rats exposed to 
carcinogenic dosages, IARC’s overall evaluation for 2,3,7,8-TCDD is that it is carcinogenic to humans 
(IARC 1997). The Department of Health and Human Services (DHHS), National Toxicology Program 
(NTP) considers it to be a substance that is “reasonably anticipated to be a carcinogen.”  Again, the 
supporting data indicate that the evidence of 2,3,7,8-TCDD carcinogenicity in humans is limited, but that 
there is sufficient evidence of carcinogenic effects in studies involving experimental animals (NTP 1998). 
NTP is currently considering a reclassification of 2,3,7,8-TCDD and the decision is pending. 
EPA regulates dioxins as hazardous air pollutants (HAPs) in accordance with the provisions of the Clean 
Air Act (CAA). EPA has promulgated guidelines and performance standards limiting dioxin and other 
HAP emissions from various sources (i.e., major, stationary, and area).  A wide variety of health effects 
(e.g., cancer, respiratory problems, developmental and/or reproductive effects) have been associated with 
exposure to HAP emissions (EPA 1998c).  Some of the sources for which EPA has most recently 
promulgated or proposed guidelines and standards under the authority of the CAA are municipal waste 
combustors (MWCs), hospital/medical/infectious/waste combustors (HMIWI), and process operations in 
the Portland Cement industry (EPA 1997a, 1997b, 1998c). 
Owners and operators of facilities that have chemicals subject to  "The Emergency Planning and 
Community Right-to-Know Act (EPCRA) of 1986" on their sites in amounts exceeding a designated 
“reporting threshold level” are required to annually report releases of such chemicals to any environmental 
media (U.S. Congress 1986).  On May 7, 1997, EPA proposed adding a chemical category that includes 
dioxin and 27 dioxin-like compounds to the list of toxic chemicals subject to the EPCRA reporting 
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2,3,7,8-TCDD is also regulated as a drinking water contaminant.  As an impurity in the production of some 
pesticides, 2,3,7,8-TCDD may get into drinking water by industrial discharge of waste.  EPA has set a 
drinking water standard (Maximum Contaminant Level [MCL]) for dioxin at 3×10-8 ppm (EPA 1994d). 
People who drink water containing dioxin in excess of the MCL over many years could experience 
problems with their reproductive systems and may have an increased risk of cancer (EPA 1998d).  There is 
little to no risk associated with drinking-water that meets the MCL (EPA 1994d).  In February 1998, as 
mandated by the Safe Drinking Water Act (SDWA), EPA issued a proposed rule that would require 
community water systems to inform the public as to the quality of the water delivered by the system (EPA 
1998). The community right-to-know provisions of the SDWA mandate a reporting which informs the 
public of where their water comes from, shows them the process by which safe drinking water is delivered 
to their homes, provide access to information concerning source water assessments, and allows them to 
make informed decisions about their drinking water (EPA 1998d).  The SDWA provisions also include 
requirements for timely notifications of violations.  Within 24 hours, people served by public water 
systems must be notified of any violations of the national drinking water standard that have the potential to 
have serious adverse health effects (EPA 1998d).  The SDWA amendments of 1996 required the FDA to 
issue monitoring requirements for nine allowable contaminants in bottled water (FDA 1998a, 1998b). 
2,3,7,8-TCDD is included among these nine chemicals.
 2,3,7,8-TCDD is regulated by the Clean Water Effluent Guidelines for the following industrial point 
sources: electroplating (EPA 1981a), steam electric power generating (EPA 1982a), and metal finishing 
(EPA 1986g). Limitations depend on the type of industry and plant.  If waters and their sediments become 
contaminated from sources such as atmospheric deposition and discharges from industrial, municipal, or 
agricultural operations, toxic substances could concentrate in the tissue of fish and wildlife.  Sixty-six 
advisories have been issued by 21 states recommending consumers limit their consumption of fish and 
shellfish (EPA 1998b). For 14 states (Wisconsin, Rhode Island, New Hampshire, West Virginia, 
Louisiana, Arkansas, Virginia, Michigan, Mississippi, Florida, Massachusetts, Oregon, Tennessee, and 
Delaware) advisories were issued for freshwater fish (EPA 1998b).  Only two states (Texas and California) 
issued advisories for marine waters only (EPA 1998b).  An advisory for woodduck (migratory fowl) was 
issued for the state of Arkansas. This information is current as of December 1997, based on the EPA Fish 
and Wildlife Advisory Database searched October 1998 at: http://www.epa.gov/OST/fishadvice/. More 
detailed information can be obtained from the state Public Health Department or the state Department of 
Natural Resources. A fish or wildlife advisory will specify the bodies of water or hunting areas with 
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may completely ban consumption or recommend limiting meals of a certain fish or wildlife species to a 
particular frequency.  For example, an advisory may recommend that a person eat a certain type of fish no 
more than once a month.  The advisory may indicate that only certain parts of the fish or game should be 
consumed and recommend preparation methods that minimize exposure.  Fish and wildlife advisories may 
also provide restrictions specifically targeting pregnant women, nursing mothers, and young children. 
Each state, Native American Tribe, or U.S. Territory chooses its own criteria for issuing fish and wildlife 
advisories. 
2,3,7,8-TCDD is regulated as a hazardous waste constituent under the requirements of the Resource 
Conservation and Recovery Act (RCRA) (EPA 1988d). Non-specific sources of 2,3,7,8-TCDD-containing 
waste are wastes from the production or manufacturing use of tri-, tetra-, or pentachlorophenols and their 
pesticide derivatives, discarded or unused formulations containing these compounds, and residues from 
incineration or thermal treatment of soil contaminated with these compounds.  RCRA prohibits land 
disposal of hazardous waste unless it meets treatment standards established by the EPA.  On May 12, 
1997, the EPA promulgated universal treatment standards (UTSs) for hazardous constituents in wood 
preserving waste. These wastes have been assigned EPA hazardous waste codes F032, F034, and F035 
(EPA 1997d). The final rule also promulgated a compliance alternative for dioxin constituents in 
nonwastewater and wastewater forms of F032 waste which allowed combustion to be used as a method of 
treatment (EPA 1997d). 
The Toxic Substance Control Act (TSCA) authorizes the EPA to determine whether the use of a chemical 
substance is a “significant new use” (EPA 1998e). Once it has been determined that a use of a chemical is 
a significant new use, it must be reported to the EPA prior to manufacturing, importing, or processing for 
the new use. The required notice will provide the EPA with an opportunity to evaluate the intended use, 
and if necessary, to prohibit or limit the activity before it occurs (EPA 1998e).  For example, brominated 
phthalate ester was included among the 163 chemical substances for which the EPA promulgated 
significant new use rules (SNURs). The toxicity concern for the new use was that when similar chemicals 
have been incinerated under combustion conditions of municipal incinerators, dibenzodioxins and 
dibenzofurans were formed (EPA 1998e).  Persons providing notice of this new use would need to 
characterize, through an incineration simulation, the potential for dioxin and furan formation and agree not 
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Absorption—The taking up of liquids by solids, or of gases by solids or liquids. 
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the Toxicological 
Profiles. 
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact. 
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of organic 
carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium. 
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by a sediment or soil (i.e., the solid phase) 
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a 
fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per gram of soil or 
sediment. 
Benchmark Dose (BMD)—is usually defined as the lower confidence limit on the dose that produces a 
specified magnitude of changes in a specified adverse response.  For example, a BMD10 would be the dose at 
the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be 10%. The 
BMD is determined by modeling the dose response curve in the region of the dose response relationship 
where biologically observable data are feasible. 
Benchmark Dose Model—is a statistical dose-response model applied to either experimental toxicological 
or epidemiological data to calculate a BMD. 
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms at a 
specific time or during a discrete time period of exposure divided by the concentration in the surrounding 
water at the same time or during the same period. 
Biomarkers—are broadly defined as indicators signaling events in biologic systems or samples.  They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility. 
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces 
significant increases in the incidence of cancer (or tumors) between the exposed population and its 
appropriate control. 
Carcinogen—A chemical capable of inducing cancer. 
Case-Control Study—A type of epidemiological study which examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-controlled study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without outcome. 
Case Report—describes a single individual with a particular disease or exposure. These may suggest some 




Case Series—describes the experience of a small number of individuals with the same disease or exposure. 
These may suggest potential topics for scientific research but are not actual research studies. 
Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously. 
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological 
Profiles. 
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a 
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are 
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group. 
Cross-sectional Study—A type of epidemiological study of a group or groups which examines the 
relationship between exposure and outcome to a chemical or to chemicals at one point in time. 
Data Needs—substance-specific informational needs that if met would reduce the uncertainties of human 
health assessment. 
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result 
from exposure to a chemical prior to conception (either parent), during prenatal development, or postnatally 
to the time of sexual maturation.  Adverse developmental effects may be detected at any point in the life span 
of the organism. 
Dose-Response Relationship—the quantitative relationship between the amount of exposure to a toxicant 
and the incidence of the adverse effects. 
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to a 
chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurs. The terms, as used here, include malformations and variations, altered growth, and 
in utero death. 
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water 
levels for a chemical substance based on health effects information.  A health advisory is not a legally 
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials. 
Epidemiology—refers to the investigation of factors that determine the frequency and distribution of disease 
or other health-related conditions within a defined human population during a specified period.  
Genotoxicity—a specific adverse effect on the genome of living cells that, upon the duplication of affected 
cells, can be expressed as a mutagenic, clastogenic or carcinogenic event because of specific alteration of the 
molecular structure of the genome. 
Half-life—a measure of rate for the time required to eliminate one half of a quantity of a chemical from the 
body or environmental media. 
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Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or 
irreversible health effects. 
Incidence—The ratio of individuals in a population who develop a specified condition to the total number of 
individuals in that population who could have developed that condition in a specified time period. 
Intermediate Exposure—Exposure to a chemical for a duration of 15-364 days, as specified in the 
Toxicological Profiles. 
Immunological Effects—are functional changes in the immune response. 
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from 
exposure to environmental agents such as chemicals. 
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube. 
In Vivo—Occurring within the living organism. 
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air which has been reported to 
have caused death in humans or animals. 
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for a 
specific length of time is expected to cause death in 50% of a defined experimental animal population. 
Lethal Dose(LO) (LDLO)—The lowest dose of a chemical introduced by a route other than inhalation that has 
been reported to have caused death in humans or animals. 
Lethal Dose(50) (LD50)—The dose of a chemical which has been calculated to cause death in 50% of a 
defined experimental animal population. 
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical is 
expected to cause death in 50% of a defined experimental animal population. 
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, or 
group of studies, that produces statistically or biologically significant increases in frequency or severity of 
adverse effects between the exposed population and its appropriate control. 
Lymphoreticular Effects—represent morphological effects involving lymphatic tissues such as the lymph 
nodes, spleen, and thymus. 
Malformations—Permanent structural changes that may adversely affect survival, development, or 
function. 
Minimal Risk Level (MRL) —An estimate of daily human exposure to a hazardous substance that is likely 





Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a minimal risk level 
(MRL) to reflect additional concerns about the database that are not covered by the uncertainty factors. The 
default value for a MF is 1. 
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population. 
Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time. 
Mutagen—A substance that causes mutations.  A mutation is a change in the DNA sequence of a cell’s 
DNA. Mutations can lead to birth defects, miscarriages, or cancer. 
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of death 
or pathological conditions. 
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a chemical. 
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between the 
exposed population and its appropriate control.  Effects may be produced at this dose, but they are not 
considered to be adverse. 
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical in 
n-octanol and water, in dilute solution. 
Odds Ratio—a means of measuring the association between an exposure (such as toxic substances and a 
disease or condition) which represents the best estimate of relative risk (risk as a ratio of the incidence 
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not 
exposed to the risk factor). An odds ratio of greater than 1 is considered to indicate greater risk of disease in 
the exposed group compared to the unexposed. 
Organophosphate or Organophosphorus Compound—a phosphorus containing organic compound and 
especially a pesticide that acts by inhibiting cholinesterase. 
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA) 
allowable exposure level in workplace air averaged over an 8-hour shift of a 40 hour workweek. 
Pesticide—general classification of chemicals specifically developed and produced for use in the control of 
agricultural and public health pests. 
Pharmacokinetics—is the science of quantitatively predicting the fate (disposition) of an exogenous 
substance in an organism. Utilizing computational techniques, it provides the means of studying the 




Pharmacokinetic Model—is a set of equations that can be used to describe the time course of a parent 
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models: data-based and 
physiologically-based.  A data-based model divides the animal system into a series of compartments which, 
in general, do not represent real, identifiable anatomic regions of the body whereby the physiologically-
based model compartments represent real anatomic regions of the body. 
Physiologically Based Pharmacodynamic (PBPD) Model—is a type of physiologically-based dose-
response model which quantitatively describes the relationship between target tissue dose and toxic end 
points. These models advance the importance of physiologically based models in that they clearly describe 
the biological effect (response) produced by the system following exposure to an exogenous substance. 
Physiologically Based Pharmacokinetic (PBPK) Model—is comprised of a series of compartments 
representing organs or tissue groups with realistic weights and blood flows.  These models require a variety 
of physiological information: tissue volumes, blood flow rates to tissues, cardiac output, alveolar ventilation 
rates and, possibly membrane permeabilities.  The models also utilize biochemical information such as 
air/blood partition coefficients, and metabolic parameters.  PBPK models are also called biologically based 
tissue dosimetry models. 
Prevalence—The number of cases of a disease or condition in a population at one point in time. 
Prospective Study--a type of cohort study in which the pertinent observations are made on events occurring 
after the start of the study.  A group is followed over time. 
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the 
multistage procedure.  The q1* can be used to calculate an estimate of carcinogenic potency, the incremental 
excess cancer risk per unit of exposure (usually µg/L for water, mg/kg/day for food, and µg/m3 for air). 
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health (NIOSH) 
time-weighted average (TWA) concentrations for up to a 10-hour workday during a 40-hour workweek. 
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of magnitude) 
of a continuous inhalation exposure to the human population (including sensitive subgroups) that is likely to 
be without an appreciable risk of deleterious noncancer health effects during a lifetime.  The inhalation 
reference concentration is for continuous inhalation exposures and is appropriately expressed in units of 
mg/m3 or ppm. 
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the daily 
exposure of the human population to a potential hazard that is likely to be without risk of deleterious effects 
during a lifetime.  The RfD is operationally derived from the No-Observed-Adverse-Effect Level (NOAEL­
from animal and human studies) by a consistent application of uncertainty factors that reflect various types 
of data used to estimate RfDs and an additional modifying factor, which is based on a professional judgment 
of the entire database on the chemical.  The RfDs are not applicable to nonthreshold effects such as cancer. 
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Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under the 
Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  Reportable 
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 




ATSDR MINIMAL RISK LEVELS AND WORKSHEETS 
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 9601 
et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99–499], 
requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with the U.S. 
Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most commonly 
found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological profiles for each 
substance included on the priority list of hazardous substances; and assure the initiation of a research 
program to fill identified data needs associated with the substances. 
The toxicological profiles include an examination, summary, and interpretation of available toxicological 
information and epidemiologic evaluations of a hazardous substance.  During the development of 
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a given 
route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance that is 
likely to be without appreciable risk of adverse noncancer health effects over a specified duration of 
exposure. MRLs are based on noncancer health effects only and are not based on a consideration of cancer 
effects. These substance-specific estimates, which are intended to serve as screening levels, are used by 
ATSDR health assessors to identify contaminants and potential health effects that may be of concern at 
hazardous waste sites. It is important to note that MRLs are not intended to define clean-up or action levels. 
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor 
approach. They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects.  MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method 
suitable for this route of exposure. MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans.  Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level above 
the MRL does not mean that adverse health effects will occur.  MRLs are intended only to serve as a 
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screening tool to help public health professionals decide where to look more closely.  They may also be 
viewed as a mechanism to identify those hazardous waste sites that are not expected to cause adverse 
health effects. Most MRLs contain a degree of uncertainty because of the lack of precise toxicological 
information on the people who might be most sensitive (e.g., infants, elderly, nutritionally or 
immunologically  compromised) to the effects of hazardous substances.  ATSDR uses a conservative (i.e., 
protective) approach to address this uncertainty consistent with the public health principle of prevention. 
Although human data are preferred, MRLs often must be based on animal studies because relevant human 
studies are lacking. In the absence of evidence to the contrary, ATSDR assumes that humans are more 
sensitive to the effects of hazardous substance than animals and that certain persons may be particularly 
sensitive. Thus, the resulting MRL may be as much as a hundredfold below levels that have been shown 
to be nontoxic in laboratory animals. 
Proposed MRLs undergo a rigorous review process: Health Effects/MRL Workgroup reviews within the 
Division of Toxicology, expert panel peer reviews, and agencywide MRL Workgroup reviews, with 
participation from other federal agencies and comments from the public.  They are subject to change as 
new information becomes available concomitant with updating the toxicological profiles.  Thus, MRLs in 
the most recent toxicological profiles supersede previously published levels.  For additional information 
regarding MRLs, please contact the Division of Toxicology, Agency for Toxic Substances and Disease 







Chemical Name: 2,3,7,8-Tetrachlorodibenzo-p-dioxin (2,3,7,8-TCDD) 
CAS Number: 1746-01-6 
Date: December 10, 1998 
Profile Status: Final Draft 
Route: [ ] Inhalation  [X] Oral 
Duration: [X ] Acute  [ ] Intermediate  [] Chronic 
Key to Figure: 78m 
Species: Mice 
Minimal Risk Level: 0.0002 (2×10-4) [X] µg/kg/day   [ ] ppm 
Reference: Burleson et al. 1996 
Experimental design: (human study details or strain, number of animals per exposure/control groups, sex, 
dose administration details): 
Groups of 20 female B6C3F1 mice were administered a single gavage dose of  0, 0.001, 0.005, 0.01, 0.05, 
or 0.1 µg/kg 2,3,7,8-TCDD in corn oil.  Seven days after 2,3,7,8-TCDD exposure, the mice were infected 
intranasally with influenza A/Hong Kong/8/68 (H3N2) virus diluted at 10-48, 10-50, 10-52, or 10-54. In a 
separate experiment, groups of 18 female mice received a single gavage dose of 0, 0.001, 0.01, or 0.1 
µg/kg 2,3,7,8-TCDD and were infected 7 days later with influenza A virus at a dose not known to cause 
mortality (10-54 and 10-58) or were sham-infected.  Body weight, thymus weight, and wet lung weights were 
measured 3, 9, or 12 days postinfection.  Pulmonary virus titers were determined in groups of 72 mice 
exposed to 0, 0.001, 0.01, or 0.01 µg/kg 2,3,7,8-TCDD and infected with influenza A virus seven days 
later. For the virus titer study, groups mice were killed 2 hours, 1, 4, 6, 7, 8, 9, 10, and 11 days post-
infection. 
Effects noted in study and corresponding doses: 
Statistically significant increases in mortality were observed in the influenza A infected mice exposed to 
0.01, 0.05, or 0.1 µg/kg 2,3,7,8-TCDD. However, no between group differences in mortality were 
observed at these 2,3,7,8-TCDD dosages. Mortality in mice receiving 0.001 or 0.005 µg/kg did not 
significantly differ from the mortality in the control group.  Exposure to 2,3,7,8-TCDD did not enhance the 
increase in relative lung weight normally seen in mice infected with influenza A virus.  As compared to 
controls, no significant alterations in thymus weights were observed in 2,3,7,8-TCDD-exposed mice 
sham-infected or those infected with influenza A virus.  2,3,7,8-TCDD exposure did not result in a 
significant increase in viral titers in the lung, as compared to titers from the control group.  The authors 
noted that the lack of dose-response in mortality and the lack of effect on the relative lung weight, thymus 
weight, and viral titers suggest that 2,3,7,8-TCDD may be exerting an effect via an indirect mechanism 
such as through an effect on cytokines. 
Dose and end point used for MRL derivation: Impaired resistance to influenza A virus infection, as 
evidence by the significant increase in mortality, was observed in female B6C3F1 mice administered a 
single gavage dose of $0.01 µg/kg. No significant effects were observed at lower doses. Thus, 0.005 and 
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[X] NOAEL [ ] LOAEL 
Uncertainty Factors used in MRL derivation: 
[ ]	 10 for use of a LOAEL 
[X] 3 for extrapolation from animals to humans-  	A comparison of species sensitivity suggests that even 
though there are wide ranges of sensitivity for some 2,3,7,8-TCDD-induced health effects, for most 
health effects, the LOAELs for the majority of animal species cluster within an order of magnitude. 
Based on the weight of evidence of animal species comparisons and human and animal mechanistic 
data, it is reasonable to assume that human sensitivity would fall within the range of animal 
sensitivity. 
[X] 10 for human variability 
Was a conversion factor used from ppm in food or water to a mg/body weight dose? 
No. A modifying factor of 0.7 was applied to adjust for the difference in higher bioavailability of 
2,3,7,8-TCDD from gavage with an oil vehicle than from food.  Support for this modifying factor comes 
from toxicokinetic studies in Sprague Dawley rats.  In rats fed 0.35 or 1 µg/kg/day 2,3,7,8-TCDD in the 
diet for 42 days, approximately 60% of the administered dose was absorbed (Fries and Marrow 1975).  In 
contrast, 70-84% of a single or repeated gavage dose of 0.01-50 µg/kg 2,3,7,8-TCDD in corn oil was 
absorbed in rats (Piper et al. 1973; Rose et al. 1976).  Thus, the ratio of 2,3,7,8-TCDD absorption from the 
diet to gavage with an oil vehicle is 0.71-0.85. 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose:
NA 
Was a conversion used from intermittent to continuous exposure?
No 
Other additional studies or pertinent information that lend support to this MRL: 
2,3,7,8-TCDD is a known immunosuppressant in animals in acute-, intermediate, and chronic-duration 
studies (Kerkvliet 1995). Suppression of the antibody response to sheep erythrocytes was observed in 
B6C3F1 mice administered 14 daily doses of 0.1 µg 2,3,7,8-TCDD/kg/day (Holsapple et al. 1986), and a 
significant increase in mortality was observed in B6C3F1 mice administered 1.0 µg/kg/day 2,3,7,8-TCDD 
for 14 days and challenged with Streptococcus pneumoniae (White et al. 1986). Decreased survival after 
viral infection was also reported in female B6C3F1 mice after a single intraperitoneal dose of 0.1 µg 
2,3,7,8-TCDD/kg (House et al. 1990). A significant suppression of complement hemolytic activity was 
observed in mice administered 0.01 µg/kg/day via gavage for 14 days (White et al. 1986).  Furthermore, 
2,3,7,8-TCDD alters the immune system of offspring when exposed through lactation and/or in utero. For 
example, a dose-related decrease in relative thymus weights were seen in offspring of rats dosed at levels 
of 0.005-0.35 µg 2,3,7,8-TCDD/kg on day 16 of pregnancy (Madsen and Larsen 1979). 






Chemical Name: 2,3,7,8-Tetrachlorodibenzo-p-dioxin (2,3,7,8-TCDD) 
CAS Number: 1746-01-6 
Date: December 10, 1998 
Profile Status: Final Draft 
Route: [ ] Inhalation  [X] Oral 
Duration: [ ] Acute  [X ] Intermediate  [] Chronic 
Key to Figure: 187g 
Species: Guinea pig 
Minimal Risk Level: 0.00002 (2×10-5) [X] µg/kg/day   [ ] ppm 
Reference: DeCaprio et al. 1986 
Experimental design: (human study details or strain, number of animals per exposure/control groups, sex, 
dose administration details): 
Groups of weanling Hartley guinea pigs (10/sex) were administered a diet containing 2, 10, 76 or 430 ppt 
for 90 days.  These diets provided an average of 0.0001, 0.0007, 0.005, or 0.028 µg 2,3,7,8-TCDD/kg/day. 
The average doses were estimated by the investigators. A group of control guinea pigs was fed a diet 
without added 2,3,7,8-TCDD. Body weights and food consumption were monitored throughout the 
experiment. At the end of the dosing period the animals were sacrificed and clinical chemistries, 
hematology, organ weights and histopathology examinations were performed. The recovery following 
treatment was studied in groups of 10 guinea pigs fed a diet containing 430 ppt 2,3,7,8-TCDD for 11, 21, 
or 35 days and  allowed to recover for 79, 69, or 55 additional days, respectively. 
Effects noted in study and corresponding doses: 
The highest dietary level of 2,3,7,8-TCDD caused net body  weight loss and mortality. Four males and 
four females died and additional animals had to be sacrificed due to poor health.  Food consumption was 
significantly reduced in the highest dose group only. Body weight gain in the 0.0007 and 0.005 µg/kg/day 
male groups was reduced by 9% and 20%, respectively. In the corresponding female groups, body weight 
gain was reduced by 6% and 15%.  Gross lesions were observed only in the highest dose group and 
included thymic atrophy, depletion of body fat, and liver enlargement. Significant changes in organ 
weights included a decrease in absolute kidney weight and in absolute and relative thymus weight in males 
dosed with 0.005 µg/kg/day, increase in relative liver weight in males and females at the 0.005 µg/kg/day 
level, and increase in relative brain weight in males at this same dose level. Organ weights from high dose 
animals were not monitored. Administration of 2,3,7,8-TCDD did not cause any significant hematological 
effect (blood was not collected from the highest dose group). In the 0.005 µg/kg/day groups, serum ALT 
was significantly reduced in females whereas triglycerides were elevated in males. No other significant 
changes in clinical chemistries were observed. Treatment-related histological alterations were observed 
only in the two higher dose groups and consisted of hepatocellular cytoplasmic inclusion bodies and 
atrophy of the thymic cortex. In the recovery study there was 10% mortality in the groups treated for 11 
and 21 days and 70% mortality in the group treated for 35 days. Surviving animals in all groups exhibited 






Dose and end point used for MRL derivation: The dose of 0.0007 µg/kg/day represents a  NOAEL for 
decreased thymus weight, whereas the 0.005 µg/kg/day is a  LOAEL. 
[X ] NOAEL  [ ] LOAEL 
Uncertainty Factors used in MRL derivation: 
[ ] 10 for use of a LOAEL 
[X] 3 for extrapolation from animals to humans-A comparison of species sensitivity suggests that even 
though there are wide ranges of sensitivity for some 2,3,7,8-TCDD-induced health effects, for most 
health effects, the LOAELs for the majority of animal species cluster within an order of magnitude. 
Based on the weight of evidence of animal species comparisons and human and animal mechanistic 
data, it is reasonable to assume that human sensitivity would fall within the range of animal 
sensitivity. 
[X] 10 for human variability 
Was a conversion factor used from ppm in food or water to a mg/body weight dose? 
No. The doses were estimated by the investigators. 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose:
NA 
Was a conversion used from intermittent to continuous exposure?
No 
Other additional studies or pertinent information that lend support to this MRL: 
2,3,7,8-TCDD is a known immunosuppressant in animals in acute-, intermediate, and chronic-duration 
studies (Kerkvliet 1995). Reduction of thymus weight was also observed in intermediate-duration oral 
studies in rats (Van Birgelen et al. 1995; Viluksela et al. 1994). Another sensitive species for 
immunological effects of 2,3,7,8-TCDD is the marmoset monkey in which alterations in lymphocyte 
subsets have been reported after subcutaneous application of an average 0.0015 µg 2,3,7,8-TCDD/kg/day 
for 26 weeks (Neubert et al. 1992). Furthermore, 2,3,7,8-TCDD alters the immune system of offspring 
when exposed through lactation and/or in utero. For example, a dose-related decrease in relative thymus 
weights were seen in offspring of rats dosed at levels of 0.005-0.35 µg 2,3,7,8-TCDD/kg on day 16 of 
pregnancy (Madsen and Larsen 1979). 










Chemical Name: 2,3,7,8-Tetrachlorodibenzo-p-dioxin (2,3,7,8-TCDD) 
CAS Number: 1746-01-6 
Date: December 10, 1998 
Profile Status: Final Draft 
Route: [ ] Inhalation  [X] Oral 
Duration: [ ] Acute  [ ] Intermediate  [X] Chronic 
Key to Figure: 226k 
Species: Monkey 
Minimal Risk Level: 0.000001 (1×10-6) [X] µg/kg/day   [ ] ppm 
Reference: Schantz et al. 1992 
Experimental design: (human study details or strain, number of animals per exposure/control groups, sex, 
dose administration details): 
Groups of 8 female rhesus monkeys were fed a diet containing 0, 5, or 25 ppt 2,3,7,8-TCDD  for a total of 
16.2 ± 0.4 months.  After 7 months of exposure, the monkeys were mated with unexposed males.  (Only 1 
monkey in the 25 ppt group delivered a viable offspring; this offspring was not studied behaviorally).  The 
monkeys were fed the 2,3,7,8-TCDD diet throughout the mating period, gestation, and lactation.  The 
authors estimated that the total 2,3,7,8-TCDD intake over the course of the study was 59.6 ± 5.0 ng/kg for 
the 5 ppt group. The offspring were weaned at 4 months and individually housed.  Mesenteric fat samples 
were collected from the offspring at age 5 months; the average 2,3,7,8-TCDD levels in the fat samples was 
377 ±141 ppt (range of 290-950) for the 5 ppt group and below the detection limit of 2-200 ppt for the 
controls. When the offspring were 8.6 months of age, they were placed in peer groups of 4 monkeys and 
allowed to play for 1.5 hours without interference.  The peer groups consisted of two 2,3,7,8-TCDD­
exposed monkeys and two control monkeys.  Behavioral patterns (social interactions and other behaviors 
such as vocalization, locomotion, self-directed behavior and environmental exploration) were monitored 
4 days/week for 9 weeks. 
Effects noted in study and corresponding doses: 
No overt signs of toxicity were observed in the mothers or offspring, and  birth weights and growth were 
not adversely affected by 2,3,7,8-TCDD exposure.  Significant alterations were observed in play behavior, 
displacement, and self-directed behavior in the 2,3,7,8-TCDD -exposed offspring.  2,3,7,8-TCDD-exposed 
monkeys tended to initiate more rough-tumble play bouts and retreated less from play bouts than controls, 
were less often displaced from preferred positions in the playroom than the controls, and engaged in more 
self-directed behavior than controls. No other significant alterations in behavior were observed. 
Dose and end point used for MRL derivation: 
Although the mothers were exposed to 5 or 25 ppt 2,3,7,8-TCDD, only the offspring from the 5 ppt group 
underwent behavioral testing. The 5 ppt dietary concentration is equivalent to a daily dose of 1.2 x 10-4 
µg/kg/day.  This dose is a LOAEL for altered social behavior. 





Uncertainty Factors used in MRL derivation: 
[X] 3 for use of a  minimal LOAEL 
[X] 3 for extrapolation from animals to humans A comparison of species sensitivity suggests that even 
though there are wide ranges of sensitivity for some 2,3,7,8-TCDD-induced health effects, for most 
health effects, the LOAELs for the majority of animal species cluster within an order of magnitude. 
Based on the weight of evidence of animal species comparisons and human and animal mechanistic 
data, it is reasonable to assume that human sensitivity would fall within the range of animal 
sensitivity. 
[X] 10 for human variability. 
Was a conversion factor used from ppm in food or water to a mg/body weight dose? 
Monkeys were exposed to a dietary concentration of 5 ppt 2,3,7,8-TCDD; the authors estimated that the 
total maternal intake during the 16.2 months of exposure (492 days) was 59.6 ng/kg. 
Daily dose = (59.6 ng/kg) / (492 days) = 0.12 ng/kg/day (1.2 x 10-4 µg/kg/day) 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose:
NA 
Was a conversion used from intermittent to continuous exposure?
No 
Other additional studies or pertinent information that lend support to this MRL: 
A behavioral teratology test battery was performed in monkey infants exposed to 2,3,7,8-TCDD during 
gestation and lactation; the results of this test battery was published in a series of papers (Bowman et al. 
1989a; Schantz and Bowman 1989; Schantz et al. 1992).  No significant alterations in reflex development, 
visual exploration, locomotor activity, or fine motor control were found (Bowman et al. 1989a).  In tests of 
cognitive function, object learning was significantly impaired, but no effect on spatial learning was 
observed (Schantz and Bowman 1989).  When the monkey infants were placed in social groups, altered 
social behavior was observed (Bowman et al. 1989a; Schantz et al. 1992). Additional data on the 
neurodevelopmental toxicity of 2,3,7,8-TCDD are limited to a study in which prenatal exposure to 
2,3,7,8-TCDD resulted in masculinized behavior in female rats (Schantz et al. 1991).  No chronic duration 
animal neurotoxicity studies were located, decreased motor activity was reported in rats acutely exposed to 
2 (Giavini et al. 1983) or 5 (Seefeld et al. 1984a) µg/kg/day.  The Schantz and Bowman studies are the 
only available chronic developmental toxicity studies.  Acute and intermediate duration studies provide 
evidence that 2,3,7,8-TCDD is a potent developmental toxicant.  Other sensitive developmental effects that 
have been observed included cleft palate [lowest LOAEL- 0.1 µg/kg/day (Giavini et al. 1982)], 
hydronephrosis [lowest LOAEL- 1 µg/kg (Moore et al. 1973)], immunosuppression [lowest LOAEL­
0.005 µg/kg (Madsen and Larsen 1979)], impaired development of the reproductive system [lowest 
LOAEL- 0.064 µg/kg (Mably et al. 1992a, 1992b, 1992c)], and increased newborn mortality [lowest 
LOAEL-0.7 µg/kg (Bjerke et al. 1994a)]; NOAELs were not identified for these effects in the most 
sensitive species or strain. 
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Some human studies have reported effects on the central and peripheral nervous systems shortly after 
exposure to high levels of 2,3,7,8-TCDD (Filippini et al. 1981; Moses et al. 1984; Pazderova-Vejlupkova 
et al. 1981; Pocchiari et al. 1979; Suskind 1977). However, follow-up studies did not find neurological 
effects years after exposure termination (Barbieri et al. 1988), suggesting that the effects may be transient. 
No human studies examined the effect of 2,3,7,8-TCDD on the developing neurologic system.   
It should be also noted that 10 years after termination of 2,3,7,8-TCDD exposure in the Schantz et al. 
(1992) study, Rier et al. (1993) reported a dose-related increase in the incidence and severity of 
endometriosis in these same rhesus monkeys.  Rier et al. (1993) identified a less serious LOAEL of 5 ppt 
(0.00012 µg/kg/day) for moderate endometriosis.  However, monkeys appear to be more susceptible to 
endometriosis, based on a background incidence of endometriosis in monkeys of 30% (Rier et al. 1993) 
compared to a background incidence of 10% in humans (Wheeler et al. 1992).  Thus, derivation of a 
chronic oral MRL based on endometriosis would necessitate using an uncertainty factor of less than 1 (or 
at most, 1) to account for the increased sensitivity of monkeys to endometriosis as compared to humans.  If 
the Rier et al. (1993) study was used to calculate an oral MRL, the LOAEL of 0.00012 µg/kg/day would 
be divided by an uncertainty factor of 100 (10 to extrapolate from a LOAEL, 10 for human variability and 
1 for interspecies differences). This would result in a computed MRL essentially the same as the chronic 
oral MRL of 1 pg/kg/day based on developmental toxicity as described in the preceding paragraph. 
Moreover, (1) the clinical history for these rhesus monkeys during the 10 year period between the Schantz 
et al. (1992) study and examination by Rier et al. (1993) is unknown (not reported); (2) Boyd et al. (1995) 
did not find an association between exposure to CDDs, CDFs, or PCBs and endometriosis in a clinical 
study in women; and (3) the EPA (1997) concluded that “the evidence for supporting the hypothesis that 
CDDs and PCBs are causally related to human endometriosis via an endocrine-disruption mechanism is 
very weak.”  So, even though there is information to indicate that endometriosis may also be a sensitive 
toxicological end point for 2,3,7,8-TCDD exposure, the developmental end point (altered social behavior) 
reported in the Schantz et al. (1992) study was determined to be the most appropriate end point for 
derivation of an MRL for chronic oral 2,3,7,8-TCDD exposure. 















Update to the ATSDR Policy Guideline for  

Dioxins and Dioxin-Like Compounds in Residential Soil 

Purpose 
The Agency for Toxic Substances and Disease Registry (ATSDR) is updating its Policy 
Guideline for Dioxins and Dioxin-Like Compounds in Residential Soil. 
The objective of this update is to ensure that ATSDR health assessors evaluate dioxin levels that 
exceed the ATSDR established screening level of 0.05 ppb as described in the ATSDR Public 
Health Assessment Guidance Manual (PHAGM) (ATSDR 2005).  The 0.05 ppb value should be 
used as the comparison value when following the PHAGM.  The comparison value is not a 
threshold for toxicity and should not be used to predict adverse health effects (ATSDR 2005).  
This update replaces Appendix B in the Toxicological Profile for Chlorinated Dibenzo-p-dioxins 
(CDDs) (December, 1998).  It does not reflect a change in ATSDR’s scientific assessment on 
dioxin toxicity or the ATSDR Minimal Risk Level (MRL). This update does not impact the EPA 
guidance which continues to identify 1 ppb as the preliminary remediation goal for residential 
exposure scenarios. (EPA 1998). 
History of the Dioxin Policy Guideline 
In 1998, ATSDR adopted a Policy Guideline for Dioxin and Dioxin-like Compounds (ATSDR, 
1998). The policy was developed to guide health assessors in evaluating the public health 
implications of dioxin and dioxin-like compounds (including 2,3,7,8-tetrachlorodibenzo-p-dioxin 
and other structurally related halogenated aromatic hydrocarbons) in residential soils near or on 
hazardous waste sites. The 1998 guideline established three levels as criteria for comparing 
dioxin levels in residential soil: 
• a screening level, 
• an evaluation level, and 
• an action level. 
The 1998 guideline also recommended specific considerations for public health actions within 
each of these levels. 
Since the release of the Policy Guideline in 1998, ATSDR issued the PHAGM.  By issuing this 
update to the guideline, ATSDR is ensuring that health assessors will use the screening level as 
the appropriate comparison value for following the PHAGM, rather than the “action level” 
described in the earlier version of this policy guidance.  This does not reflect a change in dioxin 
science; it is simply a reiteration to ensure that the appropriate value is used as a starting point 
when following the procedures described in the PHAGM.  
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If health assessors follow the PHAGM, the evaluation and action levels values, as set in 1998, 
are no longer necessary.   
Changes Being Made to the ATSDR Policy Guideline for Dioxins and Dioxin-Like 
Compounds in Residential Soil 
The specific changes to the policy guideline, the reason for those changes, and the expected 
impact of those changes are summarized in the following table: 
Change Reason for Change Impact of Change 
Elimination of Confusion about interpretation of the This change brings the guidelines up-
the “evaluation evaluation and action levels was a to-date with ATSDR’s PHAGM 
level” and the barrier to a more consistent evaluation which uses only screening levels
“action level” of exposure to dioxin in residential soils. 
The public health actions described in 
the 1998 policy guideline remain 
options that may be applied as 
appropriate rather than being triggered 
by a prescribed soil concentration. 
The minimal risk level (MRL) for 
dioxin exposure described in the 1998
Toxicological Profile remains the 
same.  
Ensure PHAGM was not referenced in the Consistency with 2005 PHAGM will
consistency previous policy. ensure more comprehensive 
with ATSDR evaluation, for instance assessing both
PHAGM direct and indirect exposure pathways
should result in a more comprehensive 
evaluation of exposure conditions at 
sites with dioxin contamination.
Summary 
This policy update replaces Appendix B in the Toxicological Profile for Chlorinated Dibenzo-p­
dioxins (CDDs) (December, 1998).  ATSDR will no longer refer to an Action Level for dioxin in 
these evaluations. The 0.05 ppb screening level is retained as an initial comparison value for 
health assessments.  The update does not change the assessment of health hazards associated 
with dioxin exposure, as summarized in the 1998 ATSDR Toxicological Profile and in the 
derivation of the Minimal Risk Level (MRL).  The policy update impacts site-specific health 
assessments evaluating exposure to dioxin directly from residential soils. The update ensures 














EPA’s preliminary remediation goal for dioxin in soil has not changed and remains at 1 ppb.  
ATSDR does not establish clean-up goals or preliminary remediation goals, but ATSDR believes 
that health risks associated with levels of dioxins in soil below 1 ppb would be low under most 
scenarios where the primary exposure pathway is incidental ingestion through direct exposure to 
soil. In such instances, ATSDR public health recommendations may include community health 
education or limiting access to contaminated areas.  Consistency with 2005 PHAGM also 
ensures that a comprehensive evaluation of dioxins from contaminated soils includes the 
consideration of scenarios where dioxins may enter the food chain pathway.  
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Public Health Statement 
This chapter of the profile is a health effects summary written in non-technical language.  Its intended 
audience is the general public especially people living in the vicinity of a hazardous waste site or chemical 
release. If the Public Health Statement were removed from the rest of the document, it would still 
communicate to the lay public essential information about the chemical. 
The major headings in the Public Health Statement are useful to find specific topics of concern.  The topics 
are written in a question and answer format.  The answer to each question includes a sentence that will 
direct the reader to chapters in the profile that will provide more information on the given topic. 
Chapter 2 
Tables and Figures for Levels of Significant Exposure (LSE) 
Tables (2-1, 2-2, and 2-3) and figures (2-1 and 2-2) are used to summarize health effects and illustrate 
graphically levels of exposure associated with those effects.  These levels cover health effects observed at 
increasing dose concentrations and durations, differences in response by species, minimal risk levels 
(MRLs) to humans for noncancer end points, and EPA's estimated range associated with an upper- bound 
individual lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  Use the LSE tables and figures for a 
quick review of the health effects and to locate data for a specific exposure scenario.  The LSE tables and 
figures should always be used in conjunction with the text.  All entries in these tables and figures represent 
studies that provide reliable, quantitative estimates of No-Observed-Adverse- Effect Levels (NOAELs), 
Lowest-Observed-Adverse-Effect Levels (LOAELs), or Cancer Effect Levels (CELs). 
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 2-1 and Figure 2-1 are shown.  The numbers in the left column of the legends 
correspond to the numbers in the example table and figure. 
LEGEND 
See LSE Table 2-1 
(1)	 Route of Exposure  One of the first considerations when reviewing the toxicity of a substance using 
these tables and figures should be the relevant and appropriate route of exposure.  When sufficient 
data exists, three LSE tables and two LSE figures are presented in the document.  The three LSE 
tables present data on the three principal routes of exposure, i.e., inhalation, oral, and dermal (LSE 
Table 2-1, 2-2, and 2-3, respectively).  LSE figures are limited to the inhalation (LSE Figure 2-1) 
and oral (LSE Figure 2-2) routes. Not all substances will have data on each route of exposure and 
will not therefore have all five of the tables and figures. 
 CDDs	 C-2 
APPENDIX C 
(2)	 Exposure Period  Three exposure periods - acute (less than 15 days), intermediate (15–364 days), 
and chronic (365 days or more) are presented within each relevant route of exposure.  In this 
example, an inhalation study of intermediate exposure duration is reported.  For quick reference to 
health effects occurring from a known length of exposure, locate the applicable exposure period 
within the LSE table and figure. 
(3)	 Health Effect  The major categories of health effects included in LSE tables and figures are death, 
systemic, immunological, neurological, developmental, reproductive, and cancer.  NOAELs and 
LOAELs can be reported in the tables and figures for all effects but cancer. Systemic effects are 
further defined in the "System" column of the LSE table (see key number 18). 
(4)	 Key to Figure  Each key number in the LSE table links study information to one or more data points 
using the same key number in the corresponding LSE figure.  In this example, the study represented 
by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL (also see the 2 
"18r" data points in Figure 2-1). 
(5)	 Species  The test species, whether animal or human, are identified in this column.  Section 2.5, 
"Relevance to Public Health," covers the relevance of animal data to human toxicity and Section 2.3, 
"Toxicokinetics," contains any available information on comparative toxicokinetics.  Although 
NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent human doses to 
derive an MRL. 
(6)	 Exposure Frequency/Duration  The duration of the study and the weekly and daily exposure regimen 
are provided in this column.  This permits comparison of NOAELs and LOAELs from different 
studies. In this case (key number 18), rats were exposed to 1,1,2,2-Tetrachloroethane via inhalation 
for 6 hours per day, 5 days per week, for 3 weeks.  For a more complete review of the dosing 
regimen refer to the appropriate sections of the text or the original reference paper, i.e., Nitschke et 
al. 1981. 
(7)	 System  This column further defines the systemic effects.  These systems include:  respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and dermal/ocular. 
"Other" refers to any systemic effect (e.g., a decrease in body weight) not covered in these systems. 
In the example of key number 18, 1 systemic effect (respiratory) was investigated. 
(8)	 NOAEL  A No-Observed-Adverse-Effect Level (NOAEL) is the highest exposure level at which no 
harmful effects were seen in the organ system studied.  Key number 18 reports a NOAEL of 3 ppm 
for the respiratory system which was used to derive an intermediate exposure, inhalation MRL of 
0.005 ppm (see footnote "b"). 
(9)	 LOAEL  A Lowest-Observed-Adverse-Effect Level (LOAEL) is the lowest dose used in the study 
that caused a harmful health effect.  LOAELs have been classified into "Less Serious" and "Serious" 
effects. These distinctions help readers identify the levels of exposure at which adverse health 
effects first appear and the gradation of effects with increasing dose. A brief description of the 
specific end point used to quantify the adverse effect accompanies the LOAEL.  The respiratory 
effect reported in key number 18 (hyperplasia) is a Less serious LOAEL of 10 ppm.  MRLs are not 
derived from Serious LOAELs. 
(10)	 Reference  The complete reference citation is given in chapter 8 of the profile. 
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(11)	 CEL  A Cancer Effect Level (CEL) is the lowest exposure level associated with the onset of 
carcinogenesis in experimental or epidemiologic studies.  CELs are always considered serious 
effects. The LSE tables and figures do not contain NOAELs for cancer, but the text may report 
doses not causing measurable cancer increases. 
(12)	 Footnotes  Explanations of abbreviations or reference notes for data in the LSE tables are found in 
the footnotes. Footnote "b" indicates the NOAEL of 3 ppm in key number 18 was used to derive an 
MRL of 0.005 ppm. 
LEGEND 
See Figure 2-1 
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the 
reader quickly compare health effects according to exposure concentrations for particular exposure 
periods. 
(13) Exposure Period	  The same exposure periods appear as in the LSE table.  In this example, health 
effects observed within the intermediate and chronic exposure periods are illustrated. 
(14)	 Health Effect  These are the categories of health effects for which reliable quantitative data exists. 
The same health effects appear in the LSE table. 
(15) Levels of Exposure	  concentrations or doses for each health effect in the LSE tables are graphically 
displayed in the LSE figures.  Exposure concentration or dose is measured on the log scale "y" axis. 
Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in mg/kg/day. 
(16)	 NOAEL  In this example, 18r NOAEL is the critical end point for which an intermediate inhalation 
exposure MRL is based. As you can see from the LSE figure key, the open-circle symbol indicates 
to a NOAEL for the test species-rat. The key number 18 corresponds to the entry in the LSE table. 
The dashed descending arrow indicates the extrapolation from the exposure level of 3 ppm (see entry 
18 in the Table) to the MRL of 0.005 ppm (see footnote "b" in the LSE table). 
(17)	 CEL  Key number 38r is 1 of 3 studies for which Cancer Effect Levels were derived.  The diamond 
symbol refers to a Cancer Effect Level for the test species-mouse.  The number 38 corresponds to the 
entry in the LSE table. 
(18)	 Estimated Upper-Bound Human Cancer Risk Levels  This is the range associated with the 
upper-bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the cancer 
dose response curve at low dose levels (q1*). 
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39 Rat	 89–104 wk 10 (CEL, lung tumors, NTP 1982 
5d/wk nasal tumors) 
6hr/d 
40 Mouse	 79–103 wk 10 (CEL, lung tumors, NTP 1982 
5d/wk hemangiosarcomas) 
6hr/d 
a The number corresponds to entries in Figure 2-1. 
6 b Used to derive an intermediate inhalation  Minimal Risk Level (MRL) of 5 x 10-3 ppm; dose adjusted for intermittent exposure and divided by an 
12 uncertainty factor of 100 (10 for extrapolation from animal to humans, 10 for human variability). 
CEL = cancer effect level; d = days(s); hr = hour(s); LOAEL = lowest-observed-adverse-effect level; mo = month(s); NOAEL = no-observed-adverse­



















Chapter 2 (Section 2.5) 
Relevance to Public Health 
The Relevance to Public Health section provides a health effects summary based on evaluations of existing 
toxicologic, epidemiologic, and toxicokinetic information.  This summary is designed to present 
interpretive, weight-of-evidence discussions for human health end points by addressing the following 
questions. 
1.	 What effects are known to occur in humans? 
2.	 What effects observed in animals are likely to be of concern to humans? 
3.	 What exposure conditions are likely to be of concern to humans, especially around hazardous 
waste sites? 
The section covers end points in the same order they appear within the Discussion of Health Effects by 
Route of Exposure section, by route (inhalation, oral, dermal) and within route by effect.  Human data are 
presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  In vitro 
data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also considered in 
this section. If data are located in the scientific literature, a table of genotoxicity information is included. 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using 
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer potency 
or perform cancer risk assessments.  Minimal risk levels (MRLs) for noncancer end points (if derived) and 
the end points from which they were derived are indicated and discussed. 
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Data Needs section. 
Interpretation of Minimal Risk Levels 
Where sufficient toxicologic information is available, we have derived minimal risk levels (MRLs) for 
inhalation and oral routes of entry at each duration of exposure (acute, intermediate, and chronic).  These 
MRLs are not meant to support regulatory action; but to acquaint health professionals with exposure levels 
at which adverse health effects are not expected to occur in humans.  They should help physicians and 
public health officials determine the safety of a community living near a chemical emission, given the 
concentration of a contaminant in air or the estimated daily dose in water.  MRLs are based largely on 
toxicological studies in animals and on reports of human occupational exposure. 
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 
2.5, "Relevance to Public Health," contains basic information known about the substance.  Other sections 
such as 2.8, "Interactions with Other Substances,” and 2.9, "Populations that are Unusually Susceptible" 
provide important supplemental information. 
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a modified 
version of the risk assessment methodology the Environmental Protection Agency (EPA) provides (Barnes 
and Dourson 1988) to determine reference doses for lifetime exposure (RfDs).  
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To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR cannot 
make this judgement or derive an MRL unless information (quantitative or qualitative) is available for all 
potential systemic, neurological, and developmental effects.  If this information and reliable quantitative 
data on the chosen end point are available, ATSDR derives an MRL using the most sensitive species 
(when information from multiple species is available) with the highest NOAEL that does not exceed any 
adverse effect levels. When a NOAEL is not available, a lowest-observed-adverse-effect level (LOAEL) 
can be used to derive an MRL, and an uncertainty factor (UF) of 10 must be employed.  Additional 
uncertainty factors of 10 must be used both for human variability to protect sensitive subpopulations 
(people who are most susceptible to the health effects caused by the substance) and for interspecies 
variability (extrapolation from animals to humans).  In deriving an MRL, these individual uncertainty 
factors are multiplied together.  The product is then divided into the inhalation concentration or oral 
dosage selected from the study.  Uncertainty factors used in developing a substance-specific MRL are 
provided in the footnotes of the LSE Tables. 
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ACRONYMS, ABBREVIATIONS, AND SYMBOLS 
2,4-D 2,4-dichlorophenoxyacetic acid 
2,4,5-T 2,4,5-trichlorophenoxyacetic acid 
2,4,5-TCP 2,4,5-trichlorophenol 
AAH arylhydrocarbon hydroxylase 
ACGIH American Conference of Governmental Industrial Hygienists 
ACOH acetanylide-4-hydroxylase 
ACTH adenocorticotropin 
ADI Acceptable Daily Intake 
ADME Absorption, Distribution, Metabolism, and Excretion 
AFID alkali flame ionization detector 
AFOSH Air Force Office of Safety and Health 
ALT alanine aminotransferase 
AML acute myeloid leukemia 
AOAC Association of Official Analytical Chemists 
AST aspartate aminotransferase 
atm atmosphere 
ATSDR Agency for Toxic Substances and Disease Registry 
AWQC Ambient Water Quality Criteria 
BAT Best Available Technology 
BCF bioconcentration factor 
BEI Biological Exposure Index 
BSC Board of Scientific Counselors 
C Centigrade 
CAA Clean Air Act 
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency 
CAS Chemical Abstract Services 
CDC Centers for Disease Control and Prevention 
CEL Cancer Effect Level 
CELDS Computer-Environmental Legislative Data System 
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act 
CFR Code of Federal Regulations 
Ci curie 
CL ceiling limit value 
CLP Contract Laboratory Program 
cm centimeter 
CML chronic myeloid leukemia 
CNS central nervous system 
CPSC Consumer Products Safety Commission 
CTL cytotoxic T-lymphocyte 
CWA Clean Water Act 
d  day  
Derm dermal 




DHHS Department of Health and Human Services 
DNA deoxyribonucleic acid 
DOD Department of Defense 
DOE Department of Energy 
DOL Department of Labor 
DOT Department of Transportation 
DOT/UN/ Department of Transportation/United Nations/
 NA/IMCO North America/International Maritime Dangerous Goods Code 
DTH delayed-type hypersensitivity 
DWEL Drinking Water Exposure Level 
ECD electron capture detection 
ECG/EKG electrocardiogram 
EEG electroencephalogram 
EEGL Emergency Exposure Guidance Level 
EGF epidermal growth factor 
EPA Environmental Protection Agency 
EROD ethoxyresorufin-O-deethylase 
F Fahrenheit 
F1 first-filial generation 
FAO Food and Agricultural Organization of the United Nations 
FDA Food and Drug Administration 
FEMA Federal Emergency Management Agency 
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act 
FPD flame photometric detection 
fpm feet per minute 
ft foot 
FR Federal Register 
FSH follicle-stimulating hormone 
g  gram  
GC gas chromatography 
Gd gestational day 
gen generation 
GGT gamma-glutamyl transferase 
GLC gas liquid chromatography 
GPC gel permeation chromatography 
HDL high density lipoprotein 
HPLC high-performance liquid chromatography 
hr hour 
HRGC high resolution gas chromatography 
HSDB Hazardous Substance Data Bank 
IDLH Immediately Dangerous to Life and Health 
IARC International Agency for Research on Cancer 
ILO International Labor Organization 
in inch 
IRIS Integrated Risk Information System
Kd adsorption ratio 
kg kilogram 
kkg metric ton 
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Koc organic carbon partition coefficient 
Kow octanol-water partition coefficient 
L liter 
LC liquid chromatography 
LCLo lethal concentration, low 
LC50 lethal concentration, 50% kill 
LDL low density lipoprotein 
LDLo lethal dose, low 
LD50 lethal dose, 50% kill 
LH lteinizing hormone 
LT50 lethal time, 50% kill 
LOAEL lowest-observed-adverse-effect level 
LSE Levels of Significant Exposure 
m meter 
MA trans,trans-muconic acid 
MAL Maximum Allowable Level 
mCi millicurie 
MCL Maximum Contaminant Level 
MCLG Maximum Contaminant Level Goal 





mm Hg millimeters of mercury 
mmol millimole 
mo month 
mppcf millions of particles per cubic foot 
MRL Minimal Risk Level 
MS mass spectrometry 
NAAQS National Ambient Air Quality Standard 
NAS National Academy of Science 
NATICH National Air Toxics Information Clearinghouse 
NATO North Atlantic Treaty Organization 
NCE normochromatic erythrocytes 
NCI National Cancer Institute 
NIEHS National Institute of Environmental Health Sciences 
NIOSH National Institute for Occupational Safety and Health 
NIOSHTIC NIOSH's Computerized Information Retrieval System 
NFPA National Fire Protection Association 
ng nanogram 
NK cells natural killer cells 
NLM National Library of Medicine 
nm nanometer 
NHANES National Health and Nutrition Examination Survey 
nmol nanomole 
NOAEL no-observed-adverse-effect level 
NOES National Occupational Exposure Survey 
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NOHS National Occupational Hazard Survey 
NPD nitrogen phosphorus detection 
NPDES National Pollutant Discharge Elimination System 
NPL National Priorities List 
NR not reported 
NRC National Research Council 
NS not specified 
NSPS New Source Performance Standards 
NTIS National Technical Information Service 
NTP National Toxicology Program 
ODW Office of Drinking Water, EPA 
OERR Office of Emergency and Remedial Response, EPA 
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System 
OPP Office of Pesticide Programs, EPA 
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA 
OPPT Office of Pollution Prevention and Toxics, EPA 
OSHA Occupational Safety and Health Administration 
OSW Office of Solid Waste, EPA 
OTS Office of Toxic Substances 
OW Office of Water 
OWRS Office of Water Regulations and Standards, EPA 
PAH Polycyclic Aromatic Hydrocarbon 
PBPD Physiologically Based Pharmacodynamic 
PBPK Physiologically Based Pharmacokinetic 
PCE polychromatic erythrocytes 
PEL permissible exposure limit 
PEPCK phosphoenolpyruvate carboxykinase 
PID photo ionization detector 
pg picogram 
pmol picomole 
PHS Public Health Service 
PMR proportionate mortality ratio 
ppb parts per billion 
ppm parts per million 
ppt parts per trillion 
PSNS Pretreatment Standards for New Sources 
REL recommended exposure level/limit 
RfC Reference Concentration 
RfD Reference Dose 
RNA ribonucleic acid 
RTECS Registry of Toxic Effects of Chemical Substances 
RQ Reportable Quantity 
SARA Superfund Amendments and Reauthorization Act 
SCE sister chromatid exchange 
sec second 
SIC Standard Industrial Classification 
SIM selected ion monitoring 
SMCL Secondary Maximum Contaminant Level 
SMR standard mortality ratio 
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SNARL Suggested No Adverse Response Level 
SPEGL Short-Term Public Emergency Guidance Level 
SRBC sheep red blood cell 
STEL short-term exposure limit 




TD50 toxic dose, 50% specific toxic effect 
TLV threshold limit value 
TOC Total Organic Compound 
TPQ Threshold Planning Quantity 
TRI Toxics Release Inventory 
TSCA Toxic Substances Control Act 
TSH thyroid-stimulating hormone 
TRI Toxics Release Inventory 
TTR transthyretin 
TWA time-weighted average 
UDPGT UDP-glucuronosyltransferase 
U.S. United States 
UF uncertainty factor 
VLDL very low density lipoprotein 
VOC Volatile Organic Compound 
yr year 
WHO World Health Organization 
wk week 
> greater than 
> greater than or equal to 
= equal to 
< less than 








q1* cancer slope factor 
– negative 
+ positive 
(+) weakly positive result 
(–) weakly negative result 
